Drug;Gene;Genotype;Alleles;Outcome;Variation;Effect;Entity;Entity_name;Therapeutic_Outcome;AlleleOutcome
NIFEDIPINE;CYP3A4;CYP3A4*1;*17;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NIFEDIPINE;CYP3A4;CYP3A4*17;*17;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SITAGLIPTIN;DPP4;rs2909451;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SITAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
WARFARIN;CYP2C9;CYP2C9*11;*11/*11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SITAGLIPTIN;KCNQ1;rs163184;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*18;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*18;*1/*18;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
SITAGLIPTIN;DPP4;rs4664443;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
CODEINE;CYP2D6;CYP2D6*1xN;*1xN;LADME-PK;INCREASED_METABOLISM;LIKELIHOOD_TOXICITY;ENZYME;CYP2D6;CAUTION_SIDE_EFFECT;
SITAGLIPTIN;CYP2C9;rs1799853;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SITAGLIPTIN;GLP1R;rs3765467;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
FLUOXETINE;CYP2C19;CYP2C19 intermediate metabolizer;;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
PAROXETINE;CYP2C19;CYP2C19 ultrarapid metabolizer;;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SITAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
EXENATIDE;GLP1R;rs3765467;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
LIRAGLUTIDE;GLP1R;rs3765467;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
CITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FLUOXETINE;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
PAROXETINE;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
ALBIGLUTIDE;GLP1R;rs6923761;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DULAGLUTIDE;GLP1R;rs6923761;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
GLP-1 RECEPTOR AGONISTS;GLP1R;rs6923761;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
EXENATIDE;TCF7L2;rs7903146;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
RIFAPENTINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;DECREASED_EXPOSURE;OTHER;HISTORY OF GASTRIC BYPASS SURGERY;;;
ALBIGLUTIDE;ARRB1;rs140226575;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DULAGLUTIDE;ARRB1;rs140226575;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
GLP-1 RECEPTOR AGONISTS;ARRB1;rs140226575;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
EFAVIRENZ;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
PROPAFENONE;CYP2D6;CYP2D6*1;*10/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;CARDIAC RHYTHM DISEASE;;
PROPAFENONE;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;CARDIAC RHYTHM DISEASE;;
PROPAFENONE;CYP2D6;CYP2D6*1;*10/*10;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CARDIAC RHYTHM DISEASE;;
PROPAFENONE;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CARDIAC RHYTHM DISEASE;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*6;*4/*6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NEVIRAPINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
ALBIGLUTIDE;ARRB1;rs78979036;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DULAGLUTIDE;ARRB1;rs78979036;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
GLP-1 RECEPTOR AGONISTS;ARRB1;rs78979036;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METHADONE;CYP2D6;CYP2D6*1;*1/*2xN + *2/*2xN;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2D6;CYP2D6*2;*1/*2xN + *2/*2xN;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2D6;CYP2D6*2xN;*1/*2xN + *2/*2xN;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
LURBINECTEDIN;CYP3A4;CYP3A4*1;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
LURBINECTEDIN;CYP3A4;CYP3A4*22;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE;ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE;ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;;
ALBIGLUTIDE;ARRB1;rs78052828;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DULAGLUTIDE;ARRB1;rs78052828;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
GLP-1 RECEPTOR AGONISTS;ARRB1;rs78052828;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METHYLMERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
METHYLMERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS;;
ALBIGLUTIDE;ARRB1;rs58428187;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DULAGLUTIDE;ARRB1;rs58428187;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
GLP-1 RECEPTOR AGONISTS;ARRB1;rs58428187;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*10/*36;DOSAGE;INCREASED_DOSE;OTHER;BREAST NEOPLASMS;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*10/*36;DOSAGE;INCREASED_DOSE;OTHER;BREAST NEOPLASMS;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*36;DOSAGE;INCREASED_DOSE;OTHER;BREAST NEOPLASMS;;;
TAMOXIFEN;CYP2D6;CYP2D6*36;*10/*36;DOSAGE;INCREASED_DOSE;OTHER;BREAST NEOPLASMS;;;
RALOXIFENE 6-GLUCURONIDE;UGT1A1;UGT1A1*1;*28/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOPOROSIS;;
RALOXIFENE 6-GLUCURONIDE;UGT1A1;UGT1A1*28;*28/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOPOROSIS;;
RALOXIFENE-4′-GLUCURONIDE;UGT1A1;UGT1A1*1;*28/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOPOROSIS;;
RALOXIFENE-4′-GLUCURONIDE;UGT1A1;UGT1A1*28;*28/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOPOROSIS;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
TRAMADOL;CYP2D6;CYP2D6*1;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
TRAMADOL;CYP2D6;CYP2D6*4;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
TRAMADOL;CYP2D6;CYP2D6*5;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
TRAMADOL;CYP2D6;CYP2D6*9;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
TRAMADOL;CYP2D6;CYP2D6*10;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
TRAMADOL;CYP2D6;CYP2D6*17;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
CLOZAPINE;CYP1A2;CYP1A2*35;*35;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2*35;*35;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;OTHER;LACTATION;;;
LURBINECTEDIN;CYP3A5;CYP3A5*1;*1/*1;LADME-PK;INCREASED_CLEARANCE;OTHER;NEOPLASMS;;;
LURBINECTEDIN;CYP3A5;CYP3A5*3;*1/*1;LADME-PK;INCREASED_CLEARANCE;OTHER;NEOPLASMS;;;
LURBINECTEDIN;CYP3A5;CYP3A5*1;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
LURBINECTEDIN;CYP3A5;CYP3A5*3;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
LEFLUNOMIDE;PON1;rs705379;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
(S)-METHADONE;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
(S)-METHADONE;CYP2B6;CYP2B6*5;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
(S)-METHADONE;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
(S)-METHADONE;CYP2B6;CYP2B6*7;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ANTIEPILEPTICS;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY;;;
ANTIEPILEPTICS;SCN1A;rs10167228;T;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY;;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*1;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*3;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*4;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*6;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*10;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CODEINE;CYP2D6;CYP2D6*2;*2/*2xN;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
CODEINE;CYP2D6;CYP2D6*2xN;*2/*2xN;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;WARFARIN;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;WARFARIN;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*5;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;WARFARIN;;
WARFARIN;CYP2C9;CYP2C9*5;*1/*5;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;WARFARIN;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;WARFARIN;;
WARFARIN;CYP2C9;CYP2C9*11;*1/*11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;WARFARIN;;
METHADONE;CYP3A4;LOW_ACTIVITY;;LADME-PK;DECREASED_CLEARANCE;METABOLISM;ENZYME;CYP3A4,2B6,2D6,2C9,1A2;CAUTION_DRUG_ACCUMULATION;
METHADONE;2B6;LOW_ACTIVITY;;LADME-PK;DECREASED_CLEARANCE;METABOLISM;ENZYME;CYP3A4,2B6,2D6,2C9,1A2;CAUTION_DRUG_ACCUMULATION;
METHADONE;2D6;LOW_ACTIVITY;;LADME-PK;DECREASED_CLEARANCE;METABOLISM;ENZYME;CYP3A4,2B6,2D6,2C9,1A2;CAUTION_DRUG_ACCUMULATION;
METHADONE;2C9;LOW_ACTIVITY;;LADME-PK;DECREASED_CLEARANCE;METABOLISM;ENZYME;CYP3A4,2B6,2D6,2C9,1A2;CAUTION_DRUG_ACCUMULATION;
METHADONE;1A2;LOW_ACTIVITY;;LADME-PK;DECREASED_CLEARANCE;METABOLISM;ENZYME;CYP3A4,2B6,2D6,2C9,1A2;CAUTION_DRUG_ACCUMULATION;
SN-38;UGT1A1;UGT1A1*1;*28/*28;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS;;;
SN-38;UGT1A1;UGT1A1*28;*28/*28;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS;;;
SN-38;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS;;;
SN-38;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS;;;
CARVEDILOL;UGT1A1;UGT1A1*1;*28;LADME-PK;INCREASED_METABOLISM;OTHER;ANGINA PECTORIS;;;
CARVEDILOL;UGT1A1;UGT1A1*28;*28;LADME-PK;INCREASED_METABOLISM;OTHER;ANGINA PECTORIS;;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;nan;;;
ACENOCOUMAROL;VKORC1;rs9934438;A;DOSAGE;DOSE;OTHER;A STABLE MAINTENANCE DOSE;;;
WARFARIN;CYP2C9;CYP2C9*1;*3/*3 + *1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*3 + *1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LIRAGLUTIDE;CNR1;rs1049353;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2,OBESITY;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;VKORC1;rs104894542;C;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CLONIDINE;ADRA2C;rs11269124;GGGGAGCTTTCCCAGAGACCC/del + del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LIVER CIRRHOSIS;;
SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CARDIOVASCULAR DISEASE;;;
SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DYSLIPIDAEMIA;;;
SIMVASTATIN ACID;SLCO1B1;rs2306283;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CARDIOVASCULAR DISEASE;;;
SIMVASTATIN ACID;SLCO1B1;rs2306283;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DYSLIPIDAEMIA;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*2xN;*4/*2xN;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERCHOLESTEROLEMIA;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*3;*4/*2xN;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERCHOLESTEROLEMIA;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*2xN;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERCHOLESTEROLEMIA;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*5;*4/*2xN;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERCHOLESTEROLEMIA;;;
ASPIRIN;P2RY1;rs1371097;T;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;STROKE;;;
ASPIRIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;STROKE;;;
SN-38;UGT1A1;UGT1A1*1;*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;COLONIC NEOPLASMS;;;
SN-38;UGT1A1;UGT1A1*28;*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;COLONIC NEOPLASMS;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SIROLIMUS;CYP3A4;CYP3A4*8;*8/*20;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SEIZURES;;;
SIROLIMUS;CYP3A4;CYP3A4*8;*8/*20;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INTESTINAL DISEASES;;;
SIROLIMUS;CYP3A4;CYP3A4*8;*8/*20;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CONGENITAL ABNORMALITIES;;;
SIROLIMUS;CYP3A4;CYP3A4*20;*8/*20;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SEIZURES;;;
SIROLIMUS;CYP3A4;CYP3A4*20;*8/*20;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INTESTINAL DISEASES;;;
SIROLIMUS;CYP3A4;CYP3A4*20;*8/*20;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CONGENITAL ABNORMALITIES;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;OTHER;CHRONIC_HEPATITIS_C;;;
SOFOSBUVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;OTHER;CHRONIC_HEPATITIS_C;;;
RIFAMPIN;SLCO1B1;rs4149032;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
MODAFINIL;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;OTHER;METHAMPHETAMINE DEPENDENCE;;;
ISONIAZID;nan;rs1495741;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
VALSARTAN;AGT;rs699;GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
NALTREXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ALCOHOL ABUSE;;;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ELEXACAFTOR;CFTR;CFTR deficiency;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CYSTIC FIBROSIS;;;
REMIFENTANIL;ADRA2A;rs1800544;CG + GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
WARFARIN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;DOSAGE;INCREASED_DOSE;OTHER;THROMBOEMBOLISM;;;
WARFARIN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;DOSAGE;INCREASED_DOSE;OTHER;THROMBOEMBOLISM;;;
REMIFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
ELIGLUSTAT;CYP2D6;CYP2D6 ultrarapid metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;GAUCHER DISEASE;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;LIVER TRANSPLANTATION;;;
POSACONAZOLE;ABCB1;rs1045642;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*6;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*6;*6;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
LACOSAMIDE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
LACOSAMIDE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
LACOSAMIDE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*7;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*7;*7;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;ORGAN TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;ORGAN TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*6;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;CONCENTRATIONS;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;CONCENTRATIONS;nan;nan;;;
COUMARIN;CYP2A6;CYP2A6*1;*4/*4 + *4/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
COUMARIN;CYP2A6;CYP2A6*4;*4/*4 + *4/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
COUMARIN;CYP2A6;CYP2A6*10;*4/*4 + *4/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;TOBACCO USE DISORDER;;
NICOTINE;CYP2A6;CYP2A6*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;TOBACCO USE DISORDER;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
BELINOSTAT;UGT1A1;UGT1A1*1;*28/*28 + *1/*60 + *60/*60;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS;;;
BELINOSTAT;UGT1A1;UGT1A1*28;*28/*28 + *1/*60 + *60/*60;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS;;;
BELINOSTAT;UGT1A1;UGT1A1*60;*28/*28 + *1/*60 + *60/*60;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS;;;
MOXIFLOXACIN;UGT1A1;UGT1A1*1;*1/*36;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
MOXIFLOXACIN;UGT1A1;UGT1A1*28;*1/*36;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
MOXIFLOXACIN;UGT1A1;UGT1A1*36;*1/*36;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
MOXIFLOXACIN;UGT1A1;UGT1A1*37;*1/*36;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;BREAST NEOPLASMS;;;
NICOTINE;CYP2A6;CYP2A6*1;*46/*46;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*46;*46/*46;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
BUPRENORPHINE;SLC39A10;rs149319538;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;OPIOID-RELATED DISORDERS;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*2/*2;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*2;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
SIMVASTATIN;CYP2C9;CYP2C9*1;*3;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
SIMVASTATIN;CYP2C9;CYP2C9*3;*3;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, LADME-PK;DOSE;nan;nan;;;
LETROZOLE;CYP2A6;CYP2A6*1;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*2;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*4;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*9;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*12;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*1;*1/*46 + *1/*46 + *46/*46;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
LETROZOLE;CYP2A6;CYP2A6*4;*1/*46 + *1/*46 + *46/*46;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
LETROZOLE;CYP2A6;CYP2A6*7;*1/*46 + *1/*46 + *46/*46;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
LETROZOLE;CYP2A6;CYP2A6*9;*1/*46 + *1/*46 + *46/*46;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
LETROZOLE;CYP2A6;CYP2A6*46;*1/*46 + *1/*46 + *46/*46;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
WARFARIN;CYP4F2;CYP4F2*3;*3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;STROKE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;VENOUS THROMBOSIS;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;STROKE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;VENOUS THROMBOSIS;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;STROKE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;VENOUS THROMBOSIS;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;OTHER;STROKE;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;OTHER;VENOUS THROMBOSIS;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ARIPIPRAZOLE;DRD2;rs1799732;G/del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER;;
RIVAROXABAN;ABCB1;rs4148738;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
RIVAROXABAN;ABCB1;rs1128503;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
METHOTREXATE;TYMS;rs2853542;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*9;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*21;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*33;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*9;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*21;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*33;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;ATIC;rs4673993;TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
FLUOXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;EFFICACY;MAJOR DEPRESSIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOAFFECTIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;DEPRESSIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*3;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*3;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOAFFECTIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*3;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*3;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;DEPRESSIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOAFFECTIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;DEPRESSIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOAFFECTIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;DEPRESSIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOAFFECTIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;DEPRESSIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*9;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*9;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOAFFECTIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*9;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*9;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;DEPRESSIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOAFFECTIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;DEPRESSIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOAFFECTIVE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;DEPRESSIVE DISORDER;;;
SN-38;UGT1A1;UGT1A1*1;*6/*60 + *6/*28;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*6;*6/*60 + *6/*28;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*28;*6/*60 + *6/*28;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*60;*6/*60 + *6/*28;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
TAMOXIFEN;CYP2D6;rs16947;A;EFFICACY, TOXICITY;INCREASED_DISCONTINUATION;OTHER;BREAST NEOPLASMS;;;
DIHYDROPYRIDINE DERIVATIVES;NUMA1;rs10898815;AA + AG;OTHER;INCREASED_DISCONTINUATION;nan;nan;;;
TAMOXIFEN;ABCC2;rs3740065;G;EFFICACY, TOXICITY;INCREASED_DISCONTINUATION;OTHER;BREAST NEOPLASMS;;;
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
HYDRALAZINE;NAT2;NAT2 rapid acetylator;;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;HYPERTENSION;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HEART TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HEART TRANSPLANTATION;;
LANSOPRAZOLE;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;DECREASED_CLEARANCE;OTHER;GASTROESOPHAGEAL REFLUX;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
SULFONAMIDES;CYP2C19;CYP2C19*1;*2/*2  + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SULFONAMIDES;CYP2C19;CYP2C19*2;*2/*2  + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SULFONAMIDES;CYP2C19;CYP2C19*3;*2/*2  + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
UREA DERIVATIVES;CYP2C19;CYP2C19*1;*2/*2  + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
UREA DERIVATIVES;CYP2C19;CYP2C19*2;*2/*2  + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
UREA DERIVATIVES;CYP2C19;CYP2C19*3;*2/*2  + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
CORTICOSTEROIDS;NR3C1;rs10482634;GG;EFFICACY;INCREASED_RESISTANCE;OTHER;NEPHROTIC SYNDROME;;;
WARFARIN;CYP2C9;CYP2C9*1;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*5;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*6;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*10;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*11;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;HEART TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;HEART TRANSPLANTATION;;
VALPROIC ACID;UGT1A6;rs6759892;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
METHYLPHENIDATE;SYT1;rs2251214;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ADHD;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SEVERE COMBINED IMMUNODEFICIENCY;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERTENSION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CHOP;CBR3;rs8133052;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;;;
RITUXIMAB;CBR3;rs8133052;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;;;
CHOP;ABCC2;rs8187710;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;;;
RITUXIMAB;ABCC2;rs8187710;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;;;
N-DESMETHYLTAMOXIFEN;SEPTIN3;rs11914200;AG;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
FENTANYL;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS,PAIN;;
FENTANYL;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS,PAIN;;
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs34130495;A;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;nan;;;
N-DESMETHYLTAMOXIFEN;SREBF2;rs133290;AC;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
N-DESMETHYLTAMOXIFEN;TCF20;rs5751251;GG;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
N-DESMETHYLTAMOXIFEN;SREBF2;rs2267439;TT;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
N-DESMETHYLTAMOXIFEN;SREBF2;rs9607850;TT;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
N-DESMETHYLTAMOXIFEN;CENPM;rs8140869;AG;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
N-DESMETHYLTAMOXIFEN;SMIM45;rs8140869;AG;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RIBAVIRIN;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
SOFOSBUVIR;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
VARENICLINE;CYP2A6;CYP2A6 high activity;;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
WARFARIN;CYP2C9;CYP2C9*1;*2/*24;DOSAGE;DECREASED_CLEARANCE;OTHER;CARDIOMYOPATHIES;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*24;DOSAGE;DECREASED_CLEARANCE;OTHER;CARDIOMYOPATHIES;;;
WARFARIN;CYP2C9;CYP2C9*24;*2/*24;DOSAGE;DECREASED_CLEARANCE;OTHER;CARDIOMYOPATHIES;;;
ETOPOSIDE;nan;rs446112;AA;OTHER;INCREASED_RESISTANCE;nan;nan;;;
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_EXPOSURE;OTHER;DIABETES MELLITUS;;;
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_EXPOSURE;OTHER;HYPERCHOLESTEROLEMIA;;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;CYP2D6;CYP2D6*2;*2/*2;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
OPIOIDS;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PAIN;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*2/*24;DOSAGE;DECREASED_DOSE;OTHER;CARDIOMYOPATHIES;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*24;DOSAGE;DECREASED_DOSE;OTHER;CARDIOMYOPATHIES;;;
WARFARIN;CYP2C9;CYP2C9*24;*2/*24;DOSAGE;DECREASED_DOSE;OTHER;CARDIOMYOPATHIES;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANIC DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANIC DISORDER;;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;PROTEIN;SLC6A4;;;
AFATINIB;EGFR;rs28929495;GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;NON-SMALL CELL LUNG CARCINOMA;;;
HYDROMORPHONE;CYP2D6;CYP2D6*5;*5/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
HYDROMORPHONE;CYP2D6;CYP2D6*17;*5/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
3-AMINOISOBUTYRATE;DPYD;rs3918290;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
HYDRALAZINE;NAT2;NAT2 rapid acetylator;;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;HYPERTENSION;;;
MEXILETINE;CYP2D6;CYP2D6*41;*41;EFFICACY;DECREASED_RESPONSE;OTHER;MYOTONIC DYSTROPHY;;;
MEXILETINE;CYP2D6;CYP2D6*41;*41;EFFICACY;DECREASED_RESPONSE;OTHER;NONDYSTROPHIC MYOTONIA;;;
HYDROCODONE;CYP2D6;CYP2D6*5;*5/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
HYDROCODONE;CYP2D6;CYP2D6*17;*5/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*5;*5/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*17;*5/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
3-AMINOISOBUTYRATE;UPB1;rs143493067;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
3-AMINOISOBUTYRATE;AGXT2;rs114286107;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
FENTANYL;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;POSTOPERATIVE_PAIN;;
FENTANYL;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;POSTOPERATIVE_PAIN;;
URACIL;DPYD;rs3918290;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
2-AMINOHEPTANOATE;ACAD11;rs41272317;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
2-AMINOOCTANOIC ACID;ACAD11;rs41272317;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
2-HYDROXYLAURATE;ACAD11;rs41272317;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CYSTEINE-S-SULFATE;NPC2;rs140130028;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
L-ORNITHINE;NPC2;rs140130028;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
5;UPB1;rs143493067;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
6-DIHYDROTHYMINE;UPB1;rs143493067;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERTENSION;;;
10-MONOHYDROXY OXCARBAZEPINE;ABCC2;rs2273697;G;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RIVAROXABAN;CYP3A5;rs776746;TT;TOXICITY;DECREASED_PLASMATIC-CONCENTRATION;OTHER;VENOUS THROMBOEMBOLISM;;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
CYTARABINE;SLC29A1;rs2396243;T;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
CYTARABINE;NME4;rs5841;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
PRAZIQUANTEL;CYP1A2;CYP1A2*1;*1/*30 + *30/*30;LADME-PK;INCREASED_METABOLISM;OTHER;SCHISTOSOMIASIS;;;
PRAZIQUANTEL;CYP1A2;CYP1A2*30;*1/*30 + *30/*30;LADME-PK;INCREASED_METABOLISM;OTHER;SCHISTOSOMIASIS;;;
PRAZIQUANTEL;CYP2C9;CYP2C9*1;*1/*9 + *9/*9;LADME-PK;INCREASED_METABOLISM;OTHER;SCHISTOSOMIASIS;;;
PRAZIQUANTEL;CYP2C9;CYP2C9*9;*1/*9 + *9/*9;LADME-PK;INCREASED_METABOLISM;OTHER;SCHISTOSOMIASIS;;;
CYTARABINE;CDA;rs10916819;AG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
CYTARABINE;CMPK1;rs17103168;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CYTARABINE;CTPS1;rs12067645;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
CYTARABINE;RRM1;rs11030918;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
CYTARABINE;DCK;rs4643786;C;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
CYTARABINE;RRM2;rs1138729;AG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
CYTARABINE;CMPK1;rs1044457;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
CYTARABINE;SLC28A3;rs17343066;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
ARIPIPRAZOLE;CYP2D6;rs1065852;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;TIC DISORDERS;;;
ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;TIC DISORDERS;;;
QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;PROTEIN;ACE;;;
ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;EFFICACY;DECREASED_CLEARANCE;OTHER;TIC DISORDERS;;;
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;LEUKEMIA;;;
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;LYMPHOCYTIC;;;
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC;;;
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;B-CELL;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1;*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;LEUKEMIA;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1;*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;LYMPHOCYTIC;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1;*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1;*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;B-CELL;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*3;*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;LEUKEMIA;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*3;*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;LYMPHOCYTIC;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*3;*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*3;*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;B-CELL;;;
WARFARIN;CYP2C9;rs72558189;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*1;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*3A;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*3C;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
WARFARIN;CYP2C9;rs28371686;C;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;rs1057910;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;UGT1A4;rs2011425;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;rs35599367;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;LIVER TRANSPLANTATION;;;
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_EXPOSURE;OTHER;DIABETES MELLITUS;;;
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_EXPOSURE;OTHER;HYPERCHOLESTEROLEMIA;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*22;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;CYP3A4*22;*22;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*28;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*28;*28;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ALOGLIPTIN;PNPLA3;rs738409;CG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2,FATTY LIVER DISEASE,BODY WEIGHT CHANGES;;
AMLODIPINE;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HYPERTENSION;;
AMLODIPINE;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HYPERTENSION;;
IVACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
SERTRALINE;DRD3;rs167770;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;OBSESSIVE-COMPULSIVE DISORDER;;;
SERTRALINE;DRD3;rs11721264;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;OBSESSIVE-COMPULSIVE DISORDER;;;
ILOPERIDONE;CYP2D6;rs1065852;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
ILOPERIDONE METABOLITE P88;CYP2D6;rs1065852;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ASPIRIN;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ASPIRIN;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*4;*1/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
VALPROIC ACID;CACNA1H;rs3751664;T;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY;;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
PENICILLIN G;IFNG;rs1861494;CC;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SYPHILIS;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
ASPIRIN;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
PENICILLIN G;IFNG;rs2430561;TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SYPHILIS;;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
IMIPRAMINE;CYP2D6;CYP2D6*1;*1/*1xN + *1/*2xN;DOSAGE;INCREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2D6;CYP2D6*1xN;*1/*1xN + *1/*2xN;DOSAGE;INCREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2D6;CYP2D6*2;*1/*1xN + *1/*2xN;DOSAGE;INCREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2D6;CYP2D6*2xN;*1/*1xN + *1/*2xN;DOSAGE;INCREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ISONIAZID;NAT2;NAT2*4;*6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;OTHER;TUBERCULOSIS;;;
ISONIAZID;NAT2;NAT2*5;*6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;OTHER;TUBERCULOSIS;;;
ISONIAZID;NAT2;NAT2*6;*6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;OTHER;TUBERCULOSIS;;;
ISONIAZID;NAT2;NAT2*7;*6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;OTHER;TUBERCULOSIS;;;
SIMVASTATIN;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
SIMVASTATIN;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*3 + *5 + *2 + *1;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*2;*3 + *5 + *2 + *1;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*3;*3 + *5 + *2 + *1;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*5;*3 + *5 + *2 + *1;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VENETOCLAX;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ACUTE_MYELOID_LEUKEMIA;;
CLOZAPINE;NFIB;rs28379954;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A4;rs2740574;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
METHYLPHENIDATE;SLC6A2;rs998424;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ADHD;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LUPUS NEPHRITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LUPUS NEPHRITIS;;
LITHIUM;nan;rs7405404;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
NICOTINE;CYP2A6;rs28399454;CT + TT;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
3;CYP2D6;CYP2D6*1;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*2;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*3;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*4;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*5;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*6;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*9;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*10;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*2;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*3;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*4;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*5;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*6;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*9;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*10;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*2 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*2 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs35167514;del;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;nan;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FENTANYL;CYP2D6;CYP2D6*1;*10/*10;DOSAGE;INCREASED_DOSE;OTHER;GASTROINTESTINAL NEOPLASMS;;;
FENTANYL;CYP2D6;CYP2D6*1;*10/*10;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
FENTANYL;CYP2D6;CYP2D6*10;*10/*10;DOSAGE;INCREASED_DOSE;OTHER;GASTROINTESTINAL NEOPLASMS;;;
FENTANYL;CYP2D6;CYP2D6*10;*10/*10;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
VARENICLINE;HYKK;rs7164594;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
SIROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
SIROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
3;CYP2D6;CYP2D6*1;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
3;CYP2D6;CYP2D6*2;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
3;CYP2D6;CYP2D6*3;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
3;CYP2D6;CYP2D6*4;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
3;CYP2D6;CYP2D6*5;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
3;CYP2D6;CYP2D6*6;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
3;CYP2D6;CYP2D6*9;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
3;CYP2D6;CYP2D6*10;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
3;CYP2D6;CYP2D6*41;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*2;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*3;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*4;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*5;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*6;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*9;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*10;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*41;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*5;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VENLAFAXINE;CYP2D6;CYP2D6*5;*4/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY DISEASE;;
LOSARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY DISEASE;;
VENLAFAXINE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
BENAZEPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
BUPROPION;CYP2B6;rs8109525;GG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*4;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*5;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NEPHROTIC SYNDROME;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NEPHROTIC SYNDROME;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
MESALAZINE;NAT1;NAT1*3;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ULCERATIVE COLITIS,CROHN DISEASE,INFLAMMATORY BOWEL DISEASES;;
MESALAZINE;NAT1;NAT1*4;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ULCERATIVE COLITIS,CROHN DISEASE,INFLAMMATORY BOWEL DISEASES;;
MESALAZINE;NAT1;NAT1*10;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ULCERATIVE COLITIS,CROHN DISEASE,INFLAMMATORY BOWEL DISEASES;;
THIOGUANINE;NAT1;NAT1*3;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ULCERATIVE COLITIS,CROHN DISEASE,INFLAMMATORY BOWEL DISEASES;;
THIOGUANINE;NAT1;NAT1*4;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ULCERATIVE COLITIS,CROHN DISEASE,INFLAMMATORY BOWEL DISEASES;;
THIOGUANINE;NAT1;NAT1*10;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ULCERATIVE COLITIS,CROHN DISEASE,INFLAMMATORY BOWEL DISEASES;;
PIOGLITAZONE;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
PIOGLITAZONE;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;ORGAN TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;ORGAN TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;ORGAN TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;ORGAN TRANSPLANTATION;;
EXEMESTANE;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
EXEMESTANE;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
WARFARIN;CYP4F2;CYP4F2*1;*3;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP4F2;CYP4F2*3;*3;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HEART TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HEART TRANSPLANTATION;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4 + *5;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4 + *5;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4 + *5;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4 + *5 + *10 +*14;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4 + *5 + *10 +*14;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4 + *5 + *10 +*14;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*10;*4 + *5 + *10 +*14;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*14;*4 + *5 + *10 +*14;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
METOPROLOL;CYP2D6;CYP2D6*4;*4;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART FAILURE;;
CETUXIMAB;VEGFA;rs144854329;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS;;;
SN-38;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;RHEUMATOID ARTHRITIS,ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;RHEUMATOID ARTHRITIS,ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;ULCERATIVE COLITIS;;
SN-38;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS;;;
SN-38;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*6;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*6;*1/*6;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;DOSAGE;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;DOSAGE;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DOSE;nan;DISEASE;STROKE;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DOSE;nan;DISEASE;STROKE;;
VENLAFAXINE;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VENLAFAXINE;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VENLAFAXINE;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;;;
PROPOFOL;CYP2C9;CYP2C9*1;*1/*1 + *1/*2;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PROPOFOL;CYP2C9;CYP2C9*2;*1/*1 + *1/*2;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
WARFARIN;VKORC1;rs104894540;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;CLEARANCE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;CLEARANCE;nan;DISEASE;HEART DISEASES;;
CODEINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
NOROXYCODONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CITALOPRAM;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
CITALOPRAM;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
ESCITALOPRAM;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
ESCITALOPRAM;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
FLUOXETINE;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
FLUOXETINE;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
FLUVOXAMINE;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
FLUVOXAMINE;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
PAROXETINE;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
PAROXETINE;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
SERTRALINE;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
SERTRALINE;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DISULFIRAM;SLC6A3;rs28363170;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;;;
BENAZEPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
PERINDOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;PSYCHOTIC DISORDER;;
RISPERIDONE;CYP2D6;CYP2D6*3;*4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;PSYCHOTIC DISORDER;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;PSYCHOTIC DISORDER;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;PSYCHOTIC DISORDER;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
THIOGUANINE;TPMT;TPMT*1;*1/*3A + *1/*3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;CROHN DISEASE;;
THIOGUANINE;TPMT;TPMT*3A;*1/*3A + *1/*3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;CROHN DISEASE;;
THIOGUANINE;TPMT;TPMT*3C;*1/*3A + *1/*3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;CROHN DISEASE;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;HUMAN LIVER MICROSOMES;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;HUMAN LIVER MICROSOMES;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;ULCERATIVE COLITIS;;
PROGUANIL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MALARIA;;
PROGUANIL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MALARIA;;
PROGUANIL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MALARIA;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
CITALOPRAM;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OBSESSIVE-COMPULSIVE DISORDER;;
N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1;*17;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*17;*17;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
WARFARIN;VKORC1;rs104894541;C;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs36118214;GG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;VKORC1;rs104894539;A;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1;*6;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*6;*6;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1;*1/*30;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*30;*1/*30;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1;*1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*29;*1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
QUINAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,VENOUS THROMBOEMBOLISM;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,VENOUS THROMBOEMBOLISM;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,VENOUS THROMBOEMBOLISM;;
TESTOSTERONE;UGT1A4;UGT1A4*1a;*3a;EFFICACY, LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
TESTOSTERONE;UGT1A4;UGT1A4*3a;*3a;EFFICACY, LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
LAMOTRIGINE;UGT1A4;UGT1A4*1a;*2 + *3a;EFFICACY, LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
LAMOTRIGINE;UGT1A4;UGT1A4*2;*2 + *3a;EFFICACY, LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
LAMOTRIGINE;UGT1A4;UGT1A4*3a;*2 + *3a;EFFICACY, LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
CURCUMIN;CFTR;rs77010898;AA + AG;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
IVACAFTOR;CFTR;rs77010898;AA + AG;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENTAL DISORDERS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENTAL DISORDERS;;
3-HYDROXYCOTININE;CYP2A6;CYP2A6*1;*1/*12;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
3-HYDROXYCOTININE;CYP2A6;CYP2A6*12;*1/*12;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MENTAL DISORDERS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MENTAL DISORDERS;;
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LIVER TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2/*2;DOSAGE, LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;DOSAGE, LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
METOPROLOL;CYP2D6;CYP2D6*1;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*9;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*10;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*17;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*29;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*45;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*46;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_RESISTANCE;OTHER;CORONARY DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_RESISTANCE;OTHER;CORONARY DISEASE;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*17/*17;DOSAGE, LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;DOSAGE, LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
METHOTREXATE;HLA-G;rs371194629;del/del;EFFICACY;INCREASED_RESPONSE;EFFICACY;RHEUMATOID ARTHRITIS;;;
METOPROLOL;CYP2D6;CYP2D6*1;*4 + *3 + *5  + *6;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*3;*4 + *3 + *5  + *6;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*4;*4 + *3 + *5  + *6;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*5;*4 + *3 + *5  + *6;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
METOPROLOL;CYP2D6;CYP2D6*6;*4 + *3 + *5  + *6;TOXICITY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HYPERTENSION;;
SN-38;UGT1A1;UGT1A1*1;*28/*28;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*28;*28/*28;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*1;*17;EFFICACY;DECREASED_RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS;;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*17;*17;EFFICACY;DECREASED_RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2;DOSAGE, LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2;DOSAGE, LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;NEOPLASMS;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6/*6 + *28/*28 + *6/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6/*6 + *28/*28 + *6/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
IRINOTECAN;UGT1A1;UGT1A1*28;*6/*6 + *28/*28 + *6/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
TEZACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
TRAMADOL;CYP2D6;CYP2D6*1;*1/*1xN;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*1xN;*1/*1xN;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LOSARTAN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
LOSARTAN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
LOSARTAN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
CHIGLITAZAR;PPARA;rs1800234;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
LAMOTRIGINE;UGT1A4;UGT1A4*1a;*1b;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
LAMOTRIGINE;UGT1A4;UGT1A4*1b;*1b;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
HALOPERIDOL;CYP2D6;CYP2D6*1;*5 + *10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*5;*5 + *10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*10;*5 + *10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*1;*3 + *4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*3;*3 + *4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*4;*3 + *4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1;*1/*4 + *3/*4;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*3;*1/*4 + *3/*4;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*4;*1/*4 + *3/*4;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA;;;
AZATHIOPRINE;TPMT;TPMT low activity;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
MERCAPTOPURINE;TPMT;TPMT low activity;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
O-DESMETHYLTRAMADOL;SLC22A1;SLC22A1 deficiency;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PAIN;;
MERCAPTOPURINE;TPMT;TPMT intermediate activity;;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
SULFASALAZINE;NAT2;NAT2 slow acetylator;;OTHER;INCREASED_DISCONTINUATION;nan;DISEASE;RHEUMATOID ARTHRITIS;;
FENTANYL;CYP3A4;rs2242480;T/T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;POSTOPERATIVE_PAIN;;
ETHANOL;OPRM1;rs1799971;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
SUFENTANIL;CYP3A4;rs2242480;T/T;EFFICACY;INCREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
SUFENTANIL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
SUFENTANIL;CYP3A4;rs2242480;T/T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PAIN;;
TACROLIMUS;CYP3A4;rs2242480;C/C;OTHER, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
SUFENTANIL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
BETA BLOCKING AGENTS;GRK5;rs4752292;T;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE;;;
INTERFERON BETA-1A;HLA-B;HLA-B*15:01;*15:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;nan;DISEASE;HEART DISEASES;;
RUBELLA VACCINES;HLA-B;HLA-B*35:03;*35:03;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PEGINTERFERON ALFA-2A;HLA-B;HLA-B*38:01;*38:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-B;HLA-B*38:01;*38:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-B;HLA-B*38:01;*38:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);OPRM1;rs671531;GG;EFFICACY;DECREASED_RESPONSE;OTHER;HIV INFECTIOUS DISEASE;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*18;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*18;*1/*18;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CYCLOSPORINE;CYP3A4;CYP3A4*1;*18/*18;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CYCLOSPORINE;CYP3A4;CYP3A4*18;*18/*18;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
METHOTREXATE;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
FENTANYL;CYP3A4;CYP3A4*1;*18/*18;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
FENTANYL;CYP3A4;CYP3A4*18;*18/*18;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
RUBELLA VACCINES;HLA-C;HLA-C*15:02;*15:02;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*01:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*02:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*03:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*04:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*05:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*06:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*07:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*08:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*12:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*14:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*15:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*16:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-C;HLA-C*17:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*01:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*02:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*03:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*04:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*05:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*06:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*07:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*08:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*12:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*14:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*15:02;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*16:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-C;HLA-C*17:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
MEASLES VACCINES;HLA-DQA1;HLA-DQA1*01:04;*01:04;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*01:01;*01:01;EFFICACY;RESPONSE;nan;nan;;;
CYCLOSPORINE;CYP3A4;CYP3A4*1;*1/*1;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CYCLOSPORINE;CYP3A4;CYP3A4*18;*1/*1;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
INTERFERON BETA-1A;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
ADALIMUMAB;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
HEPATITIS VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*08:01;*08:01;EFFICACY;RESPONSE;nan;nan;;;
INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*13:01;*13:01;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP2C8;CYP2C8*1;*1/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP2C8;CYP2C8*3;*1/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
METHOTREXATE;GGH;rs11545078;AA + AG;TOXICITY;INCREASED_DISCONTINUATION;SIDE EFFECT;RHEUMATOID ARTHRITIS;;;
IBUPROFEN;CYP2C8;CYP2C8*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
IBUPROFEN;CYP2C8;CYP2C8*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHADONE;CYP2B6;CYP2B6*1;*1/*6 + *1/*18 + *6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2B6;CYP2B6*5;*1/*6 + *1/*18 + *6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2B6;CYP2B6*6;*1/*6 + *1/*18 + *6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2B6;CYP2B6*7;*1/*6 + *1/*18 + *6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2B6;CYP2B6*18;*1/*6 + *1/*18 + *6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;OTHER;OPIOID-RELATED DISORDERS;;;
DISULFIRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele), HTTLPR short form (S allele) + HTTLPR short form (S allele), L allele-rs25531C + L allele-rs25531C, L allele-rs25531C;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE;;;
DISULFIRAM;SLC6A4;SLC6A4 L allele-rs25531C;HTTLPR short form (S allele), HTTLPR short form (S allele) + HTTLPR short form (S allele), L allele-rs25531C + L allele-rs25531C, L allele-rs25531C;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE;;;
DISULFIRAM;SLC6A4;SLC6A4 L allele-rs25531T;HTTLPR short form (S allele), HTTLPR short form (S allele) + HTTLPR short form (S allele), L allele-rs25531C + L allele-rs25531C, L allele-rs25531C;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE;;;
SERTRALINE;CYP2B6;CYP2B6*1;*1/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2B6;CYP2B6*4;*1/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2B6;CYP2B6*1;*6 + *9;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2B6;CYP2B6*6;*6 + *9;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2B6;CYP2B6*9;*6 + *9;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*1;*2 + *3 + *4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*2;*2 + *3 + *4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*3;*2 + *3 + *4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*4;*2 + *3 + *4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*1;*1/*15;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*15;*1/*15;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;;;
RIFAMPIN;CYP2C9;CYP2C9*1;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER;TUBERCULOSIS;;;
RIFAMPIN;CYP2C9;CYP2C9*2;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER;TUBERCULOSIS;;;
RIFAMPIN;CYP2C9;CYP2C9*3;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER;TUBERCULOSIS;;;
RIFAMPIN;CYP2C9;CYP2C9*11;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER;TUBERCULOSIS;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER;TUBERCULOSIS;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER;TUBERCULOSIS;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER;TUBERCULOSIS;;;
WARFARIN;CYP2C9;CYP2C9*11;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER;TUBERCULOSIS;;;
ACYCLOVIR;NUDT15;NUDT15*1;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ACYCLOVIR;NUDT15;NUDT15*2;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ACYCLOVIR;NUDT15;NUDT15*3;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ACYCLOVIR;NUDT15;NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUVASTATIN;SLCO1B1;SLCO1B1*1;*14;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
FLUVASTATIN;SLCO1B1;SLCO1B1*14;*14;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;DECREASED_METABOLISM;OTHER;POSTOPERATIVE_PAIN;;;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;DECREASED_METABOLISM;OTHER;SCOLIOSIS;;;
METHOTREXATE;SLCO1B1;SLCO1B1*1;*31;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*31;*31;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*37;*31;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*1;*20;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*20;*20;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*37;*20;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
CONJUGATED ESTROGENS;SLCO1B1;rs4149056;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENOPAUSE;;
METHOTREXATE;SLCO1B1;SLCO1B1*1;*23;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*23;*23;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*37;*23;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ACENOCOUMAROL;CYP2C18;rs1998591;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ACENOCOUMAROL;VKORC1;rs9934438;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_RESISTANCE;OTHER;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_RESISTANCE;OTHER;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_RESISTANCE;OTHER;STROKE;;;
METHOTREXATE;SLCO1B1;SLCO1B1*1;*15;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*15;*15;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*37;*15;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ATORVASTATIN;SLCO1B1;SLCO1B1*1;*15;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERCHOLESTEROLEMIA;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*15;*15;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERCHOLESTEROLEMIA;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*37;*15;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERCHOLESTEROLEMIA;;;
ATRASENTAN;SLCO1B1;SLCO1B1*1;*15/*15 + *1/*15 + *15/*37 + *14/*37;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*14;*15/*15 + *1/*15 + *15/*37 + *14/*37;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*15;*15/*15 + *1/*15 + *15/*37 + *14/*37;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*37;*15/*15 + *1/*15 + *15/*37 + *14/*37;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_STEADY-STATE CONCENTRATION;OTHER;TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_STEADY-STATE CONCENTRATION;OTHER;TRANSPLANTATION;;;
3;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CEREBRAL INFARCTION;;;
3;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CEREBRAL INFARCTION;;;
4-DEHYDROCILOSTAZOL;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CEREBRAL INFARCTION;;;
4-DEHYDROCILOSTAZOL;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CEREBRAL INFARCTION;;;
BETA BLOCKING AGENTS;ADRA2C;rs61767072;del;EFFICACY;INCREASED_RESPONSE;OTHER;CARDIOMYOPATHY;;;
BETA BLOCKING AGENTS;ADRA2C;rs61767072;del;EFFICACY;INCREASED_RESPONSE;OTHER;DILATED;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*1;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*1xN;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*3;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*4;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*4xN;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*5;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*10;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*41;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ADHD;;;
DOCETAXEL;SULT1C4;rs1402467;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;SULT1C4;rs1402467;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;DOSAGE;DECREASED_DOSE;OTHER;ADHD;;;
ATOMOXETINE;CYP2C19;CYP2C19*1;*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ADHD;;;
ATOMOXETINE;CYP2C19;CYP2C19*2;*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ADHD;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*17/*17;OTHER;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*17;*17/*17;OTHER;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
CLOMIPRAMINE;CYP2C19;CYP2C19*1;*17/*17;OTHER;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
CLOMIPRAMINE;CYP2C19;CYP2C19*17;*17/*17;OTHER;INCREASED_DISCONTINUATION;OTHER;BIPOLAR_DISORDER;;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*2 + *1/*3 + *1/*5 + *1/*6;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*1/*2 + *1/*3 + *1/*5 + *1/*6;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*2 + *1/*3 + *1/*5 + *1/*6;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*5;*1/*2 + *1/*3 + *1/*5 + *1/*6;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*6;*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*7;*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*1;*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*2;*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*1;*9 +*10 + *14 + *17 + *29 + *41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*9;*9 +*10 + *14 + *17 + *29 + *41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*10;*9 +*10 + *14 + *17 + *29 + *41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*14;*9 +*10 + *14 + *17 + *29 + *41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*17;*9 +*10 + *14 + *17 + *29 + *41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*29;*9 +*10 + *14 + *17 + *29 + *41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*41;*9 +*10 + *14 + *17 + *29 + *41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*1;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEAD AND NECK NEOPLASMS;;;
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*2;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEAD AND NECK NEOPLASMS;;;
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*5;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEAD AND NECK NEOPLASMS;;;
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*10;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEAD AND NECK NEOPLASMS;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VENLAFAXINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
VENLAFAXINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;EFFICACY;INCREASED_RESPONSE;OTHER;ANXIETY DISORDERS;;;
VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;EFFICACY;DECREASED_RESPONSE;OTHER;DEPRESSION;;;
KETOROLAC;CYP2C9;CYP2C9*1;*2 + *3;EFFICACY;INCREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
KETOROLAC;CYP2C9;CYP2C9*2;*2 + *3;EFFICACY;INCREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
KETOROLAC;CYP2C9;CYP2C9*3;*2 + *3;EFFICACY;INCREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
TRAMADOL;CYP2D6;CYP2D6*1;*4;EFFICACY;DECREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
TRAMADOL;CYP2D6;CYP2D6*4;*4;EFFICACY;DECREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
FLUOROURACIL;ERCC1;rs3212948;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;ERCC1;rs3212948;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;ERCC1;rs3212948;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER;PANIC DISORDER;;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER;PANIC DISORDER;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
ENDOXIFEN;CYP3A4;CYP3A4*1;*22/*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ENDOXIFEN;CYP3A4;CYP3A4*22;*22/*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*22;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;CYP3A4*22;*22;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
MIDAZOLAM;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS;;;
MIDAZOLAM;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS;;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*17/*29 + *17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*17/*29 + *17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ENDOXIFEN;CYP2D6;CYP2D6*17;*17/*29 + *17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ENDOXIFEN;CYP2D6;CYP2D6*29;*17/*29 + *17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
LIRAGLUTIDE;GLP1R;rs10305420;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
TAMOXIFEN;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TAMOXIFEN;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
N-DESMETHYLTAMOXIFEN;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
N-DESMETHYLTAMOXIFEN;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TAMOXIFEN;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TAMOXIFEN;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
OXYCODONE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
OXYCODONE;CYP3A4;CYP3A4*1;*22;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
OXYCODONE;CYP3A4;CYP3A4*22;*22;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;LUNG TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;LUNG TRANSPLANTATION;;;
BEVACIZUMAB;CXCL8;rs4073;AA + AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
CYCLOPHOSPHAMIDE;CXCL8;rs4073;AA + AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
NICOTINE;CYP2A6;CYP2A6*1;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DULOXETINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
N-DESMETHYLCLOZAPINE;CYP3A4;CYP3A4 low activity;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;OTHER;INCREASED_DISCONTINUATION;nan;nan;;;
DESVENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2 low activity;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
DESVENLAFAXINE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
DESVENLAFAXINE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSIVE DISORDER;;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*35 + *9/*35 + *17/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*1/*35 + *9/*35 + *17/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*17;*1/*35 + *9/*35 + *17/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*35;*1/*35 + *9/*35 + *17/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DISULFIRAM;ALDH2;ALDH2 deficiency;;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*46 + *46/*46;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*46;*1/*46 + *46/*46;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*2;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*4;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*12;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*17;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*20;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*23;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*24;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*25;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*26;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*27;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*28;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*35;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
NICOTINE;CYP2A6;rs137904044;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*35;*35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs571335587;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs28399454;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs140471703;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs199515342;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs61605570;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs768416963;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs1302192284;C;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs111869995;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs200554095;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs772964366;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs145308399;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs758479488;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs145157460;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs148693084;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs1303839356;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs374515279;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;rs777098658;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;VKORC1;rs11150606;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
NICOTINE;CYP2A6;rs5031016;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*1 + *46 + *9 + *14 + *38;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*2;*1 + *46 + *9 + *14 + *38;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*4;*1 + *46 + *9 + *14 + *38;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*1 + *46 + *9 + *14 + *38;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*14;*1 + *46 + *9 + *14 + *38;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*38;*1 + *46 + *9 + *14 + *38;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*46;*1 + *46 + *9 + *14 + *38;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*1 + *9 + *12 + *38;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*1 + *9 + *12 + *38;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*12;*1 + *9 + *12 + *38;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*38;*1 + *9 + *12 + *38;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*46;*1 + *9 + *12 + *38;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OXALIPLATIN;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;EFFICACY;INCREASED_RESPONSE;OTHER;ANXIETY DISORDERS;;;
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
ENDOXIFEN;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
CLOZAPINE;ABCG2;rs2231142;GT + TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;SCHIZOPHRENIA;;
DOLUTEGRAVIR;UGT1A1;UGT1A1*1;*28/*28 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
DOLUTEGRAVIR;UGT1A1;UGT1A1*6;*28/*28 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
DOLUTEGRAVIR;UGT1A1;UGT1A1*28;*28/*28 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
ASPIRIN;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTIONS AND DRUG-ELUTING STENTS;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTIONS AND DRUG-ELUTING STENTS;;;
(S)-METHADONE;CYP2B6;CYP2B6*1;*6 + *7 + *9 + *18;LADME-PK;DECREASED_CLEARANCE;OTHER;SCOLIOSIS;;;
(S)-METHADONE;CYP2B6;CYP2B6*6;*6 + *7 + *9 + *18;LADME-PK;DECREASED_CLEARANCE;OTHER;SCOLIOSIS;;;
(S)-METHADONE;CYP2B6;CYP2B6*7;*6 + *7 + *9 + *18;LADME-PK;DECREASED_CLEARANCE;OTHER;SCOLIOSIS;;;
(S)-METHADONE;CYP2B6;CYP2B6*9;*6 + *7 + *9 + *18;LADME-PK;DECREASED_CLEARANCE;OTHER;SCOLIOSIS;;;
(S)-METHADONE;CYP2B6;CYP2B6*18;*6 + *7 + *9 + *18;LADME-PK;DECREASED_CLEARANCE;OTHER;SCOLIOSIS;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*1;*1/*3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*3C;*1/*3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*1;*1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
THIOGUANINE;TPMT;TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
NICOTINE;CYP2A6;CYP2A6*1;*4/*4 + *4/*7;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*4;*4/*4 + *4/*7;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*7;*4/*4 + *4/*7;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
HYDRALAZINE;NAT2;NAT2 rapid acetylator;;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;HYPERTENSION;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*13;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*13;*1/*13;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
L-METHYLFOLATE;MTHFR;rs1801133;AG;EFFICACY;INCREASED_RESPONSE;OTHER;BIPOLAR_DISORDER;;;
L-METHYLFOLATE;MTHFR;rs1801133;AG;EFFICACY;INCREASED_RESPONSE;OTHER;DEPRESSION;;;
L-METHYLFOLATE;MTHFR;rs1801133;AG;EFFICACY;INCREASED_RESPONSE;OTHER;OBSESSIVE-COMPULSIVE DISORDER;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA,LYMPHOMA,ACUTE_MYELOID_LEUKEMIA;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA,LYMPHOMA,ACUTE_MYELOID_LEUKEMIA;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA,LYMPHOMA,ACUTE_MYELOID_LEUKEMIA;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERTENSION;;;
VENLAFAXINE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT;;;
ESCITALOPRAM;CYP2C19;CYP2C19 intermediate metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT;;;
SOMATROPIN RECOMBINANT;COL1A1;rs1800012;AA;DOSAGE;DECREASED_DOSE;OTHER;GROWTH HORMONE DEFICIENCY;;;
NICOTINE;CYP2A6;CYP2A6*1;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*2;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*4;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*7;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*10;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*11;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*13;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*15;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*17;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*19;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*20;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TEGAFUR;CYP2A6;CYP2A6*1;*11/*4;LADME-PK;DECREASED_METABOLISM;OTHER;STOMACH NEOPLASMS;;;
TEGAFUR;CYP2A6;CYP2A6*4;*11/*4;LADME-PK;DECREASED_METABOLISM;OTHER;STOMACH NEOPLASMS;;;
TEGAFUR;CYP2A6;CYP2A6*11;*11/*4;LADME-PK;DECREASED_METABOLISM;OTHER;STOMACH NEOPLASMS;;;
LETROZOLE;CYP2A6;CYP2A6*1;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*2;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*4;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*9;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*12;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*17;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*20;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*23;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*35;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
L-METHYLFOLATE;MTHFR;rs1801131;GT;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*46;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*46;*1/*46;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
COUMARIN;CYP2A6;CYP2A6*5;*5/*47;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
COUMARIN;CYP2A6;CYP2A6*47;*5/*47;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*2;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*4;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*12;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*17;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*20;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*23;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*24;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*25;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*26;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*27;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*28;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*35;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*46;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VITAMIN B-COMPLEX;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
INCL. COMBINATIONS;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VITAMIN B-COMPLEX;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
INCL. COMBINATIONS;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
WARFARIN;VKORC1;rs9923231;G;DOSAGE;DOSE;nan;DISEASE;HEART DISEASES;;
ATOMOXETINE;SLC6A2;rs12708954;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
CYCLOSPORINE;CYP3A4;rs2740574;C;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;rs2740574;C;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;KIDNEY TRANSPLANTATION;;;
MERCAPTOPURINE;NUDT15;rs746071566;del;DOSAGE, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RIZATRIPTAN;DRD2;rs6275;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;rs1799853;C;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;VKORC1;rs61162043;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
SULFONAMIDES;CYP2C9;rs1057910;CC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
UREA DERIVATIVES;CYP2C9;rs1057910;CC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
NICOTINE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
RISPERIDONE;DRD3;rs6280;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTISM;;
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SIROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SIROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CYSTEAMINE;CFTR;rs113993960;CTT/del + del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANIC DISORDER;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANIC DISORDER;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANIC DISORDER;;
WARFARIN;CYP2C9;CYP2C9*1;*3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERTENSION;;;
FLUOROURACIL;DPYD;DPYD deficiency;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *1/*3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;TRANSPLANTATION;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *1/*3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;TRANSPLANTATION;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *1/*3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;TRANSPLANTATION;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION;;;
CODEINE;CYP2D6;CYP2D6*17;*17;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ANEMIA, SICKLE CELL;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;DOSAGE;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;DOSAGE;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17 + *1/*2 + *17/*17;DOSAGE;DOSE;nan;DISEASE;CYSTIC FIBROSIS,LUNG TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*17 + *1/*2 + *17/*17;DOSAGE;DOSE;nan;DISEASE;CYSTIC FIBROSIS,LUNG TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17 + *1/*2 + *17/*17;DOSAGE;DOSE;nan;DISEASE;CYSTIC FIBROSIS,LUNG TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*1;*4 + *5 + *6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*4;*4 + *5 + *6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*5;*4 + *5 + *6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*6;*4 + *5 + *6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17 + *1/*2;DOSAGE;DOSE;nan;DISEASE;CYSTIC FIBROSIS,LUNG TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*17 + *17/*17 + *1/*2;DOSAGE;DOSE;nan;DISEASE;CYSTIC FIBROSIS,LUNG TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17 + *1/*2;DOSAGE;DOSE;nan;DISEASE;CYSTIC FIBROSIS,LUNG TRANSPLANTATION;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1 + *1/*17;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1 + *1/*17;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
PANTOPRAZOLE;CYP2C19;CYP2C19*17;*1/*1 + *1/*17;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;GSTM1 non-null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;GSTM1 null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CAPECITABINE;GSTM1;GSTM1 non-null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CAPECITABINE;GSTM1;GSTM1 null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CYCLOPHOSPHAMIDE;GSTM1;GSTM1 non-null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CYCLOPHOSPHAMIDE;GSTM1;GSTM1 null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
FLUOROURACIL;GSTM1;GSTM1 non-null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
FLUOROURACIL;GSTM1;GSTM1 null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TAXANES;GSTM1;GSTM1 non-null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TAXANES;GSTM1;GSTM1 null;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
MIANSERIN;CYP2D6;CYP2D6*1;*1/*10 + *5/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;DEPRESSION;;
MIANSERIN;CYP2D6;CYP2D6*5;*1/*10 + *5/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;DEPRESSION;;
MIANSERIN;CYP2D6;CYP2D6*10;*1/*10 + *5/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;DEPRESSION;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SALVIANOLIC ACID B;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;OTHER;CORONARY DISEASE;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VALPROIC ACID;UGT1A6;UGT1A6*1a;*1a;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;UGT1A6*2a;*1a;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;UGT1A6*3a;*1a;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;UGT1A6*4a;*1a;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;UGT1A6*8;*1a;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;MYASTHENIA GRAVIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;MYASTHENIA GRAVIS;;
VALPROIC ACID;UGT1A6;UGT1A6*1a;*1a;DOSAGE;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;UGT1A6*2a;*1a;DOSAGE;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;UGT1A6*3a;*1a;DOSAGE;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;UGT1A6*4a;*1a;DOSAGE;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;UGT1A6*8;*1a;DOSAGE;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
WARFARIN;CYP2C9;CYP2C9*1;*8/*8;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*8;*8/*8;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LIVER TRANSPLANTATION;;
CYCLOSPORINE;CYP3A4;CYP3A4*1;*1/*1;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CYCLOSPORINE;CYP3A4;CYP3A4*22;*1/*1;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CAPECITABINE;DPYD;rs55886062;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUOROURACIL;DPYD;rs55886062;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
SIROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
SIROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;CYP2D6*1;*4/*4;DOSAGE;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;CYP2D6*4;*4/*4;DOSAGE;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*18;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*18;*18;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TRAMADOL;CYP2D6;CYP2D6*1;*10/*10;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
TRAMADOL;CYP2D6;CYP2D6*10;*10/*10;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
TRAMADOL;CYP2D6;CYP2D6*1;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*3;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*4;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*5;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*10;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
IMIPRAMINE;CYP2C19;CYP2C19*1;*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2C19;CYP2C19*2;*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LOW BACK PAIN,OSTEOARTHRITIS;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
ISONIAZID;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TUBERCULOSIS;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*17;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
PANTOPRAZOLE;CYP2C19;CYP2C19*17;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RABEPRAZOLE;CYP2C19;CYP2C19*17;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CORTICOSTEROIDS;NR1I2;rs3842689;del/del;EFFICACY;INCREASED_RESISTANCE;nan;nan;;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*26;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
MEPHENYTOIN;CYP2C19;CYP2C19*26;*26;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*26;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*26;*26;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
IRBESARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*2 + *3 + *4;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*2 + *3 + *4;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*2 + *3 + *4;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*4;*2 + *3 + *4;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
SIPOGLITAZAR;UGT2B15;UGT2B15*1;*2/*2;EFFICACY, LADME-PK;INCREASED_RESPONSE;nan;nan;;;
SIPOGLITAZAR;UGT2B15;UGT2B15*2;*2/*2;EFFICACY, LADME-PK;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;CYP2B6;CYP2B6*1;*6/*9 + *1/*6 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;CYP2B6;CYP2B6*6;*6/*9 + *1/*6 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;CYP2B6;CYP2B6*9;*6/*9 + *1/*6 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CLOMIPRAMINE;CYP2D6;CYP2D6*1;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;DEPRESSION;;
CLOMIPRAMINE;CYP2D6;CYP2D6*1xN;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;DEPRESSION;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10 + *1/*10;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;BREAST NEOPLASMS;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10 + *1/*10;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;BREAST NEOPLASMS;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;STROKE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;STROKE;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN;*2/*1xN;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2;*2/*1xN;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*26 + *6/*6 + *6/*26;DOSAGE;DECREASED_DOSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*1/*26 + *6/*6 + *6/*26;DOSAGE;DECREASED_DOSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*26;*1/*26 + *6/*6 + *6/*26;DOSAGE;DECREASED_DOSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1 + *1/*2 + *1/*3;EFFICACY;RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*1 + *1/*2 + *1/*3;EFFICACY;RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
PRASUGREL;CYP2C19;CYP2C19*1;*1/*1 + *1/*2 + *1/*3;EFFICACY;RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
PRASUGREL;CYP2C19;CYP2C19*2;*1/*1 + *1/*2 + *1/*3;EFFICACY;RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
PRASUGREL;CYP2C19;CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *17;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *17;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2 + *3 + *17;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
CLOMIPRAMINE;CYP2D6;CYP2D6*1xN;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE;nan;DISEASE;AGORAPHOBIA;;
CLOMIPRAMINE;CYP2D6;CYP2D6*2;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE;nan;DISEASE;AGORAPHOBIA;;
SERTRALINE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*1;*17/*17;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*4;*4/*17 + *9/*26;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*4/*17 + *9/*26;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*17;*4/*17 + *9/*26;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*26;*4/*17 + *9/*26;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SERTRALINE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;STROKE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;STROKE;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*1xN;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2xN;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*3;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*9;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*3/*4 + *4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *3/*4 + *4/*5 + *4/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*4/*4 + *3/*4 + *4/*5 + *4/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*3;*4/*4 + *3/*4 + *4/*5 + *4/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *3/*4 + *4/*5 + *4/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *3/*4 + *4/*5 + *4/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*6;*4/*4 + *3/*4 + *4/*5 + *4/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
MORPHINE;SLC22A1;rs72552763;GAT/del + del/del;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*17;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*3;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
IMATINIB;GSTT1;GSTT1 non-null;null/null;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
IMATINIB;GSTT1;GSTT1 null;null/null;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
GLUCOCORTICOIDS;HSD3B1;rs1047303;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER;ASTHMA;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4xN;*12/*84 + *4xN/*29;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*12;*12/*84 + *4xN/*29;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*29;*12/*84 + *4xN/*29;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*84;*12/*84 + *4xN/*29;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*17/*17;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*1 + *1/*17;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*1 + *1/*17;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*3;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*9;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*17;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
SIMVASTATIN;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;CONCENTRATIONS;nan;nan;;;
SIMVASTATIN;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;CONCENTRATIONS;nan;nan;;;
MORPHINE;SLC22A1;rs72552763;del/del;LADME-PK;DECREASED_CLEARANCE;OTHER;ADENOTONSILLECTOMY;;;
METHOTREXATE;SLCO1B1;SLCO1B1*1;*5;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*5;*5;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*37;*5;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ACUTE CORONARY SYNDROME;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
SILDENAFIL;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEART FAILURE;;
SILDENAFIL;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEART FAILURE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
SN-38;UGT1A1;UGT1A1*1;*28/*28 + *1/*28;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*28;*28/*28 + *1/*28;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs55918055;C;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;nan;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
BILIRUBIN;UGT1A1;UGT1A1*1;*1/*6 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS;;
BILIRUBIN;UGT1A1;UGT1A1*6;*1/*6 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS;;
METHADONE;CYP2C9;CYP2C9*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;CYP2C9;CYP2C9*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;CYP2C9;CYP2C9*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
BILIRUBIN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS;;
BILIRUBIN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS;;
METHADONE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHOTREXATE;SLCO1B1;SLCO1B1*1;*14;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*14;*14;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;SLCO1B1*37;*14;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME-PK;INCREASED_DOSE;nan;nan;;;
SN-38;UGT1A1;UGT1A1*1;*6/*6 + *1/*6;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*6;*6/*6 + *1/*6;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
PAROXETINE;CYP2D6;CYP2D6*1;*1/*1;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;CYP2D6;CYP2D6*1xN;*1/*1;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
VENLAFAXINE;CYP2D6;CYP2D6*1;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*3;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*9;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*10;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*17;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*41;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PACLITAXEL;CYP2C8;CYP2C8*3;*3;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;BREAST NEOPLASMS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
CLOBAZAM;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;METABOLISM;nan;nan;;;
CLOBAZAM;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;METABOLISM;nan;nan;;;
CLOBAZAM;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
GLATIRAMER ACETATE;CCR5;rs333;del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*13 + *1/*16 + *1/*60;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*13 + *1/*16 + *1/*60;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*13;*1/*13 + *1/*16 + *1/*60;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*16;*1/*13 + *1/*16 + *1/*60;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*60;*1/*13 + *1/*16 + *1/*60;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*1;LADME-PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*1;LADME-PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
AZATHIOPRINE;TPMT;TPMT*1;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;CROHN DISEASE;;
AZATHIOPRINE;TPMT;TPMT*3A;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;CROHN DISEASE;;
AZATHIOPRINE;TPMT;TPMT*3C;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;CROHN DISEASE;;
AZATHIOPRINE;TPMT;TPMT*1;*3A/*3A;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;CROHN DISEASE;;
AZATHIOPRINE;TPMT;TPMT*3A;*3A/*3A;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;CROHN DISEASE;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*2 + *3 + *8 + *9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ASTHMA;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*2 + *3 + *8 + *9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ASTHMA;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*2 + *3 + *8 + *9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ASTHMA;;
LANSOPRAZOLE;CYP2C19;CYP2C19*8;*2 + *3 + *8 + *9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ASTHMA;;
LANSOPRAZOLE;CYP2C19;CYP2C19*9;*2 + *3 + *8 + *9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ASTHMA;;
GLIPIZIDE;TCF7L2;rs7903146;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CAROTID ARTERY DISEASES;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CAROTID ARTERY DISEASES;;
CLOPIDOGREL;SLC14A2;rs12456693;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B VIRUS INFECTION;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
CISPLATIN;TPMT;TPMT*3C;*3C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
FLUOROURACIL;TPMT;TPMT*3C;*3C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CAVOSONSTAT;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
BUPROPION;CYP2B6;CYP2B6*6;*6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
RISPERIDONE;CYP2D6;CYP2D6*5;*10 + *5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*10;*10 + *5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOPHRENIA;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2 + *3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2 + *3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*2 + *3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*2 + *3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;nan;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1;*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*4;*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
NEVIRAPINE;NR1I2;rs3842689;GAGAAG/del + del/del;DOSAGE, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
MIDAZOLAM;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MIDAZOLAM;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SN-38;UGT1A1;UGT1A1*1;*6 + *28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;COLORECTAL NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*6;*6 + *28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;COLORECTAL NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*28;*6 + *28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;COLORECTAL NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;DOSAGE;DECREASED_DOSE;nan;DISEASE;TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;DOSAGE;DECREASED_DOSE;nan;DISEASE;TRANSPLANTATION;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
HALOPERIDOL;CYP2D6;CYP2D6*1;*5;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*5;*5;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ULCERATIVE COLITIS;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*8 + *2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*8 + *2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*8 + *2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*1/*2 + *1/*8 + *2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*8 + *2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
MEASLES VACCINES;HLA-B;HLA-B*51:01;*51:01;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
BUCINDOLOL;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;DOSAGE;DECREASED_DOSE;nan;DISEASE;PSYCHOTIC DISORDER;;
MEASLES VACCINES;HLA-B;HLA-B*07:02;*07:02;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
MEASLES VACCINES;HLA-B;HLA-B*13:01;*13:01;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
MEASLES VACCINES;HLA-B;HLA-B*08:01;*08:01;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
INFLUENZA VACCINES;HLA-DQB1;HLA-DQB1*03:03;*03:03;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
MEASLES VACCINES;HLA-DQA1;HLA-DQA1*02:01;*02:01;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*03:01;*03:01;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*20;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
TACROLIMUS;CYP3A4;CYP3A4*20;*1/*20;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
FLUOROURACIL;DPYD;DPYD poor metabolizer;;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS,GASTROINTESTINAL NEOPLASMS,RECTAL NEOPLASMS;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;DOSAGE;INCREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
CISPLATIN;TPMT;TPMT*3B;*3B;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
FLUOROURACIL;TPMT;TPMT*3B;*3B;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*4/*5 + *4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*2;*4/*5 + *4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*5 + *4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*5;*4/*5 + *4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*9;*4/*5 + *4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*10;*4/*5 + *4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SIROLIMUS;ABCB1;rs1128503;GG;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
TEMSIROLIMUS;ABCB1;rs1128503;GG;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;LUNG TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;LUNG TRANSPLANTATION;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*59;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*59;*1/*59;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHADONE;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
GRANISETRON;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
GRANISETRON;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
CODEINE;CYP2D6;CYP2D6*1;*40;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
CODEINE;CYP2D6;CYP2D6*40;*40;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
CODEINE;CYP2D6;CYP2D6*1;*17;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
CODEINE;CYP2D6;CYP2D6*17;*17;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;OTHER;INCREASED_DISCONTINUATION;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;OTHER;INCREASED_DISCONTINUATION;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CODEINE;CYP2D6;CYP2D6*1;*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
CODEINE;CYP2D6;CYP2D6*6;*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
CODEINE;CYP2D6;CYP2D6*1;*4;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
CODEINE;CYP2D6;CYP2D6*4;*4;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
ASPIRIN;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
ASPIRIN;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
ASPIRIN;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
ASPIRIN;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
CODEINE;CYP2D6;CYP2D6*1;*5;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
CODEINE;CYP2D6;CYP2D6*5;*5;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL;;
GRANISETRON;CYP1A1;CYP1A1*1;*2A;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
GRANISETRON;CYP1A1;CYP1A1*2A;*2A;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;RHEUMATOID ARTHRITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;RHEUMATOID ARTHRITIS;;
CLOMIPRAMINE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MENTAL DISORDERS;;
CLOMIPRAMINE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MENTAL DISORDERS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
ROCURONIUM;SLCO1A2;rs7967354;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*1/*2 + *2/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*1/*2 + *2/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*3 + *4 + *5 + *6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENTAL DISORDERS;;
NORTRIPTYLINE;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENTAL DISORDERS;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENTAL DISORDERS;;
NORTRIPTYLINE;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENTAL DISORDERS;;
NORTRIPTYLINE;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENTAL DISORDERS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENTAL DISORDERS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MENTAL DISORDERS;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*11;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
EFAVIRENZ;CYP2B6;CYP2B6*11;*11;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs12208357;T;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;nan;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3 + *2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*3 + *2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3 + *2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MENTAL DISORDERS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MENTAL DISORDERS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
CARVEDILOL;CYP2D6;CYP2D6*3;*3/*10 + *4/*4;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART FAILURE;;
CARVEDILOL;CYP2D6;CYP2D6*4;*3/*10 + *4/*4;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART FAILURE;;
CARVEDILOL;CYP2D6;CYP2D6*10;*3/*10 + *4/*4;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART FAILURE;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
WARFARIN;CYP2C9;CYP2C9*1;*3/*3 + *1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*3 + *1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
WARFARIN;CYP2C9;CYP2C9*1;*58;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*58;*58;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VORICONAZOLE;CYP3A4;CYP3A4*1;*22;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
VORICONAZOLE;CYP3A4;CYP3A4*22;*22;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17;DOSAGE;INCREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17;DOSAGE;INCREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MENTAL DISORDERS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MENTAL DISORDERS;;
IMIPRAMINE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *2/*3 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*3 + *2/*3 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *2/*3 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VARENICLINE;CYP2A6;CYP2A6 normal metabolizer;;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
AZATHIOPRINE;GSTM1;GSTM1 non-null;;LADME-PK;INCREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;GSTM1;GSTM1 null;;LADME-PK;INCREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*12;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*12;*1/*12;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RALOXIFENE;UGT1A8;UGT1A8*1a;*1a/*3;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
RALOXIFENE;UGT1A8;UGT1A8*2;*1a/*3;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
RALOXIFENE;UGT1A8;UGT1A8*3;*1a/*3;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
PHENAZEPAM;CYP2C19;CYP2C19*1;*17;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ALCOHOL ABUSE;;;
PHENAZEPAM;CYP2C19;CYP2C19*1;*17;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ANXIETY DISORDERS;;;
PHENAZEPAM;CYP2C19;CYP2C19*17;*17;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ALCOHOL ABUSE;;;
PHENAZEPAM;CYP2C19;CYP2C19*17;*17;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ANXIETY DISORDERS;;;
DAUNORUBICIN;G6PD;G6PD Mediterranean;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DAUNORUBICIN;G6PD;Dallas;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DAUNORUBICIN;G6PD;Panama;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DAUNORUBICIN;G6PD;Sassari;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DAUNORUBICIN;G6PD;Cagliari;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DAUNORUBICIN;G6PD;Birmingham;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*5;*5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*6;*5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*11;*5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
DOLUTEGRAVIR;UGT1A1;UGT1A1*1;*28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
DOLUTEGRAVIR;UGT1A1;UGT1A1*6;*28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
DOLUTEGRAVIR;UGT1A1;UGT1A1*28;*28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
DOLUTEGRAVIR;UGT1A1;UGT1A1*36;*28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
DOLUTEGRAVIR;UGT1A1;UGT1A1*37;*28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
NICOTINE;CYP2B6;CYP2B6*1;*6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2B6;CYP2B6*6;*6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3C;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
DIMETHYL FUMARATE;GSTP1;rs1695;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
MERCAPTOPURINE;TPMT;TPMT*3A;*3A/*3A;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
VENLAFAXINE;CYP2D6;CYP2D6*1;*1/*3 + *1/*4 + *1/*5;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*3;*1/*3 + *1/*4 + *1/*5;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*1/*3 + *1/*4 + *1/*5;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*5;*1/*3 + *1/*4 + *1/*5;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ULCERATIVE COLITIS;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *1/*3C + *3A/*3A;OTHER;INCREASED_DISCONTINUATION;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *1/*3C + *3A/*3A;OTHER;INCREASED_DISCONTINUATION;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;OTHER;INCREASED_DISCONTINUATION;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3 + *5 + *8 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3 + *5 + *8 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3 + *5 + *8 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*5;*2 + *3 + *5 + *8 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*8;*2 + *3 + *5 + *8 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*11;*2 + *3 + *5 + *8 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LOW BACK PAIN,OSTEOARTHRITIS;;
TOREMIFENE;CYP2D6;CYP2D6*10;*10;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BREAST NEOPLASMS;;;
PRIMAQUINE;CYP2D6;CYP2D6*1;*4/*41 + *5/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*4;*4/*41 + *5/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*5;*4/*41 + *5/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*6;*4/*41 + *5/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*10;*4/*41 + *5/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*41;*4/*41 + *5/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
TAMOXIFEN;CYP2C19;CYP2C19*1;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
TAMOXIFEN;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs34059508;A;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;OTHER;INCREASED_RESISTANCE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;OTHER;INCREASED_RESISTANCE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CAPECITABINE;TYMP;rs11479;AA + AG;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;TYMP;rs11479;AA + AG;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;nan;DISEASE;ATRIAL FIBRILLATION,PULMONARY EMBOLISM,STROKE,VENOUS THROMBOSIS;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
DOXEPIN;CYP2D6;CYP2D6*3;*3/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DOXEPIN;CYP2D6;CYP2D6*4;*3/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PHENYTOIN;CYP2C19;CYP2C19*2;*2 + *3;DOSAGE;DOSE;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP2C19;CYP2C19*3;*2 + *3;DOSAGE;DOSE;nan;DISEASE;EPILEPSY;;
CLOZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOZAPINE;SLC6A4;SLC6A4 L allele-rs25531C;HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOZAPINE;SLC6A4;SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;nan;DISEASE;EPILEPSY;;
ANTIPSYCHOTICS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
OLANZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
OLANZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
FOLIC ACID;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
FOLIC ACID;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
HYDROXYCHLOROQUINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
HYDROXYCHLOROQUINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
SULFASALAZINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
SULFASALAZINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
FLUVASTATIN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
ONDANSETRON;CYP2D6;CYP2D6*1;*1/*1xN;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ONDANSETRON;CYP2D6;CYP2D6*1xN;*1/*1xN;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
INTERFERON ALFA-2A;HLA-B;HLA-B*44:02;*44:02;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RECOMBINANT;HLA-B;HLA-B*44:02;*44:02;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-B;HLA-B*44:02;*44:02;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ONDANSETRON;CYP2D6;CYP2D6*1;*1/*1xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NEOPLASMS;;
ONDANSETRON;CYP2D6;CYP2D6*1xN;*1/*1xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NEOPLASMS;;
TROPISETRON;CYP2D6;CYP2D6*1;*1/*1xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NEOPLASMS;;
TROPISETRON;CYP2D6;CYP2D6*1xN;*1/*1xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NEOPLASMS;;
CYCLOSPORINE;CYP3A5;CYP3A5*1;*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
CYCLOSPORINE;CYP3A5;CYP3A5*3;*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
PRAVASTATIN;ACE;rs1799752;del/del;EFFICACY;RESPONSE;OTHER;NON-HYPERCHOLESTEROLAEMIC PATIENTS SCHEDULED FOR ANGIOPLASTY;;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*2 + *1/*3 + *1/*4 + *1/*6;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*1/*2 + *1/*3 + *1/*4 + *1/*6;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*2 + *1/*3 + *1/*4 + *1/*6;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*4;*1/*2 + *1/*3 + *1/*4 + *1/*6;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*18;*1/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*9;*1/*9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CAPECITABINE;DPYD;rs3918290;CT;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;DPYD;rs3918290;CT;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
(S)-METHADONE;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
(S)-METHADONE;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
METOPROLOL;ADRA2C;rs61767072;del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
ENDOXIFEN;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
IMATINIB;ABCG2;rs2231142;GT + TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;GASTROINTESTINAL STROMAL TUMORS;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CAPECITABINE;DPYD;rs67376798;AT;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;DPYD;rs67376798;AT;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;LADME-PK;DECREASED_METABOLISM;OTHER;LUNG TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;LADME-PK;DECREASED_METABOLISM;OTHER;LUNG TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*6;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;LADME-PK;DECREASED_METABOLISM;OTHER;LUNG TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*7;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;LADME-PK;DECREASED_METABOLISM;OTHER;LUNG TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
GEFITINIB;EGFR;rs121434568;GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
VINCRISTINE;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
VINCRISTINE;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*9/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*9;*9/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*9/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*9/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*1/*4 + *1/*5 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*1/*4 + *1/*5 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*1/*4 + *1/*5 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*6;*1/*4 + *1/*5 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*9/*41 + *10/*10 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*9;*9/*41 + *10/*10 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*9/*41 + *10/*10 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*9/*41 + *10/*10 + *41/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*1/*9 + *1/*10 + *1/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*9;*1/*9 + *1/*10 + *1/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*1/*9 + *1/*10 + *1/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*1/*9 + *1/*10 + *1/*41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*1/*81;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*81;*1/*81;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CAPECITABINE;DPYD;rs75017182;CG;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;DPYD;rs75017182;CG;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
SIROLIMUS;NR1I2;rs6785049;GG;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
TEMSIROLIMUS;NR1I2;rs6785049;GG;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;;
TACROLIMUS;nan;rs4646458;G;DOSAGE;DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*3;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*5;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ROCURONIUM;IAPP;rs11045995;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ROCURONIUM;SLCO1A2;rs11045995;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
MEASLES VACCINES;HLA-B;HLA-B*44:02;*44:02;EFFICACY;RESPONSE;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*3 + *4 + *5 + *6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN;*2/*1xN;LADME-PK;INCREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2;*2/*1xN;LADME-PK;INCREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY;;
METOPROLOL;CYP2D6;rs5030655;del/del;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
AMOXICILLIN;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
AMOXICILLIN;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
AMOXICILLIN;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;RESPONSE;nan;nan;;;
AMOXICILLIN;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
AMOXICILLIN;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
AMOXICILLIN;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*2/*3;TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*2/*3;TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*2/*3;TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*2 + *1/*3 + *1/*5;TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*1/*2 + *1/*3 + *1/*5;TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*2 + *1/*3 + *1/*5;TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;NUDT15;NUDT15*5;*1/*2 + *1/*3 + *1/*5;TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
HMG COA REDUCTASE INHIBITORS;CXCL5;rs352046;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
AMOXICILLIN;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
AMOXICILLIN;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
AMOXICILLIN;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;DOSAGE, LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;DOSAGE, LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
DEBRISOQUINE;CYP2D6;CYP2D6*3;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEBRISOQUINE;CYP2D6;CYP2D6*4;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEBRISOQUINE;CYP2D6;CYP2D6*5;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEBRISOQUINE;CYP2D6;CYP2D6*6;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEBRISOQUINE;CYP2D6;CYP2D6*15;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LEUKEMIA;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LEUKEMIA;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*3;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*5;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*6;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*15;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ATAZANAVIR;UGT1A1;UGT1A1*36;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RITONAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RITONAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RITONAVIR;UGT1A1;UGT1A1*36;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*5;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*6;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*11;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*5;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*6;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*8;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*9;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*11;*2 + *6 + *5 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CYCLOSPORINE;CYP3A5;CYP3A5*1;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CYCLOSPORINE;CYP3A5;CYP3A5*3;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
ENDOXIFEN;CYP2D6;CYP2D6*1;*4 + *6 + *8;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*4 + *6 + *8;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6*6;*4 + *6 + *8;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6*8;*4 + *6 + *8;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
METFORMIN;CSMD1;rs2954625;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;OTHER;HIV INFECTIOUS DISEASE;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;OTHER;HIV INFECTIOUS DISEASE;;;
RITONAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;OTHER;HIV INFECTIOUS DISEASE;;;
RITONAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;OTHER;HIV INFECTIOUS DISEASE;;;
ESTRONE;SLCO1B1;SLCO1B1*1;*5/*5;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ESTRONE;SLCO1B1;SLCO1B1*5;*5/*5;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
VORICONAZOLE;ABCB1;rs1045642;AA;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;nan;;;
MERCAPTOPURINE;NT5C2;rs72846714;AA + AG;LADME-PK;DECREASED_METABOLISM;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
HALOPERIDOL;CYP2D6;CYP2D6*1;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*2;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOPHRENIA;;
CYCLOSPORINE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CYCLOSPORINE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
IRINOTECAN;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TEGAFUR;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
GIMERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OTERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*8 + *8/*8;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;CYP2C9;CYP2C9*8;*1/*8 + *8/*8;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
ENDOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2xN;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*3;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*9;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*17;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*29;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*35;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
AZATHIOPRINE;TPMT;TPMT*1;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;TPMT;TPMT*2;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;TPMT;TPMT*3A;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;TPMT;TPMT*3B;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;TPMT;TPMT*3C;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*1;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*2;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*3A;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*3B;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*3C;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*1;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*2;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*3A;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*3B;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*3C;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
SERTRALINE;CYP2C18;rs11188059;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
IRINOTECAN;CYP2A6;CYP2A6*1;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;CYP2A6;CYP2A6*4;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;CYP2A6;CYP2A6*7;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;CYP2A6;CYP2A6*9;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;CYP2A6;CYP2A6*1;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;CYP2A6;CYP2A6*4;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;CYP2A6;CYP2A6*7;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;CYP2A6;CYP2A6*9;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TEGAFUR;CYP2A6;CYP2A6*1;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TEGAFUR;CYP2A6;CYP2A6*4;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TEGAFUR;CYP2A6;CYP2A6*7;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TEGAFUR;CYP2A6;CYP2A6*9;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
GIMERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
GIMERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
GIMERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
GIMERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OTERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OTERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OTERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OTERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
DONEPEZIL;CYP2D6;CYP2D6*4;*4/*4 + *4/*5;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ALZHEIMER DISEASE;;
DONEPEZIL;CYP2D6;CYP2D6*5;*4/*4 + *4/*5;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ALZHEIMER DISEASE;;
DEBRISOQUINE;CYP2D6;CYP2D6*4;*4/*17;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEBRISOQUINE;CYP2D6;CYP2D6*17;*4/*17;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6 high activity;;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;TPMT;TPMT*2;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*1;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*2;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
PURINE ANALOGUES;TPMT;TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
FENTANYL;CYP2D6;CYP2D6*1;*29;LADME-PK;DECREASED_CLEARANCE;OTHER;BURNS;;;
FENTANYL;CYP2D6;CYP2D6*29;*29;LADME-PK;DECREASED_CLEARANCE;OTHER;BURNS;;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*1xN;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2xN;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*3;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*9;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*35;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4xN;*4xN/*56;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*56;*4xN/*56;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
LEVONORGESTREL;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
ADALIMUMAB;nan;rs9828223;T;EFFICACY;DECREASED_RESPONSE;OTHER;CROHN DISEASE;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;OTHER;COLORECTAL NEOPLASMS;;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PROGESTERONE;CYP2C19;CYP2C19*1;*1/*2 + *2/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
PROGESTERONE;CYP2C19;CYP2C19*2;*1/*2 + *2/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
PROGESTERONE;CYP2C19;CYP2C19*17;*1/*2 + *2/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3 + *6 + *7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*6;*3 + *6 + *7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*7;*3 + *6 + *7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DONEPEZIL;CYP2D6;CYP2D6*1;*1/*1xN + *1xN/*1xN;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ALZHEIMER DISEASE;;
DONEPEZIL;CYP2D6;CYP2D6*1xN;*1/*1xN + *1xN/*1xN;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ALZHEIMER DISEASE;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1;*1/*6 + *6/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*6;*1/*6 + *6/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
FLUDARABINE;CYP2B6;CYP2B6*1;*1/*6 + *6/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
FLUDARABINE;CYP2B6;CYP2B6*6;*1/*6 + *6/*6;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
LEVONORGESTREL;CYP2B6;rs4803419;CT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
MERCAPTOPURINE;TPMT;TPMT poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ATORVASTATIN;IFNL3;rs12979860;CC;EFFICACY;DECREASED_CLEARANCE;nan;nan;;;
ATORVASTATIN;IFNL4;rs12979860;CC;EFFICACY;DECREASED_CLEARANCE;nan;nan;;;
SORAFENIB;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;NEOPLASMS;;
SORAFENIB;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;NEOPLASMS;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3B;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CLOBAZAM;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*2;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
OMEPRAZOLE;CYP2C19;CYP2C19*17;*2;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
ATENOLOL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;KIDNEY DISORDER;;
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;KIDNEY DISORDER;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3C + *1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*3C + *1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3C + *1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3C + *1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
CLOBAZAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
BREXPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA;;;
CLOBAZAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
LOPINAVIR;CYP3A4;CYP3A4*1;*22/*22;LADME-PK;DECREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;;;
LOPINAVIR;CYP3A4;CYP3A4*22;*22/*22;LADME-PK;DECREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;;;
CLOBAZAM;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
NICOTINE;CYP2A6;CYP2A6*1;*4/*9 + *9/*9;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*4;*4/*9 + *9/*9;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*4/*9 + *9/*9;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOBAZAM;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
EFAVIRENZ;ABCB1;rs3842;C;LADME-PK;METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOBAZAM;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;METABOLISM;nan;DISEASE;EPILEPSY;;
CITALOPRAM;SERPINE1;rs2227631;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SERPINE1;rs2227631;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PHENYTOIN;CYP2C9;rs12782374;AG;OTHER, LADME-PK;INCREASED_METABOLISM;nan;nan;;;
PHENYTOIN;CYP2C9;rs71486745;GT/del + del/del;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
ATENOLOL;SLC25A31;rs201279313;TTA/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;SLC25A31;rs201279313;TTA/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
METOPROLOL;SLC25A31;rs201279313;TTA/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28;DOSAGE;DECREASED_DOSE;OTHER;ADENOCARCINOMA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28;DOSAGE;DECREASED_DOSE;OTHER;GASTROINTESTINAL NEOPLASMS;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28;DOSAGE;DECREASED_DOSE;OTHER;ADENOCARCINOMA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28;DOSAGE;DECREASED_DOSE;OTHER;GASTROINTESTINAL NEOPLASMS;;;
TEGAFUR;CYP2A6;CYP2A6*1;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;BILIARY TRACT NEOPLASM;;
TEGAFUR;CYP2A6;CYP2A6*4;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;BILIARY TRACT NEOPLASM;;
TEGAFUR;CYP2A6;CYP2A6*7;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;BILIARY TRACT NEOPLASM;;
TEGAFUR;CYP2A6;CYP2A6*9;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;BILIARY TRACT NEOPLASM;;
TEGAFUR;CYP2A6;CYP2A6*10;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;BILIARY TRACT NEOPLASM;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*6;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TAMOXIFEN;CYP2C19;CYP2C19*1;*17;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TAMOXIFEN;CYP2C19;CYP2C19*17;*17;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*1;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*1;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TAMOXIFEN;CYP2C19;CYP2C19*1;*2;EFFICACY, LADME-PK;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TAMOXIFEN;CYP2C19;CYP2C19*2;*2;EFFICACY, LADME-PK;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
MERCAPTOPURINE;CNNM2;rs58700372;CC + CT;LADME-PK;DECREASED_METABOLISM;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
OXYCODONE;CYP3A5;CYP3A5*1;*3/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;NEOPLASMS;;
OXYCODONE;CYP3A5;CYP3A5*3;*3/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*1 + *1/*17;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOLOGIC DISORDER;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*1 + *1/*17;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOLOGIC DISORDER;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*1 + *1/*17;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOLOGIC DISORDER;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*1 + *1/*17;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOLOGIC DISORDER;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENYTOIN;CYP2C9;CYP2C9*2;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PRIMAQUINE;CYP2D6;CYP2D6*1;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*2;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*4;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*9;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*10;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*41;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENYTOIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENYTOIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PRIMAQUINE;CYP2D6;CYP2D6*1;*4/*41 + *5/*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*4;*4/*41 + *5/*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*5;*4/*41 + *5/*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*6;*4/*41 + *5/*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*10;*4/*41 + *5/*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*41;*4/*41 + *5/*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MALARIA;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3C;DOSAGE, TOXICITY;INCREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3C;DOSAGE, TOXICITY;INCREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 deficiency;;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;PAIN;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*10/*10 + *5/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*10/*10 + *5/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*10/*10 + *5/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
TACROLIMUS;CYP3A7;CYP3A7*1A;*1A/*1A;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A7;CYP3A7*1C;*1A/*1A;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
KETAMINE;CYP2B6;CYP2B6*1;*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NEOPLASMS,PAIN;;
KETAMINE;CYP2B6;CYP2B6*6;*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NEOPLASMS,PAIN;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOMIPRAMINE;CYP3A5;CYP3A5*1;*1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
CLOMIPRAMINE;CYP3A5;CYP3A5*3;*1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;CHRONIC GRANULOMATOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;CHRONIC GRANULOMATOUS DISEASE;;
CLOMIPRAMINE;CYP2C19;CYP2C19*1;*1/*17;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
CLOMIPRAMINE;CYP2C19;CYP2C19*17;*1/*17;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
CAPECITABINE;DPYD;rs3918290;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUOROURACIL;DPYD;rs3918290;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ETHANOL;DRD2;rs1800497;A;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
VARDENAFIL;CYP3A5;rs776746;TT;OTHER, LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
ETHANOL;OPRM1;rs1799971;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
IMATINIB;SLC22A1;rs683369;CC;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
CAPECITABINE;DPYD;rs56038477;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUOROURACIL;DPYD;rs56038477;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
ACETAMINOPHEN;UGT1A6;UGT1A6*1a;*2a;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
ACETAMINOPHEN;UGT1A6;UGT1A6*2a;*2a;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
CAPECITABINE;DPYD;rs67376798;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUOROURACIL;DPYD;rs67376798;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,ATRIAL FLUTTER,VENOUS THROMBOSIS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,ATRIAL FLUTTER,VENOUS THROMBOSIS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
HALOPERIDOL;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
METHADONE;OPRK1;rs3802281;TT;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
AZATHIOPRINE;TPMT;rs1142345;CT;DOSAGE;DECREASED_DOSE;OTHER;ULCERATIVE COLITIS;;;
AZATHIOPRINE;TPMT;rs1142345;CT;DOSAGE;DECREASED_DOSE;OTHER;CROHN DISEASE;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DEBRISOQUINE;CYP2D6;CYP2D6*17;*17/*17;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TOLTERODINE;CYP2D6;CYP2D6*1;*3 + *4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TOLTERODINE;CYP2D6;CYP2D6*3;*3 + *4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TOLTERODINE;CYP2D6;CYP2D6*4;*3 + *4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CITALOPRAM;CYP2D6;CYP2D6*1xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
CITALOPRAM;CYP2D6;CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
MIANSERIN;CYP2D6;CYP2D6*1xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
MIANSERIN;CYP2D6;CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
MIRTAZAPINE;CYP2D6;CYP2D6*1xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
MIRTAZAPINE;CYP2D6;CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
PAROXETINE;CYP2D6;CYP2D6*1xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
PAROXETINE;CYP2D6;CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*1xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
SPARTEINE;CYP2D6;CYP2D6*1;*10/*10 + *4/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SPARTEINE;CYP2D6;CYP2D6*4;*10/*10 + *4/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SPARTEINE;CYP2D6;CYP2D6*10;*10/*10 + *4/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;AUTOIMMUNE DISEASES;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;AUTOIMMUNE DISEASES;;
HYDROXYUREA;SIN3A;rs7166737;GG;EFFICACY;DECREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HELICOBACTER INFECTIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*6;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*1/*6;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799964;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SPONDYLITIS, ANKYLOSING;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*1;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DOSE;nan;DISEASE;ATRIAL FIBRILLATION,VENOUS THROMBOEMBOLISM;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DOSE;nan;DISEASE;ATRIAL FIBRILLATION,VENOUS THROMBOEMBOLISM;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;G/TT + TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs11322783;G/TT + TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT;;;
DEBRISOQUINE;CYP2D6;CYP2D6*3;*4/*4 + *3/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEBRISOQUINE;CYP2D6;CYP2D6*4;*4/*4 + *3/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SPARTEINE;CYP2D6;CYP2D6*3;*4/*4 + *3/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SPARTEINE;CYP2D6;CYP2D6*4;*4/*4 + *3/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19 normal metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*3;TOXICITY;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*3;TOXICITY;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENYTOIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1;*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;LYMPHOMA, B-CELL;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*6;*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;LYMPHOMA, B-CELL;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER;POSTTRAUMATIC STRESS DISORDER;;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER;POSTTRAUMATIC STRESS DISORDER;;;
MIDAZOLAM;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;GASTROINTESTINAL NEOPLASMS;;
MIDAZOLAM;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;GASTROINTESTINAL NEOPLASMS;;
BUPROPION;HTR2A;rs2770296;CC;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
CAPECITABINE;HLA-G;rs371194629;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;HLA-G;rs371194629;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19 ultrarapid metabolizer;*1/*17 + *17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer;*2/*2 + *2/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS;;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS;;;
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;CYP2C9*1;*2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
DONEPEZIL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ALZHEIMER DISEASE;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
FLUOXETINE;ABCB1;rs2032582;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *4/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *4/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *4/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *4/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *4/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *4/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
BUPROPION;CYP2B6;CYP2B6*1;*1/*6 + *6/*6;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
BUPROPION;CYP2B6;CYP2B6*6;*1/*6 + *6/*6;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
COLCHICINE;CYP2D6;CYP2D6*1;*1/*1;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;FAMILIAL MEDITERRANEAN FEVER;;
COLCHICINE;CYP2D6;CYP2D6*4;*1/*1;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;FAMILIAL MEDITERRANEAN FEVER;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TEGAFUR;CYP2A6;CYP2A6*1;*1/*4 + *4/*4 + *4/*7 + *4/*9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
TEGAFUR;CYP2A6;CYP2A6*4;*1/*4 + *4/*4 + *4/*7 + *4/*9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
TEGAFUR;CYP2A6;CYP2A6*7;*1/*4 + *4/*4 + *4/*7 + *4/*9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
TEGAFUR;CYP2A6;CYP2A6*9;*1/*4 + *4/*4 + *4/*7 + *4/*9;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
AZATHIOPRINE;GSTM1;GSTM1 non-null;;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ULCERATIVE COLITIS;;;
AZATHIOPRINE;GSTM1;GSTM1 non-null;;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CROHN DISEASE;;;
AZATHIOPRINE;GSTM1;GSTM1 null;;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ULCERATIVE COLITIS;;;
AZATHIOPRINE;GSTM1;GSTM1 null;;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CROHN DISEASE;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*10 + *5/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*2;*4/*10 + *5/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*10 + *5/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4/*10 + *5/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*4/*10 + *5/*10;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
OXYCODONE;CYP2D6;CYP2D6*4;*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
NILOTINIB;UGT1A1;UGT1A1*1;*6/*6 + *6/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
NILOTINIB;UGT1A1;UGT1A1*6;*6/*6 + *6/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
NILOTINIB;UGT1A1;UGT1A1*27;*6/*6 + *6/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
NILOTINIB;UGT1A1;UGT1A1*28;*6/*6 + *6/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*5;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHADONE;CYP2B6;CYP2B6*1;*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
METHADONE;CYP2B6;CYP2B6*6;*6;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
BUPROPION;DBH;rs2873804;CC;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;RHEUMATOID ARTHRITIS,SYSTEMIC LUPUS ERYTHEMATOSUS;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NEOPLASM OF ESOPHAGUS,STOMACH NEOPLASMS;;
LEUCOVORIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NEOPLASM OF ESOPHAGUS,STOMACH NEOPLASMS;;
OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NEOPLASM OF ESOPHAGUS,STOMACH NEOPLASMS;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION;;;
PACLITAXEL;GSTM1;GSTM1 non-null;non-null;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
PACLITAXEL;GSTM1;GSTM1 null;non-null;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
PLATINUM COMPOUNDS;GSTM1;GSTM1 non-null;non-null;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
PLATINUM COMPOUNDS;GSTM1;GSTM1 null;non-null;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
WARFARIN;CYP2C9;CYP2C9*1;*3/*13;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*13;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*13;*3/*13;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
BLEOMYCIN;GSTM1;GSTM1 non-null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HODGKIN DISEASE;;
BLEOMYCIN;GSTM1;GSTM1 null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HODGKIN DISEASE;;
DACARBAZINE;GSTM1;GSTM1 non-null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HODGKIN DISEASE;;
DACARBAZINE;GSTM1;GSTM1 null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HODGKIN DISEASE;;
DOXORUBICIN;GSTM1;GSTM1 non-null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HODGKIN DISEASE;;
DOXORUBICIN;GSTM1;GSTM1 null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HODGKIN DISEASE;;
VINBLASTINE;GSTM1;GSTM1 non-null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HODGKIN DISEASE;;
VINBLASTINE;GSTM1;GSTM1 null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HODGKIN DISEASE;;
METHADONE;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
S-EDDP;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
S-EDDP;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CITALOPRAM;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
LISINOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
BUPROPION;SLC18A2;rs363225;CC;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
RALTEGRAVIR;UGT1A9;UGT1A9*3a;*3a;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*2 + *1/*9;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*2;*1/*2 + *1/*9;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*1/*2 + *1/*9;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SERTRALINE;CYP2C18;rs2860840;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DOSE;nan;DISEASE;HEART DISEASES;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;RHEUMATIC HEART DISEASE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;RHEUMATIC HEART DISEASE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;nan;DISEASE;RHEUMATIC HEART DISEASE;;
ARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
4-HYDROXYTAMOXIFEN;CYP3A4;CYP3A4*1;*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
4-HYDROXYTAMOXIFEN;CYP3A4;CYP3A4*22;*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
TAMOXIFEN;CYP3A4;CYP3A4*1;*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
TAMOXIFEN;CYP3A4;CYP3A4*22;*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;OTHER;RECTAL NEOPLASMS;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*14;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*14;*1/*14;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SPONDYLITIS, ANKYLOSING;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACETYLCYSTEINE;EPHX1;EPHX1 poor metabolizer;;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;;
BUPROPION;SLC18A2;rs363226;GG;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ISONIAZID;NAT2;NAT2*4;*4;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
LEVODOPA;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PARKINSON DISEASE;;
METHYLPHENIDATE;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PARKINSON DISEASE;;
ATOMOXETINE;CYP2D6;CYP2D6*1;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*2;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*3;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*4;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*4xN;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*5;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*9;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*29;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*41;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ADHD;;
WARFARIN;CYP2C9;CYP2C9*1;*3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
LEVODOPA;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PARKINSON DISEASE;;
WARFARIN;CYP2C9;CYP2C9*1;*2/*3;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*3;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*3;*2/*3;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
FLUOROURACIL;DPYD;DPYD deficiency;;LADME-PK;CLEARANCE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
ATOMOXETINE;CYP2D6;CYP2D6*1;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*2;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*3;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*4;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*4xN;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*5;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*9;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*17;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*29;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
ATOMOXETINE;CYP2D6;CYP2D6*41;*4/*4xN + *4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ADHD;;
BUPROPION;FKBP5;rs17614642;TT;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
INTERFERON BETA-1A;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
ETHANOL;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;EPHX1;rs2260863;CG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LUNG TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LUNG TRANSPLANTATION;;
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESOPHAGITIS,GASTROESOPHAGEAL REFLUX;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESOPHAGITIS,GASTROESOPHAGEAL REFLUX;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESOPHAGITIS,GASTROESOPHAGEAL REFLUX;;
LOSARTAN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
TACROLIMUS;CYP3A4;rs35599367;GG;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
THALIDOMIDE;CYP2C19;CYP2C19*1;*2;DOSAGE;INCREASED_DOSE;nan;DISEASE;ERYTHEMA NODOSUM,LEPROSY;;
THALIDOMIDE;CYP2C19;CYP2C19*2;*2;DOSAGE;INCREASED_DOSE;nan;DISEASE;ERYTHEMA NODOSUM,LEPROSY;;
CARVEDILOL;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ANGINA PECTORIS;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*1;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, LADME-PK;DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_DOSE;OTHER;VENOUS THROMBOSIS;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;OTHER;VENOUS THROMBOSIS;;;
WARFARIN;CYP2C9;CYP2C9*8;*8;DOSAGE, LADME-PK;DOSE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
DIHYDROCODEINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DIHYDROCODEINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3 + *1/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3 + *1/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*6;*1/*1 + *1/*3 + *1/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
NICOTINE;CYP2A6;CYP2A6 low activity;;DOSAGE;DECREASED_DOSE;nan;DISEASE;TOBACCO USE DISORDER;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
IMATINIB;CYP3A5;rs776746;CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
PACLITAXEL;SLCO1B1;SLCO1B1*5;*5 + *15;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;BREAST NEOPLASMS;;
PACLITAXEL;SLCO1B1;SLCO1B1*15;*5 + *15;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;BREAST NEOPLASMS;;
IMIPRAMINE;CYP2C19;CYP2C19*1;*2/*3 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2C19;CYP2C19*2;*2/*3 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2C19;CYP2C19*3;*2/*3 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LAMOTRIGINE;UGT2B7;rs7668258;CC;DOSAGE, LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
BUPRENORPHINE;UGT2B7;UGT2B7;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PAIN;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;DOSAGE;INCREASED_DOSE;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;DOSAGE;INCREASED_DOSE;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
IMATINIB;ABCB1;rs1045642;AG;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;CONCENTRATIONS;nan;DISEASE;BREAST NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEPATITIS C VIRUS INFECTION,LYMPHOMA,SHOCK, SEPTIC;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEPATITIS C VIRUS INFECTION,LYMPHOMA,SHOCK, SEPTIC;;
NELFINAVIR;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NELFINAVIR;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
HYDROXYBUPROPION;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
HYDROXYBUPROPION;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
NELFINAVIR;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PANCREATIC NEOPLASMS;;
NELFINAVIR;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PANCREATIC NEOPLASMS;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
BUPROPION;CYP2B6;CYP2B6*1;*1/*6 + *1/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*4;*1/*6 + *1/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*5;*1/*6 + *1/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*6;*1/*6 + *1/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*18;*1/*6 + *1/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*22;*1/*6 + *1/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
TEZACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
BUPROPION;CYP2B6;CYP2B6*1;*6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*4;*6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*5;*6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*6;*6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*18;*6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
BUPROPION;CYP2B6;CYP2B6*22;*6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
IVACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
TEZACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
WARFARIN;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
WARFARIN;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
WARFARIN;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
WARFARIN;CYP2C19;CYP2C19*1;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
WARFARIN;CYP2C19;CYP2C19*2;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
WARFARIN;CYP2C19;CYP2C19*3;*1/*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3 + *1/*6;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3 + *1/*6;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*6;*1/*1 + *1/*3 + *1/*6;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer;;DOSAGE;DECREASED_DOSE;nan;DISEASE;ADHD;;
GEMCITABINE;CDA;rs60369023;A;OTHER, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
APIXABAN;ABCB1;rs1045642;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;THROMBOEMBOLISM;;;
DABIGATRAN;ABCB1;rs1045642;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;THROMBOEMBOLISM;;;
EDOXABAN;ABCB1;rs1045642;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;THROMBOEMBOLISM;;;
RIVAROXABAN;ABCB1;rs1045642;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;THROMBOEMBOLISM;;;
ATAZANAVIR;NR1I2;rs2472677;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
IMATINIB;ABCB1;rs2032582;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
IMATINIB;ABCB1;rs2032582;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
ANTIDEPRESSANTS;FKBP5;rs1360780;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMATINIB;ABCB1;rs1128503;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
IMATINIB;ABCB1;rs1128503;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
ANTIDEPRESSANTS;GNB3;rs5443;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMATINIB;ABCB1;rs1045642;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
IMATINIB;ABCB1;rs1045642;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHADONE;OPRK1;rs963549;CC;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
ANTIPSYCHOTICS;ABCB1;rs1128503;AA;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;SCHIZOPHRENIA;;
IMATINIB;ABCG2;rs2231142;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
IMATINIB;ABCG2;rs2231142;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;PPARA;rs4823613;G;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
INFLIXIMAB;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;POR;rs1057868;T;LADME-PK;INCREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
DALCETRAPIB;ADCY9;rs1967309;AA;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ANTIDEPRESSANTS;BDNF;rs6265;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
BETA BLOCKING AGENTS;ADRB1;rs1801253;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;TACHYCARDIA;;
FLECAINIDE;ADRB1;rs1801253;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;TACHYCARDIA;;
METHOTREXATE;ABCC2;rs717620;T;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
RITUXIMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;NEUROMYELITIS OPTICA;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*18;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*18;*18;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
DRUGS USED IN ALCOHOL DEPENDENCE;GATA4;rs13273672;CC;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;ALCOHOL ABUSE;;
CHORIONIC GONADOTROPIN;FSHR;rs6166;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
BEPRIDIL;CYP2D6;CYP2D6*10;*10;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;CARDIAC RHYTHM DISEASE;;
TACROLIMUS;CYP3A4;rs35599367;GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
NICARDIPINE;CACNA1B;rs2739260;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BIPOLAR_DISORDER;;;
NIMODIPINE;CACNA1B;rs2739260;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BIPOLAR_DISORDER;;;
CITALOPRAM;GLDC;rs10975641;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;GLDC;rs10975641;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DOSE;OTHER;A STABLE MAINTENANCE DOSE;;;
CORTISONE ACETATE;CYP3A7;CYP3A7*1A;*1C;DOSAGE;DECREASED_DOSE;nan;DISEASE;ADRENAL HYPERPLASIA, CONGENITAL;;
CORTISONE ACETATE;CYP3A7;CYP3A7*1C;*1C;DOSAGE;DECREASED_DOSE;nan;DISEASE;ADRENAL HYPERPLASIA, CONGENITAL;;
DAUNORUBICIN;G6PD;G6PD A- 202A_376G;A-202A_376G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TEGAFUR;CYP2A6;CYP2A6*1;*4/*4 + *4/*7 + *7/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NEOPLASMS;;
TEGAFUR;CYP2A6;CYP2A6*4;*4/*4 + *4/*7 + *7/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NEOPLASMS;;
TEGAFUR;CYP2A6;CYP2A6*7;*4/*4 + *4/*7 + *7/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NEOPLASMS;;
EFAVIRENZ;CYP2A6;CYP2A6*2;*2;OTHER, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;OTHER;A STABLE MAINTENANCE DOSE;;;
METFORMIN;HNF1B;rs11868513;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ATORVASTATIN;CYP3A4;rs2242480;C/C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
GLATIRAMER ACETATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME-PK;INCREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1 + *1/*17 + *2/*17 + *3/*17;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ANGINA PECTORIS;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*1 + *1/*17 + *2/*17 + *3/*17;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ANGINA PECTORIS;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*1 + *1/*17 + *2/*17 + *3/*17;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ANGINA PECTORIS;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*1 + *1/*17 + *2/*17 + *3/*17;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ANGINA PECTORIS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ATORVASTATIN;CYP3A4;rs2242480;C/C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
DIAZEPAM;CYP2C19;CYP2C19*1;*2 + *3;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DIAZEPAM;CYP2C19;CYP2C19*2;*2 + *3;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DIAZEPAM;CYP2C19;CYP2C19*3;*2 + *3;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
INTERFERON ALFA-2A;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2B;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERONS;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
FLUOXETINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
PAROXETINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
THIOGUANOSINE DIPHOSPHATE;TPMT;TPMT poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
THIOGUANOSINE MONOPHOSPHATE;TPMT;TPMT poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
COUMARIN;CYP2A6;CYP2A6*1;*12;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
COUMARIN;CYP2A6;CYP2A6*12;*12;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VALPROIC ACID;CYP2A6;CYP2A6*1;*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;CYP2A6;CYP2A6*4;*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
TEGAFUR;CYP2A6;CYP2A6*4;*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;STOMACH NEOPLASMS;;
TEGAFUR;CYP2A6;CYP2A6*1;*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TEGAFUR;CYP2A6;CYP2A6*4;*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*7;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*7;*1/*7;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*3/*3;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*3;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2/*2;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*2;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
WARFARIN;CYP4F2;CYP4F2*1;*3/*3;DOSAGE;INCREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
WARFARIN;CYP4F2;CYP4F2*3;*3/*3;DOSAGE;INCREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2/*3;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*3;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
PACLITAXEL;CYP2C8;CYP2C8*1;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
PACLITAXEL;CYP2C8;CYP2C8*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CAFFEINE;CYP2A6;CYP2A6*1;*7 + *10 + *11;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;CYP2A6;CYP2A6*7;*7 + *10 + *11;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;CYP2A6;CYP2A6*10;*7 + *10 + *11;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;CYP2A6;CYP2A6*11;*7 + *10 + *11;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;CYP2A6;CYP2A6*1;*1/*4 + *1/*9 + *4/*4 + *4/*9;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;CYP2A6;CYP2A6*4;*1/*4 + *1/*9 + *4/*4 + *4/*9;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;CYP2A6;CYP2A6*9;*1/*4 + *1/*9 + *4/*4 + *4/*9;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;THROMBOEMBOLISM;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;THROMBOEMBOLISM;;
TOCILIZUMAB;IL6R;rs4845625;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ATORVASTATIN;CYP3A4;rs2242480;T/T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
WARFARIN;CYP2C9;CYP2C9*1;*3;OTHER, LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;OTHER, LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;OTHER, LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;OTHER, LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
LETROZOLE;CYP2A6;CYP2A6*1;*1/*26;LADME-PK;METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP2A6;CYP2A6*26;*1/*26;LADME-PK;METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
METHOTREXATE;SLC19A1;rs1051266;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
WARFARIN;CYP2C9;CYP2C9*2;*2;LADME-PK;DECREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
INTERFERON ALFA-2A;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2B;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERONS;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6;LADME-PK;DECREASED_METABOLISM;OTHER;HUMAN LIVER MICROSOMES;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;DECREASED_METABOLISM;OTHER;HUMAN LIVER MICROSOMES;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ISONIAZID;NAT2;NAT2*4;*4/*4;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*4;*4/*4;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;TROUGH CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;TROUGH CONCENTRATION;nan;nan;;;
LOSARTAN;CYP2C9;CYP2C9*1;*1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;KIDNEY DISORDER;;
LOSARTAN;CYP2C9;CYP2C9*2;*1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;KIDNEY DISORDER;;
LOSARTAN;CYP2C9;CYP2C9*3;*1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;KIDNEY DISORDER;;
TROPISETRON;CYP2D6;CYP2D6*3;*3/*3;EFFICACY;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
LOSARTAN;CYP2C9;CYP2C9*1;*1/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;KIDNEY DISORDER;;
LOSARTAN;CYP2C9;CYP2C9*2;*1/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;KIDNEY DISORDER;;
LOSARTAN;CYP2C9;CYP2C9*3;*1/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;KIDNEY DISORDER;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MYOCARDIAL ISCHEMIA;;
TACROLIMUS;CYP2C19;CYP2C19*1;*2/*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP2C19;CYP2C19*2;*2/*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
METOPROLOL;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
SIMVASTATIN;CYP3A4;CYP3A4*1;*1/*4;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
SIMVASTATIN;CYP3A4;CYP3A4*4;*1/*4;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*2 + *3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2 + *3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*2 + *3;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ONDANSETRON;CYP2D6;CYP2D6*1;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ONDANSETRON;CYP2D6;CYP2D6*1xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ONDANSETRON;CYP2D6;CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
DEBRISOQUINE;CYP2D6;CYP2D6*2xN;*2xN;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
HALOPERIDOL;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
CARVEDILOL;CYP2D6;CYP2D6*1;*1/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART DISEASES;;
CARVEDILOL;CYP2D6;CYP2D6*4;*1/*4;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART DISEASES;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*17;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
CARVEDILOL;CYP2D6;CYP2D6*4;*4/*5 + *4/*6;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART FAILURE;;
CARVEDILOL;CYP2D6;CYP2D6*5;*4/*5 + *4/*6;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART FAILURE;;
CARVEDILOL;CYP2D6;CYP2D6*6;*4/*5 + *4/*6;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART FAILURE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
CARVEDILOL;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART DISEASES;;
CARVEDILOL;CYP2D6;CYP2D6*1;*1/*5;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART DISEASES;;
CARVEDILOL;CYP2D6;CYP2D6*5;*1/*5;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART DISEASES;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1;*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*3;*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*4;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
FLUOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_RESPONSE;EFFICACY;ALCOHOL ABUSE;;;
FLUOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_RESPONSE;EFFICACY;EFFICACY:MAJOR DEPRESSIVE DISORDER;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
CLOMIPRAMINE;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
CLOMIPRAMINE;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
DOXEPIN;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
DOXEPIN;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
IMIPRAMINE;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
IMIPRAMINE;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
MAPROTILINE;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
MAPROTILINE;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
OPIPRAMOL;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
OPIPRAMOL;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
SUFENTANIL;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
SUFENTANIL;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
METFORMIN;nan;rs6719578;CG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*10;EFFICACY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*10;*10;EFFICACY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY, LADME-PK;DECREASED_CLEARANCE;OTHER;ONE SUICIDE CASE;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
HALOPERIDOL;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
METHOTREXATE;ATIC;rs4673993;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCER;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCER;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCER;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *2/*2 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *2/*2 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *2/*2 + *2/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
HYDROMORPHONE;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
KETOROLAC;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
MORPHINE;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
OPIOIDS;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
OXYCODONE;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
BUPROPION;CYP2B6;CYP2B6*1;*1/*22;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
BUPROPION;CYP2B6;CYP2B6*22;*1/*22;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME-PK;INCREASED_DOSE;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;CYSTIC FIBROSIS,LUNG TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;CYSTIC FIBROSIS,LUNG TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;CYSTIC FIBROSIS,LUNG TRANSPLANTATION;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANIC DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANIC DISORDER;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY, TOXICITY;DECREASED_RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY, TOXICITY;DECREASED_RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY, TOXICITY;DECREASED_RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;;;
PEGINTERFERON ALFA-2A;HLA-A;HLA-A*01:01;*01:01;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;HLA-A;HLA-A*01:01;*01:01;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;HLA-A;HLA-A*01:01;*01:01;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;VKORC1;rs104894542;AC + CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
ASPIRIN;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
MEPHENYTOIN;CYP2C19;rs28399504;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10 + *5/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*5;*10/*10 + *5/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10 + *5/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*10/*10 + *5/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*5;*10/*10 + *5/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*10/*10 + *5/*5;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*3 + *3/*3 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*3 + *3/*3 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*3 + *3/*3 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOBAZAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *2/*2;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LAMIVUDINE;HLA-B;HLA-B*40:01;*40:01;EFFICACY;RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NEVIRAPINE;HLA-B;HLA-B*40:01;*40:01;EFFICACY;RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
STAVUDINE;HLA-B;HLA-B*40:01;*40:01;EFFICACY;RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
BELINOSTAT;UGT1A1;UGT1A1*1;*1/*60 + *60/*60;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS;;
BELINOSTAT;UGT1A1;UGT1A1*60;*1/*60 + *60/*60;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS;;
BELINOSTAT;UGT1A1;UGT1A1*1;*1/*60 + *60/*60;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
BELINOSTAT;UGT1A1;UGT1A1*60;*1/*60 + *60/*60;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*3;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*5;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
BOCEPREVIR;IFNL4;rs11322783;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs11322783;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL4;rs11322783;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3 + *5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3 + *5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3 + *5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*5;*2 + *3 + *5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*6;*2 + *3 + *5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*11;*2 + *3 + *5 + *6 + *11;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP2C19;CYP2C19*2;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
ACENOCOUMAROL;CYP2C19;CYP2C19*3;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
PHENPROCOUMON;CYP2C19;CYP2C19*2;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
PHENPROCOUMON;CYP2C19;CYP2C19*3;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;nan;DISEASE;STROKE;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
COUMARIN;CYP2A6;CYP2A6*1;*6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
COUMARIN;CYP2A6;CYP2A6*6;*6;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ECULIZUMAB;C5;rs56040400;CT;EFFICACY;DECREASED_RESPONSE;OTHER;PAROXYSMAL NOCTURNAL HEMOGLOBINURIA;;;
DEFERASIROX;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ANEMIA;;
DEFERASIROX;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ANEMIA;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
PRASUGREL;CYP2C19;rs4244285;A;EFFICACY;RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
TICAGRELOR;CYP2C19;rs4244285;A;EFFICACY;RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
WARFARIN;CYP2C9;rs9332131;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;rs28371685;C;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE CORONARY SYNDROME,STROKE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE CORONARY SYNDROME,STROKE;;
VALPROIC ACID;CYP2C9;CYP2C9*1;*1/*2 + *1/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;BIPOLAR_DISORDER,PSYCHOTIC DISORDER;;
VALPROIC ACID;CYP2C9;CYP2C9*2;*1/*2 + *1/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;BIPOLAR_DISORDER,PSYCHOTIC DISORDER;;
VALPROIC ACID;CYP2C9;CYP2C9*3;*1/*2 + *1/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;BIPOLAR_DISORDER,PSYCHOTIC DISORDER;;
WARFARIN;POR;rs41301394;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CARBOPLATIN;GSTP1;rs1695;G;TOXICITY;DECREASED_RESPONSE;OTHER;OVARIAN NEOPLASMS;;;
PACLITAXEL;GSTP1;rs1695;G;TOXICITY;DECREASED_RESPONSE;OTHER;OVARIAN NEOPLASMS;;;
VORICONAZOLE;CYP2C19;CYP2C19 ultrarapid metabolizer;;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*6 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*1/*6 + *6/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*1;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*18;*1/*1;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
CISPLATIN;MIR335;rs3807348;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;MESOTHELIOMA;;;
HYDROCODONE;CYP2D6;CYP2D6*2;*2/*41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
HYDROCODONE;CYP2D6;CYP2D6*41;*2/*41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CYCLOPHOSPHAMIDE;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOXORUBICIN;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
BUPRENORPHINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
BUPRENORPHINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
METHADONE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
METHADONE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
DESVENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;VKORC1;VKORC1 low activity;;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2 + *2/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2 + *2/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*2 + *2/*17;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
CLOMIPRAMINE;CYP2D6;CYP2D6*4;*4/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOMIPRAMINE;CYP2D6;CYP2D6*5;*4/*5;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;LIVER TRANSPLANTATION;;
CLOZAPINE;CYP3A5;CYP3A5*1;*1/*3;DOSAGE;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
CLOZAPINE;CYP3A5;CYP3A5*3;*1/*3;DOSAGE;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE;DECREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
SIROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SIROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;ULCERATIVE COLITIS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CARBAMAZEPINE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
CARBAMAZEPINE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
FENTANYL;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS,PAIN;;
FENTANYL;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS,PAIN;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
FENTANYL;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;POSTOPERATIVE_PAIN;;
FENTANYL;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;POSTOPERATIVE_PAIN;;
MIDAZOLAM;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
MIDAZOLAM;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
CYCLOSPORINE;CYP3A5;CYP3A5*1;*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CYCLOSPORINE;CYP3A5;CYP3A5*3;*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
FENTANYL;CYP2D6;CYP2D6*1;*9;LADME-PK;DECREASED_CLEARANCE;OTHER;BURNS;;;
FENTANYL;CYP2D6;CYP2D6*9;*9;LADME-PK;DECREASED_CLEARANCE;OTHER;BURNS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SIMVASTATIN;F3;rs3917643;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYOCARDIAL ISCHEMIA;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
FLUVASTATIN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
IVACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTERIOSCLEROSIS;;
BEVACIZUMAB;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
CISPLATIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
DOCETAXEL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
EPIRUBICIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
TRASTUZUMAB;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
IMATINIB;CYP3A5;rs776746;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
IMATINIB;CYP3A5;rs776746;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
FENTANYL;CYP3A5;CYP3A5 poor metabolizer;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION;;;
MEPERIDINE;CYP3A5;CYP3A5 poor metabolizer;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION;;;
MIDAZOLAM;CYP3A5;CYP3A5 poor metabolizer;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION;;;
FENTANYL;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION;;;
MEPERIDINE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION;;;
MIDAZOLAM;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION;;;
FENTANYL;UGT1A1;UGT1A1 poor metabolizer;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION;;;
MEPERIDINE;UGT1A1;UGT1A1 poor metabolizer;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION;;;
MIDAZOLAM;UGT1A1;UGT1A1 poor metabolizer;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION;;;
BELZUTIFAN;UGT2B17;UGT2B17 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VON HIPPEL-LINDAU DISEASE;;;
BELZUTIFAN;UGT2B17;UGT2B17 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;RENAL CELL CARCINOMA;;;
BELZUTIFAN;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VON HIPPEL-LINDAU DISEASE;;;
BELZUTIFAN;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;RENAL CELL CARCINOMA;;;
TACROLIMUS;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;PAIN;;;
4-HYDROXYTAMOXIFEN;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
4-HYDROXYTAMOXIFEN;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
TAMSULOSIN;CYP2D6;CYP2D6*1;*1/*4 + *4/*10;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
TAMSULOSIN;CYP2D6;CYP2D6*3;*1/*4 + *4/*10;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
TAMSULOSIN;CYP2D6;CYP2D6*4;*1/*4 + *4/*10;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
TAMSULOSIN;CYP2D6;CYP2D6*9;*1/*4 + *4/*10;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
TAMSULOSIN;CYP2D6;CYP2D6*10;*1/*4 + *4/*10;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
TAMSULOSIN;CYP2D6;CYP2D6*41;*1/*4 + *4/*10;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
IMATINIB;CYP3A4;rs2242480;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
IMATINIB;CYP3A4;rs2242480;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
FULVESTRANT;CYP2C9;CYP2C9 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
FULVESTRANT;CYP2C9;CYP2C9 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;METASTATIC NEOPLASM;;;
ANASTROZOLE;CYP2C9;CYP2C9 intermediate metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ANASTROZOLE;CYP2C9;CYP2C9 intermediate metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;METASTATIC NEOPLASM;;;
ANASTROZOLE;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ANASTROZOLE;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;METASTATIC NEOPLASM;;;
ANASTROZOLE;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ANASTROZOLE;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;METASTATIC NEOPLASM;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;LEUKEMIA;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;LEUKEMIA;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;LEUKEMIA;;
ABATACEPT;HLA-DRB1;HLA-DRB1*04:05;*04:05;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
APATINIB;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS;;;
APATINIB;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS;;;
ESCITALOPRAM;CYP2C19;CYP2C19 rapid metabolizer;;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
SERTRALINE;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
DULOXETINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
AMOXICILLIN;VDR;rs7975232;A;EFFICACY;INCREASED_RESPONSE;OTHER;HELICOBACTER INFECTIONS;;;
CLARITHROMYCIN;VDR;rs7975232;A;EFFICACY;INCREASED_RESPONSE;OTHER;HELICOBACTER INFECTIONS;;;
OMEPRAZOLE;VDR;rs7975232;A;EFFICACY;INCREASED_RESPONSE;OTHER;HELICOBACTER INFECTIONS;;;
AMOXICILLIN;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE;OTHER;HELICOBACTER INFECTIONS;;;
CLARITHROMYCIN;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE;OTHER;HELICOBACTER INFECTIONS;;;
OMEPRAZOLE;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE;OTHER;HELICOBACTER INFECTIONS;;;
BUPROPION;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;OBESITY;;;
BUPROPION;DRD2;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;OBESITY;;;
NALTREXONE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;OBESITY;;;
NALTREXONE;DRD2;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;OBESITY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;HEART TRANSPLANTATION;;;
RISPERIDONE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;AUTISM SPECTRUM DISORDER;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*1;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*1;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
DOCETAXEL;PPARD;rs6922548;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;PPARD;rs6922548;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*1;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;RECTAL NEOPLASMS;;;
SN-38;UGT1A1;UGT1A1*6;*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;RECTAL NEOPLASMS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME-PK;DECREASED_RESPONSE_TIME;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;POSTOPERATIVE_PAIN;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
NALDEMEDINE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
NALDEMEDINE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PAIN;;;
NALDEMEDINE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CONSTIPATION;;;
NALDEMEDINE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
NALDEMEDINE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PAIN;;;
NALDEMEDINE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CONSTIPATION;;;
METHADONE;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*10/*10 + *10/*65 + *10/*41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*2;*10/*10 + *10/*65 + *10/*41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*10/*10 + *10/*65 + *10/*41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*41;*10/*10 + *10/*65 + *10/*41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*65;*10/*10 + *10/*65 + *10/*41;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
DOCETAXEL;PPARD;rs7769719;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;PPARD;rs7769719;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;NEDD4;rs2288344;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
QUETIAPINE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;BIPOLAR_DISORDER;;;
QUETIAPINE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;BIPOLAR_DISORDER;;;
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;DDHD1;rs17126068;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer;;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION;;;
CISPLATIN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
DESVENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
SALBUTAMOL;nan;rs7903366;T;EFFICACY;DECREASED_RESPONSE;OTHER;ASTHMA;;;
PRAZIQUANTEL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_EXPOSURE;OTHER;SCHISTOSOMIASIS;;;
PRAZIQUANTEL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_EXPOSURE;OTHER;SCHISTOSOMIASIS;;;
PRAZIQUANTEL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_EXPOSURE;OTHER;SCHISTOSOMIASIS;;;
PRAZIQUANTEL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3;LADME-PK;INCREASED_EXPOSURE;OTHER;SCHISTOSOMIASIS;;;
LOSARTAN;CYP2C9;rs1057910;C;LADME-PK;DECREASED_METABOLISM;PK;NO DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STROKE;;
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;BIPOLAR_DISORDER,DEPRESSION,PSYCHOTIC DISORDER,SUBSTANCE-RELATED DISORDERS;;
ISONIAZID;NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;;
ISONIAZID;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;;
ISONIAZID;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;;
ISONIAZID;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;;
ISONIAZID;NAT2;NAT2*4;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*6;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*7;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*16;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
SALBUTAMOL;nan;rs7081864;A;EFFICACY;DECREASED_RESPONSE;OTHER;ASTHMA;;;
SULFINPYRAZONE;UGT1A9;rs72551330;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
SULFAMETHOXAZOLE;NAT2;NAT2*4;*4/*4;LADME-PK;INCREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
SULFAMETHOXAZOLE;NAT2;NAT2*6;*4/*4;LADME-PK;INCREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
SULFAMETHOXAZOLE;NAT2;NAT2*7;*4/*4;LADME-PK;INCREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
SULFAMETHOXAZOLE;NAT2;NAT2*16;*4/*4;LADME-PK;INCREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SPONDYLARTHROPATHIES;;;
WARFARIN;VKORC1;rs9923231;GG;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;VKORC1;rs9923231;GG;DOSAGE;INCREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;VKORC1;rs9923231;GG;DOSAGE;INCREASED_DOSE;OTHER;VENOUS THROMBOSIS;;;
METHADONE;CYP2D6;CYP2D6*1;*1/*2xN + *2/*2xN;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2D6;CYP2D6*2;*1/*2xN + *2/*2xN;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2D6;CYP2D6*2xN;*1/*2xN + *2/*2xN;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
LITHIUM;GSK3B;rs6438552;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
TACROLIMUS;ABCB1;rs1045642;AA;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
LITHIUM;NR1D1;rs2071427;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;THRA;rs2071427;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
TACROLIMUS;CYP3A5;CYP3A5 poor metabolizers;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MORPHINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;PSYCHOTIC DISORDER;;
ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CAFFEINE;NAT2;NAT2*1;*4/*5 + *1/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
CAFFEINE;NAT2;NAT2*4;*4/*5 + *1/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
CAFFEINE;NAT2;NAT2*5;*4/*5 + *1/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
CAFFEINE;NAT2;NAT2*6;*4/*5 + *1/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
CAFFEINE;NAT2;NAT2*7;*4/*5 + *1/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
CAFFEINE;NAT2;NAT2*16;*4/*5 + *1/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3 + *1/*6 + *1/*7;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3 + *1/*6 + *1/*7;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*6;*1/*1 + *1/*3 + *1/*6 + *1/*7;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION;;;
ISONIAZID;NAT2;NAT2*1;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*4;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*5;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*6;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*6J;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*7;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*7G;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*39;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY;CROHN DISEASE;;;
TACROLIMUS;ABCB1;rs1045642;AA;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ENZYME INHIBITORS;CYP19A1;rs700518;CC;OTHER;RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TACROLIMUS;ABCB1;rs1128503;AA;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CORTICOSTEROIDS;FCER2;rs28364072;G;DOSAGE;INCREASED_DOSE;nan;DISEASE;ASTHMA;;
TACROLIMUS;ABCB1;rs2032582;AA;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ISONIAZID;NAT2;NAT2*1;*16 + *6 + *7 + *14;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ISONIAZID;NAT2;NAT2*4;*16 + *6 + *7 + *14;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ISONIAZID;NAT2;NAT2*6;*16 + *6 + *7 + *14;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ISONIAZID;NAT2;NAT2*7;*16 + *6 + *7 + *14;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ISONIAZID;NAT2;NAT2*14;*16 + *6 + *7 + *14;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ISONIAZID;NAT2;NAT2*16;*16 + *6 + *7 + *14;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
HYDRALAZINE;NAT2;NAT2*4;*4/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERTENSION;;;
HYDRALAZINE;NAT2;NAT2*4;*4/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;OTHER;PREGNANCY;;;
HYDRALAZINE;NAT2;NAT2*6;*4/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERTENSION;;;
HYDRALAZINE;NAT2;NAT2*6;*4/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;OTHER;PREGNANCY;;;
HYDRALAZINE;NAT2;NAT2*7;*4/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERTENSION;;;
HYDRALAZINE;NAT2;NAT2*7;*4/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;OTHER;PREGNANCY;;;
HYDRALAZINE;NAT2;NAT2*16;*4/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERTENSION;;;
HYDRALAZINE;NAT2;NAT2*16;*4/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;OTHER;PREGNANCY;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*59;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*59;*4/*59;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
HALOPERIDOL;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;PSYCHOTIC DISORDER;;
ESCITALOPRAM;nan;rs12154537;G;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
MORPHINE;ABCB1;rs1128503;AG + GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ISONIAZID;NAT2;NAT2*4;*4/*4;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*6;*4/*4;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*7;*4/*4;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*14;*4/*4;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*16;*4/*4;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*19;*4/*4;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;TUBERCULOSIS;;
DOCETAXEL;SLCO1B3;rs11045585;G;OTHER, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NASOPHARYNGEAL NEOPLASMS;;
DOCETAXEL;SLCO1B3;rs7311358;A;OTHER, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NASOPHARYNGEAL NEOPLASMS;;
DOCETAXEL;SLCO1B3;rs4149118;G;OTHER, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NASOPHARYNGEAL NEOPLASMS;;
CAFFEINE;NAT2;NAT2*5;*16/*5 + *5/*5 + *5/*6 + *5/*34 + *5/*7 + *6/*6 + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;NAT2;NAT2*6;*16/*5 + *5/*5 + *5/*6 + *5/*34 + *5/*7 + *6/*6 + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;NAT2;NAT2*7;*16/*5 + *5/*5 + *5/*6 + *5/*34 + *5/*7 + *6/*6 + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;NAT2;NAT2*16;*16/*5 + *5/*5 + *5/*6 + *5/*34 + *5/*7 + *6/*6 + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CAFFEINE;NAT2;NAT2*34;*16/*5 + *5/*5 + *5/*6 + *5/*34 + *5/*7 + *6/*6 + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ISONIAZID;NAT2;NAT2*4;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*5;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*6;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*6J;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*7;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
ISONIAZID;NAT2;NAT2*7G;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TUBERCULOSIS;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HEART TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HEART TRANSPLANTATION;;
MIDAZOLAM;VDR;rs1544410;C;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;KLRC4;rs1154831;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SPONDYLARTHROPATHIES;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;DOSAGE;INCREASED_DOSE;OTHER;LUNG TRANSPLANTATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19 intermediate metabolizer;;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;DEPRESSION,ANXIETY DISORDERS;;
METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;EFFICACY;DECREASED_RESPONSE;OTHER;HEROIN DEPENDENCE;;;
FLUOXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;MAJOR DEPRESSIVE DISORDER;;;
FLUOXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;EFFICACY:OBSESSIVE-COMPULSIVE DISORDER;;;
HYDRALAZINE;NAT2;NAT2*6;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;EFFICACY;INCREASED_RESPONSE;OTHER;RESISTANT HYPERTENSION;;;
HYDRALAZINE;NAT2;NAT2*7;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;EFFICACY;INCREASED_RESPONSE;OTHER;RESISTANT HYPERTENSION;;;
HYDRALAZINE;NAT2;NAT2*14;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;EFFICACY;INCREASED_RESPONSE;OTHER;RESISTANT HYPERTENSION;;;
HYDRALAZINE;NAT2;NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;EFFICACY;INCREASED_RESPONSE;OTHER;RESISTANT HYPERTENSION;;;
ISONIAZID;NAT2;NAT2*4;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ISONIAZID;NAT2;NAT2*6;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ISONIAZID;NAT2;NAT2*7;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ISONIAZID;NAT2;NAT2*14;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ISONIAZID;NAT2;NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ACETYLISONIAZID;NAT2;NAT2*4;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ACETYLISONIAZID;NAT2;NAT2*6;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ACETYLISONIAZID;NAT2;NAT2*7;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ACETYLISONIAZID;NAT2;NAT2*14;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ACETYLISONIAZID;NAT2;NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
ACETAMINOPHEN;CYP2D6;CYP2D6*10;*10;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PATENT DUCTUS ARTERIOSUS;;;
BUPROPION;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
WARFARIN;VKORC1;rs7294;T;DOSAGE, LADME-PK;INCREASED_DOSE;nan;nan;;;
PARAMETHOXYMETHAMPHETAMINE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;SUBSTANCE-RELATED DISORDERS;;
VORICONAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;*1/*2 + *1/*3 + *2/*17;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
MARAVIROC;CYP3A5;CYP3A5 intermediate metabolizers;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
CITALOPRAM;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
CITALOPRAM;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
CITALOPRAM;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
CITALOPRAM;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
HALOPERIDOL;DRD2;rs1799978;C;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
OLANZAPINE;DRD2;rs1799978;C;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
PERPHENAZINE;DRD2;rs1799978;C;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
QUETIAPINE;DRD2;rs1799978;C;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;DRD2;rs1799978;C;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CITALOPRAM;CYP2C19;CYP2C19*1;*17/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
CITALOPRAM;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*17/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE, LADME-PK;DECREASED_RESPONSE_TIME;METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
NORTRIPTYLINE;CYP2D6;CYP2D6 intermediate metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;nan;DISEASE;DIABETIC NEUROPATHIES;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
HYDROCODONE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;PSYCHOTIC DISORDER;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CORONARY ARTERY DISEASE;;
TAMOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;LADME-PK;INCREASED_DOSE;nan;DISEASE;BREAST NEOPLASMS;;
PROPAFENONE;CYP2D6;CYP2D6*1;*1/*5 + *2/*36 + *5/*10 + *5/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TACHYCARDIA;;;
PROPAFENONE;CYP2D6;CYP2D6*2;*1/*5 + *2/*36 + *5/*10 + *5/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TACHYCARDIA;;;
PROPAFENONE;CYP2D6;CYP2D6*5;*1/*5 + *2/*36 + *5/*10 + *5/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TACHYCARDIA;;;
PROPAFENONE;CYP2D6;CYP2D6*10;*1/*5 + *2/*36 + *5/*10 + *5/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TACHYCARDIA;;;
PROPAFENONE;CYP2D6;CYP2D6*36;*1/*5 + *2/*36 + *5/*10 + *5/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TACHYCARDIA;;;
IMIPRAMINE;CYP2D6;CYP2D6*1;*4/*4 + *4/*5;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2D6;CYP2D6*2;*4/*4 + *4/*5;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CITALOPRAM;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
CITALOPRAM;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
METHAMPHETAMINE;CYP2D6;CYP2D6*1;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHAMPHETAMINE;CYP2D6;CYP2D6*2;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHAMPHETAMINE;CYP2D6;CYP2D6*4;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHAMPHETAMINE;CYP2D6;CYP2D6*5;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHAMPHETAMINE;CYP2D6;CYP2D6*10;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHAMPHETAMINE;CYP2D6;CYP2D6*14;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHAMPHETAMINE;CYP2D6;CYP2D6*18;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHAMPHETAMINE;CYP2D6;CYP2D6*36;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_EXPOSURE;OTHER;PSYCHOTIC DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_EXPOSURE;OTHER;SCHIZOPHRENIA;;;
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;DOSAGE, EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
4-HYDROXYTAMOXIFEN;CYP2C9;CYP2C9*1;*2 + *3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
4-HYDROXYTAMOXIFEN;CYP2C9;CYP2C9*2;*2 + *3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
4-HYDROXYTAMOXIFEN;CYP2C9;CYP2C9*3;*2 + *3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2C9;CYP2C9*1;*2 + *3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2C9;CYP2C9*2;*2 + *3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2C9;CYP2C9*3;*2 + *3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
DESVENLAFAXINE;CYP2D6;CYP2D6*99;*99;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*36 + *4x2/*36;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4x2;*4/*36 + *4x2/*36;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*36;*4/*36 + *4x2/*36;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*5/*10 + *4/*10 + *10/*10 + *10/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*2;*5/*10 + *4/*10 + *10/*10 + *10/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*5/*10 + *4/*10 + *10/*10 + *10/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*5;*5/*10 + *4/*10 + *10/*10 + *10/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*5/*10 + *4/*10 + *10/*10 + *10/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*41;*5/*10 + *4/*10 + *10/*10 + *10/*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
METHADONE;CYP2D6;CYP2D6*1;*1/*2xN + *2/*2xN;DOSAGE;INCREASED_DOSE;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2D6;CYP2D6*2;*1/*2xN + *2/*2xN;DOSAGE;INCREASED_DOSE;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2D6;CYP2D6*2xN;*1/*2xN + *2/*2xN;DOSAGE;INCREASED_DOSE;OTHER;OPIOID-RELATED DISORDERS;;;
VENLAFAXINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
DESIPRAMINE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DESIPRAMINE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMIPRAMINE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TRANS 4-HYDROXYPRAZIQUANTEL;CYP2J2;rs890293;AA + AC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHISTOSOMIASIS;;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
PERPHENAZINE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
TACROLIMUS;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 +*2/*3;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 +*2/*3;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 +*2/*3;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
VORTIOXETINE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_DISCONTINUATION;nan;nan;;;
VORTIOXETINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_DISCONTINUATION;nan;nan;;;
DEBRISOQUINE;CYP2D6;CYP2D6*4;*4/*38;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEBRISOQUINE;CYP2D6;CYP2D6*38;*4/*38;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NORTRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FENTANYL;nan;poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;PAIN;;
ESCITALOPRAM;CYP2C19;CYP2C19 ultrarapid metabolizer phenotype;;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ETHANOL;OPRM1;rs2075572;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HELICOBACTER INFECTIONS;;;
DEXAMETHASONE;CHRM3;rs2165870;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING;;
METOPROLOL;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ETHANOL;OPRM1;rs548646;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
GLICLAZIDE;KCNQ1;rs2237892;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*31;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*31;*4/*31;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NICOTINE;DRD2;rs1799732;G/del + del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
LINAGLIPTIN;TCF7L2;rs7903146;CC + CT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*5;*5/*13;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*13;*5/*13;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CITALOPRAM;CYP2C19;CYP2C19 poor metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ETHANOL;OPRM1;rs681243;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
AMOXICILLIN;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTRITIS;;
CLARITHROMYCIN;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTRITIS;;
ESOMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTRITIS;;
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;EFFICACY;DECREASED_RESPONSE;EFFICACY;MAJOR DEPRESSIVE DISORDER;;;
BUPROPION;COMT;rs4680;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CODEINE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
CODEINE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
FENTANYL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
FENTANYL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
HYDROCODONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
HYDROCODONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
HYDROMORPHONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
HYDROMORPHONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
METHADONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
METHADONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
MORPHINE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
MORPHINE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
TRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
TRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
TRIMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;OTHER;MAJOR DEPRESSIVE DISORDER;;;
ETHANOL;OPRM1;rs1461773;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*3;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*4;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*5;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*9;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*10;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
3;CYP2D6;CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*3;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*4;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*5;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*9;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*10;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ETHANOL;OPRM1;rs3778148;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
AMOXICILLIN;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;;;
CLARITHROMYCIN;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;;;
LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;;;
AMOXICILLIN;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;;;
CLARITHROMYCIN;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;;;
OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;HELICOBACTER INFECTIONS;;;
MIDAZOLAM;VDR;rs4516035;T;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;OTHER;PHANTOM LIMB SYNDROME;;;
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;OTHER;PHANTOM LIMB SYNDROME;;;
MORPHINE;COMT;rs4680;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LOW BACK PAIN;;
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;nan;;;
TRIMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;SCHIZOPHRENIA;;
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
ATENOLOL;ADRB2;rs1042714;CC;EFFICACY;INCREASED_RESPONSE;OTHER;TACHYCARDIA;;;
METOPROLOL;ADRB2;rs1042714;CC;EFFICACY;INCREASED_RESPONSE;OTHER;TACHYCARDIA;;;
GLICLAZIDE;KCNQ1;rs2237895;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
WARFARIN;CYP2C9;CYP2C9 normal metabolizers;;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
SOLANIDINE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;DECREASED_METABOLISM;OTHER;DEPRESSION;;;
FLECAINIDE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME-PK;CONCENTRATIONS;nan;DISEASE;TACHYCARDIA, SUPRAVENTRICULAR;;
NOROXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
NOROXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PAIN;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PAIN;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PIMOZIDE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PERPHENAZINE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
BUPROPION;CYP2C19;CYP2C19*2;*2 + *3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;PREGNANCY;;
BUPROPION;CYP2C19;CYP2C19*3;*2 + *3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;PREGNANCY;;
BUPROPION;CYP2C19;CYP2C19*17;*2 + *3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;PREGNANCY;;
(R)-METHADONE;CYP2D6;CYP2D6*1;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(R)-METHADONE;CYP2D6;CYP2D6*1xN;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(R)-METHADONE;CYP2D6;CYP2D6*3;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(R)-METHADONE;CYP2D6;CYP2D6*4;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(R)-METHADONE;CYP2D6;CYP2D6*5;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(R)-METHADONE;CYP2D6;CYP2D6*6;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*1;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*1xN;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*3;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*4;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*5;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*6;*1/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
METHADONE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;OPIOID-RELATED DISORDERS;;;
ARSENIC COMPOUNDS;CBS;rs4920037;AA + AG;TOXICITY, LADME-PK;INCREASED_METABOLISM;nan;nan;;;
(R)-METHADONE;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(R)-METHADONE;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(R)-METHADONE;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(R)-METHADONE;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(R)-METHADONE;CYP2D6;CYP2D6*6;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
(S)-METHADONE;CYP2D6;CYP2D6*6;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
MORPHINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
CODEINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;PAIN;;;
(S)-METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*3;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*6;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;CYP2D6;CYP2D6*9;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
METHOTREXATE;FOXP3;rs3761548;G;OTHER;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ATENOLOL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;OTHER;TACHYCARDIA;;;
METOPROLOL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;OTHER;TACHYCARDIA;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PAIN;;;
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
GEMCITABINE;NT5C2;rs11598702;TT;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
GEMCITABINE;CDA;rs1048977;TT;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;ABCB1;rs1045642;AG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CLOMIPRAMINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
OXYMORPHONE;CYP2D6;CYP2D6*1;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
OXYMORPHONE;CYP2D6;CYP2D6*2;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
OXYMORPHONE;CYP2D6;CYP2D6*4;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
OXYMORPHONE;CYP2D6;CYP2D6*5;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
OXYMORPHONE;CYP2D6;CYP2D6*6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
OXYMORPHONE;CYP2D6;CYP2D6*9;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
OXYMORPHONE;CYP2D6;CYP2D6*17;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
OXYMORPHONE;CYP2D6;CYP2D6*41;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1;rs7202877;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB2;rs7202877;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
LANSOPRAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HELICOBACTER INFECTIONS;;;
OMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HELICOBACTER INFECTIONS;;;
SERTRALINE;CYP2B6;CYP2B6*1;*6/*6 + *6/*9;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2B6;CYP2B6*6;*6/*6 + *6/*9;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SERTRALINE;CYP2B6;CYP2B6*9;*6/*6 + *6/*9;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ARSENIC COMPOUNDS;CBS;rs234709;CT + TT;TOXICITY, LADME-PK;INCREASED_METABOLISM;nan;nan;;;
3-HYDROXYCOTININE;CYP2A6;CYP2A6*1;*1 + *2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
3-HYDROXYCOTININE;CYP2A6;CYP2A6*2;*1 + *2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
3-HYDROXYCOTININE;CYP2A6;CYP2A6*9;*1 + *2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
3-HYDROXYCOTININE;CYP2A6;CYP2A6*10;*1 + *2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;CYP2A6*1;*1 + *2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;CYP2A6*2;*1 + *2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;CYP2A6*9;*1 + *2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;CYP2A6*10;*1 + *2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;PSYCHOTIC DISORDER;;
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs2239179;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*1/*1 + *2/*2 + *1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*1/*1 + *2/*2 + *1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*3;*1/*1 + *2/*2 + *1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*4;*1/*1 + *2/*2 + *1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*9;*1/*1 + *2/*2 + *1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*1/*1 + *2/*2 + *1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6*41;*1/*1 + *2/*2 + *1/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;DEPRESSION;;
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs1540339;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
ENDOXIFEN;CYP2C9;CYP2C9 poor metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOLOGIC DISORDER,INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOLOGIC DISORDER,INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOLOGIC DISORDER,INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;HEMATOLOGIC DISORDER,INFECTIOUS DISEASE;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DEBRISOQUINE;CYP2D6;CYP2D6*21;*21/*36xN;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEBRISOQUINE;CYP2D6;CYP2D6*36xN;*21/*36xN;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
GEMIGLIPTIN;GLP1R;rs3765467;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
LINAGLIPTIN;GLP1R;rs3765467;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SAXAGLIPTIN;GLP1R;rs3765467;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SITAGLIPTIN;GLP1R;rs3765467;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
VILDAGLIPTIN;GLP1R;rs3765467;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METHADONE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
FENTANYL;CYP3A5;CYP3A5*1;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
FENTANYL;CYP3A5;CYP3A5*3;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
FENTANYL;CYP3A5;CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
NORQUETIAPINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
CODEINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN;;;
VORICONAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;*1/*2 + *1/*3;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
CITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *3/*3 + *2/*3;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
CITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *3/*3 + *2/*3;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
CITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *3/*3 + *2/*3;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *3/*3 + *2/*3;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *3/*3 + *2/*3;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *3/*3 + *2/*3;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
INDOMETHACIN;CYP2C9;rs2153628;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
GEMCITABINE;CDA;rs2072671;AA;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
TACROLIMUS;CYP3A5;CYP3A5 poor metabolizer genotype;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LIVER TRANSPLANTATION;;
VENLAFAXINE;SLC6A4;rs25531;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;ANXIETY DISORDERS;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
CODEINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN;;;
MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
VENLAFAXINE;GABRQ;rs3810651;AA + AT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
METOPROLOL;CYP2D6;CYP2D6 normal metabolizers;;LADME-PK;INCREASED_CLEARANCE;OTHER;PREGNANCY;;;
CYTARABINE;DCK;rs80143932;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
IDARUBICIN;DCK;rs80143932;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CLOMIPRAMINE;CYP1A2;rs762551;AA;EFFICACY;INCREASED_DOSE;nan;DISEASE;DEPRESSION;;
FENTANYL;CYP2D6;CYP2D6 ultrarapid metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
HYDROMORPHONE;CYP2D6;CYP2D6 ultrarapid metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
OPIOIDS;CYP2D6;CYP2D6 ultrarapid metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
OXYCODONE;CYP2D6;CYP2D6 ultrarapid metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
CLOZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
IBOGAINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_CLEARANCE;OTHER;OPIOID-RELATED DISORDERS;;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;INCREASED_EXPOSURE;OTHER;ADHD;;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ADHD;;;
AMPHETAMINE;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ADHD;;;
LISDEXAMFETAMINE;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ADHD;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;rs502434;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;GRIA3;rs502434;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NICOTINE;CYP2A6;CYP2A6*1;*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*41;*41;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*55;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*55;*55;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*39;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*39;*39;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ISONIAZID;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;INFLAMMATORY BOWEL DISEASES;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;INFLAMMATION;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;DOSAGE, EFFICACY;DOSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;rs3761554;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;GRIA3;rs3761554;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ISONIAZID;NAT2;NAT2 intermediate acetylator;;LADME-PK;INCREASED_CLEARANCE;OTHER;TUBERCULOSIS;;;
OPIOIDS;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
DIHYDROARTEMISININ;CYP2B6;CYP2B6*1;*6/*6 + *18/*18 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
DIHYDROARTEMISININ;CYP2B6;CYP2B6*1;*6/*6 + *18/*18 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;FALCIPARUM;;;
DIHYDROARTEMISININ;CYP2B6;CYP2B6*6;*6/*6 + *18/*18 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
DIHYDROARTEMISININ;CYP2B6;CYP2B6*6;*6/*6 + *18/*18 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;FALCIPARUM;;;
DIHYDROARTEMISININ;CYP2B6;CYP2B6*18;*6/*6 + *18/*18 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
DIHYDROARTEMISININ;CYP2B6;CYP2B6*18;*6/*6 + *18/*18 + *1/*6;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;FALCIPARUM;;;
DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;FALCIPARUM;;;
DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;FALCIPARUM;;;
DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*6;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*6;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;FALCIPARUM;;;
SERTRALINE;CYP2D6;CYP2D6*1;*2;LADME-PK;DECREASED_CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;;;
SERTRALINE;CYP2D6;CYP2D6*1;*2;LADME-PK;DECREASED_CLEARANCE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;CYP2D6;CYP2D6*1;*2;LADME-PK;DECREASED_CLEARANCE;OTHER;ANXIETY DISORDERS;;;
SERTRALINE;CYP2D6;CYP2D6*1;*2;LADME-PK;DECREASED_CLEARANCE;OTHER;BORDERLINE PERSONALITY DISORDER;;;
SERTRALINE;CYP2D6;CYP2D6*2;*2;LADME-PK;DECREASED_CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;;;
SERTRALINE;CYP2D6;CYP2D6*2;*2;LADME-PK;DECREASED_CLEARANCE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;CYP2D6;CYP2D6*2;*2;LADME-PK;DECREASED_CLEARANCE;OTHER;ANXIETY DISORDERS;;;
SERTRALINE;CYP2D6;CYP2D6*2;*2;LADME-PK;DECREASED_CLEARANCE;OTHER;BORDERLINE PERSONALITY DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;ANXIETY DISORDERS;;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;BORDERLINE PERSONALITY DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;;;
SERTRALINE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;ANXIETY DISORDERS;;;
SERTRALINE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;BORDERLINE PERSONALITY DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19*17;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS;;;
SERTRALINE;CYP2C19;CYP2C19*17;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;CYP2C19;CYP2C19*17;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;ANXIETY DISORDERS;;;
SERTRALINE;CYP2C19;CYP2C19*17;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;BORDERLINE PERSONALITY DISORDER;;;
TACROLIMUS;ABCC2;rs3740066;TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
LEVONORGESTREL;CYP2B6;CYP2B6 poor metabolizer;;LADME-PK;INCREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;rs3761555;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VENLAFAXINE;GRIA3;rs3761555;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;NKX2-6;rs310279;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
CYTARABINE;DCK;rs2306744;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
IDARUBICIN;DCK;rs2306744;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
VENLAFAXINE;HTR2A;rs7997012;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;ANXIETY DISORDERS;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES;;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES;;;
ANTIEPILEPTICS;nan;rs16935279;CC + CT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BIPOLAR_DISORDER,PSYCHOTIC DISORDER;;
FOLLITROPIN BETA;FSHR;rs6166;CC + CT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
UROFOLLITROPIN;FSHR;rs6166;CC + CT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
PAROXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;DECREASED_STEADY-STATE CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
PAROXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;DECREASED_STEADY-STATE CONCENTRATION;OTHER;ANXIETY DISORDERS;;;
PAROXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;DECREASED_STEADY-STATE CONCENTRATION;OTHER;PANIC DISORDER;;;
PAROXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
CLOMIPRAMINE;CYP2D6;CYP2D6*1xN;*2/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;AGORAPHOBIA;;
CLOMIPRAMINE;CYP2D6;CYP2D6*2;*2/*1xN;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;AGORAPHOBIA;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOMIPRAMINE;CYP2D6;CYP2D6*4;*4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CLOMIPRAMINE;CYP2D6;CYP2D6*6;*4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
WARFARIN;CYP2C19;CYP2C19*2;*1/*17 + *17/*17;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
WARFARIN;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
ATORVASTATIN;CYP2C19;CYP2C19*1;*2 + *4 + *8;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CARDIOVASCULAR DISEASE;;;
ATORVASTATIN;CYP2C19;CYP2C19*2;*2 + *4 + *8;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CARDIOVASCULAR DISEASE;;;
ATORVASTATIN;CYP2C19;CYP2C19*4;*2 + *4 + *8;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CARDIOVASCULAR DISEASE;;;
ATORVASTATIN;CYP2C19;CYP2C19*8;*2 + *4 + *8;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CARDIOVASCULAR DISEASE;;;
ATORVASTATIN;CYP2C19;CYP2C19*11;*2 + *4 + *8;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CARDIOVASCULAR DISEASE;;;
CISPLATIN;UBE2I;rs9597;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
IRINOTECAN;UBE2I;rs9597;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
WARFARIN;FRAS1;rs4386623;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
WARFARIN;FAM201A;rs1890109;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
VALPROIC ACID;SCN1A;rs3812718;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCER;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCER;;
PANTOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCER;;
PANTOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCER;;
PANTOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCER;;
PANTOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCER;;
CAPECITABINE;DPYD;rs1801159;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROESOPHAGEAL CANCER;;
NICOTINE;DRD2;rs6277;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;DIABETES MELLITUS;;
APIXABAN;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;THROMBOEMBOLISM;;;
DABIGATRAN;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;THROMBOEMBOLISM;;;
EDOXABAN;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;THROMBOEMBOLISM;;;
RIVAROXABAN;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;THROMBOEMBOLISM;;;
BUPROPION;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
BUPROPION;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
ETHANOL;OPRM1;rs648007;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
MIDAZOLAM;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MIDAZOLAM;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CLOZAPINE;NFIB;rs28379954;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;;;
ETHANOL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PRIMAQUINE;CYP2D6;CYP2D6*1;*4/*41 + *5/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*4;*4/*41 + *5/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*5;*4/*41 + *5/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*6;*4/*41 + *5/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*10;*4/*41 + *5/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MALARIA;;
PRIMAQUINE;CYP2D6;CYP2D6*41;*4/*41 + *5/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MALARIA;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
NICOTINE;UGT2B10;rs61750900;T;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CHRNA7;rs2337980;CC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
BUPROPION;DRD2;rs1799732;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CLOZAPINE;CYP1A1;rs2472297;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;;;
SIMVASTATIN;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;CONCENTRATIONS;nan;nan;;;
SIMVASTATIN;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;CONCENTRATIONS;nan;nan;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
QUETIAPINE;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
QUETIAPINE;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
WARFARIN;EPHX1;rs1131873;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOZAPINE;CYP1A1;rs2472297;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;nan;;;
METFORMIN;SLC2A2;rs8192675;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;CONNECTIVE TISSUE DISEASES;;
WARFARIN;CYP2C9;rs28371685;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
DULOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ALCOHOL ABUSE;;;
DULOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;DEPRESSIVE DISORDER;;;
SN-38;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS;;
SN-38;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS;;
WARFARIN;CYP2C9;rs9332131;del;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CLOZAPINE;NFIB;rs28379954;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;nan;;;
HYDROXYUREA;BCL11A;rs4671393;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ROSIGLITAZONE;CYP2C8;CYP2C8*1;*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
ROSIGLITAZONE;CYP2C8;CYP2C8*3;*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
BETA BLOCKING AGENTS;KL;rs36217263;A/del + del/del;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6/*6 + *1/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6 + *1/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *1/*2 + *1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *1/*2 + *1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *1/*2 + *1/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
GEMCITABINE;RRM1;rs12806698;AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
FLUOXETINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
BUPROPION;ACE;rs8075924;TT;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
SUNITINIB;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
SUNITINIB;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
HYDROXYCHLOROQUINE;CYP3A4;rs3735451;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;RHEUMATOID ARTHRITIS;;;
HYDROXYCHLOROQUINE;CYP3A4;rs3735451;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
FLUOROURACIL;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;DEPRESSION;;
CLOBAZAM;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
GEMCITABINE;RRM1;rs11030918;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *2/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*3 + *2/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *2/*3;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
RISPERIDONE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;DOSAGE, EFFICACY;DECREASED_RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION;;;
PACLITAXEL;CYP2C8;rs11572080;T;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
PACLITAXEL;CYP2C8;rs10509681;C;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CYCLOSPORINE;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CYCLOSPORINE;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CYCLOSPORINE;CYP3A4;rs35599367;A;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUOXETINE;CYP2D6;CYP2D6*1;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ANXIETY DISORDERS;;;
FLUOXETINE;CYP2D6;CYP2D6*1;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSION;;;
FLUOXETINE;CYP2D6;CYP2D6*1;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FLUOXETINE;CYP2D6;CYP2D6*4;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ANXIETY DISORDERS;;;
FLUOXETINE;CYP2D6;CYP2D6*4;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSION;;;
FLUOXETINE;CYP2D6;CYP2D6*4;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FLUOXETINE;CYP2D6;CYP2D6*10;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ANXIETY DISORDERS;;;
FLUOXETINE;CYP2D6;CYP2D6*10;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSION;;;
FLUOXETINE;CYP2D6;CYP2D6*10;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
CODEINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CHRONIC KIDNEY FAILURE;;
CODEINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CHRONIC KIDNEY FAILURE;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;INCREASED_METABOLISM;OTHER;PATIENTS WITH DECREASED CONCENTRATIONS OF VORICONAZOLE;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;INCREASED_METABOLISM;OTHER;PATIENTS WITH DECREASED CONCENTRATIONS OF VORICONAZOLE;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
DOCETAXEL;PPARD;rs3734254;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;PPARD;rs3734254;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
ATENOLOL;OR10P1;rs17117817;G;LADME-PD;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
METOPROLOL;OR10P1;rs17117817;G;LADME-PD;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CARBOPLATIN;RRM1;rs12806698;AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;RRM1;rs12806698;AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
METFORMIN;C11orf65;rs11212617;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ABATACEPT;HLA-DRB1;HLA-DRB1*04:01;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ABATACEPT;HLA-DRB1;HLA-DRB1*04:04;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ABATACEPT;HLA-DRB1;HLA-DRB1*04:05;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ABATACEPT;HLA-DRB1;HLA-DRB1*04:10;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ABATACEPT;HLA-DRB1;HLA-DRB1*10:01;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
METHADONE;nan;rs17180299;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
VINCRISTINE;nan;rs1247117;G;LADME-PD;INCREASED_RESISTANCE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
ATENOLOL;SNX9;rs2364349;A;LADME-PD;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
METOPROLOL;SNX9;rs2364349;A;LADME-PD;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
TACROLIMUS;nan;rs11265572;GT + TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
WARFARIN;STX4;rs10871454;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SIROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
TEMSIROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2 + *3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2 + *3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*2 + *3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
URACIL;DPYD;DPYD c.295_298delTCAT (*7);c.295_298delTCAT (*7);LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
URACIL;DPYD;DPYD Reference;c.295_298delTCAT (*7);LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
URACIL;DPYD;DPYD c.2846A>T;c.2846A>T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
URACIL;DPYD;DPYD Reference;c.2846A>T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
URACIL;DPYD;DPYD c.1679T>G (*13);c.1679T>G (*13);LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
URACIL;DPYD;DPYD Reference;c.1679T>G (*13);LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
URACIL;DPYD;DPYD c.1905+1G>A (*2A);c.1905+1G>A (*2A);LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
URACIL;DPYD;DPYD Reference;c.1905+1G>A (*2A);LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1xN;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*2;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*2xN;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*3;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*4;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*5;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*9;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*10;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*29;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*35;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*41;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*2;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*3;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*9;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*10;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*17;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*29;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*35;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
ATORVASTATIN;CYP3A5;CYP3A5*3;*3/*3;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10 + *1/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10 + *1/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ESCITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ESCITALOPRAM;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*2/*2 + *1/*2;TOXICITY, LADME-PK;DECREASED_METABOLISM;SIDE EFFECT;POSTMORTEM TOXICOLOGY CASES;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*2/*2 + *1/*2;TOXICITY, LADME-PK;DECREASED_METABOLISM;SIDE EFFECT;POSTMORTEM TOXICOLOGY CASES;;;
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*03:01;*03:01;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*03:01;*03:01;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*23:17;*23:17;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*23:17;*23:17;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;HLA-B*57:03;*57:03;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;HLA-B*57:03;*57:03;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*7;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*2 + *9 + *10 + *35 + *41;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
RISPERIDONE;CYP2D6;CYP2D6*2;*2 + *9 + *10 + *35 + *41;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
RISPERIDONE;CYP2D6;CYP2D6*9;*2 + *9 + *10 + *35 + *41;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*2 + *9 + *10 + *35 + *41;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
RISPERIDONE;CYP2D6;CYP2D6*35;*2 + *9 + *10 + *35 + *41;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
RISPERIDONE;CYP2D6;CYP2D6*41;*2 + *9 + *10 + *35 + *41;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SUMATRIPTAN;SLC22A1;rs1349294037;TAAGTTGT/TAAGTTGT;OTHER;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;CYP2B6;CYP2B6*1;*6 + *18;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2B6;CYP2B6*6;*6 + *18;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;CYP2B6;CYP2B6*18;*6 + *18;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
LAMOTRIGINE;UGT1A4;UGT1A4*3b;*3b;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;nan;;;
DOCETAXEL;PPARD;rs2016520;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;PPARD;rs2016520;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION;;;
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;DECREASED_RESPONSE;OTHER;CROHN DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *4;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *4;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*4;*2 + *4;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2 + *4;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
DOCETAXEL;CHST3;rs1871450;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;CHST3;rs1871450;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
PROPOFOL;CYP2B6;CYP2B6*1;*6;TOXICITY;DECREASED_RESPONSE;OTHER;BRAIN INJURY;;;
PROPOFOL;CYP2B6;CYP2B6*6;*6;TOXICITY;DECREASED_RESPONSE;OTHER;BRAIN INJURY;;;
TILDRAKIZUMAB;PDE4D;rs10556657;CT/CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
BUPRENORPHINE;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
DIHYDROCODEINE;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
FENTANYL;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
HYDROMORPHONE;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
METHADONE;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
MORPHINE;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
OXYCODONE;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
PIRITRAMIDE;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
TILIDINE;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
TRAMADOL;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;DOSAGE;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;DOSAGE;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;DECREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;;;
SIROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
SIROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
DOCETAXEL;PPARD;rs1883322;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;PPARD;rs1883322;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
PHENYTOIN;CYP2C19;CYP2C19 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VALPROIC ACID;CYP2C19;CYP2C19 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CARBAMAZEPINE;CYP3A5;CYP3A5 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VALPROIC ACID;CYP2C9;CYP2C9 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VALPROIC ACID;UGT1A6;UGT1A6*1a;*2a;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VALPROIC ACID;UGT1A6;UGT1A6*2a;*2a;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENYTOIN;CYP2C9;CYP2C9 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SN-38;UGT1A1;UGT1A1*1;*1/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;COLORECTAL NEOPLASMS;;;
SN-38;UGT1A1;UGT1A1*1;*1/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;METASTATIC NEOPLASM;;;
SN-38;UGT1A1;UGT1A1*28;*1/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;COLORECTAL NEOPLASMS;;;
SN-38;UGT1A1;UGT1A1*28;*1/*28;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;METASTATIC NEOPLASM;;;
DOCETAXEL;CHST3;rs12418;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;CHST3;rs12418;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
FOLFIRI;UGT1A1;UGT1A1*1;*28 + *60;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28 + *60;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS;;;
FOLFIRI;UGT1A1;UGT1A1*60;*28 + *60;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28 + *60;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28 + *60;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS;;;
IRINOTECAN;UGT1A1;UGT1A1*60;*28 + *60;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *1/*28;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *1/*28;DOSAGE;DECREASED_DOSE;OTHER;METASTATIC NEOPLASM;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *1/*28;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *1/*28;DOSAGE;DECREASED_DOSE;OTHER;METASTATIC NEOPLASM;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;PEPTIC ULCER DISEASE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;GASTROESOPHAGEAL REFLUX;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;ESOPHAGITIS;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;PEPTIC ULCER DISEASE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;GASTROESOPHAGEAL REFLUX;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;ESOPHAGITIS;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;PEPTIC ULCER DISEASE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;GASTROESOPHAGEAL REFLUX;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;ESOPHAGITIS;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*8;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
MERCAPTOPURINE;TPMT;TPMT*8;*1/*8;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ABROCITINIB;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3 + *8;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3 + *8;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3 + *8;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;CYP2C9*8;*2 + *3 + *8;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OPIOIDS;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER;CAESARIAN SECTION;;;
OPIOIDS;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
DULOXETINE;DRD3;rs963468;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANXIETY DISORDERS;;
SIMVASTATIN;CYP3A4;CYP3A4*1;*1/*22;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
SIMVASTATIN;CYP3A4;CYP3A4*22;*1/*22;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
METFORMIN;C11orf65;rs11212617;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
CYCLOSPORINE;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
EFAVIRENZ;NR1I3;rs2307424;AA + AG;EFFICACY;INCREASED_RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;;;
NEVIRAPINE;NR1I3;rs2307424;AA + AG;EFFICACY;INCREASED_RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*1 + *1/*2;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HEMATOLOGIC NEOPLASMS,HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*1 + *1/*2;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HEMATOLOGIC NEOPLASMS,HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*1 + *1/*2;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HEMATOLOGIC NEOPLASMS,HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
ARIPIPRAZOLE;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DEHYDROARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PIMOZIDE;CYP3A4;CYP3A4*1;*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PSYCHOTIC DISORDER;;
PIMOZIDE;CYP3A4;CYP3A4*22;*22;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PSYCHOTIC DISORDER;;
DOCETAXEL;CHST3;rs4148943;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;CHST3;rs4148943;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
DOCETAXEL;CHST3;rs4148945;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;CHST3;rs4148945;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
ELEXACAFTOR;CFTR;rs80034486;CG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs80034486;CG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs80034486;CG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
GLYBURIDE;ABCB11;rs4148776;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IMATINIB;SLCO1B3;rs7311358;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
IMATINIB;SLCO1B3;rs4149117;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
PRAZIQUANTEL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2 + *1/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHISTOSOMIASIS;;;
PRAZIQUANTEL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2 + *1/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHISTOSOMIASIS;;;
PRAZIQUANTEL;CYP2C19;CYP2C19*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHISTOSOMIASIS;;;
PRAZIQUANTEL;CYP2C19;CYP2C19*17;*1/*2 + *2/*2 + *1/*3 + *3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHISTOSOMIASIS;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA,LYMPHOMA,ACUTE_MYELOID_LEUKEMIA;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA,LYMPHOMA,ACUTE_MYELOID_LEUKEMIA;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA,LYMPHOMA,ACUTE_MYELOID_LEUKEMIA;;
GLYBURIDE;CHST13;rs1054097;C;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
LACOSAMIDE;CYP2C19;CYP2C19 normal metabolizer;;LADME-PK;DECREASED_EXPOSURE;OTHER;EPILEPSY;;;
LACOSAMIDE;ABCC2;rs717620;T;LADME-PK;DECREASED_EXPOSURE;OTHER;EPILEPSY;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1;*1/*3 + *1/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*3;*1/*3 + *1/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*4;*1/*3 + *1/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*3;*4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SURGERY;;;
PHENYTOIN;CYP2C9;CYP2C9*2;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SURGERY;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*1;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SURGERY;;;
CLOZAPINE;CYP2D6;CYP2D6 normal metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP2D6;CYP2D6 normal metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;PSYCHOTIC DISORDER;;;
EFAVIRENZ;CYP2B6;CYP2B6 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
MERCAPTOPURINE;TPMT;TPMT deficiency;;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
THIOGUANOSINE DIPHOSPHATE;TPMT;TPMT*1;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE DIPHOSPHATE;TPMT;TPMT*3A;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE DIPHOSPHATE;TPMT;TPMT*3B;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE DIPHOSPHATE;TPMT;TPMT*3C;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE MONOPHOSPHATE;TPMT;TPMT*1;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE MONOPHOSPHATE;TPMT;TPMT*3A;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE MONOPHOSPHATE;TPMT;TPMT*3B;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE MONOPHOSPHATE;TPMT;TPMT*3C;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT*1;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT*3A;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT*3B;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT*3C;*3A + *3B + *3C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TOLTERODINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METOPROLOL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOZAPINE;ITIH3;rs2535629;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
EFAVIRENZ;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
COTININE;CYP2A6;CYP2A6 low activity;;LADME-PK;INCREASED_METABOLISM;OTHER;TOBACCO USE DISORDER;;;
COTININE;CYP2A6;CYP2A6 low activity;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*1;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*2;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*4;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*9;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*12;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*17;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*20;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*23;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*24;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*25;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*26;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*27;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*28;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
NICOTINE;CYP2A6;CYP2A6*35;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
DEOXY-THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT deficiency;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT deficiency;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
CAFFEINE;ADORA1;rs10920573;CC;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;APNEA OF PREMATURITY;;;
NORQUETIAPINE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
NORQUETIAPINE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
QUETIAPINE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
QUETIAPINE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
AMLODIPINE;CACNA1D;rs312481;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
PEGINTERFERON ALFA-2A;ZHX2;rs17289471;C;EFFICACY;INCREASED_RESPONSE;OTHER;HEPATITIS B VIRUS INFECTION;;;
BERBERINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY, OTHER;RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
RANIBIZUMAB;VEGFA;rs833069;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
TACROLIMUS;CYP3A5;rs4646449;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
ONDANSETRON;CYP2D6;CYP2D6 poor metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
IMATINIB;ABCA3;rs150929;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
METFORMIN;CBARP;rs2301759;TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;STK11;rs2301759;TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;SLC22A3;rs3127602;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;PRKAA1;rs11749180;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;SLC29A4;rs10234709;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;PRKAG2;rs4725434;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;SLC47A1;rs2120274;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;STK11;rs2301759;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;SLC47A2;rs4621031;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ALECTINIB;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NON-SMALL CELL LUNG CARCINOMA;;;
ALECTINIB;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NON-SMALL CELL LUNG CARCINOMA;;;
METFORMIN;TCF7L2;rs7903146;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METHADONE;OPRK1;rs3802279;CC;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
ELEXACAFTOR;CFTR;rs80034486;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs80034486;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs80034486;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
LACOSAMIDE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
LACOSAMIDE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
LACOSAMIDE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
N-DESMETHYLTRAMADOL;SLC22A1;rs41267797;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
O-DESMETHYLTRAMADOL;SLC22A1;rs41267797;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
N;CYP2D6;CYP2D6*1;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N;CYP2D6;CYP2D6*2;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N;CYP2D6;CYP2D6*4;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N;CYP2D6;CYP2D6*5;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N;CYP2D6;CYP2D6*6;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N;CYP2D6;CYP2D6*10;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N;CYP2D6;CYP2D6*17;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N;CYP2D6;CYP2D6*29;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N;CYP2D6;CYP2D6*41;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N;CYP2D6;CYP2D6*45;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*1;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*2;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*4;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*5;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*6;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*10;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*17;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*29;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*41;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*45;*4/*6 + *4/*5;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;IMMUNOGLOBULIN A VASCULITIS;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;IMMUNOGLOBULIN A VASCULITIS;;
ELEXACAFTOR;CFTR;rs75961395;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs75961395;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs75961395;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TOCILIZUMAB;IL6R;rs35717427;AG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
N-DESMETHYLTRAMADOL;ABCC2;rs17216317;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
O-DESMETHYLTRAMADOL;ABCC2;rs17216317;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
TOCILIZUMAB;IL6R;rs6690230;CG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
TOCILIZUMAB;IL6R;rs11265621;AA + AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
TOCILIZUMAB;nan;rs10108210;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
TOCILIZUMAB;CLEC2D;rs1560011;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
TOCILIZUMAB;KCNMB1;rs703505;AA + AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ELDERLY ADULT,MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ELDERLY ADULT,MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ELDERLY ADULT,MAJOR DEPRESSIVE DISORDER;;
MORPHINE;CCL11;rs17809012;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;NEOPLASMS;;;
MORPHINE;CCL11;rs17809012;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
MORPHINE;IL16;rs4778889;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;NEOPLASMS;;;
MORPHINE;IL16;rs4778889;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
N-DESMETHYLTRAMADOL;SLC22A1;rs35235578;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
O-DESMETHYLTRAMADOL;SLC22A1;rs35235578;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
VALPROIC ACID;SLC16A1;rs7169;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
N-DESMETHYLTRAMADOL;SLC22A1;rs9457841;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
O-DESMETHYLTRAMADOL;SLC22A1;rs9457841;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
N-DESMETHYLTRAMADOL;SLC22A1;rs34134157;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
O-DESMETHYLTRAMADOL;SLC22A1;rs34134157;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
TENOFOVIR;ABCC4;rs3742106;AC + CC;TOXICITY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
ANTIDEPRESSANTS;FKBP5;rs1360780;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ACETAMINOPHEN SULFATE;CYP2E1;CYP2E1*1;*1/*5B;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PATENT DUCTUS ARTERIOSUS;;;
ACETAMINOPHEN SULFATE;CYP2E1;CYP2E1*1;*1/*5B;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PREMATURE BIRTH;;;
ACETAMINOPHEN SULFATE;CYP2E1;CYP2E1*5B;*1/*5B;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PATENT DUCTUS ARTERIOSUS;;;
ACETAMINOPHEN SULFATE;CYP2E1;CYP2E1*5B;*1/*5B;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PREMATURE BIRTH;;;
FENTANYL;ABCC1;rs58572178;(A)14;LADME-PK;INCREASED_CLEARANCE;OTHER;PAIN;;;
FENTANYL;ABCC1;rs58572178;(A)14;LADME-PK;INCREASED_CLEARANCE;OTHER;PREMATURE BIRTH;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2 + *17;DOSAGE;DOSE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*2 + *17;DOSAGE;DOSE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;;
ACETAMINOPHEN;CYP1A2;rs2069514;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PATENT DUCTUS ARTERIOSUS;;;
DOXORUBICIN;CBR1;rs20572;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
SUNITINIB;KDR;rs34231037;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
ANTIDEPRESSANTS;FKBP5;rs3800373;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
GLICLAZIDE;KCNQ1;rs163184;GT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
GLIMEPIRIDE;KCNQ1;rs163184;GT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
GLIPIZIDE;KCNQ1;rs163184;GT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
GLYBURIDE;KCNQ1;rs163184;GT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ISONIAZID;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
MORPHINE;CYP2D6;CYP2D6*10;*41;LADME-PK;INCREASED_EXPOSURE;OTHER;POSTOPERATIVE_PAIN;;;
MORPHINE;CYP2D6;CYP2D6*41;*41;LADME-PK;INCREASED_EXPOSURE;OTHER;POSTOPERATIVE_PAIN;;;
DULOXETINE;DRD3;rs324026;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANXIETY DISORDERS;;
CYTARABINE;RAD50;rs2299014;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
DAUNORUBICIN;RAD50;rs2299014;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER;ACUTE_MYELOID_LEUKEMIA;;;
TENOFOVIR;ABCC4;rs1751034;TT;TOXICITY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
DULOXETINE;DRD3;rs324023;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANXIETY DISORDERS;;
EFAVIRENZ;NR1I2;rs1523127;AA + AC;EFFICACY;DECREASED_RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;;;
NEVIRAPINE;NR1I2;rs1523127;AA + AC;EFFICACY;DECREASED_RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;;;
EZETIMIBE;ABCG8;ABCG8 deficiency;;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;;;
EZETIMIBE;ABCG5;ABCG5 deficiency;;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;;;
RABEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
DULOXETINE;DRD3;rs167770;AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ANXIETY DISORDERS;;
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BIPOLAR_DISORDER,SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
TAMSULOSIN;CYP2D6;CYP2D6*10;*10 + *41;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PROSTATIC HYPERPLASIA;;;
TAMSULOSIN;CYP2D6;CYP2D6*41;*10 + *41;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PROSTATIC HYPERPLASIA;;;
HYDROXYUREA;HBG2;rs7482144;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
HYDROXYUREA;HBG2;rs7482144;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ALPHA-THALASSEMIA;;;
HYDROXYUREA;HBG2;rs7482144;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
HYDROXYUREA;HBG2;rs7482144;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
HYDROXYUREA;BCL11A;rs766432;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
IMATINIB;PDGFRB;rs201866603;CT;EFFICACY;DECREASED_RESPONSE;EFFICACY;INFANTILE MYOFIBROMATOSIS;;;
FLUOROURACIL;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
VORTIOXETINE;CYP2D6;CYP2D6*1;*4/*4 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORTIOXETINE;CYP2D6;CYP2D6*4;*4/*4 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORTIOXETINE;CYP2D6;CYP2D6*10;*4/*4 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ANTIEPILEPTICS;SCN1A;rs121917953;AA + AT;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY;;;
NICOTINE;CYP2A6;rs778019189;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
METHOTREXATE;ENG;rs1800956;G;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
METHOTREXATE;PKD1L2;rs16954698;A;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*4;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
ANTIDEPRESSANTS;FKBP5;rs1360780;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;ADVERSE EVENTS;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;SIDE EFFECT:CHOLESTASIS;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;ADVERSE EVENTS;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;SIDE EFFECT:CHOLESTASIS;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;ADVERSE EVENTS;;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;SIDE EFFECT:CHOLESTASIS;;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;ADVERSE EVENTS;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;SIDE EFFECT:CHOLESTASIS;;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;SIDE EFFECT;SIDE EFFECT:THROMBOCYTOPENIA;;;
EFAVIRENZ;NR1I3;rs3003596;AG + GG;EFFICACY;DECREASED_RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;;;
NEVIRAPINE;NR1I3;rs3003596;AG + GG;EFFICACY;DECREASED_RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE;;;
ANTIDEPRESSANTS;FKBP5;rs4713916;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
ENDOXIFEN;CYP2D6;CYP2D6*1;*10/*10 + *2/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ENDOXIFEN;CYP2D6;CYP2D6*2;*10/*10 + *2/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ENDOXIFEN;CYP2D6;CYP2D6*10;*10/*10 + *2/*10;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOZAPINE;CYP2D6;rs202102799;C;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP2D6;rs202102799;C;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
CLOZAPINE;CYP2D6;rs28371726;G;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP2D6;rs28371726;G;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
CLOZAPINE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
CLOZAPINE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
CLOZAPINE;DRD4;rs762502;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;DRD4;rs762502;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSYCHOTIC DISORDER;;;
NIFEDIPINE;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;PREGNANCY;;
CLOZAPINE;DRD4;rs2133251840;del;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;DRD4;rs2133251840;del;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSYCHOTIC DISORDER;;;
CLOZAPINE;CYP1A2;CYP1A2 ultrarapid metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP1A2;CYP1A2 ultrarapid metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2 ultrarapid metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2 ultrarapid metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
EXENATIDE;SORCS1;rs1416406;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
LINAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SITAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
VILDAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
LINAGLIPTIN;PRKD1;rs57803087;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SAXAGLIPTIN;PRKD1;rs57803087;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SITAGLIPTIN;PRKD1;rs57803087;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
VILDAGLIPTIN;PRKD1;rs57803087;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
CLOZAPINE;CYP1A2;CYP1A2*8;*8;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
MIDAZOLAM;NR1I2;rs2461817;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;RESPIRATORY FAILURE REQUIRING ASSISTED VENTILATION;;;
METHADONE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
R-EDDP;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
S-EDDP;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
FLUOROURACIL;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ULCERATIVE COLITIS,CROHN DISEASE,AUTOIMMUNE HEPATITIS;;
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;APOE;rs7412;CC;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;APOE;rs7412;CC;DOSAGE;INCREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;APOE;rs7412;CC;DOSAGE;INCREASED_DOSE;OTHER;VENOUS THROMBOSIS;;;
METHACHOLINE;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TEMSIROLIMUS;NR1I2;rs3814055;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
TEMSIROLIMUS;ABCB1;rs2032582;CC;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;nan;rs4646457;C;DOSAGE;DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs15524;G;DOSAGE;DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;rs12333983;A;DOSAGE;DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;RHEUMATIC HEART DISEASE;;
FLECAINIDE;SCN4A;rs80338792;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYOTONIA;;
ATENOLOL;nan;rs294610;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
METOPROLOL;nan;rs294610;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
ATENOLOL;SLC4A1;rs45545233;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
METOPROLOL;SLC4A1;rs45545233;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CAPECITABINE;DPYD;rs56038477;CT;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;DPYD;rs56038477;CT;DOSAGE;DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
SUNITINIB;ABCB1;rs2032582;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RENAL CELL CARCINOMA;;
FLUOROURACIL;DPYD;rs17376848;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;COLORECTAL NEOPLASMS;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
HYDROCHLOROTHIAZIDE;nan;rs11065987;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
METHADONE;ABCB1;rs1128503;AA;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ETHANOL;OPRM1;rs553202;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ETHANOL;OPRM1;rs524731;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
S-EDDP;ABCB1;rs1128503;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
NICOTINE;HINT1;rs3852209;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
S-EDDP;ABCB1;rs1045642;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
OPIOIDS;OPRM1;rs1799971;AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
METHADONE;ABCB1;rs1128503;AG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUOXETINE;CYP2D6;rs3892097;CT;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;EFFICACY;ALCOHOL ABUSE;;;
FLUOXETINE;CYP2D6;rs3892097;CT;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;EFFICACY;EFFICACY:MAJOR DEPRESSIVE DISORDER;;;
LEVODOPA;DBH;rs1611115;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COCAINE DEPENDENCE;;
VENLAFAXINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
AXITINIB;OR2B11;rs35305980;A;LADME-PK;CONCENTRATIONS;nan;DISEASE;RENAL CELL CARCINOMA;;
SULFONAMIDES;KCNJ11;rs5219;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
UREA DERIVATIVES;KCNJ11;rs5219;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
WARFARIN;VKORC1;rs7294;T;DOSAGE, LADME-PK;INCREASED_DOSE;nan;nan;;;
SULFONAMIDES;ABCC8;rs757110;AA + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
UREA DERIVATIVES;ABCC8;rs757110;AA + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
TIPIRACIL HYDROCHLORIDE;SLC29A1;rs9394992;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TRIFLURIDINE;SLC29A1;rs9394992;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ANTIDEPRESSANTS;BDNF;rs61888800;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DESIPRAMINE;BDNF;rs61888800;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;BDNF;rs61888800;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
AXITINIB;UGT1A10;rs3832043;del;LADME-PK;CONCENTRATIONS;nan;DISEASE;RENAL CELL CARCINOMA;;
AXITINIB;UGT1A8;rs3832043;del;LADME-PK;CONCENTRATIONS;nan;DISEASE;RENAL CELL CARCINOMA;;
AXITINIB;UGT1A9;rs3832043;del;LADME-PK;CONCENTRATIONS;nan;DISEASE;RENAL CELL CARCINOMA;;
AXITINIB;UGT1A7;rs17868323;G;LADME-PK;CONCENTRATIONS;nan;DISEASE;RENAL CELL CARCINOMA;;
RISPERIDONE;HTR2C;rs3813928;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;AUTISM;;
METHOTREXATE;MTRR;rs1532268;CT + TT;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
RISPERIDONE;HTR2A;rs6311;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTISM;;
AXITINIB;ABCB1;rs1045642;A;LADME-PK;CONCENTRATIONS;nan;DISEASE;RENAL CELL CARCINOMA;;
AXITINIB;ABCG2;rs2231142;T;LADME-PK;CONCENTRATIONS;nan;DISEASE;RENAL CELL CARCINOMA;;
AXITINIB;ABCB1;rs2032582;T;LADME-PK;CONCENTRATIONS;nan;DISEASE;RENAL CELL CARCINOMA;;
VORICONAZOLE;CYP2C19;rs4244285;AA + AG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
ERLOTINIB;EGFR;rs121434568;GT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
METHOTREXATE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CYTARABINE;SLC29A1;rs3734703;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
SUNITINIB;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;RENAL CELL CARCINOMA,METASTATIC NEOPLASM;;
METHOTREXATE;SLC19A1;rs1051266;CC + TT;EFFICACY;DECREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
SN-38;UGT1A9;rs3832043;TT;DOSAGE;INCREASED_METABOLISM;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RISPERIDONE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTISM;;
EFAVIRENZ;CYP2B6;rs2279345;CT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
GLUCOCORTICOIDS;CRHR1;rs1876828;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
ANTIDEPRESSANTS;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
SN-38;SLCO1B1;rs4149056;CC + CT;DOSAGE;INCREASED_DOSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
(S)-METHADONE;CYP3A4;rs2740574;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
VORICONAZOLE;CYP2C19;rs4986893;AA + AG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;nan;;;
METHYLPHENIDATE;GRIN2B;rs2284411;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
WARFARIN;VKORC1;rs17708472;A;DOSAGE, LADME-PK;INCREASED_DOSE;nan;nan;;;
FENTANYL;CYP3A4;rs2740574;C;LADME-PK;DECREASED_CLEARANCE;OTHER;BURNS;;;
METHOTREXATE;SLC19A1;rs1051266;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
SALBUTAMOL;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
ATORVASTATIN;ABCA1;rs2230806;T;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ROSUVASTATIN;ABCA1;rs2230806;T;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
SIMVASTATIN;ABCA1;rs2230806;T;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
SALBUTAMOL;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
ATORVASTATIN;CYP2D6;rs3892097;T;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ROSUVASTATIN;CYP2D6;rs3892097;T;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
SIMVASTATIN;CYP2D6;rs3892097;T;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
NICARDIPINE;CACNA1B;rs2739258;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BIPOLAR_DISORDER;;;
NIMODIPINE;CACNA1B;rs2739258;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BIPOLAR_DISORDER;;;
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_RESPONSE;OTHER;NON-HODGKIN LYMPHOMA;;;
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
IMATINIB;CYP3A5;rs776746;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
IMATINIB;SLC22A1;rs683369;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
SIMVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DYSLIPIDAEMIA;;
IRBESARTAN;APOB;rs1367117;AG;EFFICACY, LADME-PK;RESPONSE;nan;DISEASE;HYPERTENSION;;
IRBESARTAN;APOB;rs1367117;GG;EFFICACY;RESPONSE;nan;DISEASE;HYPERTENSION;;
ATORVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DYSLIPIDAEMIA;;
EFAVIRENZ;CYP2A6;rs28399433;C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
BENAZEPRIL;PRCP;rs2229437;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
EFAVIRENZ;UGT2B7;rs28365062;GG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, OTHER;RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
EFAVIRENZ;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HIV INFECTIOUS DISEASE;;;
LAMIVUDINE;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HIV INFECTIOUS DISEASE;;;
TENOFOVIR;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HIV INFECTIOUS DISEASE;;;
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
CLOPIDOGREL;ABCB1;rs1045642;G;EFFICACY, OTHER;RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
QUETIAPINE;RGS4;rs951439;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ZIPRASIDONE;RGS4;rs951439;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
MIDAZOLAM;VDR;rs11568820;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
METHYLDOPA;ARG2;rs3742879;G;EFFICACY;INCREASED_RESPONSE;OTHER;PREGNANCY;;;
METHYLDOPA;ARG2;rs3742879;G;EFFICACY;INCREASED_RESPONSE;OTHER;PRE-ECLAMPSIA;;;
FLUOROURACIL;MTHFR;rs1801133;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ARIPIPRAZOLE;ABCB1;rs1128503;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
OMEPRAZOLE;CYP2C19;rs12248560;TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;NO DISEASE;;;
MEPHENYTOIN;CYP2C19;rs12248560;TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;NO DISEASE;;;
OMEPRAZOLE;CYP2C19;rs11188072;TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;NO DISEASE;;;
MEPHENYTOIN;CYP2C19;rs11188072;TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;NO DISEASE;;;
METHADONE;CYP2B6;rs3211371;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
MERCAPTOPURINE;SLCO1B1;rs4149056;CC + CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
GEMCITABINE;CMPK1;rs1044457;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
DEXMEDETOMIDINE;ADRA2A;rs1800035;CG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
BUDESONIDE;IL10;rs3024498;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
FLUTICASONE;IL10;rs3024498;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
SALMETEROL;IL10;rs3024498;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
FORMOTEROL;IL10;rs3024498;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
OMALIZUMAB;IL10;rs3024498;CC + CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
DEXMEDETOMIDINE;ADRA2A;rs775887911;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
DEXMEDETOMIDINE;ADRA2A;rs201376588;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
GEMCITABINE;CMPK1;rs35687416;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
GEMCITABINE;DCTD;rs12507552;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
BETA BLOCKING AGENTS;nan;rs139945292;T;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
ROSUVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DYSLIPIDAEMIA;;
GEMCITABINE;TENT4A;rs274713;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
METHOTREXATE;FPGS;rs1544105;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
GEMCITABINE;CDC5L;rs992160;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
METHOTREXATE;TYMS;rs2853539;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ATORVASTATIN;APOA5;rs662799;AA;OTHER;RESPONSE;nan;DISEASE;DYSLIPIDAEMIA;;
ROSUVASTATIN;APOA5;rs662799;AA;OTHER;RESPONSE;nan;DISEASE;DYSLIPIDAEMIA;;
SIMVASTATIN;APOA5;rs662799;AA;OTHER;RESPONSE;nan;DISEASE;DYSLIPIDAEMIA;;
BUDESONIDE;IL17A;rs3819024;AG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
FLUTICASONE;IL17A;rs3819024;AG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
SALMETEROL;IL17A;rs3819024;AG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
FORMOTEROL;IL17A;rs3819024;AG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
OMALIZUMAB;IL17A;rs3819024;AG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
GEMCITABINE;SH2D5;rs10916852;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
ROSUVASTATIN;CETP;rs708272;A;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ATORVASTATIN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CORONARY ARTERY DISEASE;;;
ATORVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CORONARY ARTERY DISEASE;;;
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE, TOXICITY;DECREASED_DOSE;nan;nan;;;
AZATHIOPRINE;TPMT;rs1142345;CT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;ITPA;rs1127354;AC;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
BUPRENORPHINE;CYP3A4;rs2740574;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ISCHEMIA,PAIN;;
PERINDOPRIL;AGTR1;rs5186;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
NITRENDIPINE;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
LAMOTRIGINE;HNF4A;rs2071197;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
LAMOTRIGINE;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
LAMOTRIGINE;ABCG2;rs3114020;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
CYCLOSPORINE;TSPYL1;rs3828743;AG + GG;LADME-PK;INCREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;;;
GEMCITABINE;CMPK1;rs7543016;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
GEMCITABINE;ESR2;rs944050;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
RISPERIDONE;DRD2;rs1799978;TT;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
IRINOTECAN;ABCC2;rs2273697;AA + AG;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;COLORECTAL NEOPLASMS;;
RISPERIDONE;DRD2;rs1799978;T;OTHER;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
LETROZOLE;CYP19A1;rs4646;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;BREAST NEOPLASMS;;
ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
WARFARIN;nan;rs12777823;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
CONJUGATED ESTROGENS;SLCO1B1;rs4149056;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MENOPAUSE;;
CISPLATIN;ERCC1;rs3212986;A;EFFICACY;DECREASED_RESPONSE;OTHER;OVARIAN NEOPLASMS;;;
ANTIPSYCHOTICS;ABCB1;rs1045642;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;ABCB1;rs2032582;AA;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;SCHIZOPHRENIA;;
DIAZEPAM;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ALCOHOL ABUSE;;;
ALPRAZOLAM;CYP3A4;rs35599367;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ALCOHOL ABUSE;;;
ALPRAZOLAM;CYP3A4;rs35599367;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ANXIETY DISORDERS;;;
DIAZEPAM;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ALCOHOL ABUSE;;;
CLOZAPINE;POR;rs1057868;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;POR;rs1057868;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;;;
SALBUTAMOL;IGF2R;rs8191725;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
SALBUTAMOL;SLC24A4;rs77441273;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
ALPRAZOLAM;CYP3A4;rs35599367;AG;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
ALPRAZOLAM;CYP3A4;rs35599367;AG;EFFICACY;DECREASED_RESPONSE;OTHER;ANXIETY DISORDERS;;;
LANSOPRAZOLE;IL1B;rs16944;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;IL1B;rs16944;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;IL1B;rs16944;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
LANSOPRAZOLE;IL1B;rs16944;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
OMEPRAZOLE;IL1B;rs16944;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
RABEPRAZOLE;IL1B;rs16944;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
METHOTREXATE;AHRR;rs2292596;G;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
WARFARIN;VKORC1;rs2359612;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PLATINUM COMPOUNDS;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;OVARIAN NEOPLASMS;;;
PLATINUM COMPOUNDS;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;NEOPLASM OF ESOPHAGUS;;;
PLATINUM COMPOUNDS;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;NEOPLASMS;;;
ULINASTATIN;MMP2;rs243865;T;EFFICACY;DECREASED_RESPONSE;OTHER;PANCREATITIS;;;
ANTIPSYCHOTICS;ABCB1;rs1128503;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ULINASTATIN;MMP9;rs3918242;T;EFFICACY;INCREASED_RESPONSE;OTHER;PANCREATITIS;;;
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;NR1I2;rs2276707;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ANTIPSYCHOTICS;ABCB1;rs1045642;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
IRINOTECAN;NR1I2;rs10934498;AA;TOXICITY, LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;COLONIC NEOPLASMS;;
TACROLIMUS;IL10;rs1800896;CC;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
OLANZAPINE;RGS4;rs2842030;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PERPHENAZINE;RGS4;rs2842030;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
OLANZAPINE;DRD3;rs324026;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
CYTARABINE;ADH1A;rs6811453;A;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
FLUDARABINE;ADH1A;rs6811453;A;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
GEMTUZUMAB OZOGAMICIN;ADH1A;rs6811453;A;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
IDARUBICIN;ADH1A;rs6811453;A;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
RISPERIDONE;RGS4;rs2842030;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
MEASLES VACCINES;TLR3;rs3775291;CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CYTARABINE;ADH1A;rs1826909;T;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
FLUDARABINE;ADH1A;rs1826909;T;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
GEMTUZUMAB OZOGAMICIN;ADH1A;rs1826909;T;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
IDARUBICIN;ADH1A;rs1826909;T;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TAMOXIFEN;ABCC2;rs717620;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
SALBUTAMOL;nan;rs77149876;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
ETANERCEPT;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
SALBUTAMOL;PAPPA2;rs77977790;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
NORBUPRENORPHINE;OPRD1;rs569356;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS;;;
TACROLIMUS;CYP3A4;rs2740574;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SALMETEROL;ADRB2;rs1042713;G;EFFICACY;INCREASED_RESPONSE;OTHER;ASTHMA;;;
SALBUTAMOL;nan;rs116551936;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
SALBUTAMOL;NCOA3;rs115501901;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
LITHIUM;CACNG2;rs2284017;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
SALBUTAMOL;nan;rs74973995;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
SALBUTAMOL;CRHR2;rs73294475;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
PHENPROCOUMON;CYP3A4;rs2740574;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SALBUTAMOL;ADCY9;rs144315541;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
PERPHENAZINE;MCPH1;rs17570753;A;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PERPHENAZINE;CDH13;rs2116971;G;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PERPHENAZINE;SKOR2;rs9952628;G;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
METFORMIN;SLC47A2;rs12943590;AA;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
QUETIAPINE;KCNMA1;rs35793;G;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PERPHENAZINE;MAML3;rs11100483;A;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
VALPROIC ACID;UGT2B7;rs7668258;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
METHACHOLINE;RUNX1;rs11702779;AA;OTHER;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
RISPERIDONE;LRP1B;rs874295;G;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
BEVACIZUMAB;HTRA1;rs11200638;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
RISPERIDONE;PSMD14;rs9713;A;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;AGAP1;rs1869295;C;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
BEVACIZUMAB;ARMS2;rs10490924;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
VALPROIC ACID;APEH;rs3816877;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
RISPERIDONE;NPAS3;rs1315115;G;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;TMEFF2;rs3738883;G;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
METFORMIN;PCK1;rs4810083;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ZIPRASIDONE;CDH4;rs4925300;A;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ZIPRASIDONE;LYN;rs1546519;G;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
BEVACIZUMAB;CFH;rs800292;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
WARFARIN;CYP2C9;rs1799853;CT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ZIPRASIDONE;NALCN;rs9585618;C;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ZIPRASIDONE;CNTN4;rs17194378;A;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;NEOPLASMS,PAIN;;
IMATINIB;SLCO1A2;rs4148978;CT + TT;TOXICITY, LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;GASTROINTESTINAL STROMAL TUMORS;;
IMATINIB;SLCO1B3;rs4149117;GG;TOXICITY, LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;GASTROINTESTINAL STROMAL TUMORS;;
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;CALU;rs2290228;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OLANZAPINE;nan;rs12610827;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
REMIFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
FENOFIBRATE;APOB;rs676210;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
METHACHOLINE;RUNX1;rs11702779;AG + GG;OTHER;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
CITALOPRAM;SERPINE1;rs1799889;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SERPINE1;rs1799889;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
METHOTREXATE;MTR;rs1805087;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NON-HODGKIN LYMPHOMA;;;
METHOTREXATE;MTR;rs1805087;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
CITALOPRAM;FKBP5;rs4713916;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
FLUOXETINE;FKBP5;rs4713916;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
MIRTAZAPINE;FKBP5;rs4713916;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
PAROXETINE;FKBP5;rs4713916;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;FKBP5;rs4713916;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
VENLAFAXINE;FKBP5;rs4713916;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MOOD DISORDER;;
OLANZAPINE;CSMD1;rs17070785;A;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
OLANZAPINE;PLAGL1;rs2247408;C;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
SIROLIMUS;CYP3A5;rs15524;AA;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
OLANZAPINE;PLAGL1;rs3819811;A;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
SIROLIMUS;CYP3A5;rs4646453;CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
ACETAMINOPHEN;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OLANZAPINE;PTPRN2;rs221253;C;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
IMATINIB;SLC22A1;rs628031;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
WARFARIN;NQO1;rs1800566;AA + AG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
PERPHENAZINE;PRKCE;rs2278773;C;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PERPHENAZINE;nan;rs11774231;C;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
HYDROCHLOROTHIAZIDE;DOT1L;rs2269879;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PAROXETINE;ADM;rs11042725;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TILDRAKIZUMAB;ATG5;rs9373839;CT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
TILDRAKIZUMAB;IL17RC;rs708567;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
CITALOPRAM;BDNF;rs7124442;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ARIPIPRAZOLE;ABCB1;rs2032582;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;nan;;;
CLOZAPINE;OXT;rs2740204;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
DIAZEPAM;CYP3A4;rs35599367;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ALCOHOL ABUSE;;;
METHOTREXATE;MTHFR;rs1801133;G;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CROHN DISEASE;;;
METHOTREXATE;DHFR;rs408626;C;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CROHN DISEASE;;;
REPAGLINIDE;NOS1AP;rs10494366;T;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
CITALOPRAM;BDNF;rs7103411;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CITALOPRAM;BDNF;rs6265;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
LAMIVUDINE;ABCC1;rs212091;CC + CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
LOPINAVIR;ABCC1;rs212091;CC + CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RITONAVIR;ABCC1;rs212091;CC + CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ZIDOVUDINE;ABCC1;rs212091;CC + CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
FLUOXETINE;BDNF;rs6265;CT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TILDRAKIZUMAB;TNFAIP3;rs610604;GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
ANTIDEPRESSANTS;ERICH3;rs11580409;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
CLOPIDOGREL;CYP2C19;rs12248560;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
ARIPIPRAZOLE;ABCB1;rs1045642;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;nan;;;
IVACAFTOR;CFTR;rs77932196;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
PAROXETINE;DRD3;rs6280;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ENTACAPONE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PARKINSON DISEASE;;
CLOZAPINE;CYP2D6;rs1065852;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CLOZAPINE;CYP2D6;rs16947;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
ATORVASTATIN;ABCG8;rs11887534;CC + CG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;DYSLIPIDAEMIA;;;
SIMVASTATIN;ABCG8;rs11887534;CC + CG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;DYSLIPIDAEMIA;;;
IVACAFTOR;CFTR;rs121909011;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
IMATINIB;ULK3;rs2290573;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
CLOZAPINE;DRD1;rs265976;GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
INTERFERONS;STAT3;rs4796793;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RENAL CELL CARCINOMA;;
TAMOXIFEN;SLCO2B1;rs12422149;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
ACENOCOUMAROL;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs2359612;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RISPERIDONE;HRH3;rs3787430;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
WARFARIN;nan;rs12777823;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs2884737;AC + CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
RISPERIDONE;HRH3;rs3787429;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ACENOCOUMAROL;VKORC1;rs17708472;AA + AG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ARIPIPRAZOLE;TAAR6;rs4305746;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PEGINTERFERON ALFA-2A;IL6;rs1800795;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IL6;rs1800796;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IL6;rs1800797;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;VKORC1;rs104894540;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ROSUVASTATIN;ABCG2;rs2199936;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;VKORC1;rs104894542;C;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ILOPERIDONE;CNTF;rs1800169;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ILOPERIDONE;ZFP91-CNTF;rs1800169;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
DISULFIRAM;OPRD1;rs678849;CC;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE;;;
ERYTHROPOIETIN;STIM1;rs1561876;AG + GG;EFFICACY;INCREASED_RESISTANCE;OTHER;KIDNEY DISORDER;;;
ERYTHROPOIETIN;STIM1;rs1561876;AG + GG;EFFICACY;INCREASED_RESISTANCE;OTHER;ANEMIA;;;
LATANOPROST;PTGFR;rs3753380;CC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
RANIBIZUMAB;VEGFA;rs699947;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
FUROSEMIDE;ABCC4;rs17268282;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
METFORMIN;SLC22A1;rs622342;CC;EFFICACY;RESPONSE;OTHER;GENETIC VARIATION AT RS2289669;;;
MORPHINE;COMT;rs737866;T;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
MORPHINE;COMT;rs2075507;G;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
ANTIEPILEPTICS;CYP1A1;rs2606345;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
MORPHINE;COMT;rs5746849;A;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
MORPHINE;COMT;rs7287550;C;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
MORPHINE;TXNRD2;rs7287550;C;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
MORPHINE;COMT;rs6269;A;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
CARBAMAZEPINE;CYP3A4;rs2740574;TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
MORPHINE;COMT;rs740603;A;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
MORPHINE;ABCC3;rs4793665;T;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
TACROLIMUS;POR;rs1057868;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
N-DESMETHYLTRAMADOL;CYP2D6;rs35742686;DELT/T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
O-DESMETHYLTRAMADOL;CYP2D6;rs35742686;DELT/T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
N-DESMETHYLTRAMADOL;CYP3A4;rs35599367;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
TRAMADOL;CYP3A4;rs35599367;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE;;;
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE;;;
CLOPIDOGREL;ABCC2;rs717620;CC;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE;;;
ATAZANAVIR;SORCS2;rs73208473;A;LADME-PK;DECREASED_EXPOSURE;OTHER;HIV INFECTIOUS DISEASE;;;
WARFARIN;VKORC1;rs104894539;A;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs104894541;C;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ZNF816;rs9304742;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
CARBAMAZEPINE;UGT2B7;rs28365063;AA;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
CARBAMAZEPINE;NR1I2;rs3814055;T;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PGLYRP4;rs2916205;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
SULFONAMIDES;CYP2C9;rs1799853;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
UREA DERIVATIVES;CYP2C9;rs1799853;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
SUMATRIPTAN;GNB3;rs5443;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CLUSTER HEADACHE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs2546890;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1135840;G;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
CANNABINOIDS;TRPV1;rs8065080;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
RIVAROXABAN;ABCB1;rs4728709;AA + AG;LADME-PK;INCREASED_CLEARANCE;OTHER;ATRIAL FIBRILLATION;;;
CANNABINOIDS;UGT2B7;rs7438135;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTNNA2;rs11126740;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
IMATINIB;ABCG2;rs2231142;GT;OTHER, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
REPAGLINIDE;KCNJ11;rs5219;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
TRAMADOL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
REPAGLINIDE;TCF7L2;rs290487;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
MORPHINE;COMT;rs4680;A;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
CARBAMAZEPINE;EPHX1;rs1051740;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
MORPHINE;COMT;rs4818;C;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
ERYTHROPOIETIN;ORAI1;rs12320939;GG + GT;EFFICACY;INCREASED_RESISTANCE;OTHER;KIDNEY DISORDER;;;
ERYTHROPOIETIN;ORAI1;rs12320939;GG + GT;EFFICACY;INCREASED_RESISTANCE;OTHER;ANEMIA;;;
CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
MORPHINE;COMT;rs2239393;A;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MORPHINE;ARVCF;rs165728;T;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
MORPHINE;COMT;rs165728;T;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
CARBAMAZEPINE;ABCB1;rs4148740;AG;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
CARBAMAZEPINE;ABCB1;rs4148739;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
MORPHINE;ARVCF;rs174699;T;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
MORPHINE;COMT;rs174699;T;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS;;
ANTIPSYCHOTICS;DRD2;rs1799732;del;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
HMG COA REDUCTASE INHIBITORS;CETP;rs1532624;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CDKAL1;rs6908425;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
HMG COA REDUCTASE INHIBITORS;SIK3;rs533556;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-C;rs12191877;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
RITODRINE;KCNMB2;rs7624046;TT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CARBAMAZEPINE;ABCC2;rs4148386;AA + AG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
WARFARIN;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CARBAMAZEPINE;ABCC2;rs3740066;CT + TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAP3K1;rs96844;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
RITODRINE;KCNMB2;rs9839376;CC;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
WARFARIN;GGCX;rs11676382;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CARBAMAZEPINE;NR1I2;rs7643645;G;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
MORPHINE;METTL21A;rs2952768;CC;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
CARBAMAZEPINE;NR1I2;rs4688040;T;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
CANNABINOIDS;ABCB1;rs1045642;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
CARBAMAZEPINE;NR1I2;rs2461817;C;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
METOPROLOL;ADRB1;rs1801252;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs2884737;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CITALOPRAM;SRP19;rs495794;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;SRP19;rs495794;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;SRP19;rs495794;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;SRP19;rs495794;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CITALOPRAM;REEP5;rs153560;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;REEP5;rs153560;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;REEP5;rs153560;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;REEP5;rs153560;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;VKORC1;rs8050894;GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CITALOPRAM;REEP5;rs153549;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;REEP5;rs153549;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;REEP5;rs153549;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SERTRALINE;REEP5;rs153549;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ATAZANAVIR;ABCB1;rs1045642;AA + AG;DOSAGE;DOSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ATAZANAVIR;SLCO1B1;rs4149056;TT;DOSAGE;DOSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
FLUOROURACIL;DPYD;rs3918290;CT;OTHER, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
ATAZANAVIR;NR1I2;rs2472677;TT;DOSAGE;DOSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;VKORC1;rs61742245;AC;DOSAGE;INCREASED_DOSE;OTHER;WARFARIN MAINTENANCE TREATMENT;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
DOCETAXEL;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PACLITAXEL;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
VINORELBINE;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
DOCETAXEL;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PACLITAXEL;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
VINORELBINE;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
DOCETAXEL;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PACLITAXEL;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
VINORELBINE;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
DOCETAXEL;CASP7;rs7921977;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;CASP7;rs7921977;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PACLITAXEL;CASP7;rs7921977;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;CASP7;rs7921977;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
VINORELBINE;CASP7;rs7921977;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
OLANZAPINE;SLC26A9;rs11240594;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
SOLANIDINE;NFIB;rs28379954;CC + CT;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ZIPRASIDONE;EHF;rs286913;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOZAPINE;SLC6A3;rs2975226;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
OLANZAPINE;IL1A;rs11677416;C;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CYCLOSPORINE;POR;rs1057868;TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CARBAMAZEPINE;EPHX1;rs1051740;C;DOSAGE, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
PIOGLITAZONE;PTPRD;rs17584499;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ACENOCOUMAROL;VKORC1;rs9923231;CC + CT;EFFICACY;INCREASED_DOSE;nan;nan;;;
WARFARIN;VKORC1;rs9923231;CC + CT;EFFICACY;INCREASED_DOSE;nan;nan;;;
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
ACAMPROSATE;GRIN2B;rs2058878;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALCOHOL ABUSE;;
OLANZAPINE;ATP1A2;rs6688363;T;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;nan;rs8050896;T;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;TNFRSF11A;rs2980976;A;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;PPA2;rs2636697;G;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
METHOTREXATE;nan;rs1232027;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTHRITIS, PSORIATIC;;
FENTANYL;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
HYDROMORPHONE;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
OPIOIDS;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
OXYCODONE;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
TRAMADOL;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
RISPERIDONE;PPA2;rs2636719;A;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
REPAGLINIDE;IGF2BP2;rs4402960;GT + TT;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
REPAGLINIDE;IGF2BP2;rs1470579;AC + CC;DOSAGE, EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DISULFIRAM;MTHFR;rs1801133;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COCAINE DEPENDENCE;;
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTHRITIS, PSORIATIC,CROHN DISEASE,PSORIASIS,SPONDYLITIS, ANKYLOSING;;
ISONIAZID;NAT2;rs4646244;AT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
ISONIAZID;NAT2;rs1799930;AA;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TUBERCULOSIS;;
HYDROCHLOROTHIAZIDE;BEST3;rs61747221;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
DEFERIPRONE;UGT1A6;rs2070959;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTHRITIS, PSORIATIC,CROHN DISEASE,PSORIASIS,SPONDYLITIS, ANKYLOSING;;
NIFEDIPINE;ADRA1A;rs1048101;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
DEFERIPRONE;UGT1A6;rs2070959;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
DEFERIPRONE;UGT1A6;rs6759892;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
PIOGLITAZONE;PPARG;rs1801282;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
PACLITAXEL;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
OPIOIDS;TNF;rs1800629;GG;DOSAGE;INCREASED_DOSE;OTHER;NEOPLASMS;;;
OPIOIDS;TNF;rs1800629;GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
CARBAMAZEPINE;SCN1A;rs3812718;CT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
PACLITAXEL;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
RISPERIDONE;TJP1;rs813676;T;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
OPIOIDS;IL6;rs1800797;A;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS;;;
OPIOIDS;IL6;rs1800797;A;DOSAGE;DECREASED_DOSE;OTHER;PAIN;;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
METHYLPHENIDATE;ADGRL3;rs734644;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
PACLITAXEL;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
FLUTICASONE PROPIONATE;CA10;rs967676;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
MONTELUKAST;CA10;rs967676;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
CARBAMAZEPINE;EPHX1;rs1051740;CT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
CARBAMAZEPINE;EPHX1;rs1051740;CC;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
GEMCITABINE;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
FLUTICASONE PROPIONATE;nan;rs1786929;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
MONTELUKAST;nan;rs1786929;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
CYTARABINE;CDA;rs2072671;CC;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;T-CELL_LYMPHOMA;;
TACROLIMUS;ABCB1;rs2032582;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHYLPHENIDATE;ADGRL3;rs1355368;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;ADGRL3;rs6813183;CC + CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
RISPERIDONE;nan;rs7395555;C;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
RANIBIZUMAB;CFH;rs1061170;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
OLANZAPINE;SPOPL;rs10170310;C;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
QUETIAPINE;PDE4D;rs17382202;T;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
QUETIAPINE;PDE4D;rs17742120;G;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
QUETIAPINE;PDE4D;rs2164660;A;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,VENOUS THROMBOEMBOLISM;;
PERINDOPRIL;AGTR1;rs5182;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
RISPERIDONE;TJP1;rs711355;T;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;TJP1;rs785423;A;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
TENOFOVIR ALAFENAMIDE;ABCB1;rs3842;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEPATITIS B VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
CLOZAPINE;SLC6A4;rs25531;T;EFFICACY;RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RALOXIFENE;UGT1A8;rs1042597;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MENOPAUSE,SCHIZOPHRENIA;;
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
PHENPROCOUMON;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
ESOMEPRAZOLE;STAT6;rs1059513;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS;;;
RISPERIDONE;CYP2D6;rs5758550;A;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP2D6;;;
PACLITAXEL;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
ADALIMUMAB;CD40LG;rs1126535;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
RALOXIFENE;ESR1;rs11543791;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA;;;
RALOXIFENE;ESR1;rs11543791;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;MENOPAUSE;;;
RALOXIFENE;ESR1;rs11543791;CC;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
RALOXIFENE;ESR1;rs11543791;CC;EFFICACY;DECREASED_RESPONSE;OTHER;MENOPAUSE;;;
PERINDOPRIL;AGTR1;rs275651;AA + AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
LITHIUM;MYO1H;rs7959663;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
INFLIXIMAB;FCGR2A;rs1801274;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
LITHIUM;EPHX2;rs59724122;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;GRAMD1B;rs61123830;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
WARFARIN;VKORC1;rs7294;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LITHIUM;nan;rs66486766;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;nan;rs324899;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;nan;rs1611259;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;nan;rs6942227;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
NEVIRAPINE;CYP2D6;rs28371706;AA + AG;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CATECHOLAMINES;ADRB1;rs1801253;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
ACENOCOUMAROL;APOE;rs429358;CC;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,VENOUS THROMBOEMBOLISM;;
PERINDOPRIL;BDKRB1;rs12050217;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
NICOTINE_SUBSTITUTES;CHRNA5;rs680244;C;OTHER;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
ADALIMUMAB;NFATC2;rs3787186;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;NFATC2;rs3787186;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;NFATC2;rs3787186;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
NICOTINE_SUBSTITUTES;CHRNA3;rs16969968;G;OTHER;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
NICOTINE_SUBSTITUTES;CHRNA5;rs16969968;G;OTHER;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
NICOTINE_SUBSTITUTES;CHRNA5;rs680244;T;OTHER;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;OTHER;GOUT;;;
LITHIUM;FAM177A1;rs79403677;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
CLOPIDOGREL;nan;rs2487032;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TNF-ALFA_INHIBITORS;CHUK;rs11591741;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LITHIUM;ADCY1;rs1521470;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
REPAGLINIDE;KCNQ1;rs2237892;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
LITHIUM;nan;rs7588746;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;FAM178B;rs6728642;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;HEART FAILURE;;;
ZILEUTON;PRORP;rs12436663;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
LITHIUM;ZNF804A;rs62200793;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;nan;rs1611255;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;nan;rs209474;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
REPAGLINIDE;KCNQ1;rs2237895;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
LITHIUM;nan;rs3919583;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GLATIRAMER ACETATE;TGFB1;rs1800469;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
ANTIEPILEPTICS;ABCC2;rs3740066;CT + TT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
N-DESMETHYLTAMOXIFEN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
GLUCOCORTICOIDS;GLCCI1;rs37973;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
AMLODIPINE;CYP3A4;rs2246709;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
NICOTINE;CYP2B6;rs2279343;G;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
TENELIGLIPTIN;FMO3;rs2266780;AG + GG;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
NICOTINE_SUBSTITUTES;CHRNA3;rs16969968;A;OTHER;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
NICOTINE_SUBSTITUTES;CHRNA5;rs16969968;A;OTHER;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
QUETIAPINE;COMT;rs4818;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
HYDROCHLOROTHIAZIDE;GPR83;rs3758785;GG;EFFICACY;DECREASED_RESPONSE;EFFICACY;ESSENTIAL HYPERTENSION;;;
QUETIAPINE;COMT;rs5993883;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TENELIGLIPTIN;FMO3;rs909530;CT + TT;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
QUETIAPINE;COMT;rs6269;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CANDESARTAN;GPR83;rs3758785;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
TACROLIMUS;IL6;rs1800795;GG;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TENELIGLIPTIN;FMO3;rs2266782;AG + GG;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
PACLITAXEL;ABCB1;rs2032582;CT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;OVARIAN NEOPLASMS;;
HYDROCHLOROTHIAZIDE;HSD3B1;rs7553527;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;TTC6;rs177852;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
TENELIGLIPTIN;CYP3A4;rs2242480;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
GLATIRAMER ACETATE;IFNAR1;rs1012335;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
DARUNAVIR;SLCO3A1;rs8027174;GT + TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ATORVASTATIN;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_RESPONSE;OTHER;CARDIOVASCULAR DISEASE;;;
ATORVASTATIN;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERLIPIDEMIAS;;;
ELEXACAFTOR;CFTR;rs121909047;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs121909047;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs121909047;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ELEXACAFTOR;CFTR;rs75961395;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs75961395;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs75961395;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
6-HYDROXY S-WARFARIN;nan;rs368245720;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
6-HYDROXY S-WARFARIN;nan;rs368245720;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VENOUS THROMBOEMBOLISM;;;
6-HYDROXY S-WARFARIN;nan;rs368245720;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEART VALVE DISEASES;;;
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE;OTHER;CARDIOVASCULAR DISEASE;;;
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERLIPIDEMIAS;;;
CITALOPRAM;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
ESCITALOPRAM;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FLUOXETINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
6-HYDROXY S-WARFARIN;PARP14;rs10433340;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
6-HYDROXY S-WARFARIN;PARP14;rs10433340;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VENOUS THROMBOEMBOLISM;;;
6-HYDROXY S-WARFARIN;PARP14;rs10433340;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEART VALVE DISEASES;;;
METOPROLOL;ADRB1;rs1801253;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ELEXACAFTOR;CFTR;rs121909019;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs121909019;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs121909019;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
ELEXACAFTOR;CFTR;rs121909011;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs121909011;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs121909011;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
ELEXACAFTOR;CFTR;rs75549581;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs75549581;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs75549581;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
EFAVIRENZ;NR1I3;rs3003596;GG;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
IMATINIB;ABCG2;rs12505410;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
IMATINIB;ABCG2;rs12505410;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
TAMOXIFEN;CYP19A1;rs4646;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
6-HYDROXY R-WARFARIN;GRID2;rs558364281;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
6-HYDROXY R-WARFARIN;GRID2;rs558364281;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VENOUS THROMBOEMBOLISM;;;
6-HYDROXY R-WARFARIN;GRID2;rs558364281;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEART VALVE DISEASES;;;
6-HYDROXY S-WARFARIN;GRID2;rs558364281;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
6-HYDROXY S-WARFARIN;GRID2;rs558364281;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VENOUS THROMBOEMBOLISM;;;
6-HYDROXY S-WARFARIN;GRID2;rs558364281;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEART VALVE DISEASES;;;
IMATINIB;ABCG2;rs13120400;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
METHOTREXATE;SLCO1B1;rs10841753;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
IMATINIB;ABCG2;rs2725252;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
LACIDIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
NIFEDIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
NITRENDIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
LUMEFANTRINE;CYP3A4;rs2740574;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MALARIA,PREGNANCY;;
QUETIAPINE;HTR1A;rs10042486;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
AMITRIPTYLINE;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
CLOMIPRAMINE;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
DULOXETINE;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
IMIPRAMINE;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
MILNACIPRAN;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
VENLAFAXINE;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
CHLORPROMAZINE;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOZAPINE;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
HALOPERIDOL;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
OLANZAPINE;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
QUETIAPINE;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TRIFLUOPERAZINE;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
AMLODIPINE;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
FELODIPINE;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
WARFARIN;CYP2C18;rs41291550;A;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C18;rs41291550;A;LADME-PK;DECREASED_METABOLISM;OTHER;VENOUS THROMBOEMBOLISM;;;
WARFARIN;CYP2C18;rs41291550;A;LADME-PK;DECREASED_METABOLISM;OTHER;HEART VALVE DISEASES;;;
ATORVASTATIN;CYP3A4;rs2740574;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CARDIOVASCULAR DISEASE;;;
ATORVASTATIN;CYP3A4;rs2740574;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERLIPIDEMIAS;;;
CITALOPRAM;GSK3B;rs334558;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOXETINE;GSK3B;rs334558;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CYP2C9;rs9332241;T;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;rs9332241;T;LADME-PK;DECREASED_METABOLISM;OTHER;VENOUS THROMBOEMBOLISM;;;
WARFARIN;CYP2C9;rs9332241;T;LADME-PK;DECREASED_METABOLISM;OTHER;HEART VALVE DISEASES;;;
LUMEFANTRINE;CYP3A5;rs10264272;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MALARIA,PREGNANCY;;
ATORVASTATIN;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CARDIOVASCULAR DISEASE;;;
ATORVASTATIN;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERLIPIDEMIAS;;;
WARFARIN;FPGS;rs7856096;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;FPGS;rs7856096;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LUMEFANTRINE;CYP3A5;rs776746;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MALARIA,PREGNANCY;;
INFLIXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CETUXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALCOHOL ABUSE;;
ELEXACAFTOR;CFTR;rs80034486;CG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs80034486;CG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs80034486;CG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
AMLODIPINE;CACNA1C;rs2239128;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
FELODIPINE;CACNA1C;rs2239128;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;COLORECTAL NEOPLASMS;;
SUNITINIB;CYP3A5;rs776746;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;RENAL CELL CARCINOMA;;
N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;GT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
LUMEFANTRINE;CYP3A4;rs2740574;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MALARIA,PREGNANCY;;
CLOPIDOGREL;N6AMT1;rs2254638;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
VALPROIC ACID;UGT1A6;rs6759892;TT;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY;;;
FENTANYL;ASTN2;rs7858836;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
BENAZEPRIL;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
IMIDAPRIL;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
FENTANYL;ASTN2;rs958804;CC + CT;DOSAGE;DECREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
VALPROIC ACID;UGT1A6;rs1105879;AA;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY;;;
VALPROIC ACID;UGT1A6;rs2070959;AA;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY;;;
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;LIVER TRANSPLANTATION;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ETIDRONIC ACID;COL1A1;rs1800012;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;METABOLIC BONE DISORDER;;
VORICONAZOLE;ABCG2;rs13120400;CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;nan;;;
MORPHINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN;;;
NORTRIPTYLINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN;;;
RISPERIDONE;HTR1A;rs6295;CG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
DULOXETINE;nan;rs4858478;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;COLORECTAL NEOPLASMS;;
VALPROIC ACID;UGT1A6;rs6759892;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY;;;
DULOXETINE;ZNF385D;rs13093500;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FLUOXETINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
PAROXETINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FOLIC ACID;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
HYDROXYCHLOROQUINE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
SULFASALAZINE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
DULOXETINE;ZNF385D;rs4334661;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FOLIC ACID;MTR;rs1805087;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
HYDROXYCHLOROQUINE;MTR;rs1805087;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;MTR;rs1805087;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
SULFASALAZINE;MTR;rs1805087;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
DULOXETINE;nan;rs7625956;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;rs4646453;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TAMOXIFEN;SULT1A1;rs1042028;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DULOXETINE;ZNF385D;rs7616119;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;nan;rs2933304;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;VKORC1;rs9923231;CT;DOSAGE;INCREASED_DOSE;nan;DISEASE;THROMBOEMBOLISM;;
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
DULOXETINE;NRXN1;rs4971678;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TRAMADOL;RGL4;rs184199168;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DULOXETINE;ZNF385D;rs12630569;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TRAMADOL;nan;rs72732317;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;THROMBOEMBOLISM;;
BEVACIZUMAB;VEGFA;rs699947;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CAPECITABINE;VEGFA;rs699947;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;VEGFA;rs699947;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;VEGFA;rs699947;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;VEGFA;rs699947;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;VEGFA;rs699947;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TRAMADOL;HCN1;rs79983226;C;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TRAMADOL;ICA1;rs62435418;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ERYTHROPOIETIN;HFE;rs1800562;A;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;HEMODIALYSIS TREATMENT;;;
DULOXETINE;nan;rs6700741;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ENALAPRIL;ADRB2;rs1042714;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTROPHY, LEFT VENTRICULAR;;
ATENOLOL;ADRB2;rs1042714;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTROPHY, LEFT VENTRICULAR;;
ENALAPRIL;ADRB2;rs1042714;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTROPHY, LEFT VENTRICULAR;;
BEVACIZUMAB;VEGFA;rs3025039;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CAPECITABINE;VEGFA;rs3025039;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;VEGFA;rs3025039;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;VEGFA;rs3025039;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;VEGFA;rs3025039;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;VEGFA;rs3025039;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ERYTHROPOIETIN;HFE;rs1799945;G;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;HEMODIALYSIS TREATMENT;;;
TRAMADOL;RFPL4B;rs9384825;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DULOXETINE;TEX10;rs6479008;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;rs15524;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
DULOXETINE;TEX10;rs7035619;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;TEX10;rs10989064;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DIGOXIN;ABCB1;rs1045642;GG;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
DULOXETINE;ATP10A;rs12595802;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;TEX10;rs7472;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
MYCOPHENOLIC ACID;IMPDH2;rs11706052;G;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
DULOXETINE;nan;rs56229625;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DIGOXIN;ABCB1;rs2032582;CC;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
DULOXETINE;nan;rs61692318;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;nan;rs62319299;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
DULOXETINE;TEX10;rs10124893;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;INVS;rs10123866;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ABEMACICLIB;ABCB1;rs1045642;A;DOSAGE, TOXICITY;DECREASED_DOSE;OTHER;BREAST NEOPLASMS;;;
PALBOCICLIB;ABCB1;rs1045642;A;DOSAGE, TOXICITY;DECREASED_DOSE;OTHER;BREAST NEOPLASMS;;;
RIBOCICLIB;ABCB1;rs1045642;A;DOSAGE, TOXICITY;DECREASED_DOSE;OTHER;BREAST NEOPLASMS;;;
DULOXETINE;nan;rs10007051;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
DULOXETINE;ZNF385D;rs9879065;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;nan;rs55881666;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
INFLIXIMAB;nan;rs2097432;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;CROHN DISEASE;;;
VALPROIC ACID;CYP2C9;rs4918758;CC + CT;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY;;;
DULOXETINE;nan;rs11933890;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VALPROIC ACID;CYP2C19;rs4244285;AA + AG;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY;;;
DULOXETINE;ZNF385D;rs9310658;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ZNF385D;rs7653345;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VALPROIC ACID;ABAT;rs1731017;GG;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY;;;
DULOXETINE;ZNF385D;rs9310657;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ZNF385D;rs9824595;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ZNF385D;rs9873889;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ZNF385D;rs9819548;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CAPECITABINE;CDA;rs532545;CC;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
HYDRALAZINE;NOS3;rs1799983;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HEART FAILURE;;;
ISOSORBIDE DINITRATE;NOS3;rs1799983;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HEART FAILURE;;;
WARFARIN;CYP2C9;rs56165452;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;ABCB1;rs1045642;AA;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ADALIMUMAB;CRP;rs1130864;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
OLANZAPINE;CYP3A43;rs472660;AA;DOSAGE, EFFICACY, TOXICITY, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;SCHIZOPHRENIA;;
GLATIRAMER ACETATE;EOMES;rs2371108;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
CARVEDILOL;UGT1A1;rs4148323;A;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ANGINA PECTORIS;;
ETOPOSIDE;ABCB1;rs1045642;GG;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ADALIMUMAB;ATG5;rs9373839;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
DULOXETINE;MIEF2;rs56355515;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;MIEF2;rs12603700;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ADALIMUMAB;ATG5;rs510432;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;INCREASED_DOSE;nan;DISEASE;TRANSPLANTATION;;
DULOXETINE;MIEF2;rs3889402;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
AZATHIOPRINE;AOX1;rs55754655;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
AZATHIOPRINE;AOX1;rs55754655;AG + GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
HYDRALAZINE;CYP11B2;rs1799998;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HEART FAILURE;;;
ISOSORBIDE DINITRATE;CYP11B2;rs1799998;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HEART FAILURE;;;
DULOXETINE;nan;rs58042962;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A4;rs2740574;C;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DULOXETINE;nan;rs10771997;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
FENOFIBRATE;LPL;rs320;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
DULOXETINE;FCN2;rs3124955;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FENOFIBRATE;APOA1;rs2727786;CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
DULOXETINE;FCN2;rs3128624;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;nan;rs7306991;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
GLATIRAMER ACETATE;CLEC16A;rs6498169;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
TACROLIMUS;CYP3A4;rs2740574;C;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DIGOXIN;ABCB1;rs1045642;AA;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DULOXETINE;nan;rs10771999;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;nan;rs10771998;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;SKIC3;rs12657120;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ETHOSUXIMIDE;CACNA1H;rs61734410;T;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;EPILEPSY;;;
DULOXETINE;SKIC3;rs4639250;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;nan;rs4437856;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ETHOSUXIMIDE;CACNA1I;rs3747178;T;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;EPILEPSY;;;
DULOXETINE;TREML4;rs9369266;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
AZATHIOPRINE;MOCOS;rs594445;AA + AC;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DULOXETINE;TREML4;rs13204353;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
LAMOTRIGINE;ABCB1;rs2032582;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;EFFICACY;EPILEPSY;;;
CYCLOSPORINE;CALM1;rs12885713;T;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS;;;
IRBESARTAN;AGT;rs699;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTROPHY, LEFT VENTRICULAR;;
DULOXETINE;nan;rs2419128;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
DULOXETINE;nan;rs12502866;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
METHOTREXATE;GGH;rs3758149;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
DULOXETINE;nan;rs12094644;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CAPECITABINE;CDA;rs2072671;AA + AC;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS;;;
LAMOTRIGINE;CACNA1H;rs2753326;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;EFFICACY;EPILEPSY;;;
RIVAROXABAN;ABCB1;rs4728709;GG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ATRIAL FIBRILLATION;;
ATENOLOL;ADRA2A;rs1800545;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTROPHY, LEFT VENTRICULAR;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CYCLOSPORINE;nan;rs2874116;G;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS;;;
IRBESARTAN;APOB;rs1801701;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTROPHY, LEFT VENTRICULAR;;
RIVAROXABAN;ABCB1;rs4148738;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;ATRIAL FIBRILLATION;;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
MEPHENYTOIN;CYP2C19;rs183701923;T;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
MEPHENYTOIN;CYP2C19;rs140278421;A;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
EFAVIRENZ;CYP2B6;rs4803419;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOZAPINE;CYP1A2;rs34067076;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;CYP1A2;rs34067076;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CHLORPROMAZINE;DRD2;rs1799732;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOZAPINE;CYP1A2;rs59410695;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;CYP1A2;rs59410695;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs28371685;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;AMPD1;rs17602729;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs56165452;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
BENAZEPRIL;AGT;rs7079;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PLATINUM COMPOUNDS;XRCC3;rs861539;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
CLOZAPINE;CYP1A2;rs200571120;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;CYP1A2;rs200571120;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
OMEPRAZOLE;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;GASTROESOPHAGEAL REFLUX;;
OPIOIDS;OPRM1;rs1799971;AA;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
NELFINAVIR;CYP2C19;rs4244285;AA;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TOLBUTAMIDE;CYP2C9;rs771237265;C;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TOLBUTAMIDE;CYP2C9;rs762081829;T;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
METFORMIN;SLC22A1;rs628031;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
MEPHENYTOIN;CYP2C19;rs145119820;A;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TOLBUTAMIDE;CYP2C9;rs761895497;C;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;F7;rs510317;AA + AG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
FLUOXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
MEPHENYTOIN;CYP2C19;rs61311738;T;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
SULFONAMIDES;TCF7L2;rs7903146;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
UREA DERIVATIVES;TCF7L2;rs7903146;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
BENAZEPRIL;AGT;rs4762;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
BENAZEPRIL;AGT;rs699;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
FLUOROURACIL;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
BENAZEPRIL;AGT;rs7079;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FENOFIBRATE;APOA5;rs3135506;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
PRAVASTATIN;RHOA;rs11716445;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
SIMVASTATIN;RHOA;rs11716445;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
SULFONAMIDES;KCNJ11;rs587783672;T;EFFICACY;RESPONSE;nan;nan;;;
UREA DERIVATIVES;KCNJ11;rs587783672;T;EFFICACY;RESPONSE;nan;nan;;;
EFAVIRENZ;CYP2B6;rs35303484;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
CLOZAPINE;CYP1A2;rs72547516;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;CYP1A2;rs72547516;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CITALOPRAM;nan;rs585719;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOZAPINE;CYP1A2;rs566851431;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
N-DESMETHYLCLOZAPINE;CYP1A2;rs566851431;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
WARFARIN;nan;rs12777823;A;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;nan;rs12777823;A;LADME-PK;DECREASED_METABOLISM;OTHER;VENOUS THROMBOEMBOLISM;;;
WARFARIN;nan;rs12777823;A;LADME-PK;DECREASED_METABOLISM;OTHER;HEART VALVE DISEASES;;;
WARFARIN;CYP2C9;rs7900194;A;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;rs7900194;A;LADME-PK;DECREASED_METABOLISM;OTHER;VENOUS THROMBOEMBOLISM;;;
WARFARIN;CYP2C9;rs7900194;A;LADME-PK;DECREASED_METABOLISM;OTHER;HEART VALVE DISEASES;;;
ISONIAZID;CYP2E1;rs6413432;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TUBERCULOSIS;;;
EFAVIRENZ;CYP2B6;rs4803419;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;GATA4;rs2645400;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs28371685;T;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;rs28371685;T;LADME-PK;DECREASED_METABOLISM;OTHER;VENOUS THROMBOEMBOLISM;;;
WARFARIN;CYP2C9;rs28371685;T;LADME-PK;DECREASED_METABOLISM;OTHER;HEART VALVE DISEASES;;;
WARFARIN;GATA4;rs4841588;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7662029;GG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
BUPRENORPHINE;UGT2B7;rs7439366;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
METHOTREXATE;SLCO1B1;rs4149056;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7439366;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
METHOTREXATE;SLC19A1;rs2838958;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
SILDENAFIL;VEGFA;rs1570360;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ERECTILE DYSFUNCTION;;
SILDENAFIL;VEGFA;rs699947;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ERECTILE DYSFUNCTION;;
CAPTOPRIL;ACE2;rs2106809;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
CYCLOPHOSPHAMIDE;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOXORUBICIN;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
PACLITAXEL;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TRASTUZUMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
BUPRENORPHINE;UGT2B7;rs7662029;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
ECULIZUMAB;CR1;rs2274567;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PAROXYSMAL NOCTURNAL HEMOGLOBINURIA;;
TACROLIMUS;NR1I2;rs3814055;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;rs2740574;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
MYCOPHENOLIC ACID;UGT1A1;rs4148323;AG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOZAPINE;DRD1;rs686;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7438135;AA;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
CLOZAPINE;DRD3;rs6280;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
FOLLITROPIN BETA;FSHR;rs6166;CT;EFFICACY;DECREASED_RESPONSE;OTHER;INFERTILITY DISORDER;;;
MENOTROPINS;FSHR;rs6166;CT;EFFICACY;DECREASED_RESPONSE;OTHER;INFERTILITY DISORDER;;;
THYROTROPIN ALFA;FSHR;rs6166;CT;EFFICACY;DECREASED_RESPONSE;OTHER;INFERTILITY DISORDER;;;
UROFOLLITROPIN;FSHR;rs6166;CT;EFFICACY;DECREASED_RESPONSE;OTHER;INFERTILITY DISORDER;;;
MERCAPTOPURINE;TPMT;rs12199316;G;DOSAGE;INCREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
TICAGRELOR;CYP3A4;rs56324128;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CANDESARTAN;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
IRBESARTAN;AGTR1;rs5186;AC;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTROPHY;;;
IRBESARTAN;AGTR1;rs5186;AC;EFFICACY;INCREASED_RESPONSE;OTHER;LEFT VENTRICULAR;;;
WARFARIN;CYP2C9;rs2256871;G;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;rs2256871;G;LADME-PK;DECREASED_METABOLISM;OTHER;VENOUS THROMBOEMBOLISM;;;
WARFARIN;CYP2C9;rs2256871;G;LADME-PK;DECREASED_METABOLISM;OTHER;HEART VALVE DISEASES;;;
DOCETAXEL;CYP3A5;rs776746;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
PACLITAXEL;CYP3A5;rs776746;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CAPECITABINE;DPYD;rs1801159;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
FLUOROURACIL;DPYD;rs1801159;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
TEGAFUR;DPYD;rs1801159;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
GIMERACIL;DPYD;rs1801159;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
OTERACIL;DPYD;rs1801159;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
CANDESARTAN;AGTR1;rs5186;AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
TICAGRELOR;SLCO1B1;rs113681054;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE CORONARY SYNDROME;;
TICAGRELOR;SLCO1B1;rs4149056;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE CORONARY SYNDROME;;
GEMCITABINE;SLC29A1;rs760370;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
PACLITAXEL;SLC29A1;rs760370;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CITALOPRAM;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
ESCITALOPRAM;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FLUOXETINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FLUVOXAMINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
PAROXETINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
WARFARIN;CYP2C19;rs11188082;T;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C19;rs11188082;T;LADME-PK;DECREASED_METABOLISM;OTHER;VENOUS THROMBOEMBOLISM;;;
WARFARIN;CYP2C19;rs11188082;T;LADME-PK;DECREASED_METABOLISM;OTHER;HEART VALVE DISEASES;;;
METHYLPHENIDATE;CES1;rs71647871;CT;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;ADHD;;
TICAGRELOR;UGT2B7;rs61361928;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE CORONARY SYNDROME;;
QUETIAPINE;HTR1A;rs6295;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
TICAGRELOR;CYP3A43;rs62471956;G;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE CORONARY SYNDROME;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
SIMVASTATIN;LEPR;rs1137101;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
LAMOTRIGINE;ABCG2;rs2231142;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
OPIOIDS;IL2;rs2069762;AA;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
OPIOIDS;IL2;rs2069762;AA;DOSAGE;INCREASED_DOSE;OTHER;NEOPLASMS;;;
OPIOIDS;BDNF;rs6265;CC;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
OPIOIDS;BDNF;rs6265;CC;DOSAGE;INCREASED_DOSE;OTHER;NEOPLASMS;;;
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
VORICONAZOLE;CYP3A4;rs4646437;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;FUNGAL INFECTIOUS DISEASE;;
OPIOIDS;IL6;rs1800795;CC;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
OPIOIDS;IL6;rs1800795;CC;DOSAGE;INCREASED_DOSE;OTHER;NEOPLASMS;;;
ATENOLOL;AGT;rs4762;AG;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTROPHY;;;
ATENOLOL;AGT;rs4762;AG;EFFICACY;INCREASED_RESPONSE;OTHER;LEFT VENTRICULAR;;;
IRBESARTAN;AGT;rs4762;AG;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTROPHY;;;
IRBESARTAN;AGT;rs4762;AG;EFFICACY;INCREASED_RESPONSE;OTHER;LEFT VENTRICULAR;;;
TENOFOVIR;ABCC4;rs1059751;AA + AG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEPATITIS B;;;
TENOFOVIR;ABCC4;rs1059751;AA + AG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CHRONIC;;;
CAFFEINE;CYP1A1;rs2472297;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
DOCETAXEL;VEGFA;rs1570360;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
OPIOIDS;IL1B;rs1143634;AA + AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
OPIOIDS;IL1B;rs1143634;AA + AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;NEOPLASMS;;;
FENOFIBRATE;SCARB1;rs4238001;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
TENOFOVIR;SLC22A6;rs4149170;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEPATITIS B;;;
TENOFOVIR;SLC22A6;rs4149170;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CHRONIC;;;
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
OPIOIDS;OPRD1;rs678849;CC;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
OPIOIDS;OPRD1;rs678849;CC;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;NEOPLASMS;;;
ACENOCOUMAROL;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
IRBESARTAN;AGT;rs699;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTROPHY;;;
IRBESARTAN;AGT;rs699;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;LEFT VENTRICULAR;;;
PEGINTERFERON ALFA-2A;CXCL10;rs56061981;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;CXCL10;rs56061981;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ATORVASTATIN;ABCB1;rs2032582;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
ATORVASTATIN;ABCB1;rs2032582;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
FOLIC ACID;MTHFR;rs1801131;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ATALUREN;CFTR;rs75039782;T;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
FOLIC ACID;MTHFR;rs1801133;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
FENOFIBRATE;APOA5;rs3135506;CC + CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
METHYLPHENIDATE;DRD1;rs5326;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTISM SPECTRUM DISORDER;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
FENTANYL;ABCB1;rs1045642;GG;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
FOLIC ACID;ATIC;rs2372536;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;ATIC;rs2372536;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CORTICOSTEROIDS;ADAM33;rs2853209;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADAM33;rs2853209;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LITHIUM;GADL1;rs17026688;T;EFFICACY;INCREASED_RESPONSE;OTHER;BIPOLAR_DISORDER;;;
TACROLIMUS;POR;rs1057868;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
FOLIC ACID;ITPA;rs1127354;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;ITPA;rs1127354;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;ATIC;rs4673993;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
WARFARIN;GGCX;rs12714145;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;ADA;rs244076;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;ADORA2A;rs5751876;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
FOLIC ACID;AMPD1;rs17602729;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;AMPD1;rs17602729;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RITUXIMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FLUOROURACIL;EGFR;rs2293347;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ANTIDEPRESSANTS;TGFBR3;rs12082710;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
WARFARIN;VKORC1;rs7294;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ALLOPURINOL;ABCG2;rs2231142;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;GOUT;;
WARFARIN;VKORC1;rs2884737;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RIFAMPIN;AADAC;rs1803155;GG;LADME-PK;DECREASED_EXPOSURE;OTHER;TUBERCULOSIS;;;
CETUXIMAB;AREG;rs9996584;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
PANITUMUMAB;AREG;rs9996584;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
NEVIRAPINE;CYP2B6;rs28399499;CT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CETUXIMAB;AREG;rs1353295;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
PANITUMUMAB;AREG;rs1353295;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
NEVIRAPINE;CYP2B6;rs28399499;CT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BURKITT LYMPHOMA,T-CELL_LYMPHOMA,ACUTE LYMPHOBLASTIC LEUKEMIA;;
RIFAMPIN;ABCB1;rs3842;CC;LADME-PK;INCREASED_EXPOSURE;OTHER;TUBERCULOSIS;;;
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
METHOTREXATE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BURKITT LYMPHOMA,T-CELL_LYMPHOMA,ACUTE LYMPHOBLASTIC LEUKEMIA;;
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ACUTE CORONARY SYNDROME;;;
FENTANYL;P2RX7;rs1718125;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS;;;
FENTANYL;P2RX7;rs1718125;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
METHYLPHENIDATE;DRD1;rs4867798;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTISM SPECTRUM DISORDER;;
METHYLPHENIDATE;DRD3;rs6280;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTISM SPECTRUM DISORDER;;
METHYLPHENIDATE;DRD4;rs11246226;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTISM SPECTRUM DISORDER;;
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
METHYLPHENIDATE;ADRA2A;rs1800544;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTISM SPECTRUM DISORDER;;
METHYLPHENIDATE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTISM SPECTRUM DISORDER;;
ESTRONE SULFATE;SLCO1B1;rs10841753;C;EFFICACY;DECREASED_PLASMATIC-CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
WARFARIN;GGCX;rs12714145;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CETUXIMAB;AREG;rs13104811;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
PANITUMUMAB;AREG;rs13104811;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CETUXIMAB;AREG;rs11942466;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
PANITUMUMAB;AREG;rs11942466;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ANTIDEPRESSANTS;CRHR1;rs28364032;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TOPIRAMATE;UGT1A1;rs4148324;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TOPIRAMATE;UGT1A10;rs4148324;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TOPIRAMATE;UGT1A3;rs4148324;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TOPIRAMATE;UGT1A4;rs4148324;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TOPIRAMATE;UGT1A5;rs4148324;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TOPIRAMATE;UGT1A6;rs4148324;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TOPIRAMATE;UGT1A7;rs4148324;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TOPIRAMATE;UGT1A8;rs4148324;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TOPIRAMATE;UGT1A9;rs4148324;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
CAPECITABINE;EXO1;rs1047840;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
FLUOROURACIL;EXO1;rs1047840;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
CAPECITABINE;CYP19A1;rs2236722;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
FLUOROURACIL;CYP19A1;rs2236722;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
CAPECITABINE;PTEN;rs17431184;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
FLUOROURACIL;PTEN;rs17431184;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
CYCLOSPORINE;POR;rs1057868;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CAPECITABINE;DLG5;rs2289310;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
FLUOROURACIL;DLG5;rs2289310;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
PEGINTERFERON ALFA-2A;SLC29A1;rs760370;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;SLC29A1;rs760370;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;SLC29A1;rs760370;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TIPIRACIL HYDROCHLORIDE;SLC29A1;rs760370;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TRIFLURIDINE;SLC29A1;rs760370;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ETHANOL;ADH1B;rs2018417;A;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
ETHANOL;ADH1B;rs17033;C;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
ETHANOL;ADH1B;rs1229985;G;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
PHENPROCOUMON;PPARA;rs4253728;A;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ETHANOL;ADH1A;rs931635;A;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
ETHANOL;ADH1C;rs283416;A;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
CAPECITABINE;ABCB1;rs17160359;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
FLUOROURACIL;ABCB1;rs17160359;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM;;
ROSIGLITAZONE;PPARG;rs1801282;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ETHANOL;ADH1C;rs283411;A;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
ETHANOL;ADH1C;rs1662060;C;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
TACROLIMUS;SUMO4;rs237025;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
ACENOCOUMAROL;VKORC1;rs17878544;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ACENOCOUMAROL;VKORC1;rs7200749;AA + AG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;G;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ACENOCOUMAROL;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs7200749;A;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CITALOPRAM;NEDD4L;rs520210;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
HMG COA REDUCTASE INHIBITORS;TOMM40;rs2075650;G;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ACENOCOUMAROL;VKORC1;rs55894764;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
VALPROIC ACID;UGT1A10;rs28898617;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A3;rs28898617;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A4;rs28898617;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A5;rs28898617;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;rs28898617;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A7;rs28898617;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A8;rs28898617;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A9;rs28898617;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
IVACAFTOR;CFTR;rs78655421;AA + AG;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
METHYLPHENIDATE;PEBP4;rs17685420;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
VERAPAMIL;ITGAL;rs2230433;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE DISORDER;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERCHOLESTEROLEMIA;;;
PAZOPANIB;KDR;rs34231037;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RENAL CELL CARCINOMA;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ETHANOL;ADH7;rs1154461;C;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
HEPATITIS VACCINES;IL4R;rs1805015;C;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;OTHER;HIV INFECTIOUS DISEASE;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ETHANOL;ADH1A;rs1229967;C;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ETHANOL;ADH1A;rs2276332;C;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
BENAZEPRIL;AGT;rs5051;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
IMIDAPRIL;AGT;rs5051;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ETHANOL;ADH1A;rs1229976;C;TOXICITY, LADME-PK;METABOLISM;nan;nan;;;
URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHOLANGITIS;;;
CLOPIDOGREL THIOL METABOLITE H4;CYP2C19;rs4244285;A;LADME-PK;EXPOSURE;nan;nan;;;
HEPATITIS VACCINES;IL13;rs1295686;T;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
PHENPROCOUMON;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TACROLIMUS;ABCB1;rs1045642;AA;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;RHEUMATOID ARTHRITIS;;
PEGINTERFERON ALFA-2B;CYP27B1;rs10877012;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;CYP27B1;rs10877012;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
DABIGATRAN;CES1;rs8192935;AA + AG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;;;
IRINOTECAN;VDR;rs11574077;TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;COLORECTAL NEOPLASMS;;
METHYLPHENIDATE;ADGRL3;rs1868790;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;SNAP25;rs3746544;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;SLC6A3;rs2550948;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
INTERFERONS;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
INTERFERONS;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
MORPHINE;SLC22A1;rs34059508;AA + AG;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
METHYLPHENIDATE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
PLATINUM;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;nan;rs10514475;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;PLCB1;rs6108160;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
WARFARIN;LRP1;rs1800139;TT;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ADHD;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, EFFICACY;INCREASED_DOSE;nan;nan;;;
WARFARIN;LRP1;rs1800154;CC;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
NICOTINE;CYP2A6;rs56113850;T;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
INTERFERONS;IFNL3;rs8099917;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PHENPROCOUMON;VKORC1;rs2359612;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, EFFICACY;INCREASED_DOSE;nan;nan;;;
PLATINUM COMPOUNDS;XRCC1;rs1799782;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
MORPHINE;SLC22A1;rs12208357;TT;LADME-PK;DECREASED_CLEARANCE;OTHER;ADENOTONSILLECTOMY;;;
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ADHD;;
FLUOROURACIL;LGR5;rs17109924;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLONIC NEOPLASMS;;
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
MORPHINE;SLC22A1;rs34059508;AA;LADME-PK;DECREASED_CLEARANCE;OTHER;ADENOTONSILLECTOMY;;;
METHYLPHENIDATE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
MORPHINE;SLC22A1;rs34130495;AA;LADME-PK;DECREASED_CLEARANCE;OTHER;ADENOTONSILLECTOMY;;;
ATORVASTATIN;KIF6;rs9462535;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PRAVASTATIN;KIF6;rs9462535;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CAPECITABINE;MTHFR;rs1801133;AA + AG;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS;;;
FLUOROURACIL;MTHFR;rs1801133;AA + AG;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS;;;
ROSUVASTATIN;ABCG2;rs1481012;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
SOMATROPIN RECOMBINANT;CDK4;rs2069502;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;TURNER SYNDROME;;
ATORVASTATIN;KIF6;rs9471077;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PRAVASTATIN;KIF6;rs9471077;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METFORMIN;FMO5;rs7541245;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
METHYLPHENIDATE;ADGRL3;rs6858066;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;ADGRL3;rs1947274;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;DECREASED_RESPONSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ROSUVASTATIN;USP24;rs17111584;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
METHYLPHENIDATE;ADGRL3;rs6551665;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;ADGRL3;rs2345039;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;ADGRL3;rs6858066;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;ADGRL3;rs1947274;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
INTERFERON BETA-1A;RORA;rs4774388;TT;EFFICACY;INCREASED_RESPONSE;OTHER;MULTIPLE SCLEROSIS;;;
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;ADGRL3;rs6551665;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ADHD;;
REMIMAZOLAM;CES1;rs71647871;CT + TT;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
NICOTINE;nan;rs113288603;T;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
ROSUVASTATIN;APOE;rs71352238;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
NICOTINE;nan;rs12461964;A;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
ROSUVASTATIN;APOE;rs7412;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
IDARUBICIN;NCF4;rs1883112;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
SIMVASTATIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
IDARUBICIN;RAC2;rs13058338;AT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYELOPROLIFERATIVE DISORDER;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYELOPROLIFERATIVE DISORDER;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYELOPROLIFERATIVE DISORDER;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYELOPROLIFERATIVE DISORDER;;
ROSUVASTATIN;LPA;rs10455872;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ATORVASTATIN;UGT1A1;rs887829;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATORVASTATIN;UGT1A10;rs887829;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATORVASTATIN;UGT1A3;rs887829;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATORVASTATIN;UGT1A4;rs887829;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATORVASTATIN;UGT1A5;rs887829;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATORVASTATIN;UGT1A6;rs887829;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATORVASTATIN;UGT1A7;rs887829;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATORVASTATIN;UGT1A8;rs887829;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATORVASTATIN;UGT1A9;rs887829;T;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
METHYLPHENIDATE;BDNF;rs6265;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
EFAVIRENZ;CYP2B6;rs3745274;GG + GT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
IVACAFTOR;CFTR;rs78655421;AA + AG;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ATORVASTATIN;CYP3A7;rs45446698;G;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
METHYLPHENIDATE;GRM7;rs3792452;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;TOBACCO USE DISORDER;;;
EFAVIRENZ;CYP2B6;rs2279343;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
EFAVIRENZ;CYP2B6;rs2279345;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
ATORVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METHYLPHENIDATE;ADGRL3;rs6551665;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
EFAVIRENZ;ABCB1;rs1045642;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
SOMATROPIN RECOMBINANT;CDK4;rs2270777;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GROWTH HORMONE DEFICIENCY;;
IVACAFTOR;CFTR;rs78655421;AG;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
METHYLPHENIDATE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ATALUREN;CFTR;rs75039782;T;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METFORMIN;PRPF31;rs254271;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
GABAPENTIN;SLC7A5;rs4240803;AG;DOSAGE;INCREASED_DOSE;OTHER;NEUROPATHIC PAIN;;;
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
METFORMIN;NBEA;rs57081354;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;LUPUS NEPHRITIS;;;
DRUGS USED IN DIABETES;IRS1;rs1801278;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
FLUOROURACIL;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
METHOTREXATE;MTRR;rs1801394;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
SALBUTAMOL;DUSP1;rs881152;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
FLUOROURACIL;ERCC1;rs11615;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;ERCC1;rs11615;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;ERCC1;rs11615;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
METFORMIN;SLC22A1;rs622342;AC + CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
WARFARIN;CYP4F2;rs2108622;CT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYELOPROLIFERATIVE DISORDER;;
PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYELOPROLIFERATIVE DISORDER;;
EMTRICITABINE;ABCC2;rs2273897;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,PREGNANCY;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
GABAPENTIN;SLC7A5;rs4240803;AG;EFFICACY;DECREASED_RESPONSE;OTHER;NEUROPATHIC PAIN;;;
PREGABALIN;SLC7A5;rs4240803;AG;EFFICACY;DECREASED_RESPONSE;OTHER;NEUROPATHIC PAIN;;;
MORPHINE;COMT;rs4680;AA;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
METFORMIN;CPA6;rs2162145;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SALBUTAMOL;DUSP1;rs881152;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
MIGALASTAT;GLA;rs372966991;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
TACROLIMUS;CYP3A4;rs2242480;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;LUNG TRANSPLANTATION;;
MIGALASTAT;GLA;rs869312146;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
WARFARIN;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TRAMADOL;SLC22A1;rs34059508;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
TACROLIMUS;SLCO1B3;rs4149117;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;LUNG TRANSPLANTATION;;
MIGALASTAT;GLA;rs397515870;G;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
ESCITALOPRAM;IL11;rs1126757;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOPIDOGREL;CES1;rs2307240;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
MIGALASTAT;GLA;rs398123223;G;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
MIGALASTAT;GLA;rs190347120;A;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
TACROLIMUS;SLC2A2;rs1499821;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;LUNG TRANSPLANTATION;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
MIGALASTAT;GLA;rs28935490;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
ABIRATERONE;YBX1;rs10493112;AC + CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PROSTATIC NEOPLASMS;;;
TACROLIMUS;NFATC4;rs1955915;CC + CT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;LUNG TRANSPLANTATION;;
GRAZOPREVIR;SLCO1B1;rs4149056;C;LADME-PD;INCREASED_EXPOSURE;OTHER;CHRONIC_HEPATITIS_C;;;
BISOPROLOL;CYP2D6;rs1080985;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CARDIOVASCULAR DISEASE;;;
GRAZOPREVIR;SLCO1B1;rs11045819;A;LADME-PD;INCREASED_EXPOSURE;OTHER;CHRONIC_HEPATITIS_C;;;
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9923231;C;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;nan;nan;;;
WARFARIN;VKORC1;rs9923231;C;LADME-PK;INCREASED_DOSE;nan;nan;;;
MIGALASTAT;GLA;rs398123212;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
WARFARIN;nan;rs12777823;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
MIGALASTAT;GLA;rs398123217;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
METHADONE;BDNF;rs7127507;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
METHADONE;BDNF-AS;rs7127507;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
O-DESMETHYLTRAMADOL;SLC22A1;rs12208357;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PAIN;;
MIGALASTAT;GLA;rs397515874;G;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
MIGALASTAT;GLA;rs727505292;G;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ENALAPRIL;NOS3;rs2070744;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
METHADONE;BDNF;rs11030118;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
METHADONE;BDNF-AS;rs11030118;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
MIGALASTAT;GLA;rs869312399;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
WARFARIN;VKORC1;rs2359612;AG + GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs7089580;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
MIGALASTAT;GLA;rs104894828;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHADONE;BDNF;rs1967554;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
METHADONE;BDNF-AS;rs1967554;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
BISOPROLOL;CYP2D6;rs1080985;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE CORONARY SYNDROME;;;
MIGALASTAT;GLA;rs398123226;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
MIGALASTAT;GLA;rs398123226;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
METHADONE;BDNF;rs2030324;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
MIGALASTAT;GLA;rs727504348;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
BISOPROLOL;CYP2D6;rs3892097;CT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE CORONARY SYNDROME;;;
BUSULFAN;GSTA1;rs3957357;AA;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;TRANSPLANTATION;;
O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PAIN;;
O-DESMETHYLTRAMADOL;SLC22A1;rs34059508;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PAIN;;
ENALAPRIL;BDKRB2;rs1799722;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
METHADONE;BDNF;rs988748;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
O-DESMETHYLTRAMADOL;SLC22A1;rs55918055;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;PAIN;;
WARFARIN;VKORC1;rs61742245;A;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
MIGALASTAT;GLA;rs869312136;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
TRAMADOL;SLC22A1;rs55918055;C;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
MIGALASTAT;GLA;rs28935195;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
METHADONE;BDNF;rs11030119;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;LUNG TRANSPLANTATION;;
TRAMADOL;SLC22A1;rs12208357;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
MIGALASTAT;GLA;rs104894827;A;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
FENTANYL;CYP3A4;rs2242480;T;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
MIGALASTAT;GLA;rs869312138;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
CELECOXIB;CYP2C9;rs1057910;CC;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BISOPROLOL;CYP3A5;rs776746;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE CORONARY SYNDROME;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TRAMADOL;SLC22A1;rs34130495;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
MIGALASTAT;GLA;rs1569304898;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs4149570;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CROHN DISEASE,INFLAMMATORY BOWEL DISEASES;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR4;rs5030728;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
METFORMIN;SLC47A1;rs8065082;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;GLUCOSE INTOLERANCE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2430561;AA + AT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CROHN DISEASE,INFLAMMATORY BOWEL DISEASES;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CROHN DISEASE,INFLAMMATORY BOWEL DISEASES;;
WARFARIN;VKORC1L1;rs4072879;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs3804099;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs1816702;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CROHN DISEASE;;
TACROLIMUS;CYP3A4;rs35599367;A;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
SUFENTANIL;OPRM1;rs1799971;G;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
OPIOIDS;ENPP2;rs2249015;AA;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
DONEPEZIL;APOE;rs429358;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
GALANTAMINE;APOE;rs429358;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
RIVASTIGMINE;APOE;rs429358;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
ROSIGLITAZONE;PAX4;rs6467136;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ROSIGLITAZONE;PAX4;rs6467136;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ATORVASTATIN;APOE;rs429358;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
OPIOIDS;ABCB1;rs1045642;AA;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs10499563;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS,INFLAMMATORY BOWEL DISEASES;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;rs2275913;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS,INFLAMMATORY BOWEL DISEASES;;
LATANOPROST;ABCC4;rs11568658;AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPEN-ANGLE GLAUCOMA;;
ADALIMUMAB;TNFRSF1B;rs1061622;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ETANERCEPT;TNFRSF1B;rs1061622;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
INFLIXIMAB;TNFRSF1B;rs1061622;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
USTEKINUMAB;TNFRSF1B;rs1061622;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CNPY4;rs1554973;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
BOTULINUM TOXIN TYPE A;CALCA;rs3781719;G;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE DISORDER;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CD14;rs2569190;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS,INFLAMMATORY BOWEL DISEASES;;
BOTULINUM TOXIN TYPE A;TRPV1;rs222749;A;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE DISORDER;;;
OPIOIDS;ENPP2;rs7832704;AA;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;rs4848306;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS,INFLAMMATORY BOWEL DISEASES;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1RN;rs4251961;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6927172;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS,INFLAMMATORY BOWEL DISEASES;;
HMG COA REDUCTASE INHIBITORS;APOE;rs429358;CC;EFFICACY;INCREASED_RESPONSE;OTHER;ALZHEIMER DISEASE;;;
LOSARTAN;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PEMETREXED;FOLR3;rs61734430;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA,MESOTHELIOMA;;
PEGINTERFERON ALFA-2A;IFNL3;rs4803217;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs4803217;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
METOPROLOL;GRK4;rs1801058;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS;;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
FLUOXETINE;HTR2A;rs7997012;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;INFLAMMATION;;
DIRECT ACTING ANTIVIRALS;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
DIRECT ACTING ANTIVIRALS;IFNL4;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
ELBASVIR;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
ELBASVIR;IFNL4;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
GRAZOPREVIR;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
GRAZOPREVIR;IFNL4;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
LEDIPASVIR;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
LEDIPASVIR;IFNL4;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
SOFOSBUVIR;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
SOFOSBUVIR;IFNL4;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
METOPROLOL;GRK4;rs2960306;GT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS;;
TACROLIMUS;ABCC2;rs3740066;CT + TT;LADME-PK;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;ABCC2;rs3740066;CT + TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
METHOTREXATE;ABCC2;rs717620;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LYMPHOMA;;
TACROLIMUS;ABCC2;rs717620;CT + TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
METOPROLOL;GRK4;rs1024323;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;INFLAMMATION;;
WARFARIN;CYP2C19;rs3814637;T;OTHER, LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
METHADONE;GAD1;rs3762556;G;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
WARFARIN;CYP3A4;rs2242480;CT;OTHER, LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
INFLIXIMAB;IL1B;rs1143634;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CROHN DISEASE;;
METHADONE;GAD1;rs769404;TT;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
CLOZAPINE;CYP1A2;rs762551;AA + AC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
ACENOCOUMAROL;VKORC1;rs9934438;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CAPECITABINE;DPYD;rs67376798;AT;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CLOZAPINE;UGT1A4;rs2011404;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;UGT1A4;rs2011404;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
CAPECITABINE;DPYD;rs3918290;CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
URIC ACID;VEGFC;rs1002976;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HYPERTENSION;;
LETERMOVIR;SLCO1B1;rs4149032;TT;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
CLOZAPINE;UGT1A1;rs34946978;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;UGT1A1;rs34946978;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
METFORMIN;CAPN10;rs3792269;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
LETERMOVIR;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
LETERMOVIR;UGT1A1;rs4148323;AA + AG;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
INTERFERON BETA-1A;FHIT;rs760316;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1B;FHIT;rs760316;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
GLYBURIDE;FMO2;rs7512785;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METHOTREXATE;MTRR;rs1801394;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;;
PROPRANOLOL;ADRB2;rs1042713;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LIVER CIRRHOSIS;;
METHOTREXATE;ABCB1;rs1128503;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;;
METHOTREXATE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;;
CLOZAPINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSYCHOTIC DISORDER;;;
METHOTREXATE;SLC16A7;rs3763980;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B, CHRONIC;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B, CHRONIC;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B, CHRONIC;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B, CHRONIC;;
METHOTREXATE;SLC16A7;rs12231740;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;;
METHOTREXATE;ARID5B;rs4948496;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
CLOZAPINE;UGT1A1;rs4148323;A;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;UGT1A1;rs4148323;A;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;PSYCHOTIC DISORDER;;;
FENOFIBRATE;APOE;rs7412;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
METHOTREXATE;SLCO1B1;rs4149056;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B, CHRONIC;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B, CHRONIC;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B, CHRONIC;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B, CHRONIC;;
METHADONE;GAD1;rs3762555;G;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;JUVENILE RHEUMATOID ARTHRITIS;;
METHADONE;GAD1;rs3749034;G;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
CLOZAPINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSYCHOTIC DISORDER;;;
IGURATIMOD;NAT2;rs1495741;AG + GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INTERFERON BETA-1A;nan;rs4278350;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1B;nan;rs4278350;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
SITAGLIPTIN;KCNQ1;rs163184;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
VILDAGLIPTIN;KCNQ1;rs163184;GG + GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
IGURATIMOD;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INTERFERON BETA-1A;GAPVD1;rs2291858;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1B;GAPVD1;rs2291858;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
METHADONE;OPRD1;rs204047;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
METHADONE;OPRD1;rs797397;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHADONE;OPRD1;rs204047;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ANTIPSYCHOTICS;ZNF804A;rs1344706;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PLATINUM COMPOUNDS;XRCC1;rs25487;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
INTERFERON BETA-1A;GAPVD1;rs10819043;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1B;GAPVD1;rs10819043;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1A;nan;rs3133084;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1B;nan;rs3133084;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
CAPECITABINE;CYP1A1;rs1048943;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOCETAXEL;CYP1A1;rs1048943;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
GLYBURIDE;CYP51A1;rs7793861;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
INTERFERON BETA-1A;nan;rs1448673;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1B;nan;rs1448673;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
GLYBURIDE;FMO2;rs7515157;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ANASTROZOLE;ABCB1;rs2032582;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
AMISULPRIDE;HTR1A;rs10042486;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;HTR1A;rs10042486;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
OLANZAPINE;HTR1A;rs10042486;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
QUETIAPINE;HTR1A;rs10042486;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;HTR1A;rs10042486;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
URIC ACID;BRINP3;rs950569;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HYPERTENSION;;
GLYBURIDE;UGT2B15;rs4148269;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
INTERFERON BETA-1A;GAPVD1;rs10760397;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1B;GAPVD1;rs10760397;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
URIC ACID;PADI4;rs2477134;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HYPERTENSION;;
INTERFERON BETA-1A;ZNF697;rs10494227;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1B;ZNF697;rs10494227;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
DOXORUBICIN;ABCC5;rs1533682;TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
PLATINUM COMPOUNDS;XRCC3;rs861539;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GLYBURIDE;MAPK1;rs1803545;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
GLYBURIDE;ABCC5;rs3749442;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
GLYBURIDE;SPINK5;rs2303070;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
GLYBURIDE;BDKRB2;rs5224;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
GLYBURIDE;MAPK1;rs3729910;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IGURATIMOD;ABCB1;rs2032582;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ETHANOL;KLB;rs11940694;A;TOXICITY;DECREASED_DOSE;nan;nan;;;
PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GLYBURIDE;ESR1;rs2077647;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE;OTHER;AUTOIMMUNE DISEASES;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ANTIDEPRESSANTS;BDNF;rs6265;C;EFFICACY;INCREASED_RESISTANCE;nan;nan;;;
FLUNISOLIDE;TBXT;rs2305089;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
GRANISETRON;ERCC1;rs3212986;AC + CC;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;NAUSEA;;;
GRANISETRON;ERCC1;rs3212986;AC + CC;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;SIDE EFFECT:VOMITING;;;
PALONOSETRON;ERCC1;rs3212986;AC + CC;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;NAUSEA;;;
PALONOSETRON;ERCC1;rs3212986;AC + CC;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;SIDE EFFECT:VOMITING;;;
TACROLIMUS;IL6;rs1800795;GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;KIDNEY TRANSPLANTATION;;;
VALPROIC ACID;CYP2D6;rs3892097;CT + TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;T;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS;;;
TACROLIMUS;IL6;rs1800795;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS;;;
TACROLIMUS;CYP3A4;rs4646437;GG;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
RASAGILINE;DRD2;rs1076560;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PARKINSON DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;rs2242480;CC;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
RASAGILINE;DRD2;rs2283265;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PARKINSON DISEASE;;
TACROLIMUS;CYP3A4;rs4646437;GG;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CTLA4;rs4553808;AG + GG;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ANTIDEPRESSANTS;BDNF-AS;rs10501087;T;EFFICACY;INCREASED_RESISTANCE;nan;nan;;;
TACROLIMUS;IL3;rs181781;AA;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
LAMOTRIGINE;UGT1A4;rs6755571;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
WARFARIN;CYP2C9;rs4917639;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TELAPREVIR;CYP24A1;rs2585428;C;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TACROLIMUS;CTLA4;rs4553808;AA;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;rs2242480;CC;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VARENICLINE;CHRNA4;rs1044396;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
ESCITALOPRAM;CYP1A2;rs4646425;T;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;CYP1A2;rs2069526;G;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;CYP1A2;rs4646427;C;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE;OTHER;SPONDYLARTHROPATHIES;;;
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
MORPHINE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;EFFICACY;INCREASED_RESISTANCE;nan;nan;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;EFFICACY;INCREASED_RESISTANCE;nan;nan;;;
EFAVIRENZ;CYP2B6;rs2279343;AG;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS;;;
FLUTICASONE PROPIONATE;ORMDL3;rs2872507;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RITUXIMAB;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ABATACEPT;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
RITUXIMAB;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TOCILIZUMAB;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
VALPROIC ACID;CYP2C9;rs1057910;AC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;EPILEPSY;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ATAZANAVIR;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RITONAVIR;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
DEFERASIROX;ABCG2;rs13120400;CT + TT;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
ATAZANAVIR;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RITONAVIR;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;rs10509680;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ADALIMUMAB;VDR;rs7975232;AA + AC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
CERTOLIZUMAB PEGOL;VDR;rs7975232;AA + AC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;VDR;rs7975232;AA + AC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
GOLIMUMAB;VDR;rs7975232;AA + AC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;VDR;rs7975232;AA + AC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ANTIEPILEPTICS;NR3C1;rs41423247;GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DEFERASIROX;ABCC2;rs2273697;AG;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
FLUVASTATIN;APOE;rs7412;CT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METFORMIN;SLC47A1;rs2289669;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
LAMOTRIGINE;UGT2B7;rs7439366;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
TACROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
RITODRINE;PDE4B;rs598961;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PREMATURE BIRTH;;;
TACROLIMUS;CYP3A4;rs4986910;G;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
LAMOTRIGINE;UGT2B15;rs1902023;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
PLATINUM COMPOUNDS;XPA;rs1800975;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
ARIPIPRAZOLE;ABCB1;rs2032582;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DEHYDROARIPIPRAZOLE;ABCB1;rs2032582;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ARIPIPRAZOLE;ABCB1;rs1045642;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DEHYDROARIPIPRAZOLE;ABCB1;rs1045642;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ARIPIPRAZOLE;ABCB1;rs1128503;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DEHYDROARIPIPRAZOLE;ABCB1;rs1128503;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;IL10;rs1800871;AA;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION;;;
ANTIHYPERTENSIVES;MMP9;rs3918242;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GESTATIONAL HYPERTENSION;;
HYDRALAZINE;MMP9;rs3918242;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GESTATIONAL HYPERTENSION;;
METHYLDOPA;MMP9;rs3918242;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GESTATIONAL HYPERTENSION;;
NIFEDIPINE;MMP9;rs3918242;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GESTATIONAL HYPERTENSION;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;nan;nan;;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;OTHER;RHEUMATIC HEART DISEASE;;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE DISEASES;;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;OTHER;CORONARY ARTERY DISEASE;;;
DACLATASVIR;VDR;rs11568820;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
MORPHINE;COMT;rs4680;AG + GG;EFFICACY;INCREASED_DOSE;nan;nan;;;
CLOMIPRAMINE;CYP2D6;rs1080985;CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
METHYLDOPA;MMP9;rs3918242;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GESTATIONAL HYPERTENSION;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
DACLATASVIR;CYP24A1;rs2248359;CT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
WARFARIN;VKORC1;rs9923231;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CARBAMAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE;nan;DISEASE;EPILEPSY;;
OXCARBAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE;nan;DISEASE;EPILEPSY;;
METOPROLOL;ADRB1;rs1801252;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
ELEXACAFTOR;CFTR;rs139304906;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
TEZACAFTOR;CFTR;rs139304906;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
IVACAFTOR;CFTR;rs139304906;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
CALCIUM CHANNEL BLOCKERS;NUMA1;rs10898815;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
CARBAMAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE;nan;DISEASE;EPILEPSY;;
OXCARBAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE;nan;DISEASE;EPILEPSY;;
CALCIUM CHANNEL BLOCKERS;TANC2;rs2429427;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
SIBUTRAMINE;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE;OTHER;OBESITY;;;
CARBAMAZEPINE;ABCC2;rs2273697;AG;EFFICACY;RESISTANCE;nan;DISEASE;EPILEPSY;;
OXCARBAZEPINE;ABCC2;rs2273697;AG;EFFICACY;RESISTANCE;nan;DISEASE;EPILEPSY;;
METHOTREXATE;ABCC2;rs765027508;AG;LADME-PK;INCREASED_EXPOSURE;OTHER;LYMPHOMA;;;
METHOTREXATE;ABCC2;rs765027508;AG;LADME-PK;INCREASED_EXPOSURE;OTHER;B-CELL;;;
BUSULFAN;GSTA1;rs3957356;T;LADME-PK;DECREASED_CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;;
S-EDDP;CYP2B6;rs8192709;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
BUSULFAN;GSTA1;rs3957357;A;LADME-PK;DECREASED_CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;;
SIMVASTATIN;UGT1A9;rs12052787;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SIMVASTATIN;UGT1A9;rs2003569;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PLATINUM COMPOUNDS;ERCC4;rs1799801;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
AMITRIPTYLINE;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
CLOMIPRAMINE;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
DOXEPIN;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
IMIPRAMINE;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
MAPROTILINE;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
NORTRIPTYLINE;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
OPIPRAMOL;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;DEPRESSION;;
PLATINUM COMPOUNDS;ERCC3;rs3738948;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
TEGAFUR;CYP2A6;rs8192720;AA + AG;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ANTIPSYCHOTICS;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
CHLORPROMAZINE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
HALOPERIDOL;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
OLANZAPINE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
QUETIAPINE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
OXYCODONE;UGT2B7;rs7439366;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NEOPLASMS,PAIN;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
BUPROPION;CYP2B6;rs3745274;T;LADME-PK;INCREASED_EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
RISPERIDONE;HRH4;rs4483927;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ATENOLOL;GRK4;rs2960306;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ATENOLOL;GRK4;rs1024323;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
CALCIUM CHANNEL BLOCKERS;PICALM;rs588076;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
DELEOBUVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
DELEOBUVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
FALDAPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
FALDAPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
WARFARIN;CYP2C9;rs9332131;del;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;PULMONARY EMBOLISM;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs28371686;G;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;PULMONARY EMBOLISM;;
PROPOFOL;GABRA2;rs11503014;CC;OTHER;DECREASED_RESPONSE;nan;nan;;;
WARFARIN;HNF4A;rs3212198;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
CODEINE;CYP1B1;rs1056836;C;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
TRAMADOL;CYP1B1;rs1056836;C;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
WARFARIN;NR1I3;rs2501873;TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
VERAPAMIL;PCDHB8;rs3733694;G;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE DISORDER;;;
RIVAROXABAN;POR;rs1057868;TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;;;
VERAPAMIL;PCDHB6;rs17844444;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE DISORDER;;;
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CAPECITABINE;KRAS;rs61764370;AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
CETUXIMAB;KRAS;rs61764370;AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
OXALIPLATIN;KRAS;rs61764370;AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
LOSARTAN;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LIVER CIRRHOSIS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
HEROIN;OPRM1;rs9479757;AG;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEROIN DEPENDENCE;;
5-HYDROXYINDOLE-3-ACETIC ACID;MAOB;rs1799836;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SEROTONIN;MAOB;rs1799836;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
ANTIDEPRESSANTS;GRIK4;rs1954787;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
RIVAROXABAN;ABCB1;rs4148738;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
5-HYDROXYINDOLE-3-ACETIC ACID;MAOB;rs1799836;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SEROTONIN;MAOB;rs1799836;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
APIXABAN;POR;rs1057868;T;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION;;;
OXCARBAZEPINE;UGT1A9;rs2741049;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SEIZURES;;
CODEINE;CYP1B1;rs1056837;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
TRAMADOL;CYP1B1;rs1056837;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
CANDESARTAN;CYP11B2;rs1799998;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
3-HYDROXYCOTININE;nan;rs4105144;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
HYDROCODONE;CYP2D6;rs35742686;DELT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
OXYCODONE;CYP2D6;rs35742686;DELT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
3-HYDROXYCOTININE;EGLN2;rs3733829;AA + AG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
HYDROCODONE;MACROD2;rs76026520;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
OXYCODONE;MACROD2;rs76026520;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
BENAZEPRIL;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DEFERASIROX;CYP1A1;rs2606345;AC + CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PITRAKINRA;IL4R;rs1029489;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
RADIOTHERAPY;CACNA2D3;rs11130424;AG + GG;EFFICACY;INCREASED_RESISTANCE;OTHER;NASOPHARYNGEAL NEOPLASMS;;;
HYDROXYUREA;MAP3K5;rs9483947;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
ANTIHYPERTENSIVES;CLNK;rs13144136;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROXYUREA;MAP3K5;rs9376230;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
IMATINIB;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
IMATINIB;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
ATORVASTATIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
LENALIDOMIDE;FGF2;rs308395;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
THALIDOMIDE;FGF2;rs308395;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
METHOTREXATE;ABCC2;rs717620;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
ANTIDEPRESSANTS;MAOA;rs979605;AA;LADME-PK;DECREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
METHOTREXATE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ANTIDEPRESSANTS;GRIK4;rs1954787;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ETHANOL;ALDH2;rs671;AG;OTHER;INCREASED_EXPOSURE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
HYDROCHLOROTHIAZIDE;NEDD4L;rs292449;CC + CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PITRAKINRA;IL4R;rs8832;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PITRAKINRA;IL4R;rs3024530;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
PITRAKINRA;IL4R;rs1110470;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
PITRAKINRA;IL4R;rs2239347;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
BENAZEPRIL;MTR;rs1805087;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
PITRAKINRA;IL4R;rs1805010;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
VORICONAZOLE;ABCC2;rs717620;CT + TT;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;nan;;;
ACENOCOUMAROL;VKORC1;rs9934438;GG;DOSAGE, TOXICITY;INCREASED_DOSE;nan;nan;;;
PHENPROCOUMON;VKORC1;rs9934438;GG;DOSAGE, TOXICITY;INCREASED_DOSE;nan;nan;;;
MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;A;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MORPHINE;ABCC3;rs4793665;CC;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8105790;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8105790;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ATORVASTATIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8103142;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8103142;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
MEMANTINE;NR1I2;rs1523130;CT + TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;DEMENTIA;;
BENAZEPRIL;ADRB2;rs1042713;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
PEGINTERFERON ALFA-2A;IFNL3;rs11881222;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs11881222;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs7248668;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs7248668;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
AMISULPRIDE;ANKS1B;rs7968606;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PEGINTERFERON ALFA-2A;IFNL3;rs28416813;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs28416813;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs4803219;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs4803219;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
MORPHINE;OPRM1;rs1799971;AG;DOSAGE;INCREASED_DOSE;nan;DISEASE;NEOPLASMS;;
ESCITALOPRAM;nan;rs2069521;A;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
IMATINIB;CYP3A5;rs776746;CC;LADME-PK;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
ROSUVASTATIN;SCARB1;rs4238001;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MYOCARDIAL ISCHEMIA;;;
IMATINIB;ABCB1;rs1045642;AA;LADME-PK;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
IMATINIB;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
LACOSAMIDE;ABCC2;rs2273697;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
IMATINIB;ABCB1;rs1045642;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DYSLIPIDAEMIA;;
OLANZAPINE;SV2C;rs11960832;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CORTICOSTEROIDS;TBX21;rs2240017;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
METHOTREXATE;ABCC1;rs2238476;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ANTIDEPRESSANTS;HTR2A;rs6314;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CARBAMAZEPINE;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
LAMOTRIGINE;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PRIMIDONE;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
CARBAMAZEPINE;CYP2C9;rs9332120;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
LAMOTRIGINE;CYP2C9;rs9332120;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP2C9;rs9332120;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PRIMIDONE;CYP2C9;rs9332120;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;CYP2C9;rs9332120;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CARBAMAZEPINE;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
LAMOTRIGINE;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PRIMIDONE;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
CARBAMAZEPINE;CYP3A4;rs2740574;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
LAMOTRIGINE;CYP3A4;rs2740574;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP3A4;rs2740574;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PRIMIDONE;CYP3A4;rs2740574;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;CYP3A4;rs2740574;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
CARBAMAZEPINE;CYP3A4;rs2687116;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
LAMOTRIGINE;CYP3A4;rs2687116;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP3A4;rs2687116;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PRIMIDONE;CYP3A4;rs2687116;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;CYP3A4;rs2687116;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
DULOXETINE;ANO2;rs61908411;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs61908409;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs61908410;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs78615940;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs78482393;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs61908405;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs61908406;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ARG1;rs2781659;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
DULOXETINE;ANO2;rs61908404;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs61908408;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs61908407;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs17786412;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
DULOXETINE;ANO2;rs17786400;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
METHADONE;ABCB1;rs9282564;C;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
DULOXETINE;ANO2;rs61908403;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs61908402;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs17724452;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
GLATIRAMER ACETATE;PVT1;rs2114358;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
DULOXETINE;nan;rs7316769;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs17724494;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CYP2C9;rs56165452;CT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHADONE;ABCB1;rs1045642;A;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
DULOXETINE;ANO2;rs17786394;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DULOXETINE;ANO2;rs17724464;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
METHADONE;UGT2B7;rs7439366;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
TENOFOVIR;ABCC4;rs1751034;TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEMETREXED;CCND1;rs9344;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;LUNG NEOPLASMS;;;
PLATINUM COMPOUNDS;CCND1;rs9344;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;LUNG NEOPLASMS;;;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
LIRAGLUTIDE;GLP1R;rs10305420;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OBESITY,POLYCYSTIC OVARY SYNDROME;;
LAMOTRIGINE;CACNA1H;rs2753325;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;EFFICACY;EPILEPSY;;;
AZATHIOPRINE;TPMT;TPMT low activity;;LADME-PK;DECREASED_DOSE;nan;nan;;;
FLUOROURACIL;DPYD;rs3918290;CT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
FLUOROURACIL;DPYD;rs2297595;CC + CT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
ASPIRIN;GP1BA;rs6065;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
FLUOROURACIL;DPYD;rs1801160;CT + TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
FLUOROURACIL;DPYD;rs1801265;GG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
LACOSAMIDE;ABCC2;rs717620;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
ANASTROZOLE;nan;rs11648166;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LACOSAMIDE;ABCC2;rs2273697;A;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY;;;
LACOSAMIDE;ABCC2;rs717620;T;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY;;;
ANASTROZOLE;nan;rs28845026;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;LUPUS ERYTHEMATOSUS;;
APIXABAN;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ATRIAL FIBRILLATION;;
METHOTREXATE;ARID5B;rs10994982;A;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
OXYCODONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;LUPUS ERYTHEMATOSUS;;
IMATINIB;ABCB1;rs1045642;AG + GG;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;GASTROINTESTINAL STROMAL TUMORS;;;
FENOFIBRATE;PPARA;rs4253778;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
METHOTREXATE;SLC22A11;rs11231809;AT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;ABCC1;rs246240;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
HMG COA REDUCTASE INHIBITORS;HMGCR;rs3846662;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;FAMILIAL HYPERCHOLESTEROLEMIA;;
METHOTREXATE;ABCC1;rs3784864;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LUPUS NEPHRITIS;;
4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;rs776746;CC + CT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LUPUS NEPHRITIS;;
CYCLOPHOSPHAMIDE;CYP2B6;rs7254579;C;LADME-PK;METABOLISM;nan;DISEASE;LUPUS ERYTHEMATOSUS;;
HMG COA REDUCTASE INHIBITORS;nan;rs445925;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
FENOFIBRATE;IL6;rs1800795;CC + CG;EFFICACY;INCREASED_RESPONSE;OTHER;PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASE;;;
RANIBIZUMAB;NRP1;rs2070296;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
ATORVASTATIN;CETP;rs708272;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
PEGINTERFERON ALFA-2A;MICB;rs3828913;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;MICB;rs3828913;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;MICB;rs3828913;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
METHOTREXATE;ABCG2;rs13120400;CC;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;PSORIASIS;;;
NICOTINE;DBH;rs77905;GG;DOSAGE;DECREASED_DOSE;nan;DISEASE;TOBACCO USE DISORDER;;
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
NICOTINE;MAOA;rs1137070;TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;TOBACCO USE DISORDER;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OMEPRAZOLE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
PANTOPRAZOLE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HELICOBACTER INFECTIONS;;
DEFERASIROX;CYP24A1;rs2248359;TT;LADME-PK;METABOLISM;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
DEFERASIROX;VDR;rs7975232;AA;LADME-PK;METABOLISM;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
FLUVOXAMINE;HTR1A;rs1364043;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
MILNACIPRAN;HTR1A;rs1364043;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;HTR1A;rs1364043;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DEFERASIROX;VDR;rs2228570;G;LADME-PK;METABOLISM;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
ANTIPSYCHOTICS;GRM3;rs6465084;AA;TOXICITY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
METFORMIN;SLC47A1;rs2289669;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
METFORMIN;SLC47A1;rs2289669;AA;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
BETA BLOCKING AGENTS;GRK5;rs2230345;AA + AT;EFFICACY;RESPONSE;nan;DISEASE;HEART FAILURE;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;NR1I3;rs2307424;G;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;NR1I3;rs2307424;AG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ANTIHYPERTENSIVES;ATP2B1;rs12817819;CT + TT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;CORONARY ARTERY DISEASE,HYPERTENSION;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;EPHX1;rs1051741;CT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ISONIAZID;NAT2;rs1799930;AA;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
MERCAPTOPURINE;NUDT15;rs73189762;T;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
WARFARIN;PRSS53;rs7294;CT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs7294;CT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ISONIAZID;NR1I2;rs2472677;TT;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
AMLODIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
FELODIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ISONIAZID;SLCO1B1;rs4149032;CC;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239128;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
MORPHINE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_DOSE;nan;nan;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2900478;A;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HMG COA REDUCTASE INHIBITORS;CELSR2;rs646776;C;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
VALPROIC ACID;UGT2B7;rs12233719;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
EFAVIRENZ;CYP2A6;rs28399454;T;LADME-PK;METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ATAZANAVIR;ABCB1;rs1045642;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs2279343;AG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
VALPROIC ACID;UGT2B7;rs7668258;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;APOC1;rs429358;T;DOSAGE;DECREASED_DOSE;OTHER;HAPLOTYPE EPSILON2;;;
WARFARIN;APOE;rs429358;T;DOSAGE;DECREASED_DOSE;OTHER;HAPLOTYPE EPSILON2;;;
VALPROIC ACID;UGT2B7;rs7668258;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
WARFARIN;APOC1;rs7412;T;DOSAGE;DECREASED_DOSE;OTHER;HAPLOTYPE EPSILON2;;;
WARFARIN;APOE;rs7412;T;DOSAGE;DECREASED_DOSE;OTHER;HAPLOTYPE EPSILON2;;;
INFLIXIMAB;nan;rs2097432;CC + CT;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY;CROHN DISEASE;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHOTODYNAMIC THERAPY;CFH;rs1061170;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
VALPROIC ACID;UGT2B7;rs7439366;TT;LADME-PK;CONCENTRATIONS;nan;DISEASE;EPILEPSY;;
RISPERIDONE;ABCG2;rs2231142;GT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;nan;;;
FLUOXETINE;HTR1B;rs9361233;CC + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
EFAVIRENZ;CYP2B6;rs8192709;CC;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
INFLIXIMAB;nan;rs73277969;T;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY;CROHN DISEASE;;;
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ASPIRIN;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ASPIRIN;PEAR1;rs2768759;AC + CC;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
PRASUGREL;PEAR1;rs2768759;AC + CC;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CYCLOSPORINE;ABCB1;rs2032582;AC + CC;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ASPIRIN;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PRASUGREL;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
HYDRALAZINE;GNB3;rs5443;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
ISOSORBIDE DINITRATE;GNB3;rs5443;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
IVACAFTOR;CFTR;rs397508453;C;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
WARFARIN;VKORC1;rs72547529;T;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_PLASMATIC-CONCENTRATION;OTHER;LIVER TRANSPLANTATION;;;
IVACAFTOR;CFTR;rs121909013;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
IVACAFTOR;CFTR;rs121909041;C;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
TACROLIMUS;CYP3A4;rs2242480;T;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ASPIRIN;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
IVACAFTOR;CFTR;rs74503330;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
NEVIRAPINE;CYP1A2;rs762551;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PAIN;;
ANASTROZOLE;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
LETROZOLE;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
IVACAFTOR;CFTR;rs267606723;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
SEROTONIN;ERICH3;rs696692;T;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;DEPRESSIVE DISORDER;;
IVACAFTOR;CFTR;rs80282562;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
TACROLIMUS;ABCB1;rs1045642;AG + GG;DOSAGE;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ANASTROZOLE;CYP19A1;rs4646;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
LETROZOLE;CYP19A1;rs4646;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_RESISTANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA;;;
SEROTONIN;TSPAN5;rs11947402;G;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;DEPRESSIVE DISORDER;;
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TRAF1;rs3761847;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
THALIDOMIDE;CTNNB1;rs4533622;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
WARFARIN;VKORC1;rs9934438;AG;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,CARDIOMYOPATHIES,HEART VALVE REPLACEMENT,PERIPHERAL VASCULAR DISEASES,PULMONARY EMBOLISM,VENOUS THROMBOSIS;;
FENTANYL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_DOSE;nan;DISEASE;PAIN;;
IVACAFTOR;CFTR;rs193922525;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
CYCLOPHOSPHAMIDE;CTNNB1;rs4135385;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
DEXAMETHASONE;CTNNB1;rs4135385;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
THALIDOMIDE;CTNNB1;rs4135385;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
OPIOIDS;IL17A;rs2275913;A;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
PLATINUM COMPOUNDS;CYP1A1;rs1048943;CC + CT;EFFICACY;INCREASED_RESISTANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA;;;
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
TACROLIMUS;ABCB1;rs2032582;AC + CC;DOSAGE;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
ANTIDEPRESSANTS;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
CITALOPRAM;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
ESCITALOPRAM;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_DOSE;nan;nan;;;
CYCLOSPORINE;ABCB1;rs2032582;AC + CC;DOSAGE;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A7;rs10211;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;nan;;;
WARFARIN;VKORC1;rs9923231;C;DOSAGE, EFFICACY;INCREASED_DOSE;nan;nan;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;INCREASED_DOSE;OTHER;LIVER TRANSPLANTATION;;;
ACETAMINOPHEN;OPRM1;rs1799971;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NEUROPATHIC PAIN;;
TRAMADOL;OPRM1;rs1799971;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NEUROPATHIC PAIN;;
RITUXIMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHADONE;CYP2B6;rs3745274;T;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
COTININE;UGT2B10;rs2942857;CC;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;TOBACCO USE DISORDER;;
FENTANYL;nan;rs6961071;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
RITUXIMAB;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;VKORC1;rs2359612;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CYCLOPHOSPHAMIDE;ALDH1A1;rs13959;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BREAST NEOPLASMS;;;
DOXORUBICIN;ALDH1A1;rs13959;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BREAST NEOPLASMS;;;
FEC100;ALDH1A1;rs13959;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BREAST NEOPLASMS;;;
FLUOROURACIL;ALDH1A1;rs13959;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BREAST NEOPLASMS;;;
TACROLIMUS;POR;rs1057868;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
COUMARIN;CYP2A6;rs1801272;TT;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
COUMARIN;CYP2A6;rs1801272;TT;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
METHADONE;ABCB1;rs2032582;CC;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
NICOTINE;CYP2A6;rs5031016;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TOCILIZUMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CARVEDILOL;ADRB2;rs1042714;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
FENTANYL;nan;rs13093031;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTERIOSCLEROSIS;;
LOVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTERIOSCLEROSIS;;
SIMVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTERIOSCLEROSIS;;
COTININE;UGT2B10;rs2942857;CC;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;TOBACCO USE DISORDER;;
CLOPIDOGREL;ABCB1;rs1045642;A;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE CORONARY SYNDROME;;;
CISPLATIN;ERCC1;rs11615;A;EFFICACY;DECREASED_RESPONSE;OTHER;OVARIAN NEOPLASMS;;;
WARFARIN;VKORC1;rs2884737;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
WARFARIN;PRSS53;rs7294;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs7294;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENOBARBITAL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
TACROLIMUS;FMO3;rs1800822;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
FENOFIBRATE;CRP;rs1417938;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METABOLIC SYNDROME;;
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DYSLIPIDAEMIA;;
IVACAFTOR;CFTR;rs397508442;T;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
FLUOXETINE;HTR1B;rs9361235;CC + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
WARFARIN;NQO1;rs10517;GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FENOFIBRATE;CRP;rs3091244;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METABOLIC SYNDROME;;
PRAVASTATIN;MMP3;rs35068180;A/del + AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
N-DESMETHYLCLOZAPINE;UGT1A4;rs2011425;G;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
FENOFIBRATE;CRP;rs3091244;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METABOLIC SYNDROME;;
FENTANYL;ABCB1;rs1128503;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NEOPLASMS,PAIN;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
CLOZAPINE;CYP2C18;rs1126545;T;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA;;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SIMVASTATIN;SLCO1B1;rs4149056;C;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
DESLORATADINE;FCER1A;rs2298805;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;URTICARIA;;
MIZOLASTINE;FCER1A;rs2298805;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;URTICARIA;;
ATORVASTATIN;CYP3A5;rs17161788;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
CAPECITABINE;SELE;rs3917412;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLONIC NEOPLASMS;;
FLUOROURACIL;SELE;rs3917412;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLONIC NEOPLASMS;;
LEUCOVORIN;SELE;rs3917412;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLONIC NEOPLASMS;;
OXALIPLATIN;SELE;rs3917412;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLONIC NEOPLASMS;;
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
OPIOIDS;nan;rs2952768;CC;EFFICACY;DECREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
HMG COA REDUCTASE INHIBITORS;PCSK9;rs11591147;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
IMATINIB;CYP3A4;rs28371759;AG;EFFICACY;INCREASED_RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
IMATINIB;CYP3A4;rs28371759;AG;EFFICACY;INCREASED_RESPONSE;OTHER;BCR-ABL1 POSITIVE;;;
DIGOXIN;ABCB1;rs2032582;CC;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;HEART FAILURE;;
CAPECITABINE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLONIC NEOPLASMS;;
FLUOROURACIL;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLONIC NEOPLASMS;;
LEUCOVORIN;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLONIC NEOPLASMS;;
OXALIPLATIN;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLONIC NEOPLASMS;;
PLATINUM;ERCC5;rs17655;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
ELEXACAFTOR;CFTR;rs75389940;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs75389940;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs75389940;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs75389940;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs75389940;AG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
CARVEDILOL;UGT2B7;rs12233719;T;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART DISEASES;;
BUPROPION;CHRNA5;rs2036527;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
NICOTINE;CHRNA5;rs2036527;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
VARENICLINE;CHRNA5;rs2036527;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
BUPROPION;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
NICOTINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
VARENICLINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
CARVEDILOL;UGT2B7;rs28365063;G;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART DISEASES;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;FMO3;rs909530;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
DIGOXIN;ABCB1;rs2032582;AA + AT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART FAILURE;;
LUMACAFTOR;CFTR;rs121909047;AA;EFFICACY;RESPONSE;nan;nan;;;
METHADONE;CDH2;rs8094439;AA;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PERTUSSIS VACCINES;TLR4;rs4986790;AA;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
METHADONE;CDH2;rs17446819;CC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SORAFENIB;ABCG2;rs2231137;CT;LADME-PK;CONCENTRATIONS;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
NICOTINE;CYP2A6;rs376817657;CT + TT;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SORAFENIB;ABCG2;rs2231142;GT;LADME-PK;CONCENTRATIONS;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
IVACAFTOR;CFTR;rs397508602;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
IMATINIB;SLC22A1;rs683369;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
FENOFIBRATE;GCKR;rs780094;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
IVACAFTOR;CFTR;rs121909011;T;EFFICACY;RESPONSE;nan;nan;;;
LUMACAFTOR;CFTR;rs121909011;T;EFFICACY;RESPONSE;nan;nan;;;
IMATINIB;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
FENTANYL;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
IVACAFTOR;CFTR;rs74551128;A;EFFICACY;RESPONSE;nan;nan;;;
LUMACAFTOR;CFTR;rs74551128;A;EFFICACY;RESPONSE;nan;nan;;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
BILIRUBIN;UGT1A1;rs887829;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
WARFARIN;CYP2C9;rs1799853;CT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;GGH;rs3758149;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MERCAPTOPURINE;NUDT15;rs186364861;A;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
FENOFIBRATE;APOA5;rs662799;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
IMIQUIMOD;TLR7;rs179008;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BASAL CELL CARCINOMA;;
MERCAPTOPURINE;NUDT15;rs116855232;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
METHOTREXATE;GGH;rs11545077;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE, OTHER;DECREASED_DOSE;nan;nan;;;
FENOFIBRATE;APOA5;rs3135506;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
CLONIDINE;GNB3;rs5443;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LIVER CIRRHOSIS;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
CLOZAPINE;UGT2B10;rs61750900;T;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
OPIOIDS;TAOK3;rs1277441;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;NEOPLASMS;;;
OPIOIDS;TAOK3;rs1277441;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
OPIOIDS;TAOK3;rs795484;TT;DOSAGE;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
OPIOIDS;TAOK3;rs795484;TT;DOSAGE;DECREASED_RESPONSE;OTHER;PAIN;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
FENTANYL;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
WARFARIN;CYP2C9;rs1799853;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
OPIOIDS;TAOK3;rs795484;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;NEOPLASMS;;;
OPIOIDS;TAOK3;rs795484;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
FENTANYL;ABCB1;rs1128503;AA;DOSAGE;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
TENOFOVIR;ABCC4;rs3742106;AC + CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
VITAMIN B12 AND FOLIC ACID;MTHFR;rs1801133;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HYPERHOMOCYSTEINEMIA;;;
VITAMIN B12 AND FOLIC ACID;MTHFR;rs1801133;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;STROKE;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY, LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
CAPTOPRIL;AGTR1;rs5186;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
DAUNORUBICIN;CBR1;rs25678;CC;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
MERCAPTOPURINE;TPMT;rs1142345;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
CITALOPRAM;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
CITALOPRAM;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
BILIRUBIN;SLCO1B1;rs1910167;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
BILIRUBIN;SLCO1B3;rs1910167;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
BILIRUBIN;SLCO1B7;rs1910167;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CITALOPRAM;CYP2C19;rs4244285;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ALCOHOL ABUSE;;;
CITALOPRAM;CYP2C19;rs4244285;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ATENOLOL;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
ETANERCEPT;PSORS1C1;rs2233945;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MERCAPTOPURINE;ABCC4;rs2274407;AA;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
DISULFIRAM;TPH2;rs4290270;AA + AT;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE;;;
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
ENALAPRIL;NR3C2;rs5522;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
ATENOLOL;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
ACENOCOUMAROL;CYP2C9;rs4086116;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
ETANERCEPT;STAT4;rs7574865;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
METHOTREXATE;GGH;rs11545076;AC + CC;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GOUT;;
PRAVASTATIN;SLCO1B1;rs4149015;AG;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;nan;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
TEZACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERLIPIDEMIAS;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERLIPIDEMIAS;;;
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERLIPIDEMIAS;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERLIPIDEMIAS;;;
FENOFIBRATE;ABCA1;rs2230806;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
SERTRALINE;HTR2A;rs6313;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;DEPRESSION;;;
SERTRALINE;HTR2A;rs6313;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;ANXIETY DISORDERS;;;
FENOFIBRATE;ABCA1;rs2230808;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
PLATINUM COMPOUNDS;NUP107;rs79419059;C;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;OVARIAN NEOPLASMS;;
FENOFIBRATE;ABCA1;rs2230806;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
VENLAFAXINE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ANXIETY DISORDERS;;
WARFARIN;NQO1;rs1800566;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
KETOPROFEN;CYP2C9;rs1799853;CC;EFFICACY;INCREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ETANERCEPT;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ANTIDEPRESSANTS;CHL1;rs1516338;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER,DEPRESSIVE DISORDER,MAJOR DEPRESSIVE DISORDER;;
ADALIMUMAB;TANK;rs1267067;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs15524;AA;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
ADALIMUMAB;VEGFA;rs25648;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
DACLATASVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
DACLATASVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CARVEDILOL;ADRB1;rs1801253;GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART FAILURE;;
TACROLIMUS;CYP3A5;rs4646450;GG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
INFLIXIMAB;TNF;rs361525;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;SLCO1B1;rs11045879;CC + CT;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A4;rs4646437;GG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
HYDROCHLOROTHIAZIDE;VASP;rs10995;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ADALIMUMAB;TNFAIP3;rs2230926;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
METHOTREXATE;SLC19A1;rs2838958;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
SIMVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
SIMVASTATIN ACID;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
METHOTREXATE;SLC19A1;rs3788200;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
LITHIUM;NR1D1;rs2314339;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;THRA;rs2314339;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
NALTREXONE;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;OTHER;AMPLIFICATION OF SEXUAL BEHAVIOR;;;
NALTREXONE;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;OTHER;PARKINSON DISEASE;;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
BEVACIZUMAB;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
CAPECITABINE;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
CISPLATIN;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
DOCETAXEL;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
EPIRUBICIN;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
OXALIPLATIN;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
TRASTUZUMAB;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
ACENOCOUMAROL;APOE;rs429358;C;DOSAGE;DECREASED_DOSE;nan;DISEASE;VENOUS THROMBOEMBOLISM;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs2359612;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ATAZANAVIR;SORCS2;rs73208473;A;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
BEVACIZUMAB;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
CAPECITABINE;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
CISPLATIN;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
DOCETAXEL;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
EPIRUBICIN;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
OXALIPLATIN;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
TRASTUZUMAB;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
BEVACIZUMAB;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
CAPECITABINE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
CISPLATIN;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
DOCETAXEL;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
EPIRUBICIN;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
OXALIPLATIN;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
TRASTUZUMAB;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
METHADONE;CNR1;rs806368;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
METHADONE;TPH2;rs1386493;GG;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
MORPHINE;UGT2B7;rs7439366;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;NEOPLASMS;;;
MORPHINE;UGT2B7;rs7439366;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;PAIN;;;
ATORVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
SIMVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
EFAVIRENZ;CYP2B6;rs35303484;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
METHADONE;CYP2B6;rs16974799;CT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
LAMIVUDINE;ABCB1;rs1045642;A;EFFICACY;RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NEVIRAPINE;ABCB1;rs1045642;A;EFFICACY;RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
METHADONE;OPRL1;rs2229205;CT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
ROSUVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
ADRENERGICS;nan;rs34548976;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
INHALANTS;nan;rs34548976;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
TOPIRAMATE;GRIK1;rs2832407;AA + AC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ALCOHOL-RELATED DISORDERS;;
CISPLATIN;CDA;rs2072671;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;CDA;rs2072671;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
TOPIRAMATE;GRIK1;rs2832407;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALCOHOL-RELATED DISORDERS;;
LAMIVUDINE;ABCB1;rs2032582;A;EFFICACY;RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NEVIRAPINE;ABCB1;rs2032582;A;EFFICACY;RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ZIDOVUDINE;ABCB1;rs2032582;A;EFFICACY;RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ATORVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
CISPLATIN;ERCC1;rs11615;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;ERCC1;rs11615;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
FLUVASTATIN;ABCB1;rs1922242;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
GLICLAZIDE;KCNQ1;rs2237897;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
WARFARIN;CYP4F11;rs1060467;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CARBOPLATIN;VEGFA;rs9369421;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TAXANES;VEGFA;rs9369421;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME-PK;DECREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;;;
EFAVIRENZ;CYP2A6;rs28399433;AC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
FLUVASTATIN;CETP;rs4783961;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;ABCB1;rs9282564;CC + CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
METHOTREXATE;MTRR;rs1801394;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TENOFOVIR;IFNL3;rs12979860;C;LADME-PK;INCREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;;;
TENOFOVIR;IFNL4;rs12979860;C;LADME-PK;INCREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;;;
GLUCOCORTICOIDS;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CROHN DISEASE;;
METFORMIN;SLC22A1;rs622342;A;EFFICACY;INCREASED_RESPONSE;EFFICACY;DIABETES MELLITUS;;;
GLUCOCORTICOIDS;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CROHN DISEASE;;
HYDROXYUREA;BCL11A;rs1427407;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
HYDROXYUREA;BCL11A;rs766432;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
WARFARIN;CYP2C9;rs2860905;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FENTANYL;UGT2B7;rs7439366;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE, EFFICACY;DECREASED_DOSE;nan;nan;;;
TIOTROPIUM;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
LUMEFANTRINE;ABCC2;rs8187710;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
ELEXACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
ATORVASTATIN;APOE;rs7412;CT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METHADONE;ABCB1;rs1045642;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CLOPIDOGREL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;HYPERTENSION;;
MORPHINE;UGT2B7;rs7439366;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS;;;
MORPHINE;UGT2B7;rs7439366;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN;;;
VALPROIC ACID;UGT1A6;rs2070959;AG + GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
VALPROIC ACID;UGT1A6;rs1105879;AC + CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
CLOZAPINE;HTR2A;rs6314;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
FLUVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PRAVASTATIN;ACE;rs4341;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PRAVASTATIN;LPL;rs328;GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
LOVASTATIN;CETP;rs708272;AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FENTANYL;UGT2B7;rs10028494;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
METHOTREXATE;MTHFR;rs1801133;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
NICOTINE;CHRNA3;rs1051730;A;LADME-PK;INCREASED_DOSE;nan;nan;;;
FLUVASTATIN;LIPC;rs1800588;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CLOZAPINE;CYP1A1;rs2472297;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
METHYLPHENIDATE;CES1;rs114119971;CG;DOSAGE;DECREASED_DOSE;OTHER;ADHD;;;
SIMVASTATIN;LIPC;rs1800588;CT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CISPLATIN;VEGFA;rs25648;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
FLUOROURACIL;VEGFA;rs25648;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
OXALIPLATIN;VEGFA;rs25648;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
ATORVASTATIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ATORVASTATIN;SLCO1B1;rs4149036;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ATORVASTATIN;CYP3A5;rs776746;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PERTUSSIS VACCINES;TLR4;rs2770150;GG;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
CISPLATIN;nan;rs6025211;CC + TT;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER;;;
FLUOROURACIL;nan;rs6025211;CC + TT;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER;;;
MITOXANTRONE;nan;rs6025211;CC + TT;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER;;;
TACROLIMUS;ABCB1;rs2032582;AA + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NEPHROTIC SYNDROME;;
LOVASTATIN;SLCO1B1;rs2291073;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
SUFENTANIL;CYP3A4;rs2242480;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;PAIN;;;
TACROLIMUS;ABCB1;rs1128503;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NEPHROTIC SYNDROME;;
CATECHOLAMINES;SLC22A3;rs8187725;T;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
METFORMIN;SLC22A3;rs8187725;T;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
LOVASTATIN;LDLR;rs688;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
AMLODIPINE;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
FLUVASTATIN;CYP3A4;rs4986910;AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
NALTREXONE;ADH1C;rs698;C;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
NALTREXONE;ADH1B;rs2066702;A;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
LOVASTATIN;LDLR;rs5925;CC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CISPLATIN;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER;;;
FLUOROURACIL;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER;;;
MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER;;;
FLUOXETINE;HTR2A;rs6313;GG;EFFICACY;DECREASED_RESPONSE_TIME;OTHER;DEPRESSION;;;
FLUOXETINE;HTR2A;rs6313;GG;EFFICACY;DECREASED_RESPONSE_TIME;OTHER;ANXIETY DISORDERS;;;
NALTREXONE;ALDH2;rs671;G;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
VARENICLINE;CYP2B6;rs8109525;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
TACROLIMUS;ABCB1;rs1128503;AG;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;rs7089580;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CLOPIDOGREL;P2RY12;rs2046934;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;nan;;;
TACROLIMUS;ABCB1;rs1045642;AA;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C19;rs3814637;C;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
TACROLIMUS;ABCB1;rs2032582;AA;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;rs4917639;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
TACROLIMUS;CYP3A7;rs2257401;CG + GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;nan;;;
CLOPIDOGREL;P2RY12;rs3732759;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY DISEASE;;
ANTIBIOTICS;ABCB1;rs1045642;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HELICOBACTER INFECTIONS;;;
ESOMEPRAZOLE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HELICOBACTER INFECTIONS;;;
CARFILZOMIB;VEGFA;rs833061;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
DEXAMETHASONE;VEGFA;rs833061;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
LENALIDOMIDE;VEGFA;rs833061;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
DOLUTEGRAVIR;ABCG2;rs2231142;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOPIDOGREL;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESISTANCE;nan;nan;;;
CISPLATIN;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER;;;
FLUOROURACIL;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER;;;
CARFILZOMIB;KDR;rs2305948;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
DEXAMETHASONE;KDR;rs2305948;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
LENALIDOMIDE;KDR;rs2305948;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
CARFILZOMIB;KDR;rs1870377;AT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
DEXAMETHASONE;KDR;rs1870377;AT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
LENALIDOMIDE;KDR;rs1870377;AT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MULTIPLE MYELOMA;;
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;LIVER CANCER;;;
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
SORAFENIB;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE;OTHER;HEPATITIS C VIRUS INFECTION;;;
SORAFENIB;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER;;;
MYCOPHENOLIC ACID;ABCC2;rs2273697;A;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;OTHER;LIVER TRANSPLANTATION;;;
MYCOPHENOLIC ACID;ABCC2;rs717620;T;LADME-PK;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
FENTANYL;ATF2;rs7583431;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
MYCOPHENOLIC ACID;ABCC2;rs717620;T;LADME-PK;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;NR1I2;rs3814055;CT + TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
AFLIBERCEPT;ANO2;rs2110166;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MACULAR DEGENERATION;;;
RANIBIZUMAB;ANO2;rs2110166;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MACULAR DEGENERATION;;;
TACROLIMUS;NR1I2;rs3814055;CT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VENLAFAXINE;SLC6A2;rs2242446;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
MYCOPHENOLIC ACID;ABCC2;rs2273697;A;LADME-PK;DECREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
BOCEPREVIR;IFNL3;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
BOCEPREVIR;IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL3;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
DONEPEZIL;CHRNA7;rs6494223;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
GALANTAMINE;CHRNA7;rs6494223;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
RIVASTIGMINE;CHRNA7;rs6494223;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
ADALIMUMAB;FCGR2A;rs1801274;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
FLUOROURACIL;ENOSF1;rs2612091;CC;EFFICACY;INCREASED_RESPONSE;OTHER;STOMACH NEOPLASMS;;;
ALLOPURINOL;SLC22A12;rs505802;T;DOSAGE;INCREASED_DOSE;OTHER;GOUT;;;
ALLOPURINOL;PDZK1;rs12129861;C;DOSAGE;INCREASED_DOSE;OTHER;GOUT;;;
DACLATASVIR;HINT1;rs7728773;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
SOFOSBUVIR;HINT1;rs7728773;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ADALIMUMAB;IL6;rs1800795;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;IL6;rs1800795;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;IL6;rs1800795;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
LITHIUM;nan;rs78015114;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
BUPRENORPHINE;OPRD1;rs678849;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
CARBAMAZEPINE;SCN2A;rs17183814;A;EFFICACY;RESISTANCE;nan;nan;;;
PHENOBARBITAL;SCN2A;rs17183814;A;EFFICACY;RESISTANCE;nan;nan;;;
PHENYTOIN;SCN2A;rs17183814;A;EFFICACY;RESISTANCE;nan;nan;;;
VALPROIC ACID;SCN2A;rs17183814;A;EFFICACY;RESISTANCE;nan;nan;;;
LITHIUM;nan;rs79663003;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
APREMILAST;CYP3A4;rs1203844;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
APREMILAST;TMEM130;rs1203844;C;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
APREMILAST;CYP3A4;rs35599367;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
ATORVASTATIN;MYLIP;rs9370867;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
LITHIUM;nan;rs75222709;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;nan;rs74795342;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
APREMILAST;PDE4D;rs295943;T;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
SIMVASTATIN;SCAP;rs12487736;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;;;
CAFFEINE;CYP1A2;rs2069514;AA + AG;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
APREMILAST;CDKN2B;rs1063192;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
APREMILAST;CDKN2B-AS1;rs1063192;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
PRAVASTATIN;LIPC;rs1800588;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY;;;
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
(R)-METHADONE;NR1I3;rs2307424;GG;LADME-PK;INCREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;;;
OLANZAPINE;HTR2A;rs6314;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
(S)-METHADONE;CYP2B6;rs2279343;G;LADME-PK;DECREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;;;
SIMVASTATIN;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
AZATHIOPRINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
(R)-METHADONE;NR1I3;rs3003596;GG;LADME-PK;INCREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;;;
BEVACIZUMAB;CFH;rs1061170;CT;DOSAGE;INCREASED_DOSE;nan;DISEASE;MACULAR DEGENERATION;;
METHADONE;OPRD1;rs678849;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
AZATHIOPRINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
BEVACIZUMAB;ARMS2;rs10490924;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
SIMVASTATIN;ABCB1;rs2032582;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
WARFARIN;NQO1;rs1800566;AA + AG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DEFERASIROX;ABCC2;rs2273697;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
BUDESONIDE;nan;rs2392165;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;ASTHMA;;;
THIORIDAZINE;CYP2D6;rs1080985;CC + CG;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEFERASIROX;CYP1A2;rs2470890;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
DEFERASIROX;CYP1A2;rs762551;AC + CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
OLANZAPINE;DRD2;rs1076560;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
DEFERASIROX;CYP1A1;rs2606345;AC + CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
DEFERASIROX;UGT1A1;rs887829;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
CARBAMAZEPINE;ABCB1;rs1128503;A;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY;;;
ADALIMUMAB;FCGR2A;rs1801274;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ETANERCEPT;FCGR2A;rs1801274;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
INFLIXIMAB;FCGR2A;rs1801274;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
CAPECITABINE;MTHFR;rs1801133;GG;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;NEOPLASMS;;
DACLATASVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
SOFOSBUVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC_HEPATITIS_C;;;
BUPRENORPHINE;nan;rs6973474;T;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
CARBAMAZEPINE;ABCB1;rs2032582;A;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY;;;
METHOTREXATE;SLC19A1;rs2838958;A;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
BUPRENORPHINE;nan;rs13169373;T;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
HALOPERIDOL;CYP2D6;rs3892097;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALCOHOLIC PSYCHOSIS,ALCOHOL ABUSE,ALCOHOL-RELATED DISORDERS;;
CARBAMAZEPINE;ABCB1;rs1045642;A;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY;;;
NEVIRAPINE;CYP2B6;rs28399499;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
IMATINIB;SLC22A1;rs628031;GG;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
NICOTINE;CHRNA5;rs16969968;A;DOSAGE;INCREASED_DOSE;nan;DISEASE;TOBACCO USE DISORDER;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
BUPRENORPHINE;nan;rs62368105;G;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
BUPRENORPHINE;nan;rs11782370;T;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
METHOTREXATE;ABCC4;rs7317112;G;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
ADALIMUMAB;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ETANERCEPT;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
INFLIXIMAB;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
METHOTREXATE;SLCO1B1;rs2306283;G;LADME-PK;INCREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
BUPRENORPHINE;nan;rs7205113;T;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
ETANERCEPT;IL10;rs1800896;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
BUPRENORPHINE;ADAMTSL2;rs756770;A;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
(R)-METHADONE;ABCB1;rs2032582;AA;LADME-PK;DECREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE;;;
ETANERCEPT;TGFB1;rs1800471;CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ATORVASTATIN;SLCO1B1;rs2306283;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
EFAVIRENZ;CYP2B6;rs3745274;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;CYP2B6;rs3745274;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
METHOTREXATE;SLCO1B1;rs4149056;TT;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
XK469;AOX1;rs10931910;G;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NEOPLASMS;;
SIMVASTATIN;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
MERCAPTOPURINE;NUDT15;rs116855232;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ETANERCEPT;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
MERCAPTOPURINE;TPMT;rs1142345;CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
NEVIRAPINE;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
BUCINDOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEART FAILURE;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A4;rs4986907;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
PHENPROCOUMON;VKORC1;rs9923231;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP4F2;rs2189784;AG + GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
PHENPROCOUMON;EPHX1;rs1051740;CC;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
ASPIRIN;TNF;rs1800629;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
DICLOFENAC;TNF;rs1800629;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
IBUPROFEN;TNF;rs1800629;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
INDOMETHACIN;TNF;rs1800629;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
KETOROLAC;TNF;rs1800629;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
NAPROXEN;TNF;rs1800629;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
PHENPROCOUMON;PROC;rs1799808;CC;DOSAGE, LADME-PK;INCREASED_DOSE;nan;nan;;;
LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;nan;DISEASE;EPILEPSY;;
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GASTROINTESTINAL STROMAL TUMORS;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
IMATINIB;SLC22A5;rs2631367;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROINTESTINAL STROMAL TUMORS;;
IMATINIB;SLC22A5;rs2631372;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROINTESTINAL STROMAL TUMORS;;
ETANERCEPT;TNF;rs1799724;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;EPHX1;rs2260863;CG;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;APOE;rs7412;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-HODGKIN LYMPHOMA;;
WARFARIN;CYP3A4;rs28371759;AA;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
WARFARIN;CYP1A2;rs2069514;GG;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
IMATINIB;ABCC4;rs9561765;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GASTROINTESTINAL STROMAL TUMORS;;
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;SLC15A2;rs1143671;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LAMOTRIGINE;UGT1A4;rs2011425;GG + GT;LADME-PK;DECREASED_STEADY-STATE CONCENTRATION;nan;DISEASE;EPILEPSY;;
WARFARIN;EPHX1;rs2260863;CC;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
RITONAVIR;NR1I2;rs1523130;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
L-TRYPTOPHAN;SLC22A2;rs316019;CC;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
WARFARIN;VKORC1;rs9923231;AA;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
PHENPROCOUMON;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RITONAVIR;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RITONAVIR;ABCB1;rs2032582;AC + CC;LADME-PK;CONCENTRATIONS;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ERENUMAB;RAMP1;rs13386048;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITH AURA;;;
ERENUMAB;RAMP1;rs13386048;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;OTHER;SPONDYLITIS;;;
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;OTHER;ANKYLOSING;;;
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;OTHER;SPONDYLITIS;;;
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;OTHER;ANKYLOSING;;;
SIROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
OLANZAPINE;BDNF;rs6265;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RITONAVIR;NR1I2;rs6785049;AA + AG;LADME-PK;CONCENTRATIONS;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ERENUMAB;RAMP1;rs6431564;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITH AURA;;;
ERENUMAB;RAMP1;rs6431564;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
LOSARTAN;SLC22A12;rs1529909;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION,HYPERURICEMIA;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ERENUMAB;RAMP1;rs12465864;G;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITH AURA;;;
ERENUMAB;RAMP1;rs12465864;G;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
LOSARTAN;SLC22A12;rs3825016;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION,HYPERURICEMIA;;
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
SIROLIMUS;IL10;rs1800896;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
CYCLOSPORINE;ABCB1;rs9282564;CT;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEART TRANSPLANTATION;;;
CLADRIBINE;RRM1;rs1042919;AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CYTARABINE;RRM1;rs1042919;AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CLADRIBINE;RRM2B;rs1265138;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CYTARABINE;RRM2B;rs1265138;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
FLUOROURACIL;DPYD;rs1801265;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_EXPOSURE;nan;DISEASE;COLONIC NEOPLASMS;;
CLADRIBINE;RRM1;rs2898950;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CYTARABINE;RRM1;rs2898950;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
INTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
BUPROPION;CYP2B6;rs2279343;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
INTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CLADRIBINE;RRM1;rs1561876;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CYTARABINE;RRM1;rs1561876;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
COTININE;PSMA4;rs57064725;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TOBACCO USE DISORDER;;
METHOTREXATE;ATIC;rs16853826;GG;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;ABCC1;rs35592;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
COTININE;CHRNA5;rs16969968;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TOBACCO USE DISORDER;;
INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CLADRIBINE;RRM2;rs1130609;GT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CYTARABINE;RRM2;rs1130609;GT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
INTERFERON ALFA-2A;FTO;rs9939609;AA + AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
RECOMBINANT;FTO;rs9939609;AA + AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
INTERFERON ALFA-2B;FTO;rs9939609;AA + AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
RECOMBINANT;FTO;rs9939609;AA + AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;FTO;rs9939609;AA + AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
COTININE;nan;rs77107237;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TOBACCO USE DISORDER;;
CLOZAPINE;DTNBP1;rs742105;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLADRIBINE;RRM2;rs5030743;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CYTARABINE;RRM2;rs5030743;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
COTININE;CHRNB4;rs10851907;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TOBACCO USE DISORDER;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
SIMEPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
SIMEPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
SIROLIMUS;ABCB1;rs1045642;AA + AG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;SLCO1B3;rs7311358;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;SLC15A2;rs1143672;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
INTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;SLCO1B3;rs4149117;GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ETANERCEPT;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
COTININE;CHRNA3;rs7170068;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TOBACCO USE DISORDER;;
SUNITINIB;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RENAL CELL CARCINOMA;;
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE, EFFICACY;DECREASED_DOSE;nan;nan;;;
INTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RECOMBINANT;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
SIMEPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
SIMEPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
FLUPENTHIXOL;NFKB1;rs230504;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
MONTELUKAST;SLCO2B1;rs12422149;AG;EFFICACY, LADME-PK;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
DEFERASIROX;CYP24A1;rs927650;CT + TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
DEFERASIROX;CYP24A1;rs2585428;CT + TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
FLUPENTHIXOL;NFKB1;rs3774959;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIDEPRESSANTS;TPH2;rs10879346;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
METHOTREXATE POLYGLUTAMATE;IMPDH1;rs4731448;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
CARBOPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
CISPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
METHOTREXATE POLYGLUTAMATE;CEP72;rs924607;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
TACROLIMUS;IL10;rs1800896;TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
MIRTAZAPINE;TPH2;rs1487278;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
VENLAFAXINE;TPH2;rs1487278;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
TACROLIMUS;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
BILIRUBIN;UGT1A1;rs4124874;GG + GT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;NEOPLASMS;;
CARBOPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
CISPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
DEFERASIROX;CYP24A1;rs2248359;CT + TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
FLUPENTHIXOL;NFKB1;rs230493;AT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
METHOTREXATE POLYGLUTAMATE;SLCO1B3;rs7311358;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
NICOTINE;FMO3;rs2266780;AA;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
PAZOPANIB;VEGFA;rs699947;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RENAL CELL CARCINOMA;;
METHOTREXATE POLYGLUTAMATE;FSTL5;rs3749598;AA + AC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
METHOTREXATE POLYGLUTAMATE;ATG16L1;rs2241880;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
FLUOROURACIL;DPYD;rs3918290;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
THEOPHYLLINE;CYP1A2;rs2069514;AA + AG;OTHER, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ASTHMA;;
INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTHRITIS, PSORIATIC;;
ADALIMUMAB;TNFRSF1A;rs767455;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTHRITIS, PSORIATIC;;
ETANERCEPT;TNFRSF1A;rs767455;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTHRITIS, PSORIATIC;;
INFLIXIMAB;TNFRSF1A;rs767455;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ARTHRITIS, PSORIATIC;;
PAZOPANIB;VEGFA;rs2010963;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RENAL CELL CARCINOMA;;
ADALIMUMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ADALIMUMAB;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
PAZOPANIB;VEGFA;rs833061;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RENAL CELL CARCINOMA;;
ETANERCEPT;PTTG1;rs2431697;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
CISPLATIN;CMPK1;rs4492666;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;CMPK1;rs4492666;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
BUPROPION;CHRNA5;rs503464;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
NICOTINE;CHRNA5;rs503464;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
VARENICLINE;CHRNA5;rs503464;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
VORICONAZOLE;NR1I2;rs6785049;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ETANERCEPT;HLA-B;rs13437088;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ETANERCEPT;MAP3K1;rs96844;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
CLOZAPINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOZAPINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ETANERCEPT;GBP6;rs928655;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ATORVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ETANERCEPT;IL12B;rs2546890;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TEMOZOLOMIDE;ABCB1;rs1128503;AA + AG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;GLIOMA;;;
IVACAFTOR;SLC26A9;rs7512462;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
GEMCITABINE;DCK;rs66878317;AG + GG;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
VORICONAZOLE;NR1I2;rs3814057;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
NICOTINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
MILNACIPRAN;ADRA2A;rs1800544;CC + CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
PLATINUM COMPOUNDS;IGF2;rs4244809;GG;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;OVARIAN NEOPLASMS;;
PLATINUM COMPOUNDS;IGF2-AS;rs4244809;GG;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;OVARIAN NEOPLASMS;;
PLATINUM COMPOUNDS;INS-IGF2;rs4244809;GG;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;OVARIAN NEOPLASMS;;
VORICONAZOLE;FMO3;rs2266780;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
FLUVOXAMINE;FGF2;rs1449683;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
VORICONAZOLE;POR;rs10954732;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PLATINUM COMPOUNDS;INS-IGF2;rs3842761;GG;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;OVARIAN NEOPLASMS;;
MILNACIPRAN;HTR1A;rs6295;CC + CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
VALPROIC ACID;SCN2A;rs17183814;AA + AG;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY;;;
VALPROIC ACID;SCN1A;rs2298771;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
VORICONAZOLE;NR1I2;rs2461817;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
VORICONAZOLE;NR1I2;rs3732359;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHOTREXATE;ABCC2;rs3740066;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOSARCOMA;;
CISPLATIN;RRM1;rs720106;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;RRM1;rs720106;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
VORICONAZOLE;NR1I2;rs7643645;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
SIMVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CISPLATIN;RRM1;rs232043;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;RRM1;rs232043;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
CISPLATIN;CMPK1;rs11211524;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;CMPK1;rs11211524;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
SIMVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CISPLATIN;RRM1;rs2284449;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
GEMCITABINE;RRM1;rs2284449;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
ACENOCOUMAROL;GGCX;rs11676382;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ACENOCOUMAROL;VKORC1;rs7294;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
METHOTREXATE;NR1I2;rs6785049;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOSARCOMA;;
RITUXIMAB;TGFB1;rs1800470;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
RITUXIMAB;TGFB1;rs1800471;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12980275;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12980275;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
SIMVASTATIN;CYP3A4;rs35599367;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;;;
PIOGLITAZONE;ADIPOQ;rs2241766;GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
MORPHINE;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
MORPHINE;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ROSUVASTATIN;CYP3A5;rs776746;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
METHOTREXATE;GSK3B;rs3732361;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOSARCOMA;;
NALOXONE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_RESPONSE;nan;nan;;;
TIPIFARNIB;ABCB1;rs1128503;AA;OTHER, LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ETANERCEPT;ZNF816;rs9304742;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
EFAVIRENZ;CYP2B6;rs3745274;GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NALTREXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALCOHOL ABUSE;;
ANTIPSYCHOTICS;NRG1;rs13250975;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART DISEASES;;
METHOTREXATE;SLCO1A2;rs4149009;CC + CT;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
ANTIPSYCHOTICS;nan;rs2513265;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;ADCY2;rs1544938;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;NRG1;rs17716295;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
NICOTINE;CHRNA5;rs16969968;GG;OTHER;DECREASED_DOSE;nan;DISEASE;TOBACCO USE DISORDER;;
METHADONE;DAO;rs55944529;TT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
ANTIPSYCHOTICS;CCL2;rs4795893;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;CCL2;rs4586;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
METHADONE;DAO;rs55944529;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEROIN DEPENDENCE;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ESCITALOPRAM;HTR2A;rs3803189;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FLUOXETINE;HTR2A;rs3803189;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
FLUVOXAMINE;HTR2A;rs3803189;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
SERTRALINE;HTR2A;rs3803189;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METHADONE;DRD1;rs5326;TT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IVACAFTOR;CFTR;rs80282562;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
RIFAMPIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TUBERCULOSIS;;
METHYLPHENIDATE;CYP2D6;rs1065852;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ADHD;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs11045819;CC;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
METHYLPHENIDATE;CYP2D6;rs1135840;CG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ADHD;;;
IVACAFTOR;CFTR;rs121909041;C;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
PRAVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
IVACAFTOR;CFTR;rs193922525;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;VKORC1;rs7196161;AA + AG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
IVACAFTOR;CFTR;rs267606723;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
IVACAFTOR;CFTR;rs74503330;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IVACAFTOR;CFTR;rs121909013;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
SUNITINIB;GLP1R;rs6923761;A;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;RENAL CELL CARCINOMA;;;
SUNITINIB;GLP1R;rs6923761;A;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;GASTROINTESTINAL STROMAL TUMORS;;;
DOXORUBICIN;ABCB1;rs1128503;AA;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
ATOMOXETINE;CYP2D6;rs1135840;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ADHD;;;
BETA BLOCKING AGENTS;GRK5;rs3740563;A;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2069705;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
MONTELUKAST;MLLT3;rs6475448;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
BETA BLOCKING AGENTS;GRK5;rs10787959;A;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE;;;
BUPROPION;nan;rs1908557;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
BETA BLOCKING AGENTS;GRK5;rs11198893;A;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE;;;
RIFAMPIN;CYP27B1;rs4646536;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TUBERCULOSIS;;
CORTICOSTEROIDS;ST13;rs138335;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
RIFAMPIN;VDR;rs1544410;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TUBERCULOSIS;;
DOCETAXEL;CYP3A4;rs2740574;C;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;NEOPLASMS;;
BETA BLOCKING AGENTS;ADRB1;rs1801253;GG;EFFICACY;DECREASED_RESPONSE;OTHER;HEART FAILURE;;;
METHADONE;CYP2B6;rs3745274;GG + GT;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEROIN DEPENDENCE;;
DOCETAXEL;CYP3A5;rs776746;T;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;NEOPLASMS;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
RAMIPRIL;ADRB2;rs2053044;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;OTHER;BREAST NEOPLASMS;;;
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
METHADONE;NGF;rs2239622;AA;DOSAGE;DECREASED_DOSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
NICOTINE;CYP1A2;rs35694136;T/del + del/del;EFFICACY;INCREASED_EXPOSURE;OTHER;URINARY BLADDER NEOPLASMS;;;
METHADONE;CYP2B6;rs2279343;AA + AG;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEROIN DEPENDENCE;;
GEMCITABINE;NT5C3A;rs3750117;AA;OTHER, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;NEOPLASMS;;
GEMCITABINE;NT5C2;rs11598702;TT;OTHER, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NEOPLASMS;;
FENTANYL;PGAP6;rs199670311;T;EFFICACY;INCREASED_DOSE;nan;DISEASE;PAIN;;
REMIFENTANIL;PGAP6;rs199670311;T;EFFICACY;INCREASED_DOSE;nan;DISEASE;PAIN;;
OLANZAPINE;UGT1A4;rs2011425;GT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOPHRENIA;;
ANTIDEPRESSANTS;ADCY9;rs2230739;CC;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
DABIGATRAN;CES1;rs2244613;GG + GT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;STROKE;;;
ANTIPSYCHOTICS;PI4KA;rs165854;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;GRM3;rs1468412;AA + AT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
BUDESONIDE;ZNF432;rs3752120;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
CORTICOSTEROIDS;ZNF432;rs3752120;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
FLUTICASONE;ZNF432;rs3752120;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
SALMETEROL;ZNF432;rs3752120;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
FLUTICASONE PROPIONATE;ZNF432;rs3752120;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
AZATHIOPRINE;ITPA;rs1127354;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;;
CARBOPLATIN;ERBB2;rs1136201;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOCETAXEL;ERBB2;rs1136201;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TRASTUZUMAB;ERBB2;rs1136201;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
ANTIPSYCHOTICS;SLC1A3;rs1529461;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;GRM3;rs2299214;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CARBOPLATIN;RNF8;rs2284922;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOCETAXEL;RNF8;rs2284922;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TRASTUZUMAB;RNF8;rs2284922;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
ANTIPSYCHOTICS;GRM3;rs6465084;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CARBOPLATIN;BARD1;rs2070096;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOCETAXEL;BARD1;rs2070096;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TRASTUZUMAB;BARD1;rs2070096;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
GEMCITABINE;CDA;rs1048977;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
CARBOPLATIN;ERBB3;rs2229046;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOCETAXEL;ERBB3;rs2229046;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TRASTUZUMAB;ERBB3;rs2229046;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CORTICOSTEROIDS;ST13;rs138337;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
CARBOPLATIN;ERBB3;rs773123;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOCETAXEL;ERBB3;rs773123;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TRASTUZUMAB;ERBB3;rs773123;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
ANTIPSYCHOTICS;SLC1A4;rs10211524;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;GRM3;rs2299214;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
SUFENTANIL;COMT;rs4680;AA;DOSAGE, EFFICACY;DECREASED_DOSE;nan;nan;;;
FLUINDIONE;VKORC1;rs9923231;TT;LADME-PK;DOSE;nan;nan;;;
APREMILAST;LEPR;rs1045895;AA + AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
APREMILAST;LEPROT;rs1045895;AA + AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OPIOIDS;ABCB1;rs1045642;AA;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;NEOPLASMS,PAIN;;
CARBOPLATIN;AKT1;rs2494752;AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
CISPLATIN;AKT1;rs2494752;AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
QUINAPRIL;AGT;rs699;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
OPIOIDS;KCNJ6;rs6517442;CC;DOSAGE;INCREASED_DOSE;OTHER;LOW BACK PAIN;;;
OLANZAPINE;CYP1A2;rs35694136;T/del;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOPHRENIA;;
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;NEOPLASMS,PAIN;;
OLANZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCHIZOPHRENIA;;
FENTANYL;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
PHENPROCOUMON;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CAPECITABINE;TYMS;rs183205964;C;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;NEOPLASMS;;
FLUOROURACIL;TYMS;rs183205964;C;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;NEOPLASMS;;
TEGAFUR;TYMS;rs183205964;C;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;NEOPLASMS;;
KETOPROFEN;CYP2C9;rs1057910;AC;EFFICACY;INCREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
ATORVASTATIN;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY ARTERY DISEASE;;
IMATINIB;SLC22A1;rs683369;CC;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME-PK;INCREASED_METABOLISM;nan;nan;;;
IMATINIB;SLC22A1;rs683369;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
ETANERCEPT;TNFRSF1B;rs1061622;GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SPONDYLITIS, ANKYLOSING;;
FENTANYL;SLC9A9;rs4839603;GG;EFFICACY;DECREASED_DOSE;nan;DISEASE;PAIN;;
REMIFENTANIL;SLC9A9;rs4839603;GG;EFFICACY;DECREASED_DOSE;nan;DISEASE;PAIN;;
EFAVIRENZ;ABCB1;rs1045642;GG;EFFICACY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;T;EFFICACY;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;ABCB1;rs1045642;AA;EFFICACY, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
APREMILAST;PDE4B;rs12745871;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
ATORVASTATIN;SCARB1;rs5888;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
APREMILAST;TSPAN16;rs322144;C;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
PRAVASTATIN;FCAR;rs11666735;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MYOCARDIAL INFARCTION;;
CYCLOPHOSPHAMIDE;GSTP1;rs1695;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
EPIRUBICIN;GSTP1;rs1695;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
FENOFIBRATE;APOA1;rs964184;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTRIGLYCERIDEMIA;;
ANTIEPILEPTICS;SCN1A;rs10188577;CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
APREMILAST;DOCK6;rs12979813;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
DAPTOMYCIN;ABCB1;rs1045642;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DAPTOMYCIN;ABCB1;rs1045642;AA;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
NALTREXONE;DBH;rs1611115;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALCOHOL ABUSE;;
GEMCITABINE;SLC28A2;rs11854484;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
ANTINEOPLASTIC AGENTS;ABCG2;rs2231142;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
GEMCITABINE;SLC28A2;rs1060896;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
APREMILAST;EIF3G;rs2305795;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
APREMILAST;P2RY11;rs2305795;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
APREMILAST;PPAN-P2RY11;rs2305795;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOSARCOMA;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;GG;EFFICACY;INCREASED_RESISTANCE;OTHER;TUBERCULOSIS;;;
METHOTREXATE;SLCO1B1;rs11045879;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOSARCOMA;;
SUFENTANIL;OPRM1;rs1799971;AG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
APREMILAST;ILF3;rs76966440;T;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;PSORIASIS;;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CYCLOPHOSPHAMIDE;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
EPIRUBICIN;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
FLUOROURACIL;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
SULFASALAZINE;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TACROLIMUS;ABCB1;rs1128503;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;PRSS53;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
NORTRIPTYLINE;NOS3;rs1799983;TT;EFFICACY;INCREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA;;;
NORTRIPTYLINE;NOS3;rs1799983;TT;EFFICACY;INCREASED_RESPONSE;OTHER;MIGRAINE WITH AURA;;;
ALLOPURINOL;GREM2;rs1934341;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
COTININE;NAT1;rs13253389;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ALLOPURINOL;GREM2;rs77567654;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;ABCB1;rs2032582;CC;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ALLOPURINOL;ABCG2;rs45499402;C;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
EXENATIDE;GLP1R;rs10305420;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
TOPIRAMATE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA;;;
TOPIRAMATE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;OTHER;MIGRAINE WITH AURA;;;
LAMOTRIGINE;UGT2B7;rs7668258;TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
WARFARIN;VKORC1;rs7294;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
BENAZEPRIL;AGT;rs4762;GG;EFFICACY;RESPONSE;nan;DISEASE;HYPERTENSION;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
IMATINIB;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
LAMOTRIGINE;UGT2B7;rs28365063;GG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;ABCC4;rs7317112;GG;LADME-PK;INCREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
BENAZEPRIL;AGTR1;rs2640543;GG;EFFICACY;RESPONSE;nan;DISEASE;HYPERTENSION;;
ALENDRONATE;MVK;rs10161126;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BONE DISEASES;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;ITPA;rs1127354;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ELEXACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
TEZACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
IVACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
SARILUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
PEGINTERFERON ALFA-2A;LDLR;rs14158;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2B;LDLR;rs14158;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;LDLR;rs14158;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C,HIV INFECTIOUS DISEASE;;
BENAZEPRIL;SPTA1;rs2106089;G;EFFICACY;RESPONSE;nan;DISEASE;HYPERTENSION;;
IMATINIB;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SARILUMAB;IL6R;rs4329505;TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
IMATINIB;ABCB1;rs2032582;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
BUPRENORPHINE;OPRD1;rs678849;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ADALIMUMAB;NCR3;rs1052248;AT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
CERTOLIZUMAB PEGOL;NCR3;rs1052248;AT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;NCR3;rs1052248;AT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;NCR3;rs1052248;AT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NCR3;rs1052248;AT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SALBUTAMOL;COL2A1;rs3809324;GT + TT;LADME-PD;DECREASED_RESPONSE;OTHER;ASTHMA;;;
ANTIPSYCHOTICS;CACNA1C;rs2238087;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
DIURETICS;PRKCA;rs4791040;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;PRKCA;rs4791040;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
THIAZIDES;PRKCA;rs4791040;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PLAIN;PRKCA;rs4791040;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ANTIPSYCHOTICS;CACNA1B;rs2229949;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ACENOCOUMAROL;STX4;rs10871454;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;nan;rs12777823;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CORTICOSTEROIDS;GLCCI1;rs37973;GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;RHINITIS;;;
DEFERASIROX;GC;rs7041;AA;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ASPIRIN;CYP4F2;rs2108622;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
CLOPIDOGREL;CYP4F2;rs2108622;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
INTERFERON BETA-1A;CD58;rs12044852;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
INTERFERON BETA-1B;CD58;rs12044852;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MULTIPLE SCLEROSIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs610604;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER;ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs610604;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIATIC;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs610604;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS;;;
MORPHINE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6920220;AA;EFFICACY;DECREASED_RESPONSE;OTHER;ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6920220;AA;EFFICACY;DECREASED_RESPONSE;OTHER;PSORIATIC;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6920220;AA;EFFICACY;DECREASED_RESPONSE;OTHER;PSORIASIS;;;
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;CARDIOVASCULAR DISEASE;;
ANTIPSYCHOTICS;CACNB2;rs12245847;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TACROLIMUS;CYP3A7;rs2257401;C;LADME-PK;TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION,TRANSPLANTATION;;
DEFERASIROX;UGT1A1;rs887829;CC;EFFICACY;DECREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
ANTIPSYCHOTICS;CACNG3;rs1859204;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION,TRANSPLANTATION;;
DEFERASIROX;UGT1A3;rs1983023;TT;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
DEFERASIROX;CYP27B1;rs10877012;GG;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TACROLIMUS;CYP3A4;rs4646437;A;LADME-PK;TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION,TRANSPLANTATION;;
ADALIMUMAB;ATG16L1;rs10210302;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CROHN DISEASE;;
ANTIPSYCHOTICS;CACNB2;rs982003;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TACROLIMUS;CYP3A4;rs2242480;T;LADME-PK;TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION,TRANSPLANTATION;;
DEFERASIROX;VDR;rs731236;GG;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
DEFERASIROX;VDR;rs1544410;TT;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
TACROLIMUS;CYP3A5;rs41303343;A;LADME-PK;TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION,TRANSPLANTATION;;
CAPECITABINE;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CAPECITABINE;SLCO1B1;rs2306283;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;SLCO1B1;rs2306283;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;SLCO1B1;rs2306283;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;SLCO1B1;rs2306283;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TACROLIMUS;CYP3A5;rs4646450;A;LADME-PK;TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION,TRANSPLANTATION;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DIURETICS;nan;rs2776546;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;nan;rs2776546;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
THIAZIDES;nan;rs2776546;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PLAIN;nan;rs2776546;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
WARFARIN;CYP2C9;rs28371686;CG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ANTIPSYCHOTICS;CACNB2;rs10741058;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ATAZANAVIR;UGT1A1;rs887829;TT;TOXICITY;INCREASED_DISCONTINUATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
DIURETICS;nan;rs238;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;nan;rs238;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
THIAZIDES;nan;rs238;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PLAIN;nan;rs238;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ANTIPSYCHOTICS;CACNA2D3;rs4505744;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
DIURETICS;nan;rs4815273;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;nan;rs4815273;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
THIAZIDES;nan;rs4815273;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PLAIN;nan;rs4815273;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
IBUPROFEN;CYP2C9;rs1057910;AC;EFFICACY;DECREASED_RESPONSE_TIME;OTHER;PATENT DUCTUS ARTERIOSUS;;;
ANTIPSYCHOTICS;CACNA1E;rs12060765;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CORTICOSTEROIDS;TAAR6;rs7772821;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
SALBUTAMOL;VEGFA;rs3025039;CT + TT;LADME-PD;DECREASED_RESPONSE;OTHER;ASTHMA;;;
BEVACIZUMAB;CFH;rs1061170;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
RANIBIZUMAB;CFH;rs1061170;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
MORPHINE;TAOK3;rs795484;TT;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
PREDNISONE;NR3C1;rs6196;G;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;NEPHROTIC SYNDROME;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
SN-38;UGT1A1;rs4148323;AA;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
DOCETAXEL;nan;rs4842198;G;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;NASOPHARYNGEAL NEOPLASMS;;
FLUVOXAMINE;HTR2A;rs6311;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE, EFFICACY;DECREASED_DOSE;nan;nan;;;
PREDNISONE;NR3C1;rs258751;A;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;NEPHROTIC SYNDROME;;
LEDIPASVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
LEDIPASVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
SOFOSBUVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
SOFOSBUVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
SN-38;UGT1A9;rs3832043;del/del;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
PHENYTOIN;CYP2C9;rs28371686;G;OTHER, LADME-PK;DECREASED_METABOLISM;OTHER;NO DISEASE;;;
IMATINIB;ABCG2;rs2231137;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;GASTROINTESTINAL STROMAL TUMORS;;;
PREDNISONE;NR3C1;rs10052957;A;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;NEPHROTIC SYNDROME;;
IMATINIB;CYP1A2;rs762551;CC;DOSAGE;DECREASED_DOSE;OTHER;GASTROINTESTINAL STROMAL TUMORS;;;
PHENYTOIN;CYP2C9;rs7900194;A;OTHER, LADME-PK;DECREASED_METABOLISM;OTHER;NO DISEASE;;;
LURASIDONE;HTR1A;rs6295;CG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
PHENYTOIN;CYP2C9;rs28371685;T;OTHER, LADME-PK;INCREASED_METABOLISM;ENZYME;CYP2C9;;;
PHENYTOIN;CYP2C9;rs9332131;del;OTHER, LADME-PK;DECREASED_METABOLISM;ENZYME;CYP2C9;;;
DOCETAXEL;RXRA;rs3132291;A;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;NASOPHARYNGEAL NEOPLASMS;;
INFLIXIMAB;TNFRSF1B;rs1061622;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CODEINE;OPRM1;rs1799971;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CODEINE;UGT2B7;rs7439366;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ANTIPSYCHOTICS;CACNB2;rs4237348;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TACROLIMUS;CYP3A4;rs2740574;T;LADME-PK;TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION,TRANSPLANTATION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ANTIPSYCHOTICS;CACNB4;rs3768652;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TACROLIMUS;CYP3A4;rs35599367;A;LADME-PK;TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION,TRANSPLANTATION;;
ANTIPSYCHOTICS;CACNA2D3;rs7427395;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;CACNB2;rs1277733;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
SOFOSBUVIR;CES1;rs4513095;A;EFFICACY;DECREASED_RESPONSE;OTHER;CHRONIC_HEPATITIS_C;;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PROPOFOL;SCN9A;rs6746030;AA + AG;OTHER;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;TRANSPLANTATION;;
SALBUTAMOL;PRKG1;rs7081864;A;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
TACROLIMUS;CYP3A5;rs776746;C;DOSAGE;DECREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ANTIPSYCHOTICS;BDNF;rs11030104;AG + GG;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;SCHIZOPHRENIA;;
SUNITINIB;ABCB1;rs1045642;GG;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;RENAL CELL CARCINOMA;;
PROPOFOL;HTR2A;rs6313;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ANTIPSYCHOTICS;BDNF-AS;rs10501087;CC + CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;SCHIZOPHRENIA;;
PROPOFOL;GABRA1;rs2279020;GG;OTHER;INCREASED_RESPONSE;SENSITIVITY;nan;;;
SUNITINIB;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RENAL CELL CARCINOMA;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
OPIOIDS;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DOXORUBICIN;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
PREDNISOLONE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
VINCRISTINE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESISTANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;SCHIZOPHRENIA;;
OPIOIDS;COMT;rs4680;AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METFORMIN;ABCC8;rs5219;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METFORMIN;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SULFONAMIDES;ABCC8;rs5219;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SULFONAMIDES;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
UREA DERIVATIVES;ABCC8;rs5219;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
UREA DERIVATIVES;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
PALIPERIDONE;NFIB;rs28379954;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
RISPERIDONE;NFIB;rs28379954;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
REMIFENTANIL;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;OTHER;TONSILLECTOMY;;;
SEVOFLURANE;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;OTHER;TONSILLECTOMY;;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
MORPHINE;TAOK3;rs1277441;GG;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
DOXORUBICIN;ABCB1;rs2229109;CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHOTREXATE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
PREDNISOLONE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
VINCRISTINE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
HYDROXYUREA;KLF4;rs2236599;C;EFFICACY;INCREASED_RESPONSE;OTHER;ANEMIA;;;
HYDROXYUREA;KLF4;rs2236599;C;EFFICACY;INCREASED_RESPONSE;OTHER;SICKLE CELL;;;
HYDROXYUREA;KLF4;rs2236599;C;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES;;;
OXYCODONE;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
TACROLIMUS;CYP3A4;rs2242480;CT + TT;LADME-PK;INCREASED_CLEARANCE;OTHER;HEART TRANSPLANTATION;;;
METHOTREXATE;SLCO1B1;rs11045821;A;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
BILIRUBIN;UGT1A;rs11563250;AG + GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;COLORECTAL NEOPLASMS;;
DEFERASIROX;UGT1A3;rs1983023;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
ADALIMUMAB;CERS6;rs13393173;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
CERTOLIZUMAB PEGOL;CERS6;rs13393173;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;CERS6;rs13393173;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;CERS6;rs13393173;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
MORPHINE;SLC22A1;rs12208357;CT + TT;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
MIDAZOLAM;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
MORPHINE;SLC22A1;rs55918055;CC + CT;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
BUPROPION;CYP2A6;rs4803381;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
NICOTINE_SUBSTITUTES;CYP2A6;rs4803381;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TOBACCO USE DISORDER;;
METFORMIN;SRR;rs391300;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
METHYLPHENIDATE;SLC6A2;rs5569;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
ERYTHROMYCIN;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
NICOTINE;CYP2A6;rs4803381;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOZAPINE;ABCB1;rs7787082;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CAFFEINE;CYP1A2;rs762551;AA + AC;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ATENOLOL;nan;rs12346562;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;nan;rs12346562;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ATENOLOL;nan;rs1104514;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
MORPHINE;SLC22A1;rs34130495;AA + AG;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
ATENOLOL;nan;rs10739150;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
CLOZAPINE;ABCB1;rs10248420;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
DEFERASIROX;UGT1A3;rs3806596;CC;EFFICACY, LADME-PK;INCREASED_RESPONSE;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
TRANDOLAPRIL;PTPRD;rs4742610;T;EFFICACY;RESISTANCE;nan;DISEASE;HYPERTENSION;;
VERAPAMIL;PTPRD;rs4742610;T;EFFICACY;RESISTANCE;nan;DISEASE;HYPERTENSION;;
DEFERASIROX;ABCG2;rs13120400;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
EFAVIRENZ;ABCB1;rs3842;CC + CT;LADME-PK;INCREASED_TROUGH CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
METFORMIN;SLC47A1;rs2289669;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SULFONAMIDES;SLC47A1;rs2289669;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
UREA DERIVATIVES;SLC47A1;rs2289669;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SUNITINIB;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;NEOPLASMS;;
WARFARIN;VDR;rs11168292;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
4-HYDROXYTAMOXIFEN;SULT1A2;rs1136703;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;SULT1A2;rs1136703;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ARA-CTP;SLC28A3;rs17343066;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
WARFARIN;VDR;rs4760658;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VDR;rs11168293;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ADALIMUMAB;ALPL;rs885814;T;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
CERTOLIZUMAB PEGOL;ALPL;rs885814;T;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;ALPL;rs885814;T;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;ALPL;rs885814;T;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ALPL;rs885814;T;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
METHOTREXATE;SLCO1B1;rs4149056;C;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHOTREXATE;SLCO1B1;rs2306283;A;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ADALIMUMAB;nan;rs1350948;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
CERTOLIZUMAB PEGOL;nan;rs1350948;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;nan;rs1350948;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;nan;rs1350948;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;nan;rs1350948;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
4-HYDROXYTAMOXIFEN;SULT1A2;rs1059491;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
ENDOXIFEN;SULT1A2;rs1059491;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHOTREXATE;SLCO1B1;rs4149081;A;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
ADALIMUMAB;EYA4;rs17301249;C;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
CERTOLIZUMAB PEGOL;EYA4;rs17301249;C;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;EYA4;rs17301249;C;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;EYA4;rs17301249;C;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;EYA4;rs17301249;C;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ADALIMUMAB;nan;rs12081765;G;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
CERTOLIZUMAB PEGOL;nan;rs12081765;G;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;nan;rs12081765;G;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;nan;rs12081765;G;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;nan;rs12081765;G;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
METHOTREXATE;SLCO1B1;rs11045879;C;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
PHENYLEPHRINE;ADRB2;rs1042713;AA;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;;;
ANASTROZOLE;CSMD1;rs6990851;G;EFFICACY;INCREASED_RESPONSE;OTHER;BREAST NEOPLASMS;;;
N-DESMETHYLTRAMADOL;ABCC2;rs2273697;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
O-DESMETHYLTRAMADOL;ABCC2;rs2273697;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
PEGINTERFERON ALFA-2B;nan;rs6806020;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;nan;rs6806020;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
NICOTINE;CYP2A6;rs28399433;C;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ATORVASTATIN;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;;;
PEGINTERFERON ALFA-2B;nan;rs1931704;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;nan;rs1931704;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ACAMPROSATE;CHDH;rs6801605;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ALCOHOL ABUSE;;;
ACAMPROSATE;IL17RB;rs6801605;A;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;ALCOHOL ABUSE;;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, EFFICACY;DECREASED_DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;LEUKEMIA;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;LYMPHOCYTIC;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;B-CELL;;;
PRAVASTATIN;MTTP;rs1800591;GT + TT;EFFICACY;RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
COUMARIN;CYP2A6;rs28399433;C;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
PEGINTERFERON ALFA-2B;IL21R;rs3093390;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IL21R;rs3093390;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
BEVACIZUMAB;VEGFA;rs1570360;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;VEGFA;rs1570360;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
PEGINTERFERON ALFA-2B;nan;rs7512595;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;nan;rs7512595;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;CARD16;rs1792774;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;CARD16;rs1792774;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;CYP2C19;rs3814637;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs1057910;AA + AC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
N-DESMETHYLTRAMADOL;ABCC2;rs3740066;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
PEGINTERFERON ALFA-2B;nan;rs7750468;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;nan;rs7750468;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
WARFARIN;GGCX;rs699664;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
IVACAFTOR;CFTR;rs75527207;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CYSTIC FIBROSIS;;;
ATORVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
FENTANYL;ABCC3;rs11079921;C;LADME-PK;INCREASED_CLEARANCE;OTHER;PAIN;;;
FENTANYL;ABCC3;rs11079921;C;LADME-PK;INCREASED_CLEARANCE;OTHER;PREMATURE BIRTH;;;
PEGINTERFERON ALFA-2B;CARD16;rs1503391;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;CARD16;rs1503391;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;CASP1;rs557905;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;CASP1;rs557905;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;nan;rs2066911;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;nan;rs2066911;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
HMG COA REDUCTASE INHIBITORS;CFAP44;rs13064411;G;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ATORVASTATIN;CYP7A1;rs3808607;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
PEGINTERFERON ALFA-2B;CASP1;rs568910;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;CASP1;rs568910;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CODEINE;CYP2D6;rs3892097;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;CHRONIC KIDNEY FAILURE;;
NICOTINE;CHRNB2;rs2072658;AG;OTHER;INCREASED_RESPONSE;OTHER;DAILY SMOKING;;;
METFORMIN;SLC22A1;rs622342;AC + CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
N-DESMETHYLTRAMADOL;UGT1A8;rs8330;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
NICOTINE;CHRNA4;rs2229959;C;OTHER;INCREASED_RESPONSE;OTHER;DAILY SMOKING;;;
PEGINTERFERON ALFA-2B;TUT7;rs17461620;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;TUT7;rs17461620;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ACETYLCYSTEINE;TOLLIP;rs3750920;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PULMONARY FIBROSIS;;
OXCARBAZEPINE;ABCB1;rs1045642;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
OXCARBAZEPINE;UGT2B7;rs7439366;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
ARA-CTP;CDA;rs12404655;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ARA-CTP;RRM1;rs11030918;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOPIDOGREL;CYP3A5;rs776746;CC + CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;STROKE;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ARA-CTP;CTPS1;rs11577910;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ARA-CTP;CTPS1;rs12067645;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
ARA-CTP;CTPS1;rs4364871;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
N-DESMETHYLTRAMADOL;UGT1A8;rs10929303;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
N-DESMETHYLTRAMADOL;UGT1A8;rs34650714;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
O-DESMETHYLTRAMADOL;UGT1A8;rs34650714;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
ARA-CTP;SLC28A1;rs11853372;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
ARA-CTP;DCTD;rs4742;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ALLOPURINOL;ABCG2;rs2231142;GT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;GOUT;;
OXCARBAZEPINE;ABCB1;rs1045642;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
AMANTADINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;PARKINSON DISEASE;;
ANTICHOLINERGICS;SLC22A1;rs622342;C;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;PARKINSON DISEASE;;
LEVODOPA;SLC22A1;rs622342;C;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;PARKINSON DISEASE;;
SELEGILINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;PARKINSON DISEASE;;
ARA-CTP;DCK;rs4643786;CC + CT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ACUTE_MYELOID_LEUKEMIA;;
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;TOBACCO USE DISORDER;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
MORPHINE-3-GLUCURONIDE;ABCC3;rs4793665;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCOLIOSIS,TONSILLECTOMY;;
MORPHINE-6-GLUCURONIDE;ABCC3;rs4793665;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;SCOLIOSIS,TONSILLECTOMY;;
TACROLIMUS;ABCB1;rs1128503;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LIVER TRANSPLANTATION;;
MORPHINE-3-GLUCURONIDE;ABCC3;rs4148412;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TONSILLECTOMY;;
GLUCOSE;CRTC2;rs8450;AA + AG;TOXICITY;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TRANSPLANTATION;;
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ARTHRITIS, PSORIATIC;;
TACROLIMUS;ABCB1;rs1128503;GG;LADME-PK;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
SERTRALINE;GNB3;rs5441;GG;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
FENTANYL;CYP3A4;rs2242480;TT;EFFICACY;INCREASED_RESPONSE;OTHER;POSTOPERATIVE_PAIN;;;
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS;;;
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
SUFENTANIL;OPRM1;rs1323040;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS;;;
SUFENTANIL;OPRM1;rs1323040;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
SUFENTANIL;ABCB1;rs1128503;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS;;;
SUFENTANIL;ABCB1;rs1128503;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
CYCLOSPORINE;ABCB1;rs1045642;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
SUFENTANIL;ABCB1;rs2032582;AA + AC;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS;;;
SUFENTANIL;ABCB1;rs2032582;AA + AC;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
MORPHINE;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
HDL CHOLESTEROL;CRTC2;rs8450;AA;TOXICITY;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;TRANSPLANTATION;;
O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
MYCOPHENOLIC ACID;ABCC2;rs717620;TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
N-DESMETHYLTRAMADOL;SLC22A1;rs1867351;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
O-DESMETHYLTRAMADOL;SLC22A1;rs1867351;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;DEATH;;;
PHENYTOIN;CYP2C9;rs12782374;AA + AG;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
FENTANYL;ABCC3;rs8077268;T;LADME-PK;INCREASED_CLEARANCE;OTHER;PAIN;;;
FENTANYL;ABCC3;rs8077268;T;LADME-PK;INCREASED_CLEARANCE;OTHER;PREMATURE BIRTH;;;
METHYLPHENIDATE;COMT;rs4680;G;EFFICACY;INCREASED_CLEARANCE;nan;DISEASE;ADHD;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE, LADME-PK;DECREASED_DOSE;nan;nan;;;
PLATINUM COMPOUNDS;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CYCLOSPORINE;ABCB1;rs1045642;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
NICOTINE;CYP1A2;rs35694136;T/del + del/del;EFFICACY;DECREASED_EXPOSURE;nan;nan;;;
SIROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;TRANSPLANTATION;;
PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
MYCOPHENOLIC ACID;UGT2B7;rs7662029;G;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
METHYLPHENIDATE;TH;rs2070762;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ADHD;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TACROLIMUS;IL18;rs5744247;CC + CG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LIVER TRANSPLANTATION;;
SIROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SIROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CETUXIMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CARBAMAZEPINE;CYP3A4;rs2242480;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
RISPERIDONE;HTR2C;rs518147;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CARBAMAZEPINE;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
SITAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
VILDAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DESETHYLCHLOROQUINE;CYP2C8;rs7910936;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
HYDROXYCHLOROQUINE;CYP2C8;rs7910936;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
CARBAMAZEPINE;ABCB1;rs1045642;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
CARBAMAZEPINE;EPHX1;rs3738046;CG;LADME-PK;CONCENTRATIONS;nan;DISEASE;EPILEPSY;;
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERCHOLESTEROLEMIA;;;
PHENYTOIN;CYP2C9;rs1057910;AC;OTHER, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP2C9;rs1799853;CT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
PHENYTOIN;CYP2C19;rs4244285;AG;OTHER, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
CLOZAPINE;HTR2C;rs6318;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CARBAMAZEPINE;EPHX1;rs2234922;AG + GG;LADME-PK;CONCENTRATIONS;nan;DISEASE;EPILEPSY;;
CARBAMAZEPINE;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
SULFONAMIDES;TCF7L2;rs12255372;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
UREA DERIVATIVES;TCF7L2;rs12255372;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SIMVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERCHOLESTEROLEMIA;;;
CARBOPLATIN;XRCC1;rs25487;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;UTERINE CERVICAL NEOPLASM;;
CISPLATIN;XRCC1;rs25487;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;UTERINE CERVICAL NEOPLASM;;
FLUOROURACIL;XRCC1;rs25487;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;UTERINE CERVICAL NEOPLASM;;
TRAMADOL;ABCB1;rs2032582;AA;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
TRAMADOL;ABCB1;rs1045642;AA;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
CARBOPLATIN;SLC19A1;rs12659;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;UTERINE CERVICAL NEOPLASM;;
CISPLATIN;SLC19A1;rs12659;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;UTERINE CERVICAL NEOPLASM;;
FLUOROURACIL;SLC19A1;rs12659;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;UTERINE CERVICAL NEOPLASM;;
TRAMADOL;ABCB1;rs1128503;AA;LADME-PK;INCREASED_EXPOSURE;nan;nan;;;
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CAFFEINE;ADORA1;rs16851030;CC;EFFICACY;INCREASED_RESPONSE;OTHER;APNEA OF PREMATURITY;;;
TOCILIZUMAB;IL6R;rs4329505;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
RISPERIDONE;HTR2C;rs1023574;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;HTR2C;rs9698290;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
DIURETICS;PRKCA;rs16960228;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;PRKCA;rs16960228;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
THIAZIDES;PRKCA;rs16960228;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PLAIN;PRKCA;rs16960228;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ANTIDEPRESSANTS;RGS17;rs672170;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
LITHIUM;NTRK2;rs1387923;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
WARFARIN;CYP2C9;rs7089580;AT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs7089580;AT;DOSAGE;INCREASED_CLEARANCE;nan;nan;;;
VORICONAZOLE;SLCO1B3;rs4149117;GT + TT;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;nan;;;
LITHIUM;GSK3B;rs334558;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
OXALIPLATIN;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ANTIDEPRESSANTS;NBEA;rs9315310;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ANTIDEPRESSANTS;CRH;rs4737771;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ANTIDEPRESSANTS;FHIT;rs49411;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ANTIDEPRESSANTS;PARP11;rs2532560;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ANTIDEPRESSANTS;nan;rs2831440;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SILDENAFIL;GNB3;rs5443;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ERECTILE DYSFUNCTION;;
ANTIDEPRESSANTS;MTRF1L;rs766127;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ATORVASTATIN;POR;rs1057868;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;FAMILIAL HYPERCHOLESTEROLEMIA;;
TACROLIMUS;HSD11B1;rs846908;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
SARILUMAB;IL6R;rs4845625;CC;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
SALVIANOLIC ACID B;NOS3;rs1799983;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CORONARY DISEASE;;
BUPROPION;COMT;rs165599;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SMOKERS;;;
LITHIUM;TPH1;rs1799913;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
BUPROPION;COMT;rs737865;AA;EFFICACY;DECREASED_RESPONSE;OTHER;SMOKERS;;;
LITHIUM;TPH1;rs1800532;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;CACNG2;rs2284017;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
SALBUTAMOL;CRHR2;rs2267715;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
DESETHYLCHLOROQUINE;CYP2C8;rs10882521;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
HYDROXYCHLOROQUINE;CYP2C8;rs10882521;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
LITHIUM;BCR;rs140504;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
WARFARIN;STX1B;rs4889606;AG + GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
ADALIMUMAB;HFE;rs2071303;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CROHN DISEASE;;
ROSIGLITAZONE;LPIN1;rs10192566;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
TACROLIMUS;HSD11B1;rs4844880;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DESETHYLCHLOROQUINE;CYP2D6;rs1065852;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
TACROLIMUS;HSD11B1;rs846910;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ACENOCOUMAROL;GATA4;rs3735814;AG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
BETA BLOCKING AGENTS;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
SELECTIVE;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
DIURETICS;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ANTIDEPRESSANTS;CTNNA3;rs10997242;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ALDOSTERONE ANTAGONISTS;NEDD4L;rs4149601;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
AMILORIDE;NEDD4L;rs4149601;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
LITHIUM;DRD1;rs4532;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
ANTIDEPRESSANTS;HTR2A;rs7997012;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SALBUTAMOL;CRHR2;rs255100;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
ANTIDEPRESSANTS;HTR2A;rs6313;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ANTIDEPRESSANTS;CACNA1A;rs2112460;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SALBUTAMOL;CRHR2;rs2284220;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
WARFARIN;ORM1;rs17650;AG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ANTIDEPRESSANTS;nan;rs521093;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
MORPHINE;UGT2B7;rs7439366;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
WARFARIN;VKORC1;rs7294;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ANTIDEPRESSANTS;RAPGEF5;rs16873129;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
VALPROIC ACID;ABCB1;rs1128503;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
ANTIDEPRESSANTS;PON2;rs2299267;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CISPLATIN;GALNT18;rs7937567;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
EFAVIRENZ;CYP2B6;rs2279343;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RITUXIMAB;nan;rs3759467;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;VASCULITIS;;
ANTIPSYCHOTICS;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
ARIPIPRAZOLE;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
CLOZAPINE;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
HALOPERIDOL;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
OLANZAPINE;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
QUETIAPINE;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
RISPERIDONE;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9923231;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CORTICOSTEROIDS;HDAC1;rs1741981;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
VINCRISTINE;MTNR1B;rs8192552;AG;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
VINCRISTINE;MTNR1B;rs8192552;AG;LADME-PK;INCREASED_EXPOSURE;OTHER;HODGKIN DISEASE;;;
VINCRISTINE;MTNR1B;rs8192552;AG;LADME-PK;INCREASED_EXPOSURE;OTHER;RHABDOMYOSARCOMA;;;
VINCRISTINE;MTNR1B;rs8192552;AG;LADME-PK;INCREASED_EXPOSURE;OTHER;MEDULLOBLASTOMA;;;
VINCRISTINE;MTNR1B;rs8192552;AG;LADME-PK;INCREASED_EXPOSURE;OTHER;GLIOMA;;;
MORPHINE;TLR2;rs3804100;CC + CT;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CT;OTHER, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DOCETAXEL;CHST3;rs4148947;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;CHST3;rs4148947;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
MORPHINE;IL1B;rs1143634;A;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CISPLATIN;MLLT3;rs10964552;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MORPHINE;IL1B;rs1143634;A;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
DOCETAXEL;CHST3;rs4148950;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;CHST3;rs4148950;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ATORVASTATIN;MTTP;rs1800591;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERLIPOPROTEINEMIA TYPE II;;
NITROGLYCERIN;ALDH2;rs671;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CONGENITAL HEART DEFECTS;;
TOCILIZUMAB;GALNT18;rs4910008;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CISPLATIN;RARS1;rs244898;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;URINARY BLADDER NEOPLASMS;;
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DOSE;nan;DISEASE;STROKE;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RISPERIDONE;ABCB1;rs2235048;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_DOSE;OTHER;HEART TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
NITROGLYCERIN;ALDH2;rs671;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;CONGENITAL HEART DEFECTS,PULMONARY HYPERTENSION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TOCILIZUMAB;CD69;rs11052877;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PHENAZEPAM;CYP2C19;rs12248560;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALCOHOL-RELATED DISORDERS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
VINCRISTINE;SNU13;rs6519270;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
VINCRISTINE;SNU13;rs6519270;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HODGKIN DISEASE;;;
VINCRISTINE;SNU13;rs6519270;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;RHABDOMYOSARCOMA;;;
VINCRISTINE;SNU13;rs6519270;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MEDULLOBLASTOMA;;;
VINCRISTINE;SNU13;rs6519270;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;GLIOMA;;;
ATENOLOL;nan;rs7184292;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
ATENOLOL;XIRP2;rs7606603;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
CYCLOSPORINE;CYP3A7;rs10211;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
CYCLOSPORINE;CYP3A7;rs2257401;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;JAK2;rs12343867;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
NILOTINIB;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
NILOTINIB;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;OTHER;BCR-ABL1 POSITIVE;;;
HYDROCHLOROTHIAZIDE;nan;rs16872401;C;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
CYCLOSPORINE;CYP3A4;rs4646437;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PAROXETINE;ABCB1;rs2032582;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
NILOTINIB;CYP1A1;rs1048943;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
NILOTINIB;CYP1A1;rs1048943;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;BCR-ABL1 POSITIVE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NLRP3;rs10754558;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
ATENOLOL;nan;rs7184292;GG;DOSAGE;DECREASED_DOSE;OTHER;HYPERTENSION;;;
ATORVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HYPERLIPIDEMIAS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL18;rs1946518;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
RISPERIDONE;AKT1;rs3803300;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;AKT1;rs2494732;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
IMATINIB;CYP2B6;rs3745274;GG + TT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
WARFARIN;CYP2C19;rs4986893;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CYCLOSPORINE;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C19;rs3814637;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CANNABIDIOL;AOC1;rs12539;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;EPILEPSY;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TBX21;rs17250932;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ULCERATIVE COLITIS;;
VINCRISTINE;RAB7A;rs4548;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
VINCRISTINE;RAB7A;rs4548;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;HODGKIN DISEASE;;;
VINCRISTINE;RAB7A;rs4548;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;RHABDOMYOSARCOMA;;;
VINCRISTINE;RAB7A;rs4548;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;MEDULLOBLASTOMA;;;
VINCRISTINE;RAB7A;rs4548;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;GLIOMA;;;
DOCETAXEL;CHST3;rs730720;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
THALIDOMIDE;CHST3;rs730720;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR2;rs8126756;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CROHN DISEASE;;
CANNABIDIOL;SLC15A1;rs1339067;TT;EFFICACY;DECREASED_RESPONSE;OTHER;EPILEPSY;;;
WARFARIN;nan;rs12772169;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
ROSIGLITAZONE;SLCO1B1;rs4149056;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CROHN DISEASE;;
CORTICOSTEROIDS FOR SYSTEMIC USE;HDAC1;rs1741981;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
WARFARIN;NQO1;rs1800566;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;THROMBOTIC DISEASE;;
RISPERIDONE;COMT;rs165599;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
WARFARIN;VKORC1;rs9923231;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
RISPERIDONE;GRM3;rs724226;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
ATENOLOL;KCNH2;rs1137617;GG;EFFICACY;RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
BISOPROLOL;KCNH2;rs1137617;GG;EFFICACY;RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
CELIPROLOL;KCNH2;rs1137617;GG;EFFICACY;RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
DOXAZOSIN;KCNH2;rs1137617;GG;EFFICACY;RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR5;rs5744174;AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CROHN DISEASE;;
MORPHINE;KCNJ6;rs6517442;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PAIN;;
METHOTREXATE;ABCG2;rs2231142;GT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_TROUGH CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MORPHINE;KCNJ6;rs6517442;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PAIN;;
REMIFENTANIL;KCNJ6;rs6517442;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PAIN;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
LOW DENSITY LIPOPROTEIN;SH2B1;rs3888190;CC;OTHER;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BIPOLAR_DISORDER,DEPRESSIVE DISORDER,PSYCHOTIC DISORDER,SCHIZOAFFECTIVE DISORDER;;
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ENALAPRIL;VEGFA;rs699947;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
LITHIUM;CACNG2;rs2284018;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
EFAVIRENZ;ABCB1;rs1045642;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ANASTROZOLE;nan;rs1437153;T;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DOCETAXEL;ORM2;rs2250242;AA;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;PROSTATIC NEOPLASMS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ETANERCEPT;CARD8;rs2043211;TT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;CARD8;rs2043211;TT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
METHOTREXATE;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TELAPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TELAPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
ETANERCEPT;NLRP3;rs4612666;TT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;NLRP3;rs4612666;TT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ANASTROZOLE;DLG2;rs2449598;T;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;NEPHROTIC SYNDROME;;
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A4;rs2242480;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;NEPHROTIC SYNDROME;;
METHOTREXATE;MTHFR;rs1801133;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
PEGINTERFERON ALFA-2B;HLA-DPA1;rs3077;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS B, CHRONIC;;
RIVASTIGMINE;BCHE;rs1803274;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;ABCB1;rs1045642;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
ADALIMUMAB;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
PRAVASTATIN;LDLR;rs1433099;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;VASCULAR DISEASES;;
PRAVASTATIN;LDLR;rs2738466;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;VASCULAR DISEASES;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CANNABIDIOL;ABCC5;rs3749442;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;EPILEPSY;;;
PEGINTERFERON ALFA-2B;IFNL3;rs4803217;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL3;rs4803217;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
SUFENTANIL;NFKBIA;rs696;TT;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
PEGINTERFERON ALFA-2B;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
GLUCOSE;RABEP1;rs1000940;AG + GG;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BIPOLAR_DISORDER,DEPRESSIVE DISORDER,PSYCHOTIC DISORDER,SCHIZOAFFECTIVE DISORDER;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
PAROXETINE;BDNF;rs6265;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
REMIFENTANIL;COMT;rs4680;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PAIN;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
MORPHINE;COMT;rs4680;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PAIN;;
MORPHINE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PAIN;;
REMIFENTANIL;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PAIN;;
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ANTIPSYCHOTICS;ABCB1;rs2032582;CC;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;SCHIZOPHRENIA;;
ADALIMUMAB;TLR2;rs3804099;T;EFFICACY;DECREASED_RESPONSE;OTHER;CROHN DISEASE;;;
INFLIXIMAB;TLR2;rs3804099;T;EFFICACY;DECREASED_RESPONSE;OTHER;CROHN DISEASE;;;
ANTIPSYCHOTICS;ABCB1;rs2032582;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
INTERFERON ALFA-N1;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-N1;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
MORPHINE;COMT;rs4680;G;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;CORONARY ARTERY DISEASE;;;
MORPHINE;COMT;rs4680;G;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;EFFICACY:POSTOPERATIVE_PAIN;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
INTERFERON ALFA-N1;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;T;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;OTHER;HSCT;;;
PEGINTERFERON ALFA-2B;IFNL3;rs28416813;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL3;rs28416813;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;OTHER;KIDNEY DISEASE;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
IMATINIB;ABCG2;rs2231142;GT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA;;;
IMATINIB;ABCG2;rs2231142;GT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BCR-ABL1 POSITIVE;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2B;nan;rs8113007;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;nan;rs8113007;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
CLOZAPINE;CHRM1;rs2075748;CC;DOSAGE;DECREASED_DOSE;OTHER;SCHIZOPHRENIA;;;
CYCLOPHOSPHAMIDE;CYP1B1;rs1056836;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
EPIRUBICIN;CYP1B1;rs1056836;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
FLUOROURACIL;CYP1B1;rs1056836;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2A;IFNL3;rs28416813;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs28416813;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs28416813;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
INTERFERON ALFA-N1;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
INTERFERON ALFA-N1;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
INTERFERON ALFA-N1;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ERENUMAB;nan;rs12615320;G;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA;;;
ERENUMAB;nan;rs12615320;G;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE WITH AURA;;;
FREMANEZUMAB;nan;rs12615320;G;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA;;;
FREMANEZUMAB;nan;rs12615320;G;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE WITH AURA;;;
GALCANEZUMAB;nan;rs12615320;G;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA;;;
GALCANEZUMAB;nan;rs12615320;G;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE WITH AURA;;;
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
HYDROXYUREA;ASS1;rs10901080;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL,BETA-THALASSEMIA AND RELATED DISEASES;;
ANASTROZOLE;CSMD1;rs6981827;T;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS;;;
HYDROXYUREA;ASS1;rs10793902;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ANEMIA, SICKLE CELL,BETA-THALASSEMIA AND RELATED DISEASES;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
DOXORUBICIN;ABCB1;rs2032582;AA;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL3;rs8103142;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8103142;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8103142;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
EPIRUBICIN;NQO1;rs1800566;AA;EFFICACY, TOXICITY;DECREASED_RESPONSE;OTHER;BREAST CANCER CELL LINES;;;
DOCETAXEL;MDM4;rs1563828;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
EPIRUBICIN;MDM4;rs1563828;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
GEMCITABINE;CDA;rs2072671;C;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
HYDROCHLOROTHIAZIDE;NEDD4L;rs75982813;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
GLICLAZIDE;KCNJ11;rs5219;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
WARFARIN;nan;rs12777823;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
DOXORUBICIN;ABCB1;rs1045642;AA;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;BREAST NEOPLASMS;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ARIPIPRAZOLE;DRD2;rs6277;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
CAPECITABINE;AREG;rs11942466;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
RADIOTHERAPY;AREG;rs11942466;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
(S)-METHADONE;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
(R)-METHADONE;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
CAPECITABINE;ERCC1;rs11615;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
RADIOTHERAPY;ERCC1;rs11615;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RECTAL NEOPLASMS;;
CAPECITABINE;VEGFA;rs2010963;CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;VEGFA;rs2010963;CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ARIPIPRAZOLE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
MORPHINE;COMT;rs4633;C;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;CORONARY ARTERY DISEASE;;;
MORPHINE;COMT;rs4633;C;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;EFFICACY:POSTOPERATIVE_PAIN;;;
CLOZAPINE;HTR3A;rs1150226;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;GRM7;rs2069062;CC;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CLOZAPINE;HTR3A;rs2276302;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
GLUCOSE;COMT;rs4680;AA + AG;TOXICITY;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CLOZAPINE;HTR3A;rs1062613;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ACUTE CORONARY SYNDROME;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ADALIMUMAB;PTPRC;rs10919563;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;PTPRC;rs10919563;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;PTPRC;rs10919563;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_DISCONTINUATION;nan;DISEASE;KIDNEY DISORDER;;
RISPERIDONE;GRID2;rs1875705;GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ACUTE CORONARY SYNDROME;;
PACLITAXEL;ABCB1;rs2032582;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
TACROLIMUS;NR1I2;rs2276707;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CAPECITABINE;VEGFA;rs699947;AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
OXALIPLATIN;VEGFA;rs699947;AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
WARFARIN;PRSS53;rs17886199;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs17886199;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
4-HYDROXYATORVASTATIN;SLCO2B1;rs12422149;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CORONARY DISEASE;;;
4-HYDROXYATORVASTATIN LACTONE;SLCO2B1;rs12422149;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CORONARY DISEASE;;;
PACLITAXEL;ABCB1;rs2032582;AA + AT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PEGINTERFERON ALFA-2B;IFNL3;rs11881222;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs11881222;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
2-HYDROXYATORVASTATIN LACTONE;UGT1A1;rs887829;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CORONARY DISEASE;;;
4-HYDROXYATORVASTATIN LACTONE;UGT1A1;rs887829;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CORONARY DISEASE;;;
ATORVASTATIN LACTONE;UGT1A1;rs887829;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CORONARY DISEASE;;;
BEVACIZUMAB;RGS5;rs1056515;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;RGS5;rs1056515;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;RGS5;rs1056515;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;RGS5;rs1056515;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
SN-38;UGT1A1;rs4148323;AA;DOSAGE;DECREASED_METABOLISM;nan;DISEASE;NEOPLASMS;;
PEGINTERFERON ALFA-2B;IFNL3;rs8105790;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8105790;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12980275;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
VALPROIC ACID;GABRA1;rs10068980;AA + AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CLOZAPINE;CHRM1;rs1942499;GG;DOSAGE;DECREASED_DOSE;OTHER;SCHIZOPHRENIA;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ROSUVASTATIN;SCAP;rs12487736;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METABOLIC SYNDROME;;
PEGINTERFERON ALFA-2B;IFNL3;rs4803219;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs4803219;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
BEVACIZUMAB;RALBP1;rs329007;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;RALBP1;rs329007;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;RALBP1;rs329007;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;RALBP1;rs329007;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ROCURONIUM;ABCB1;rs1128503;AA;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
MYCOPHENOLIC ACID;UGT1A9;rs6714486;AA + AT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
ROCURONIUM;SLCO1B1;rs2306283;AA;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PERAMPANEL;CYP3A5;rs776746;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
PERAMPANEL;ZSCAN25;rs776746;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
MORPHINE;UGT2B7;rs7438135;AA + AG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;LIVER TRANSPLANTATION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs7248668;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs7248668;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;nan;rs10853728;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;nan;rs10853728;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HYPERCHOLESTEROLEMIA;;;
PEGINTERFERON ALFA-2B;nan;rs10853728;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;nan;rs10853728;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
ACENOCOUMAROL;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
IMATINIB;ABCG2;rs2725252;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
PHENPROCOUMON;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;OTHER;MAINTENANCE DOSAGE BY 1.5 MG/WEEK;;;
ATENOLOL;EDN1;rs5370;GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
IRBESARTAN;EDN1;rs5370;GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
PAROXETINE;HTR2A;rs6311;CC;EFFICACY;INCREASED_RESPONSE;OTHER;OBSESSIVE-COMPULSIVE DISORDER;;;
PHENPROCOUMON;CYP2C9;rs4086116;T;DOSAGE;DECREASED_DOSE;OTHER;MAINTENANCE DOSAGE BY 2.2 MG/WEEK;;;
ATORVASTATIN;APOE;rs7412;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
PRAVASTATIN;APOE;rs7412;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
SIMVASTATIN;APOE;rs7412;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
IMATINIB;ABCG2;rs2725252;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
ATAZANAVIR;NR1I2;rs2472677;CT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
PRAVASTATIN;SLCO1B1;rs4149015;AG;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HYPERLIPOPROTEINEMIA TYPE II;;
APIXABAN;CYP3A5;rs776746;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ATRIAL FIBRILLATION;;
IMATINIB;ABCG2;rs12505410;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
NIACIN;HCAR2;rs2454727;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
ATORVASTATIN;ABCA1;rs12003906;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
PRAVASTATIN;ABCA1;rs12003906;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
SIMVASTATIN;ABCA1;rs12003906;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERLIPIDEMIAS;;
CEFTRIAXONE;ABCG2;rs13120400;TT;LADME-PK;CONCENTRATIONS;nan;DISEASE;CENTRAL NERVOUS SYSTEM INFECTIOUS DISORDER;;
RIBAVIRIN;ITPA;rs1127354;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PRAVASTATIN;SLCO1B1;rs4149015;AG;LADME-PK;INCREASED_RESPONSE;nan;DISEASE;HYPERLIPOPROTEINEMIA TYPE II;;
CREATINE;MOBP;rs616147;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;AMYOTROPHIC LATERAL SCLEROSIS;;;
PEMETREXED;EXO1;rs1047840;AA + AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;LUNG NEOPLASMS;;;
PRAVASTATIN;SLCO1B1;rs4149056;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;TRANSPLANTATION;;
PHENPROCOUMON;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE;OTHER;MAINTENANCE DOSAGE BY 4.8 MG/WEEK;;;
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;TRANSPLANTATION;;
PROPOFOL;CYP2B6;rs3745274;GT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ADALIMUMAB;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ETANERCEPT;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
INFLIXIMAB;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
VALPROIC ACID;CYP2C19;rs4244285;AA + AG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;MYELODYSPLASTIC SYNDROMES;;
APIXABAN;ABCG2;rs2231142;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ATRIAL FIBRILLATION;;
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
3;SLC6A2;rs2242446;TT;OTHER;DECREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs2242446;TT;OTHER;DECREASED_RESPONSE;nan;nan;;;
ATENOLOL;AGT;rs699;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
3;SLC6A2;rs1861647;GG;OTHER;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs1861647;GG;OTHER;INCREASED_RESPONSE;nan;nan;;;
3;SLC6A2;rs36029;AA;OTHER;INCREASED_RESPONSE;nan;nan;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs36029;AA;OTHER;INCREASED_RESPONSE;nan;nan;;;
ATENOLOL;AGT;rs5051;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
TEMOZOLOMIDE;ABCB1;rs2229109;CT;EFFICACY;DECREASED_RESPONSE;OTHER;GLIOMA;;;
FOLLITROPIN BETA;FSHR;rs6166;T;TOXICITY;INCREASED_RESPONSE;nan;nan;;;
UROFOLLITROPIN;FSHR;rs6166;T;TOXICITY;INCREASED_RESPONSE;nan;nan;;;
ADALIMUMAB;HLA-E;rs1264457;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CERTOLIZUMAB PEGOL;HLA-E;rs1264457;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;HLA-E;rs1264457;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
GLUCOCORTICOIDS;HLA-E;rs1264457;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;HLA-E;rs1264457;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;HLA-E;rs1264457;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
REPAGLINIDE;SLC30A8;rs13266634;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
DISULFIRAM;ADRA1A;rs1048101;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE;;;
ADALIMUMAB;ATP5F1E;rs1059150;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CERTOLIZUMAB PEGOL;ATP5F1E;rs1059150;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;ATP5F1E;rs1059150;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
GLUCOCORTICOIDS;ATP5F1E;rs1059150;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;ATP5F1E;rs1059150;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;ATP5F1E;rs1059150;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
SIROLIMUS;ABCB1;rs1045642;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
DEXMEDETOMIDINE;CYP2A6;rs28399433;C;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
IRBESARTAN;CYP2C9;rs1799853;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
FENTANYL;CALCA;rs145837941;GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
NITRIC OXIDE;NAMPT;rs1319501;TT;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PRE-ECLAMPSIA;;;
TOCILIZUMAB;GALNT18;rs4910008;CC + CT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
BUPRENORPHINE;OPRD1;rs529520;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
NICOTINE;nan;rs12459249;C;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
WARFARIN;GGCX;rs2592551;AA + AG;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
ESCITALOPRAM;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
ATOMOXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
DESVENLAFAXINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
DULOXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
VENLAFAXINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
TOCILIZUMAB;IL6;rs2069840;CC;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ANTIDEPRESSANTS;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
BENAZEPRIL;MTHFR;rs1801131;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
FLUOXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
PAROXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
BENAZEPRIL;MTHFR;rs1801133;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
IRBESARTAN;CYP2C9;rs1057910;AC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ESSENTIAL HYPERTENSION;;
PAROXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
FENTANYL;CALCA;rs145837941;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
FENTANYL;CALCA;rs145837941;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;CAESARIAN SECTION;;;
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
PEMETREXED;CAMKK2;rs1653586;GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;LUNG NEOPLASMS;;;
ABIRATERONE;SRD5A2;rs523349;CC;EFFICACY;INCREASED_RESPONSE;OTHER;PROSTATIC NEOPLASMS;;;
BUPRENORPHINE;OPRD1;rs581111;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
CARBOPLATIN;FNTB;rs11623866;GG;EFFICACY;RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
LONAFARNIB;FNTB;rs11623866;GG;EFFICACY;RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
PACLITAXEL;FNTB;rs11623866;GG;EFFICACY;RESPONSE;nan;DISEASE;OVARIAN NEOPLASMS;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
METHOTREXATE;ABCG2;rs12505410;GG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
ESCITALOPRAM;BMP5;rs41271330;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ESCITALOPRAM;BMP5;rs41271330;AA + AG;EFFICACY;INCREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
METHOTREXATE;ABCG2;rs13137622;GT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;ABCG2;rs13120400;CC;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
AMLODIPINE;CYP3A4;rs2740574;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
TACROLIMUS;IL18;rs1946518;GG + GT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LUNG TRANSPLANTATION;;
TACROLIMUS;IL10;rs1800896;TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LUNG TRANSPLANTATION;;
RIVASTIGMINE;BCHE;rs1803274;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;CONCENTRATIONS;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs35303484;G;LADME-PK;CONCENTRATIONS;nan;DISEASE;HIV INFECTIOUS DISEASE;;
VALPROIC ACID;CYP2C9;rs1057910;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
METHOTREXATE;MTHFR;rs1801133;AG + GG;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
AZATHIOPRINE;NUDT15;rs116855232;TT;TOXICITY;DECREASED_DOSE;nan;DISEASE;LEUKOPENIA;;
CLOZAPINE;NFIB;rs28379954;CT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LUNG TRANSPLANTATION;;
METFORMIN;SLC22A1;rs594709;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
IRINOTECAN;TDP1;rs2401863;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
METFORMIN;SLC47A1;rs2289669;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
TACROLIMUS;IL18;rs5744247;CC + CG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;LUNG TRANSPLANTATION;;
METHOTREXATE;SLC19A1;rs1051266;TT;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
DEXMEDETOMIDINE;CYP2D6;rs16947;GG;DOSAGE;INCREASED_DOSE;OTHER;SURGERY;;;
CARBAMAZEPINE;CYP1A2;rs762551;AA;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
RIVAROXABAN;CYP3A4;rs2242480;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
CYCLOSPORINE;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;LIVER TRANSPLANTATION;;;
METHOTREXATE;UGT1A1;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;UGT1A10;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;UGT1A3;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;UGT1A4;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;UGT1A5;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;UGT1A6;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;UGT1A7;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;UGT1A8;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;UGT1A9;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OSTEOSARCOMA;;
EFAVIRENZ;ABCB1;rs3842;C;LADME-PK;CONCENTRATIONS;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CYCLOSPORINE;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;LIVER TRANSPLANTATION;;;
DEXMEDETOMIDINE;WBP2NL;rs5758550;AG + GG;TOXICITY;INCREASED_RESPONSE;OTHER;SURGERY;;;
MEMANTINE;BCHE;rs1803274;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
RIVASTIGMINE;BCHE;rs1803274;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
IVACAFTOR;CFTR;rs75527207;AA;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;GGCX;rs699664;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
METHOTREXATE;MTHFR;rs1801131;GT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CLOPIDOGREL;ABCB1;rs1045642;AA;LADME-PK;DECREASED_EXPOSURE;nan;nan;;;
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
RIVASTIGMINE;BCHE;rs1803274;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LEWY BODY DISEASE;;
FENTANYL;CALCA;rs145837941;GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
APIXABAN;ABCG2;rs2231142;G;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
DEXMEDETOMIDINE;CYP1A2;rs762551;AC + CC;LADME-PK;INCREASED_CLEARANCE;OTHER;SEDATION;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
LATANOPROST;PTGFR;rs3766355;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;GLAUCOMA,OCULAR HYPERTENSION;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061631;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHADONE;NECTIN4;rs11265549;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOID ANESTHETICS;OPRM1;rs1799971;GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
OTHER GENERAL ANESTHETICS;OPRM1;rs1799971;GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
VOLATILE ANESTHETICS;OPRM1;rs1799971;GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
OPIOID ANESTHETICS;ABCG2;rs2231142;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
OTHER GENERAL ANESTHETICS;ABCG2;rs2231142;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
VOLATILE ANESTHETICS;ABCG2;rs2231142;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METHADONE;NECTIN4;rs11265549;AA;DOSAGE;DECREASED_DOSE;OTHER;OPIOID-RELATED DISORDERS;;;
DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;DOSAGE;DECREASED_DOSE;OTHER;SURGERY;;;
DABIGATRAN;CES1;rs2244613;GG + GT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
ATORVASTATIN;ABCG8;rs11887534;CC + CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
CAPECITABINE;DPYD;rs3918290;CT;DOSAGE;DOSE;nan;DISEASE;NEOPLASMS;;
CAPECITABINE;DPYD;rs56038477;CT;DOSAGE;DOSE;nan;DISEASE;NEOPLASMS;;
CAPECITABINE;DPYD;rs67376798;AT;DOSAGE;DOSE;nan;DISEASE;NEOPLASMS;;
DEXMEDETOMIDINE;ADRA2A;rs1800544;GG;DOSAGE;DECREASED_DOSE;OTHER;SURGERY;;;
TAMOXIFEN-N-GLUCURONIDE;UGT1A4;rs2011425;GG + GT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
IMATINIB;CYP2B6;rs3745274;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
ATORVASTATIN;CYP7A1;rs3808607;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
METHOTREXATE;ATIC;rs4673993;CC;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
BENAZEPRIL;AGT;rs7079;GG;EFFICACY;RESPONSE;nan;DISEASE;HYPERTENSION;;
WARFARIN;CYP2C9;rs9332098;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CANNABIDIOL;nan;rs6729738;CC;EFFICACY;INCREASED_RESPONSE;OTHER;EPILEPSY;;;
METHOTREXATE;MTHFR;rs1801133;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
DEXMEDETOMIDINE;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;OTHER;SURGERY;;;
WARFARIN;CYP2C9;rs9332092;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
HYDROCHLOROTHIAZIDE;TXNDC11;rs3784921;G;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
WARFARIN;CYP2C9;rs1057910;CC;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP2C9;;;
PAROXETINE;CYP1A2;rs762551;A;LADME-PK;INCREASED_DOSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
WARFARIN;CYP2C9;rs1799853;TT;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP2C9;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;TOXICITY;INCREASED_RESPONSE;OTHER;SURGERY;;;
TOPOTECAN;ABCG2;rs4148157;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BRAIN NEOPLASMS;;
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RIVAROXABAN;CYP3A4;rs2246709;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
DULOXETINE;KMT2E;rs117986340;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
RIVASTIGMINE;ACHE;rs2571598;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
DULOXETINE;NCAM1;rs2303377;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
RIVAROXABAN;CYP3A5;rs776746;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;HEART TRANSPLANTATION;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
DULOXETINE;ZNF385D;rs4261893;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
EFAVIRENZ;CYP2B6;rs2279343;AG + GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
RIVAROXABAN;CYP3A4;rs3735451;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;VKORC1;rs2359612;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs7294;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
DEXMEDETOMIDINE;nan;rs141294036;CC;TOXICITY;INCREASED_RESPONSE;OTHER;SURGERY;;;
AMPHETAMINE;CDH13;rs3784943;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
EVEROLIMUS;CYP3A4;rs35599367;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
PRAVASTATIN;SLCO1B1;rs4149056;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY STENOSIS;;
DEXMEDETOMIDINE;KCNMB1;rs11739136;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER;SURGERY;;;
MORPHINE;UGT2B7;rs7668282;CC + CT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;ANEMIA, SICKLE CELL;;
MIVACURIUM;BCHE;rs755648929;AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
SUCCINYLCHOLINE;BCHE;rs772583466;CT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
EFAVIRENZ;CYP2A7P1;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PREGNANCY;;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;PREGNANCY;;;
DABIGATRAN;CES1;rs8192935;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
ETHANOL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;CLCN6;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;C1orf167;rs1801131;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;CLCN6;rs1801131;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;MTR;rs1805087;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
RANIBIZUMAB;CXCL8;rs4073;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
ETHANOL;OPRM1;rs10485057;AA;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OPIOIDS;COMT;rs4680;AA + AG;DOSAGE;DECREASED_DOSE;OTHER;PAIN;;;
OPIOIDS;COMT;rs4680;AA + AG;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS;;;
METHOTREXATE;BIRC5;rs9904341;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ACENOCOUMAROL;VKORC1;rs9934438;GG;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
SALBUTAMOL;nan;rs17834628;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
NICOTINE;CHRNA3;rs1051730;A;DOSAGE;DECREASED_DOSE;OTHER;TOBACCO USE DISORDER;;;
ABIRATERONE;TSPYL1;rs3828743;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
PREDNISOLONE;TSPYL1;rs3828743;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PROSTATIC NEOPLASMS;;
PLATINUM;RICTOR;rs6878291;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOZAPINE;DRD2;rs2514218;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
METHOTREXATE;FASTKD3;rs1801394;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;MTRR;rs1801394;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
RANIBIZUMAB;KDR;rs2071559;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
ETHANOL;OPRM1;rs1799971;AG;OTHER;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
BUSULFAN;GSTA1;rs3957356;CT;LADME-PK;DECREASED_CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;;
METHOTREXATE;ATIC;rs12995526;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CLOZAPINE;HTR3A;rs1062613;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
METHOTREXATE;ATIC;rs7563206;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;ATIC;rs2372536;CC + CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;ATIC;rs4673993;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CANDESARTAN;KCNK3;rs1275988;C;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
RISPERIDONE;NR1I2;rs1523130;CC;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BIPOLAR_DISORDER,DEPRESSION,SUBSTANCE-RELATED DISORDERS;;
SUFENTANIL;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
ADALIMUMAB;IL17F;rs763780;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
IMMUNOGLOBULINS;CASP3;rs113420705;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME;;
IMMUNOGLOBULINS;PRIMPOL;rs113420705;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME;;
SUFENTANIL;COMT;rs4680;AA;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
WARFARIN;VKORC1;rs7294;CC;DOSAGE;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HEART VALVE REPLACEMENT;;;
IMMUNOGLOBULINS;COQ8B;rs28493229;CC + CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME;;
IMMUNOGLOBULINS;ITPKC;rs28493229;CC + CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME;;
USTEKINUMAB;IL17F;rs763780;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
INFLIXIMAB;IL17F;rs763780;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
EFAVIRENZ;CYP2B6;rs3745274;TT;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
HYDROCHLOROTHIAZIDE;CSK;rs1378942;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
SALBUTAMOL;nan;rs35661809;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ANTIPSYCHOTICS;DRD3;rs6280;CT + TT;EFFICACY;INCREASED_RESISTANCE;OTHER;MOOD DISORDER;;;
ANTIPSYCHOTICS;DRD3;rs6280;CT + TT;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
HYDROCHLOROTHIAZIDE;PDE3A;rs12579720;C;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
CANDESARTAN;SULT1C3;rs6722745;T;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
ATENOLOL;STN1;rs4387287;A;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
METFORMIN;nan;rs10783050;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
METFORMIN;IL1B;rs1143623;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs9923231;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CISPLATIN;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
PACLITAXEL;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
RIFAPENTINE;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
BEVACIZUMAB;VEGFA;rs2010963;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHOROIDAL NEOVASCULARIZATION;;
PEGAPTANIB;VEGFA;rs2010963;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHOROIDAL NEOVASCULARIZATION;;
RANIBIZUMAB;VEGFA;rs2010963;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHOROIDAL NEOVASCULARIZATION;;
EPIRUBICIN;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM,STOMACH NEOPLASMS;;
FLUOROURACIL;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM,STOMACH NEOPLASMS;;
OXALIPLATIN;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM,STOMACH NEOPLASMS;;
WARFARIN;VKORC1;rs9923231;CT;EFFICACY;INCREASED_DOSE;OTHER;LEFT VENTRICULAR DYSFUNCTION;;;
EPIRUBICIN;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM,STOMACH NEOPLASMS;;
FLUOROURACIL;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM,STOMACH NEOPLASMS;;
OXALIPLATIN;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;METASTATIC NEOPLASM,STOMACH NEOPLASMS;;
RISPERIDONE;NR1I2;rs2276707;CC;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;BIPOLAR_DISORDER,DEPRESSION,SUBSTANCE-RELATED DISORDERS;;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
WARFARIN;VKORC1;rs9923231;CT;EFFICACY;DECREASED_RESPONSE;OTHER;LEFT VENTRICULAR DYSFUNCTION;;;
RITUXIMAB;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE;OTHER;AUTOIMMUNE DISEASES;;;
NICOTINE;CHRNA3;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
NICOTINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
CLOZAPINE;HTR3A;rs2276302;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
IMATINIB;ABCB1;rs2032582;AT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
IMATINIB;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
TELMISARTAN;GNB3;rs5443;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
EFAVIRENZ;CYP2B6;rs8192719;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
LITHIUM;nan;rs2769605;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
VALPROIC ACID;nan;rs2769605;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
CISPLATIN;GNAS;rs7121;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NEOPLASM OF ESOPHAGUS;;
FLUOROURACIL;GNAS;rs7121;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NEOPLASM OF ESOPHAGUS;;
ATENOLOL;ZMAT4;rs1367094;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
METOPROLOL;ZMAT4;rs1367094;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
ATENOLOL;LRRC15;rs11313667;del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;LRRC15;rs11313667;del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
METOPROLOL;LRRC15;rs11313667;del;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ONDANSETRON;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
LITHIUM;DRD2;rs1800497;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BIPOLAR_DISORDER;;;
OLANZAPINE;DRD2;rs1800497;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BIPOLAR_DISORDER;;;
HMG COA REDUCTASE INHIBITORS;nan;rs247616;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
BOCEPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
BOCEPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TELAPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TELAPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
ADALIMUMAB;KLRC1;rs7301582;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CERTOLIZUMAB PEGOL;KLRC1;rs7301582;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;KLRC1;rs7301582;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
GLUCOCORTICOIDS;KLRC1;rs7301582;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;KLRC1;rs7301582;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;KLRC1;rs7301582;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
HYDROCHLOROTHIAZIDE;PRKAG2;rs10224002;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
AGOMELATINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
MELATONIN RECEPTOR AGONISTS;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
VENLAFAXINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSIVE DISORDER;;
ADALIMUMAB;KLRD1;rs2302489;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CERTOLIZUMAB PEGOL;KLRD1;rs2302489;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;KLRD1;rs2302489;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
GLUCOCORTICOIDS;KLRD1;rs2302489;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;KLRD1;rs2302489;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
METHOTREXATE;KLRD1;rs2302489;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
HYDROCHLOROTHIAZIDE;PLCE1;rs932764;A;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
SIMEPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
METOPROLOL;nan;rs1446468;T;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
ATENOLOL;RRP1B;rs9306160;T;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
ATENOLOL;TBX2;rs8068318;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
AMISULPRIDE;DRD2;rs1079597;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
USTEKINUMAB;NFKBIA;rs2145623;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
HYDROCHLOROTHIAZIDE;ADO;rs10995311;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
PLATINUM COMPOUNDS;XBP1;rs2269577;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
CANDESARTAN;DOT1L;rs740406;A;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
CANDESARTAN;PLEKHJ1;rs740406;A;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
USTEKINUMAB;ADAM33;rs2787094;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
HYDROCHLOROTHIAZIDE;NUCB2;rs757081;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
USTEKINUMAB;nan;rs1975974;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
EXENATIDE;KCNQ1;rs163184;G;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
USTEKINUMAB;AGBL4;rs191190;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
NORTRIPTYLINE;SLC39A14;rs17060812;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
USTEKINUMAB;CHUK;rs11591741;CC + CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
USTEKINUMAB;HTR2A;rs6311;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
HYDROCHLOROTHIAZIDE;C5orf56;rs12521868;G;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
CANDESARTAN;SH2B3;rs3184504;T;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
CARBAMAZEPINE;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
APIXABAN;ABCG2;rs2231142;GG + GT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;ATRIAL FIBRILLATION;;
CARBAMAZEPINE;CYP3A5;rs15524;AA;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
PAROXETINE;COMT;rs4680;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
CAPECITABINE;TP53;rs1042522;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
PACLITAXEL;TP53;rs1042522;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
SUFENTANIL;CYP3A4;rs2242480;CC;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
TRIGLYCERIDES;CYP19A1;rs749292;A;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
HDL CHOLESTEROL;CYP19A1;rs1062033;G;OTHER;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CLOBAZAM;POR;rs1057868;TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;EPILEPSY;;
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE DISEASES;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NORTRIPTYLINE;PPM1A;rs2273623;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DEPRESSION;;
AMILORIDE;CYP4A11;rs1126742;GG;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
SPIRONOLACTONE;CYP4A11;rs1126742;GG;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
AZATHIOPRINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
DEFERASIROX;UGT1A3;rs3806596;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
LOPINAVIR;CYP3A5;rs776746;C;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
PROPOFOL;CYP2B6;rs2279343;AA + AG;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
SPIRONOLACTONE;CYP4A11;rs3890011;CC;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION;;;
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
ATAZANAVIR;NR1I2;rs2472677;TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;LIVER TRANSPLANTATION;;;
RIFAMPIN;AADAC;rs1803155;AA;LADME-PK;DECREASED_CLEARANCE;OTHER;TUBERCULOSIS;;;
APATINIB;CYP2C9;rs1934968;GG;LADME-PK;INCREASED_EXPOSURE;OTHER;NEOPLASMS;;;
APATINIB METABOLITE M1-1;CYP2C9;rs1934968;GG;LADME-PK;INCREASED_EXPOSURE;OTHER;NEOPLASMS;;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs11075995;AT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;NEOPLASMS;;;
AMPRENAVIR;SLCO1B1;rs4149056;C;LADME-PK;DECREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
ACAMPROSATE;nan;rs77583603;G;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
EVEROLIMUS;CYP3A5;rs776746;CC + CT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HEART TRANSPLANTATION;;
NALTREXONE;nan;rs12749274;A;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
DEFERASIROX;ABCG2;rs13120400;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES;;
FLUVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
FLUVASTATIN;APOE;rs429358;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
DOXORUBICIN;CBR1;rs20572;CC;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
DEHYDROARIPIPRAZOLE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_EXPOSURE;OTHER;SCHIZOPHRENIA;;;
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_EXPOSURE;OTHER;TOBACCO USE DISORDER;;;
ETHANOL;OPRM1;rs1799971;AA;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
PREDNISOLONE;GATA3;rs3824662;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
TACROLIMUS;GSTM3;rs7483;TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;LIVER TRANSPLANTATION;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AG;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ADALIMUMAB;TNF;rs1799724;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;GG;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
FLUOXETINE;HTR1B;rs130058;AA + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MENTAL DISORDERS;;
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CLOZAPINE;CYP1A2;rs762551;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
FLUVASTATIN;APOE;rs7412;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
ADALIMUMAB;TNF;rs361525;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CARBAMAZEPINE;CYP1A2;rs762551;AA;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY;;;
MORPHINE;SLC6A4;rs1042173;CC;DOSAGE;DECREASED_DOSE;OTHER;LUNG NEOPLASMS;;;
MORPHINE;SLC6A4;rs1042173;CC;DOSAGE;DECREASED_DOSE;OTHER;PAIN;;;
FLUOROURACIL;ABCA2;rs2271862;G;LADME-PK;INCREASED_CLEARANCE;OTHER;COLORECTAL NEOPLASMS;;;
FLUOXETINE;TPH2;rs4570625;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MENTAL DISORDERS;;
5'-DEOXY-5-FLUOROURIDINE;ABCG5;rs6720173;C;LADME-PK;INCREASED_CLEARANCE;OTHER;COLORECTAL NEOPLASMS;;;
METHOTREXATE;ADORA2A-AS1;rs17004921;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
ANTIEPILEPTICS;ABCB1;rs2032582;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
ATENOLOL;nan;rs35123024;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;nan;rs35123024;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
ATENOLOL;ALDH1A2;rs261316;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
HYDROCHLOROTHIAZIDE;ALDH1A2;rs261316;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
CISPLATIN;REV3L;rs462779;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OSTEOSARCOMA;;
CISPLATIN;REV1;rs3087403;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;OSTEOSARCOMA;;
ANTIEPILEPTICS;SCN1A;rs2298771;CC + CT;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY;;;
LOPINAVIR;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
FENTANYL;OPRM1;rs9384179;AA;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE EFFECT;POSTOPERATIVE_PAIN;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
FLUVASTATIN;CYP2C9;rs1057910;AC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
FENTANYL;KCNJ6;rs2835859;TT;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE EFFECT;POSTOPERATIVE_PAIN;;;
ABIRATERONE;HSD3B1;rs1047303;AC;LADME-PK;INCREASED_METABOLISM;OTHER;PROSTATIC NEOPLASMS;;;
FENTANYL;nan;rs2952768;CC;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE EFFECT;POSTOPERATIVE_PAIN;;;
FENTANYL;nan;rs11959113;AA;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE EFFECT;POSTOPERATIVE_PAIN;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART TRANSPLANTATION;;
CYCLOPHOSPHAMIDE;GSTA1;rs3957356;CT;EFFICACY, TOXICITY, LADME-PK;DECREASED_RESPONSE;nan;DISEASE;LUPUS NEPHRITIS;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
BILIRUBIN;SOD2;rs4880;GG;TOXICITY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;HEART TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;KIDNEY TRANSPLANTATION;;
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ADHD;;
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;HEART TRANSPLANTATION;;
IVACAFTOR;CFTR;rs77010898;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
DOCETAXEL;AKR1C3;rs1937840;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOXORUBICIN;AKR1C3;rs1937840;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS;;
ANTIDEPRESSANTS;GRIK4;rs1954787;TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;;
ANTIDEPRESSANTS;GRIK4;rs1954787;C;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;OTHER;AN INTERNATIONAL NORMALIZED RATIO (INR) OF 2.0-3.0;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;CYP2C9;rs1057910;A;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
BUPRENORPHINE;OPRM1;rs2075572;CC + CG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;rs2651899;C;EFFICACY;INCREASED_RESPONSE;OTHER;MIGRAINE WITH AURA;;;
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;rs2651899;C;EFFICACY;INCREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA;;;
AFATINIB;NR1I2;rs6785049;AA + AG;LADME-PK;DECREASED_CLEARANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA;;;
WARFARIN;CYP2C9;rs4917639;C;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
LOPINAVIR;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;HIV INFECTIOUS DISEASE;;;
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALCOHOL ABUSE;;
ANTIDEPRESSANTS;ABCB1;rs1128503;A;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
METHADONE;COMT;rs933271;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
VALPROIC ACID;UGT1A10;rs2070959;AG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;rs2070959;AG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A7;rs2070959;AG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A8;rs2070959;AG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A9;rs2070959;AG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
METHOTREXATE;MTHFR;rs1801131;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
VALPROIC ACID;GRIN2B;rs1019385;AC;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;GRIN2B;rs1019385;CC;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;EPILEPSY;;
METHOTREXATE;SLC19A1;rs1051266;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
CARBAMAZEPINE;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
CLOBAZAM;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
ETHOSUXIMIDE;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
LAMOTRIGINE;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
LEVETIRACETAM;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
OXCARBAZEPINE;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
LOPINAVIR;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
VALPROIC ACID;UGT1A6;rs1105879;AC;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
FLUVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
EVEROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_TROUGH CONCENTRATION;OTHER;BREAST NEOPLASMS;;;
EVEROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_TROUGH CONCENTRATION;OTHER;KIDNEY NEOPLASMS;;;
EVEROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_TROUGH CONCENTRATION;OTHER;NEUROENDOCRINE TUMORS;;;
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
AMISULPRIDE;SNAP25;rs8636;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOPIDOGREL;ABCA1;rs2487032;A;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
CLOPIDOGREL;N6AMT1;rs2254638;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
TENOFOVIR;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
SIROLIMUS;ABCB1;rs2032582;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;
ANTIPSYCHOTICS;NRXN1;rs12467557;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
ANTIPSYCHOTICS;NRXN1;rs10490162;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
CLOPIDOGREL;CYP2C19;rs4986893;AA;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
DABIGATRAN;CES1;rs8192935;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ATRIAL FIBRILLATION;;
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BEHCET SYNDROME;;;
CERTOLIZUMAB PEGOL;TNF;rs1800629;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BEHCET SYNDROME;;;
GOLIMUMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BEHCET SYNDROME;;;
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;BEHCET SYNDROME;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;OTHER, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
BEVACIZUMAB;CFH;rs1061170;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
VALPROIC ACID;UGT1A10;rs2070959;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;rs2070959;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A7;rs2070959;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A8;rs2070959;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A9;rs2070959;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
CISPLATIN;DPYD;rs3918290;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
FLUOROURACIL;DPYD;rs3918290;CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
CISPLATIN;XRCC3;rs861539;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
DOCETAXEL;XRCC3;rs861539;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
IRINOTECAN;XRCC3;rs861539;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
VALPROIC ACID;UGT1A10;rs6759892;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;rs6759892;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A7;rs6759892;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A8;rs6759892;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A9;rs6759892;GG;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A10;rs6759892;GT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A6;rs6759892;GT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A7;rs6759892;GT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A8;rs6759892;GT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
VALPROIC ACID;UGT1A9;rs6759892;GT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
VALPROIC ACID;UGT1A6;rs1105879;CC;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
10-MONOHYDROXY OXCARBAZEPINE;INSR;rs2396185;C;LADME-PK;DECREASED_CLEARANCE;OTHER;EPILEPSY;;;
ETHANOL;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
RISPERIDONE;HTR1A;rs6295;GG;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
FENTANYL;CACNA1E;rs3845446;CC + CT;DOSAGE;DECREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
FENTANYL;LAMB3;rs2076222;G;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;POSTOPERATIVE_PAIN;;
CETUXIMAB;VEGFA;rs833061;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CETUXIMAB;VEGFA;rs1570360;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CISPLATIN;MECP2;rs1734791;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;MECP2;rs1734791;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;MECP2;rs1734791;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;MECP2;rs1734787;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;MECP2;rs1734787;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;MECP2;rs1734787;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;MECP2;rs17435;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;MECP2;rs17435;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;MECP2;rs17435;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;nan;rs5906072;T;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;nan;rs5906072;T;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;nan;rs5906072;T;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
PROCHLORPERAZINE;ANKK1;rs1800497;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;NAUSEA;;;
PROCHLORPERAZINE;DRD2;rs1800497;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;NAUSEA;;;
PROCHLORPERAZINE;DRD2;rs1079597;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;NAUSEA;;;
METFORMIN;ATM;rs11212617;AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
MORPHINE;OPRK1;rs1051660;A;DOSAGE, EFFICACY;DECREASED_DOSE;nan;DISEASE;PAIN;;
CISPLATIN;GALNT14;rs12613732;G;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;GALNT14;rs12613732;G;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;GALNT14;rs12613732;G;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;GALNT14;rs5009910;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;GALNT14;rs5009910;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;GALNT14;rs5009910;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
ATORVASTATIN;HMGCR;rs17671591;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
ESCITALOPRAM;TPH1;rs1800532;GT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;DEPRESSION;;;
CISPLATIN;GALNT14;rs6752303;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;GALNT14;rs6752303;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;GALNT14;rs6752303;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;GALNT14;rs10209881;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;GALNT14;rs10209881;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;GALNT14;rs10209881;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
DABIGATRAN;CES1;rs2244613;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;ATRIAL FIBRILLATION;;
CISPLATIN;GALNT14;rs12999804;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;GALNT14;rs12999804;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;GALNT14;rs12999804;A;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
TACROLIMUS;CYP3A4;rs2740574;TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
APATINIB;CYP2C9;rs34532201;TT;LADME-PK;INCREASED_EXPOSURE;OTHER;NEOPLASMS;;;
APATINIB METABOLITE M1-1;CYP2C9;rs34532201;TT;LADME-PK;INCREASED_EXPOSURE;OTHER;NEOPLASMS;;;
CISPLATIN;nan;rs5934731;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;nan;rs5934731;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;nan;rs5934731;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;nan;rs715171;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;nan;rs715171;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;nan;rs715171;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;nan;rs4932551;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;nan;rs4932551;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;nan;rs4932551;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;nan;rs7170769;T;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;nan;rs7170769;T;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;nan;rs7170769;T;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;nan;rs6458232;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;nan;rs6458232;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;nan;rs6458232;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
CISPLATIN;GALNT14;rs7608731;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;GALNT14;rs7608731;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;GALNT14;rs7608731;C;EFFICACY;RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
ELEXACAFTOR;CFTR;rs758900656;A;LADME-PD;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
TEZACAFTOR;CFTR;rs758900656;A;LADME-PD;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
IVACAFTOR;CFTR;rs758900656;A;LADME-PD;INCREASED_CLINICAL-BENEFIT;nan;nan;;;
ALLOPURINOL;AOX1;rs3731722;G;DOSAGE;DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;AOX1;rs3731722;G;DOSAGE;DOSE;nan;DISEASE;GOUT;;
PAZOPANIB;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS;;;
RITUXIMAB;IL2;rs6822844;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;AUTOIMMUNE DISEASES;;
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;KIDNEY TRANSPLANTATION;;
RITUXIMAB;IL2;rs6822844;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS;;
ALLOPURINOL;AOX1;rs11678615;T;DOSAGE;DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;AOX1;rs11678615;T;DOSAGE;DOSE;nan;DISEASE;GOUT;;
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ALLOPURINOL;UGT1A1;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;UGT1A10;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;UGT1A3;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;UGT1A4;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;UGT1A5;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;UGT1A6;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;UGT1A7;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;UGT1A8;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;UGT1A9;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;UGT1A1;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;UGT1A10;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;UGT1A3;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;UGT1A4;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;UGT1A5;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;UGT1A6;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;UGT1A7;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;UGT1A8;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;UGT1A9;rs34650714;T;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;XDH;rs1884725;G;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;XDH;rs1884725;G;DOSAGE;DECREASED_DOSE;nan;DISEASE;GOUT;;
ALLOPURINOL;AOX1;rs75995567;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;GOUT;;
FEBUXOSTAT;AOX1;rs75995567;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;GOUT;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, LADME-PK;DOSE;nan;nan;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE, LADME-PK;DOSE;nan;nan;;;
WARFARIN;GGCX;rs699664;T;DOSAGE, LADME-PK;DOSE;nan;nan;;;
METFORMIN;SLC22A1;rs622342;AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
PROPOFOL;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
REMIFENTANIL;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
METHOTREXATE;ABCC3;rs4148416;TT;LADME-PK;INCREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
TACROLIMUS;CYP3A4;rs2740574;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
METHOTREXATE;SLC19A1;rs17004785;CG;LADME-PK;INCREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
DONEPEZIL;BCHE;rs1803274;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
CISPLATIN;MTHFD1;rs2236225;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;OSTEOSARCOMA;;;
DOXORUBICIN;MTHFD1;rs2236225;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;OSTEOSARCOMA;;;
METHOTREXATE;MTHFD1;rs2236225;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;OSTEOSARCOMA;;;
CISPLATIN;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
FLUOROURACIL;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATOCELLULAR CARCINOMA;;
PAROXETINE;GDNF;rs2973049;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;GDNF;rs2216711;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17RA;rs4819554;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ATOMOXETINE;SLC6A2;rs3785143;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ADHD;;
PAROXETINE;BDNF;rs6265;CC + CT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ROSUVASTATIN;CETP;rs5882;G;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
DISULFIRAM;DBH;rs1611115;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALCOHOL ABUSE;;
RIVAROXABAN;CYP3A5;rs776746;TT;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
RISPERIDONE;COMT;rs9606186;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RIVAROXABAN;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_CLEARANCE;OTHER;ATRIAL FIBRILLATION;;;
TACROLIMUS;C6;rs10052999;CC + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TACROLIMUS;C6;rs9200;CC + CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
CISPLATIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;OSTEOSARCOMA;;;
DOXORUBICIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;OSTEOSARCOMA;;;
METHOTREXATE;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;OSTEOSARCOMA;;;
RISPERIDONE;RGS4;rs2661319;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
LAMOTRIGINE;SLC22A1;rs628031;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
RISPERIDONE;ANKK1;rs1800497;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
TACROLIMUS;CYP3A4;rs2740574;CT;LADME-PK;INCREASED_DOSE;OTHER;TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CISPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;OSTEOSARCOMA;;;
DOXORUBICIN;GSTP1;rs1695;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;OSTEOSARCOMA;;;
METHOTREXATE;GSTP1;rs1695;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;OSTEOSARCOMA;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;DISEASE;LIVER TRANSPLANTATION;;
PHENYTOIN;CYP2C9;rs1057910;C;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
PHENYTOIN;SCN1A;rs3812718;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
INDINAVIR;CYP3A4;rs2740574;CC;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;ABCB1;rs2032582;T;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ALPHA-HYDROXYMETOPROLOL;CYP2D6;rs28371738;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
RIVAROXABAN;ABCB1;rs1128503;AG + GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
FLUVOXAMINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
MILNACIPRAN;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
LANSOPRAZOLE;ABCB1;rs1045642;G;OTHER, LADME-PK;INCREASED_METABOLISM;nan;nan;;;
FLUVOXAMINE;HTR1A;rs10042486;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
MILNACIPRAN;HTR1A;rs10042486;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
PAROXETINE;HTR1A;rs10042486;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
LAMOTRIGINE;ABCG2;rs2231142;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
RIVAROXABAN;ABCB1;rs1045642;AG + GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
RIVAROXABAN;ABCB1;rs4148738;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ATRIAL FIBRILLATION;;;
PHENYTOIN;CYP2C9;rs1934969;AT + TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;EPILEPSY;;
DEXAMETHASONE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
DIPHENHYDRAMINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
PACLITAXEL;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
RANITIDINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,HEART VALVE REPLACEMENT,PULMONARY HYPERTENSION,PULMONARY EMBOLISM,VENOUS THROMBOSIS;;
HMG COA REDUCTASE INHIBITORS;APOC1;rs4420638;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CARDIOVASCULAR DISEASE,HYPERCHOLESTEROLEMIA;;
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,HEART VALVE REPLACEMENT,PULMONARY HYPERTENSION,PULMONARY EMBOLISM,VENOUS THROMBOSIS;;
PHOTODYNAMIC THERAPY;F13A1;rs5985;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHOROIDAL NEOVASCULARIZATION;;
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION,HEART VALVE REPLACEMENT,PULMONARY HYPERTENSION,PULMONARY EMBOLISM,VENOUS THROMBOSIS;;
CITALOPRAM;TPH1;rs1800532;GT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
HMG COA REDUCTASE INHIBITORS;NPC1L1;rs2072183;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CARDIOVASCULAR DISEASE,HYPERCHOLESTEROLEMIA;;
HMG COA REDUCTASE INHIBITORS;SORT1;rs629301;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CARDIOVASCULAR DISEASE,HYPERCHOLESTEROLEMIA;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
MYCOPHENOLIC ACID;UGT1A9;rs3832043;del;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;KIDNEY TRANSPLANTATION;;
BISOPROLOL;ACY3;rs2514036;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
MYCOPHENOLIC ACID;SLCO1B1;rs2306283;AA + AG;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
IMATINIB;BCL2L11;rs724710;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
FLUOROURACIL;DPYD;rs3918290;CT;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;COLORECTAL NEOPLASMS;;
METOPROLOL;SEPTIN3;rs56234624;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
ALEMTUZUMAB;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
CHLORAMBUCIL;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
CYCLOPHOSPHAMIDE;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
FLUDARABINE;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
PREDNISONE;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
RITUXIMAB;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
VINCRISTINE;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;;
MYCOPHENOLIC ACID;ABCC2;rs3740066;CT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LUNG TRANSPLANTATION;;
GEMCITABINE;RRM1;rs9937;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
TACROLIMUS;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LUNG TRANSPLANTATION;;
BEVACIZUMAB;CXCL8;rs4073;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
GEMCITABINE;RRM1;rs183484;AC;EFFICACY, TOXICITY;DECREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
SN-38;UGT1A1;rs4148323;AA;DOSAGE;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NON-SMALL CELL LUNG CARCINOMA;;;
COTININE GLUCURONIDE;UGT1A9;rs12471326;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
NICOTINE;CYP2A6;rs145014075;GT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
BEVACIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
RANIBIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
GRANISETRON;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;NAUSEA;;;
GRANISETRON;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;SIDE EFFECT:VOMITING;;;
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;OTHER;HEART FAILURE;;;
CARBAMAZEPINE;SCN1A;rs3812718;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
BEVACIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
RANIBIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MACULAR DEGENERATION;;
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
ETANERCEPT;CD84;rs6427528;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
LOPINAVIR;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
CARBAMAZEPINE;SCN1A;rs2298771;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
METHADONE;OPRM1;rs10485058;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
CARBAMAZEPINE;GABRA1;rs2290732;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
USTEKINUMAB;IL12B;rs3213094;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
GEMCITABINE;CDA;rs2072671;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PANCREATIC NEOPLASMS;;
TOCILIZUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
EFAVIRENZ;ABCB1;rs2032582;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ALFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;PAIN;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;ABCB1;rs1045642;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CETUXIMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
CETUXIMAB;FCGR2A;rs1801274;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEAD AND NECK NEOPLASMS;;
EFAVIRENZ;HNF4A;rs1884613;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
METHADONE;ALDH5A1;rs2760118;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
ATAZANAVIR;UGT1A1;rs887829;TT;TOXICITY;INCREASED_DISCONTINUATION;nan;nan;;;
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS,STOMACH NEOPLASMS;;
OLANZAPINE;CHAT;rs1880676;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RAMIPRIL;ACE;rs4359;CC + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
RAMIPRIL;ACE;rs4344;AA + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERTENSION;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GLOMERULONEPHRITIS;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MEMBRANOUS;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
OXYCODONE;OPRD1;rs581111;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
PEGINTERFERON ALFA-2B;KLRK1;rs1049174;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;KLRK1;rs1049174;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CITALOPRAM;CRHR2;rs2270007;CC + CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
RIFAMPIN;NR1I2;rs3732357;AA + AG;LADME-PK;DECREASED_EXPOSURE;OTHER;TUBERCULOSIS;;;
METHOTREXATE;SLC19A1;rs1051266;CT + TT;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;OSTEOSARCOMA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
TELAPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
OXYCODONE;nan;rs6848893;CT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
PLATINUM COMPOUNDS;ATP7B;rs9535826;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
DEXAMETHASONE;NR3C1;rs6198;CC;EFFICACY;DECREASED_RESPONSE_TIME;METABOLISM;OTHER;COVID-19;;
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;BIPOLAR_DISORDER;;;
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;DEPRESSION;;;
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
PLATINUM COMPOUNDS;ATP7B;rs9535828;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
DEXAMETHASONE;NR3C1;rs33388;AA;EFFICACY;DECREASED_RESPONSE_TIME;METABOLISM;OTHER;COVID-19;;
RISPERIDONE;CCL2;rs4795893;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
RISPERIDONE;CCL2;rs4586;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
METHOTREXATE;FPGS;rs1544105;TT;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
METHOTREXATE;FPGS;rs1544105;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
DEXAMETHASONE;NR3C1;rs33389;TT;EFFICACY;DECREASED_RESPONSE_TIME;METABOLISM;OTHER;COVID-19;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ATORVASTATIN;ABCA1;rs769705621;AAAA;EFFICACY;DECREASED_RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;;;
ROSUVASTATIN;ABCA1;rs769705621;AAAA;EFFICACY;DECREASED_RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;;;
SIMVASTATIN;ABCA1;rs769705621;AAAA;EFFICACY;DECREASED_RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA;;;
CORTICOSTEROIDS;ADRB2;rs1042713;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADRB2;rs1042713;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ASTHMA;;
RISPERIDONE;CCL2;rs2857657;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
LAMOTRIGINE;UGT1A4;rs2011425;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;EPILEPSY;;
MERCAPTOPURINE;ITPA;rs1127354;A;LADME-PK;METABOLISM;nan;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA;;
LAMOTRIGINE;UGT1A4;rs2011425;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;EPILEPSY;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
EFAVIRENZ;CYP2B6;rs28399499;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NICOTINE;CHRNB3;rs4950;G;EFFICACY, OTHER;INCREASED_RESPONSE;OTHER;SMOKERS;;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
PLATINUM COMPOUNDS;HMGB1;rs1412125;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
NICOTINE;CHRNB3;rs13280604;G;EFFICACY, OTHER;INCREASED_RESPONSE;OTHER;SMOKERS;;;
WARFARIN;VKORC1;rs749671;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
DEXAMETHASONE;CYP3A4;rs35599367;AG;EFFICACY;DECREASED_RESPONSE_TIME;METABOLISM;OTHER;COVID-19;;
PLATINUM COMPOUNDS;HMGB1;rs2249825;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
EFAVIRENZ;CYP2B6;rs2279343;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CISPLATIN;XRCC1;rs25487;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NASOPHARYNGEAL NEOPLASMS,TOBACCO USE DISORDER;;
RADIOTHERAPY;XRCC1;rs25487;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NASOPHARYNGEAL NEOPLASMS,TOBACCO USE DISORDER;;
LOSARTAN;ACE;rs4291;AT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
VEGF/VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;VEGFA;rs699947;AC + CC;EFFICACY;INCREASED_RESPONSE;OTHER;MACULAR DEGENERATION;;;
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
OXYCODONE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ADALIMUMAB;IL12B;rs2546890;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
INFLIXIMAB;IL12B;rs2546890;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TACROLIMUS;CYP3A4;rs2740574;T;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
ADALIMUMAB;IVL;rs6661932;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
INFLIXIMAB;IVL;rs6661932;CT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
OPIOIDS;COMT;rs4680;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;PAIN;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
USTEKINUMAB;TIRAP;rs8177374;CT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
NICOTINE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE;OTHER;SCHIZOPHRENIA;;;
USTEKINUMAB;TLR5;rs5744174;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;LY96;rs11465996;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;AT + TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;rs1143623;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
USTEKINUMAB;IL1B;rs1143623;CG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
WARFARIN;ABCB1;rs1045642;A;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;APOE;rs429358;CC + CT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;rs1143627;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
USTEKINUMAB;IL1B;rs1143627;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
REPAGLINIDE;NR1I2;rs2276706;GG;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
COTININE;OPRM1;rs510769;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
RISPERIDONE;COMT;rs9606186;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
REPAGLINIDE;NR1I2;rs3814058;CC;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ATEZOLIZUMAB;IL7;rs16906115;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HEPATOCELLULAR CARCINOMA;;;
BEVACIZUMAB;IL7;rs16906115;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;HEPATOCELLULAR CARCINOMA;;;
COTININE;OPRM1;rs12209447;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
RISPERIDONE;COMT;rs2020917;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
COTININE;OPRM1;rs3798676;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FENTANYL;ABCB1;rs1045642;AA;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
RISPERIDONE;COMT;rs933271;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
COTININE;OPRM1;rs553202;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
COTININE;OPRM1;rs1074287;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
METHADONE;OPRD1;rs529520;AA + AC;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEROIN DEPENDENCE;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION;;
COTININE;OPRM1;rs1799971;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
COTININE;OPRM1;rs6912029;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
PREDNISONE;EDNRA;rs5333;CC + CT;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;NEPHROTIC SYNDROME;;
REPAGLINIDE;NR1I2;rs3814058;CC;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LIVER TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;TLR4;rs1927907;CC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;LIVER TRANSPLANTATION;;
PAZOPANIB;NR1I2;rs3814055;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;RENAL CELL CARCINOMA;;
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
ADALIMUMAB;ZNF816;rs9304742;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
INFLIXIMAB;ZNF816;rs9304742;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ACENOCOUMAROL;CALU;rs1043550;G;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HIV INFECTIOUS DISEASE;;
TACROLIMUS;IL18;rs1946518;GG + GT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;KIDNEY TRANSPLANTATION;;
ADALIMUMAB;NFKBIA;rs2145623;CC + CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
INFLIXIMAB;NFKBIA;rs2145623;CC + CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ADALIMUMAB;TNFRSF1B;rs1061624;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
INFLIXIMAB;TNFRSF1B;rs1061624;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
REPAGLINIDE;NR1I2;rs2276706;GG;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
ADALIMUMAB;SLC9A8;rs645544;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
INFLIXIMAB;SLC9A8;rs645544;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
FLUOROURACIL;XRCC4;rs10040363;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
PLATINUM COMPOUNDS;XRCC4;rs10040363;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
RADIOTHERAPY;XRCC4;rs10040363;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
FENTANYL;OPRM1;rs79910351;TT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
REMIFENTANIL;OPRM1;rs79910351;TT;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
FLUOROURACIL;XRCC4;rs2075685;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
PLATINUM COMPOUNDS;XRCC4;rs2075685;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
RADIOTHERAPY;XRCC4;rs2075685;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
MYCOPHENOLIC ACID;SLCO1B1;rs4149056;TT;LADME-PK;INCREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
SIMVASTATIN;PPARA;rs4253728;AA + AG;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
FLUOROURACIL;ERCC1;rs2298881;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
PLATINUM COMPOUNDS;ERCC1;rs2298881;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
RADIOTHERAPY;ERCC1;rs2298881;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;STOMACH NEOPLASMS;;
COTININE;OPRM1;rs563649;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
COTININE;OPRM1;rs2075572;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
SIMVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
COTININE;OPRM1;rs7748401;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
COTININE;OPRM1;rs495491;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
COTININE;OPRM1;rs10457090;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
COTININE;OPRM1;rs3778152;G;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
PRAVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
COTININE;OPRM1;rs589046;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;HEROIN DEPENDENCE;;
METHOTREXATE;NR1I2;rs3814055;T;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
METHOTREXATE;ABCC3;rs4793665;C;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;NR1I2;rs7643038;G;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;OSTEOSARCOMA;;
METHOTREXATE;ABCB1;rs9282564;C;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
METHOTREXATE;ABCG2;rs2231142;T;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;OSTEOSARCOMA;;
GLUCOCORTICOIDS;nan;rs17446593;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;THROMBOCYTOPENIA;;;
SUNITINIB;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
CLOZAPINE;NTRK2;rs10465180;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;SCHIZOPHRENIA;;
SIMVASTATIN;CYP3A5;rs776746;TT;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
SIMVASTATIN;SLCO2B1;rs12422149;AA;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
WARFARIN;CYP2C9;rs9332238;G;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER;CORONARY DISEASE;;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
DOXORUBICIN;CBR1;rs20572;CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ADRA2A;rs1800544;CG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ERLOTINIB;ABCB1;rs1045642;AA;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
ERLOTINIB;ABCB1;rs1128503;AA;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
NICOTINE;CYP2A6;rs28399468;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
METHOTREXATE;ABCC1;rs28364006;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
DOLUTEGRAVIR;NR1I2;rs2472677;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
ERLOTINIB;ABCB1;rs2032582;AA;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;NON-SMALL CELL LUNG CARCINOMA;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
LOSARTAN;AGTR1;rs5186;CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ESSENTIAL HYPERTENSION;;
CLOPIDOGREL;KDR;rs2305948;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CORONARY DISEASE;;
LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;EPILEPSY;;;
MERCAPTOPURINE;NUDT15;rs73189762;T;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
METFORMIN;ARFGEF3;rs143276236;AC;EFFICACY;DECREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
TRASTUZUMAB;ERBB2;rs1136201;G;TOXICITY;RESPONSE;nan;nan;;;
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;BREAST NEOPLASMS;;
METFORMIN;PRKAB2;rs7541245;A;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;nan;DISEASE;INFLAMMATORY BOWEL DISEASES,ACUTE LYMPHOBLASTIC LEUKEMIA;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
TACROLIMUS;POR;rs1057868;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS;;
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;BREAST NEOPLASMS;;
PRAMIPEXOLE;DRD3;rs6280;T;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs7196161;GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ANTIDEPRESSANTS;GAL;rs948854;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
BENZODIAZEPINE DERIVATIVES;GAL;rs948854;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
MIRTAZAPINE;GAL;rs948854;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GAL;rs948854;C;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;PREGNANCY;;;
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs41303343;A;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
METFORMIN;SLC22A1;rs628031;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
TACROLIMUS;CYP3A5;rs10264272;T;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
WARFARIN;VKORC1;rs2884737;AA;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs61742245;A;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs776746;C;DOSAGE, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MYCOPHENOLIC ACID;ABCC2;rs717620;CC;LADME-PK;INCREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION;;;
WARFARIN;PRSS53;rs2359612;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;TOBACCO USE DISORDER;;
DOXORUBICIN;CBR1;rs20572;CC;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;BREAST NEOPLASMS;;
WARFARIN;GGCX;rs11676382;CG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME-PK;INCREASED_METABOLISM;OTHER;HEAVY COFFEE CONSUMPTION;;;
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS;;;
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME-PK;DECREASED_CLEARANCE;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;rs2740574;C;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;rs35599367;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;OTHER;LIVER TRANSPLANTATION;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION;;;
WARFARIN;PRSS53;rs7294;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;rs2069885;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SPONDYLITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;rs2069885;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;ANKYLOSING;;;
RITUXIMAB;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;NEUROMYELITIS OPTICA;;
PREDNISOLONE;CD40;rs1883832;CC;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;THROMBOCYTOPENIA;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;LIVER TRANSPLANTATION;;;
METFORMIN;SLC47A1;rs2289669;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ERENUMAB;CALCRL;rs6710852;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITH AURA;;;
ERENUMAB;CALCRL;rs6710852;G;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;MIGRAINE WITHOUT AURA;;;
TACROLIMUS;ABCB1;rs2032582;AA + TT;DOSAGE, LADME-PK;DECREASED_CLEARANCE;OTHER;LIVER TRANSPLANTATION;;;
WARFARIN;VKORC1;rs7294;CC;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
HALOTHANE;RYR1;rs118192161;T;OTHER;INCREASED_RESPONSE;nan;nan;;;
WARFARIN;VKORC1;rs8050894;CC;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;VKORC1;rs2359612;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;rs2069812;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SPONDYLITIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;rs2069812;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;ANKYLOSING;;;
BETA BLOCKING AGENTS;BST1;rs28404156;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
SELECTIVE;BST1;rs28404156;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HEPATITIS C VIRUS INFECTION,HIV INFECTIOUS DISEASE;;
TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
BISPHOSPHONATES;FDPS;rs2297480;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;OSTEOPOROSIS;;
SIMVASTATIN;CETP;rs5882;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;HYPERCHOLESTEROLEMIA;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;APOE;rs405509;TT;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER;;;
METHOTREXATE;ABCG2;rs17731538;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CROHN DISEASE,INFLAMMATORY BOWEL DISEASES,PSORIASIS,SPONDYLARTHROPATHIES;;
CYCLOSPORINE;UMOD;rs12917707;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
MODAFINIL;ABCB1;rs2032582;AC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NARCOLEPSY;;
MODAFINIL;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NARCOLEPSY;;
WARFARIN;MYC;rs4645962;CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;MYC;rs4645943;CT + TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
CARBAMAZEPINE;EPHX1;rs2234922;G;DOSAGE, LADME-PK;DECREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
MODAFINIL;ABCB1;rs1128503;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;NARCOLEPSY;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CROHN DISEASE,INFLAMMATORY BOWEL DISEASES,PSORIASIS,SPONDYLARTHROPATHIES;;
BISPHOSPHONATES;FDPS;rs11264359;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;OSTEOPOROSIS;;
WARFARIN;MYC;rs4645974;CC;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CROHN DISEASE,INFLAMMATORY BOWEL DISEASES,PSORIASIS,SPONDYLARTHROPATHIES;;
ATORVASTATIN;ABCC2;rs717620;T;EFFICACY;DECREASED_DOSE;nan;nan;;;
SIMVASTATIN;ABCC2;rs717620;T;EFFICACY;DECREASED_DOSE;nan;nan;;;
LEFLUNOMIDE;DHODH;rs3213422;CC;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
ANTIPSYCHOTICS;DRD2;rs1799732;G;EFFICACY;INCREASED_RESISTANCE;OTHER;MOOD DISORDER;;;
ANTIPSYCHOTICS;DRD2;rs1799732;G;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
RISPERIDONE;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
ANTIPSYCHOTICS;HTR2A;rs7997012;AG;EFFICACY;INCREASED_RESISTANCE;OTHER;MOOD DISORDER;;;
ANTIPSYCHOTICS;HTR2A;rs7997012;AG;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
METHADONE;CYP2B6;rs3745274;TT;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;HEROIN DEPENDENCE;;
METHADONE;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;OPIOID-RELATED DISORDERS;;;
OLANZAPINE;HTR2A;rs6313;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
OLANZAPINE;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
CARBAMAZEPINE;EPHX1;rs1051740;CC;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
EFAVIRENZ;CYP2B6;rs3745274;GG;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
CARBAMAZEPINE;EPHX1;rs2234922;GG;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
AZATHIOPRINE;ITPA;rs7270101;AC + CC;TOXICITY, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;INFLAMMATORY BOWEL DISEASES,ACUTE LYMPHOBLASTIC LEUKEMIA;;
MERCAPTOPURINE;ITPA;rs7270101;AC + CC;TOXICITY, LADME-PK;INCREASED_METABOLISM;nan;DISEASE;INFLAMMATORY BOWEL DISEASES,ACUTE LYMPHOBLASTIC LEUKEMIA;;
IMATINIB;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CARBAMAZEPINE;ABCB1;rs1045642;AG;LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
ANTIEPILEPTICS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
RALOXIFENE;COMT;rs737865;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
RALOXIFENE;COMT;rs737865;AG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOAFFECTIVE DISORDER;;;
PACLITAXEL;ABCC2;rs717620;CT;TOXICITY;DECREASED_DOSE;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
RALOXIFENE;COMT;rs737865;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
RALOXIFENE;COMT;rs737865;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOAFFECTIVE DISORDER;;;
BUPRENORPHINE;OPRD1;rs678849;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS;;;
METHADONE;ABCB1;rs2032582;AC;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE;nan;nan;;;
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESISTANCE;nan;DISEASE;EPILEPSY;;
RISPERIDONE;TNIK;rs7627954;CC;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
RALOXIFENE;COMT;rs4818;CG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
RALOXIFENE;COMT;rs4818;CG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOAFFECTIVE DISORDER;;;
METHADONE;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
SUNITINIB;ABCB1;rs2032582;AA + AT;DOSAGE, TOXICITY;INCREASED_DOSE;nan;DISEASE;RENAL CELL CARCINOMA;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS;;;
ADALIMUMAB;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ETANERCEPT;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
INFLIXIMAB;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
SUNITINIB;ABCB1;rs1128503;AA;DOSAGE, TOXICITY;INCREASED_DOSE;nan;DISEASE;RENAL CELL CARCINOMA;;
METHADONE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
METHADONE;ABCB1;rs1128503;AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;OPIOID-RELATED DISORDERS;;
METHADONE;POR;rs1057868;CT + TT;LADME-PK;INCREASED_CLEARANCE;nan;DISEASE;OPIOID-RELATED DISORDERS;;
METHADONE;CYP2B6;rs2279343;AA;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
DOLUTEGRAVIR;ABCG2;rs2231142;TT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
METHADONE;CYP2B6;rs3745274;GG;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
PREDNISOLONE;TLR4;rs4986791;T;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;THROMBOCYTOPENIA;;;
PERAMPANEL;CYP3A4;rs4986908;CG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
TELBIVUDINE;TK2;rs3826160;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;HEPATITIS B;;;
TELBIVUDINE;TK2;rs3826160;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;CHRONIC;;;
WARFARIN;EPHX1;rs1877724;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
NEVIRAPINE;CYP2B6;rs3745274;TT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
ETHANOL;OPRM1;rs3778150;CC + CT;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE;nan;DISEASE;CYSTIC FIBROSIS;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
NEVIRAPINE;CYP2B6;rs3745274;T;OTHER, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NEVIRAPINE;CYP2C19;rs12768009;AA;OTHER, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
ESCITALOPRAM;CYP2C18;rs11188059;G;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DONEPEZIL;PRKCE;rs6720975;T;EFFICACY;INCREASED_RESPONSE;OTHER;ALZHEIMER DISEASE;;;
GALANTAMINE;PRKCE;rs6720975;T;EFFICACY;INCREASED_RESPONSE;OTHER;ALZHEIMER DISEASE;;;
RIVASTIGMINE;PRKCE;rs6720975;T;EFFICACY;INCREASED_RESPONSE;OTHER;ALZHEIMER DISEASE;;;
ESCITALOPRAM;CYP2C18;rs2860840;T;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
EFAVIRENZ;CYP2B6;rs2279345;TT;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;HIV INFECTIOUS DISEASE;;
PERAMPANEL;CYP3A4;rs2242480;CT + TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
DONEPEZIL;nan;rs17798800;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
GALANTAMINE;nan;rs17798800;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
RIVASTIGMINE;nan;rs17798800;T;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PREDNISOLONE;TLR4;rs4986790;G;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;THROMBOCYTOPENIA;;;
METHADONE;ABCB1;rs2032582;CC;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE;;;
METHADONE;ABCB1;rs1045642;AA;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;HEROIN DEPENDENCE;;
SN-38;ABCB1;rs12720066;AC + CC;LADME-PK;DECREASED_EXPOSURE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ANTIPSYCHOTICS;GABRB1;rs4627835;T;DOSAGE;INCREASED_DOSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
ANTIPSYCHOTICS;GABRB1;rs16860087;A;DOSAGE;INCREASED_DOSE;nan;DISEASE;SCHIZOAFFECTIVE DISORDER,SCHIZOPHRENIA;;
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE;;;
SN-38;ABCC1;rs35621;CT + TT;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CARBAMAZEPINE;ABCB1;rs1045642;AA;DOSAGE;INCREASED_DOSE;OTHER;EPILEPSY;;;
LITHIUM;ASIC2;rs11869731;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
SN-38;ABCC1;rs6498588;AT + TT;LADME-PK;INCREASED_EXPOSURE;nan;DISEASE;COLORECTAL NEOPLASMS;;
CAPECITABINE;HLA-G;rs9380142;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;HLA-G;rs9380142;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
ANTIDEPRESSANTS;MAPK1;rs8136867;AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MENTAL DISORDERS;;
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CAPECITABINE;HLA-G;rs17179108;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;HLA-G;rs17179108;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
WARFARIN;VKORC1;rs9923231;CC;DOSAGE, EFFICACY;INCREASED_DOSE;nan;DISEASE;HEART DISEASES;;
PHENYTOIN;CYP2C9;rs9332238;A;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DONEPEZIL;CHAT;rs3793790;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
GALANTAMINE;CHAT;rs3793790;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
RIVASTIGMINE;CHAT;rs3793790;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
FLUVOXAMINE;COMT;rs4680;GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
LITHIUM;OR52E2;rs16909440;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
LITHIUM;OR52J3;rs2499984;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
ANTIDEPRESSANTS;CREB1;rs889895;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
DOLUTEGRAVIR;UGT1A1;rs887829;CT + TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
LITHIUM;nan;rs16973410;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;BIPOLAR_DISORDER;;
MERCAPTOPURINE;TPMT;rs1142345;C;EFFICACY;EXPOSURE;nan;DISEASE;LEUKEMIA;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE;nan;nan;;;
DOLUTEGRAVIR;AADAC;rs1803155;AG + GG;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HIV INFECTIOUS DISEASE,TUBERCULOSIS;;
DONEPEZIL;CHAT;rs2177370;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
GALANTAMINE;CHAT;rs2177370;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
RIVASTIGMINE;CHAT;rs2177370;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ALZHEIMER DISEASE;;
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
ZIDOVUDINE;UGT2B7;rs28365062;G;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DOSE;nan;DISEASE;ATRIAL FIBRILLATION,VENOUS THROMBOEMBOLISM;;
CHOLESTEROL;APOE;rs429358;TT;TOXICITY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
METHADONE;DRD2;rs6275;AA;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;HEROIN DEPENDENCE;;
METFORMIN;SLC47A2;rs12943590;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
ATENOLOL;ADRB1;rs1801253;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ATRIAL FIBRILLATION;;
CARVEDILOL;ADRB1;rs1801253;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ATRIAL FIBRILLATION;;
DILTIAZEM;ADRB1;rs1801253;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ATRIAL FIBRILLATION;;
METOPROLOL;ADRB1;rs1801253;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ATRIAL FIBRILLATION;;
VERAPAMIL;ADRB1;rs1801253;CG + GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ATRIAL FIBRILLATION;;
METHADONE;DRD2;rs1799978;CC;DOSAGE, LADME-PK;DECREASED_DOSE;nan;DISEASE;HEROIN DEPENDENCE;;
METFORMIN;SLC22A2;rs316019;AA + AC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
CARBAMAZEPINE;ABCB1;rs2032582;AA + AC;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
ERYTHROMYCIN;ABCC2;rs717620;TT;OTHER, LADME-PK;INCREASED_METABOLISM;nan;nan;;;
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
CARBAMAZEPINE;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;EPILEPSY;;;
ABIRATERONE;HSD3B1;rs1047303;AC;EFFICACY;DECREASED_RESPONSE;OTHER;PROSTATIC NEOPLASMS;;;
DUTASTERIDE;HSD3B1;rs1047303;AC;EFFICACY;DECREASED_RESPONSE;OTHER;PROSTATIC NEOPLASMS;;;
AZATHIOPRINE;PACSIN2;rs2413739;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;IRRITABLE BOWEL SYNDROME;;;
SILDENAFIL;NOS3;rs2070744;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ERECTILE DYSFUNCTION;;
NEVIRAPINE;CYP2B6;rs3745274;TT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
ABIRATERONE;SRD5A2;rs523349;CC;LADME-PK;INCREASED_METABOLISM;OTHER;PROSTATIC NEOPLASMS;;;
TRIGLYCERIDES;CYP19A1;rs10046;A;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
TRIGLYCERIDES;CYP19A1;rs3759811;C;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
WARFARIN;VKORC1;rs7196161;A;DOSAGE;DOSE;nan;DISEASE;ATRIAL FIBRILLATION,PULMONARY EMBOLISM,STROKE,VENOUS THROMBOSIS;;
HDL CHOLESTEROL;CYP19A1;rs1008805;G;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
TRIGLYCERIDES;CYP19A1;rs2289105;C;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
WARFARIN;VKORC1;rs7196161;G;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
METHOTREXATE;SLC19A1;rs1051296;AC + CC;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
HDL CHOLESTEROL;CYP19A1;rs10046;G;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
FENTANYL;CYP3A4;rs2242480;T;DOSAGE;DECREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
HDL CHOLESTEROL;CYP19A1;rs2289105;T;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
LEFLUNOMIDE;ESR1;rs2234693;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
NEVIRAPINE;CYP2B6;rs3745274;GT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
LEFLUNOMIDE;ESR1;rs9340799;AA;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;RHEUMATOID ARTHRITIS;;
USTEKINUMAB;C9orf72;rs774359;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
METHOTREXATE;GGH;rs3758149;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
HDL CHOLESTEROL;CYP19A1;rs4646;A;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
USTEKINUMAB;IL13;rs848;AA + AC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TRIGLYCERIDES;CYP19A1;rs700518;C;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
USTEKINUMAB;ZNF816;rs9304742;CC + CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
TRIGLYCERIDES;CYP19A1;rs4775936;C;OTHER;DECREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;BREAST NEOPLASMS,MENOPAUSE;;
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
USTEKINUMAB;STAT4;rs7574865;GT + TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
USTEKINUMAB;SLC22A4;rs1050152;CT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE;;;
NICOTINE;CHRNA5;rs16969968;GG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
WARFARIN;STX1B;rs72800847;AA + AG;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;CYP1A1;rs3826041;CC;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
VARENICLINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER;;;
WARFARIN;DNMT3A;rs2304429;TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;NQO1;rs10517;AA;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
RALOXIFENE;ESR1;rs2234693;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOPHRENIA;;;
RALOXIFENE;ESR1;rs2234693;TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;SCHIZOAFFECTIVE DISORDER;;;
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
PHENPROCOUMON;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
FENTANYL;DRD1;rs966775;AG + GG;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;POSTOPERATIVE_PAIN;;;
FLUTICASONE;CHRM2;rs8191992;A;EFFICACY;RESPONSE;nan;DISEASE;ASTHMA;;
SALMETEROL;CHRM2;rs8191992;A;EFFICACY;RESPONSE;nan;DISEASE;ASTHMA;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;NON-HODGKIN LYMPHOMA;;;
WARFARIN;VKORC1;rs9923231;A;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
ARIPIPRAZOLE;DRD2;rs2514218;CC;EFFICACY;INCREASED_RESPONSE;OTHER;PSYCHOTIC DISORDER;;;
ARIPIPRAZOLE;DRD2;rs2514218;CC;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOAFFECTIVE DISORDER;;;
ARIPIPRAZOLE;DRD2;rs2514218;CC;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;DRD2;rs2514218;CC;EFFICACY;INCREASED_RESPONSE;OTHER;PSYCHOTIC DISORDER;;;
RISPERIDONE;DRD2;rs2514218;CC;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOAFFECTIVE DISORDER;;;
RISPERIDONE;DRD2;rs2514218;CC;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
VORICONAZOLE;ABCG2;rs2231142;GT + TT;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;LEUKEMIA,LYMPHOMA,MYELODYSPLASTIC SYNDROMES;;
WARFARIN;STX1B;rs4889606;AG + GG;DOSAGE;DECREASED_METABOLISM;DECREASED_DOSE;DRUG;;;
WARFARIN;UGT1A1;rs887829;CC;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE;nan;DISEASE;HEART VALVE REPLACEMENT;;
AZATHIOPRINE;ITPA;rs1127354;AA + AC;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
MERCAPTOPURINE;ITPA;rs1127354;AA + AC;LADME-PK;DECREASED_METABOLISM;nan;DISEASE;INFLAMMATORY BOWEL DISEASES;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
BEVACIZUMAB;SHMT1;rs1979277;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
FLUOROURACIL;SHMT1;rs1979277;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
IRINOTECAN;SHMT1;rs1979277;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
LEUCOVORIN;SHMT1;rs1979277;A;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;COLORECTAL NEOPLASMS;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs1800795;G;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;PSORIASIS;;
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;INCREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
PLATINUM COMPOUNDS;nan;rs6983267;GG + GT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
METFORMIN;SLC22A2;rs316009;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;PAIN;;;
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;POSTOPERATIVE_PAIN;;;
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;DECREASED_METABOLISM;DRUG_ACCUMULATION;OTHER;HYPERCHOLESTEROLEMIA;;
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
PLATINUM COMPOUNDS;MALAT1;rs619586;AG + GG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
PLATINUM COMPOUNDS;HOTAIR;rs7958904;CC + CG;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
PLATINUM COMPOUNDS;H19;rs2839698;AA + AG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;LUNG NEOPLASMS;;
TACROLIMUS;CYP3A4;rs35599367;AG;DOSAGE;DECREASED_DOSE;nan;DISEASE;KIDNEY TRANSPLANTATION;;
CARBAMAZEPINE;EPHX1;rs1051740;C;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
FLUTICASONE;CHRM2;rs6962027;A;EFFICACY;RESPONSE;nan;DISEASE;ASTHMA;;
SALMETEROL;CHRM2;rs6962027;A;EFFICACY;RESPONSE;nan;DISEASE;ASTHMA;;
NICOTINE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE;nan;nan;;;
BETA BLOCKING AGENTS;ADRB1;rs1801253;C;EFFICACY;INCREASED_RESPONSE;OTHER;CARDIOMYOPATHY;;;
BETA BLOCKING AGENTS;ADRB1;rs1801253;C;EFFICACY;INCREASED_RESPONSE;OTHER;DILATED;;;
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;STROKE;;
BETA BLOCKING AGENTS;ADRB2;rs1042713;A;EFFICACY;INCREASED_RESPONSE;OTHER;CARDIOMYOPATHY;;;
BETA BLOCKING AGENTS;ADRB2;rs1042713;A;EFFICACY;INCREASED_RESPONSE;OTHER;DILATED;;;
FLUTICASONE;CHRM2;rs6962027;A;EFFICACY;RESPONSE;nan;DISEASE;ASTHMA;;
SALMETEROL;CHRM2;rs6962027;A;EFFICACY;RESPONSE;nan;DISEASE;ASTHMA;;
CARBAMAZEPINE;EPHX1;rs2234922;G;DOSAGE, LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
FLUTICASONE PROPIONATE;CRHR1;rs1876831;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
RISPERIDONE;TNIK;rs2088885;AA;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA;;;
FLUTICASONE PROPIONATE;CRHR1;rs1876828;T;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
METFORMIN;CSMD1;rs2617102;AC + CC;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
FLUTICASONE PROPIONATE;CRHR1;rs1876829;C;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
FLUTICASONE PROPIONATE;CRHR1;rs739645;G;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;ASTHMA;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;INCREASED_SENSITIVITY;METABOLISM;DOSE_ADJUST;TROUGH_PLASMATIC_CONCENTRATION;CAUTION_SIDE_EFFECT;
NEVIRAPINE;CYP2B6;rs3745274;T;TOXICITY, LADME-PK;DECREASED_CLEARANCE;nan;DISEASE;HIV INFECTIOUS DISEASE;;
NICOTINE;POR;rs1057868;CT + TT;LADME-PK;INCREASED_METABOLISM;PK;CYP2A6 NORMAL;;;
NICOTINE;POR;rs1057868;CT + TT;LADME-PK;INCREASED_METABOLISM;PK;BUT NOT REDUCED;;;
NICOTINE;POR;rs1057868;CT + TT;LADME-PK;INCREASED_METABOLISM;PK;METABOLIZERS;;;
CARBAMAZEPINE;SCN1A;rs3812718;TT;LADME-PK;INCREASED_METABOLISM;nan;DISEASE;EPILEPSY;;
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
VORICONAZOLE;CYP2C18;rs2860840;T;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;;;
VORICONAZOLE;CYP2C18;rs2860840;T;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LYMPHOMA;;;
VORICONAZOLE;CYP2C18;rs2860840;T;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELODYSPLASTIC SYNDROMES;;;
VORICONAZOLE;CYP2C18;rs11188059;G;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA;;;
VORICONAZOLE;CYP2C18;rs11188059;G;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LYMPHOMA;;;
VORICONAZOLE;CYP2C18;rs11188059;G;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;MYELODYSPLASTIC SYNDROMES;;;
REMIFENTANIL;ABCB1;rs1045642;GG;DOSAGE;INCREASED_METABOLISM;INCREASED_DOSE;DRUG;;;
WARFARIN;GGCX;rs12714145;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION;;;
WARFARIN;GGCX;rs12714145;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT;;;
WARFARIN;GGCX;rs12714145;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;PULMONARY EMBOLISM;;;
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
REMIFENTANIL;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;nan;nan;;;
FLUOROURACIL;DPYD;rs1801159;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;COLORECTAL NEOPLASMS;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;nan;DISEASE;ATRIAL FIBRILLATION;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;CHRONIC_HEPATITIS_C;;
CARBAMAZEPINE;SCN1A;rs3812718;TT;LADME-PK;INCREASED_DOSE;nan;DISEASE;EPILEPSY;;
NALTREXONE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;OPIOID-RELATED DISORDERS;;;
ASPIRIN;P2RY1;rs1371097;T;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;STROKE;;;
GEMCITABINE;CMPK1;rs1044457;TT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;NON-SMALL CELL LUNG CARCINOMA;;;
TACROLIMUS;SLC7A8;rs7141505;AC + CC;LADME-PK;DECREASED_METABOLISM;OTHER;LIVER TRANSPLANTATION;;;
MERCAPTOPURINE;NUDT15;rs55713253;CC;DOSAGE;INCREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA;;;
CYCLOPHOSPHAMIDE;ABCC2;rs145008610;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;BREAST NEOPLASMS;;;
DOXORUBICIN;ABCC2;rs145008610;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;BREAST NEOPLASMS;;;
PACLITAXEL;ABCC2;rs145008610;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;BREAST NEOPLASMS;;;
DEOXY-THIOGUANOSINE TRIPHOSPHATE;TPMT;rs1142345;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
THIOGUANOSINE TRIPHOSPHATE;TPMT;rs1142345;CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;INFLAMMATORY BOWEL DISEASES;;;
AZATHIOPRINE;PACSIN2;rs2413739;CC + CT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;INFLAMMATORY BOWEL DISEASES;;;
CLOPIDOGREL CARBOXYLIC ACID;ABCB1;rs1045642;AA + AG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;CARDIOVASCULAR DISEASE;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA;;;
BREXPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
THIORIDAZINE;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MENTAL DISORDERS;;;
THIORIDAZINE;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MENTAL DISORDERS;;;
THIORIDAZINE;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MENTAL DISORDERS;;;
THIORIDAZINE;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MENTAL DISORDERS;;;
THIORIDAZINE;CYP2D6;CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MENTAL DISORDERS;;;
PRIMAQUINE;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
PRIMAQUINE;CYP2D6;CYP2D6*2;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*2;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
PRIMAQUINE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
PRIMAQUINE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
PRIMAQUINE;CYP2D6;CYP2D6*9;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*9;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
PRIMAQUINE;CYP2D6;CYP2D6*17;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*17;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
PRIMAQUINE;CYP2D6;CYP2D6*29;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*29;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
PRIMAQUINE;CYP2D6;CYP2D6*34;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*34;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
PRIMAQUINE;CYP2D6;CYP2D6*39;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*39;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
PRIMAQUINE;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MALARIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_PLASMATIC-CONCENTRATION;OTHER;VIVAX;;;
CYCLOSPORINE;CYP3A5;rs776746;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION;;;
RISPERIDONE;CYP2D6;CYP2D6*17;*17;LADME-PK;INCREASED_METABOLISM;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*17;*17;LADME-PK;INCREASED_METABOLISM;OTHER;ADHD;;;
RISPERIDONE;CYP2D6;CYP2D6*17;*17;LADME-PK;INCREASED_METABOLISM;OTHER;AUTISM;;;
RISPERIDONE;CYP2D6;CYP2D6*17;*17;LADME-PK;INCREASED_METABOLISM;OTHER;BIPOLAR_DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6*29;*29;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*29;*29;LADME-PK;DECREASED_METABOLISM;OTHER;ADHD;;;
RISPERIDONE;CYP2D6;CYP2D6*29;*29;LADME-PK;DECREASED_METABOLISM;OTHER;AUTISM;;;
RISPERIDONE;CYP2D6;CYP2D6*29;*29;LADME-PK;DECREASED_METABOLISM;OTHER;BIPOLAR_DISORDER;;;
DULAGLUTIDE;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
LIRAGLUTIDE;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
SEMAGLUTIDE;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
N-DESMETHYLCLOZAPINE;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;SCHIZOPHRENIA;;;
NORCLOBAZAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;EPILEPSY;;;
NORCLOBAZAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;EPILEPSY;;;
NORCLOBAZAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;EPILEPSY;;;
NORCLOBAZAM;CYP2C19;CYP2C19*17;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;EPILEPSY;;;
ARTEMETHER;CYP2B6;rs3745274;GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MALARIA;;;
LUMEFANTRINE;CYP2B6;rs3745274;GT;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;MALARIA;;;
4-ENE VALPROIC ACID;CPT1A;rs2228502;GG;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;EPILEPSY;;;
TACROLIMUS;SULT1E1;rs3775770;CC;LADME-PK;DECREASED_METABOLISM;OTHER;LIVER TRANSPLANTATION;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
METHOTREXATE;ATIC;rs4673991;CC + CT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
QUETIAPINE;CYP3A4;CYP3A4*22;*22;LADME-PK;INCREASED_EXPOSURE;OTHER;LIVER CIRRHOSIS;;;
METHOTREXATE;ATIC;rs4673993;CT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
METHOTREXATE;ADA;rs2057638;GT + TT;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
METHOTREXATE;ATIC;rs2372536;CC + CG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
METHOTREXATE;ADA;rs6017375;CG + GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
METHOTREXATE;ADA;rs371927;AA;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;RHEUMATOID ARTHRITIS;;;
PROPOFOL;UGT1A9;rs72551330;CT;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYP;;;
PROPOFOL;UGT1A9;rs2741045;CC;LADME-PK;INCREASED_CLEARANCE;nan;nan;;;
CODEINE;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
HYDROCODONE;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;PAIN;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6 normal metabolizer;;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;nan;nan;;;
SITAGLIPTIN;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;HYPERTENSION;;;
SITAGLIPTIN;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL-BENEFIT;OTHER;DIABETES MELLITUS;;;
SALBUTAMOL;ADRB2;rs1042717;AA;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
SALBUTAMOL;ADRB2;rs1042714;GG;EFFICACY;DECREASED_CLINICAL-BENEFIT;OTHER;ASTHMA;;;
THIORIDAZINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;DEPRESSION;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MENTAL DISORDERS;;;
PERPHENAZINE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;OTHER;MENTAL DISORDERS;;;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7754840;CC;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7756992;GG;EFFICACY;INCREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS;;
SITAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
VILDAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_RESPONSE;nan;DISEASE;DIABETES MELLITUS, TYPE 2;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*5;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*10;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
NORTRIPTYLINE;CYP2D6;CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER;MENTAL DISORDERS;;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER;NEUROTIC DISORDER;;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER;PERSONALITY DISORDER;;;
ANTIPSYCHOTICS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
ANTIPSYCHOTICS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER;MENTAL DISORDERS;;;
ANTIPSYCHOTICS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER;NEUROTIC DISORDER;;;
ANTIPSYCHOTICS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER;PERSONALITY DISORDER;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;DISEASE;MAJOR DEPRESSIVE DISORDER;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER;MENTAL DISORDERS;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER;NEUROTIC DISORDER;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER;PERSONALITY DISORDER;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER;MENTAL DISORDERS;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER;NEUROTIC DISORDER;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER;PERSONALITY DISORDER;;;
ANTIDEPRESSANTS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
ANTIDEPRESSANTS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER;MENTAL DISORDERS;;;
ANTIDEPRESSANTS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER;NEUROTIC DISORDER;;;
ANTIDEPRESSANTS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER;PERSONALITY DISORDER;;;
ANTIPSYCHOTICS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA;;;
ANTIPSYCHOTICS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER;MENTAL DISORDERS;;;
ANTIPSYCHOTICS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER;NEUROTIC DISORDER;;;
ANTIPSYCHOTICS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER;PERSONALITY DISORDER;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*6;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;OTHER;LIVER TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;rs35599367;AG;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
TACROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION;;;
EFAVIRENZ;CYP2B6;rs4803419;C;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE;;;
EFAVIRENZ;CYP2B6;rs4803419;C;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;OTHER;MISSED DOSE;;;
ANTIDEPRESSANTS;SLC22A3;rs2292334;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;DEPRESSION;;;
KETANSERIN;HTR1B;rs130060;C;LADME-PD;DECREASED_AFFINITY;nan;HTR1B;;;
THIOXANTHINE;XDH;rs2295474;T;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPXDH;;;
PAROMOMYCIN;MT-RNR1;rs267606617;G;LADME-PD;DECREASED_ACTIVITY;nan;MT-RNR1;;;
THIOXANTHINE;XDH;rs45442092;T;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPXDH;;;
DIHYDROERGOTAMINE;HTR1B;rs130060;C;LADME-PD;INCREASED_AFFINITY;RECEPTOR;HTR1B;;;
METHYSERGIDE;HTR1B;rs130060;C;LADME-PD;INCREASED_AFFINITY;RECEPTOR;HTR1B;;;
SUMATRIPTAN;HTR1B;rs130060;C;LADME-PD;INCREASED_AFFINITY;RECEPTOR;HTR1B;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;TYMS;;;
CISPLATIN;UBE2I;rs9597;CG;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;SAE1;;;
IRINOTECAN;UBE2I;rs9597;CG;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;SAE1;;;
METHOTREXATE;SHMT1;rs1979277;AA;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;TYMS;;;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs397508139;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
FLUOROURACIL;DPYD;rs1335150891;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
IVACAFTOR;CFTR;rs141033578;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs121909011;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs77409459;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs397508510;C;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs397508435;C;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs77010898;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
ESTRADIOL;TCL1A;rs7158782;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL17RA;;;
IVACAFTOR;CFTR;rs397508328;G;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs77932196;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
NIMESULIDE;PTGS2;rs5272;C;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;PTGS2;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;PROTEIN-STABILITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs1800111;C;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs74551128;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs186045772;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs78769542;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs397508537;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs397508256;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs121908751;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
CISPLATIN;TPMT;TPMT*1;*3A;OTHER;INCREASED_EXPRESSION;RECEPTOR;TLR4;;;
CISPLATIN;TPMT;TPMT*3A;*3A;OTHER;INCREASED_EXPRESSION;RECEPTOR;TLR4;;;
IVACAFTOR;CFTR;rs368505753;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
NIMESULIDE;PTGS2;rs5273;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;PTGS2;;;
IVACAFTOR;CFTR;rs115545701;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
SACUBITRIL;CES1;rs71647871;CT;EFFICACY;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CES1;;
IVACAFTOR;CFTR;rs1800100;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL12RB2;;;
ESTRADIOL;TCL1A;rs7158782;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;TCL1A;;;
ANASTROZOLE;CYP19A1;rs6493497;AG;OTHER;ACTIVITY;nan;CYP19A1;;;
EXEMESTANE;CYP19A1;rs6493497;AG;OTHER;ACTIVITY;nan;CYP19A1;;;
LETROZOLE;CYP19A1;rs6493497;AG;OTHER;ACTIVITY;nan;CYP19A1;;;
ANASTROZOLE;CYP19A1;rs7176005;CT;OTHER;ACTIVITY;nan;CYP19A1;;;
EXEMESTANE;CYP19A1;rs7176005;CT;OTHER;ACTIVITY;nan;CYP19A1;;;
LETROZOLE;CYP19A1;rs7176005;CT;OTHER;ACTIVITY;nan;CYP19A1;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*9;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*21;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*32;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*33;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
THIOGUANINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
THIOGUANINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
THIOGUANINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
THIOGUANINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
THIOGUANINE;TPMT;TPMT*9;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
THIOGUANINE;TPMT;TPMT*21;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
THIOGUANINE;TPMT;TPMT*32;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
THIOGUANINE;TPMT;TPMT*33;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
THIOGUANINE;TPMT;TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
SITAGLIPTIN;DPP4;rs759717;CC;LADME-PD;INCREASED_ACTIVITY;METABOLISM;PROTEIN;DPP4;;
SITAGLIPTIN;DPP4;rs2909451;TT;LADME-PD;INCREASED_ACTIVITY;METABOLISM;PROTEIN;DPP4;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION;RECEPTOR;MKI67;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION;RECEPTOR;MKI67;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION;RECEPTOR;MKI67;;;
TAMOXIFEN;CYP2D6;CYP2D6*14;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION;RECEPTOR;MKI67;;;
TAMOXIFEN;CYP2D6;CYP2D6*18;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION;RECEPTOR;MKI67;;;
TAMOXIFEN;CYP2D6;CYP2D6*21;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION;RECEPTOR;MKI67;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION;RECEPTOR;MKI67;;;
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL1R2;;;
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL17A;;;
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL1R2;;;
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL12RB2;;;
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL17A;;;
ESTRADIOL;TCL1A;rs7159713;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;TCL1A;;;
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs397508759;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs150212784;G;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs34911792;G;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs397508513;C;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
ESTRADIOL;TCL1A;rs7159713;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL17RA;;;
METHOXSALEN;CYP2A6;CYP2A6*15;*15 + *21 + *22;OTHER;DECREASED_ENZYME_ACTIVITY;nan;CYP2A6;;;
METHOXSALEN;CYP2A6;CYP2A6*21;*15 + *21 + *22;OTHER;DECREASED_ENZYME_ACTIVITY;nan;CYP2A6;;;
METHOXSALEN;CYP2A6;CYP2A6*22;*15 + *21 + *22;OTHER;DECREASED_ENZYME_ACTIVITY;nan;CYP2A6;;;
ATORVASTATIN;SCAP;rs12487736;TT;OTHER;DECREASED_TRANSCRIPTION;nan;GENE:SCAP;;;
IVACAFTOR;CFTR;rs202179988;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*2;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*2;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VITAMIN E;CYP4F2;rs3093105;C;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CYP4F2;;;
ESTRADIOL;nan;rs11849538;C;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL17A;;;
ESTRADIOL;nan;rs11849538;C;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL1R2;;;
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
LUMACAFTOR;CFTR;rs78655421;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
NPPB;CFTR;rs75527207;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP3A4;;
FLUOROURACIL;DPYD;rs56005131;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
ESTRADIOL;nan;rs2369049;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL17RA;;;
ESTRADIOL;nan;rs2369049;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL12RB2;;;
ESTRADIOL;nan;rs2369049;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL17A;;;
ELEXACAFTOR;CFTR;rs80034486;CG;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs80034486;CG;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs80034486;CG;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
CORR-4A;CFTR;rs113993960;del/del;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
ESTRADIOL;nan;rs2369049;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL1R2;;;
IVACAFTOR;CFTR;rs397508288;G;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs75541969;C;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
ESCITALOPRAM;IL11;rs1126757;CT + TT;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;IL11;;
ESCITALOPRAM;IL11;rs1126757;CT + TT;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;IL11;;
ESTRADIOL;nan;rs11849538;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;TCL1A;;;
ESTRADIOL;nan;rs11849538;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL17RA;;;
ESTRADIOL;nan;rs11849538;C;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL12RB2;;;
IVACAFTOR;CFTR;rs11971167;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
ESTRADIOL;nan;rs2369049;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;TCL1A;;;
IVACAFTOR;CFTR;rs121909019;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs121908753;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs77834169;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs397508442;T;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs121909047;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
GLYBURIDE;KCNJ11;rs5219;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;KCNJ11;;;
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;LADME-PK;DECREASED_EXPRESSION;nan;YEATS4;;;
IVACAFTOR;CFTR;rs121908752;G;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
VITAMIN E;CYP4F2;rs2108622;T;OTHER;DECREASED_ENZYME_ACTIVITY;nan;CYP4F2;;;
IVACAFTOR;CFTR;rs121909020;A;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs113993958;C;EFFICACY;ACTIVITY;PROTEIN;CFTR;;;
DISOPYRAMIDE;KCNH2;rs104894021;T;EFFICACY;DECREASED_INHIBITION;nan;KCNH2;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*10;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
QUINIDINE;KCNH2;rs104894021;T;EFFICACY;DECREASED_INHIBITION;nan;KCNH2;;;
CHLOROCRESOL;RYR1;rs193922803;T;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;RYR1;;
CYTARABINE;CDA;rs60369023;AA + AG;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CDA;;
GENTAMICIN;MT-RNR1;rs267606619;T;LADME-PD;DECREASED_ACTIVITY;nan;MT-RNR1;;;
QUINIDINE;KCNH2;rs104894021;C;EFFICACY;DECREASED_INHIBITION;nan;KCNH2;;;
BUPROPION;CYP2B6;CYP2B6*1;*1/*30;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
BUPROPION;CYP2B6;CYP2B6*30;*1/*30;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
GEMCITABINE;DCTD;rs35932500;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;DCTD;;
BUPROPION;POR;rs2868177;AG + GG;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2B6;;
GEMCITABINE;CDA;rs2072671;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CDA;;
ADALIMUMAB;TNF;rs1800629;AG;LADME-PK;DECREASED_STEADY-STATE-LEVEL;nan;TNF;;;
PAROMOMYCIN;MT-RNR1;rs267606617;G;LADME-PD;DECREASED_ACTIVITY;nan;MT-RNR1;;;
SIMVASTATIN;HLA-G;rs1063320;GG;OTHER;INCREASED_EXPRESSION;RECEPTOR;HLA-G;;;
ACETAMINOPHEN;CYP2E1;rs2515641;T;OTHER;INCREASED_EXPRESSION;RECEPTOR;CYP2E1;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*19;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*19;*19;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
BUPRENORPHINE;OPRM1;rs1799971;G;EFFICACY;DECREASED_ACTIVITY;nan;OPRM1;;;
TAMOXIFEN;UGT1A4;rs8330;CC;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;UGT1A4;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*19;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;INCREASED_METABOLISM;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*19;*19;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;INCREASED_METABOLISM;ENZYME;CYP2C19;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*28;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;INCREASED_METABOLISM;ENZYME;CYP2C19;;
CLOPIDOGREL;CYP2C19;CYP2C19*28;*28;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;INCREASED_METABOLISM;ENZYME;CYP2C19;;
GEMCITABINE;FKBP5;rs73748206;CT;OTHER;INCREASED_EXPRESSION;RECEPTOR;FKBP5;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*10;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*14;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*19;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*25;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*26;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*10;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*13;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*14;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*15;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*18;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*23;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*25;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*26;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*26;*26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
OMEPRAZOLE;CYP2C19;CYP2C19*26;*26;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
ACETAMINOPHEN;UGT1A;rs8330;CC;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;UGT1A;;;
ETHANOL;ADH1B;rs1229984;CT + TT;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;ADH1B;;;
ELEXACAFTOR;CFTR;rs113993960;del/del;OTHER;INCREASED_TRANSPORT;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs113993960;del/del;OTHER;INCREASED_TRANSPORT;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs113993960;del/del;OTHER;INCREASED_TRANSPORT;PROTEIN;CFTR;;;
ACETAMINOPHEN;UGT1A;rs10929303;CC;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;UGT1A;;;
XENOBIOTICS;AHR;rs2066853;A;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;CYP1A1;;;
OMEPRAZOLE;AHR;rs75519181;G;LADME-PK;DECREASED_EXPRESSION;nan;CYP1A1;;;
XENOBIOTICS;AHR;rs75519181;G;LADME-PK;DECREASED_EXPRESSION;nan;CYP1A1;;;
ACETAMINOPHEN;UGT1A;rs1042640;CC;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;UGT1A;;;
GEMCITABINE;FKBP5;rs73748206;CT;OTHER;INCREASED_EXPRESSION;RECEPTOR;NR3C1;;;
ESTRADIOL;nan;rs3802201;GG;OTHER;INCREASED_EXPRESSION;RECEPTOR;MIR2052;;;
ALDOSTERONE;SCNN1B;rs34241435;A;OTHER;INCREASED_TRANSCRIPTION;GENE;SCNN1B;;;
INSULIN RECOMBINANT;SCNN1B;rs34241435;A;OTHER;INCREASED_TRANSCRIPTION;GENE;SCNN1B;;;
ESTRADIOL;nan;rs4476990;CC;OTHER;INCREASED_EXPRESSION;RECEPTOR;MIR2052;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*9;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*9;*9;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*10;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
BERBERINE;CYP2D6;CYP2D6*1;*1/*1;LADME-PK;INCREASED_INHIBITION;nan;CYP2D6;;;
COPTISINE;CYP2D6;CYP2D6*1;*1/*1;LADME-PK;INCREASED_INHIBITION;nan;CYP2D6;;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1;*8 + *10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*8;*8 + *10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*10;*8 + *10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*23;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;INCREASED_METABOLISM;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*23;*23;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;INCREASED_METABOLISM;ENZYME;CYP2C19;;
BERBERINE;CYP2D6;CYP2D6*1;*1/*10;LADME-PK;INCREASED_INHIBITION;nan;CYP2D6;;;
BERBERINE;CYP2D6;CYP2D6*10;*1/*10;LADME-PK;INCREASED_INHIBITION;nan;CYP2D6;;;
COPTISINE;CYP2D6;CYP2D6*1;*1/*10;LADME-PK;INCREASED_INHIBITION;nan;CYP2D6;;;
COPTISINE;CYP2D6;CYP2D6*10;*1/*10;LADME-PK;INCREASED_INHIBITION;nan;CYP2D6;;;
DISOPYRAMIDE;KCNH2;rs104894021;C;EFFICACY;DECREASED_INHIBITION;nan;KCNH2;;;
IVACAFTOR;CFTR;rs74503330;A;OTHER;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
FLUOROURACIL;DPYD;rs372307932;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
MIDAZOLAM;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
DEXTROMETHORPHAN;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*10;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*16;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*16;*16;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*16;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*16;*16;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*18;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*18;*18;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOROURACIL;DPYD;rs376073289;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs374527058;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs538336580;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*9;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*9;*9;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*9;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*9;*9;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOROURACIL;DPYD;rs568367673;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs558354142;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
MEPHENYTOIN;CYP2C19;rs770829708;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs770829708;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOROURACIL;DPYD;rs374825099;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
ESTRONE SULFATE;SLCO2B1;rs199654337;T;LADME-PK;DECREASED_TRANSPORT;nan;SLCO2B1;;;
ROSUVASTATIN;SLCO2B1;rs199654337;T;LADME-PK;DECREASED_TRANSPORT;nan;SLCO2B1;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*9 + *10 + *16;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*9;*9 + *10 + *16;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*10;*9 + *10 + *16;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*16;*9 + *10 + *16;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*9 + *10 + *16;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*9;*9 + *10 + *16;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*10;*9 + *10 + *16;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*16;*9 + *10 + *16;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_CLEARANCE;ENZYME;CYPENZYME;CYP2C19;;
ESTRONE SULFATE;SLCO2B1;rs1009122956;C;LADME-PK;DECREASED_TRANSPORT;nan;SLCO2B1;;;
ROSUVASTATIN;SLCO2B1;rs1009122956;C;LADME-PK;DECREASED_TRANSPORT;nan;SLCO2B1;;;
ESTRONE SULFATE;SLCO2B1;rs1621378;T;LADME-PK;DECREASED_TRANSPORT;nan;SLCO2B1;;;
ROSUVASTATIN;SLCO2B1;rs1621378;T;LADME-PK;DECREASED_TRANSPORT;nan;SLCO2B1;;;
ESTRONE SULFATE;SLCO2B1;rs2306168;T;LADME-PK;DECREASED_TRANSPORT;nan;SLCO2B1;;;
FLUOROURACIL;DPYD;rs548783838;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;CYP2B6;CYP2B6*1;*1/*1;EFFICACY;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2B6;;
nan;CYP2B6;CYP2B6*6;*1/*1;EFFICACY;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2B6;;
BUPROPION;CYP2B6;CYP2B6*1;*1/*1;EFFICACY;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2B6;;
BUPROPION;CYP2B6;CYP2B6*6;*1/*1;EFFICACY;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2B6;;
FLUOROURACIL;DPYD;rs140989814;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*13;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*13;*13;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
BLONANSERIN;CYP3A4;CYP3A4*1;*29;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP3A4;;
BLONANSERIN;CYP3A4;CYP3A4*29;*29;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP3A4;;
TESTOSTERONE;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
ACALABRUTINIB;CYP3A4;CYP3A4*1;*2 + *3 + *11 + *29 + *33;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CYP3A4;;;
ACALABRUTINIB;CYP3A4;CYP3A4*2;*2 + *3 + *11 + *29 + *33;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CYP3A4;;;
ACALABRUTINIB;CYP3A4;CYP3A4*3;*2 + *3 + *11 + *29 + *33;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CYP3A4;;;
ACALABRUTINIB;CYP3A4;CYP3A4*11;*2 + *3 + *11 + *29 + *33;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CYP3A4;;;
ACALABRUTINIB;CYP3A4;CYP3A4*29;*2 + *3 + *11 + *29 + *33;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CYP3A4;;;
ACALABRUTINIB;CYP3A4;CYP3A4*33;*2 + *3 + *11 + *29 + *33;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CYP3A4;;;
ACALABRUTINIB;CYP3A4;CYP3A4*1;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
ACALABRUTINIB;CYP3A4;CYP3A4*9;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
ACALABRUTINIB;CYP3A4;CYP3A4*14;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
ACALABRUTINIB;CYP3A4;CYP3A4*16;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
ACALABRUTINIB;CYP3A4;CYP3A4*19;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
ACALABRUTINIB;CYP3A4;CYP3A4*23;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
ACALABRUTINIB;CYP3A4;CYP3A4*24;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
ACALABRUTINIB;CYP3A4;CYP3A4*28;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
ACALABRUTINIB;CYP3A4;CYP3A4*32;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
VANDETANIB;CYP3A4;CYP3A4*1;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESSCYP3A4;
VANDETANIB;CYP3A4;CYP3A4*2;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESSCYP3A4;
VANDETANIB;CYP3A4;CYP3A4*3;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESSCYP3A4;
VANDETANIB;CYP3A4;CYP3A4*9;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESSCYP3A4;
VANDETANIB;CYP3A4;CYP3A4*15;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESSCYP3A4;
VANDETANIB;CYP3A4;CYP3A4*16;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESSCYP3A4;
VANDETANIB;CYP3A4;CYP3A4*29;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESSCYP3A4;
VANDETANIB;CYP3A4;CYP3A4*32;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESSCYP3A4;
VANDETANIB;CYP3A4;CYP3A4*33;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESSCYP3A4;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*10;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*10;*10;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOROURACIL;DPYD;rs1801266;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
DEXTROMETHORPHAN;SEPTIN3;rs1062753;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;CYP2D6;;;
DEXTROMETHORPHAN;WBP2NL;rs1062753;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;CYP2D6;;;
BUMETANIDE;SLC17A3;rs34376145;A;LADME-PK;DECREASED_TRANSPORT;nan;SLC17A3;;;
BUMETANIDE;SLC17A3;rs34902660;A;LADME-PK;DECREASED_TRANSPORT;nan;SLC17A3;;;
BUMETANIDE;SLC17A3;rs11966370;A;LADME-PK;DECREASED_TRANSPORT;nan;SLC17A3;;;
BUMETANIDE;SLC17A3;rs56027330;T;LADME-PK;DECREASED_TRANSPORT;nan;SLC17A3;;;
OMEPRAZOLE;CYP2C19;rs148247410;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOROURACIL;DPYD;rs528152707;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs570122671;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs201268750;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs527580106;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs55886062;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
MEPHENYTOIN;CYP2C19;rs550527959;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs550527959;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOROURACIL;DPYD;rs538703919;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
IBUPROFEN;CYP3A4;CYP3A4*1;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*5;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*18;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*23;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*28;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*29;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*31;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*32;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*33;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
IBUPROFEN;CYP3A4;CYP3A4*34;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;nan;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*1;*20;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*20;*20;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
MEPHENYTOIN;CYP2C19;rs763625282;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs763625282;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
BLONANSERIN;CYP3A4;CYP3A4*1;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*5;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*7;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*8;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*9;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*10;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*12;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*13;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*14;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*16;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*17;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*18;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*23;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*24;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*28;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*31;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*33;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
BLONANSERIN;CYP3A4;CYP3A4*34;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
REGORAFENIB;CYP3A4;CYP3A4*1;*20;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
REGORAFENIB;CYP3A4;CYP3A4*20;*20;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
FLUOROURACIL;DPYD;rs72549307;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
OMEPRAZOLE;CYP2C19;rs1431015009;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
BUFURALOL;CYP2D6;rs1058171;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6;;;
DICLOFENAC;CYP2C9;CYP2C9*72;*72;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
LOSARTAN;CYP2C9;CYP2C9*72;*72;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
TOLBUTAMIDE;CYP2C9;CYP2C9*72;*72;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
SUMATRIPTAN;HTR1B;rs130060;C;LADME-PD;INCREASED_PLASMATIC-CONCENTRATION;nan;AMPc;;;
BUFURALOL;CYP2D6;rs1230912765;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6;;;
PURINE ANALOGUES;PACSIN2;rs2413739;C;OTHER, LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;TPMT;;
L-PHENYLALANINE;PAH;rs76394784;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH;;;
CARBOCISTEINE;PAH;rs62516101;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH;;;
CARBOCISTEINE;PAH;rs75193786;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH;;;
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
LOSARTAN;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
TOLBUTAMIDE;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
LOSARTAN;CYP2C9;CYP2C9*75;*75;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
L-PHENYLALANINE;PAH;rs62516101;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH;;;
CARBOCISTEINE;PAH;rs5030860;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH;;;
L-PHENYLALANINE;PAH;rs5030849;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH;;;
CARBOCISTEINE;PAH;rs76394784;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH;;;
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
WARFARIN;CYP2C9;CYP2C9*60;*60;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
DICLOFENAC;CYP2C9;CYP2C9*37;*37;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*46;*46;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
CARBOCISTEINE;PAH;rs5030849;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH;;;
L-PHENYLALANINE;PAH;rs5030860;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;PAH;;;
DICLOFENAC;CYP2C9;CYP2C9*54;*54;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;INCREASED_METABOLISM;ENZYME;CYP2C9;;
DICLOFENAC;CYP2C9;CYP2C9*74;*74;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
LOSARTAN;CYP2C9;CYP2C9*74;*74;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
TOLBUTAMIDE;CYP2C9;CYP2C9*74;*74;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
TOLBUTAMIDE;CYP2C9;rs9332239;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
BUFURALOL;CYP2D6;CYP2D6*1;*49 + *55;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*49;*49 + *55;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*55;*49 + *55;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
TOLTERODINE;CYP2D6;CYP2D6*92;*92 + *96;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6;;;
TOLTERODINE;CYP2D6;CYP2D6*96;*92 + *96;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6;;;
GEFITINIB;CYP2D6;CYP2D6*92;*92 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
GEFITINIB;CYP2D6;CYP2D6*96;*92 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*10;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*18;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*36;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*47;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*49;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*50;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*51;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*54;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*55;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*114;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*1;*18;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*18;*18;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
HYDRALAZINE;NAT2;NAT2*4;*4/*5 + *4/*6;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;NAT2;;
HYDRALAZINE;NAT2;NAT2*5;*4/*5 + *4/*6;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;NAT2;;
HYDRALAZINE;NAT2;NAT2*6;*4/*5 + *4/*6;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;NAT2;;
HYDRALAZINE;NAT2;NAT2*7;*4/*5 + *4/*6;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;NAT2;;
HYDRALAZINE;NAT2;NAT2*4;*4/*4;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;NAT2;;
HYDRALAZINE;NAT2;NAT2*5;*4/*4;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;NAT2;;
HYDRALAZINE;NAT2;NAT2*6;*4/*4;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;NAT2;;
BUFURALOL;CYP2D6;CYP2D6*1;*36;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*36;*36;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DICLOFENAC;CYP2C9;CYP2C9*73;*73;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
LOSARTAN;CYP2C9;CYP2C9*73;*73;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
BUFURALOL;CYP2D6;CYP2D6*1;*36;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*36;*36;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
FLUOXETINE;CYP2D6;CYP2D6*2;*10 + *92 + *93 + *96 + *87 + *2;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
FLUOXETINE;CYP2D6;CYP2D6*10;*10 + *92 + *93 + *96 + *87 + *2;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
FLUOXETINE;CYP2D6;CYP2D6*87;*10 + *92 + *93 + *96 + *87 + *2;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
FLUOXETINE;CYP2D6;CYP2D6*92;*10 + *92 + *93 + *96 + *87 + *2;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
FLUOXETINE;CYP2D6;CYP2D6*93;*10 + *92 + *93 + *96 + *87 + *2;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
FLUOXETINE;CYP2D6;CYP2D6*96;*10 + *92 + *93 + *96 + *87 + *2;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*1;*2 + *10 + *89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*2;*2 + *10 + *89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*10;*2 + *10 + *89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*89;*2 + *10 + *89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*92;*2 + *10 + *89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*93;*2 + *10 + *89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*96;*2 + *10 + *89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
TOLBUTAMIDE;CYP2C9;CYP2C9*60;*60;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
TOLBUTAMIDE;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
DICLOFENAC;CYP2C9;CYP2C9*60;*60;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
WARFARIN;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
BUFURALOL;CYP2D6;CYP2D6*1;*50;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*50;*50;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DICLOFENAC;CYP2C9;CYP2C9*44;*44;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*42;*42;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*40;*40;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;INCREASED_METABOLISM;ENZYME;CYP2C9;;
MEPHENYTOIN;CYP2C19;rs200346442;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs200346442;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;rs200150287;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs200150287;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;rs150152656;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs150152656;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
BUPROPION;POR;rs2868177;AA;OTHER, LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
BUPROPION;POR;rs2868177;GG;OTHER, LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2B6;;
BUFURALOL;CYP2D6;CYP2D6*1;*51;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*51;*51;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*32;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*32;*32;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*29;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*30;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*31;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*33;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*29;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*30;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*31;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*33;*29 + *30 + *31 + *33;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
nan;POR;rs2868177;AA;OTHER, LADME-PK;DECREASED_ACTIVITY;nan;CYP2B6;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
CLOPIDOGREL;CYP2C19;CYP2C19*10;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
OMEPRAZOLE;CYP2C19;rs140278421;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs1361528097;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*3;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*3;*3;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*3;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*3;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOROURACIL;DPYD;rs536577604;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
DEBRISOQUINE;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEBRISOQUINE;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
MEPHENYTOIN;CYP2C19;rs1267723490;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs1267723490;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
BUFURALOL;CYP2D6;CYP2D6*1;*54;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*54;*54;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*1;*29;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*29;*29;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEBRISOQUINE;CYP2D6;CYP2D6*1;*29;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEBRISOQUINE;CYP2D6;CYP2D6*29;*29;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*1;*47;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*47;*47;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
MEPHENYTOIN;CYP2C19;rs764137538;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs764137538;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
IBUPROFEN;CYP2C19;CYP2C19*1;*3 + *35;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
IBUPROFEN;CYP2C19;CYP2C19*3;*3 + *35;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
IBUPROFEN;CYP2C19;CYP2C19*35;*3 + *35;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
IBUPROFEN;CYP2C19;CYP2C19*1;*33 + *30 + *31 + *32;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
IBUPROFEN;CYP2C19;CYP2C19*30;*33 + *30 + *31 + *32;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
IBUPROFEN;CYP2C19;CYP2C19*31;*33 + *30 + *31 + *32;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
IBUPROFEN;CYP2C19;CYP2C19*32;*33 + *30 + *31 + *32;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
IBUPROFEN;CYP2C19;CYP2C19*33;*33 + *30 + *31 + *32;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C19;
DEXTROMETHORPHAN;PHETA2;rs1807493;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;CYP2D6;;;
DEXTROMETHORPHAN;SMDT1;rs1807493;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;CYP2D6;;;
BUFURALOL;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
DICLOFENAC;CYP2C9;CYP2C9*52;*52;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*43;*43;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*45;*45;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*36;*36;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*55;*55;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*39;*39;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*50;*50;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*47;*47;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*53;*53;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*38;*38;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
DICLOFENAC;CYP2C9;CYP2C9*48;*48;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ENZYME;CYP2C9;
MEPHENYTOIN;CYP2C19;rs1463550071;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs1463550071;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;rs1349931378;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs1349931378;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
DEBRISOQUINE;CYP2D6;CYP2D6*1;*75;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEBRISOQUINE;CYP2D6;CYP2D6*75;*75;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
OMEPRAZOLE;CYP2C19;rs1393133490;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs1466428833;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;rs749678783;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;rs749678783;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
IBRUTINIB;CYP3A4;CYP3A4*1;*17 + *24;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
IBRUTINIB;CYP3A4;CYP3A4*17;*17 + *24;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
IBRUTINIB;CYP3A4;CYP3A4*24;*17 + *24;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
EFAVIRENZ;CYP2B6;rs58871670;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
FLUOROURACIL;DPYD;rs72547601;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
BUPROPION;CYP2B6;rs201500445;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *1/*3B;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *1/*3B;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3B;*1/*3A + *1/*3B;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
FLUOROURACIL;DPYD;rs188052243;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
DAUNORUBICIN;AKR7A2;rs1043657;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;AKR7A2;;
DOXORUBICIN;AKR7A2;rs1043657;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;AKR7A2;;
DAUNORUBICIN;AKR1C4;rs17134592;G;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;AKR1C4;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*1;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*1;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*1;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;TPMT;;;
MERCAPTOPURINE;TPMT;rs3931660;AT;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;rs1142345;CT;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
DAUNORUBICIN;AKR1C3;rs4987102;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;AKR1C3;;
DAUNORUBICIN;AKR1C3;rs35575889;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;AKR1C3;;
DOXORUBICIN;AKR1C3;rs35575889;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;AKR1C3;;
DAUNORUBICIN;AKR1C3;rs34186955;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;AKR1C3;;
DOXORUBICIN;AKR1C3;rs34186955;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;AKR1C3;;
nan;TPMT;TPMT*1;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME-PK;DECREASED_EXPRESSION;nan;TPMT;;;
nan;TPMT;TPMT*2;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME-PK;DECREASED_EXPRESSION;nan;TPMT;;;
nan;TPMT;TPMT*3A;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME-PK;DECREASED_EXPRESSION;nan;TPMT;;;
nan;TPMT;TPMT*5;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME-PK;DECREASED_EXPRESSION;nan;TPMT;;;
nan;TPMT;TPMT*12;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME-PK;DECREASED_EXPRESSION;nan;TPMT;;;
nan;TPMT;TPMT*14;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME-PK;DECREASED_EXPRESSION;nan;TPMT;;;
nan;TPMT;TPMT*18;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME-PK;DECREASED_EXPRESSION;nan;TPMT;;;
nan;TPMT;TPMT*22;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME-PK;DECREASED_EXPRESSION;nan;TPMT;;;
FLUOROURACIL;DPYD;rs72549306;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
SN-38;UGT1A1;UGT1A1*1;*1/*28 + *28/*28 + *1/*37;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
SN-38;UGT1A1;UGT1A1*28;*1/*28 + *28/*28 + *1/*37;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
SN-38;UGT1A1;UGT1A1*37;*1/*28 + *28/*28 + *1/*37;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
SN-38;UGT1A1;rs4148323;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
FLUOROURACIL;DPYD;rs137999090;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs145773863;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs200858900;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ABCC4;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
FLUOROURACIL;DPYD;rs59086055;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
MERCAPTOPURINE;TPMT;TPMT*1;*3B/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3B;*3B/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3C;*3B/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
PURINE ANALOGUES;TPMT;rs1142345;CT;OTHER, LADME-PK;DECREASED_ACTIVITY;nan;TPMT;;;
ELEXACAFTOR;CFTR;rs1792306355;T;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs1792306355;T;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
ELEXACAFTOR;CFTR;rs186089140;CT;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs186089140;CT;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs186089140;CT;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
ELEXACAFTOR;CFTR;rs35516286;A;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs35516286;A;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs35516286;A;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
IVACAFTOR;CFTR;rs35516286;A;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs35516286;A;LADME-PD;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
CLOPIDOGREL;CES1;rs143718310;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ENALAPRIL;CES1;rs143718310;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SACUBITRIL;CES1;rs143718310;G;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ENALAPRIL;CES1;rs202121317;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;;;
REMIMAZOLAM;CES1;rs2307240;T;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CES1;;;
CLOPIDOGREL;CES1;rs202001817;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;;;
REMIMAZOLAM;CES1;rs71647871;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CES1;;
REMIMAZOLAM;CES1;rs151291296;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CES1;;
CLOPIDOGREL;CES1;rs151291296;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;;;
ENALAPRIL;CES1;rs151291296;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;;;
SACUBITRIL;CES1;rs151291296;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;;;
CLOPIDOGREL;CES1;rs146456965;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ENALAPRIL;CES1;rs146456965;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SACUBITRIL;CES1;rs146456965;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
REMIMAZOLAM;CES1;rs143718310;G;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CES1;;
CLOPIDOGREL;CES1;rs200707504;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;;;
ENALAPRIL;CES1;rs200707504;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;;;
SACUBITRIL;CES1;rs200707504;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;;;
ENALAPRIL;CES1;rs2307243;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;;;
REMIMAZOLAM;CES1;rs200707504;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CES1;;
BUPROPION;CYP2B6;rs58871670;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
FLUOROURACIL;DPYD;rs755692084;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
MERCAPTOPURINE;TPMT;TPMT*1;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*2;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3A;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3B;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3C;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*5;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*6;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*8;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*10;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*11;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*12;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*13;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*1;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*2;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*3A;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*3B;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*3C;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*5;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*6;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*7;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*9;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*10;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*12;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*14;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*17;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*18;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*19;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*20;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*21;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*22;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*23;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
THIOGUANINE;TPMT;TPMT*30;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *1/*3B + *1/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *1/*3B + *1/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3B;*1/*3A + *1/*3B + *1/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A + *1/*3B + *1/*3C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
ELEXACAFTOR;CFTR;rs758900656;T;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs758900656;T;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568681;T;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;ABCC4;;;
FLUOROURACIL;DPYD;rs183385770;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
ESLICARBAZEPINE ACETATE;AADAC;rs35084477;A;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;AADAC;;;
ESLICARBAZEPINE ACETATE;AADAC;rs1803155;A;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;AADAC;;;
ESLICARBAZEPINE ACETATE;AADAC;rs61733692;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;AADAC;;
FLUOROURACIL;DPYD;rs114096998;T;LADME-PK;INCREASED_ACTIVITY;PROTEIN;DPYD;;;
FLUOROURACIL;DPYD;rs60139309;C;LADME-PK;INCREASED_ACTIVITY;PROTEIN;DPYD;;;
FLUOROURACIL;DPYD;rs143986398;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
SN-38;UGT1A9;rs11692021;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
SN-38;UGT1A9;rs72551344;G;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
SN-38;UGT1A9;rs34993780;G;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
FLUOROURACIL;DPYD;rs72549308;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs1184321568;del;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
FLUOROURACIL;DPYD;rs143879757;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
FLUOROURACIL;DPYD;rs59086055;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
FLUOROURACIL;DPYD;rs148994843;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
DEXTROMETHORPHAN;nan;rs729559;GG;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;CYP2D6;;;
FLUOROURACIL;DPYD;rs748620513;G;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
DEXTROMETHORPHAN;nan;rs4073010;TT;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;CYP2D6;;;
FLUOROURACIL;DPYD;rs72549304;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs200687447;T;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;DPYD;;
ESLICARBAZEPINE ACETATE;AADAC;rs144650170;G;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;AADAC;;;
FLUOROURACIL;DPYD;rs146356975;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
ESLICARBAZEPINE ACETATE;AADAC;rs140197497;G;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;AADAC;;;
FLUOROURACIL;DPYD;rs2297595;C;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;DPYD;;
FLUOROURACIL;DPYD;rs183105782;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs190577302;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568644;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;ABCC4;;
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs142211148;T;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;ABCC4;;;
FLUOROURACIL;DPYD;rs186169810;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs143154602;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs368146607;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs371258350;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs575853463;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs569661196;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs138616379;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
AMISULPRIDE;ABCB1;rs2229109;T;LADME-PK;DECREASED_TRANSPORT;nan;ABCB1;;;
ARIPIPRAZOLE;ABCB1;rs2229109;T;LADME-PK;DECREASED_TRANSPORT;nan;ABCB1;;;
OLANZAPINE;ABCB1;rs2229109;T;LADME-PK;DECREASED_TRANSPORT;nan;ABCB1;;;
RISPERIDONE;ABCB1;rs2229109;T;LADME-PK;DECREASED_TRANSPORT;nan;ABCB1;;;
FLUOROURACIL;DPYD;rs115232898;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
CLOZAPINE;UGT1A4;rs2011425;G;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;UGT1A4;;;
FLUOROURACIL;DPYD;rs111858276;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
ACETAMINOPHEN;UGT1A6;UGT1A6*1a;*2a;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;UGT1A6;;
ACETAMINOPHEN;UGT1A6;UGT1A6*2a;*2a;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;UGT1A6;;
FLUOROURACIL;DPYD;rs140039091;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs187713395;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
SN-38;UGT1A9;rs35350960;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
ESLICARBAZEPINE ACETATE;AADAC;rs186388618;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;AADAC;;
ELEXACAFTOR;CFTR;rs397508139;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs397508139;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
FLUOROURACIL;MIR27A;rs895819;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;DPYD;;
ELEXACAFTOR;CFTR;rs397508609;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs397508609;A;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
FLUOROURACIL;DPYD;rs141044036;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
ARACHIDONIC ACID;CYP4F2;rs753169154;G;LADME-PD;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP4F2;;
EFAVIRENZ;CYP2B6;rs201500445;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
BUPROPION;CYP2B6;rs535039125;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs117872433;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
BUPROPION;CYP2B6;rs200238771;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
ARACHIDONIC ACID;CYP4F2;rs114396708;A;LADME-PD;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP4F2;;
COUMARIN;CYP2A6;CYP2A6*1;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
COUMARIN;CYP2A6;CYP2A6*7;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
COUMARIN;CYP2A6;CYP2A6*19;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
NICOTINE;CYP2A6;CYP2A6*1;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
NICOTINE;CYP2A6;CYP2A6*7;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
NICOTINE;CYP2A6;CYP2A6*19;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
TEGAFUR;CYP2A6;CYP2A6*1;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
TEGAFUR;CYP2A6;CYP2A6*7;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
TEGAFUR;CYP2A6;CYP2A6*19;*7 + *19;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
BUPROPION;CYP2B6;CYP2B6*47;*47;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
NICOTINE;CYP2A6;rs4803381;CC + CT;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2A6;;
EFAVIRENZ;CYP2B6;CYP2B6*47;*47;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
NICOTINE;CYP2A6;rs57837628;AG + GG;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2A6;;
COUMARIN;CYP2A6;CYP2A6*1;*18;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
COUMARIN;CYP2A6;CYP2A6*18;*18;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
TEGAFUR;CYP2A6;CYP2A6*1;*18;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
TEGAFUR;CYP2A6;CYP2A6*18;*18;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
FLUOROURACIL;DPYD;rs67376798;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
EFAVIRENZ;CYP2B6;CYP2B6*46;*46;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
NICOTINE;CYP2A6;rs72549435;C;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
EFAVIRENZ;CYP2B6;rs535039125;T;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
PREGNENOLONE;SULT2B1;rs746398875;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;SULT2B1;;
PREGNENOLONE;SULT2B1;rs762765702;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;SULT2B1;;
COUMARIN;CYP2A6;CYP2A6*4;*4/*9;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
COUMARIN;CYP2A6;CYP2A6*9;*4/*9;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
BUPROPION;CYP2B6;rs374099483;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
BUPROPION;CYP2B6;rs764288403;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
BUPROPION;CYP2B6;CYP2B6*46;*46;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs374099483;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
BUPROPION;CYP2B6;rs117872433;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
FLUOROURACIL;DPYD;rs112766203;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs1801158;TT;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;DPYD;;
FLUOROURACIL;DPYD;rs188052243;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
PREGNENOLONE;SULT2B1;rs527454384;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;SULT2B1;;
FLUOROURACIL;DPYD;rs61757362;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
ARACHIDONIC ACID;CYP4F2;rs2108622;T;LADME-PD;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP4F2;;
NICOTINE;CYP2A6;CYP2A6*1;*17 + *35;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
NICOTINE;CYP2A6;CYP2A6*17;*17 + *35;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
NICOTINE;CYP2A6;CYP2A6*35;*17 + *35;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2A6;;
BUPROPION;CYP2B6;rs148009906;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
ELEXACAFTOR;CFTR;rs397508293;T;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
TEZACAFTOR;CFTR;rs397508293;T;EFFICACY;INCREASED_ACTIVITY;PROTEIN;CFTR;;;
FLUOROURACIL;DPYD;rs1801268;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
BUPROPION;CYP2B6;rs200458614;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs764288403;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs200238771;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
FLUOROURACIL;DPYD;rs367619008;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
EFAVIRENZ;CYP2B6;rs200458614;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
NICOTINE;CYP2A6;rs56113850;CC + CT;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2A6;;
FLUOROURACIL;DPYD;rs758649719;T;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
NICOTINE;CYP2A6;rs7259706;TT;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2A6;;
FLUOROURACIL;DPYD;rs369103276;G;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
VANDETANIB;CYP3A4;CYP3A4*1;*6 + *30;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
VANDETANIB;CYP3A4;CYP3A4*6;*6 + *30;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
VANDETANIB;CYP3A4;CYP3A4*30;*6 + *30;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP3A4;;
NICOTINE;CYP2A6;rs28399453;AA + AG;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2A6;;
NICOTINE;CYP2A6;rs8192733;CC + CG;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2A6;;
EFAVIRENZ;CYP2B6;rs148009906;A;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2B6;;
PREGNENOLONE;SULT2B1;rs777924668;G;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;SULT2B1;;
FLUOROURACIL;DPYD;rs55674432;A;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs55886062;CC;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
LETROZOLE;CYP2A6;CYP2A6*1;*1/*4 + *1/*7 + *4/*4 + *4/*9;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
LETROZOLE;CYP2A6;CYP2A6*4;*1/*4 + *1/*7 + *4/*4 + *4/*9;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
LETROZOLE;CYP2A6;CYP2A6*7;*1/*4 + *1/*7 + *4/*4 + *4/*9;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
LETROZOLE;CYP2A6;CYP2A6*9;*1/*4 + *1/*7 + *4/*4 + *4/*9;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
NICOTINE;CYP2A6;rs7260629;GG;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CYP2A6;;
FLUOROURACIL;DPYD;rs1801265;GG;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;DPYD;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*89;*89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*92;*89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*93;*89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*96;*89 + *92 + *93 + *96;LADME-PK;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;CYP2D6;;
PREGNENOLONE;SULT2B1;rs777140014;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;SULT2B1;;
TESTOSTERONE;CYP3A5;rs55817950;A;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP3A5;;
NIFEDIPINE;CYP3A5;rs72552791;C;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP3A5;;
PREGNENOLONE;SULT2B1;rs774212320;T;LADME-PK;DECREASED_ENZYME_ACTIVITY;DRUG_ACCUMULATION;ENZYME;SULT2B1;;
nan;CYP2C9;rs762081829;T;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:CYP2C9protein;;
nan;CYP2C9;rs762081829;T;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP2C9protein;;
nan;SLCO1B1;SLCO1B1*1;*14;OTHER;INCREASED_EXPRESSION;RECEPTOR;SLCO1B1protein;;;
nan;SLCO1B1;SLCO1B1*14;*14;OTHER;INCREASED_EXPRESSION;RECEPTOR;SLCO1B1protein;;;
nan;VDR;rs11568820;T;OTHER;INCREASED_STEADY-STATE-LEVEL;nan;CYP3A4protein;;;
nan;A2M;rs669;T;LADME-PK;INCREASED_STEADY-STATE-LEVEL;nan;A2Mprotein;;;
nan;SLCO1B1;SLCO1B1*1;*37;OTHER;INCREASED_EXPRESSION;RECEPTOR;SLCO1B1protein;;;
nan;SLCO1B1;SLCO1B1*37;*37;OTHER;INCREASED_EXPRESSION;RECEPTOR;SLCO1B1protein;;;
nan;NAMPT;rs1319501;CC + CT;OTHER;DECREASED_STEADY-STATE-LEVEL;nan;NAMPcTprotein;;;
nan;DPYD;rs1801160;T;OTHER;INCREASED_EXPRESSION;INCREASED_ACTIVITY;RECEPTOR;DPYDprotein;;
nan;NAMPT;rs3801266;CC + CT;OTHER;INCREASED_STEADY-STATE-LEVEL;nan;NAMPcTprotein;;;
nan;SLCO1B1;SLCO1B1*1;*20;OTHER;INCREASED_EXPRESSION;RECEPTOR;SLCO1B1protein;;;
nan;SLCO1B1;SLCO1B1*20;*20;OTHER;INCREASED_EXPRESSION;RECEPTOR;SLCO1B1protein;;;
nan;ABCC11;rs17822471;AA + AG;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ABCC11protein;;
nan;ABCC11;rs17822471;AA + AG;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ABCC11protein;;
nan;CYP2C9;rs771237265;C;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:CYP2C9protein;;
nan;CYP2C9;rs771237265;C;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP2C9protein;;
nan;CYP2C9;rs761895497;C;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:CYP2C9protein;;
nan;CYP2C9;rs761895497;C;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP2C9protein;;
nan;CYP2C19;rs183701923;T;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:CYP2C19protein;;
nan;CYP2C19;rs183701923;T;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP2C19protein;;
nan;DPYD;rs748620513;G;OTHER;INCREASED_EXPRESSION;INCREASED_ACTIVITY;RECEPTOR;DPYDprotein;;
nan;CYP2C19;rs61311738;T;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:CYP2C19protein;;
nan;CYP2C19;rs61311738;T;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP2C19protein;;
nan;DPYD;rs143879757;A;OTHER;INCREASED_EXPRESSION;INCREASED_ACTIVITY;RECEPTOR;DPYDprotein;;
nan;DPYD;rs1212037891;T;OTHER;INCREASED_EXPRESSION;INCREASED_ACTIVITY;RECEPTOR;DPYDprotein;;
nan;DPYD;rs72549306;A;OTHER;INCREASED_EXPRESSION;INCREASED_ACTIVITY;RECEPTOR;DPYDprotein;;
nan;CYP2C19;rs140278421;A;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:CYP2C19protein;;
nan;CYP2C19;rs140278421;A;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP2C19protein;;
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CBR1;;;
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;CBR1;;;
nan;ADRB2;rs1042713;G;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;ADRB2;;
nan;IL18;rs5744247;CC + CG;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL18mRNA;;;
nan;IL18;rs1946518;GG + GT;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL18mRNA;;;
nan;CYP3A5;rs776746;CC;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CYP3A5mRNA;;
nan;CYP3A5;rs776746;CC;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CYP3A5mRNA;;
nan;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;nan;HDAC2mRNA;;;
nan;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;nan;HDAC2mRNA;;;
nan;CYP3A5;rs776746;TT;OTHER;INCREASED_EXPRESSION;RECEPTOR;CYP3A5mRNA;;;
nan;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;nan;FKBP5mRNA;;;
nan;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;nan;FKBP5mRNA;;;
nan;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;nan;NR3C1mRNA;;;
nan;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;nan;NR3C1mRNA;;;
nan;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;nan;GLCCI1mRNA;;;
nan;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PD;DECREASED_EXPRESSION;nan;GLCCI1mRNA;;;
nan;ERCC1;rs2298881;A;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ERCC1mRNA;;
nan;ERCC1;rs2298881;A;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ERCC1mRNA;;
nan;HSPA5;rs430397;TT;OTHER;INCREASED_EXPRESSION;RECEPTOR;HSPA5mRNA;;;
nan;CCND1;rs9344;AA + AG;OTHER;INCREASED_TRANSCRIPTION;GENE;CCND1mRNA;;;
nan;ABCC2;rs113646094;CG;OTHER;INCREASED_EXPRESSION;RECEPTOR;ABCC2mRNA;;;
nan;XRCC4;rs2075685;T;OTHER;INCREASED_EXPRESSION;RECEPTOR;XRCC4mRNA;;;
nan;XRCC4;rs10040363;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;ERCC1mRNA;;;
nan;GCLC;rs761142;CC;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;GCLCmRNA;;
nan;GCLC;rs761142;CC;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;GCLCmRNA;;
nan;BCL2L11;rs724710;T;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;BCL2L11mRNA;;
nan;BCL2L11;rs724710;T;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;BCL2L11mRNA;;
nan;EPO;rs1617640;AA;OTHER;INCREASED_EXPRESSION;RECEPTOR;EPOmRNA;;;
nan;KDR;rs34231037;G;OTHER;DECREASED_STEADY-STATE-LEVEL;nan;KDR;;;
METHOTREXATE;GGH;rs11545078;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;DPYD;rs1801265;G;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;DPYD;;
nan;DPYD;rs114096998;T;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
nan;DPYD;rs55886062;AC;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;MGMT;rs4751104;G;LADME-PK;INCREASED_TRANSCRIPTION;GENE;MGMT;;;
CISPLATIN;ERCC2;rs13181;GG;TOXICITY;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
nan;GSTT1;rs1007888;T;LADME-PK;INCREASED_TRANSCRIPTION;GENE;GSTT1;;;
nan;KCNQ3;rs7818112;AA;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
CISPLATIN;GSTP1;rs1695;AG;TOXICITY;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
BUSULFAN;GSTM1;rs3754446;C;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
nan;DPYD;rs780025995;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
nan;F12;rs1801020;G;LADME-PK;INCREASED_ENZYME_ACTIVITY;nan;F12;;;
nan;IL7;rs16906115;AA + AG;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL7;;;
nan;DPYD;rs56038477;CT + TT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;DPYD;rs2297595;C;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;DPYD;rs1801160;CT + TT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;DPYD;rs2297595;CC + CT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;HPR;rs2000999;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;HP;;;
FLUOROURACIL;DPYD;rs4294451;A;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;DPYD;rs115232898;CT;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;DPYD;rs4294451;T;OTHER;INCREASED_EXPRESSION;RECEPTOR;DPYD;;;
TAMOXIFEN;E2F7;rs310786;CC;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;ECHDC1;rs6569487;AA;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
nan;HLA-G;rs1063320;C;OTHER;INCREASED_EXPRESSION;RECEPTOR;HLA-G;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;IFNL3;rs4803217;C;OTHER;INCREASED_EXPRESSION;RECEPTOR;IFNL3;;;
nan;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
CISPLATIN;ERCC1;rs11615;GG;TOXICITY;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
nan;DPYD;rs748639205;G;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
nan;DPYD;rs75017182;CG;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
FLUOROURACIL;DPYD;rs3918290;CT;OTHER;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;IFNL4;rs11322783;TT/TT;OTHER;INCREASED_EXPRESSION;RECEPTOR;IFNAR1;;;
nan;DPYD;rs75017182;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;IMPDH2;rs121434586;A;OTHER;DECREASED_ENZYME_ACTIVITY;nan;IMPDH2;;;
nan;DPYD;rs67376798;A;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
CALCIUM;RYR1;rs118192167;AG;OTHER;INCREASED_STEADY-STATE-LEVEL;nan;nan;;;
nan;MIR6076;rs1463411;G;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;P2RY12;;
nan;MIR6076;rs1463411;G;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;P2RY12;;
DESMETHYLNAPROXEN;SULT1A1;rs28374453;G;LADME-PK;DECREASED_SULFATION;INCREASED_METABOLISM;nan;;;
ACETAMINOPHEN;SULT1A1;rs28374453;G;LADME-PK;DECREASED_SULFATION;INCREASED_METABOLISM;nan;;;
DESMETHYLNAPROXEN;SULT1A1;rs1042008;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
ACETAMINOPHEN;SULT1A1;rs1042008;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
DESMETHYLNAPROXEN;SULT1A1;rs758145522;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
DESMETHYLNAPROXEN;SULT1A1;rs767487725;C;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
ACETAMINOPHEN;SULT1A1;rs72547527;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
TAPENTADOL;SULT1A1;rs1042008;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
ACETAMINOPHEN;SULT1A1;rs767487725;C;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
DESMETHYLNAPROXEN;SULT1A1;rs1042028;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
ACETAMINOPHEN;SULT1A1;rs544820732;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
nan;TBXAS1;rs6962291;AA;OTHER;DECREASED_STEADY-STATE-LEVEL;nan;TBX2;;;
nan;TBXAS1;rs6962291;AA;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;TBXAS1;;
nan;TBXAS1;rs6962291;AA;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;TBXAS1;;
nan;TNF;rs1800629;AA + AG;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;TNF;;
nan;TPH2;rs7305115;AA;OTHER;INCREASED_EXPRESSION;RECEPTOR;TPH2;;;
nan;TPH2;rs4290270;T;OTHER;INCREASED_EXPRESSION;RECEPTOR;TPH2;;;
THIOGUANINE;TPMT;TPMT*1;*7 + *10 + *12 + *13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
THIOGUANINE;TPMT;TPMT*7;*7 + *10 + *12 + *13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
THIOGUANINE;TPMT;TPMT*10;*7 + *10 + *12 + *13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
THIOGUANINE;TPMT;TPMT*12;*7 + *10 + *12 + *13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
THIOGUANINE;TPMT;TPMT*13;*7 + *10 + *12 + *13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;TPMT;TPMT*1;*3A + *3C;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
nan;TPMT;TPMT*3A;*3A + *3C;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
nan;TPMT;TPMT*3C;*3A + *3C;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;TPMT;;
ACETAMINOPHEN;SULT1A1;rs765399160;T;LADME-PK;DECREASED_SULFATION;INCREASED_METABOLISM;nan;;;
nan;TPMT;TPMT*1;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;TPMT;;
nan;TPMT;TPMT*1;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;TPMT;;
nan;TPMT;TPMT*3A;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;TPMT;;
nan;TPMT;TPMT*3A;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;TPMT;;
nan;TPMT;TPMT*3C;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;TPMT;;
nan;TPMT;TPMT*3C;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;TPMT;;
nan;TPMT;TPMT*24;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;TPMT;;
nan;TPMT;TPMT*24;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;TPMT;;
ACETAMINOPHEN;SULT1A1;rs552524124;G;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
TAPENTADOL;SULT1A1;rs1042028;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*1;*15;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*15;*15;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
CERIVASTATIN;SLCO1B1;SLCO1B1*1;*15;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
CERIVASTATIN;SLCO1B1;SLCO1B1*15;*15;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*1;*15;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*15;*15;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
PACLITAXEL;SLCO1B3;rs7311358;A;OTHER;DECREASED_TRANSPORT;nan;nan;;;
ROSUVASTATIN;SLCO2B1;rs2306168;T;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
ROSUVASTATIN;SLCO2B1;rs142693902;A;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
ROSUVASTATIN;SLCO2B1;rs35199625;A;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
METHOTREXATE;SOD2;rs4880;G;TOXICITY;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
nan;SPAG16;rs35945601;CC;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
nan;SQSTM1;rs10277;C;LADME-PK;INCREASED_TRANSCRIPTION;GENE;SQSTM1;;;
nan;STXBP4;rs9303363;AA;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
DESMETHYLNAPROXEN;SULT1A1;rs552524124;G;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
TAPENTADOL;SULT1A1;rs758145522;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
TAPENTADOL;SULT1A1;rs72547527;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
TAPENTADOL;SULT1A1;rs544820732;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
TAPENTADOL;SULT1A1;rs767487725;C;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
DESMETHYLNAPROXEN;SULT1A1;rs544820732;A;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
ACETAMINOPHEN;SULT1A1;rs1042028;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
DESMETHYLNAPROXEN;SULT1A1;rs72547527;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
TAPENTADOL;SULT1A1;rs552524124;G;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
TAPENTADOL;SULT1A1;rs28374453;G;LADME-PK;DECREASED_SULFATION;INCREASED_METABOLISM;nan;;;
ACETAMINOPHEN;SULT1A1;rs758145522;T;LADME-PK;DECREASED_SULFATION;DECREASED_METABOLISM;nan;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*1;*5;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*5;*5;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
CERIVASTATIN;SLCO1B1;SLCO1B1*1;*5;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
CERIVASTATIN;SLCO1B1;SLCO1B1*5;*5;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*1;*5;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*5;*5;LADME-PK;DECREASED_UPTAKE;nan;nan;;;
MERCAPTOPURINE;TPMT;TPMT deficiency;;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
CISPLATIN;TPMT;TPMT*1;*3A;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CISPLATIN;TPMT;TPMT*3A;*3A;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
SN-38;UGT1A9;rs2741049;CT + TT;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
nan;UGT1A9;rs3832043;T/del + TT;LADME-PK;INCREASED_FORMATION;nan;UGT1A9;;;
nan;UGT1A9;rs2741049;TT;LADME-PK;INCREASED_FORMATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
SN-38;UGT1A9;rs3806598;AA;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
nan;UGT1A9;rs3832043;T/del + TT;LADME-PK;INCREASED_FORMATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
SN-38;UGT1A9;rs3832043;T/del + TT;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
nan;UGT1A9;rs2741049;CT + TT;LADME-PK;INCREASED_FORMATION;nan;UGT1A9;;;
OLANZAPINE;UGT2B10;rs61750900;GT + TT;LADME-PK;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT2B15;;
LORAZEPAM;UGT2B15;rs1902023;AA;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;UGT2B15;;
OXAZEPAM;UGT2B15;rs1902023;A;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT2B15;;
nan;UGT2B17;rs6817882;C;OTHER;INCREASED_EXPRESSION;RECEPTOR;UGT2B17;;;
BUPRENORPHINE;UGT2B7;rs7438135;A;LADME-PK;INCREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT2B7;;
nan;UMPS;rs1801019;C;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;UMPS;;;
nan;VKORC1;rs56314408;C;OTHER;INCREASED_TRANSCRIPTION;GENE;VKORC1;;;
nan;WBP2NL;rs5758550;AG + GG;OTHER;INCREASED_EXPRESSION;RECEPTOR;CYP2D6;;;
nan;YEATS4;rs7297610;CC;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;YEATS4;;;
RALOXIFENE;UGT1A8;UGT1A8*1a;*2/*2;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
RALOXIFENE;UGT1A8;UGT1A8*2;*2/*2;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
THIOGUANINE;TPMT;TPMT*1;*16;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
THIOGUANINE;TPMT;TPMT*16;*16;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VALPROIC ACID;UGT1A6;rs1105879;C;LADME-PK;INCREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT;;
CLOZAPINE 5-N-GLUCURONIDE;UGT1A4;rs2011425;G;LADME-PK;INCREASED_FORMATION;nan;nan;;;
DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;rs2011425;G;LADME-PK;INCREASED_FORMATION;nan;nan;;;
CISPLATIN;TPMT;TPMT*1;*3A;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CISPLATIN;TPMT;TPMT*3A;*3A;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;TXLNB;rs9495425;CC;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
nan;UGT1A1;rs4124874;GG + GT;LADME-PK;DECREASED_FORMATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
SN-38;UGT1A1;rs4124874;GG + GT;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXAZEPAM;UGT1A1;rs10929302;A;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT1A1;;
nan;UGT1A1;rs10929302;A;OTHER;DECREASED_PLASMATIC-CONCENTRATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
nan;UGT1A1;rs28967009;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;UGT1A1;;;
SN-38;UGT1A1;rs4148323;AG;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;UGT1A1;rs4148323;AG;LADME-PK;DECREASED_FORMATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
OXAZEPAM;UGT1A1;rs887829;T;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT1A1;;
OXAZEPAM;UGT1A1;rs4124874;G;OTHER;INCREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT1A1  ;;
nan;UGT1A1;UGT1A1*1;*28;OTHER;DECREASED_PLASMATIC-CONCENTRATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
nan;UGT1A1;UGT1A1*28;*28;OTHER;DECREASED_PLASMATIC-CONCENTRATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
CLOZAPINE;UGT1A1;UGT1A1*1;*28/*28;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOZAPINE;UGT1A1;UGT1A1*28;*28/*28;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BELINOSTAT;UGT1A1;UGT1A1*1;*28;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BELINOSTAT;UGT1A1;UGT1A1*28;*28;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
nan;UGT1A1;rs887829;T;OTHER;DECREASED_PLASMATIC-CONCENTRATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
nan;UGT1A1;rs4124874;G;OTHER;DECREASED_PLASMATIC-CONCENTRATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
RALOXIFENE 6-GLUCURONIDE;UGT1A1;UGT1A1*1;*28;LADME-PK;DECREASED_FORMATION;nan;nan;;;
RALOXIFENE 6-GLUCURONIDE;UGT1A1;UGT1A1*28;*28;LADME-PK;DECREASED_FORMATION;nan;nan;;;
nan;UGT1A1;rs11568319;CG;LADME-PK;DECREASED_FORMATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
nan;UGT1A3;rs7604115;T;OTHER;INCREASED_EXPRESSION;RECEPTOR;UGT1A3;;;
OLANZAPINE;UGT1A4;UGT1A4*1a;*3a;LADME-PK;INCREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT1A4;;
OLANZAPINE;UGT1A4;UGT1A4*3a;*3a;LADME-PK;INCREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT1A4;;
nan;SLCO1B1;SLCO1B1*1;*15;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;SLCO1B1;;
nan;SLCO1B1;SLCO1B1*1;*15;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;SLCO1B1;;
nan;SLCO1B1;SLCO1B1*15;*15;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;SLCO1B1;;
nan;SLCO1B1;SLCO1B1*15;*15;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;SLCO1B1;;
ATRASENTAN;SLCO1B1;SLCO1B1*1;*14;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*14;*14;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*37;*14;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*1;*9;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*9;*9;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*37;*9;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
nan;PACSIN2;rs2413739;CT + TT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;TPMT;;;
nan;PHETA2;rs1807493;G;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;CYP2D6;;;
nan;SMDT1;rs1807493;G;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;CYP2D6;;;
nan;PKNOX1;rs2839629;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;PKNOX1;;;
nan;PKNOX1;rs2839629;A;OTHER;INCREASED_EXPRESSION;RECEPTOR;CBS;;;
nan;PLG;rs783145;G;LADME-PK;DECREASED_TRANSCRIPTION;nan;GENE:PRSS55;;;
nan;PLG;rs783145;G;LADME-PK;INCREASED_TRANSCRIPTION;GENE;PLG;;;
nan;POR;rs2868177;AG;EFFICACY;INCREASED_ENZYME_ACTIVITY;nan;CYP2B6;;;
nan;PPARA;rs4253728;AA;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;CYP3A4;;;
nan;RALGAPA2;rs3827963;GG;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
DOXORUBICIN;RARG;rs2229774;A;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;RARG;rs2229774;A;OTHER;DECREASED_PROTEIN-STABILITY;PROTEIN;RARG;;;
nan;RGMA;rs7165938;GG;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
CAFFEINE;RYR1;rs193922753;T;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;ORMDL3;rs2872507;AG + GG;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;ORMDL3;;;
CAFFEINE;RYR1;rs118204423;C;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CHLOROCRESOL;RYR1;rs118204423;C;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
HALOTHANE;RYR1;rs118204423;C;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
ETHANOL;OPRM1;rs1799971;GG;EFFICACY;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
nan;NT5C2;rs11191612;GG;LADME-PK;INCREASED_TRANSCRIPTION;GENE;NT5C2;;;
PAROMOMYCIN;MT-RNR1;rs267606619;T;LADME-PD;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
GEMCITABINE;MTHFR;rs1801131;GG + GT;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;NAF1;rs17571991;AA;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCC1;;;
SOLITHROMYCIN;NAT2;NAT2*4;*4;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
SOLITHROMYCIN;NAT2;NAT2*5;*4;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
SOLITHROMYCIN;NAT2;NAT2*6;*4;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
SOLITHROMYCIN;NAT2;NAT2*7;*4;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
SOLITHROMYCIN;NAT2;NAT2*14;*4;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
nan;NAT2;rs4646244;A;OTHER;DECREASED_TRANSCRIPTION;nan;GENE:NAT2;;;
nan;NFATC2;rs6021191;T;OTHER;INCREASED_EXPRESSION;RECEPTOR;NFATC2;;;
nan;NHLH1;rs11265375;T;OTHER;INCREASED_LUCIFERASE_ACTIVITY;nan;nan;;;
MIDAZOLAM;NR1I2;rs1464602;G;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;NR1I2;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MIDAZOLAM;NR1I2;rs1464603;G;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;NR1I2;LIKELIHOOD_THERAPEUTIC_SUCCESS;
CLADRIBINE;NT5C1A;rs201045130;G;OTHER;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOROURACIL;NT5C1A;rs201045130;G;OTHER;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
GEMCITABINE;NT5C1A;rs201045130;G;OTHER;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
CLADRIBINE;NT5C1A;rs370457585;T;OTHER;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOROURACIL;NT5C1A;rs370457585;T;OTHER;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
GEMCITABINE;NT5C1A;rs370457585;T;OTHER;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
CLADRIBINE;NT5C1A;rs374150125;A;OTHER;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOROURACIL;NT5C1A;rs374150125;A;OTHER;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
GEMCITABINE;NT5C1A;rs374150125;A;OTHER;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
CYTARABINE;NT5C2;rs1163075;G;EFFICACY;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
nan;NT5C2;rs1163075;G;LADME-PK;INCREASED_TRANSCRIPTION;GENE;NT5C2;;;
CYTARABINE;NT5C2;rs11191612;GG;EFFICACY;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
CHLOROCRESOL;RYR1;rs121918596;del;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs193922843;T;DOSAGE;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs193922816;T;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs118192176;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;SEMA6A;rs3806915;A;OTHER;INCREASED_LUCIFERASE_ACTIVITY;nan;nan;;;
nan;SEPTIN3;rs1062753;G;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;CYP2D6;;;
nan;WBP2NL;rs1062753;G;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;CYP2D6;;;
RANITIDINE;SLC22A1;rs12208357;T;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
RANITIDINE;SLC22A1;rs72552763;del;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
RANITIDINE;SLC22A1;rs34130495;A;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
nan;SLC22A3;rs2076828;G;OTHER;DECREASED_EXPRESSION;DRUG_ACCUMULATION;ENZYME;SLC22A3;;
nan;SLC22A3;rs884742;C;LADME-PK;INCREASED_TRANSCRIPTION;GENE;SLC22A3;;;
ADEFOVIR;SLC22A6;rs11568634;T;OTHER;DECREASED_UPTAKE;nan;nan;;;
CEFOTAXIME;SLC22A8;rs11568482;A;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
GEMCITABINE TRIPHOSPHATE;SLC28A3;rs7867504;CC;LADME-PK;INCREASED_FORMATION;nan;nan;;;
DOXORUBICIN;SLC28A3;rs11140490;AA;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;SLC29A1;rs731780;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;SLC29A1;;;
ATRASENTAN;SLCO1B1;SLCO1B1*1;*15;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*15;*15;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*37;*15;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
nan;SLCO1B1;rs4149056;C;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;SLCO1B1;;
nan;SLCO1B1;rs4149056;C;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;SLCO1B1;;
ATRASENTAN;SLCO1B1;SLCO1B1*1;*5;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*5;*5;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
ATRASENTAN;SLCO1B1;SLCO1B1*37;*5;LADME-PK;DECREASED_TRANSPORT;nan;nan;;;
CAFFEINE;RYR1;rs28933397;CT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
HALOTHANE;RYR1;rs28933397;CT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
CAFFEINE;RYR1;rs186983396;T;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CHLOROCRESOL;RYR1;rs186983396;T;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs118192178;T;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CHLOROCRESOL;RYR1;rs118192178;T;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CHLOROCRESOL;RYR1;rs118192124;T;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs118192167;G;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs193922803;T;DOSAGE;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs118192122;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs193922809;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs118192168;A;DOSAGE;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs193922832;A;DOSAGE;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs112563513;A;DOSAGE;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs121918594;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CHLOROCRESOL;RYR1;rs121918594;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
HALOTHANE;RYR1;rs121918594;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs193922878;G;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;MIR27A;rs895819;CC;OTHER;INCREASED_EXPRESSION;RECEPTOR;MIR27A;;;
CAFFEINE;RYR1;rs118192161;T;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs118192177;T;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs118192167;AG;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs118192172;CT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
HALOTHANE;RYR1;rs118192172;CT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
CAFFEINE;RYR1;rs193922772;GT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
HALOTHANE;RYR1;rs193922772;GT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
CAFFEINE;RYR1;rs118192175;CT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
HALOTHANE;RYR1;rs118192175;CT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
CAFFEINE;RYR1;rs193922747;CT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
HALOTHANE;RYR1;rs193922747;CT;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
CAFFEINE;RYR1;rs118192176;AG;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
HALOTHANE;RYR1;rs118192176;AG;OTHER;ASSOCIATED_SENSITIVITY;nan;nan;;;
CHLOROCRESOL;RYR1;rs118192124;T;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs118192178;G;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CHLOROCRESOL;RYR1;rs118192178;G;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CAFFEINE;RYR1;rs193922818;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CHLOROCRESOL;RYR1;rs193922818;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
PRIMAQUINE;CYP2D6;CYP2D6*1;*17 + *18 + *35 + *39 + *53;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PRIMAQUINE;CYP2D6;CYP2D6*17;*17 + *18 + *35 + *39 + *53;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PRIMAQUINE;CYP2D6;CYP2D6*18;*17 + *18 + *35 + *39 + *53;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PRIMAQUINE;CYP2D6;CYP2D6*35;*17 + *18 + *35 + *39 + *53;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PRIMAQUINE;CYP2D6;CYP2D6*39;*17 + *18 + *35 + *39 + *53;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PRIMAQUINE;CYP2D6;CYP2D6*53;*17 + *18 + *35 + *39 + *53;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;DPYD;rs1801158;T;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
EFAVIRENZ;CYP2B6;rs142421637;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs373442191;A;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PROPOFOL;CYP2B6;rs752695347;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
PROPOFOL;CYP2B6;rs142421637;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
PROPOFOL;CYP2B6;rs1282926098;T;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PROPOFOL;CYP2B6;rs1969136524;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs773494867;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs1969376664;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
PROPOFOL;CYP2B6;rs138264188;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PROPOFOL;CYP2B6;rs373442191;A;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs1969255598;T;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs1248477767;G;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs750671397;G;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs141666881;A;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs1968919352;G;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EFAVIRENZ;CYP2B6;rs1282926098;T;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS;
nan;CYP2B6;rs70950385;CA/CA;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs1969136524;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs772413158;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs752695347;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
EFAVIRENZ;CYP2B6;rs553968231;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
DACARBAZINE;CYP1A2;CYP1A2*1;*11;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP1A2;;
DACARBAZINE;CYP1A2;CYP1A2*11;*11;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP1A2;;
nan;CYP1A2;rs762551;AA + AC;LADME-PK;INCREASED_TRANSCRIPTION;GENE;CYP1A2;;;
DACARBAZINE;CYP1A2;CYP1A2*1;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP1A2;;
DACARBAZINE;CYP1A2;CYP1A2*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP1A2;;
COUMARIN;CYP2A6;rs28399454;T;LADME-PK;DECREASED_METABOLISM;ENZYME;CYP2A6;;;
COUMARIN;CYP2A6;CYP2A6*1;*1/*4;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
COUMARIN;CYP2A6;CYP2A6*4;*1/*4;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
COUMARIN;CYP2A6;CYP2A6*1;*1/*9;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
COUMARIN;CYP2A6;CYP2A6*9;*1/*9;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2A6;;
nan;CYP2B6;rs3745274;TT;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CYP2B6;;
nan;CYP2B6;rs3745274;TT;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CYP2B6;;
PROPOFOL;CYP2B6;rs553968231;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
PROPOFOL;CYP2B6;rs1969376664;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
PROPOFOL;CYP2B6;rs773494867;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2B6;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1;*8 + *9 + *10 + *16 + *19;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*8;*8 + *9 + *10 + *16 + *19;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*9;*8 + *9 + *10 + *16 + *19;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*10;*8 + *9 + *10 + *16 + *19;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*16;*8 + *9 + *10 + *16 + *19;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*19;*8 + *9 + *10 + *16 + *19;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
NEBIVOLOL;CYP2C19;CYP2C19*1;*30 + *31 + *32 + *33 + *6 + *18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
NEBIVOLOL;CYP2C19;CYP2C19*6;*30 + *31 + *32 + *33 + *6 + *18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
NEBIVOLOL;CYP2C19;CYP2C19*18;*30 + *31 + *32 + *33 + *6 + *18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
NEBIVOLOL;CYP2C19;CYP2C19*30;*30 + *31 + *32 + *33 + *6 + *18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
NEBIVOLOL;CYP2C19;CYP2C19*31;*30 + *31 + *32 + *33 + *6 + *18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
NEBIVOLOL;CYP2C19;CYP2C19*32;*30 + *31 + *32 + *33 + *6 + *18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
NEBIVOLOL;CYP2C19;CYP2C19*33;*30 + *31 + *32 + *33 + *6 + *18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*10;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*14;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*19;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*25;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*26;*10 + *14 + *19 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*6;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
VORICONAZOLE;CYP2C19;CYP2C19*6;*6;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs550527959;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
METHADONE;CYP2C19;rs1463550071;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs200346442;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs200150287;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs118203756;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUVOXAMINE;CYP2C19;CYP2C19*1;*15;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;CYP2C19*15;*15;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*15;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*15;*15;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;CYP2C19*1;*18;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;CYP2C19*18;*18;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*18;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*18;*18;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CELECOXIB;CYP2C19;CYP2C19*1;*18;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
CELECOXIB;CYP2C19;CYP2C19*18;*18;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*1;*18;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*18;*18;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*1;*18;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*18;*18;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TICLOPIDINE;CYP2C19;CYP2C19*1;*18;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TICLOPIDINE;CYP2C19;CYP2C19*18;*18;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;rs778258371;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
CELECOXIB;CYP2C19;CYP2C19*1;*19;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CELECOXIB;CYP2C19;CYP2C19*19;*19;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CELECOXIB;CYP2C19;CYP2C19*1;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
CELECOXIB;CYP2C19;CYP2C19*16;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*1;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*16;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*1;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*16;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*1;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*16;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TICLOPIDINE;CYP2C19;CYP2C19*1;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TICLOPIDINE;CYP2C19;CYP2C19*16;*16;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUVOXAMINE;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUVOXAMINE;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
OMEPRAZOLE;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TICLOPIDINE;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TICLOPIDINE;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TRANYLCYPROMINE;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TRANYLCYPROMINE;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
nan;CYP2C19;CYP2C19*1;*16;OTHER;DECREASED_FORMATION;nan;ENZYME;CYP2C19;;
nan;CYP2C19;CYP2C19*16;*16;OTHER;DECREASED_FORMATION;nan;ENZYME;CYP2C19;;
FLUCONAZOLE;CYP2C19;CYP2C19*1;*11;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUCONAZOLE;CYP2C19;CYP2C19*11;*11;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;CYP2C19*1;*11;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;CYP2C19*11;*11;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
SERTRALINE;CYP2C19;CYP2C19*1;*11;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
SERTRALINE;CYP2C19;CYP2C19*11;*11;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUOXETINE;CYP2C19;CYP2C19*1;*10;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*10;*10;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
CELECOXIB;CYP2C19;CYP2C19*1;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
CELECOXIB;CYP2C19;CYP2C19*9;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*1;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*9;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*1;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*9;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*1;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*9;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TROGLITAZONE;CYP2C19;CYP2C19*1;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TROGLITAZONE;CYP2C19;CYP2C19*9;*9;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUCONAZOLE;CYP2C19;CYP2C19*1;*9;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUCONAZOLE;CYP2C19;CYP2C19*9;*9;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;CYP2C19*1;*9;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;CYP2C19*9;*9;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*10;*10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUCONAZOLE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUCONAZOLE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUVOXAMINE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUVOXAMINE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
OMEPRAZOLE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TICLOPIDINE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TICLOPIDINE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TRANYLCYPROMINE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TRANYLCYPROMINE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TROGLITAZONE;CYP2C19;CYP2C19*1;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TROGLITAZONE;CYP2C19;CYP2C19*8;*8;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*1;*15;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*15;*15;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TRANYLCYPROMINE;CYP2C19;CYP2C19*1;*15;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TRANYLCYPROMINE;CYP2C19;CYP2C19*15;*15;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO_SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
MEPHENYTOIN;CYP2C19;CYP2C19*26;*26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*26;*26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*23;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
VORICONAZOLE;CYP2C19;CYP2C19*23;*23;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*10 + *14 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
CLOPIDOGREL;CYP2C19;CYP2C19*10;*10 + *14 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
CLOPIDOGREL;CYP2C19;CYP2C19*14;*10 + *14 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
CLOPIDOGREL;CYP2C19;CYP2C19*19;*10 + *14 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
CLOPIDOGREL;CYP2C19;CYP2C19*23;*10 + *14 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
CLOPIDOGREL;CYP2C19;CYP2C19*25;*10 + *14 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
CLOPIDOGREL;CYP2C19;CYP2C19*26;*10 + *14 + *19 + *23 + *25 + *26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs370803989;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs145328984;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs763625282;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs147255955;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs3758581;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs559628884;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs764137538;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs1349931378;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
VORICONAZOLE;CYP2C19;CYP2C19*33;*33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs1463550071;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
METHADONE;CYP2C19;rs778258371;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
VORICONAZOLE;CYP2C19;CYP2C19*18;*18;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
METHADONE;CYP2C19;rs72552267;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
METHADONE;CYP2C19;rs118203756;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
METHADONE;CYP2C19;rs764137538;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
METHADONE;CYP2C19;rs550527959;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
METHADONE;CYP2C19;rs1349931378;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs770829708;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
METHADONE;CYP2C19;rs1267723490;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
FLUOXETINE;CYP2C19;rs1267723490;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C19;;
DACARBAZINE;CYP1A1;CYP1A1*1;*2C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP1A1;;
DACARBAZINE;CYP1A1;CYP1A1*2C;*2C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP1A1;;
DACARBAZINE;CYP1A1;CYP1A1*1;*4;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP1A1;;
DACARBAZINE;CYP1A1;CYP1A1*4;*4;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP1A1;;
nan;CHD2;rs28458425;TT;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
OXAZEPAM;UGT1A5;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT;;
OXAZEPAM;UGT1A7;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT;;
OXAZEPAM;UGT1A3;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT;;
OXAZEPAM;UGT1A4;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT;;
OXAZEPAM;UGT1A9;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT;;
OXAZEPAM;UGT1A10;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT;;
OXAZEPAM;UGT1A8;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT;;
OXAZEPAM;UGT1A6;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;METABOLISM;ENZYME;UGT;;
nan;nan;rs247616;T;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CETP;;
nan;nan;rs247616;T;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CETP;;
nan;ABCB1;rs1045642;AG + GG;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;ABCB1;;
nan;nan;rs1976391;G;OTHER;DECREASED_PLASMATIC-CONCENTRATION;DRUG_ACCUMULATION;ENZYME;UGT1A1;;
nan;ABCB1;rs1128503;AG + GG;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;ABCB1;;
nan;ABCB1;rs1045642;AA;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ABCB1;;
nan;ABCB1;rs1045642;AA;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ABCB1;;
nan;ABCB1;rs1128503;AA;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ABCB1;;
nan;ABCB1;rs1128503;AA;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ABCB1;;
nan;ABCB1;rs2032582;AA;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ABCB1;;
nan;ABCB1;rs2032582;AA;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ABCB1;;
DOCETAXEL;ABCC10;rs2125739;TT;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;ABCC11;rs11861379;C;LADME-PK;INCREASED_TRANSCRIPTION;GENE;ABCC11;;;
nan;ABCB1;rs2032582;AC + CC;LADME-PK;INCREASED_ACTIVITY;METABOLISM;PROTEIN;ABCB1;;
nan;nan;rs729559;GG;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;CYP2D6;;;
nan;nan;rs6539870;GG;OTHER;INCREASED_EXPRESSION;RECEPTOR;IL1B;;;
nan;nan;rs478437;CC;OTHER;INCREASED_EXPRESSION;RECEPTOR;USP7;;;
nan;nan;rs9999111;C;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ABCG2;;
nan;nan;rs9999111;C;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ABCG2;;
nan;nan;rs149713212;A;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ABCG2;;
nan;nan;rs149713212;A;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ABCG2;;
nan;nan;rs12508471;G;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ABCG2;;
nan;nan;rs12508471;G;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ABCG2;;
ENDOXIFEN;nan;rs4386686;C;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;nan;rs4073010;TT;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;CYP2D6;;;
nan;nan;rs35283911;G;OTHER;INCREASED_EXPRESSION;RECEPTOR;HP;;;
nan;nan;rs4386686;C;TOXICITY, OTHER;INCREASED_EXPRESSION;RECEPTOR;MIRLET7I;;;
TAMOXIFEN;nan;rs478437;CC;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;nan;rs2784917;AA;OTHER;INCREASED_EXPRESSION;RECEPTOR;WNT5B;;;
nan;nan;rs9999111;C;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ABCG2;;
nan;nan;rs9999111;C;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ABCG2;;
nan;nan;rs10242455;AG;LADME-PK;INCREASED_TRANSCRIPTION;GENE;CYP3A5;;;
nan;nan;rs446112;AA;OTHER;INCREASED_EXPRESSION;RECEPTOR;AGPAT2;;;
nan;nan;rs10871454;C;LADME-PK;INCREASED_TRANSCRIPTION;GENE;VKORC1;;;
nan;nan;rs4386686;C;TOXICITY, OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;TRAF1;;
nan;nan;rs4386686;C;TOXICITY, OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;TRAF1;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*28;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
CLOPIDOGREL;CYP2C19;CYP2C19*28;*28;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
nan;ABCC4;rs11568658;A;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;ABCC4;;;
MERCAPTOPURINE;ABCC4;rs3765534;TT;TOXICITY, LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;CACNA1S;rs1800559;T;OTHER;INCREASED_ACTIVITY;METABOLISM;PROTEIN;CACNA1S;;
CAFFEINE;CACNA1S;rs1800559;T;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
HALOTHANE;CACNA1S;rs772226819;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
ISOFLURANE;CACNA1S;rs772226819;A;OTHER;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;CBS;rs915854;C;OTHER;INCREASED_EXPRESSION;RECEPTOR;PKNOX1;;;
nan;CDA;rs3215400;C/del + del/del;OTHER;INCREASED_EXPRESSION;RECEPTOR;CDA;;;
nan;CDA;rs2072671;CC;OTHER;INCREASED_EXPRESSION;RECEPTOR;CDA;;;
DEXAMETHASONE;BCL2L11;rs2241843;AA;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;CDA;rs532545;CC;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CDA;;
nan;CDA;rs2072671;AA;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CDA;;
nan;CDA;rs1048977;TT;OTHER;INCREASED_EXPRESSION;RECEPTOR;CDA;;;
nan;CDA;rs602950;AA;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZYME;CDA;;
nan;CDA;rs602950;GG;OTHER;INCREASED_EXPRESSION;RECEPTOR;CDA;;;
PALBOCICLIB;CDKN2A;rs759922342;C;EFFICACY;INCREASED_RESPONSE;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
REMIMAZOLAM;CES1;rs71647871;T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
CLOPIDOGREL;CES1;rs201065375;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ENALAPRIL;CES1;rs201065375;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SACUBITRIL;CES1;rs201065375;A;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
nan;CETP;rs708272;GG;OTHER;INCREASED_EXPRESSION;RECEPTOR;CETP;;;
nan;CDA;rs532545;TT;OTHER;INCREASED_EXPRESSION;RECEPTOR;CDA;;;
MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;TOXICITY, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
DEXAMETHASONE;BCL2L11;rs724710;CC;TOXICITY;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
nan;ARNT;rs2134688;GG;LADME-PK;DECREASED_PLASMATIC-CONCENTRATION;nan;CYP3A4;;;
nan;ABCC4;rs11568684;C;LADME-PK;INCREASED_CATALYTIC_ACTIVITY;nan;ABCC4;;;
nan;ABCC9;rs704212;T;OTHER;INCREASED_EXPRESSION;RECEPTOR;ABCC9;;;
nan;ABCG2;rs2725263;C;OTHER;INCREASED_EXPRESSION;RECEPTOR;ABCG2;;;
nan;ADCYAP1;rs304400;AA;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
LOSARTAN;AGTR1;rs12721226;A;OTHER;DECREASED_AFFINITY;TOLERANCE;nan;;;
DOXORUBICINOL;AKR1A1;rs2229540;G;LADME-PK;DECREASED_FORMATION;LIKELIHOOD_LESS_CARDIOTOXICITY;nan;;;
DAUNORUBICINOL;AKR1A1;rs6690497;C;LADME-PK;DECREASED_FORMATION;LIKELIHOOD_LESS_CARDIOTOXICITY;nan;;;
DAUNORUBICINOL;AKR1A1;rs2229540;G;LADME-PK;DECREASED_FORMATION;LIKELIHOOD_LESS_CARDIOTOXICITY;nan;;;
EXEMESTANE;AKR1C3;rs62621365;T;LADME-PK;DECREASED_AFFINITY;nan;nan;;;
DOXORUBICIN;AKR1C3;rs62621365;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DOXORUBICIN;AKR1C3;rs34186955;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DOXORUBICIN;AKR1C3;rs28943579;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
EXEMESTANE;AKR1C4;rs11253043;A;LADME-PK;DECREASED_AFFINITY;nan;nan;;;
nan;ALDH1A2;rs12915901;AA + AG;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:ALDH1A2;;
nan;ALDH1A2;rs12915901;AA + AG;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:ALDH1A2;;
nan;AMPH;rs12701634;CC;OTHER;INCREASED_TRANSCRIPTION;nan;PROTEIN:MDR;;;
DOXORUBICINOL;AKR1A1;rs6690497;C;LADME-PK;DECREASED_FORMATION;nan;nan;;;
nan;DPYD;rs2297595;C;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;CYP2C19;CYP2C19*1;*19;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:CYP2C19;;
nan;CYP2C19;CYP2C19*1;*19;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP2C19;;
nan;CYP2C19;CYP2C19*19;*19;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:CYP2C19;;
nan;CYP2C19;CYP2C19*19;*19;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP2C19;;
SERTRALINE;CYP2C19;CYP2C19*1;*13;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;;
SERTRALINE;CYP2C19;CYP2C19*13;*13;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;;
EBASTINE;CYP2J2;rs201379188;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TERFENADINE;CYP2J2;rs201379188;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TERFENADINE;CYP2J2;rs199717190;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*1;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*2;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*3;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*5;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*7;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*8;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*9;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*10;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*11;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*12;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*13;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*14;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*15;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*16;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*18;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*19;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*23;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*24;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*28;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*29;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*31;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*32;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*33;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*34;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*1;*6 + *17 + *20 + *21 + *26 + *30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*6;*6 + *17 + *20 + *21 + *26 + *30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*17;*6 + *17 + *20 + *21 + *26 + *30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*20;*6 + *17 + *20 + *21 + *26 + *30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*21;*6 + *17 + *20 + *21 + *26 + *30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*26;*6 + *17 + *20 + *21 + *26 + *30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OXYCODONE;CYP3A4;CYP3A4*30;*6 + *17 + *20 + *21 + *26 + *30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SIROLIMUS;CYP3A4;CYP3A4*1;*1/*22 + *22/*22;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SIROLIMUS;CYP3A4;CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SILDENAFIL;CYP3A4;CYP3A4*1;*3 + *10 + *14 + *32;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
SILDENAFIL;CYP3A4;CYP3A4*3;*3 + *10 + *14 + *32;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
SILDENAFIL;CYP3A4;CYP3A4*10;*3 + *10 + *14 + *32;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
SILDENAFIL;CYP3A4;CYP3A4*14;*3 + *10 + *14 + *32;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
SILDENAFIL;CYP3A4;CYP3A4*32;*3 + *10 + *14 + *32;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
IBRUTINIB;CYP3A4;CYP3A4*1;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*2;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*5;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*14;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*15;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*16;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*28;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*29;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*31;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*32;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP3A4;rs2242480;TT;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP3A4;;;
TESTOSTERONE;CYP3A4;CYP3A4*1;*2 + *3 + *11 + *15 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TESTOSTERONE;CYP3A4;CYP3A4*2;*2 + *3 + *11 + *15 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TESTOSTERONE;CYP3A4;CYP3A4*3;*2 + *3 + *11 + *15 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TESTOSTERONE;CYP3A4;CYP3A4*11;*2 + *3 + *11 + *15 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TESTOSTERONE;CYP3A4;CYP3A4*15;*2 + *3 + *11 + *15 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TESTOSTERONE;CYP3A4;CYP3A4*31;*2 + *3 + *11 + *15 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TESTOSTERONE;CYP3A4;CYP3A4*1;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*5;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*10;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*14;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*16;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*17;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*23;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*24;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*28;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*29;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*32;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*33;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TESTOSTERONE;CYP3A4;CYP3A4*34;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LIDOCAINE;CYP3A4;CYP3A4*1;*2 + *5 + *9 + *16 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LIDOCAINE;CYP3A4;CYP3A4*2;*2 + *5 + *9 + *16 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LIDOCAINE;CYP3A4;CYP3A4*5;*2 + *5 + *9 + *16 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LIDOCAINE;CYP3A4;CYP3A4*9;*2 + *5 + *9 + *16 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LIDOCAINE;CYP3A4;CYP3A4*16;*2 + *5 + *9 + *16 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LIDOCAINE;CYP3A4;CYP3A4*24;*2 + *5 + *9 + *16 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MIDAZOLAM;CYP3A4;rs12721627;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FENTANYL;CYP3A4;rs2242480;T/T;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
REGORAFENIB;CYP3A4;CYP3A4*1;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*2;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*3;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*7;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*8;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*9;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*10;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*11;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*12;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*13;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*17;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*18;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*23;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*32;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*33;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
REGORAFENIB;CYP3A4;CYP3A4*34;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*1;*11 + *18 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TICAGRELOR;CYP3A4;CYP3A4*11;*11 + *18 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TICAGRELOR;CYP3A4;CYP3A4*18;*11 + *18 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TICAGRELOR;CYP3A4;CYP3A4*33;*11 + *18 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TICAGRELOR;CYP3A4;CYP3A4*1;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*2;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*3;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*5;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*9;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*14;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*15;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*16;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*17;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*19;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*24;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*28;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*29;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TICAGRELOR;CYP3A4;CYP3A4*31;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LURASIDONE;CYP3A4;CYP3A4*1;*12;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LURASIDONE;CYP3A4;CYP3A4*12;*12;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LURASIDONE;CYP3A4;CYP3A4*1;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LURASIDONE;CYP3A4;CYP3A4*15;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LURASIDONE;CYP3A4;CYP3A4*19;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LURASIDONE;CYP3A4;CYP3A4*23;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LURASIDONE;CYP3A4;CYP3A4*24;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LURASIDONE;CYP3A4;CYP3A4*28;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LURASIDONE;CYP3A4;CYP3A4*29;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LURASIDONE;CYP3A4;CYP3A4*32;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LURASIDONE;CYP3A4;CYP3A4*33;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
SAXAGLIPTIN;CYP3A4;CYP3A4*1;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*2;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*3;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*5;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*7;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*8;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*9;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*10;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*11;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*12;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*13;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*14;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*15;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*16;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*17;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*18;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*19;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*20;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*23;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*24;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*28;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*29;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*31;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*32;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SAXAGLIPTIN;CYP3A4;CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
EBASTINE;CYP2J2;rs759510111;A;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
TERFENADINE;CYP2J2;rs759510111;A;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
EBASTINE;CYP2J2;rs757528200;(CTC)1;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP2E1;CYP2E1*7A;*7B;LADME-PK;INCREASED_TRANSCRIPTION;GENE;CYP2E1;;;
nan;CYP2E1;CYP2E1*7B;*7B;LADME-PK;INCREASED_TRANSCRIPTION;GENE;CYP2E1;;;
nan;CYP2E1;CYP2E1*7;*7A;LADME-PK;INCREASED_TRANSCRIPTION;GENE;CYP2E1;;;
nan;CYP2E1;CYP2E1*7A;*7A;LADME-PK;INCREASED_TRANSCRIPTION;GENE;CYP2E1;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*2;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*28;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*35;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
BUFURALOL;CYP2D6;CYP2D6*1;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;CYP2D6*17;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEBRISOQUINE;CYP2D6;CYP2D6*1;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEBRISOQUINE;CYP2D6;CYP2D6*17;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*17;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP2D6;CYP2D6*1;*1/*4;LADME-PK;DECREASED_EXPRESSION;nan;CYP2D6;;;
nan;CYP2D6;CYP2D6*4;*1/*4;LADME-PK;DECREASED_EXPRESSION;nan;CYP2D6;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*169;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*169;*169;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;rs76187628;G;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
nan;CYP2D6;CYP2D6*1;*169;LADME-PK;DECREASED_EXPRESSION;nan;CYP2D6;;;
nan;CYP2D6;CYP2D6*169;*169;LADME-PK;DECREASED_EXPRESSION;nan;CYP2D6;;;
nan;CYP2D6;rs76187628;G;LADME-PK;INCREASED_EXPRESSION;RECEPTOR;CYP2D6;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*2;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
IBRUTINIB;CYP3A4;CYP3A4*1;*3 + *4 + *9 + *19 +*34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
IBRUTINIB;CYP3A4;CYP3A4*3;*3 + *4 + *9 + *19 +*34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
IBRUTINIB;CYP3A4;CYP3A4*4;*3 + *4 + *9 + *19 +*34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
IBRUTINIB;CYP3A4;CYP3A4*9;*3 + *4 + *9 + *19 +*34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
IBRUTINIB;CYP3A4;CYP3A4*19;*3 + *4 + *9 + *19 +*34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
IBRUTINIB;CYP3A4;CYP3A4*34;*3 + *4 + *9 + *19 +*34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
RISPERIDONE;CYP2D6;CYP2D6*1;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*2;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*28;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
RISPERIDONE;CYP2D6;CYP2D6*35;*2 + *28 + *35;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*26;*26;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;rs750996195;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;rs750996195;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;CYP2D6*1;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;CYP2D6*17;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*17;*17;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;CYP2D6*1;*14;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;CYP2D6*14;*14;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1;*53;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*53;*53;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
DAPOXETINE;CYP2D6;CYP2D6*1;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DAPOXETINE;CYP2D6;CYP2D6*2;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DAPOXETINE;CYP2D6;CYP2D6*10;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DAPOXETINE;CYP2D6;CYP2D6*87;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DAPOXETINE;CYP2D6;CYP2D6*88;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DAPOXETINE;CYP2D6;CYP2D6*91;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DAPOXETINE;CYP2D6;CYP2D6*93;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DAPOXETINE;CYP2D6;CYP2D6*95;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DAPOXETINE;CYP2D6;CYP2D6*97;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DAPOXETINE;CYP2D6;CYP2D6*98;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;CYP2D6*1;*53;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
BUFURALOL;CYP2D6;CYP2D6*53;*53;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*10/*10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP2E1;rs2515641;T;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CYP2E1;;
nan;CYP2E1;rs2515641;T;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CYP2E1;;
nan;ZBED5;rs10840501;GG;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
REGORAFENIB;CYP3A4;CYP3A4*1;*14 + *15 + *28 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
REGORAFENIB;CYP3A4;CYP3A4*14;*14 + *15 + *28 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
REGORAFENIB;CYP3A4;CYP3A4*15;*14 + *15 + *28 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
REGORAFENIB;CYP3A4;CYP3A4*28;*14 + *15 + *28 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
REGORAFENIB;CYP3A4;CYP3A4*31;*14 + *15 + *28 + *31;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*1;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*11;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*14;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*15;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*18;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*19;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*23;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*29;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*31;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*32;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
LIDOCAINE;CYP3A4;CYP3A4*34;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
CABOZANTINIB;CYP3A4;CYP3A4*1;*14 + *15;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
CABOZANTINIB;CYP3A4;CYP3A4*14;*14 + *15;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
CABOZANTINIB;CYP3A4;CYP3A4*15;*14 + *15;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
VITAMIN E;CYP4F2;rs2108622;T;LADME-PK;INCREASED_STEADY-STATE-LEVEL;nan;nan;;;
nan;CYP4F2;rs2189784;A;OTHER;INCREASED_EXPRESSION;METABOLISM;ENZYME;CYP4F2;;
nan;CYP4F2;rs2189784;A;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;ENZYME:CYP4F12;;
nan;CYP4F2;rs2189784;A;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP4F12;;
nan;CYP4F2;rs2108622;CT;OTHER;INCREASED_PLASMATIC-CONCENTRATION;nan;ENZYME;CYP4F2;;
VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;CT + TT;OTHER, LADME-PK;INCREASED_PLASMATIC-CONCENTRATION;nan;nan;;;
nan;CYP4F2;rs2108622;T;OTHER;INCREASED_EXPRESSION;METABOLISM;ENZYME;CYP4F2;;
nan;CYP4F2;rs2108622;T;OTHER;INCREASED_EXPRESSION;METABOLISM;ENZYME;CYP4F11;;
nan;DCK;rs2306744;T;OTHER;INCREASED_EXPRESSION;RECEPTOR;ENZYME; DCK;;
nan;DHRS4L1;rs10147475;GG;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
VITAMIN E;CYP4F2;rs2108622;T;LADME-PK;INCREASED_STEADY-STATE-LEVEL;nan;nan;;;
nan;DISP1;rs61840266;TT;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCC1;;;
nan;DPYD;rs568132506;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
nan;DPYD;rs760663364;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;DPYD;rs1801158;CT;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
nan;DPYD;rs547099198;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
nan;DPYD;rs67376798;AT;OTHER;DECREASED_CATALYTIC_ACTIVITY;PK;ENZYME;DPYD;;
nan;DPYD;rs1801265;G;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;DPYD;rs1801160;T;OTHER;DECREASED_ACTIVITY;DRUG_ACCUMULATION;ENZIME:DPD;;;
nan;DISP1;rs17535305;GG;OTHER;INCREASED_TRANSCRIPTION;GENE;ABCB1;;;
BUFURALOL;CYP2D6;rs777560972;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;rs777560972;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP4F11;rs1060467;A;OTHER;INCREASED_EXPRESSION;METABOLISM;CYP4F2;;;
nan;CYP3A5;CYP3A5*1;*3/*3;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CYP3A5;;
nan;CYP3A5;CYP3A5*1;*3/*3;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CYP3A5;;
nan;CYP3A5;CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CYP3A5;;
nan;CYP3A5;CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CYP3A5;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*1;*14 + *15;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
BREXPIPRAZOLE;CYP3A4;CYP3A4*14;*14 + *15;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
BREXPIPRAZOLE;CYP3A4;CYP3A4*15;*14 + *15;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
ALECTINIB;CYP3A4;CYP3A4*1;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*7;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*8;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*12;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*14;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*16;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*17;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*18;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*19;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*20;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*23;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
ALECTINIB;CYP3A4;CYP3A4*24;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
METHADONE;CYP3A4;CYP3A4*1;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*2;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*3;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*5;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*14;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*15;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*16;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*17;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*18;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*19;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*24;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*29;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*31;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP3A4;CYP3A4*1;*11 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
METHADONE;CYP3A4;CYP3A4*11;*11 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
METHADONE;CYP3A4;CYP3A4*32;*11 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
METHADONE;CYP3A4;CYP3A4*34;*11 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
nan;CYP3A4;rs35599367;A;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CYP3A4;;
nan;CYP3A4;rs35599367;A;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CYP3A4;;
MIDAZOLAM;CYP3A4;CYP3A4*1;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MIDAZOLAM;CYP3A4;CYP3A4*39;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MIDAZOLAM;CYP3A4;CYP3A4*40;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MIDAZOLAM;CYP3A4;CYP3A4*41;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MIDAZOLAM;CYP3A4;CYP3A4*42;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MIDAZOLAM;CYP3A4;CYP3A4*43;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MIDAZOLAM;CYP3A4;CYP3A4*44;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MIDAZOLAM;CYP3A4;CYP3A4*46;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*1;*3 + *4 + *5 + *10 +*15 + *16;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MACITENTAN;CYP3A4;CYP3A4*3;*3 + *4 + *5 + *10 +*15 + *16;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MACITENTAN;CYP3A4;CYP3A4*4;*3 + *4 + *5 + *10 +*15 + *16;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MACITENTAN;CYP3A4;CYP3A4*5;*3 + *4 + *5 + *10 +*15 + *16;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MACITENTAN;CYP3A4;CYP3A4*10;*3 + *4 + *5 + *10 +*15 + *16;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MACITENTAN;CYP3A4;CYP3A4*15;*3 + *4 + *5 + *10 +*15 + *16;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MACITENTAN;CYP3A4;CYP3A4*16;*3 + *4 + *5 + *10 +*15 + *16;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
VANDETANIB;CYP3A4;CYP3A4*1;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*5;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*7;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*8;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*10;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*11;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*12;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*13;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*14;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*17;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*18;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*19;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*20;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*23;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*24;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*31;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VANDETANIB;CYP3A4;CYP3A4*34;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP3A5;CYP3A5*1;*3/*3;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CYP3A5;;
nan;CYP3A5;CYP3A5*1;*3/*3;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CYP3A5;;
nan;CYP3A5;CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CYP3A5;;
nan;CYP3A5;CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CYP3A5;;
CABOZANTINIB;CYP3A4;CYP3A4*1;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*2;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*3;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*5;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*7;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*8;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*9;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*11;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*12;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*13;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*16;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*17;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*18;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*19;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*23;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*24;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*28;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*29;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*31;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*32;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*33;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CABOZANTINIB;CYP3A4;CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMIODARONE;CYP3A4;CYP3A4*1;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*2;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*9;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*10;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*11;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*16;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*18;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*19;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*23;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*29;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*31;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*32;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
AMIODARONE;CYP3A4;CYP3A4*34;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
SILDENAFIL;CYP3A4;CYP3A4*1;*2 + *5 + *24 + *28 + *29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SILDENAFIL;CYP3A4;CYP3A4*2;*2 + *5 + *24 + *28 + *29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SILDENAFIL;CYP3A4;CYP3A4*5;*2 + *5 + *24 + *28 + *29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SILDENAFIL;CYP3A4;CYP3A4*24;*2 + *5 + *24 + *28 + *29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SILDENAFIL;CYP3A4;CYP3A4*28;*2 + *5 + *24 + *28 + *29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SILDENAFIL;CYP3A4;CYP3A4*29;*2 + *5 + *24 + *28 + *29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*1;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*3;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*5;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*9;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*10;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*11;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*12;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*13;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*16;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*18;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*23;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*29;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*31;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*32;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*33;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*34;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*1;*2 + *7 + *8 + *17 + *20;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*2;*2 + *7 + *8 + *17 + *20;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*7;*2 + *7 + *8 + *17 + *20;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*8;*2 + *7 + *8 + *17 + *20;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*17;*2 + *7 + *8 + *17 + *20;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BREXPIPRAZOLE;CYP3A4;CYP3A4*20;*2 + *7 + *8 + *17 + *20;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMIODARONE;CYP3A4;CYP3A4*1;*17 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMIODARONE;CYP3A4;CYP3A4*17;*17 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMIODARONE;CYP3A4;CYP3A4*24;*17 + *24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MIDAZOLAM;CYP3A5;CYP3A5*1;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
MIDAZOLAM;CYP3A5;CYP3A5*3;*1/*1;LADME-PK;INCREASED_METABOLISM;nan;nan;;;
MACITENTAN;CYP3A4;CYP3A4*1;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*9;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*11;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*12;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*13;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*17;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*20;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*23;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*24;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*28;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*29;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*33;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MACITENTAN;CYP3A4;CYP3A4*34;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;rs138417770;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;rs138417770;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;rs371793722;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;rs371793722;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;CYP2C19*1;*29 + *30 + *31 + *32 + *33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;CYP2C19*29;*29 + *30 + *31 + *32 + *33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;CYP2C19*30;*29 + *30 + *31 + *32 + *33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;CYP2C19*31;*29 + *30 + *31 + *32 + *33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;CYP2C19*32;*29 + *30 + *31 + *32 + *33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;CYP2C19*33;*29 + *30 + *31 + *32 + *33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;rs778258371;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;CYP2C19*1;*32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;CYP2C19*32;*32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;rs138142612;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
MEPHENYTOIN;CYP2C19;CYP2C19*24;*24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OMEPRAZOLE;CYP2C19;CYP2C19*24;*24;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*32;*32;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;CYP2C19*1;*31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;CYP2C19*31;*31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1;*11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*11;*11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*23;*11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*9;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*11;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*23;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*29;*29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;CYP2C19*1;*29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;CYP2C19*29;*29;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*31;*31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;CYP2C19*30;*30;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
SIPONIMOD;CYP2C9;CYP2C9*2;*3/*3 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
SIPONIMOD;CYP2C9;CYP2C9*3;*3/*3 + *2/*2;LADME-PK;DECREASED_METABOLISM;nan;nan;;;
DICLOFENAC;CYP2C9;CYP2C9*13;*13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TOLBUTAMIDE;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ANDROSTENEDIONE;CYP2C19;CYP2C19*1;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
ANDROSTENEDIONE;CYP2C19;CYP2C19*9;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
ANDROSTENEDIONE;CYP2C19;CYP2C19*11;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
ANDROSTENEDIONE;CYP2C19;CYP2C19*23;*9 + *11 + *23;LADME-PK;INCREASED_FORMATION;nan;nan;;;
PHENYTOIN;CYP2C9;CYP2C9*52;*52;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;rs749678783;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;rs770829708;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;rs72552267;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;rs200150287;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;rs749678783;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;rs138142612;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
FLUOXETINE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
KETOCONAZOLE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
TICLOPIDINE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUVOXAMINE;CYP2C19;rs181297724;C;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
OMEPRAZOLE;CYP2C19;rs181297724;C;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUOXETINE;CYP2C19;rs17878459;C;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
CELECOXIB;CYP2C19;rs17878459;C;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESSLIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUCONAZOLE;CYP2C19;rs17878459;C;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESSLIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;rs17878459;C;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESSLIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
MEPHENYTOIN;CYP2C19;CYP2C19*1;*23;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
MEPHENYTOIN;CYP2C19;CYP2C19*23;*23;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
FLUVOXAMINE;CYP2C19;rs3758581;G;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
VORICONAZOLE;CYP2C19;rs763625282;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;rs3758581;G;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*19;LADME-PK;DECREASED_AFFINITY;TOLERANCE/LESS_EFFICACY;ENZYME;CYP2C19;;
OMEPRAZOLE;CYP2C19;CYP2C19*19;*19;LADME-PK;DECREASED_AFFINITY;TOLERANCE/LESS_EFFICACY;ENZYME;CYP2C19;;
VORICONAZOLE;CYP2C19;rs770829708;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CELECOXIB;CYP2C19;CYP2C19*1;*14;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
CELECOXIB;CYP2C19;CYP2C19*14;*14;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUCONAZOLE;CYP2C19;CYP2C19*1;*14;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUCONAZOLE;CYP2C19;CYP2C19*14;*14;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUOXETINE;CYP2C19;CYP2C19*1;*14;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUOXETINE;CYP2C19;CYP2C19*14;*14;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*1;*14;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
SERTRALINE;CYP2C19;CYP2C19*14;*14;LADME-PK;DECREASED_SENSITIVITY;DECREASED_EFFICACY;EVENT;NO SURVIVAL;LIKELIHOOD_THERAPEUTIC_FAILURE;
FLUCONAZOLE;CYP2C19;CYP2C19*1;*13;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUCONAZOLE;CYP2C19;CYP2C19*13;*13;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;CYP2C19*1;*13;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
FLUVOXAMINE;CYP2C19;CYP2C19*13;*13;LADME-PK;INCREASED_SENSITIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS;nan;;;
VORICONAZOLE;CYP2C19;rs181297724;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2C19;rs200346442;A;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
VORICONAZOLE;CYP2C19;rs550527959;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP2C19;rs7902257;A;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;ENZYME:CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE;
PHENYTOIN;CYP2C9;CYP2C9*51;*51;LADME-PK;INCREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS;
nan;CYP2C9;rs4918758;C;OTHER;DECREASED_TRANSCRIPTION;METABOLISM;GENE:CYP2C9;;;
PHENYTOIN;CYP2C9;CYP2C9*33;*33;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PHENYTOIN;CYP2C9;CYP2C9*13;*13;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PHENYTOIN;CYP2C9;CYP2C9*16;*16;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PHENYTOIN;CYP2C9;CYP2C9*45;*45;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP2D6;rs16947;AA + AG;OTHER;DECREASED_EXPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE;ENZYME;CYP2D6;;
nan;CYP2D6;rs16947;AA + AG;OTHER;DECREASED_EXPRESSION;METABOLISM;ENZYME;CYP2D6;;
PRIMAQUINE;CYP2D6;CYP2D6*1;*22 + *48;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PRIMAQUINE;CYP2D6;CYP2D6*22;*22 + *48;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PRIMAQUINE;CYP2D6;CYP2D6*26;*22 + *48;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PRIMAQUINE;CYP2D6;CYP2D6*48;*22 + *48;LADME-PK;INCREASED_CLEARANCE;METABOLISM;ENZYME;;LIKELIHOOD_THERAPEUTIC_SUCCESS;
METHADONE;CYP2D6;CYP2D6*1;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2D6;CYP2D6*2;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2D6;CYP2D6*10;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2D6;CYP2D6*87;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2D6;CYP2D6*89;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2D6;CYP2D6*90;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2D6;CYP2D6*93;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2D6;CYP2D6*95;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2D6;CYP2D6*97;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
METHADONE;CYP2D6;CYP2D6*98;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP2D6;CYP2D6*1;*92 + *96;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6;;;
nan;CYP2D6;CYP2D6*92;*92 + *96;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6;;;
nan;CYP2D6;CYP2D6*96;*92 + *96;LADME-PK;DECREASED_ACTIVITY;DRUG_ACCUMULATION;CYP2D6;;;
VENLAFAXINE;CYP2D6;CYP2D6*1;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*2;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*10;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*87;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*88;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*89;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*90;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*91;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*93;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*94;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*95;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*97;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
VENLAFAXINE;CYP2D6;CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
PHENYTOIN;CYP2C9;CYP2C9*36;*36;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
GEFITINIB;CYP2D6;CYP2D6*1;*10 + *87 + *90 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
GEFITINIB;CYP2D6;CYP2D6*10;*10 + *87 + *90 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
GEFITINIB;CYP2D6;CYP2D6*87;*10 + *87 + *90 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
GEFITINIB;CYP2D6;CYP2D6*90;*10 + *87 + *90 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
GEFITINIB;CYP2D6;CYP2D6*93;*10 + *87 + *90 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
GEFITINIB;CYP2D6;CYP2D6*95;*10 + *87 + *90 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
GEFITINIB;CYP2D6;CYP2D6*98;*10 + *87 + *90 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;CYP2D6*1;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*2;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*10;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*87;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*88;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*89;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*90;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*91;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*93;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*94;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*95;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*97;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*134;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
BUFURALOL;CYP2D6;CYP2D6*153;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2D6;;
RISPERIDONE;CYP2D6;CYP2D6*1;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*2;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*87;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*88;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*89;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*90;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*91;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*93;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*94;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*95;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*97;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
RISPERIDONE;CYP2D6;CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*1;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*2;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*10;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*87;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*88;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*89;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*90;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*91;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*93;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
CITALOPRAM;CYP2D6;CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*1;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*2;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*87;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*88;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*90;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*91;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*93;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*95;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
ATOMOXETINE;CYP2D6;CYP2D6*97;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TAMOXIFEN;CYP2D6;CYP2D6*87;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TAMOXIFEN;CYP2D6;CYP2D6*90;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TAMOXIFEN;CYP2D6;CYP2D6*91;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TAMOXIFEN;CYP2D6;CYP2D6*93;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TAMOXIFEN;CYP2D6;CYP2D6*95;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TAMOXIFEN;CYP2D6;CYP2D6*98;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TOLTERODINE;CYP2D6;CYP2D6*1;*10 + *93 + *94 + *95;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TOLTERODINE;CYP2D6;CYP2D6*10;*10 + *93 + *94 + *95;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TOLTERODINE;CYP2D6;CYP2D6*93;*10 + *93 + *94 + *95;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TOLTERODINE;CYP2D6;CYP2D6*94;*10 + *93 + *94 + *95;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TOLTERODINE;CYP2D6;CYP2D6*95;*10 + *93 + *94 + *95;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*87;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*90;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*91;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*93;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*94;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*95;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*97;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*98;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*134;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*153;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*2;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*10;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*87;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*88;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*89;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*90;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*91;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*93;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*94;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*95;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*97;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
BUFURALOL;CYP2D6;rs745746329;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DEXTROMETHORPHAN;CYP2D6;rs745746329;T;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OLANZAPINE;CYP2D6;CYP2D6*1;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OLANZAPINE;CYP2D6;CYP2D6*10;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OLANZAPINE;CYP2D6;CYP2D6*87;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OLANZAPINE;CYP2D6;CYP2D6*88;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OLANZAPINE;CYP2D6;CYP2D6*90;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OLANZAPINE;CYP2D6;CYP2D6*91;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OLANZAPINE;CYP2D6;CYP2D6*93;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OLANZAPINE;CYP2D6;CYP2D6*95;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
OLANZAPINE;CYP2D6;CYP2D6*97;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
nan;CYP2C9;rs9332094;C;OTHER;DECREASED_TRANSCRIPTION;nan;GENE:CYP2C9;;;
PHENYTOIN;CYP2C9;CYP2C9*37;*37;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
PHENYTOIN;CYP2C9;CYP2C9*42;*42;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
nan;CYP2C9;rs7089580;AT + TT;OTHER;INCREASED_EXPRESSION;RECEPTOR;ENZYME;CYP2C9;;
PHENYTOIN;CYP2C9;CYP2C9*55;*55;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PHENYTOIN;CYP2C9;CYP2C9*56;*56;LADME-PK;INCREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PHENYTOIN;CYP2C9;CYP2C9*53;*53;LADME-PK;INCREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PHENYTOIN;CYP2C9;CYP2C9*50;*50;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PHENYTOIN;CYP2C9;CYP2C9*54;*54;LADME-PK;INCREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PHENYTOIN;CYP2C9;CYP2C9*19;*19;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PHENYTOIN;CYP2C9;CYP2C9*31;*31;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LOSARTAN;CYP2C9;rs1057910;C;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PHENYTOIN;CYP2C9;CYP2C9*41;*41;LADME-PK;INCREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PHENYTOIN;CYP2C9;CYP2C9*27;*27;LADME-PK;INCREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PHENYTOIN;CYP2C9;CYP2C9*14;*14;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DICLOFENAC;CYP2C9;CYP2C9*62;*62;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LOSARTAN;CYP2C9;CYP2C9*62;*62;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TOLBUTAMIDE;CYP2C9;CYP2C9*62;*62;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DICLOFENAC;CYP2C9;CYP2C9*2;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LOSARTAN;CYP2C9;CYP2C9*2;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TOLBUTAMIDE;CYP2C9;CYP2C9*2;*2;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
LOSARTAN;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
TOLBUTAMIDE;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;;;
PHENYTOIN;CYP2C9;CYP2C9*47;*47;LADME-PK;INCREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PHENYTOIN;CYP2C9;CYP2C9*49;*49;LADME-PK;INCREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
PHENYTOIN;CYP2C9;CYP2C9*43;*43;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
PHENYTOIN;CYP2C9;CYP2C9*39;*39;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
PHENYTOIN;CYP2C9;CYP2C9*8;*8;LADME-PK;DECREASED_CLEARANCE;DRUG_ACCUMULATION;ENZYME;CYP2C9;;
NICOTINE;CYP2A6;rs1801272;AA + AT;TOXICITY;DECREASED_RISK;OTHER;TOBACCO USE DISORDER;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
TACROLIMUS;CYP3A4;rs2740574;T;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO);;;
ARIPIPRAZOLE;CYP2D6;CYP2D6 ultrarapid metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
SULFAMETHOXAZOLE;NAT2;rs1799930;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
TRIMETHOPRIM;NAT2;rs1799930;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
ATORVASTATIN;HLA-DRB1;HLA-DRB1*01:01;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
ATORVASTATIN;HLA-DRB1;HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
FLUVASTATIN;HLA-DRB1;HLA-DRB1*01:01;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
FLUVASTATIN;HLA-DRB1;HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
HMG COA REDUCTASE INHIBITORS;HLA-DRB1;HLA-DRB1*01:01;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
HMG COA REDUCTASE INHIBITORS;HLA-DRB1;HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
PITAVASTATIN;HLA-DRB1;HLA-DRB1*01:01;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
PITAVASTATIN;HLA-DRB1;HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
PRAVASTATIN;HLA-DRB1;HLA-DRB1*01:01;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
PRAVASTATIN;HLA-DRB1;HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
ROSUVASTATIN;HLA-DRB1;HLA-DRB1*01:01;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
ROSUVASTATIN;HLA-DRB1;HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
SIMVASTATIN;HLA-DRB1;HLA-DRB1*01:01;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
SIMVASTATIN;HLA-DRB1;HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
ETHANOL;CHRNA5;rs615470;T;TOXICITY, OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;ALCOHOL ABUSE ;;
LIRAGLUTIDE;GLP1R;rs2254336;AT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
LIRAGLUTIDE;GLP1R;rs2254336;AT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
LIRAGLUTIDE;GLP1R;rs2254336;AT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
LIRAGLUTIDE;GLP1R;rs2254336;AT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1041983;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED AUC24;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED AUC24;;;
GEFITINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
LIRAGLUTIDE;GLP1R;rs3765467;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
LIRAGLUTIDE;GLP1R;rs3765467;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
LIRAGLUTIDE;GLP1R;rs3765467;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
LIRAGLUTIDE;GLP1R;rs3765467;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;HEMORRHAGE ;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ATORVASTATIN;HTR3B;rs2276307;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYALGIA ;;
PRAVASTATIN;HTR3B;rs2276307;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYALGIA ;;
SIMVASTATIN;HTR3B;rs2276307;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYALGIA ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_LIKELIHOODPK;PK;ACHIEVING OPTIMAL TROUGH LEVEL;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_LIKELIHOODPK;PK;ACHIEVING OPTIMAL TROUGH LEVEL;;;
NORTRIPTYLINE;UST;rs2500535;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;IMPROVEMENT OF DEPRESSION SYMPTOMS;;;
TACROLIMUS;CYP3A4;rs1851426;G;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO);;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;;SIDE_EFFECT;EFFICACY;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;;SIDE_EFFECT;EFFICACY;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;;SIDE_EFFECT;EFFICACY;TIME TO THERAPEUTIC INR;;;
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING;;;
OSIMERTINIB;IL6;rs1800796;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RISPERIDONE;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
TAMOXIFEN;CYP2D6;CYP2D6*6;*6/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_SEVERITY;OTHER;INTERSTITIAL INFLAMMATORY CELL INFILTRATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_SEVERITY;OTHER;INTERSTITIAL INFLAMMATORY CELL INFILTRATION;;;
RISPERIDONE;HTR2A;rs6313;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
OXAZEPAM;UGT2B15;rs1902023;AA;LADME-PK;DECREASED_PK;METABOLISM;S-OXAZEPAM GLUCURONIDATION IN HUMAN LIVER MICROSOMES;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
OXAZEPAM;UGT2B15;rs1902023;AA;LADME-PK;DECREASED_PK;METABOLISM;OXAZEPAM ORAL CLEARANCE;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
ISONIAZID;CYP2B6;CYP2B6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS ;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TACROLIMUS;PPARA;rs4823613;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ACUTE CELLULAR REJECTION;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY, INFECTIOUS DISEASE, STOMATITIS, ;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY, INFECTIOUS DISEASE, STOMATITIS, ;;
METHOTREXATE;TPMT;TPMT*1;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY, INFECTIOUS DISEASE, STOMATITIS, ;;
METHOTREXATE;TPMT;TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY, INFECTIOUS DISEASE, STOMATITIS, ;;
NITROUS OXIDE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PLASMA TOTAL HOMOCYSTEINE CONCENTRATIONS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DEATH;;;
RISPERIDONE;DRD3;rs167771;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1;*1/*10 + *10/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*10;*1/*10 + *10/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
FLUCLOXACILLIN;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
FLUCLOXACILLIN;HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
AMOXICILLIN;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CISPLATIN;GGT1;rs5751901;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CISPLATIN;GGT1;rs5751901;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
PACLITAXEL;GGT1;rs5751901;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
PACLITAXEL;GGT1;rs5751901;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
BUSULFAN;CYP2B6;CYP2B6*1;*1/*1 + *1/*5 + *1/*9;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
BUSULFAN;CYP2B6;CYP2B6*5;*1/*1 + *1/*5 + *1/*9;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
BUSULFAN;CYP2B6;CYP2B6*9;*1/*1 + *1/*5 + *1/*9;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;UTERINE DISORDER;;;
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEIOMYOMA;;;
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ENDOMETRIAL HYPERPLASIA;;;
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;POLYPS;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
CAPECITABINE;ABCC11;rs17822471;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;ABCC11;rs17822471;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1;*1/*4 + *1/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*4;*1/*4 + *1/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*5;*1/*4 + *1/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
FLUVOXAMINE;CYP2D6;CYP2D6*1;*1/*10 + *1/*5 + *10/*10 + *5/*10;LADME-PK;PK;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY;;;
FLUVOXAMINE;CYP2D6;CYP2D6*5;*1/*10 + *1/*5 + *10/*10 + *5/*10;LADME-PK;PK;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY;;;
FLUVOXAMINE;CYP2D6;CYP2D6*10;*1/*10 + *1/*5 + *10/*10 + *5/*10;LADME-PK;PK;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY;;;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BULLOUS PEMPHIGOID;;;
PEGINTERFERON ALFA-2A;IDO1;rs9657182;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEPRESSION;;;
PEGINTERFERON ALFA-2B;IDO1;rs9657182;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEPRESSION;;;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;nan;rs3129763;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BULLOUS PEMPHIGOID;;;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BULLOUS PEMPHIGOID;;;
NITROUS OXIDE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PLASMA TOTAL HOMOCYSTEINE CONCENTRATIONS;;;
CIPROFLOXACIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
LEVOFLOXACIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
MOXIFLOXACIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
OMEPRAZOLE;CYP2C19;rs11188072;TT;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;AUC;;;
METHADONE;CYP3A4;rs3735451;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SIDE EFFECTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CARBOPLATIN;ABCB1;rs2032582;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;ABCB1;rs2032582;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*1/*1;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*1/*1;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1;*10;TOXICITY;RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*10;*10;TOXICITY;RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*2;*2/*2xN;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*2xN;*2/*2xN;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ASPARAGINASE;ATL2;rs59569490;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
AZATHIOPRINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCREATITIS;;;
MERCAPTOPURINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCREATITIS;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAXIMAL PLATELET AGGREGATION;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAXIMAL PLATELET AGGREGATION;;;
ASPIRIN;CYP2C19;CYP2C19*3;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAXIMAL PLATELET AGGREGATION;;;
CILOSTAZOL;CYP2C19;CYP2C19*1;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAXIMAL PLATELET AGGREGATION;;;
CILOSTAZOL;CYP2C19;CYP2C19*2;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAXIMAL PLATELET AGGREGATION;;;
CILOSTAZOL;CYP2C19;CYP2C19*3;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAXIMAL PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAXIMAL PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAXIMAL PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAXIMAL PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS (ST) AFTER 1 YEAR;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS (ST) AFTER 1 YEAR;;;
ESCITALOPRAM;CYP2C19;rs4986893;A;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
PLATINUM COMPOUNDS;RETN;rs1862513;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *1/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *1/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *1/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *1/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
NILOTINIB;UGT1A1;UGT1A1*1;*6/*6 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
NILOTINIB;UGT1A1;UGT1A1*6;*6/*6 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
NILOTINIB;UGT1A1;UGT1A1*27;*6/*6 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
NILOTINIB;UGT1A1;UGT1A1*28;*6/*6 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
PRIMAQUINE;MAOA;rs1137070;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
OMEPRAZOLE;CYP2C19;rs12248560;TT;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;AUC;;;
PRIMAQUINE;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RECURRENCE;;;
AZATHIOPRINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
PRIMAQUINE;CYP2D6;CYP2D6*4;*4;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
ESCITALOPRAM;CYP2C19;rs11188072;TT;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION/DOSE RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION/DOSE RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION/DOSE RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION/DOSE RATIO;;;
TENOFOVIR;ABCC10;rs2125739;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;KIDNEY TUBULAR DYSFUNCTION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;LADME-PK;INCREASED_PK;METABOLISM;BLOOD CONCENTRATION/DOSAGE RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;LADME-PK;INCREASED_PK;METABOLISM;BLOOD CONCENTRATION/DOSAGE RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION/DOSE RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION/DOSE RATIO;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;CYP2B6;CYP2B6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
TACROLIMUS;CYP3A4;rs2687116;A;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO);;;
CARBOPLATIN;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
PACLITAXEL;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
CARBOPLATIN;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
PACLITAXEL;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
ESCITALOPRAM;CYP2C19;rs4244285;A;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
nan;IFNL4;rs11322783;TT/TT;OTHER;INCREASED_LIKELIHOOD;OTHER;SPONTANEOUS HCV CLEARANCE;;;
MERCAPTOPURINE;SLC22A1;rs72552763;del;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;INFECTIOUS DISEASE;;;
CARBOPLATIN;nan;rs6856089;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
CISPLATIN;nan;rs6856089;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED_PK;METABOLISM;6-MMPN LEVELS;;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED_PK;METABOLISM;6-MMPN LEVELS;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED_PK;METABOLISM;6-MMPN LEVELS;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED_PK;METABOLISM;6-MMPN LEVELS;;;
nan;SOD1;rs36232792;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;OTHER;DECREASED_LIKELIHOOD;OTHER;OPIOID-RELATED DISORDERS;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY;;;
PURINE ANALOGUES;TPMT;TPMT*1;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY;;;
PURINE ANALOGUES;TPMT;TPMT*3A;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY;;;
PURINE ANALOGUES;TPMT;TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY;;;
ETHAMBUTOL;NAT2;NAT2*1;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*5;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*6;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*7;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*1;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*5;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*6;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*7;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*1;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*5;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*6;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*7;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*1;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*5;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*6;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*7;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
LACOSAMIDE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;EFFICACY;DISCONTINUATION;;;
LACOSAMIDE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;EFFICACY;DISCONTINUATION;;;
LACOSAMIDE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;EFFICACY;DISCONTINUATION;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS;;;
PURINE ANALOGUES;TPMT;TPMT*1;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS;;;
PURINE ANALOGUES;TPMT;TPMT*3A;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS;;;
PURINE ANALOGUES;TPMT;TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS;;;
nan;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;OTHER;INCREASED_LIKELIHOOD;OTHER;DECREASED GLOMERULAR FILTRATION RATE;;;
nan;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;OTHER;INCREASED_LIKELIHOOD;OTHER;DECREASED GLOMERULAR FILTRATION RATE;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;TREATMENT MODIFICATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;TREATMENT MODIFICATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;TREATMENT MODIFICATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;TREATMENT MODIFICATION;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;TREATMENT MODIFICATION;;;
SERTRALINE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
SERTRALINE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;TREATMENT MODIFICATION;;;
SERTRALINE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
SERTRALINE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;TREATMENT MODIFICATION;;;
SERTRALINE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
SERTRALINE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_LIKELIHOOD;OTHER;TREATMENT MODIFICATION;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *1/*3B + *1/*3C;TOXICITY;DECREASED_;SIDE_EFFECT;HEMATOLOGICAL INDICES;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *1/*3B + *1/*3C;TOXICITY;DECREASED_;SIDE_EFFECT;HEMATOLOGICAL INDICES;;;
AZATHIOPRINE;TPMT;TPMT*3B;*1/*3A + *1/*3B + *1/*3C;TOXICITY;DECREASED_;SIDE_EFFECT;HEMATOLOGICAL INDICES;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *1/*3B + *1/*3C;TOXICITY;DECREASED_;SIDE_EFFECT;HEMATOLOGICAL INDICES;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CYCLOSPORINE;TPMT;TPMT*1;*1/*3A + *1/*3B + *1/*3C;TOXICITY;INCREASED_PK;PK;PLASMA LEVELS;;;
CYCLOSPORINE;TPMT;TPMT*3A;*1/*3A + *1/*3B + *1/*3C;TOXICITY;INCREASED_PK;PK;PLASMA LEVELS;;;
CYCLOSPORINE;TPMT;TPMT*3B;*1/*3A + *1/*3B + *1/*3C;TOXICITY;INCREASED_PK;PK;PLASMA LEVELS;;;
CYCLOSPORINE;TPMT;TPMT*3C;*1/*3A + *1/*3B + *1/*3C;TOXICITY;INCREASED_PK;PK;PLASMA LEVELS;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1;;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1;;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1;;;
CISPLATIN;MTHFR;rs1801131;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PEMETREXED;MTHFR;rs1801131;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ESCITALOPRAM;CYP2C19;rs12248560;TT;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SUFENTANIL;ADRB1;rs1801253;GG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE_PAIN;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*2;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*4;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*35;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*36;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*41;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*35;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*36;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
TENOFOVIR;ABCC10;rs9349256;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;KIDNEY TUBULAR DYSFUNCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MORTALITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MORTALITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYOCARDIAL INFARCTION ;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYOCARDIAL INFARCTION ;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYOCARDIAL INFARCTION ;;
IMATINIB;ABCB1;rs1045642;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
IMATINIB;NR1I2;rs3814055;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;rs6295;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
FLUOROURACIL;CYP2A6;CYP2A6*1;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;DECREASED_PK;METABOLISM;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE;;;
FLUOROURACIL;CYP2A6;CYP2A6*4;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;DECREASED_PK;METABOLISM;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE;;;
FLUOROURACIL;CYP2A6;CYP2A6*7;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;DECREASED_PK;METABOLISM;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE;;;
FLUOROURACIL;CYP2A6;CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;DECREASED_PK;METABOLISM;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE;;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
METHOTREXATE;MTRR;rs1801394;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
TEGAFUR;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;OTHER;INCREASED_LIKELIHOOD;OTHER;P2Y12 REACTION UNIT(PRU) VALUES;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;OTHER;INCREASED_LIKELIHOOD;OTHER;P2Y12 REACTION UNIT(PRU) VALUES;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;OTHER;INCREASED_LIKELIHOOD;OTHER;P2Y12 REACTION UNIT(PRU) VALUES;;;
ROSUVASTATIN;CYP2C19;CYP2C19*1;*2 + *3;OTHER;INCREASED_LIKELIHOOD;OTHER;P2Y12 REACTION UNIT(PRU) VALUES;;;
ROSUVASTATIN;CYP2C19;CYP2C19*2;*2 + *3;OTHER;INCREASED_LIKELIHOOD;OTHER;P2Y12 REACTION UNIT(PRU) VALUES;;;
ROSUVASTATIN;CYP2C19;CYP2C19*3;*2 + *3;OTHER;INCREASED_LIKELIHOOD;OTHER;P2Y12 REACTION UNIT(PRU) VALUES;;;
METHADONE;CYP3A4;rs4646437;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SIDE EFFECTS;;;
TEGAFUR;CYP2A6;CYP2A6*1;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE;;;
TEGAFUR;CYP2A6;CYP2A6*4;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE;;;
TEGAFUR;CYP2A6;CYP2A6*7;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE;;;
TEGAFUR;CYP2A6;CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*17/*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17/*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*7;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*14;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
AZATHIOPRINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
AZATHIOPRINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
LAMOTRIGINE;HLA-C;HLA-C*07:18;*07:18;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
LAMOTRIGINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
RIVAROXABAN;ABCB1;rs4148738;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
LAMOTRIGINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
RIVAROXABAN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;THROMBOEMBOLISM;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ENDOMETRIAL HYPERPLASIA;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CLOPIDOGREL RESISTANCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CLOPIDOGREL RESISTANCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CLOPIDOGREL RESISTANCE;;;
METHOTREXATE;MTHFD1;rs2236225;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
METHADONE;CYP3A4;rs2242480;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SIDE EFFECTS;;;
CARBOPLATIN;CD274;rs2297136;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;CD274;rs2297136;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING EVENTS;;;
CARBOPLATIN;CD274;rs822336;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;CD274;rs822336;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
CARBOPLATIN;CD274;rs2282055;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;CD274;rs2282055;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
HYDROMORPHONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PRURITUS;;;
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PRURITUS;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1;*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6*2;*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
DOXORUBICIN;NCF4;rs1883112;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
AZATHIOPRINE;NUDT15;NUDT15*1;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;NUDT15;NUDT15*1;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;NUDT15;NUDT15*2;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;NUDT15;NUDT15*2;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;NUDT15;NUDT15*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;NUDT15;NUDT15*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*2;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;TPMT;TPMT*2;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*8;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;TPMT;TPMT*8;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*9;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;TPMT;TPMT*9;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*12;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;TPMT;TPMT*12;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*24;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
AZATHIOPRINE;TPMT;TPMT*24;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
DOXORUBICIN;CBR1;rs3787728;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
DOXORUBICIN;CBR1;rs3787728;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:04;*04:04;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DOXORUBICIN;CBR1;rs1005695;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
DOXORUBICIN;CBR1;rs1005695;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*1;*1/*5 + *5/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*1;*1/*5 + *5/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*5;*1/*5 + *5/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*5;*1/*5 + *5/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;OTHER;INCREASED_LIKELIHOOD;OTHER;PLATELET REACTIVITY BY P2Y12 REACTION UNITS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;OTHER;INCREASED_LIKELIHOOD;OTHER;PLATELET REACTIVITY BY P2Y12 REACTION UNITS;;;
DABIGATRAN;CES1;rs2244613;GG + GT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
OLANZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIZZINESS ;;
OLANZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIZZINESS ;;
QUETIAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIZZINESS ;;
QUETIAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIZZINESS ;;
RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIZZINESS ;;
RISPERIDONE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIZZINESS ;;
RIVAROXABAN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOEMBOLISM;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
CAPECITABINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PLATINUM;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PLATINUM;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ONDANSETRON;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_SEVERITY;OTHER;PERCENTAGE OF DAYS ABSTINENT AND LOWER NUMBER OF DRINKS PER DRINKING DAY;;;
ONDANSETRON;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_SEVERITY;OTHER;PERCENTAGE OF DAYS ABSTINENT AND LOWER NUMBER OF DRINKS PER DRINKING DAY;;;
CHOP;CBR3;rs8133052;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
RITUXIMAB;CBR3;rs8133052;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
CHOP;ABCC2;rs8187710;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
RITUXIMAB;ABCC2;rs8187710;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1;*5/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*5;*5/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*6;*5/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
METHOTREXATE;SLC19A1;rs1051266;T;;SIDE_EFFECT;EFFICACY;WORSE PROGNOSES;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEXUAL DYSFUNCTION;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEXUAL DYSFUNCTION;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*11;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR);;;
WARFARIN;CYP2C9;CYP2C9*11;*1/*11;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR);;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
PURINE ANALOGUES;TPMT;TPMT*1;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
PURINE ANALOGUES;TPMT;TPMT*3C;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
GEMCITABINE;RRM1;rs1042927;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL PROBABILITY;;;
PLATINUM COMPOUNDS;RRM1;rs1042927;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL PROBABILITY;;;
METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TREMOR;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
AMOXICILLIN;HLA-B;HLA-B*15:18;*15:18;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-B;HLA-B*15:18;*15:18;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ASTHENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ASTHENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*37;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ASTHENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*37;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*37;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
CAPECITABINE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
AZATHIOPRINE;PTPN2;rs11664064;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;PTPN2;rs11664064;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*41;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
BEVACIZUMAB;SHMT1;rs1979277;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034);;;
FLUOROURACIL;SHMT1;rs1979277;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034);;;
IRINOTECAN;SHMT1;rs1979277;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034);;;
LEUCOVORIN;SHMT1;rs1979277;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034);;;
METHOTREXATE;MTHFD1;rs2236225;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TAMOXIFEN;CYP2D6;rs3892097;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
METHOTREXATE;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;GSTP1;rs1695;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
MERCAPTOPURINE;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GI TOXICITY;;;
METHOTREXATE;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GI TOXICITY;;;
METHOTREXATE;SLCO1B1;rs11045879;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MUCOSITIS ;;
AMOXICILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
AMOXICILLIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
AMOXICILLIN;ERAP1;rs1363907;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
AMOXICILLIN;ERAP2;rs1363907;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;ERAP1;rs1363907;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;ERAP2;rs1363907;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CYCLOPHOSPHAMIDE;GSTT1;GSTT1 non-null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CYCLOPHOSPHAMIDE;GSTT1;GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
AMOXICILLIN;PTPN22;rs2476601;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;PTPN22;rs2476601;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CYCLOPHOSPHAMIDE;GSTM1;GSTM1 non-null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CYCLOPHOSPHAMIDE;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;TYMS;rs3786362;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;TYMS;rs699517;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;ENOSF1;rs11280056;TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;ENOSF1;rs2790;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;TYMS;rs2790;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
nan;NME1;rs2302254;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
nan;NME1;rs2302254;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RECURRENCE FREE SURVIVAL;;;
nan;NME1-NME2;rs2302254;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
nan;NME1-NME2;rs2302254;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RECURRENCE FREE SURVIVAL;;;
IRINOTECAN;UGT1A7;UGT1A7*1a;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A7;UGT1A7*2;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A7;UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
RIVAROXABAN;SUSD3;rs76292544;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A7;UGT1A7*1a;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A7;UGT1A7*2;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A7;UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;SLCO1B1;rs4149081;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GI TOXICITY;;;
SULFAMETHOXAZOLE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
SULFAMETHOXAZOLE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
TRIMETHOPRIM;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
TRIMETHOPRIM;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ASPIRIN;FCER1G;rs11587213;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA;;;
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*6;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;INCREASED_PK;METABOLISM;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO);;;
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
nan;MS4A2;rs569108;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;OTHER;ATOPY IN PATIENTS WITH ASPIRIN-INTOLERANT CHRONIC URTICARIA;;;
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PACLITAXEL;ABCB1;rs2032582;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;CHANCE OF POSITIVE RESPONSE TO PACLITAXEL;;;
ETHAMBUTOL;FECH;rs536560;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;FECH;rs536560;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;FECH;rs536560;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;FECH;rs536560;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
nan;FCER1G;rs11587213;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;OTHER;ATOPY IN PATIENTS WITH ASPIRIN-INTOLERANT CHRONIC URTICARIA;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
CISPLATIN;EPHX1;rs1051740;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
RADIOTHERAPY;EPHX1;rs1051740;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
CISPLATIN;ERCC2;rs13181;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
RADIOTHERAPY;ERCC2;rs13181;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
CISPLATIN;ERCC2;rs1799793;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
RADIOTHERAPY;ERCC2;rs1799793;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GEMCITABINE;CDA;rs2072671;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;NAUSEA ;;
PLATINUM COMPOUNDS;CDA;rs2072671;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;NAUSEA ;;
nan;CYP2A6;CYP2A6*4;*4/*4;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;rs4646450;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*2 + *1/*3 + *1/*6 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*1/*2 + *1/*3 + *1/*6 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*2 + *1/*3 + *1/*6 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*6;*1/*2 + *1/*3 + *1/*6 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_;nan;DISEASE;GASTRIC PH ;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_;nan;DISEASE;GASTRIC PH ;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_;nan;DISEASE;GASTRIC PH ;;
ETHAMBUTOL;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE, OTHER;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
METHOTREXATE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CARBOPLATIN;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;THROMBOCYTOPENIA ;;
GEMCITABINE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;THROMBOCYTOPENIA ;;
METHOTREXATE;SLCO1B1;rs4149056;C;OTHER, LADME-PK;DECREASED_PK;METABOLISM;CLEARANCE;;;
ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;CHRONIC KIDNEY FAILURE ;;
SUCCINYLCHOLINE;RYR1;rs193922752;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MALIGNANT HYPERTHERMIA;;;
VOLATILE ANESTHETICS;RYR1;rs193922752;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MALIGNANT HYPERTHERMIA;;;
EGFR INHIBITORS;EGFR;rs2227983;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;EXANTHEMA ;;
GEMCITABINE;RRM1;rs12806698;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;NAUSEA ;;
PLATINUM COMPOUNDS;RRM1;rs12806698;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;NAUSEA ;;
GEMCITABINE;RRM1;rs11030918;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;NAUSEA ;;
PLATINUM COMPOUNDS;RRM1;rs11030918;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;NAUSEA ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
VERAPAMIL;ADRB1;rs1801252;AA + AG;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
HEROIN;DRD2;rs12364283;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEROIN DEPENDENCE;;;
REPAGLINIDE;CYP2C8;CYP2C8*3;*3;LADME-PK;DECREASED_PK;METABOLISM;REPAGLINIDE AUC;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAEMATOPOIETIC TOXICITY;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAEMATOPOIETIC TOXICITY;;;
SULFAMETHOXAZOLE;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TRIMETHOPRIM;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
AZATHIOPRINE;NUDT15;NUDT15*1;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*2;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*5;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*6;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
TACROLIMUS;CYP3A7;rs2257401;C;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO);;;
SIMVASTATIN;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES;;;
SIMVASTATIN;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
PHENYTOIN;CYP2C19;rs4986893;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS ;;
TRAMADOL;CYP2D6;CYP2D6*1;*3/*5;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
TRAMADOL;CYP2D6;CYP2D6*3;*3/*5;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
TRAMADOL;CYP2D6;CYP2D6*5;*3/*5;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
TRAMADOL;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
TRAMADOL;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
TACROLIMUS;CYP3A4;rs4646437;G;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO);;;
ISONIAZID;NAT2;NAT2*4;*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ASPARAGINASE;SOD2;rs4880;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
nan;CYP1A2;rs762551;AC + CC;OTHER;INCREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
TRASTUZUMAB;ERBB2;rs1136201;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
SIMVASTATIN;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
SIMVASTATIN;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;STEVENS-JOHNSON SYNDROME ;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
BETA BLOCKING AGENTS;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
PACLITAXEL;FZD3;rs7001034;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;SENSORY PERIPHERAL NEUROPATHY;;;
CAPECITABINE;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;RISK;nan;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
SERTRALINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
CLOZAPINE;HLA-DRB1;HLA-DRB1*04:02;*04:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;AGRANULOCYTOSIS;;;
DIRECT ACTING ANTIVIRALS;IFNL3;rs12979860;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEPATOCELLULAR CARCINOMA;;;
DIRECT ACTING ANTIVIRALS;IFNL4;rs12979860;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEPATOCELLULAR CARCINOMA;;;
GLICLAZIDE;CYP2C9;CYP2C9*1;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLICLAZIDE;CYP2C9;CYP2C9*2;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLICLAZIDE;CYP2C9;CYP2C9*3;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLIMEPIRIDE;CYP2C9;CYP2C9*1;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLIMEPIRIDE;CYP2C9;CYP2C9*2;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLIMEPIRIDE;CYP2C9;CYP2C9*3;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLIPIZIDE;CYP2C9;CYP2C9*1;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLIPIZIDE;CYP2C9;CYP2C9*2;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLIPIZIDE;CYP2C9;CYP2C9*3;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLIQUIDONE;CYP2C9;CYP2C9*1;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLIQUIDONE;CYP2C9;CYP2C9*2;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLIQUIDONE;CYP2C9;CYP2C9*3;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLYBURIDE;CYP2C9;CYP2C9*1;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLYBURIDE;CYP2C9;CYP2C9*2;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
GLYBURIDE;CYP2C9;CYP2C9*3;*2 + *3;OTHER;INCREASED_RISK;nan;DISEASE;HYPOGLYCEMIA ;;
TRAMADOL;CYP2D6;CYP2D6*1;*5/*5;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
TRAMADOL;CYP2D6;CYP2D6*5;*5/*5;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
ASPIRIN;NOS3;rs1799983;T;OTHER;INCREASED_RISK;OTHER;IN-STENT RESTENOSIS;;;
BETA BLOCKING AGENTS;NOS3;rs1799983;T;OTHER;INCREASED_RISK;OTHER;IN-STENT RESTENOSIS;;;
CLOPIDOGREL;NOS3;rs1799983;T;OTHER;INCREASED_RISK;OTHER;IN-STENT RESTENOSIS;;;
HMG COA REDUCTASE INHIBITORS;NOS3;rs1799983;T;OTHER;INCREASED_RISK;OTHER;IN-STENT RESTENOSIS;;;
CISPLATIN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP2D6;CYP2D6*1;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ASPIRIN;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
TACROLIMUS;CYP3A4;rs6956344;C;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO);;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CISPLATIN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:21;*15:21;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:21;*15:21;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
PACLITAXEL;ABCB1;rs1045642;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE CONTROL RATE AND LOWER OVERALL SURVIVAL RATE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_PK;METABOLISM;CLOPIDOGREL ACTIVE METABOLITE LEVEL;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_LIKELIHOODPK;PK;ACHIEVING TARGET CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_LIKELIHOODPK;PK;ACHIEVING TARGET CONCENTRATIONS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;POST-TREATMENT ADP-STIMULATED PLATELET AGGREGATION;;;
PACLITAXEL;CYP3A5;rs776746;C;TOXICITY;DECREASED_RISK;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HOT FLASHES;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HOT FLASHES;;;
INFLIXIMAB;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
INFLIXIMAB;HLA-DPB1;HLA-DPB1*10:01;*10:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
INFLIXIMAB;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1xN;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10x2;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*14;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*21;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*36;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
nan;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ASPIRIN-INDUCED ASTHMA ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*2;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TRAMADOL;CYP2D6;CYP2D6*1;*6/*6;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
TRAMADOL;CYP2D6;CYP2D6*6;*6/*6;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
TRAMADOL;CYP2D6;CYP2D6*1;*4/*5;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
TRAMADOL;CYP2D6;CYP2D6*4;*4/*5;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
TRAMADOL;CYP2D6;CYP2D6*5;*4/*5;DOSAGE, EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE AND REQUIRED HIGHER DOSE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CYCLOPHOSPHAMIDE;CPT1A;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYCLOPHOSPHAMIDE;IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYTARABINE;CPT1A;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYTARABINE;IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
DAUNORUBICIN;CPT1A;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
DAUNORUBICIN;IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
DOXORUBICIN;CPT1A;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
DOXORUBICIN;IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
MERCAPTOPURINE;CPT1A;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
MERCAPTOPURINE;IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
METHOTREXATE;CPT1A;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
METHOTREXATE;IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
PEGASPARGASE;CPT1A;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
PEGASPARGASE;IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
THIOGUANINE;CPT1A;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
THIOGUANINE;IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
VINCRISTINE;CPT1A;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
VINCRISTINE;IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
FOLFIRINOX;UGT1A1;UGT1A1*1;*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
FOLFIRINOX;UGT1A1;UGT1A1*28;*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*14;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*21;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*36;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE;DOSE-ADJUSTED BLOOD LEVELS ;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE;DOSE-ADJUSTED BLOOD LEVELS ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE;DOSE-ADJUSTED TROUGH CONCENTRATION ;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE;DOSE-ADJUSTED TROUGH CONCENTRATION ;;
TACROLIMUS;CYP3A4;rs2242480;C;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO);;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24;;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;OTHER;INCREASED_LIKELIHOOD;OTHER;CREATININE CLEARANCE;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;OTHER;INCREASED_LIKELIHOOD;OTHER;CREATININE CLEARANCE;;;
FLECAINIDE;CYP2D6;CYP2D6*1;*4 + *5 + *10 + *21 + *36;LADME-PK;INCREASED_PK;METABOLISM;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS;;;
FLECAINIDE;CYP2D6;CYP2D6*4;*4 + *5 + *10 + *21 + *36;LADME-PK;INCREASED_PK;METABOLISM;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS;;;
FLECAINIDE;CYP2D6;CYP2D6*5;*4 + *5 + *10 + *21 + *36;LADME-PK;INCREASED_PK;METABOLISM;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS;;;
FLECAINIDE;CYP2D6;CYP2D6*10;*4 + *5 + *10 + *21 + *36;LADME-PK;INCREASED_PK;METABOLISM;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS;;;
FLECAINIDE;CYP2D6;CYP2D6*21;*4 + *5 + *10 + *21 + *36;LADME-PK;INCREASED_PK;METABOLISM;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS;;;
FLECAINIDE;CYP2D6;CYP2D6*36;*4 + *5 + *10 + *21 + *36;LADME-PK;INCREASED_PK;METABOLISM;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS;;;
TRANILAST;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
TRANILAST;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*3;*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION;;;
FLECAINIDE;CYP2D6;CYP2D6*1;*5/*36 + *10/*10 + *10/*36 + *21/*36;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA;;;
FLECAINIDE;CYP2D6;CYP2D6*2;*5/*36 + *10/*10 + *10/*36 + *21/*36;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA;;;
FLECAINIDE;CYP2D6;CYP2D6*5;*5/*36 + *10/*10 + *10/*36 + *21/*36;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA;;;
FLECAINIDE;CYP2D6;CYP2D6*10;*5/*36 + *10/*10 + *10/*36 + *21/*36;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA;;;
FLECAINIDE;CYP2D6;CYP2D6*21;*5/*36 + *10/*10 + *10/*36 + *21/*36;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA;;;
FLECAINIDE;CYP2D6;CYP2D6*36;*5/*36 + *10/*10 + *10/*36 + *21/*36;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA;;;
ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
ANTITHYROID PREPARATIONS;HLA-DQA1;HLA-DQA1*01:03;*01:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
ANTITHYROID PREPARATIONS;HLA-DQB1;HLA-DQB1*06:01;*06:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1xN;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*2;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*3;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*4;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*6;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*9;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*20;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*35;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*41;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1xN;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*6;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*9;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*20;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*35;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CYTARABINE;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;3 YEAR EVENT FREE SURVIVAL;;;
IDARUBICIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;3 YEAR EVENT FREE SURVIVAL;;;
CLOPIDOGREL;CYP1A2;rs2069514;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
OPIOIDS;OPRM1;rs548646;T;TOXICITY;DECREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*10;LADME-PK;INCREASED_PK;METABOLISM;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2;*10;LADME-PK;INCREASED_PK;METABOLISM;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*10;*10;LADME-PK;INCREASED_PK;METABOLISM;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ACUTE CELLULAR REJECTION ;;
RHODAMINE 123;ABCB1;rs1045642;GG;LADME-PK;INCREASED_PK;METABOLISM;EFFLUX OF RHODAMINE FROM CD56+ NATURAL KILLER CELLS;;;
ASPIRIN;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;TOXICITY;nan;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;TOXICITY;nan;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;nan;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;nan;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*1;*1/*3A;TOXICITY;nan;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*1;*1/*3A;TOXICITY;nan;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;nan;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;nan;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ASPIRIN;PEAR1;rs2768759;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;PEAR1;rs2768759;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
TICAGRELOR;PEAR1;rs2768759;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
LAMOTRIGINE;HLA-A;HLA-A*68:01;*68:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CELECOXIB;CYP2C9;CYP2C9*1;*1/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PAIN;;;
CELECOXIB;CYP2C9;CYP2C9*3;*1/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PAIN;;;
AZATHIOPRINE;NUDT15;NUDT15*1;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*2;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*3;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*4;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*5;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*6;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*4;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*5;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*6;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CARBAMAZEPINE;HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
TETANUS ANTITOXIN;HLA-A;HLA-A*02:06;*02:06;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ACETAMINOPHEN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ACETAMINOPHEN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
INFLIXIMAB;HLA-B;HLA-B*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
PHENYTOIN;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
NEVIRAPINE;HLA-B;HLA-B*14:02;*14:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
PHENYTOIN;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
PHENYTOIN;HLA-B;HLA-B*15:13;*15:13;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
PHENYTOIN;HLA-B;HLA-B*15:13;*15:13;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*15:13;*15:13;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
AZATHIOPRINE;TPMT;TPMT*1;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*1;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3A;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3A;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3C;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3C;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*1;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*1;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*2 + *1/*3 + *1/*4 + *1/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*1/*2 + *1/*3 + *1/*4 + *1/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*2 + *1/*3 + *1/*4 + *1/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*4;*1/*2 + *1/*3 + *1/*4 + *1/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CLINDAMYCIN;HLA-B;HLA-B*15:27;*15:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
LAMOTRIGINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
LAMOTRIGINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
INFLIXIMAB;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_RISK;nan;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
OXCARBAZEPINE;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
MIRTAZAPINE;CYP2D6;CYP2D6*1;*3/*4 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT;;;
MIRTAZAPINE;CYP2D6;CYP2D6*3;*3/*4 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT;;;
MIRTAZAPINE;CYP2D6;CYP2D6*4;*3/*4 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT;;;
MIRTAZAPINE;CYP2D6;CYP2D6*6;*3/*4 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT;;;
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
NILOTINIB;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
NILOTINIB;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
CLINDAMYCIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ISONIAZID;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
MIRTAZAPINE;CYP2D6;CYP2D6*1;*4 + *5;LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*1;*4 + *5;LADME-PK;INCREASED_PK;METABOLISM;MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*4;*4 + *5;LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*4;*4 + *5;LADME-PK;INCREASED_PK;METABOLISM;MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*5;*4 + *5;LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*5;*4 + *5;LADME-PK;INCREASED_PK;METABOLISM;MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE;;;
OPIOIDS;OPRM1;rs609148;A;TOXICITY;DECREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*1/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*1/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CYCLOSPORINE;CYP3A4;CYP3A4*1;*1/*1 + *1/*18;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
CYCLOSPORINE;CYP3A4;CYP3A4*18;*1/*1 + *1/*18;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*07:27;*07:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*07:27;*07:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-C;HLA-C*07:27;*07:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-C;HLA-C*07:27;*07:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
NEVIRAPINE;HLA-C;HLA-C*08:02;*08:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
INFLIXIMAB;HLA-C;HLA-C*12:03;*12:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
nan;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ASPIRIN-INDUCED ASTHMA ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
PHENYTOIN;HLA-C;HLA-C*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-C;HLA-C*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TACROLIMUS;CYP2J2;rs890293;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NAUSEA, VOMITING ;;
CARBAMAZEPINE;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
ABACAVIR;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
FLUPIRTINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
AMOXICILLIN;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATITIS;;;
CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATITIS;;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
HYDRALAZINE;HLA-DRB1;HLA-DRB1*04:01;*04:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LUPUS ERYTHEMATOSUS DUE TO HYDRALAZINE;;;
OXCARBAZEPINE;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
ABACAVIR;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERSENSITIVITY;;;
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PEGINTERFERON ALFA-2A;nan;rs4969170;AA;TOXICITY;DECREASED_RISK;nan;DISEASE;THROMBOCYTOPENIA ;;
PEGINTERFERON ALFA-2B;nan;rs4969170;AA;TOXICITY;DECREASED_RISK;nan;DISEASE;THROMBOCYTOPENIA ;;
RIBAVIRIN;nan;rs4969170;AA;TOXICITY;DECREASED_RISK;nan;DISEASE;THROMBOCYTOPENIA ;;
PRAVASTATIN;LDLR;rs2738466;G;EFFICACY;INCREASED_RISK;nan;DISEASE;CORONARY DISEASE ;;
LAMOTRIGINE;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
FLUPIRTINE;HLA-DRB1;HLA-DRB1*16:01;*16:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
THALIDOMIDE;GSTT1;rs4630;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY;;;
MINOCYCLINE;HLA-B;HLA-B*35:02;*35:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE;;;
PHENYTOIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROTHROMBIN TIME (PT) AT INDUCTION;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROTHROMBIN TIME (PT) AT INDUCTION;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ROSIGLITAZONE;CYP2C8;CYP2C8*1;*3;TOXICITY;DECREASED_;SIDE_EFFECT;WEIGHT GAIN;;;
ROSIGLITAZONE;CYP2C8;CYP2C8*3;*3;TOXICITY;DECREASED_;SIDE_EFFECT;WEIGHT GAIN;;;
TACROLIMUS;CYP2C8;CYP2C8*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;KIDNEY DISORDER ;;
TACROLIMUS;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;KIDNEY DISORDER ;;
CALCINEURIN INHIBITORS;CYP2C8;CYP2C8*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;KIDNEY DISORDER ;;
CALCINEURIN INHIBITORS;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;KIDNEY DISORDER ;;
CYCLOSPORINE;CYP2C8;CYP2C8*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;KIDNEY DISORDER ;;
CYCLOSPORINE;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;KIDNEY DISORDER ;;
TACROLIMUS;CYP2C8;CYP2C8*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;KIDNEY DISORDER ;;
TACROLIMUS;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;KIDNEY DISORDER ;;
ASPIRIN;CYP2C19;CYP2C19*1;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*3;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CILOSTAZOL;CYP2C19;CYP2C19*1;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CILOSTAZOL;CYP2C19;CYP2C19*2;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CILOSTAZOL;CYP2C19;CYP2C19*3;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*3;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*1;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
PACLITAXEL;NAT2;rs1799931;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;NAT2;rs1799931;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CAFFEINE;CYP1A2;CYP1A2 low activity;;OTHER;INCREASED_LIKELIHOOD;OTHER;INTAKE;;;
HMG COA REDUCTASE INHIBITORS;GNB3;rs5443;CT + TT;EFFICACY;DECREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
nan;HMGCR;rs3846662;AA;OTHER;DECREASED_;OTHER;HMGCRV_1 EXPRESSION AND AN INCREASE IN THE EXPRESSION OF THE FULL-LENGTH TRANSCRIPT;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;LADME-PK;nan;nan;DISEASE;HYPERBILIRUBINEMIA ;;
RITONAVIR;UGT1A1;UGT1A1*28;*28;LADME-PK;nan;nan;DISEASE;HYPERBILIRUBINEMIA ;;
ACYCLOVIR;NUDT15;NUDT15*1;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE;;;
ACYCLOVIR;NUDT15;NUDT15*2;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE;;;
ACYCLOVIR;NUDT15;NUDT15*3;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE;;;
ACYCLOVIR;NUDT15;NUDT15*4;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE;;;
ACYCLOVIR;NUDT15;NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE;;;
METHOTREXATE;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
CAFFEINE;ADORA2A;rs35320474;T/del + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;BRONCHOPULMONARY DYSPLASIA;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;;SIDE_EFFECT;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;;SIDE_EFFECT;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;;SIDE_EFFECT;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;;SIDE_EFFECT;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY;;;
CISPLATIN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
FLUOXETINE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
FLUOXETINE;CYP2C19;CYP2C19*2;*1/*17 + *17/*17;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
FLUOXETINE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
FLUOXETINE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ANXIETY DISORDERS;;;
FLUOXETINE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ANXIETY DISORDERS;;;
NICOTINE;CYP2A6;CYP2A6*1;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME-PK;DECREASED_PK;METABOLISM;METABOLISM;;;
NICOTINE;CYP2A6;CYP2A6*9;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME-PK;DECREASED_PK;METABOLISM;METABOLISM;;;
NICOTINE;CYP2A6;CYP2A6*17;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME-PK;DECREASED_PK;METABOLISM;METABOLISM;;;
NICOTINE;CYP2A6;CYP2A6*20;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME-PK;DECREASED_PK;METABOLISM;METABOLISM;;;
NICOTINE;CYP2A6;CYP2A6*24;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME-PK;DECREASED_PK;METABOLISM;METABOLISM;;;
NICOTINE;CYP2A6;CYP2A6*26;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME-PK;DECREASED_PK;METABOLISM;METABOLISM;;;
NICOTINE;CYP2A6;CYP2A6*27;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME-PK;DECREASED_PK;METABOLISM;METABOLISM;;;
COCAINE;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
COCAINE;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
COCAINE;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ETHANOL;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
ETHANOL;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
ETHANOL;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOIDS;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
OPIOIDS;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
OPIOIDS;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FOLFOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
COCAINE;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
COCAINE;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
COCAINE;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ETHANOL;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
ETHANOL;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
ETHANOL;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOIDS;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
OPIOIDS;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
OPIOIDS;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
INTERFERON BETA-1A;HLA-DQA1;rs9272105;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTI-IFN-BETA ANTIBODIES;;;
INTERFERON BETA-1B;HLA-DQA1;rs9272105;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTI-IFN-BETA ANTIBODIES;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
FOLFOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
REPAGLINIDE;SLCO1B1;SLCO1B1*1;*37/*37;LADME-PK;DECREASED_PK;METABOLISM;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED  CLEARANCE);;;
REPAGLINIDE;SLCO1B1;SLCO1B1*5;*37/*37;LADME-PK;DECREASED_PK;METABOLISM;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED  CLEARANCE);;;
REPAGLINIDE;SLCO1B1;SLCO1B1*15;*37/*37;LADME-PK;DECREASED_PK;METABOLISM;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED  CLEARANCE);;;
REPAGLINIDE;SLCO1B1;SLCO1B1*37;*37/*37;LADME-PK;DECREASED_PK;METABOLISM;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED  CLEARANCE);;;
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
EGFR INHIBITORS;EGFR;rs2227983;A;;SIDE_EFFECT;EFFICACY;CYTOTOXICITY;;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*1;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
INTERFERON BETA-1A;nan;rs4961252;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTI-IFN-BETA ANTIBODIES;;;
INTERFERON BETA-1B;nan;rs4961252;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTI-IFN-BETA ANTIBODIES;;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PEGASPARGASE;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ASPARAGINASE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
ASPARAGINASE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
ASPARAGINASE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
ASPARAGINASE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
CYTARABINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
CYTARABINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
CYTARABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
CYTARABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
DAUNORUBICIN;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
DAUNORUBICIN;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
DAUNORUBICIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
DAUNORUBICIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
ETOPOSIDE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
ETOPOSIDE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
ETOPOSIDE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
ETOPOSIDE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
MERCAPTOPURINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
MERCAPTOPURINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
MERCAPTOPURINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
MERCAPTOPURINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
METHOTREXATE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
METHOTREXATE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
PREDNISONE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
PREDNISONE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
PREDNISONE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
PREDNISONE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
VINCRISTINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
VINCRISTINE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
VINCRISTINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CNS RELAPSE;;;
VINCRISTINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC RELAPSE;;;
METHOTREXATE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
GEMCITABINE;RRM1;rs9937;G;TOXICITY;DECREASED_RISK;nan;DISEASE;NEUTROPENIA ;;
nan;ACE;rs1799752;del/del;OTHER;INCREASED_SEVERITY;OTHER;COVID-19;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;LADME-PD;DECREASED_LIKELIHOOD;OTHER;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;LADME-PD;DECREASED_LIKELIHOOD;OTHER;TIME TO THERAPEUTIC INR;;;
ETHANOL;OPRM1;rs1381376;T;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
PEGASPARGASE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
PEGASPARGASE;HLA-DQB1;HLA-DQB1*02:02;*02:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
PEGASPARGASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
METHOTREXATE;DHFR;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;MSH3;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;ENOSF1;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
nan;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_LIKELIHOOD;OTHER;COVID-19;;;
CYCLOSPORINE;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
TACROLIMUS;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
nan;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_SEVERITY;OTHER;COVID-19;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT EMERGENT MANIA;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT EMERGENT MANIA;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*17;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT EMERGENT MANIA;;;
CLOMIPRAMINE;CYP2C19;CYP2C19*1;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT EMERGENT MANIA;;;
CLOMIPRAMINE;CYP2C19;CYP2C19*2;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT EMERGENT MANIA;;;
CLOMIPRAMINE;CYP2C19;CYP2C19*17;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT EMERGENT MANIA;;;
nan;ACE;rs1799752;del;OTHER;INCREASED_LIKELIHOOD;OTHER;COVID-19;;;
ASPIRIN;nan;rs1050450;A;OTHER;INCREASED_RISK;OTHER;IN-STENT RESTENOSIS;;;
BETA BLOCKING AGENTS;nan;rs1050450;A;OTHER;INCREASED_RISK;OTHER;IN-STENT RESTENOSIS;;;
CLOPIDOGREL;nan;rs1050450;A;OTHER;INCREASED_RISK;OTHER;IN-STENT RESTENOSIS;;;
HMG COA REDUCTASE INHIBITORS;nan;rs1050450;A;OTHER;INCREASED_RISK;OTHER;IN-STENT RESTENOSIS;;;
nan;ACE;rs1799752;del/del;OTHER;INCREASED_RISK;OTHER;DEATH;;;
SERTRALINE;CYP2C19;CYP2C19*1;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT EMERGENT MANIA;;;
SERTRALINE;CYP2C19;CYP2C19*2;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT EMERGENT MANIA;;;
SERTRALINE;CYP2C19;CYP2C19*17;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT EMERGENT MANIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*2 + *1/*3 + *1/*5 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*2;*1/*2 + *1/*3 + *1/*5 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*2 + *1/*3 + *1/*5 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*5;*1/*2 + *1/*3 + *1/*5 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;TOXICITY;DECREASED_;SIDE_EFFECT;HEMORRHAGE;;;
LEFLUNOMIDE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
LEFLUNOMIDE;CYP2C19;CYP2C19*2;*1/*17 + *17/*17;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
LEFLUNOMIDE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
ANAKINRA;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
CANAKINUMAB;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
RILONACEPT;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
TOCILIZUMAB;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS;;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS;;;
RIBAVIRIN;IFNL4;rs11322783;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*3;LADME-PK;INCREASED_PK;METABOLISM;APPARENT TERMINAL ELIMINATION HALF-LIFE;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*3;*3;LADME-PK;INCREASED_PK;METABOLISM;APPARENT TERMINAL ELIMINATION HALF-LIFE;;;
FLUCLOXACILLIN;HLA-B;HLA-B*57:03;*57:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CISPLATIN;TPMT;TPMT*1;*3B + *3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
CISPLATIN;TPMT;TPMT*3B;*3B + *3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
CISPLATIN;TPMT;TPMT*3C;*3B + *3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
PREDNISONE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RISK;OTHER;REMAINING ON STEROIDS AT 1 YEAR AFTER TRANSPLANTATION;;;
TACROLIMUS;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RISK;OTHER;REMAINING ON STEROIDS AT 1 YEAR AFTER TRANSPLANTATION;;;
CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ATAZANAVIR;CYP3A5;CYP3A5*1;*1/*3 + *1/*1;LADME-PK;INCREASED_PK;METABOLISM;ORAL CLEARANCE (CL) OF ATAZANAVIR;;;
ATAZANAVIR;CYP3A5;CYP3A5*3;*1/*3 + *1/*1;LADME-PK;INCREASED_PK;METABOLISM;ORAL CLEARANCE (CL) OF ATAZANAVIR;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *1/*3B + *1/*3C + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*3A + *1/*3B + *1/*3C + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *1/*3B + *1/*3C + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3B;*1/*3A + *1/*3B + *1/*3C + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
ANTIINFLAMMATORY AGENTS;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
NON-STEROIDS;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
EGFR INHIBITORS;EGFR;rs712829;T;TOXICITY;nan;SIDE_EFFECT;CYTOTOXICITY;;;
ANTINEOPLASTIC AGENTS;TYMS;rs11280056;TTA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CARBAMAZEPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-A;HLA-A*24:07;*24:07;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LOW LEUKOCYTE COUNTS;;;
AZATHIOPRINE;TPMT;TPMT*2;*1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LOW LEUKOCYTE COUNTS;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LOW LEUKOCYTE COUNTS;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*1;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TREATMENT DURATION;;;
AZATHIOPRINE;TPMT;TPMT*2;*1/*1;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TREATMENT DURATION;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*1;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TREATMENT DURATION;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*4;*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERBILIRUBINEMIA ;;
ATORVASTATIN;APOE;rs429358;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN C-REACTIVE PROTEIN (CRP);;;
PRAVASTATIN;APOE;rs429358;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN C-REACTIVE PROTEIN (CRP);;;
CLOZAPINE;GSTM1;GSTM1 non-null;null/null;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CLOZAPINE;GSTM1;GSTM1 null;null/null;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ASPIRIN;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
ASPIRIN;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUDDEN CARDIAC DEATH;;;
ASPIRIN;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
ASPIRIN;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
ASPIRIN;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUDDEN CARDIAC DEATH;;;
ASPIRIN;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
ASPIRIN;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
ASPIRIN;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUDDEN CARDIAC DEATH;;;
ASPIRIN;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
ASPIRIN;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
ASPIRIN;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUDDEN CARDIAC DEATH;;;
ASPIRIN;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUDDEN CARDIAC DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUDDEN CARDIAC DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUDDEN CARDIAC DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUDDEN CARDIAC DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
OPIOIDS;OPRM1;rs1799971;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*4/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*7;*4/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY, LADME-PK;DECREASED_;SIDE_EFFECT;METABOLISM OF TRAMADOL AND DECREASED RESPONSE TO TRAMADOL;;;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*6;*4/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*12:02;*12:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*12:02;*12:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2;EFFICACY;INCREASED_SEVERITY;OTHER;INTRAGASTRIC PH;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2;EFFICACY;INCREASED_SEVERITY;OTHER;INTRAGASTRIC PH;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS ;;
CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*5;LADME-PK;INCREASED_PK;METABOLISM;APPARENT TERMINAL ELIMINATION HALF-LIFE;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*5;*5;LADME-PK;INCREASED_PK;METABOLISM;APPARENT TERMINAL ELIMINATION HALF-LIFE;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
CARBAMAZEPINE;HLA-DQA1;HLA-DQA1*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
TICAGRELOR;CYP3A4;CYP3A4*1;*1/*22;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION INHIBITION;;;
TICAGRELOR;CYP3A4;CYP3A4*22;*1/*22;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION INHIBITION;;;
EFAVIRENZ;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
EFAVIRENZ;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*11;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*11;*4/*11;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CYCLOSPORINE;ABCB1;rs1128503;AA;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;TROUGH BLOOD CONCENTRATION;;;
nan;TMPRSS2;rs383510;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;COVID-19;;;
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3/*4;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
FLUVASTATIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FLUVASTATIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FLUVASTATIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*4;LADME-PK;INCREASED_PK;METABOLISM;APPARENT TERMINAL ELIMINATION HALF-LIFE;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*4;LADME-PK;INCREASED_PK;METABOLISM;APPARENT TERMINAL ELIMINATION HALF-LIFE;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*36;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*36;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
CYCLOSPORINE;ABCB1;rs2032582;AA;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;TROUGH BLOOD CONCENTRATION;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
SERTRALINE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE;;;
SERTRALINE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE;;;
SERTRALINE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE;;;
SERTRALINE;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE, EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE, EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE, EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
METHADONE;CYP3A4;rs2246709;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SIDE EFFECTS;;;
FLUVOXAMINE;CYP2D6;CYP2D6*1;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;FLUVOXAMINE PLASMA CONCENTRATIONS;;;
FLUVOXAMINE;CYP2D6;CYP2D6*5;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;FLUVOXAMINE PLASMA CONCENTRATIONS;;;
FLUVOXAMINE;CYP2D6;CYP2D6*10;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;FLUVOXAMINE PLASMA CONCENTRATIONS;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*4;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24));;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*4;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24));;;
ESCITALOPRAM;CYP2C19;CYP2C19*4;*2/*2 + *2/*4;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24));;;
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED_RISK;nan;DISEASE;CORONARY DISEASE ;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
METHAZOLAMIDE;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
METHAZOLAMIDE;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ACETAMINOPHEN;CYP2D6;CYP2D6*1;*1/*1;EFFICACY, LADME-PK;PK;PK;INHIBITION OF METABOLISM;;;
CODEINE;CYP2D6;CYP2D6*1;*1/*1;EFFICACY, LADME-PK;PK;PK;INHIBITION OF METABOLISM;;;
LEVOMEPROMAZINE;CYP2D6;CYP2D6*1;*1/*1;EFFICACY, LADME-PK;PK;PK;INHIBITION OF METABOLISM;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
METHADONE;CYP3A4;rs2242480;T;OTHER;INCREASED_SEVERITY;SIDE_EFFECT;OPIOID WITHDRAWAL SYMPTOMS;;;
DOCETAXEL;RPL13;rs12960;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
DOCETAXEL;SNORD68;rs12960;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
DOCETAXEL;SPG7;rs12960;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;RPL13;rs12960;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;SNORD68;rs12960;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;SPG7;rs12960;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
DOCETAXEL;CHST3;rs1871450;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;CHST3;rs1871450;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CITALOPRAM;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE;;;
CITALOPRAM;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE;;;
PEGINTERFERON ALFA-2B;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;DECREASED_RISK;nan;DISEASE;DEPRESSION ;;
PEGINTERFERON ALFA-2B;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;DECREASED_RISK;nan;DISEASE;DEPRESSION ;;
RIBAVIRIN;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;DECREASED_RISK;nan;DISEASE;DEPRESSION ;;
RIBAVIRIN;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;DECREASED_RISK;nan;DISEASE;DEPRESSION ;;
METHADONE;CYP3A4;rs4646440;A;OTHER;INCREASED_SEVERITY;SIDE_EFFECT;OPIOID WITHDRAWAL SYMPTOMS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *1/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *1/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *1/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *1/*17;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS;;;
CARBAMAZEPINE;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
ETHANOL;OPRM1;rs511435;T;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
ETHANOL;OPRM1;rs511435;T;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOIDS;OPRM1;rs511435;T;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
OPIOIDS;OPRM1;rs511435;T;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
DOCETAXEL;NAT2;rs1799931;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;NAT2;rs1799931;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;DECREASED_PK;METABOLISM;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;DECREASED_PK;METABOLISM;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION;;;
DOCETAXEL;CYP4B1;rs4646487;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;CYP4B1;rs4646487;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*07:02;*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY;;;
TRIMETHOPRIM;HLA-B;HLA-B*07:02;*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*07:02;*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY;;;
TRIMETHOPRIM;HLA-C;HLA-C*07:02;*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY;;;
SULFAMETHOXAZOLE;GSTM1;GSTM1 null;null/null;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TRIMETHOPRIM;GSTM1;GSTM1 null;null/null;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
OLANZAPINE;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FATIGUE ;;
OLANZAPINE;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FATIGUE ;;
FOLFIRINOX;UGT1A1;UGT1A1*1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
FOLFIRINOX;UGT1A1;UGT1A1*6;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
FOLFIRINOX;UGT1A1;UGT1A1*28;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
METHOTREXATE;DHFR;rs3045983;GGGAGCTGG/del + del/del;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
OPIOIDS;OPRM1;rs589046;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS ;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *1/*3C;TOXICITY;DECREASED_;SIDE_EFFECT;LEUKOCYTES AND NEUTROPHILS;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *1/*3C;TOXICITY;DECREASED_;SIDE_EFFECT;LEUKOCYTES AND NEUTROPHILS;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *1/*3C;TOXICITY;DECREASED_;SIDE_EFFECT;LEUKOCYTES AND NEUTROPHILS;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;INCREASED_PK;METABOLISM;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;INCREASED_PK;METABOLISM;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT;;;
ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
ASPIRIN;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
PACLITAXEL;CYP3A4;CYP3A4*1;*1/*8 + *1/*20;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
PACLITAXEL;CYP3A4;CYP3A4*1;*1/*8 + *1/*20;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TREATMENT MODIFICATION;;;
PACLITAXEL;CYP3A4;CYP3A4*8;*1/*8 + *1/*20;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
PACLITAXEL;CYP3A4;CYP3A4*8;*1/*8 + *1/*20;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TREATMENT MODIFICATION;;;
PACLITAXEL;CYP3A4;CYP3A4*20;*1/*8 + *1/*20;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
PACLITAXEL;CYP3A4;CYP3A4*20;*1/*8 + *1/*20;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TREATMENT MODIFICATION;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CARBAMAZEPINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
DOCETAXEL;VEGFA;rs144854329;del/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
WARFARIN;CYP2C9;CYP2C9*2;*3/*3 + *3/*2 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*3 + *3/*2 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;UNBOUND ORAL CLEARANCE FOR S-WARFARIN;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;UNBOUND ORAL CLEARANCE FOR S-WARFARIN;;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);L allele-rs25531T/L allele-rs25531T;TOXICITY;DECREASED_;SIDE_EFFECT;ADVERSE EFFECT BURDEN;;;
CITALOPRAM;SLC6A4;SLC6A4 L allele-rs25531C;L allele-rs25531T/L allele-rs25531T;TOXICITY;DECREASED_;SIDE_EFFECT;ADVERSE EFFECT BURDEN;;;
CITALOPRAM;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;TOXICITY;DECREASED_;SIDE_EFFECT;ADVERSE EFFECT BURDEN;;;
AZATHIOPRINE;NUDT15;NUDT15*1;*1/*3 + *3/*3 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*3;*1/*3 + *3/*3 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*6;*1/*3 + *3/*3 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*1;*1/*3 + *3/*3 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*3;*1/*3 + *3/*3 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;NUDT15*6;*1/*3 + *3/*3 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*3 + *3/*3 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2/*3 + *3/*3 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
HALOPERIDOL;CYP2D6;CYP2D6*1;*1/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
HALOPERIDOL;CYP2D6;CYP2D6*4;*1/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
nan;HLA-DPB1;HLA-DPB1*04:01;*04:01;TOXICITY;DECREASED_RISK;nan;DISEASE;ASPIRIN-INDUCED ASTHMA ;;
CARBOPLATIN;DPYD;DPYD Reference;Reference;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CARBOPLATIN;DPYD;DPYD Reference;Reference;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;DPYD;DPYD Reference;Reference;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;DPYD;DPYD Reference;Reference;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHAMPHETAMINE;DAOA;rs947267;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PSYCHOTIC DISORDER ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
PHENOBARBITAL;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
TRAMADOL;CYP2D6;CYP2D6*1;*10/*10 + *5/*10 + *36;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
TRAMADOL;CYP2D6;CYP2D6*2;*10/*10 + *5/*10 + *36;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
TRAMADOL;CYP2D6;CYP2D6*5;*10/*10 + *5/*10 + *36;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
TRAMADOL;CYP2D6;CYP2D6*10;*10/*10 + *5/*10 + *36;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
TRAMADOL;CYP2D6;CYP2D6*10x2;*10/*10 + *5/*10 + *36;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
TRAMADOL;CYP2D6;CYP2D6*36;*10/*10 + *5/*10 + *36;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME-PK;nan;OTHER;HIGHER STABLE DOSE LEVELS;;;
METHAMPHETAMINE;OPRM1;rs2075572;C;TOXICITY;DECREASED_RISK;OTHER;METHAMPHETAMINE DEPENDENCE;;;
ACETAMINOPHEN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ACETAMINOPHEN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ACETAMINOPHEN;HLA-A;HLA-A*02:06;*02:06;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ACETAMINOPHEN;HLA-A;HLA-A*02:06;*02:06;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ACETAMINOPHEN;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ACETAMINOPHEN;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;OMEPRAZOLE SULFONE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
ACETAMINOPHEN;HLA-C;HLA-C*14:03;*14:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ACETAMINOPHEN;HLA-C;HLA-C*14:03;*14:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;THROMBOTIC DISEASE ;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;THROMBOTIC DISEASE ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;THROMBOTIC DISEASE ;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;THROMBOTIC DISEASE ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*9;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*9;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*21;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*21;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*33;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*33;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*9;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*9;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*21;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*21;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*33;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*33;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
THIOGUANINE;TPMT;TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
METHADONE;CYP3A4;rs2246709;A;OTHER;DECREASED_SEVERITY;SIDE_EFFECT;OPIOID WITHDRAWAL SYMPTOMS;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;CLOPI-H4 CONCENTRATIONS AFTER 300 OR 900 MG CLOPIDOGREL LOADING DOSE;;;
ATORVASTATIN;APOE;rs7412;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PERCENT REDUCTION IN LDL-CHOLESTEROL;;;
PRAVASTATIN;APOE;rs7412;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PERCENT REDUCTION IN LDL-CHOLESTEROL;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*1;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*1;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*1;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;UGT1A1;UGT1A1*1;*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;UGT1A1;UGT1A1*28;*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
COMBINATIONS;UGT1A1;UGT1A1*1;*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
COMBINATIONS;UGT1A1;UGT1A1*28;*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
ATENOLOL;GRK5;rs2230345;AT + TT;OTHER;DECREASED_RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES;;;
HYDROCHLOROTHIAZIDE;GRK5;rs2230345;AT + TT;OTHER;DECREASED_RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES;;;
TRANDOLAPRIL;GRK5;rs2230345;AT + TT;OTHER;DECREASED_RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES;;;
VERAPAMIL;GRK5;rs2230345;AT + TT;OTHER;DECREASED_RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES;;;
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR CARDIOVASCULAR EVENTS;;;
METHAMPHETAMINE;BDNF;rs6265;CC;TOXICITY;DECREASED_SEVERITY;OTHER;METHAMPHETAMINE DEPENDENCE;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TACROLIMUS;ABCB1;rs1045642;GG;EFFICACY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;DELAYED GRAFT FUNCTION ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ANTICHOLINERGIC AGENTS;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;SERUM ANTICHOLINERGIC ACTIVITY;;;
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;FORMATION OF METABOLITES;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;FORMATION OF METABOLITES;;;
AZATHIOPRINE;NUDT15;NUDT15*2;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*2;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
AZATHIOPRINE;NUDT15;NUDT15*3;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*3;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
AZATHIOPRINE;NUDT15;NUDT15*5;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*5;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
AZATHIOPRINE;NUDT15;NUDT15*6;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;NUDT15*6;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
nan;GSTT1;GSTT1 non-null;;OTHER;INCREASED_LIKELIHOOD;OTHER;ASTHMA;;;
nan;GSTT1;GSTT1 null;;OTHER;INCREASED_LIKELIHOOD;OTHER;ASTHMA;;;
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
nan;GSTM1;GSTM1 non-null;;OTHER;INCREASED_LIKELIHOOD;OTHER;ASTHMA;;;
nan;GSTM1;GSTM1 null;;OTHER;INCREASED_LIKELIHOOD;OTHER;ASTHMA;;;
METHAMPHETAMINE;DAOA;rs2391191;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PSYCHOTIC DISORDER ;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1;*1/*6 + *6/*6 + *4/*6 + *5/*6;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*4;*1/*6 + *6/*6 + *4/*6 + *5/*6;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*5;*1/*6 + *6/*6 + *4/*6 + *5/*6;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*6;*1/*6 + *6/*6 + *4/*6 + *5/*6;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*22;*1/*6 + *6/*6 + *4/*6 + *5/*6;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1;*1/*1 + *1/*5 + *1/*4 + *1/*22;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*4;*1/*1 + *1/*5 + *1/*4 + *1/*22;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*5;*1/*1 + *1/*5 + *1/*4 + *1/*22;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*6;*1/*1 + *1/*5 + *1/*4 + *1/*22;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*22;*1/*1 + *1/*5 + *1/*4 + *1/*22;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
IRINOTECAN;HLA-DQB3;rs2859101;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOSPORINE;MTHFR;rs3737967;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;MTHFR;rs3737967;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19*2;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs55633228;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs55633228;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs55633228;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CARBOPLATIN;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CARBOPLATIN;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DEXAMETHASONE;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DEXAMETHASONE;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ETOPOSIDE;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ETOPOSIDE;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SULFASALAZINE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
AZATHIOPRINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCYTOPENIA;;;
AZATHIOPRINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCYTOPENIA;;;
MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CYCLOSPORINE;MTHFR;rs2274976;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;MTHFR;rs2274976;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
CYCLOPHOSPHAMIDE;PERP;rs117101815;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PERP;rs117101815;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PERP;rs117101815;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
AZATHIOPRINE;TPMT;TPMT*1;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*3A;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*3B;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*3C;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
CISPLATIN;ERCC1;rs11615;GG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;NEPHROTOXICITY ;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;JAUNDICE;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;JAUNDICE;;;
ATAZANAVIR;UGT1A1;UGT1A1*36;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;JAUNDICE;;;
RITONAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;JAUNDICE;;;
RITONAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;JAUNDICE;;;
RITONAVIR;UGT1A1;UGT1A1*36;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;JAUNDICE;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*15;*15/*15;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC);;;
PRAVASTATIN;SLCO1B1;SLCO1B1*37;*15/*15;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC);;;
CAPECITABINE;DPYD;DPYD low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;DPYD;DPYD low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT MODIFICATION;;;
FLUOROURACIL;DPYD;DPYD low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;DPYD low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT MODIFICATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
CISPLATIN;GSTM1;GSTM1 non-null;null/null;EFFICACY;DECREASED_LIKELIHOOD;OTHER;DEATH;;;
CISPLATIN;GSTM1;GSTM1 non-null;null/null;EFFICACY;DECREASED_LIKELIHOOD;OTHER;RECURRENCE;;;
CISPLATIN;GSTM1;GSTM1 null;null/null;EFFICACY;DECREASED_LIKELIHOOD;OTHER;DEATH;;;
CISPLATIN;GSTM1;GSTM1 null;null/null;EFFICACY;DECREASED_LIKELIHOOD;OTHER;RECURRENCE;;;
RADIOTHERAPY;GSTM1;GSTM1 non-null;null/null;EFFICACY;DECREASED_LIKELIHOOD;OTHER;DEATH;;;
RADIOTHERAPY;GSTM1;GSTM1 non-null;null/null;EFFICACY;DECREASED_LIKELIHOOD;OTHER;RECURRENCE;;;
RADIOTHERAPY;GSTM1;GSTM1 null;null/null;EFFICACY;DECREASED_LIKELIHOOD;OTHER;DEATH;;;
RADIOTHERAPY;GSTM1;GSTM1 null;null/null;EFFICACY;DECREASED_LIKELIHOOD;OTHER;RECURRENCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*3 + *1/*3 + *2/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*3 + *1/*3 + *2/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *2/*3 + *1/*3 + *2/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*3 + *1/*3 + *2/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
ANTIDEPRESSANTS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER;USE;;;
ANTIEPILEPTICS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER;USE;;;
BETA BLOCKING AGENTS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER;USE;;;
CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER;USE;;;
ANTIDEPRESSANTS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER;USE;;;
ANTIEPILEPTICS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER;USE;;;
BETA BLOCKING AGENTS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER;USE;;;
CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER;USE;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;C/D RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;C/D RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ACUTE CELLULAR REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ACUTE CELLULAR REJECTION;;;
IRINOTECAN;DPYD;rs1042482;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
PAZOPANIB;UGT1A1;UGT1A1*6;*28 + *37 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
PAZOPANIB;UGT1A1;UGT1A1*28;*28 + *37 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
PAZOPANIB;UGT1A1;UGT1A1*37;*28 + *37 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
METHADONE;CYP3A4;rs4646440;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SIDE EFFECTS;;;
WARFARIN;VKORC1;rs9923231;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;HAVING WARFARIN DOSE GREATER THAN 7.5 MG/DAY;;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
CYCLOPHOSPHAMIDE;PPP2R5D;rs3805945;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PPP2R5D;rs3805945;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PPP2R5D;rs3805945;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*36;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*37;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*1;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*28;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*36;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*37;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
LAMIVUDINE;UGT1A1;UGT1A1*1;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
LAMIVUDINE;UGT1A1;UGT1A1*28;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
LAMIVUDINE;UGT1A1;UGT1A1*36;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
LAMIVUDINE;UGT1A1;UGT1A1*37;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ZIDOVUDINE;UGT1A1;UGT1A1*1;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ZIDOVUDINE;UGT1A1;UGT1A1*28;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ZIDOVUDINE;UGT1A1;UGT1A1*36;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ZIDOVUDINE;UGT1A1;UGT1A1*37;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
CYCLOPHOSPHAMIDE;CCNK;rs77769901;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;CCNK;rs77769901;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;CCNK;rs77769901;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CARBAMAZEPINE;SCN1A;rs3812718;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
WARFARIN;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
ROSIGLITAZONE;PLIN1;rs894160;CT + TT;TOXICITY;DECREASED_;SIDE_EFFECT;WEIGHT GAIN;;;
PLATINUM;nan;rs836554;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CYCLOSPORINE;ABCC1;rs17264736;GG + GT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;ABCC1;rs17264736;GG + GT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHADONE;CYP2B6;CYP2B6*6;*6;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;PAIN ;;
OXCARBAZEPINE;HLA-B;HLA-B*15:01;*15:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs118129530;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs118129530;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs118129530;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CITALOPRAM;CYP2D6;CYP2D6*1;*1/*4;LADME-PK;INCREASED_PK;METABOLISM;AUC OF CITALOPRAM;;;
CITALOPRAM;CYP2D6;CYP2D6*4;*1/*4;LADME-PK;INCREASED_PK;METABOLISM;AUC OF CITALOPRAM;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs148013902;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs148013902;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs148013902;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
NICOTINE_SUBSTITUTES;COMT;rs4680;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
NICOTINE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
VALGANCICLOVIR;ABCC4;rs11568658;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs145623321;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs145623321;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs145623321;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOSPORINE;NFATC1;rs1017860;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;NFATC1;rs1017860;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CYCLOPHOSPHAMIDE;CYP2C8;rs117458836;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;CYP2C8;rs117458836;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;CYP2C8;rs117458836;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
PRASUGREL;PEAR1;rs822442;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
TACROLIMUS;CYP2C8;CYP2C8*1;*3;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DELAYED GRAFT FUNCTION;;;
TACROLIMUS;CYP2C8;CYP2C8*3;*3;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DELAYED GRAFT FUNCTION;;;
CARBAMAZEPINE;HLA-B;HLA-B*07:02;*15:21;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:21;*15:21;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
NICOTINE;COMT;rs4680;G;TOXICITY, OTHER;DECREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;nan;SIDE_EFFECT;DRUG TOXICITY;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*3 + *4 + *5 + *10 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *10 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *10 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *10 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*3 + *4 + *5 + *10 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*3 + *4 + *5 + *10 + *41;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
AMOXICILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4 + *4/*5 + *4/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN PSYCHOTIC SYMPTOMS;;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4/*4 + *4/*5 + *4/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN PSYCHOTIC SYMPTOMS;;;
RISPERIDONE;CYP2D6;CYP2D6*6;*4/*4 + *4/*5 + *4/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN PSYCHOTIC SYMPTOMS;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*1/*2 + *2/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*1/*2 + *2/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
BOSENTAN;CYP2C9;CYP2C9*1;*3;LADME-PK;DECREASED_PK;METABOLISM;BOSENTAN METABOLISM IN VITRO;;;
BOSENTAN;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_PK;METABOLISM;BOSENTAN METABOLISM IN VITRO;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOZAPINE;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
CLOZAPINE;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
BOSENTAN;CYP2C9;CYP2C9*1;*2;LADME-PK;DECREASED_PK;METABOLISM;BOSENTAN METABOLISM IN VITRO;;;
BOSENTAN;CYP2C9;CYP2C9*2;*2;LADME-PK;DECREASED_PK;METABOLISM;BOSENTAN METABOLISM IN VITRO;;;
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
ATORVASTATIN;TNF;rs1800629;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BONE MARROW DENSITY IN THE LUMBAR SPINE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
LAMOTRIGINE;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;G/TT + GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE IN JAPANESE PATIENTS WITH WITH CHRONIC GENOTYPE 1 HCV INFECTION;;;
RIBAVIRIN;IFNL4;rs11322783;G/TT + GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE IN JAPANESE PATIENTS WITH WITH CHRONIC GENOTYPE 1 HCV INFECTION;;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY);;;
TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR);;;
TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY);;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
LAMOTRIGINE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
LAMOTRIGINE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
LAMOTRIGINE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NICOTINE;CYP2A6;CYP2A6 low activity;;TOXICITY;DECREASED_RISK;OTHER;RECURRENCE;;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION;;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION;;;
NICOTINE;CYP2A6;CYP2A6 low activity;;TOXICITY;DECREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
PHENYTOIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
WARFARIN;CYP2C9;CYP2C9*1;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE;;;
METHOTREXATE;SLCO1B1;rs11045879;T;OTHER, LADME-PK;INCREASED_PK;METABOLISM;CLEARANCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*1;*11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*11;*11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*1;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE;;;
CODEINE;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;PAIN ;;
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;PAIN ;;
BOSENTAN;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
BOSENTAN;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;TOXICITY;INCREASED_SEVERITY;OTHER;TUBULAR VACUOLAR DEGENERATION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;TOXICITY;INCREASED_SEVERITY;OTHER;TUBULAR VACUOLAR DEGENERATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH LEVELS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH LEVELS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;INTERSTITIAL FIBROSIS ;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;INTERSTITIAL FIBROSIS ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION/DOSE RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION/DOSE RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;C/D RATIO;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;C/D RATIO;;;
CLOPIDOGREL;CYP3A5;CYP3A5*1;*3/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY AFTER 9MONTH OF TREATMENT;;;
CLOPIDOGREL;CYP3A5;CYP3A5*3;*3/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY AFTER 9MONTH OF TREATMENT;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;TOXICITY;INCREASED_RISKPK;PK;ACUTE REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;TOXICITY;INCREASED_RISKPK;PK;ACUTE REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DELAYED GRAFT FUNCTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DELAYED GRAFT FUNCTION;;;
TACROLIMUS;CYP3A5;CYP3A5*6;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DELAYED GRAFT FUNCTION;;;
TACROLIMUS;CYP3A5;CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DELAYED GRAFT FUNCTION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3 + *3/*3;LADME-PK;INCREASED_PK;METABOLISM;BLOOD CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3 + *3/*3;LADME-PK;INCREASED_PK;METABOLISM;BLOOD CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*2 + *2/*2 + *2/*3 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*2 + *2/*2 + *2/*3 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*2 + *2/*2 + *2/*3 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACE INHIBITORS;BDKRB2;rs71103505;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
ACE INHIBITORS;BDKRB2;rs71103505;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
PLAIN;BDKRB2;rs71103505;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
PLAIN;BDKRB2;rs71103505;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
CODEINE;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;EFFICACY, TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
TRAMADOL;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;EFFICACY, TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
nan;KCNE1;rs727957;T;OTHER;INCREASED_LIKELIHOOD;OTHER;QT INTERVAL;;;
AMOXICILLIN;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
OXCARBAZEPINE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN SYSTOLIC BLOOD PRESSURE;;;
METHOTREXATE;TYMS;rs11280056;del/del;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MUCOSITIS;;;
PERINDOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACEI-RELATED COUGH;;;
METHOTREXATE;TYMS;rs11280056;del/del;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
nan;RGS2;rs34717272;TC/del + del/del;OTHER;INCREASED_RISK;nan;DISEASE;HYPERTENSION ;;
CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
METHOTREXATE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*14:05;*14:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
CYCLOPHOSPHAMIDE;CBR3;rs74743371;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;CBR3;rs74743371;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;CBR3;rs74743371;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_RISK;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STOMATITIS ;;
LAMOTRIGINE;HLA-A;HLA-A*30:01;*30:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;DECREASED_RISK;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
OXCARBAZEPINE;HLA-B;HLA-B*13:02;*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
OXCARBAZEPINE;HLA-B;HLA-B*15:27;*15:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
OXCARBAZEPINE;HLA-B;HLA-B*15:19;*15:19;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
OXCARBAZEPINE;HLA-B;HLA-B*48:04;*48:04;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
RALOXIFENE;UGT1A1;UGT1A1*1;*28/*28;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BONE MINERAL DENSITY;;;
RALOXIFENE;UGT1A1;UGT1A1*28;*28/*28;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BONE MINERAL DENSITY;;;
ASPIRIN;HLA-DQB1;HLA-DQB1*03:02;*03:02;EFFICACY, TOXICITY;DECREASED_SEVERITY;nan;DISEASE;ASPIRIN-INDUCED ASTHMA ;;
OXCARBAZEPINE;HLA-B;HLA-B*27:09;*27:09;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
NEVIRAPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
TAMOXIFEN;ABCB1;rs1045642;AG;OTHER;INCREASED_RISK;OTHER;DISEASE RECURRENCE;;;
NEVIRAPINE;HLA-B;HLA-B*58:02;*58:02;TOXICITY;DECREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;;SIDE_EFFECT;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;;SIDE_EFFECT;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS;;;
RIBAVIRIN;IFNL3;rs12979860;CC;;SIDE_EFFECT;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS;;;
PRASUGREL;PEAR1;rs3737224;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
NEVIRAPINE;HLA-C;HLA-C*02:10;*02:10;TOXICITY;DECREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
CYCLOSPORINE;ABCC1;rs4781712;AA + AG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;ABCC1;rs4781712;AA + AG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
CAPECITABINE;MIR27A;rs895819;CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;MIR27A;rs895819;CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
OLANZAPINE;ABCB1;rs4728709;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ASTHENIA;;;
BUPROPION;CYP2B6;rs3211371;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
CYCLOPHOSPHAMIDE;TP53AIP1;rs118088833;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;TP53AIP1;rs118088833;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;TP53AIP1;rs118088833;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ASPIRIN;CYP2D6;CYP2D6*3;*3 + *4;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;BRAIN NEOPLASMS ;;
ASPIRIN;CYP2D6;CYP2D6*4;*3 + *4;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;BRAIN NEOPLASMS ;;
ASPIRIN;CYP2D6;CYP2D6*5;*3 + *4;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;BRAIN NEOPLASMS ;;
SULFASALAZINE;CYP2D6;CYP2D6*3;*3 + *4;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;BRAIN NEOPLASMS ;;
SULFASALAZINE;CYP2D6;CYP2D6*4;*3 + *4;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;BRAIN NEOPLASMS ;;
SULFASALAZINE;CYP2D6;CYP2D6*5;*3 + *4;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;BRAIN NEOPLASMS ;;
PRASUGREL;PEAR1;rs41273215;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO IMPROVE (BASED ON MEAN REDUCTIONS FROM BASELINE IN HRSD);;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO IMPROVE (BASED ON MEAN REDUCTIONS FROM BASELINE IN HRSD);;;
TAMOXIFEN;ABCB1;rs1045642;AG;OTHER;INCREASED_RISK;OTHER;DISEASE RECURRENCE;;;
CYCLOPHOSPHAMIDE;GNL3;rs112242273;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;GNL3;rs112242273;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;GNL3;rs112242273;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
PRASUGREL;PEAR1;rs822441;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY, LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY, LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
VORICONAZOLE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CARCINOMA, SQUAMOUS CELL ;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CARCINOMA, SQUAMOUS CELL ;;
CLOPIDOGREL;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CYTARABINE;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;COMPLETE REMISSION;;;
IDARUBICIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;COMPLETE REMISSION;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-RESPONSE;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-RESPONSE;;;
CAFFEINE;CYP1A2;CYP1A2 high activity;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ABORTION, SPONTANEOUS ;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY ;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY ;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-RESPONSE;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-RESPONSE;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-RESPONSE;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-RESPONSE;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CYCLOPHOSPHAMIDE;TOP2A;rs181501757;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;TOP2A;rs181501757;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;TOP2A;rs181501757;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
LAMOTRIGINE;HLA-B;HLA-B*13:02;*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION AFTER SECOND TREATMENT SWITCH;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION AFTER SECOND TREATMENT SWITCH;;;
LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;DECREASED_RISK;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;IMPROVED SECOND TREATMENT SWITCH RESPONSE;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;IMPROVED SECOND TREATMENT SWITCH RESPONSE;;;
BELINOSTAT;UGT1A1;UGT1A1*1;*1/*60 + *60/*60;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
BELINOSTAT;UGT1A1;UGT1A1*60;*1/*60 + *60/*60;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
CYCLOPHOSPHAMIDE;PERP;rs9402944;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PERP;rs9402944;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PERP;rs9402944;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-REMISSION;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-REMISSION;;;
PEGINTERFERON ALFA-2A;OAS1;rs2660;AG;TOXICITY;DECREASED_RISK;nan;DISEASE;ANEMIA ;;
PEGINTERFERON ALFA-2B;OAS1;rs2660;AG;TOXICITY;DECREASED_RISK;nan;DISEASE;ANEMIA ;;
RIBAVIRIN;OAS1;rs2660;AG;TOXICITY;DECREASED_RISK;nan;DISEASE;ANEMIA ;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-RESPONSE;;;
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;NON-RESPONSE;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
OLANZAPINE;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIAC RHYTHM DISEASE;;;
IRINOTECAN;UGT1A1;rs10929302;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOPHOSPHAMIDE;CBR3;rs112783657;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;CBR3;rs112783657;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;CBR3;rs112783657;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
BUPROPION;GALR1;rs2717162;CC + CT;EFFICACY;DECREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
HEROIN;OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
CYCLOSPORINE;NFATC1;rs8090560;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;NFATC1;rs8090560;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
VINCRISTINE;CYP3A5;CYP3A5*1;*1/*3;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
VINCRISTINE;CYP3A5;CYP3A5*3;*1/*3;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA AND VOMITING;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA AND VOMITING;;;
RISPERIDONE;LEP;rs7799039;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
BUPROPION;GALR1;rs2717162;CC + CT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
PEGINTERFERON ALFA-2A;CTLA4;rs231775;AG;TOXICITY;DECREASED_RISK;nan;DISEASE;ANEMIA ;;
PEGINTERFERON ALFA-2B;CTLA4;rs231775;AG;TOXICITY;DECREASED_RISK;nan;DISEASE;ANEMIA ;;
RIBAVIRIN;CTLA4;rs231775;AG;TOXICITY;DECREASED_RISK;nan;DISEASE;ANEMIA ;;
CYCLOPHOSPHAMIDE;NOS1;rs149212925;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;NOS1;rs149212925;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;NOS1;rs149212925;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOSPORINE;DHFR;rs34965641;GG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;DHFR;rs34965641;GG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
ETRAVIRINE;CYP2C19;rs4244285;AA + AG;LADME-PK;DECREASED_PK;METABOLISM;ETRAVIRINE CLEARANCE;;;
CISPLATIN;ERCC1;rs3212986;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL;;;
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVEL;;;
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;IN A GENE-DOSE-DEPENDENT MANNER;;;
FLUOROURACIL;MTHFR;rs1801131;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION;;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs58695150;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs58695150;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs58695150;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
PEMETREXED;GGH;rs11545078;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METFORMIN;SLC22A1;rs72552763;GAT/del;OTHER, LADME-PK;DECREASED_;SIDE_EFFECT;TROUGH METFORMIN STEADY-STATE CONCENTRATION;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
PHENAZEPAM;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENAZEPAM;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEHYDRATION ;;
METHOTREXATE;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
FLUOROURACIL;DPYD;DPYD low activity;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IRINOTECAN;DPYD;DPYD low activity;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
LEUCOVORIN;DPYD;DPYD low activity;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;nan;SIDE_EFFECT;DRUG TOXICITY;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs150688309;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs150688309;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs150688309;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CAPECITABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*2;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
TAMOXIFEN;CYP3A4;CYP3A4*1;*22;TOXICITY;DECREASED_;SIDE_EFFECT;HOT FLASHES;;;
TAMOXIFEN;CYP3A4;CYP3A4*22;*22;TOXICITY;DECREASED_;SIDE_EFFECT;HOT FLASHES;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
WARFARIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;;
CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CODEINE;SLC22A1;SLC22A1 low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
CODEINE;SLC22A1;SLC22A1 low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CODEINE;SLC22A1;SLC22A1 low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
CODEINE;SLC22A1;SLC22A1 low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER ANTI-COAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER ANTI-COAGULATION;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *1/*3C + *3A/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *1/*3C + *3A/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TRANSPLANT REJECTION ;;
AZATHIOPRINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TRANSPLANT REJECTION ;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TRANSPLANT REJECTION ;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TRANSPLANT REJECTION ;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;VENLAFAXINE LEVELS;;;
CYCLOPHOSPHAMIDE;HMMR;rs299293;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;HMMR;rs299293;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;HMMR;rs299293;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EXEMESTANE;nan;rs934635;AA;TOXICITY;nan;SIDE_EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS;;;
CYCLOPHOSPHAMIDE;PERP;rs9389568;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PERP;rs9389568;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PERP;rs9389568;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CYCLOPHOSPHAMIDE;FOXO1;rs144991623;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;FOXO1;rs144991623;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;FOXO1;rs144991623;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
PRASUGREL;PEAR1;rs12407843;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
DIGOXIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SUDDEN CARDIAC DEATH;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PRASUGREL;PEAR1;rs77235035;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
VENLAFAXINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;VENLAFAXINE LEVELS;;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;VENLAFAXINE LEVELS;;;
VENLAFAXINE;CYP2D6;CYP2D6*1;*1/*4;LADME-PK;INCREASED_PK;METABOLISM;VENLAFAXINE LEVELS;;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*1/*4;LADME-PK;INCREASED_PK;METABOLISM;VENLAFAXINE LEVELS;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*2 + *2/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*2 + *2/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*17/*17 + *1/*17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION INHIBITION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17/*17 + *1/*17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION INHIBITION;;;
DIGOXIN;ABCB1;rs2032582;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SUDDEN CARDIAC DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6 + *28;TOXICITY;RISK;nan;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*28;*6 + *28;TOXICITY;RISK;nan;DISEASE;NEUTROPENIA ;;
DIGOXIN;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SUDDEN CARDIAC DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_PK;METABOLISM;CMAX AND AUC OF THIOL METABOLITE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_PK;METABOLISM;CMAX AND AUC OF THIOL METABOLITE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_PK;METABOLISM;CMAX AND AUC OF THIOL METABOLITE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_PK;METABOLISM;CMAX AND AUC OF THIOL METABOLITE;;;
CAPECITABINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HAND-FOOT SYNDROME ;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALL AND MINOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALL AND MINOR HEMORRHAGE;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
CYCLOPHOSPHAMIDE;PIK3R2;rs8110364;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs8110364;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs8110364;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
OLANZAPINE;ABCB1;rs10248420;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*28;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
FLUOROURACIL;DPYD;rs56293913;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUTICASONE PROPIONATE;CD14;rs2569190;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PC20;;;
FLUTICASONE PROPIONATE;TMCO6;rs2569190;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PC20;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs117341846;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs117341846;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs117341846;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS REQUIREMENT ;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS REQUIREMENT ;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;;SIDE_EFFECT;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;;SIDE_EFFECT;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;;SIDE_EFFECT;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *1/*3;;SIDE_EFFECT;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA);;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CYCLOPHOSPHAMIDE;IRS1;rs115457081;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;IRS1;rs115457081;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;IRS1;rs115457081;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_RISK;nan;DISEASE;STEVENS-JOHNSON SYNDROME ;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;;SIDE_EFFECT;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;;SIDE_EFFECT;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;;SIDE_EFFECT;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2/*2 + *2/*3 + *3/*3;;SIDE_EFFECT;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA);;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE;;;
CYCLOPHOSPHAMIDE;INSR;rs142244113;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;INSR;rs142244113;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;INSR;rs142244113;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
ASPIRIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
ASPIRIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE ACTIVITY AS ASSESSED BY THE PHYSICIAN;;;
DOXEPIN;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_PK;METABOLISM;MEDIAN ORAL CLEARANCE OF DOXEPIN;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs79430272;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs79430272;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs79430272;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
OLANZAPINE;CYP2D6;CYP2D6*1;*1/*3 + *1/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;CYP2D6;CYP2D6*3;*1/*3 + *1/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;CYP2D6;CYP2D6*4;*1/*3 + *1/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
CYCLOPHOSPHAMIDE;TP53;rs4968187;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;TP53;rs4968187;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;TP53;rs4968187;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CISPLATIN;ERCC1;rs3212986;AA;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;NEPHROTOXICITY ;;
PALBOCICLIB;ABCG2;rs2231137;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs117951771;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs117951771;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs117951771;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE;;;
ESCITALOPRAM;CYP2C19;CYP2C19*4;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE;;;
EXEMESTANE;nan;rs934635;AA;TOXICITY;nan;SIDE_EFFECT;A SIGNIFICANTLY HIGHER ODDS OF MUSCULOSKELETAL ADVERSE EVENTS (MSAES) IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS;;;
PRIMAQUINE;G6PD;G6PD deficiency;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DECREASED HEMOCRIT LEVELS;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs148235907;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs148235907;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs148235907;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
METHAMPHETAMINE;DAOA;rs3916965;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PSYCHOTIC DISORDER ;;
nan;UGT1A1;rs34993780;G;OTHER;INCREASED_LIKELIHOOD;OTHER;GILBERT SYNDROME;;;
nan;UGT1A1;rs34993780;G;OTHER;INCREASED_LIKELIHOOD;OTHER;CRIGLER-NAJJAR SYNDROME;;;
CYCLOPHOSPHAMIDE;CYP2C9;CYP2C9 poor metabolizer;*2 + *3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
DESIPRAMINE;CYP2D6;CYP2D6*1;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO;;;
DESIPRAMINE;CYP2D6;CYP2D6*2;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO;;;
DESIPRAMINE;CYP2D6;CYP2D6*5;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO;;;
DESIPRAMINE;CYP2D6;CYP2D6*10;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;INCREASED_PK;METABOLISM;THE INTRINSIC METABOLIC ACTIVITY (V(MAX)/K(M));;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;INCREASED_PK;METABOLISM;THE MEAN MAXIMAL ELIMINATION RATES (V(MAX));;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
PALBOCICLIB;SULT2A1;rs182420;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
PALBOCICLIB;SULT2A1;rs182420;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*1/*4 + *4/*4;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*4;*1/*4 + *4/*4;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*1/*4 + *4/*4;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*1/*4 + *4/*4;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
IMIPRAMINE;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;LADME-PK;DECREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS;;;
IMIPRAMINE;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS;;;
CYCLOPHOSPHAMIDE;HMMR;rs299313;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;HMMR;rs299313;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;HMMR;rs299313;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
PRIMAQUINE;G6PD;G6PD deficiency;;OTHER;INCREASED_LIKELIHOOD;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS;;;
SULFANILAMIDE;G6PD;G6PD deficiency;;OTHER;INCREASED_LIKELIHOOD;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS;;;
CHLORAMPHENICOL;G6PD;G6PD deficiency;;OTHER;INCREASED_LIKELIHOOD;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28 + *6/*6 + *1/*6 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*6;*28/*28 + *6/*6 + *1/*6 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28 + *6/*6 + *1/*6 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *6/*6 + *1/*6 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*28/*28 + *6/*6 + *1/*6 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *6/*6 + *1/*6 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CODEINE;UGT2B7;rs73823859;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PAIN;;;
MORPHINE;UGT2B7;rs73823859;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PAIN;;;
TRAMADOL;UGT2B7;rs73823859;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PAIN;;;
CISPLATIN;ALDH2;rs671;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
CISPLATIN;ALDH2;rs671;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
DOCETAXEL;ALDH2;rs671;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
DOCETAXEL;ALDH2;rs671;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
CYCLOPHOSPHAMIDE;HMMR;rs299314;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;HMMR;rs299314;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;HMMR;rs299314;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
WARFARIN;CYP2C9;CYP2C9*1;*8;LADME-PK;DECREASED_PK;METABOLISM;IN VITRO INTRINSIC CLEARANCE OF S-WARFARIN WITH THE CDNA-EXPRESSED R150H PROTEIN;;;
WARFARIN;CYP2C9;CYP2C9*8;*8;LADME-PK;DECREASED_PK;METABOLISM;IN VITRO INTRINSIC CLEARANCE OF S-WARFARIN WITH THE CDNA-EXPRESSED R150H PROTEIN;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEART FAILURE ;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
CISPLATIN;ERCC2;rs13181;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL;;;
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;STEVENS-JOHNSON SYNDROME ;;
ANTHRACYCLINES AND RELATED SUBSTANCES;CAT;rs10836235;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIAC DAMAGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
EXEMESTANE;UGT2B17;UGT2B17 deficiency;;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FATIGUE;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING TIME;;;
PAROXETINE;SLC6A4;SLC6A4 L allele-rs25531C;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING TIME;;;
PAROXETINE;SLC6A4;SLC6A4 L allele-rs25531T;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING TIME;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3 + *2/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*3 + *3/*3 + *2/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3 + *2/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
VALPROIC ACID;XBP1;rs2269577;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROPHYLACTIC TREATMENT RESPONSE;;;
ACE INHIBITORS;ACE;rs1799752;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE;;;
PLAIN;ACE;rs1799752;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE;;;
PACLITAXEL;CYP1B1;rs1056836;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10 + *4/*10 + *5/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*10/*10 + *4/*10 + *5/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*10/*10 + *4/*10 + *5/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10 + *4/*10 + *5/*10;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
DOCETAXEL;CYP1B1;rs1056836;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
WARFARIN;CYP2C9;CYP2C9*1;*8;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO;;;
WARFARIN;CYP2C9;CYP2C9*8;*8;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO;;;
CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;ADR;;;
DOXORUBICIN;ABCC4;rs9561778;T;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;ADR;;;
FLUOROURACIL;ABCC4;rs9561778;T;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;ADR;;;
CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;TOXICITY, LADME-PK;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED PLATELET AGGREGATION (PA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED PLATELET AGGREGATION (PA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED PLATELET AGGREGATION (PA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED PLATELET AGGREGATION (PA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED PLATELET AGGREGATION (PA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED PLATELET AGGREGATION (PA);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED PLATELET AGGREGATION (PA);;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;INCREASED_LIKELIHOOD;OTHER;HYDROCHLOROTHIAZIDE INDUCED POTASSIUM EXCRETION;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VENOUS THROMBOEMBOLISM;;;
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BONE MINERAL DENSITY RESPONSE;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
PAROXETINE;CYP2D6;CYP2D6*1;*1/*1xN;LADME-PK;DECREASED_PK;METABOLISM;PAROXETINE SERUM CONCENTRATION;;;
PAROXETINE;CYP2D6;CYP2D6*1xN;*1/*1xN;LADME-PK;DECREASED_PK;METABOLISM;PAROXETINE SERUM CONCENTRATION;;;
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CAPECITABINE;ANK3;rs143414470;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
GEFITINIB;CYP2D6;CYP2D6*1;*10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
GEFITINIB;CYP2D6;CYP2D6*2;*10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
GEFITINIB;CYP2D6;CYP2D6*5;*10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
GEFITINIB;CYP2D6;CYP2D6*10;*10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
GEFITINIB;CYP2D6;CYP2D6*14;*10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*2 + *3 + *8 + *9;OTHER;INCREASED_RISK;nan;DISEASE;RESPIRATORY TRACT INFECTIONS ;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*2 + *3 + *8 + *9;OTHER;INCREASED_RISK;nan;DISEASE;RESPIRATORY TRACT INFECTIONS ;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*2 + *3 + *8 + *9;OTHER;INCREASED_RISK;nan;DISEASE;RESPIRATORY TRACT INFECTIONS ;;
LANSOPRAZOLE;CYP2C19;CYP2C19*8;*2 + *3 + *8 + *9;OTHER;INCREASED_RISK;nan;DISEASE;RESPIRATORY TRACT INFECTIONS ;;
LANSOPRAZOLE;CYP2C19;CYP2C19*9;*2 + *3 + *8 + *9;OTHER;INCREASED_RISK;nan;DISEASE;RESPIRATORY TRACT INFECTIONS ;;
NEVIRAPINE;CCHCR1;rs130072;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEVIRAPINE-INDUCED RASH;;;
NEVIRAPINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;EXANTHEMA ;;
RITONAVIR;APOC3;rs5128;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TRIGLYCERIDE LEVELS;;;
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
METFORMIN;BDNF;rs6265;C;EFFICACY;INCREASED_LIKELIHOOD;OTHER;WEIGHT REGAIN AFTER INTENTIONAL WEIGHT LOSS;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*18;LADME-PK;INCREASED_PK;METABOLISM;PLASMA EFAVIRENZ LEVELS;;;
EFAVIRENZ;CYP2B6;CYP2B6*18;*1/*18;LADME-PK;INCREASED_PK;METABOLISM;PLASMA EFAVIRENZ LEVELS;;;
LUMIRACOXIB;HLA-DRB1;HLA-DRB1*01:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
LUMIRACOXIB;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
METHADONE;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;INCREASED_PK;METABOLISM;TROUGH ( R;;;
METHADONE;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;INCREASED_PK;METABOLISM;S )-METHADONE PLASMA CONCENTRATIONS;;;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_PK;METABOLISM;TROUGH ( R;;;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_PK;METABOLISM;S )-METHADONE PLASMA CONCENTRATIONS;;;
MERCAPTOPURINE;TPMT;TPMT*1;*12;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
MERCAPTOPURINE;TPMT;TPMT*12;*12;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;TPMT;TPMT*1;*12;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;TPMT;TPMT*12;*12;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278293;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;BIOPSY-PROVEN ACUTE REJECTION;;;
MITOXANTRONE;ABCB1;rs2032582;AA;OTHER;INCREASED_LIKELIHOOD;OTHER;SENSITIVITY IN VITRO;;;
LUMIRACOXIB;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;LADME-PK;INCREASED_RISK;OTHER;OVERANTICOAGULATION;;;
ASPIRIN;PON1;rs662;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;LADME-PK;INCREASED_RISK;OTHER;OVERANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
METHADONE;CYP2B6;CYP2B6*1;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PROLONGED QTC;;;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PROLONGED QTC;;;
METHADONE;CYP2B6;CYP2B6*1;*6/*6;LADME-PK;INCREASED_PK;METABOLISM;(S)-METHADONE PLASMA LEVELS;;;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_PK;METABOLISM;(S)-METHADONE PLASMA LEVELS;;;
TRIMIPRAMINE;CYP2D6;CYP2D6*1;*4/*4 + *3/*5 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRIMIPRAMINE;CYP2D6;CYP2D6*2xN;*4/*4 + *3/*5 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRIMIPRAMINE;CYP2D6;CYP2D6*3;*4/*4 + *3/*5 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRIMIPRAMINE;CYP2D6;CYP2D6*4;*4/*4 + *3/*5 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRIMIPRAMINE;CYP2D6;CYP2D6*5;*4/*4 + *3/*5 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
CLOPIDOGREL;ABCB1;rs1045642;A;OTHER;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
NEVIRAPINE;HLA-C;rs9461684;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEVIRAPINE-INDUCED RASH;;;
ASPIRIN;IL1B;rs1143627;A;TOXICITY;nan;nan;DISEASE;PEPTIC ULCER DISEASE ;;
PACLITAXEL;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CYCLOPHOSPHAMIDE;SLC22A16;rs714368;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOPHOSPHAMIDE;SLC22A16;rs714368;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;SLC22A16;rs714368;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
DOXORUBICIN;SLC22A16;rs714368;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
PHENYTOIN;EPHX1;rs2234922;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DISORDER OF FACIAL SKELETON ;;
PHENYTOIN;EPHX1;rs1051740;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DISORDER OF FACIAL SKELETON ;;
NEVIRAPINE;TCF19;rs2073724;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*10;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*10;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
CARBOPLATIN;NRG3;rs1649942;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PACLITAXEL;NRG3;rs1649942;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PHENPROCOUMON;EPHX1;rs1051740;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BEING OVERANTICOAGULATED;;;
nan;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_PK;METABOLISM;STEROL/BILE ACID METABOLITES;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA EFAVIRENZ LEVELS;;;
ASPIRIN;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NON-RESPONSIVENESS;;;
ASPIRIN;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NON-RESPONSIVENESS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NON-RESPONSIVENESS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NON-RESPONSIVENESS;;;
CYCLOPHOSPHAMIDE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CAFFEINE;ADORA2A;rs5751876;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ANXIETY DISORDERS ;;
PACLITAXEL;NAT2;rs1208;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;NAT2;rs1208;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*05:01;*05:01 + *05:02 + *05:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*05:02;*05:01 + *05:02 + *05:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*05:03;*05:01 + *05:02 + *05:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
VENLAFAXINE;CYP2D6;CYP2D6*1;*5/*4 + *6/*6 + *6/*4;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*5/*4 + *6/*6 + *6/*4;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
VENLAFAXINE;CYP2D6;CYP2D6*5;*5/*4 + *6/*6 + *6/*4;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
VENLAFAXINE;CYP2D6;CYP2D6*6;*5/*4 + *6/*6 + *6/*4;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
FLUVOXAMINE;CYP2D6;CYP2D6*1;*1/*5 + *10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL SIDE EFFECTS;;;
FLUVOXAMINE;CYP2D6;CYP2D6*5;*1/*5 + *10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL SIDE EFFECTS;;;
FLUVOXAMINE;CYP2D6;CYP2D6*10;*1/*5 + *10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL SIDE EFFECTS;;;
NEMONAPRIDE;ANKK1;rs1800497;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PROLACTIN CONCENTRATIONS;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*3/*3 + *4/*4;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*3 + *4/*4;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3/*3 + *4/*4;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
METHOTREXATE;SLC19A1;rs1051266;TT;OTHER, LADME-PK;INCREASED_PK;METABOLISM;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
FLUVOXAMINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_PK;METABOLISM;AREAS UNDER THE SERUM CONCENTRATION-TIME CURVE;;;
METHOTREXATE;GGH;rs3758149;AA;LADME-PK;DECREASED_PK;METABOLISM;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS;;;
RISPERIDONE;DRD2;rs1799978;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERPROLACTINEMIA ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
RISPERIDONE;ANKK1;rs1800497;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERPROLACTINEMIA ;;
MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;G;OTHER;INCREASED_LIKELIHOOD;OTHER;INOSINE MONOPHOSPHATE DEHYDROGENASE ACTIVITY;;;
MERCAPTOPURINE;XDH;rs2281547;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2/*2 + *1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR);;;
ASPIRIN;CYP2C19;CYP2C19*2;*2/*2 + *1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR);;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR);;;
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;G;LADME-PK;DECREASED_PK;METABOLISM;DOSE-NORMALIZED  CMAX AND DOSE-NORMALIZED  AUC0TO12 H;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR);;;
INDINAVIR;UGT1A1;UGT1A1*1;*6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
INDINAVIR;UGT1A1;UGT1A1*6;*6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
INDINAVIR;UGT1A1;UGT1A1*28;*6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ANASTROZOLE;ABCB1;rs1045642;AA;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRALGIA;;;
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_;OTHER;EVENT-FREE SURVIVAL;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HAVING INR ABOVE TARGET RANGE IN WEEK 1;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HAVING INR ABOVE TARGET RANGE IN WEEK 1;;;
nan;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
MERCAPTOPURINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
FLECAINIDE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;SYSTEMIC EXPOSURE (AUC) AND LOWER ORAL CLEARANCE OF FLECAINIDE;;;
FLECAINIDE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;SYSTEMIC EXPOSURE (AUC) AND LOWER ORAL CLEARANCE OF FLECAINIDE;;;
ETHANOL;ALDH2;rs671;GG;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
DIDANOSINE;XDH;rs1429376;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERTENSION, PORTAL ;;
DAUNORUBICIN;SZRD1;rs6603859;T;OTHER, LADME-PK;DECREASED_PK;METABOLISM;IC50;;;
DIDANOSINE;NT5C2;rs11598702;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERTENSION, PORTAL ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
DIDANOSINE;XDH;rs1594160;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERTENSION, PORTAL ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
DAUNORUBICIN;nan;rs7929521;GG;OTHER, LADME-PK;INCREASED_PK;METABOLISM;IC50;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*37;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
AZACITIDINE;TYMS;rs11280056;del/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DAUNORUBICIN;MAN1B1;rs3750518;T;OTHER, LADME-PK;INCREASED_PK;METABOLISM;IC50;;;
OXYCODONE;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED_PK;METABOLISM;MEAN OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*1xN;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED_PK;METABOLISM;MEAN OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*2;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED_PK;METABOLISM;MEAN OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*2xN;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED_PK;METABOLISM;MEAN OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED_PK;METABOLISM;MEAN OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED_PK;METABOLISM;MEAN OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED_PK;METABOLISM;MEAN OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED_PK;METABOLISM;MEAN OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED_PK;METABOLISM;MEAN OXYMORPHONE/OXYCODONE RATIOS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
DIDANOSINE;NT5C2;rs11191561;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERTENSION, PORTAL ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQA1;HLA-DQA1*01:02;*01:02;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
IGURATIMOD;CYP2C19;rs4244285;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CYCLOSPORINE;CYP3A4;CYP3A4*1;*1/*22;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
CYCLOSPORINE;CYP3A4;CYP3A4*22;*1/*22;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
PHENYTOIN;HLA-C;HLA-C*14:02;*14:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-C;HLA-C*14:02;*14:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;HLA-B;HLA-B*56:02;*56:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*56:02;*56:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
NICOTINE;CYP2A6;rs1801272;AT + TT;TOXICITY;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
OLANZAPINE;CYP2C9;CYP2C9*1;*1/*3 + *2/*3 + *3/*6;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;HYPOTENSIVE DISORDER ;;
OLANZAPINE;CYP2C9;CYP2C9*2;*1/*3 + *2/*3 + *3/*6;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;HYPOTENSIVE DISORDER ;;
OLANZAPINE;CYP2C9;CYP2C9*3;*1/*3 + *2/*3 + *3/*6;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;HYPOTENSIVE DISORDER ;;
OLANZAPINE;CYP2C9;CYP2C9*6;*1/*3 + *2/*3 + *3/*6;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;HYPOTENSIVE DISORDER ;;
DESIPRAMINE;CYP2D6;CYP2D6*1;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT;;;
DESIPRAMINE;CYP2D6;CYP2D6*2;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT;;;
DESIPRAMINE;CYP2D6;CYP2D6*5;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT;;;
DESIPRAMINE;CYP2D6;CYP2D6*10;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT;;;
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
OLANZAPINE;TPMT;TPMT*1;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FATIGUE ;;
OLANZAPINE;TPMT;TPMT*3A;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FATIGUE ;;
OLANZAPINE;TPMT;TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FATIGUE ;;
nan;NAT1;NAT1*4;*11B/*4;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
nan;NAT1;NAT1*11B;*11B/*4;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MERCAPTOPURINE;TPMT;TPMT*9;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MERCAPTOPURINE;TPMT;TPMT*21;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MERCAPTOPURINE;TPMT;TPMT*32;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MERCAPTOPURINE;TPMT;TPMT*33;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MERCAPTOPURINE;TPMT;TPMT*34;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
THIOGUANINE;TPMT;TPMT*1;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
THIOGUANINE;TPMT;TPMT*2;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
THIOGUANINE;TPMT;TPMT*3A;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
THIOGUANINE;TPMT;TPMT*3C;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
THIOGUANINE;TPMT;TPMT*9;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
THIOGUANINE;TPMT;TPMT*21;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
THIOGUANINE;TPMT;TPMT*32;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
THIOGUANINE;TPMT;TPMT*33;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
THIOGUANINE;TPMT;TPMT*34;*1/*3C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
OLANZAPINE;GSTM3;rs1799735;CCT/CCT;LADME-PK;DECREASED_PK;METABOLISM;AREA UNDER THE CURVE;;;
OLANZAPINE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE CURVE;;;
OLANZAPINE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE CURVE;;;
MERCAPTOPURINE;XDH;rs2281547;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANASTROZOLE;CYP19A1;rs727479;AA;EFFICACY;INCREASED_SEVERITY;OTHER;RECURRENCE FREE SURVIVAL;;;
OXYCODONE;CYP2D6;CYP2D6*1;*4/*4 + *4/*6;LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*2;*4/*4 + *4/*6;LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*4;*4/*4 + *4/*6;LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*6;*4/*4 + *4/*6;LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS;;;
FLUVASTATIN;SLCO1B1;rs11045819;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;LDL-C REDUCTION;;;
OXYCODONE;CYP2D6;CYP2D6*1;*4/*4 + *3/*4;LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*2;*4/*4 + *3/*4;LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*3;*4/*4 + *3/*4;LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS;;;
OXYCODONE;CYP2D6;CYP2D6*4;*4/*4 + *3/*4;LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS;;;
EFAVIRENZ;CYP2B6;CYP2B6*18;*18/*18;LADME-PK;INCREASED_PK;METABOLISM;PLASMA EFAVIRENZ LEVELS;;;
CYCLOPHOSPHAMIDE;NQO2;rs1143684;C;;SIDE_EFFECT;EFFICACY;WORSE PROGNOSIS (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PATIENTS WHO WERE ER-VE/PR-VE NEGATIVE;;;
DOXORUBICIN;NQO2;rs1143684;C;;SIDE_EFFECT;EFFICACY;WORSE PROGNOSIS (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PATIENTS WHO WERE ER-VE/PR-VE NEGATIVE;;;
PIOGLITAZONE;CYP2C8;CYP2C8*1;*1/*2 + *2/*2;LADME-PK;DECREASED_PK;METABOLISM;M-III;;;
PIOGLITAZONE;CYP2C8;CYP2C8*1;*1/*2 + *2/*2;LADME-PK;DECREASED_PK;METABOLISM;PIOGLITAZONE AUC0-48 RATIO AND M-III;;;
PIOGLITAZONE;CYP2C8;CYP2C8*1;*1/*2 + *2/*2;LADME-PK;DECREASED_PK;METABOLISM;M-IV AUC0-48 RATIO IN HEALTHY AFRICAN-AMERICAN VOLUNTEERS;;;
PIOGLITAZONE;CYP2C8;CYP2C8*2;*1/*2 + *2/*2;LADME-PK;DECREASED_PK;METABOLISM;M-III;;;
PIOGLITAZONE;CYP2C8;CYP2C8*2;*1/*2 + *2/*2;LADME-PK;DECREASED_PK;METABOLISM;PIOGLITAZONE AUC0-48 RATIO AND M-III;;;
PIOGLITAZONE;CYP2C8;CYP2C8*2;*1/*2 + *2/*2;LADME-PK;DECREASED_PK;METABOLISM;M-IV AUC0-48 RATIO IN HEALTHY AFRICAN-AMERICAN VOLUNTEERS;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
DICLOFENAC;UGT2B7;rs7668258;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEMORRHAGE ;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEMORRHAGE ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;EFFICACY;DECREASED_RISK;OTHER;NON-FATAL MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;EFFICACY;DECREASED_RISK;OTHER;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;EFFICACY;DECREASED_RISK;OTHER;REVASCULARIZATION OR DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED_RISK;OTHER;NON-FATAL MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED_RISK;OTHER;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED_RISK;OTHER;REVASCULARIZATION OR DEATH;;;
IBUPROFEN;CYP2C8;CYP2C8*1;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;R-IBUPROFEN METABOLISM;;;
IBUPROFEN;CYP2C8;CYP2C8*2;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;R-IBUPROFEN METABOLISM;;;
CISPLATIN;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
ASPIRIN;CYP2C19;rs4244285;A;TOXICITY;nan;SIDE_EFFECT;HIGHER COMPOSITE HAR OUTCOME (CARDIAC DEATH;;;
ASPIRIN;CYP2C19;rs4244285;A;TOXICITY;nan;SIDE_EFFECT;NON FATAL MYOCARDIAL INFARCTION AND STENT THROMBOSIS) UP TO 12 MONTHS' FOLLOW UP;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;nan;SIDE_EFFECT;HIGHER COMPOSITE HAR OUTCOME (CARDIAC DEATH;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;nan;SIDE_EFFECT;NON FATAL MYOCARDIAL INFARCTION AND STENT THROMBOSIS) UP TO 12 MONTHS' FOLLOW UP;;;
nan;IRS1;rs1801123;C;OTHER;nan;OTHER;LYMPH NODE INVOLVEMENT;;;
ESTRADIOL;nan;rs1864729;A;OTHER;INCREASED_LIKELIHOOD;OTHER;PLASMA LEVEL;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEDIAN SURVIVAL TIME;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE (RR);;;
CARBIMAZOLE;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
METHIMAZOLE;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
PROPYLTHIOURACIL;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;GSTM1 non-null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOMYOPATHIES;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOMYOPATHIES;;;
ETHAMBUTOL;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*2;LADME-PK;DECREASED_PK;METABOLISM;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM;;;
CITALOPRAM;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED_PK;METABOLISM;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM;;;
DICLOFENAC;ABCC2;rs717620;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ANTIARRHYTHMICS;nan;rs10033464;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUCCESSFUL RHYTHM CONTROL;;;
CLASS I AND III;nan;rs10033464;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUCCESSFUL RHYTHM CONTROL;;;
CARBIMAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
METHIMAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SURVIVAL TIME;;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;;SIDE_EFFECT;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;;SIDE_EFFECT;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION;;;
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BETTER CLINICAL RESPONSE;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;UNBOUND ORAL CLEARANCE FOR S-WARFARIN;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;UNBOUND ORAL CLEARANCE FOR S-WARFARIN;;;
RIFAMPIN;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;;SIDE_EFFECT;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;;SIDE_EFFECT;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION;;;
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS;;;
FLUVOXAMINE;SLC6A4;SLC6A4 L allele-rs25531C;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS;;;
FLUVOXAMINE;SLC6A4;SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS;;;
PAROXETINE;SLC6A4;SLC6A4 L allele-rs25531C;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS;;;
PAROXETINE;SLC6A4;SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*5 + *4/*6 + *3/*4 + *4/*4;OTHER;DECREASED_;OTHER;WAKEFULNESS ACTIVITY LEVEL;;;
RISPERIDONE;CYP2D6;CYP2D6*1xN;*4/*5 + *4/*6 + *3/*4 + *4/*4;OTHER;DECREASED_;OTHER;WAKEFULNESS ACTIVITY LEVEL;;;
RISPERIDONE;CYP2D6;CYP2D6*3;*4/*5 + *4/*6 + *3/*4 + *4/*4;OTHER;DECREASED_;OTHER;WAKEFULNESS ACTIVITY LEVEL;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*5 + *4/*6 + *3/*4 + *4/*4;OTHER;DECREASED_;OTHER;WAKEFULNESS ACTIVITY LEVEL;;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4/*5 + *4/*6 + *3/*4 + *4/*4;OTHER;DECREASED_;OTHER;WAKEFULNESS ACTIVITY LEVEL;;;
RISPERIDONE;CYP2D6;CYP2D6*6;*4/*5 + *4/*6 + *3/*4 + *4/*4;OTHER;DECREASED_;OTHER;WAKEFULNESS ACTIVITY LEVEL;;;
nan;IGFBP3;rs2854744;T;OTHER;nan;OTHER;TUMOR SIZE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6 + *28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*6 + *28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS;;;
NEVIRAPINE;GSTM1;GSTM1 non-null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
NEVIRAPINE;GSTM1;GSTM1 non-null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
NEVIRAPINE;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
NEVIRAPINE;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CISPLATIN;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS;;;
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_RISK;nan;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CISPLATIN;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
PAROXETINE;CYP2D6;CYP2D6*1;*4/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
PAROXETINE;CYP2D6;CYP2D6*4;*4/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
PAROXETINE;CYP2D6;CYP2D6*5;*4/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
nan;GSTM3;rs36120609;TC/TC + TC/TCCTC;OTHER;INCREASED_LIKELIHOOD;OTHER;METASTATIC NEOPLASM;;;
FLUOXETINE;CYP2D6;CYP2D6*1;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE/(S)-NORFLUOXETINE RATIO;;;
FLUOXETINE;CYP2D6;CYP2D6*1xN;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE/(S)-NORFLUOXETINE RATIO;;;
FLUOXETINE;CYP2D6;CYP2D6*3;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE/(S)-NORFLUOXETINE RATIO;;;
FLUOXETINE;CYP2D6;CYP2D6*4;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE/(S)-NORFLUOXETINE RATIO;;;
FLUOXETINE;CYP2D6;CYP2D6*5;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE/(S)-NORFLUOXETINE RATIO;;;
FLUOXETINE;CYP2D6;CYP2D6*6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE/(S)-NORFLUOXETINE RATIO;;;
CARBOPLATIN;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
CYCLOPHOSPHAMIDE;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
THIOTEPA;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;AGRANULOCYTOSIS ;;
ASPIRIN;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH PLATELET REACTIVITY;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
PAROXETINE;CYP2D6;CYP2D6*1;*1/*4 + *1/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY;;;
PAROXETINE;CYP2D6;CYP2D6*4;*1/*4 + *1/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY;;;
PAROXETINE;CYP2D6;CYP2D6*5;*1/*4 + *1/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY;;;
DICLOFENAC;CYP2C8;CYP2C8*1;*1/*3 + *3/*3;LADME-PK;INCREASED_PK;METABOLISM;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO;;;
DICLOFENAC;CYP2C8;CYP2C8*3;*1/*3 + *3/*3;LADME-PK;INCREASED_PK;METABOLISM;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO;;;
PAROXETINE;CYP2D6;CYP2D6*1;*3/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
PAROXETINE;CYP2D6;CYP2D6*3;*3/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
PAROXETINE;CYP2D6;CYP2D6*4;*3/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
HEPARIN;HLA-DRB3;HLA-DRB3*01:01;*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEPARIN-INDUCED THROMBOCYTOPENIA;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*2 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*1/*2 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6 + *28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*6 + *28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL4;rs11322783;TT/TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-REMISSION;;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-REMISSION;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
IBUPROFEN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;RACEMIC;;;
IBUPROFEN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;S-IBUPROFEN AND R-IBUPROFEN METABOLISM;;;
IBUPROFEN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;WITH INCREASE OF AUC(0-INFINITY) AND REDUCTION OF CLEARANCE;;;
IBUPROFEN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;RACEMIC;;;
IBUPROFEN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;S-IBUPROFEN AND R-IBUPROFEN METABOLISM;;;
IBUPROFEN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;DECREASED_PK;METABOLISM;WITH INCREASE OF AUC(0-INFINITY) AND REDUCTION OF CLEARANCE;;;
TENOXICAM;CYP2C9;CYP2C9*1;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE;;;
TENOXICAM;CYP2C9;CYP2C9*2;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
TENOXICAM;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE;;;
TENOXICAM;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA 4BETA-OHC/CHOL RATIO;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA 4BETA-OHC/CHOL RATIO;;;
LAMIVUDINE;CYP2B6;CYP2B6*1;*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA 4BETA-OHC/CHOL RATIO;;;
LAMIVUDINE;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA 4BETA-OHC/CHOL RATIO;;;
STAVUDINE;CYP2B6;CYP2B6*1;*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA 4BETA-OHC/CHOL RATIO;;;
STAVUDINE;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA 4BETA-OHC/CHOL RATIO;;;
ZIDOVUDINE;CYP2B6;CYP2B6*1;*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA 4BETA-OHC/CHOL RATIO;;;
ZIDOVUDINE;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA 4BETA-OHC/CHOL RATIO;;;
TAMOXIFEN;CYP2D6;CYP2D6 low activity;;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
PIROXICAM;CYP2C9;CYP2C9*1;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY;;;
PIROXICAM;CYP2C9;CYP2C9*3;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY;;;
NICOTINE;CYP2A6;CYP2A6*1;*4 + *10 + *9;LADME-PK;DECREASED_PK;METABOLISM;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT);;;
NICOTINE;CYP2A6;CYP2A6*4;*4 + *10 + *9;LADME-PK;DECREASED_PK;METABOLISM;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT);;;
NICOTINE;CYP2A6;CYP2A6*9;*4 + *10 + *9;LADME-PK;DECREASED_PK;METABOLISM;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT);;;
NICOTINE;CYP2A6;CYP2A6*10;*4 + *10 + *9;LADME-PK;DECREASED_PK;METABOLISM;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT);;;
ASPIRIN;CYP2C19;CYP2C19*1;*17;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*17;*17;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*17;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
LUMIRACOXIB;HLA-DQA1;HLA-DQA1*01:01;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
LUMIRACOXIB;HLA-DQA1;HLA-DQA1*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ASPIRIN;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ASPIRIN;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
PAROXETINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE LEVELS;;;
PAROXETINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE LEVELS;;;
IBUPROFEN;CYP2C9;CYP2C9*1;*1/*2;OTHER;DECREASED_;OTHER;INOS EXPRESSION;;;
IBUPROFEN;CYP2C9;CYP2C9*2;*1/*2;OTHER;DECREASED_;OTHER;INOS EXPRESSION;;;
IRINOTECAN;UGT1A6;rs2070959;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
IBUPROFEN;CYP2C8;CYP2C8*1;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-IBUPROFEN METABOLISM;;;
IBUPROFEN;CYP2C8;CYP2C8*3;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;R-IBUPROFEN METABOLISM;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IMATINIB;EGFR;rs2072454;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIORBITAL EDEMA;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;SIDE EFFECTS;;;
KETOPROFEN;CYP2D6;CYP2D6*1;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
KETOPROFEN;CYP2D6;CYP2D6*2;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
KETOPROFEN;CYP2D6;CYP2D6*3;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
KETOPROFEN;CYP2D6;CYP2D6*4;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
KETOPROFEN;CYP2D6;CYP2D6*5;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
KETOPROFEN;CYP2D6;CYP2D6*6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
KETOPROFEN;CYP2D6;CYP2D6*9;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
KETOPROFEN;CYP2D6;CYP2D6*10;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
KETOPROFEN;CYP2D6;CYP2D6*17;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
KETOPROFEN;CYP2D6;CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*1;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*2;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*3;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*4;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*5;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*9;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*10;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*17;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
TRAMADOL;CYP2D6;CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEDATION;;;
PIROXICAM;CYP2C9;CYP2C9*1;*1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY;;;
PIROXICAM;CYP2C9;CYP2C9*2;*1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY;;;
PIROXICAM;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE;;;
PIROXICAM;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE;;;
PIROXICAM;CYP2C9;CYP2C9*1;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE;;;
PIROXICAM;CYP2C9;CYP2C9*2;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE;;;
GEFITINIB;CYP2D6;CYP2D6*1;*10/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
GEFITINIB;CYP2D6;CYP2D6*2;*10/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
GEFITINIB;CYP2D6;CYP2D6*10;*10/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
GEFITINIB;CYP2D6;CYP2D6*114;*10/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs11322783;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CITALOPRAM;CYP2D6;rs1065852;A;OTHER;nan;OTHER;PLASMA CONCENTRATION OF S-DIDESMETHYL-CITALOPRAM;;;
ESCITALOPRAM;CYP2D6;rs1065852;A;OTHER;nan;OTHER;PLASMA CONCENTRATION OF S-DIDESMETHYL-CITALOPRAM;;;
HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
ASPIRIN;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
ASPIRIN;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
MIRTAZAPINE;CYP2D6;CYP2D6*1;*1/*1xN;LADME-PK;INCREASED_PK;METABOLISM;CLEARANCE OF S(+) MIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*1xN;*1/*1xN;LADME-PK;INCREASED_PK;METABOLISM;CLEARANCE OF S(+) MIRTAZAPINE;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
nan;CYP2D6;CYP2D6*2xN;*2xN;OTHER;INCREASED_RISK;nan;DISEASE;SUICIDE ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;DECREASED_PK;METABOLISM;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_PK;METABOLISM;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
nan;CYP2C19;CYP2C19*1;*2/*2;OTHER;DECREASED_SEVERITY;nan;DISEASE;DEPRESSION ;;
nan;CYP2C19;CYP2C19*2;*2/*2;OTHER;DECREASED_SEVERITY;nan;DISEASE;DEPRESSION ;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
IRINOTECAN;UGT1A9;rs11692021;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
METOPROLOL;ADRB2;rs1042714;CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TRIGLYCERIDES;;;
LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
TAMOXIFEN;IGF1R;rs2016347;GG;EFFICACY;INCREASED_RISK;nan;DISEASE;RECURRENCE ;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
RALTITREXED;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
RALTITREXED;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
nan;CYP2D6;CYP2D6*1xN;*1xN;OTHER;INCREASED_RISK;nan;DISEASE;SUICIDE ;;
ALLOPURINOL;HLA-B;HLA-B*48:01;*48:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
PACLITAXEL;CYP2C8;rs10509681;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
RALTITREXED;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
RALTITREXED;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
PAZOPANIB;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASTHENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASTHENIA;;;
RALTITREXED;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASTHENIA;;;
RALTITREXED;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASTHENIA;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTOLERANCE;;;
CITALOPRAM;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTOLERANCE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
QUETIAPINE;CYP2C19;CYP2C19*1;*1/*2 + *2/*2 + *2/*4;LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
QUETIAPINE;CYP2C19;CYP2C19*2;*1/*2 + *2/*2 + *2/*4;LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
QUETIAPINE;CYP2C19;CYP2C19*4;*1/*2 + *2/*2 + *2/*4;LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
CAFFEINE;ADORA2A;rs35060421;TTTTTTT/TTTTTTT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANXIETY;;;
ALLOPURINOL;HLA-DRB1;HLA-DRB1*14:01;*14:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
ALLOPURINOL;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
ETHAMBUTOL;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ZONISAMIDE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;nan;nan;DISEASE;STEVENS-JOHNSON SYNDROME ;;
PHENOBARBITAL;HLA-B;HLA-B*51:01;*51:01;TOXICITY;nan;nan;DISEASE;STEVENS-JOHNSON SYNDROME ;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*17/*17;LADME-PK;DECREASED_PK;METABOLISM;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION AND HIGHER MEAN METABOLIC RATIO;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;DECREASED_PK;METABOLISM;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION AND HIGHER MEAN METABOLIC RATIO;;;
TRAMADOL;CYP2D6;CYP2D6*1;*10/*10;EFFICACY;INCREASED_SEVERITY;OTHER;PAIN;;;
TRAMADOL;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_SEVERITY;OTHER;PAIN;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
LAMIVUDINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;nan;SIDE_EFFECT;EXANTHEMA;;;
NEVIRAPINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;nan;SIDE_EFFECT;EXANTHEMA;;;
STAVUDINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;nan;SIDE_EFFECT;EXANTHEMA;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;TIME TO ACHIEVE THERAPEUTIC WINDOW;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;TIME TO ACHIEVE THERAPEUTIC WINDOW;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
METHOTREXATE;ABCC2;rs3740065;AG + GG;LADME-PK;INCREASED_PK;METABOLISM;PLASMA LEVEL;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
METOPROLOL;ADRB2;rs1042714;CC;TOXICITY;DECREASED_;SIDE_EFFECT;TOTAL CHOLESTEROL;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
METHOTREXATE;ABCC4;rs9516519;GG + GT;LADME-PK;DECREASED_PK;METABOLISM;PLASMA LEVEL;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
AZATHIOPRINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
MERCAPTOPURINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
THIOGUANINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;S-CIT SERUM CONCENTRATIONS;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;S-CIT SERUM CONCENTRATIONS;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;S-CIT SERUM CONCENTRATIONS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN ESCITALOPRAM CONCENTRATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN ESCITALOPRAM CONCENTRATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN ESCITALOPRAM CONCENTRATION;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE WHEN MEASURED BY THE GERIATRIC DEPRESSION SCALE AT DAY 7 AND DAY 28;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE WHEN MEASURED BY THE GERIATRIC DEPRESSION SCALE AT DAY 7 AND DAY 28;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;LOWER FINAL DAILY DOSE;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DECREASED DOSING COMPLIANCE AND LOWER PLASMA LEVELS AT DAY 28;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;LOWER FINAL DAILY DOSE;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DECREASED DOSING COMPLIANCE AND LOWER PLASMA LEVELS AT DAY 28;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*17/*17;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*17;*17/*17;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
MIRTAZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
MIRTAZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*3;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*3;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
LISINOPRIL;MMP3;rs35068180;del/del;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_RISK;nan;DISEASE;INFECTIOUS DISEASE ;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_RISK;nan;DISEASE;INFECTIOUS DISEASE ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;POSITIVE CORRELATION OF PAROXETINE CONCENTRATION WITH IMPROVEMENT IN HAMD SCORES AT WEEK 2;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);;SIDE_EFFECT;EFFICACY;POSITIVE CORRELATION OF PAROXETINE CONCENTRATION WITH IMPROVEMENT IN HAMD SCORES AT WEEK 2;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
ESCITALOPRAM;CYP2D6;CYP2D6*1;*4/*41;LADME-PK;INCREASED_PK;METABOLISM;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION;;;
ESCITALOPRAM;CYP2D6;CYP2D6*4;*4/*41;LADME-PK;INCREASED_PK;METABOLISM;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION;;;
ESCITALOPRAM;CYP2D6;CYP2D6*41;*4/*41;LADME-PK;INCREASED_PK;METABOLISM;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS;;;
FENTANYL;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
FENTANYL;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
DIRECT ACTING ANTIVIRALS;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*2;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*2;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
ESCITALOPRAM;CYP2C19;CYP2C19*3;*2;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;SERUM CONCENTRATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_PK;METABOLISM;DEMETHYLATION CLEARANCE OF DESMETHYLCITALOPRAM;;;
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LONG QT SYNDROME;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LONG QT SYNDROME;;;
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;NEUTROPENIA ;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;NEUTROPENIA ;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*9;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISCONTINUATION;;;
EFAVIRENZ;CYP2B6;CYP2B6*9;*9;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISCONTINUATION;;;
CAPECITABINE;DPYD;rs56038477;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs56038477;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
IRINOTECAN;UGT1A6;UGT1A6*2a;*2a;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
OXALIPLATIN;UGT1A6;UGT1A6*2a;*2a;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
TEGAFUR;UGT1A6;UGT1A6*2a;*2a;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
GIMERACIL;UGT1A6;UGT1A6*2a;*2a;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
OTERACIL;UGT1A6;UGT1A6*2a;*2a;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;UGT1A1;UGT1A1*28;*28;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TEGAFUR;UGT1A1;UGT1A1*28;*28;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GIMERACIL;UGT1A1;UGT1A1*28;*28;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OTERACIL;UGT1A1;UGT1A1*28;*28;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FOLFOX;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
IRINOTECAN;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TEGAFUR;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GIMERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OTERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ISONIAZID;NAT2;NAT2*4;*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
WARFARIN;CYP2C9;CYP2C9*1;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
METHOTREXATE;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*9/*9 + *1/*9;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
EFAVIRENZ;CYP2B6;CYP2B6*9;*9/*9 + *1/*9;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
FOLFOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3B;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;TPMT;TPMT*1;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;TPMT;TPMT*2;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;TPMT;TPMT*3B;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
EGFR INHIBITORS;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1;*1/*6 + *6/*6;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*6;*1/*6 + *6/*6;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
FLUDARABINE;CYP2B6;CYP2B6*1;*1/*6 + *6/*6;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
FLUDARABINE;CYP2B6;CYP2B6*6;*1/*6 + *6/*6;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ANTINEOPLASTIC AGENTS;UGT2B15;UGT2B15*1;*2/*2 + *1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;UGT2B15;UGT2B15*2;*2/*2 + *1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;UGT2B15;UGT2B15*1;*2/*2 + *1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;UGT2B15;UGT2B15*2;*2/*2 + *1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
EGFR INHIBITORS;HLA-A;HLA-A*03:01;*03:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASTHENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASTHENIA;;;
DOCETAXEL;SLCO1B3;rs3834935;A;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
CARBAMAZEPINE;GABRA1;rs2279020;GG;;SIDE_EFFECT;EFFICACY;DRUG-RESISTANT PHENOTYPE;;;
PHENYTOIN;GABRA1;rs2279020;GG;;SIDE_EFFECT;EFFICACY;DRUG-RESISTANT PHENOTYPE;;;
VALPROIC ACID;GABRA1;rs2279020;GG;;SIDE_EFFECT;EFFICACY;DRUG-RESISTANT PHENOTYPE;;;
PACLITAXEL;CYP2C8;CYP2C8*2;*2 + *3 + *4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;CYP2C8;CYP2C8*3;*2 + *3 + *4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;CYP2C8;CYP2C8*4;*2 + *3 + *4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
ETHAMBUTOL;CYP2B6;CYP2B6*1;*6/*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;CYP2B6;CYP2B6*1;*6/*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;CYP2B6;CYP2B6*1;*6/*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;CYP2B6;CYP2B6*1;*6/*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
AMOXICILLIN;HLA-A;HLA-A*30:02;*30:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-A;HLA-A*30:02;*30:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CITALOPRAM;nan;rs1074145;A;OTHER;nan;OTHER;CONCENTRATIONS OF S-CITALOPRAM AND METABOLIC RATIO OF OF S-DESMETHYLCITALOPRAM/CITALOPRAM;;;
ESCITALOPRAM;nan;rs1074145;A;OTHER;nan;OTHER;CONCENTRATIONS OF S-CITALOPRAM AND METABOLIC RATIO OF OF S-DESMETHYLCITALOPRAM/CITALOPRAM;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:03;*06:03;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ANTINEOPLASTIC AGENTS;CYP2C19;CYP2C19*1;*2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2C19;CYP2C19*1;*2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:03;*15:03;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
IMATINIB;CYP1A2;rs11636419;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIORBITAL EDEMA;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ETHANOL;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION INHIBITION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION INHIBITION;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;GABRA1;rs2279020;G;EFFICACY;DECREASED_EFFICACY;DISEASE;DRUG-RESISTANT EPILEPSY;;;
PHENYTOIN;GABRA1;rs2279020;G;EFFICACY;DECREASED_EFFICACY;DISEASE;DRUG-RESISTANT EPILEPSY;;;
VALPROIC ACID;GABRA1;rs2279020;G;EFFICACY;DECREASED_EFFICACY;DISEASE;DRUG-RESISTANT EPILEPSY;;;
METOPROLOL;CYP2D6;CYP2D6*1;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;nan;OTHER;GREATER HEART RATE (HR) REDUCTION;;;
METOPROLOL;CYP2D6;CYP2D6*3;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;nan;OTHER;GREATER HEART RATE (HR) REDUCTION;;;
METOPROLOL;CYP2D6;CYP2D6*4;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;nan;OTHER;GREATER HEART RATE (HR) REDUCTION;;;
METOPROLOL;CYP2D6;CYP2D6*5;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;nan;OTHER;GREATER HEART RATE (HR) REDUCTION;;;
METOPROLOL;CYP2D6;CYP2D6*6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;nan;OTHER;GREATER HEART RATE (HR) REDUCTION;;;
METOPROLOL;CYP2D6;CYP2D6*10;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;nan;OTHER;GREATER HEART RATE (HR) REDUCTION;;;
METOPROLOL;CYP2D6;CYP2D6*17;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;nan;OTHER;GREATER HEART RATE (HR) REDUCTION;;;
METOPROLOL;CYP2D6;CYP2D6*41;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;nan;OTHER;GREATER HEART RATE (HR) REDUCTION;;;
BUCILLAMINE;HLA-DRB1;HLA-DRB1*08:02;*08:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PROTEINURIA;;;
MERCAPTOPURINE;TPMT;TPMT deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOSPORINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOSPORINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOSPORINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOSPORINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
PREDNISONE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
PREDNISONE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
PREDNISONE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
PREDNISONE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
BUCILLAMINE;HLA-DQB1;HLA-DQB1*04:02;*04:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PROTEINURIA;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2 + *2/*17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2 + *2/*17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*2 + *2/*17;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3 + *5 + *6 + *11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3 + *5 + *6 + *11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3 + *5 + *6 + *11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*5;*2 + *3 + *5 + *6 + *11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*6;*2 + *3 + *5 + *6 + *11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*11;*2 + *3 + *5 + *6 + *11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
DAPSONE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
DAPSONE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;nan;OTHER;HIGH PLATELET REACTIVITY (HPR);;;
AMOXICILLIN;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
ASPIRIN;CYP2C19;CYP2C19*1;*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
CLOZAPINE;HLA-DPB1;HLA-DPB1*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
CLOZAPINE;HLA-DRB5;HLA-DRB5*02:02;*02:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ASPIRIN;CYP2C19;CYP2C19*1;*17/*17 + *1/*17;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
ASPIRIN;CYP2C19;CYP2C19*17;*17/*17 + *1/*17;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*17/*17 + *1/*17;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17/*17 + *1/*17;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
PRASUGREL;CYP2C19;CYP2C19*1;*17/*17 + *1/*17;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
PRASUGREL;CYP2C19;CYP2C19*17;*17/*17 + *1/*17;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
AMOXICILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;JAUNDICE;;;
CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;JAUNDICE;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);L allele-rs25531T/L allele-rs25531T;OTHER;nan;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES;;;
PAROXETINE;SLC6A4;SLC6A4 L allele-rs25531C;L allele-rs25531T/L allele-rs25531T;OTHER;nan;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES;;;
PAROXETINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;OTHER;nan;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES;;;
AMOXICILLIN;HLA-DRB5;HLA-DRB5*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATITIS;;;
CLAVULANATE;HLA-DRB5;HLA-DRB5*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATITIS;;;
SORAFENIB;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
SORAFENIB;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
SORAFENIB;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
SORAFENIB;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
AMOXICILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATITIS;;;
CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATITIS;;;
SUNITINIB;ABCB1;rs1128503;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
TICLOPIDINE;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EFFICACY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EFFICACY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EFFICACY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EFFICACY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*41;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA NORTRIPTYLINE;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*41;*41;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA NORTRIPTYLINE;;;
TICLOPIDINE;HLA-C;HLA-C*14:03;*14:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ATORVASTATIN;LEPR;rs1805094;GG;OTHER;INCREASED_LIKELIHOOD;OTHER;BONE MARROW DENSITY IN THE LUMBAR SPINE;;;
TICLOPIDINE;HLA-DQB1;HLA-DQB1*06:04;*06:04;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
TICLOPIDINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
BUSULFAN;ABCC3;rs4148405;G;EFFICACY, TOXICITY;DECREASED_;OTHER;DISEASE-FREE SURVIVAL;;;
CYTARABINE;ABCC3;rs4148405;G;EFFICACY, TOXICITY;DECREASED_;OTHER;DISEASE-FREE SURVIVAL;;;
ETOPOSIDE;ABCC3;rs4148405;G;EFFICACY, TOXICITY;DECREASED_;OTHER;DISEASE-FREE SURVIVAL;;;
TICLOPIDINE;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
COCAINE;OPRM1;rs1799972;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
ETHANOL;OPRM1;rs1799972;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
NICOTINE;OPRM1;rs1799972;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
ANTIPSYCHOTICS;COMT;rs4680;A;OTHER;INCREASED_LIKELIHOOD;OTHER;METHYLATION AT SITES 1 AND 2 IN THE COMT PROMOTER;;;
ISONIAZID;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ASPIRIN;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;URTICARIA;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ASPIRIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;URTICARIA;;;
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A;*1A/*5B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*5B;*1A/*5B;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ASPIRIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;DECREASED_RISK;SIDE_EFFECT;URTICARIA;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3C;TOXICITY;nan;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3C;TOXICITY;nan;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*1;*1/*3C;TOXICITY;nan;SIDE_EFFECT;THROMBOCYTOPENIA;;;
THIOGUANINE;TPMT;TPMT*3C;*1/*3C;TOXICITY;nan;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
FLUTICASONE PROPIONATE;CD14;rs2569190;AA + AG;OTHER;DECREASED_;SIDE_EFFECT;FEV1/FVC RATIO;;;
FLUTICASONE PROPIONATE;TMCO6;rs2569190;AA + AG;OTHER;DECREASED_;SIDE_EFFECT;FEV1/FVC RATIO;;;
BLEOMYCIN;GSTM1;GSTM1 non-null;non-null/non-null;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
BLEOMYCIN;GSTM1;GSTM1 null;non-null/non-null;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
DACARBAZINE;GSTM1;GSTM1 non-null;non-null/non-null;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
DACARBAZINE;GSTM1;GSTM1 null;non-null/non-null;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
DOXORUBICIN;GSTM1;GSTM1 non-null;non-null/non-null;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
DOXORUBICIN;GSTM1;GSTM1 null;non-null/non-null;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
VINBLASTINE;GSTM1;GSTM1 non-null;non-null/non-null;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
VINBLASTINE;GSTM1;GSTM1 null;non-null/non-null;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
EFAVIRENZ;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED_RISK;OTHER;ALCOHOL ABUSE;;;
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
ISONIAZID;GSTT1;GSTT1 null;;LADME-PK;DECREASED_PK;METABOLISM;SERUM HYDRAZINE CONCENTRATIONS;;;
RIFAMPIN;GSTT1;GSTT1 null;;LADME-PK;DECREASED_PK;METABOLISM;SERUM HYDRAZINE CONCENTRATIONS;;;
CAPECITABINE;DPYD;rs56038477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TEGAFUR;DPYD;rs56038477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ISONIAZID;GSTM1;GSTM1 null;;LADME-PK;INCREASED_PK;METABOLISM;SERUM HYDRAZINE CONCENTRATIONS;;;
RIFAMPIN;GSTM1;GSTM1 null;;LADME-PK;INCREASED_PK;METABOLISM;SERUM HYDRAZINE CONCENTRATIONS;;;
ALLOPURINOL;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ETHAMBUTOL;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC DISORDER;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC DISORDER;;;
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
METHADONE;CYP3A4;rs3735451;C;OTHER;INCREASED_SEVERITY;SIDE_EFFECT;OPIOID WITHDRAWAL SYMPTOMS;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*27;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*27;*1/*27;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DIABETES MELLITUS;;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CLOZAPINE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;HLA-B;HLA-B*07:02;*13:01;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS ;;
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS ;;
FLUOXETINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;PK;PK;SIGNIFICANTLY HIGHER (S)-FLUOXETINE AND LOWER AND (S)-NORFLUOXETINE CONCENTRATIONS;;;
FLUOXETINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;PK;PK;SIGNIFICANTLY HIGHER (S)-FLUOXETINE AND LOWER AND (S)-NORFLUOXETINE CONCENTRATIONS;;;
nan;TRPA1;rs920829;CT + TT;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;PAIN ;;
ETHANOL;ALDH2;rs671;A;TOXICITY;DECREASED_RISK;OTHER;ALCOHOL ABUSE;;;
nan;NAT2;NAT2 deficiency;;OTHER;nan;nan;DISEASE;INSULIN RESISTANCE ;;
FLUOXETINE;CYP2C9;CYP2C9*1;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES;;;
FLUOXETINE;CYP2C9;CYP2C9*2;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES;;;
FLUOXETINE;CYP2C9;CYP2C9*3;*1/*2 + *1/*3;LADME-PK;INCREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*1/*4 + *1/*5;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*1/*4 + *1/*5;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*5;*1/*4 + *1/*5;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO;;;
RITODRINE;CACNA1C;rs10774053;AA + AG;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
SPIRONOLACTONE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;;SIDE_EFFECT;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION;;;
SPIRONOLACTONE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;;SIDE_EFFECT;EFFICACY;END-SYSTOLIC AND END-DIASTOLIC VOLUME;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
WARFARIN;APOE;rs429358;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
WARFARIN;APOE;rs7412;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
AMOXICILLIN;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ATORVASTATIN;ACE;rs1799752;del/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN D-DIMER LEVELS;;;
QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN D-DIMER LEVELS;;;
TIMOLOL;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY, LADME-PK;INCREASED_PK;METABOLISM;PLASMA TIMOLOL CONCENTRATION AND EXCERICE HEART RATE REDUCTION;;;
LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;LADME-PK;DECREASED_;OTHER;GASTRIC PH;;;
AMOXICILLIN;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RABEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;EFFICACY;DECREASED_;OTHER;GASTRIC PH;;;
nan;AREG;rs1615111;A;OTHER;DECREASED_;OTHER;OVERALL SURVIVAL;;;
CISPLATIN;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
EPIRUBICIN;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
EPIRUBICIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;C18orf56;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ATORVASTATIN;ACE;rs1799752;del/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN IL-6 LEVELS;;;
QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN IL-6 LEVELS;;;
ATORVASTATIN;ACE;rs1799752;del/del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN CRP LEVELS;;;
QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN CRP LEVELS;;;
AMOXICILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLOPIDOGREL;CYP2C9;CYP2C9*1;*2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C9;CYP2C9*2;*2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
VINCRISTINE;CYP3A5;CYP3A5*1;*1/*3;TOXICITY;DECREASED_;SIDE_EFFECT;AVERAGE CUMULATIVE NEUROTOXICITY GRADE;;;
VINCRISTINE;CYP3A5;CYP3A5*3;*1/*3;TOXICITY;DECREASED_;SIDE_EFFECT;AVERAGE CUMULATIVE NEUROTOXICITY GRADE;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
ASPIRIN;CYP2C19;CYP2C19*17;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
ETHANOL;CYP2E1;rs2031920;T;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
CISPLATIN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
CISPLATIN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;OTHER;INCREASED_LIKELIHOOD;OTHER;BLOOD COAGULATION DISORDERS;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;OTHER;INCREASED_LIKELIHOOD;OTHER;BLOOD COAGULATION DISORDERS;;;
TOLTERODINE;CYP2D6;CYP2D6*1;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;TOLTERODINE EXPOSURE AND INCREASED  ACTIVE METABOLITE (5-HM) CONCENTRATIONS;;;
TOLTERODINE;CYP2D6;CYP2D6*5;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;TOLTERODINE EXPOSURE AND INCREASED  ACTIVE METABOLITE (5-HM) CONCENTRATIONS;;;
TOLTERODINE;CYP2D6;CYP2D6*10;*10/*10 + *5/*10;LADME-PK;INCREASED_PK;METABOLISM;TOLTERODINE EXPOSURE AND INCREASED  ACTIVE METABOLITE (5-HM) CONCENTRATIONS;;;
AMOXICILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ANASTROZOLE;CYP19A1;rs1008805;GG;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRALGIA;;;
ACE INHIBITORS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
PLAIN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
OLANZAPINE;CYP3A5;CYP3A5*1;*1/*1;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
OLANZAPINE;CYP3A5;CYP3A5*3;*1/*1;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
CYCLOPHOSPHAMIDE;INSR;rs41412545;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;INSR;rs41412545;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;INSR;rs41412545;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOSPORINE;ATIC;rs2177735;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;ATIC;rs2177735;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
LEVETIRACETAM;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
ALLOPURINOL;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs56022120;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs56022120;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs56022120;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
VALPROIC ACID;UGT1A10;rs6759892;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A6;rs6759892;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A7;rs6759892;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A8;rs6759892;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A9;rs6759892;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A10;rs2070959;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A6;rs2070959;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A7;rs2070959;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A8;rs2070959;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A9;rs2070959;G;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
CYCLOPHOSPHAMIDE;PIK3R2;rs138602176;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIK3R2;rs138602176;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIK3R2;rs138602176;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
CLOPIDOGREL;MED12L;rs5853517;T/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;P2RY12;rs5853517;T/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
EXEMESTANE;nan;rs16964189;TT;TOXICITY;nan;SIDE_EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS;;;
CYCLOPHOSPHAMIDE;PERP;rs78428806;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PERP;rs78428806;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PERP;rs78428806;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ASPIRIN;CYP2C9;CYP2C9*1;*2;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
ASPIRIN;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
CLOPIDOGREL;CYP2C9;CYP2C9*1;*2;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
CLOPIDOGREL;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
PRASUGREL;CYP2C9;CYP2C9*1;*2;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
PRASUGREL;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;INFLAMMATION ;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ANTIPSYCHOTICS;INSIG2;rs11123469;CC;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;METABOLIC SYNDROME ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
FENOFIBRATE;HLA-A;HLA-A*33:01;*33:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
SERTRALINE;HLA-A;HLA-A*33:01;*33:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TERBINAFINE;HLA-A;HLA-A*33:01;*33:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TICLOPIDINE;HLA-A;HLA-A*33:01;*33:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CARBAMAZEPINE;ABCB1;rs2032582;T;;SIDE_EFFECT;EFFICACY;DRUG-RESISTANT PHENOTYPE;;;
PHENYTOIN;ABCB1;rs2032582;T;;SIDE_EFFECT;EFFICACY;DRUG-RESISTANT PHENOTYPE;;;
VALPROIC ACID;ABCB1;rs2032582;T;;SIDE_EFFECT;EFFICACY;DRUG-RESISTANT PHENOTYPE;;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
LEUCOVORIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
WARFARIN;CYP4F2;CYP4F2*1;*3;;SIDE_EFFECT;EFFICACY;TIME TO THERAPEUTIC INR;;;
WARFARIN;CYP4F2;CYP4F2*3;*3;;SIDE_EFFECT;EFFICACY;TIME TO THERAPEUTIC INR;;;
ASPIRIN;CYP2C9;CYP2C9*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTRITIS;;;
ASPIRIN;CYP2C9;CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTRITIS;;;
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TEGAFUR;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METOPROLOL;CYP2D6;CYP2D6*1;*1/*4 + *4/*4;LADME-PK;INCREASED_PK;METABOLISM;PLASMA METOPROLOL CONCENTRATIONS;;;
METOPROLOL;CYP2D6;CYP2D6*4;*1/*4 + *4/*4;LADME-PK;INCREASED_PK;METABOLISM;PLASMA METOPROLOL CONCENTRATIONS;;;
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*28;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
nan;ACE2;rs2285666;C;OTHER;INCREASED_SEVERITY;OTHER;COVID-19;;;
"""ACE INHIBITORS";ACE;rs1799752;del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MORTALITY;;;
"PLAIN""";ACE;rs1799752;del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MORTALITY;;;
"""BETA BLOCKING AGENTS""";ACE;rs1799752;del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MORTALITY;;;
"""CALCIUM CHANNEL BLOCKERS""";ACE;rs1799752;del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MORTALITY;;;
"""DIGOXIN""";ACE;rs1799752;del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MORTALITY;;;
"""DIURETICS""";ACE;rs1799752;del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MORTALITY;;;
IVACAFTOR;CFTR;rs113993960;del/del;OTHER;DECREASED_;SIDE_EFFECT;CYSTIC FIBROSIS PULMONARY EXACERBATION;;;
TEZACAFTOR;CFTR;rs113993960;del/del;OTHER;DECREASED_;SIDE_EFFECT;CYSTIC FIBROSIS PULMONARY EXACERBATION;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE LEUKOPENIA;;;
DESIPRAMINE;CYP2D6;CYP2D6*1;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;METABOLIC RATIOS OF DESIPAMINE;;;
DESIPRAMINE;CYP2D6;CYP2D6*4;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;METABOLIC RATIOS OF DESIPAMINE;;;
DESIPRAMINE;CYP2D6;CYP2D6*5;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;METABOLIC RATIOS OF DESIPAMINE;;;
PAMAQUINE;G6PD;G6PD deficiency;;TOXICITY;nan;nan;DISEASE;HEMOLYSIS ;;
METOPROLOL;CYP2D6;CYP2D6*1;*1/*4 + *4/*4;EFFICACY, OTHER;INCREASED_LIKELIHOOD;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION;;;
METOPROLOL;CYP2D6;CYP2D6*4;*1/*4 + *4/*4;EFFICACY, OTHER;INCREASED_LIKELIHOOD;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION;;;
PRIMAQUINE;G6PD;G6PD deficiency;;TOXICITY;nan;nan;DISEASE;HEMOLYSIS ;;
ITRACONAZOLE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;OTHER, LADME-PK;DECREASED_SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE;;;
ITRACONAZOLE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;OTHER, LADME-PK;DECREASED_SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE;;;
KETOCONAZOLE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;OTHER, LADME-PK;DECREASED_SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE;;;
KETOCONAZOLE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;OTHER, LADME-PK;DECREASED_SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
HMG COA REDUCTASE INHIBITORS;nan;rs3764261;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROTECTION AGAINST MYOCARDIAL INFARCTION;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ON-TREATMENT PLATELET ACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ON-TREATMENT PLATELET ACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ON-TREATMENT PLATELET ACTIVITY;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME BELOW THERAPEUTIC RANGE;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME BELOW THERAPEUTIC RANGE;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME BELOW THERAPEUTIC RANGE;;;
OSIMERTINIB;CYP2A6;rs28399433;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1xN;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*2;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*2xN;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
FLUOXETINE;CYP2D6;CYP2D6*1;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
FLUOXETINE;CYP2D6;CYP2D6*1xN;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
FLUOXETINE;CYP2D6;CYP2D6*2;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
FLUOXETINE;CYP2D6;CYP2D6*2xN;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PAZOPANIB;VEGFA;rs833061;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
PEMETREXED;VEGFA;rs833061;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
WARFARIN;CYP2C9;CYP2C9*1;*3/*3 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*3/*3 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PENICILLIN G;HLA-B;HLA-B*55:01;*55:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
PENICILLIN V;HLA-B;HLA-B*55:01;*55:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ETHANOL;GHSR;rs2948694;AG;OTHER;nan;OTHER;WEIGHT;;;
OPIOIDS;OPRM1;rs495491;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
OPIOIDS;OPRM1;rs10457090;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;STEADY STATE CONCENTRATION PER DOSAGE;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;STEADY STATE CONCENTRATION PER DOSAGE;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01/*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;SCN2A;rs17183814;A;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-RESPONSE;;;
PHENYTOIN;SCN2A;rs17183814;A;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-RESPONSE;;;
VALPROIC ACID;SCN2A;rs17183814;A;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-RESPONSE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;;SIDE_EFFECT;EFFICACY;SHORTER TIME TO THE FIRST INR OF MORE THAN 4;;;
ATORVASTATIN;HTR7;rs1935349;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYALGIA ;;
PRAVASTATIN;HTR7;rs1935349;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYALGIA ;;
SIMVASTATIN;HTR7;rs1935349;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYALGIA ;;
METHOTREXATE;TYMS;rs45445694;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
NEVIRAPINE;CYP2B6;CYP2B6*1;*6/*18;TOXICITY, LADME-PK;INCREASED_LIKELIHOODPK;PK;ELEVATED PLASMA CONCENTRATIONS;;;
NEVIRAPINE;CYP2B6;CYP2B6*6;*6/*18;TOXICITY, LADME-PK;INCREASED_LIKELIHOODPK;PK;ELEVATED PLASMA CONCENTRATIONS;;;
NEVIRAPINE;CYP2B6;CYP2B6*18;*6/*18;TOXICITY, LADME-PK;INCREASED_LIKELIHOODPK;PK;ELEVATED PLASMA CONCENTRATIONS;;;
DOCETAXEL;CYP2A6;CYP2A6*1;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EFFICACY;;;
DOCETAXEL;CYP2A6;CYP2A6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EFFICACY;;;
TEGAFUR;CYP2A6;CYP2A6*1;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EFFICACY;;;
TEGAFUR;CYP2A6;CYP2A6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EFFICACY;;;
CISPLATIN;ERCC2;rs1799793;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL;;;
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;STEVENS-JOHNSON SYNDROME ;;
COCAINE;SLC6A3;rs3836790;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
WARFARIN;CYP2C9;CYP2C9*1;*2;DOSAGE;nan;SIDE_EFFECT;LOWER WARFARIN DOSE REQUIREMENT;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;nan;SIDE_EFFECT;LOWER WARFARIN DOSE REQUIREMENT;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS IN TAIWANESE PATIENTS RECEIVING CLOPIDOGREL AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS IN TAIWANESE PATIENTS RECEIVING CLOPIDOGREL AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
PHENYTOIN;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME;;;
PAROXETINE;CYP2D6;CYP2D6*1;*1/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE SERUM CONCENTRATIONS (CMIN);;;
PAROXETINE;CYP2D6;CYP2D6*4;*1/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE SERUM CONCENTRATIONS (CMIN);;;
PAROXETINE;CYP2D6;CYP2D6*41;*1/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE SERUM CONCENTRATIONS (CMIN);;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIPHENYLHYDANTOIN-INDUCED SKIN RASH;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIPHENYLHYDANTOIN-INDUCED SKIN RASH;;;
IBUPROFEN;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;DURATION OF INHIBITION OF PROSTANOIDS;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;INCREASED_PK;METABOLISM;THE MAXIMAL ELIMINATION RATE (VMAX);;;
ACETAMINOPHEN;CYP2E1;CYP2E1*1;*1/*5B;LADME-PK;INCREASED_PK;METABOLISM;ELIMINATION RATE;;;
ACETAMINOPHEN;CYP2E1;CYP2E1*5B;*1/*5B;LADME-PK;INCREASED_PK;METABOLISM;ELIMINATION RATE;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;TOXICITY;INCREASED_PK;PK;PLASMA METHYLMERCAPTOPURINE NUCLEOTIDES LEVELS;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;INCREASED_PK;PK;PLASMA METHYLMERCAPTOPURINE NUCLEOTIDES LEVELS;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN JAPANESE PATIENTS ;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN JAPANESE PATIENTS ;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, ;SIDE_EFFECT;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED  RISK OF OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED MAXIMUM PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED MAXIMUM PLATELET AGGREGATION;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3 + *1/*4;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3 + *1/*4;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*4;*1/*3 + *1/*4;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
MERCAPTOPURINE;CYP2A7;rs73032311;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE;;;
BUPROPION;CYP2B6;CYP2B6*18;*18;LADME-PK;DECREASED_PK;METABOLISM;HYDROXYBUPROPION CONCENTRATIONS;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CUTANEOUS REACTIONS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CUTANEOUS REACTIONS;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*3;*2/*3;LADME-PK;INCREASED_PK;METABOLISM;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
nan;NAT1;NAT1*10;*10/*11A;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
nan;NAT1;NAT1*11A;*10/*11A;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
nan;NAT1;NAT1*4;*10/*4;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
nan;NAT1;NAT1*10;*10/*4;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
ISONIAZID;GSTT1;GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;GSTT1;GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;GSTT1;GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
PACLITAXEL;CYP2C8;CYP2C8*3;*3;LADME-PK;DECREASED_PK;METABOLISM;CLERANCE OF PACLITAXEL;;;
BUPROPION;CYP2B6;CYP2B6*1;*6;LADME-PK;DECREASED_PK;METABOLISM;HYDROXYBUPROPION CONCENTRATIONS AND HYDROXYBUPROPION/BUPROPION RATIO;;;
BUPROPION;CYP2B6;CYP2B6*6;*6;LADME-PK;DECREASED_PK;METABOLISM;HYDROXYBUPROPION CONCENTRATIONS AND HYDROXYBUPROPION/BUPROPION RATIO;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;;SIDE_EFFECT;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION (MPA) IN CLOPIDOGREL-TREATED PATIENTS UNDERGOING PE RCUTANEOUS CORONARY INTERVENTION;;;
IRINOTECAN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;DECREASED_RISK;nan;DISEASE;ASTHENIA ;;
RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;DECREASED_RISK;nan;DISEASE;ASTHENIA ;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;;SIDE_EFFECT;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION (MPA) IN CLOPIDOGREL-TREATED PATIENTS UNDERGOING PE RCUTANEOUS CORONARY INTERVENTION;;;
TEMSIROLIMUS;NR1I2;rs6785049;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
nan;NAT1;NAT1*3;*11B/*3;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
nan;NAT1;NAT1*11B;*11B/*3;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
nan;NAT1;NAT1*10;*10/*10;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CALCINEURIN INHIBITORS;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS;;;
CYCLOSPORINE;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS;;;
TACROLIMUS;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS;;;
DAUNORUBICIN;NRP2;rs10932125;C;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;IC50;;;
CISPLATIN;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME-PK;DECREASED_RISK;nan;DISEASE;THROMBOCYTOPENIA ;;
CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME-PK;DECREASED_RISK;nan;DISEASE;THROMBOCYTOPENIA ;;
CISPLATIN;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME-PK;DECREASED_RISK;nan;DISEASE;ANEMIA ;;
CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME-PK;DECREASED_RISK;nan;DISEASE;ANEMIA ;;
CISPLATIN;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME-PK;DECREASED_RISK;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME-PK;DECREASED_RISK;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
METOPROLOL;CYP2D6;rs5030655;del/del;OTHER;INCREASED_PK;PK;PLASMA CONCENTRATIONS OF METOPROLOL;;;
ANTIDEPRESSANTS;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG REACTION AFTER THE SECOND SWITCH IN TREATMENT;;;
VALPROIC ACID;UGT1A10;rs1105879;C;LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A6;rs1105879;C;LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A7;rs1105879;C;LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A8;rs1105879;C;LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
VALPROIC ACID;UGT1A9;rs1105879;C;LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
NEVIRAPINE;CYP2B6;CYP2B6*1;*6/*6;TOXICITY, LADME-PK;INCREASED_LIKELIHOODPK;PK;ELEVATED PLASMA CONCENTRATIONS;;;
NEVIRAPINE;CYP2B6;CYP2B6*6;*6/*6;TOXICITY, LADME-PK;INCREASED_LIKELIHOODPK;PK;ELEVATED PLASMA CONCENTRATIONS;;;
ISONIAZID;CYP2E1;CYP2E1*1A;*1A/*1A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRIDOXAL PHOSPHATE;CYP2E1;CYP2E1*1A;*1A/*1A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ATENOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;AMITRIPTYLINE/(E)-10- OH-AT RATIO;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;AMITRIPTYLINE/(E)-10- OH-AT RATIO;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;NORTRIPTYLINE/(E)-10-OH-NT RATIO;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;NORTRIPTYLINE/(E)-10-OH-NT RATIO;;;
REPAGLINIDE;SLCO1B1;SLCO1B1*1;*37/*37;LADME-PK;DECREASED_PK;METABOLISM;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED  CLEARANCE);;;
REPAGLINIDE;SLCO1B1;SLCO1B1*37;*37/*37;LADME-PK;DECREASED_PK;METABOLISM;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED  CLEARANCE);;;
PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC OR STEVENS-JOHNSON SYNDROME;;;
BENZENE;NQO1;rs1800566;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMATOTOXICITY;;;
ATAZANAVIR;TPH2;rs4570625;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
EFAVIRENZ;TPH2;rs4570625;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
METHOTREXATE;DHFR;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;THROMBOCYTOPENIA ;;
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1;EFFICACY, LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATION OF EFAVIRENZ;;;
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*08:01;*08:01;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;AGRANULOCYTOSIS ;;
TEGAFUR;CYP2A6;CYP2A6*1;*1;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA FLUOROURACIL;;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG REACTIONS;;;
PHENYTOIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG REACTIONS;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG REACTIONS;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
CYCLOSPORINE;CYP3A4;CYP3A4*1;*1/*1;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LIVER INJURY;;;
CYCLOSPORINE;CYP3A4;CYP3A4*18;*1/*1;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LIVER INJURY;;;
ANTIEPILEPTICS;CYP2C9;CYP2C9*1;*1/*3;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;DRUG RESISTANCE ;;
ANTIEPILEPTICS;CYP2C9;CYP2C9*3;*1/*3;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;DRUG RESISTANCE ;;
ATORVASTATIN;UGT1A3;UGT1A3*1;*2/*2;EFFICACY, LADME-PK;INCREASED_PK;METABOLISM;ATORVASTATIN LACTONIZATION;;;
ATORVASTATIN;UGT1A3;UGT1A3*2;*2/*2;EFFICACY, LADME-PK;INCREASED_PK;METABOLISM;ATORVASTATIN LACTONIZATION;;;
ATORVASTATIN;UGT1A3;UGT1A3*1;*2;EFFICACY, LADME-PK;DECREASED_;SIDE_EFFECT;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE;;;
ATORVASTATIN;UGT1A3;UGT1A3*2;*2;EFFICACY, LADME-PK;DECREASED_;SIDE_EFFECT;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
DOXEPIN;CYP2C9;CYP2C9*3;*3/*3;LADME-PK;DECREASED_PK;METABOLISM;MEDIAN ORAL CLEARANCE OF DOXEPIN;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
TACROLIMUS;CYP2C19;CYP2C19*2;*2/*2;OTHER;INCREASED_LIKELIHOOD;OTHER;HOSPITAL STAY;;;
MERCAPTOPURINE;COMT;rs4680;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ROSIGLITAZONE;CYP2C8;CYP2C8*3;*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;MEAN ABSOLUTE DIFFERENCE IN HBA1C;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*1/*2xN;LADME-PK;INCREASED_PK;METABOLISM;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2xN;*1/*2xN;LADME-PK;INCREASED_PK;METABOLISM;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*1;*15;LADME-PK;INCREASED_PK;METABOLISM;RELATIVE BIOAVAILABILITY OF PRAVASTATIN;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*15;*15;LADME-PK;INCREASED_PK;METABOLISM;RELATIVE BIOAVAILABILITY OF PRAVASTATIN;;;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG HYPERSENSITIVITY ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*2/*2;LADME-PK;INCREASED_PK;METABOLISM;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_PK;METABOLISM;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
nan;CYP2C19;CYP2C19*1;*17;OTHER;RISK;nan;DISEASE;PEPTIC ULCER DISEASE ;;
nan;CYP2C19;CYP2C19*17;*17;OTHER;RISK;nan;DISEASE;PEPTIC ULCER DISEASE ;;
CAFFEINE;ADORA2A;rs5751876;TT;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANXIETY;;;
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;RHEUMATOID ARTHRITIS ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;COMPOSITE ISCHEMIC EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;COMPOSITE ISCHEMIC EVENTS;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;COMPOSITE ISCHEMIC EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;COMPOSITE ISCHEMIC EVENTS;;;
ATORVASTATIN;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SERUM CREATINE KINASE LEVELS (INCREASED  RISK OF MYALGIA AND GREATER DEGREE OF MUSCLE DAMAGE);;;
ATORVASTATIN;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SERUM CREATINE KINASE LEVELS (INCREASED  RISK OF MYALGIA AND GREATER DEGREE OF MUSCLE DAMAGE);;;
NEVIRAPINE;ABCC10;rs2125739;CC;EFFICACY, LADME-PK;INCREASED_LIKELIHOODPK;PK;LOWER NEVIRAPINE PLASMA CONCENTRATIONS;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARBAMAZEPINE-INDUCED HYPERSENSITIVITY;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARBAMAZEPINE-INDUCED STEVENS-JOHNSON SYNDROME (SJS) AND TOXIC EPIDERMAL NECROLYSIS (TEN);;;
METFORMIN;SLC22A1;rs36056065;GTAAGTTG;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL SIDE EFFECTS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;STEVENS-JOHNSON SYNDROME ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A;*1A/*1A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARBAMAZEPINE-INDUCED HYPERSENSITIVITY SYNDROME;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;;SIDE_EFFECT;EFFICACY;ENHANCED RESPONSE TO CLOPIDOGREL (AS MEASURED BY INHIBITION OF ADP-INDUCED PLATELET AGGREGATION);;;
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PHENYTOIN TOXICITY;;;
PHENYTOIN;CYP2C9;CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PHENYTOIN TOXICITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION;;;
nan;NAT1;NAT1*10;*10/*11B;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
nan;NAT1;NAT1*11B;*10/*11B;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
EFAVIRENZ;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;5-HYDROXYOMEPRAZOLE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_PK;METABOLISM;R-OMEPRAZOLE AND S-OMEPRAZOLE;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
nan;NAT1;NAT1*4;*11A/*4;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
nan;NAT1;NAT1*11A;*11A/*4;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;;SIDE_EFFECT;EFFICACY;SHORTER TIME TO THE FIRST INR OF MORE THAN 4;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A;TOXICITY;INCREASED_PK;PK;PLASMA THIOGUANINE NUCLEOTIDES METABOLITES;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A;TOXICITY;INCREASED_PK;PK;PLASMA THIOGUANINE NUCLEOTIDES METABOLITES;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*1;*1/*15;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*15;*1/*15;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*37;*1/*15;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*1;*1/*15;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX;;;
PRAVASTATIN;SLCO1B1;SLCO1B1*15;*1/*15;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*13;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY ;
WARFARIN;CYP2C9;CYP2C9*13;*1/*13;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY ;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*2 + *3;DOSAGE, TOXICITY;INCREASED_RISK;OTHER;COMPLICATIONS;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2 + *3;DOSAGE, TOXICITY;INCREASED_RISK;OTHER;COMPLICATIONS;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*2 + *3;DOSAGE, TOXICITY;INCREASED_RISK;OTHER;COMPLICATIONS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED MAXIMUM PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED MAXIMUM PLATELET AGGREGATION;;;
METOPROLOL;CYP2D6;CYP2D6*4;*4;DOSAGE, TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;BRADYCARDIA ;;
PRAVASTATIN;SLCO1B1;SLCO1B1*1;*15/*15;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC);;;
PRAVASTATIN;SLCO1B1;SLCO1B1*15;*15/*15;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC);;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
ASPIRIN;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS AFTER ADJUSTMENT FOR VKORC1*1173 ;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
DOXEPIN;CYP2D6;CYP2D6*3;*3/*5;LADME-PK;DECREASED_PK;METABOLISM;MEDIAN ORAL CLEARANCE OF DOXEPIN;;;
DOXEPIN;CYP2D6;CYP2D6*5;*3/*5;LADME-PK;DECREASED_PK;METABOLISM;MEDIAN ORAL CLEARANCE OF DOXEPIN;;;
HALOPERIDOL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ATORVASTATIN;CYP2D6;CYP2D6*4;*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCLE EFFECTS;;;
DOXEPIN;CYP2D6;CYP2D6*4;*4/*5;LADME-PK;DECREASED_PK;METABOLISM;MEDIAN ORAL CLEARANCE OF DOXEPIN;;;
DOXEPIN;CYP2D6;CYP2D6*5;*4/*5;LADME-PK;DECREASED_PK;METABOLISM;MEDIAN ORAL CLEARANCE OF DOXEPIN;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*13;;SIDE_EFFECT;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5;;;
WARFARIN;CYP2C9;CYP2C9*13;*1/*13;;SIDE_EFFECT;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, ;SIDE_EFFECT;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED  RISK OF OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*1;*1/*14;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY ;
WARFARIN;CYP2C9;CYP2C9*14;*1/*14;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY ;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN INR VALUES IN PATIENTS WITH HEART VALVE REPLACEMENT;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN INR VALUES IN PATIENTS WITH HEART VALVE REPLACEMENT;;;
CLOPIDOGREL;CYP2B6;CYP2B6*5;*5;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CYP2C19*1/*1 CARRIERS;;;
VENLAFAXINE;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;INCREASED_PK;METABOLISM;CMAX AND AUC OF VENLAFAXINE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN INR VALUE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2/*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN INR VALUE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
VENLAFAXINE;CYP2D6;CYP2D6*1;*1/*10;LADME-PK;INCREASED_PK;METABOLISM;CMAX AND AUC OF VENLAFAXINE;;;
VENLAFAXINE;CYP2D6;CYP2D6*10;*1/*10;LADME-PK;INCREASED_PK;METABOLISM;CMAX AND AUC OF VENLAFAXINE;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*14;;SIDE_EFFECT;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5;;;
WARFARIN;CYP2C9;CYP2C9*14;*1/*14;;SIDE_EFFECT;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5;;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*3;;SIDE_EFFECT;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*3;;SIDE_EFFECT;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5;;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACHIEVING A STABLE DOSE;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACHIEVING A STABLE DOSE;;;
ESCITALOPRAM;CYP2D6;CYP2D6*1;*4/*10;EFFICACY;INCREASED_LIKELIHOOD;EVENT;FREQUENCY OF REMITTERS;;;
ESCITALOPRAM;CYP2D6;CYP2D6*4;*4/*10;EFFICACY;INCREASED_LIKELIHOOD;EVENT;FREQUENCY OF REMITTERS;;;
ESCITALOPRAM;CYP2D6;CYP2D6*10;*4/*10;EFFICACY;INCREASED_LIKELIHOOD;EVENT;FREQUENCY OF REMITTERS;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_;OTHER;INTRAGASTRIC PH;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_;OTHER;INTRAGASTRIC PH;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_;OTHER;INTRAGASTRIC PH;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;DECREASED_;OTHER;INTRAGASTRIC PH;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;DECREASED_;OTHER;INTRAGASTRIC PH;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_;OTHER;INTRAGASTRIC PH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
TRAMADOL;CYP2D6;CYP2D6*1;*10/*10;LADME-PK;DECREASED_PK;METABOLISM;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS;;;
TRAMADOL;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;DECREASED_PK;METABOLISM;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS;;;
TRAMADOL;CYP2D6;CYP2D6*1;*4/*4;EFFICACY, LADME-PK;DECREASED_;SIDE_EFFECT;TRAMADOL METABOLISM AND RESPONSE;;;
TRAMADOL;CYP2D6;CYP2D6*4;*4/*4;EFFICACY, LADME-PK;DECREASED_;SIDE_EFFECT;TRAMADOL METABOLISM AND RESPONSE;;;
OMEPRAZOLE;CYP2C19;CYP2C19*1;*1/*2;EFFICACY;INCREASED_SEVERITY;OTHER;MEAL-STIMULATED PLASMA GASTRIN CONCENTRATIONS;;;
OMEPRAZOLE;CYP2C19;CYP2C19*2;*1/*2;EFFICACY;INCREASED_SEVERITY;OTHER;MEAL-STIMULATED PLASMA GASTRIN CONCENTRATIONS;;;
PAROXETINE;CYP2D6;CYP2D6*3;*4/*4 + *3/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY;;;
PAROXETINE;CYP2D6;CYP2D6*4;*4/*4 + *3/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY;;;
TRAMADOL;CYP2D6;CYP2D6*1;*4/*4;DOSAGE, EFFICACY;DECREASED_LIKELIHOOD;EVENT;METABOLISM AND DECREASED RESPONSE TO TRAMADOL;;;
TRAMADOL;CYP2D6;CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_LIKELIHOOD;EVENT;METABOLISM AND DECREASED RESPONSE TO TRAMADOL;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*3 + *3/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*3 + *3/*3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE;;;
TAMOXIFEN;CYP2D6;CYP2D6*6;*6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*7;*6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ESCITALOPRAM;CYP2D6;CYP2D6*1;*5/*10;EFFICACY;INCREASED_LIKELIHOOD;EVENT;FREQUENCY OF REMITTERS;;;
ESCITALOPRAM;CYP2D6;CYP2D6*5;*5/*10;EFFICACY;INCREASED_LIKELIHOOD;EVENT;FREQUENCY OF REMITTERS;;;
ESCITALOPRAM;CYP2D6;CYP2D6*10;*5/*10;EFFICACY;INCREASED_LIKELIHOOD;EVENT;FREQUENCY OF REMITTERS;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*6;*3/*6;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TRAMADOL;CYP2D6;CYP2D6*1;*3/*4;DOSAGE, EFFICACY;DECREASED_LIKELIHOOD;EVENT;METABOLISM AND DECREASED RESPONSE TO TRAMADOL;;;
TRAMADOL;CYP2D6;CYP2D6*3;*3/*4;DOSAGE, EFFICACY;DECREASED_LIKELIHOOD;EVENT;METABOLISM AND DECREASED RESPONSE TO TRAMADOL;;;
TRAMADOL;CYP2D6;CYP2D6*4;*3/*4;DOSAGE, EFFICACY;DECREASED_LIKELIHOOD;EVENT;METABOLISM AND DECREASED RESPONSE TO TRAMADOL;;;
CLOMIPRAMINE;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;;;
CLOMIPRAMINE;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*4;LADME-PK;INCREASED_PK;METABOLISM;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*4;LADME-PK;INCREASED_PK;METABOLISM;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION;;;
OXYCODONE;CYP2D6;CYP2D6*1;*4/*4 + *3/*4;LADME-PK;PK;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO;;;
OXYCODONE;CYP2D6;CYP2D6*3;*4/*4 + *3/*4;LADME-PK;PK;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO;;;
OXYCODONE;CYP2D6;CYP2D6*4;*4/*4 + *3/*4;LADME-PK;PK;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO;;;
PAROXETINE;CYP2D6;CYP2D6*1;*1/*1 + *1/*41;LADME-PK;DECREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY;;;
PAROXETINE;CYP2D6;CYP2D6*41;*1/*1 + *1/*41;LADME-PK;DECREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*5/*10;LADME-PK;INCREASED_PK;METABOLISM;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*5;*5/*10;LADME-PK;INCREASED_PK;METABOLISM;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*10;*5/*10;LADME-PK;INCREASED_PK;METABOLISM;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION;;;
DESIPRAMINE;CYP2D6;CYP2D6*1;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;METABOLIC RATIOS OF DESIPAMINE;;;
DESIPRAMINE;CYP2D6;CYP2D6*3;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;METABOLIC RATIOS OF DESIPAMINE;;;
DESIPRAMINE;CYP2D6;CYP2D6*4;*1/*1;LADME-PK;DECREASED_PK;METABOLISM;METABOLIC RATIOS OF DESIPAMINE;;;
TRAMADOL;CYP2D6;CYP2D6*1;*2/*10;LADME-PK;DECREASED_PK;METABOLISM;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS;;;
TRAMADOL;CYP2D6;CYP2D6*2;*2/*10;LADME-PK;DECREASED_PK;METABOLISM;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS;;;
TRAMADOL;CYP2D6;CYP2D6*10;*2/*10;LADME-PK;DECREASED_PK;METABOLISM;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS;;;
TRAMADOL;CYP2D6;CYP2D6*1;*3/*5;DOSAGE, EFFICACY;DECREASED_LIKELIHOOD;EVENT;METABOLISM AND DECREASED RESPONSE TO TRAMADOL;;;
TRAMADOL;CYP2D6;CYP2D6*3;*3/*5;DOSAGE, EFFICACY;DECREASED_LIKELIHOOD;EVENT;METABOLISM AND DECREASED RESPONSE TO TRAMADOL;;;
TRAMADOL;CYP2D6;CYP2D6*5;*3/*5;DOSAGE, EFFICACY;DECREASED_LIKELIHOOD;EVENT;METABOLISM AND DECREASED RESPONSE TO TRAMADOL;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*5;LADME-PK;INCREASED_PK;METABOLISM;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*2;*5;LADME-PK;INCREASED_PK;METABOLISM;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*5;*5;LADME-PK;INCREASED_PK;METABOLISM;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT;;;
PAROXETINE;CYP2D6;CYP2D6*1;*1/*10 + *1/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY;;;
PAROXETINE;CYP2D6;CYP2D6*5;*1/*10 + *1/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY;;;
PAROXETINE;CYP2D6;CYP2D6*10;*1/*10 + *1/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY;;;
COTININE;CYP2A6;CYP2A6*1;*1/*1;LADME-PK;PK;PK;SHORTER CONTININ HALF-LIFE;;;
COTININE;CYP2A6;CYP2A6*2;*1/*1;LADME-PK;PK;PK;SHORTER CONTININ HALF-LIFE;;;
COTININE;CYP2A6;CYP2A6*9;*1/*1;LADME-PK;PK;PK;SHORTER CONTININ HALF-LIFE;;;
COTININE;CYP2A6;CYP2A6*17;*1/*1;LADME-PK;PK;PK;SHORTER CONTININ HALF-LIFE;;;
COTININE;CYP2A6;CYP2A6*20;*1/*1;LADME-PK;PK;PK;SHORTER CONTININ HALF-LIFE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;DECREASED_PK;METABOLISM;CLEARANCE OF S(+) MIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_PK;METABOLISM;CLEARANCE OF S(+) MIRTAZAPINE;;;
PAROXETINE;CYP2D6;CYP2D6*1;*1/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE LEVELS;;;
PAROXETINE;CYP2D6;CYP2D6*4;*1/*4;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE LEVELS;;;
CLOMIPRAMINE;CYP2C19;CYP2C19*1;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;;;
CLOMIPRAMINE;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE OF CITALOPRAM;;;
CITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE OF CITALOPRAM;;;
CITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE OF CITALOPRAM;;;
PAROXETINE;CYP2D6;CYP2D6*1;*10/*10 + *1/*10;LADME-PK;INCREASED_PK;METABOLISM;PLASMA PAROXETINE CONCENTRATIONS AT ADMINISTERED DOSE OF 10MG/DAY;;;
PAROXETINE;CYP2D6;CYP2D6*10;*10/*10 + *1/*10;LADME-PK;INCREASED_PK;METABOLISM;PLASMA PAROXETINE CONCENTRATIONS AT ADMINISTERED DOSE OF 10MG/DAY;;;
MIRTAZAPINE;CYP2D6;CYP2D6*1;*1/*1xN;LADME-PK;INCREASED_PK;METABOLISM;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*1xN;*1/*1xN;LADME-PK;INCREASED_PK;METABOLISM;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE;;;
CODEINE;CYP2D6;CYP2D6*1;*36;LADME-PK;DECREASED_PK;METABOLISM;CODEINE METABOLISM AND MORPHINE AND GLUCURONIDES FORMATION;;;
CODEINE;CYP2D6;CYP2D6*36;*36;LADME-PK;DECREASED_PK;METABOLISM;CODEINE METABOLISM AND MORPHINE AND GLUCURONIDES FORMATION;;;
CODEINE;CYP2D6;CYP2D6*1;*1/*1 + *1/*4;LADME-PK;INCREASED_PK;METABOLISM;PLASMA LEVEL OF MORPHINE;;;
CODEINE;CYP2D6;CYP2D6*3;*1/*1 + *1/*4;LADME-PK;INCREASED_PK;METABOLISM;PLASMA LEVEL OF MORPHINE;;;
CODEINE;CYP2D6;CYP2D6*4;*1/*1 + *1/*4;LADME-PK;INCREASED_PK;METABOLISM;PLASMA LEVEL OF MORPHINE;;;
CODEINE;CYP2D6;CYP2D6*5;*1/*1 + *1/*4;LADME-PK;INCREASED_PK;METABOLISM;PLASMA LEVEL OF MORPHINE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-TREATMENT PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-TREATMENT PLATELET AGGREGATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
nan;UGT1A1;rs34946978;T;OTHER;INCREASED_LIKELIHOOD;OTHER;GILBERT SYNDROME;;;
nan;UGT1A1;rs34946978;T;OTHER;INCREASED_LIKELIHOOD;OTHER;CRIGLER-NAJJAR SYNDROME;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
FLURBIPROFEN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
FLURBIPROFEN;CYP2C9;CYP2C9*1;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;HIGHER HALF-LIFE AND LOWER FLURBIPROFEN CLEARANCE;;;
FLURBIPROFEN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
FLURBIPROFEN;CYP2C9;CYP2C9*3;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;HIGHER HALF-LIFE AND LOWER FLURBIPROFEN CLEARANCE;;;
DICLOFENAC;CYP2C8;CYP2C8*1;*1/*4 + *4/*4;LADME-PK;INCREASED_PK;METABOLISM;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO;;;
DICLOFENAC;CYP2C8;CYP2C8*4;*1/*4 + *4/*4;LADME-PK;INCREASED_PK;METABOLISM;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
PYRIMIDINE ANALOGUES;MIR27A;rs895819;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;INCREASED_PK;METABOLISM;PLASMA RATIO CITALOPRAM (CIT)/N-DESMETHYLCIT (DCIT);;;
TIMOLOL;CYP2D6;CYP2D6*1;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;;;
TIMOLOL;CYP2D6;CYP2D6*1;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME-PK;INCREASED_PK;METABOLISM;LONGER ELIMINATION HALF-LIVES );;;
TIMOLOL;CYP2D6;CYP2D6*3;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;;;
TIMOLOL;CYP2D6;CYP2D6*3;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME-PK;INCREASED_PK;METABOLISM;LONGER ELIMINATION HALF-LIVES );;;
TIMOLOL;CYP2D6;CYP2D6*4;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;;;
TIMOLOL;CYP2D6;CYP2D6*4;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME-PK;INCREASED_PK;METABOLISM;LONGER ELIMINATION HALF-LIVES );;;
TIMOLOL;CYP2D6;CYP2D6*5;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE;;;
TIMOLOL;CYP2D6;CYP2D6*5;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME-PK;INCREASED_PK;METABOLISM;LONGER ELIMINATION HALF-LIVES );;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
CLOPIDOGREL;PON1;rs662;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
WARFARIN;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE;;;
TENOXICAM;CYP2C9;CYP2C9*1;*3;LADME-PK;INCREASED_PK;METABOLISM;AUC AND HALF-LIFE TIME (T1/2);;;
TENOXICAM;CYP2C9;CYP2C9*2;*3;LADME-PK;INCREASED_PK;METABOLISM;AUC AND HALF-LIFE TIME (T1/2);;;
TENOXICAM;CYP2C9;CYP2C9*3;*3;LADME-PK;INCREASED_PK;METABOLISM;AUC AND HALF-LIFE TIME (T1/2);;;
IBUPROFEN;CYP2C8;CYP2C8*1;*1/*3;TOXICITY;DECREASED_;SIDE_EFFECT;INOS EXPRESSION AND FEWER ADVERSE EVENTS;;;
IBUPROFEN;CYP2C8;CYP2C8*3;*1/*3;TOXICITY;DECREASED_;SIDE_EFFECT;INOS EXPRESSION AND FEWER ADVERSE EVENTS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CLOPIDOGREL;P2RY12;rs2046934;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ANTIEPILEPTICS;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_RISK;nan;DISEASE;STEVENS-JOHNSON SYNDROME ;;
ASPIRIN;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASTHMA;;;
SULFONAMIDES;TCF7L2;rs7903146;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (REDUCTIONS IN HAEMOGLOBIN A1C (HBA1C) AND FASTING PLASMA GLUCOSE (FPG) LEVELS);;;
UREA DERIVATIVES;TCF7L2;rs7903146;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (REDUCTIONS IN HAEMOGLOBIN A1C (HBA1C) AND FASTING PLASMA GLUCOSE (FPG) LEVELS);;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
LUMACAFTOR;CFTR;rs113993960;del/del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CHANGE IN SWEAT CHLORIDE;;;
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ABORTION, SPONTANEOUS ;;
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_;SIDE_EFFECT;ACENOCOUMAROL DOSE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_;SIDE_EFFECT;ACENOCOUMAROL DOSE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_;SIDE_EFFECT;ACENOCOUMAROL DOSE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
CODEINE;CYP2D6;CYP2D6*1;*1/*10 + *10/*10;LADME-PK;DECREASED_PK;METABOLISM;PLASMA LEVELS OF MORPHINE;;;
CODEINE;CYP2D6;CYP2D6*1;*1/*10 + *10/*10;LADME-PK;DECREASED_PK;METABOLISM;M3G AND M6G LEVELS BUT NOT THOSE OF CODEINE;;;
CODEINE;CYP2D6;CYP2D6*10;*1/*10 + *10/*10;LADME-PK;DECREASED_PK;METABOLISM;PLASMA LEVELS OF MORPHINE;;;
CODEINE;CYP2D6;CYP2D6*10;*1/*10 + *10/*10;LADME-PK;DECREASED_PK;METABOLISM;M3G AND M6G LEVELS BUT NOT THOSE OF CODEINE;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TRANSPLANT REJECTION ;;
AZATHIOPRINE;TPMT;TPMT*2;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TRANSPLANT REJECTION ;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TRANSPLANT REJECTION ;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TRANSPLANT REJECTION ;;
BOSENTAN;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
BOSENTAN;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
CODEINE;CYP2D6;CYP2D6*1;*1/*1 + *1/*4;OTHER;INCREASED_LIKELIHOOD;OTHER;OROCECCAL TRANSIT TIME;;;
CODEINE;CYP2D6;CYP2D6*3;*1/*1 + *1/*4;OTHER;INCREASED_LIKELIHOOD;OTHER;OROCECCAL TRANSIT TIME;;;
CODEINE;CYP2D6;CYP2D6*4;*1/*1 + *1/*4;OTHER;INCREASED_LIKELIHOOD;OTHER;OROCECCAL TRANSIT TIME;;;
CODEINE;CYP2D6;CYP2D6*5;*1/*1 + *1/*4;OTHER;INCREASED_LIKELIHOOD;OTHER;OROCECCAL TRANSIT TIME;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS;;;
TETRABENAZINE;CYP2D6;CYP2D6 intermediate metabolizer;;;SIDE_EFFECT;EFFICACY;LESS ROBUST TREATMENT RESPONSE;;;
WARFARIN;CYP4F2;CYP4F2*1;*3;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP4F2;CYP4F2*3;*3;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/L allele-rs25531C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SIDE EFFECTS;;;
CITALOPRAM;SLC6A4;SLC6A4 L allele-rs25531C;HTTLPR short form (S allele)/L allele-rs25531C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SIDE EFFECTS;;;
CITALOPRAM;SLC6A4;SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SIDE EFFECTS;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*1/*17;LADME-PK;DECREASED_PK;METABOLISM;METABOLIC RATIO CIT/DCIT VALUES;;;
CITALOPRAM;CYP2C19;CYP2C19*17;*1/*17;LADME-PK;DECREASED_PK;METABOLISM;METABOLIC RATIO CIT/DCIT VALUES;;;
CLOPIDOGREL;PTGS1;rs1330344;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOMIPRAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;CLOMIPRAMINE-INDUCED PROLACTIN RELEASE;;;
CLOMIPRAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;CLOMIPRAMINE-INDUCED PROLACTIN RELEASE;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;LADME-PK;INCREASED_PK;METABOLISM;AUC OF CITALOPRAM;;;
CITALOPRAM;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;LADME-PK;INCREASED_PK;METABOLISM;AUC OF CITALOPRAM;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;PRESENTATION IN THE NON-REPONDER GROUP;;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOOD;EVENT;PRESENTATION IN THE NON-REPONDER GROUP;;;
PHENOBARBITAL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE DRUG REACTIONS;;;
OLANZAPINE;TPMT;TPMT*1;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIZZINESS ;;
OLANZAPINE;TPMT;TPMT*3A;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIZZINESS ;;
OLANZAPINE;TPMT;TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIZZINESS ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PRU;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PRU;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS;;;
CARBAMAZEPINE;HLA-B;HLA-B*07:02;*07:02;TOXICITY;DECREASED_RISK;nan;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
CARBAMAZEPINE;HLA-B;HLA-B*08:01;*07:02;TOXICITY;DECREASED_RISK;nan;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TRICHLOROETHYLENE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS;;;
AZATHIOPRINE;TPMT;TPMT*3A;*3A/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3C;*3A/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOSPORINE;TPMT;TPMT*3A;*3A/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOSPORINE;TPMT;TPMT*3C;*3A/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
PREDNISONE;TPMT;TPMT*3A;*3A/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
PREDNISONE;TPMT;TPMT*3C;*3A/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ALLOPURINOL;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
WARFARIN;CYP2C9;CYP2C9*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENT OCCURRENCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENT OCCURRENCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENT OCCURRENCE;;;
ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
IRINOTECAN;UGT1A7;UGT1A7*3;*3;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
OXALIPLATIN;UGT1A7;UGT1A7*3;*3;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
TEGAFUR;UGT1A7;UGT1A7*3;*3;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
GIMERACIL;UGT1A7;UGT1A7*3;*3;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
OTERACIL;UGT1A7;UGT1A7*3;*3;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;VOMITING ;;
ASPIRIN;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
ASPIRIN;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
OSIMERTINIB;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
OSIMERTINIB;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;CC;TOXICITY;DECREASED_RISK;nan;DISEASE;LEUKOPENIA ;;
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CLOZAPINE;HLA-DRB3;HLA-DRB3*02:02;*02:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
MERCAPTOPURINE;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MYCOPHENOLATE MOFETIL;UGT2B7;rs7438135;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ANEMIA ;;
CLOZAPINE;HLA-C;HLA-C*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
CLOZAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
AZATHIOPRINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCREATITIS;;;
MERCAPTOPURINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCREATITIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME ;;
CARBIMAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
METHIMAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
PROPYLTHIOURACIL;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
PLATINUM COMPOUNDS;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
PYRIMIDINE ANALOGUES;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CILOSTAZOL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CILOSTAZOL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CILOSTAZOL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
WARFARIN;CYP2C9;CYP2C9*1;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CAPECITABINE;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOLASETRON;CYP2D6;CYP2D6*1;*1/*1xN;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
DOLASETRON;CYP2D6;CYP2D6*1xN;*1/*1xN;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
CYCLOSPORINE;NFATC2;rs6123048;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;NFATC2;rs6123048;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CYCLOPHOSPHAMIDE;CYP2C8;CYP2C8*1;*4;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
CYCLOPHOSPHAMIDE;CYP2C8;CYP2C8*4;*4;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;CYP2C8;CYP2C8*1;*4;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;CYP2C8;CYP2C8*4;*4;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;CYP2C8;CYP2C8*1;*4;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;CYP2C8;CYP2C8*4;*4;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
TAMOXIFEN;CYP2C19;CYP2C19*1;*1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2C19;CYP2C19*2;*1/*2;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;nan;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
IFOSFAMIDE;ALDH1A1;rs3764435;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ASPIRIN;CYP2C19;CYP2C19*1;*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ASPIRIN;CYP2C19;CYP2C19*17;*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
CLOZAPINE;GSTT1;GSTT1 non-null;null/null;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CLOZAPINE;GSTT1;GSTT1 null;null/null;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C;;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C;;;
TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C;;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
AZATHIOPRINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCYTOPENIA;;;
AZATHIOPRINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCYTOPENIA;;;
MERCAPTOPURINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
HMG COA REDUCTASE INHIBITORS;ADAMTS1;rs402007;CC;;SIDE_EFFECT;EFFICACY;THE MOST BENEFIT FROM STATIN TREATMENT IN REDUCING THE RISK OF MYOCARDIAL INFARCTION;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NICOTINE;CYP2B6;CYP2B6*1;*1/*4 + *4/*4;TOXICITY;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
NICOTINE;CYP2B6;CYP2B6*4;*1/*4 + *4/*4;TOXICITY;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*1;TOXICITY;DECREASED_RISK;OTHER;TOBACCO USE DISORDER;;;
NICOTINE;CYP2A6;CYP2A6*12;*1/*1;TOXICITY;DECREASED_RISK;OTHER;TOBACCO USE DISORDER;;;
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
AMOXICILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;VIRUS DISEASES ;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;VIRUS DISEASES ;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;INFECTIOUS DISEASE ;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;INFECTIOUS DISEASE ;;
GEFITINIB;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
GEFITINIB;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;EFFICACY;DECREASED_RISK;SIDE_EFFECT;ALLOGRAFT REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;EFFICACY;DECREASED_RISK;SIDE_EFFECT;ALLOGRAFT REJECTION;;;
CARBOPLATIN;CYP3A5;CYP3A5*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CARBOPLATIN;CYP3A5;CYP3A5*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CARBOPLATIN;CYP3A5;CYP3A5*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CARBOPLATIN;CYP3A5;CYP3A5*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
PACLITAXEL;CYP3A5;CYP3A5*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
PACLITAXEL;CYP3A5;CYP3A5*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
PACLITAXEL;CYP3A5;CYP3A5*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
PACLITAXEL;CYP3A5;CYP3A5*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
LAMOTRIGINE;SCN1A;rs3812718;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TONIC BLOCK OF NA(V) 1.1 CHANNELS;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;FORMATION OF METABOLITES;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;LADME-PK;INCREASED_PK;METABOLISM;FORMATION OF METABOLITES;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
PEMETREXED;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
METHOTREXATE;TYMS;rs11280056;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
nan;SLCO1B1;rs4149056;C;OTHER;DECREASED_;OTHER;ERYTHROMYCIN TRANSPORT;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
LEVOFLOXACIN;HLA-B;HLA-B*13:01;*13:01 + *13:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
LEVOFLOXACIN;HLA-B;HLA-B*13:02;*13:01 + *13:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
PHENYTOIN;HLA-A;HLA-A*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ASPIRIN;CYP2C19;CYP2C19 intermediate metabolizer;;EFFICACY;INCREASED_RISK;SIDE_EFFECT;THROMBOTIC DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer;;EFFICACY;INCREASED_RISK;SIDE_EFFECT;THROMBOTIC DISEASE;;;
BETA-LACTAM ANTIBACTERIALS;HLA-DRB1;HLA-DRB1*10:01;*10:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
PENICILLINS;HLA-DRB1;HLA-DRB1*10:01;*10:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3 + *8;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *8;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *8;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*2 + *3 + *8;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2 + *3 + *8;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1 + *1/*17 + *17/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*1 + *1/*17 + *17/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19*1;*1/*1 + *1/*17 + *17/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19*17;*1/*1 + *1/*17 + *17/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10  + *1/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10  + *1/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1 + *1/*17 + *17/*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*1 + *1/*17 + *17/*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ASPIRIN;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CYCLOSPORINE;SLC19A1;rs4818789;TT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;SLC19A1;rs4818789;TT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
ATENOLOL;ADRB2;rs1042714;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERTRIGLYCERIDEMIA ;;
METOPROLOL;ADRB2;rs1042714;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERTRIGLYCERIDEMIA ;;
ZOLEDRONATE;nan;rs1152003;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OSTEONECROSIS ;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
ANTIPSYCHOTICS;CYP2C19;CYP2C19 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
ANTIPSYCHOTICS;CYP2C19;CYP2C19 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
ATORVASTATIN;HMGCR;rs17671591;T;;SIDE_EFFECT;EFFICACY;LDL-C RESPONSE;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEPRESSION;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEPRESSION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION;;;
VORICONAZOLE;CYP3A5;CYP3A5*1;*3/*3;LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION;;;
VORICONAZOLE;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION;;;
CARBOPLATIN;LIG3;rs1052536;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
PACLITAXEL;LIG3;rs1052536;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CLOPIDOGREL;CYP1A2;rs2069514;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CYCLOSPORINE;SLC19A1;rs4819128;TT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;SLC19A1;rs4819128;TT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
ETHAMBUTOL;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ATORVASTATIN;HMGCR;rs10474433;T;;SIDE_EFFECT;EFFICACY;LDL-C RESPONSE;;;
VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
ATORVASTATIN;PCSK9;rs11591147;T;;SIDE_EFFECT;EFFICACY;LDL-C RESPONSE;;;
"""BETA-LACTAM ANTIBACTERIALS";HLA-A;HLA-A*02:07;*02:07;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"PENICILLINS""";HLA-A;HLA-A*02:07;*02:07;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*02:07;*02:07;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""BETA-LACTAM ANTIBACTERIALS";HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"PENICILLINS""";HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""BETA-LACTAM ANTIBACTERIALS";HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"PENICILLINS""";HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""BETA-LACTAM ANTIBACTERIALS";HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"PENICILLINS""";HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""BETA-LACTAM ANTIBACTERIALS";HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"PENICILLINS""";HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
VALPROIC ACID;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
VALPROIC ACID;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ATORVASTATIN;APOE;rs429358;T;;SIDE_EFFECT;EFFICACY;LDL-C RESPONSE;;;
ENALAPRIL;nan;rs495828;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
RIBAVIRIN;ITPA;rs1127354;AC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;ITPA;rs1127354;AC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ENALAPRIL;nan;rs495828;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
ATORVASTATIN;APOE;rs7412;T;;SIDE_EFFECT;EFFICACY;LDL-C RESPONSE;;;
nan;GSTT1;GSTT1 non-null;;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
nan;GSTT1;GSTT1 null;;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
SIMVASTATIN;ABCG2;rs2231142;TT;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE TO DRUG;;;
CISPLATIN;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPONATREMIA;;;
DOCETAXEL;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPONATREMIA;;;
FLUOROURACIL;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPONATREMIA;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
nan;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
nan;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
nan;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
CAPECITABINE;DPYS;rs143004875;(T)7/(T)8;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYS;rs143004875;(T)7/(T)8;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FLUVASTATIN;ABCG2;rs2231142;TT;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE TO DRUG;;;
CAPECITABINE;DPYD;DPYD c.1129-5923C>G;c.1129-5923C>G, c.1236G>A (HapB3);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;DPYD;c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;DPYD c.1129-5923C>G;c.1129-5923C>G, c.1236G>A (HapB3);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
OSIMERTINIB;CYP2A6;CYP2A6*4;*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
OSIMERTINIB;ABCG2;rs2622604;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
L-ASPARAGINE;CYP3A5;CYP3A5*1;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
L-ASPARAGINE;CYP3A5;CYP3A5*3;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
L-ASPARAGINE;CYP3A5;CYP3A5*6;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
L-ASPARAGINE;CYP3A5;CYP3A5*7;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
PREDNISONE;CYP3A5;CYP3A5*1;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
PREDNISONE;CYP3A5;CYP3A5*3;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
PREDNISONE;CYP3A5;CYP3A5*6;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
PREDNISONE;CYP3A5;CYP3A5*7;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
VINCRISTINE;CYP3A5;CYP3A5*1;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
VINCRISTINE;CYP3A5;CYP3A5*3;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
VINCRISTINE;CYP3A5;CYP3A5*6;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
VINCRISTINE;CYP3A5;CYP3A5*7;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
L-ASPARAGINE;ASNS;rs3832526;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
PREDNISONE;ASNS;rs3832526;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
VINCRISTINE;ASNS;rs3832526;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
PRAVASTATIN;NPC1L1;rs17655652;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN LDL-C;;;
PRAVASTATIN;NPC1L1;rs17655652;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN LDL-C;;;
ETHAMBUTOL;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
TRAMADOL;CYP2B6;CYP2B6 poor metabolizer;;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE_PAIN;;;
TRAMADOL;CYP3A4;CYP3A4 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
TRAMADOL;CYP3A4;CYP3A4 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
CITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
IRINOTECAN;HLA-B;rs9266271;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTIINFLAMMATORY AGENTS;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NON-STEROIDS;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ANTIINFLAMMATORY AGENTS;HLA-A;HLA-A*34:01;*34:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NON-STEROIDS;HLA-A;HLA-A*34:01;*34:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ANTIINFLAMMATORY AGENTS;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NON-STEROIDS;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ATORVASTATIN;HMGCR;rs3846662;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IN BASAL STATE AND POSSIBLY IN RESPONSE TO ATORVASTATIN.;;;
CLOPIDOGREL;ABCB1;rs1128503;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREMOR;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIABETES MELLITUS;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREMOR;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIABETES MELLITUS;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION;;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
BETA BLOCKING AGENTS;ADRB1;rs1801252;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING;;;
METOPROLOL;ADRB1;rs1801252;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
LANSOPRAZOLE;CYP2C19;CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
FOLFIRI;TYMS;rs11280056;del/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FOLFOX;TYMS;rs11280056;del/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
XELOX;TYMS;rs11280056;del/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;ALOX5;rs1051713;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ETOPOSIDE;nan;rs6539870;GG;OTHER;INCREASED_LIKELIHOOD;OTHER;SENSITIVITY TO ETOPOSIDE;;;
"""INTERFERON ALFA-2B";ITPA;rs1127354;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN;;;
"RECOMBINANT""";ITPA;rs1127354;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN;;;
"""RIBAVIRIN""";ITPA;rs1127354;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
"""INTERFERON ALFA-2B";ITPA;rs1127354;CC;;SIDE_EFFECT;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN;;;
"RECOMBINANT""";ITPA;rs1127354;CC;;SIDE_EFFECT;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN;;;
"""RIBAVIRIN""";ITPA;rs1127354;CC;;SIDE_EFFECT;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN;;;
ASPARAGINASE;F5;rs6025;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOEMBOLISM;;;
DABIGATRAN;CES1;rs2244613;GG + GT;LADME-PK;DECREASED_PK;METABOLISM;ADJUSTED TROUGH CONCENTRATIONS;;;
DESIPRAMINE;MC1R;rs2228478;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
ACENOCOUMAROL;VKORC1;rs9934438;AA;DOSAGE, EFFICACY, TOXICITY;DECREASED_;SIDE_EFFECT;DOSE REQUIREMENT;;;
DESIPRAMINE;MC1R;rs2228479;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
ETHAMBUTOL;NAT2;NAT2*4;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*7;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*16;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*4;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*16;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*4;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*7;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*16;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*4;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*16;*16/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
CARBAMAZEPINE;LTA;rs1800629;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SERIOUS HYPERSENSITIVITY;;;
CARBAMAZEPINE;TNF;rs1800629;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SERIOUS HYPERSENSITIVITY;;;
ASPARAGINASE;IL16;rs11556218;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOTIC DISEASE;;;
MERCAPTOPURINE;PACSIN2;rs2413739;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGIC DISORDER;;;
GEMCITABINE;SLC29A1;rs9394992;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOCETAXEL;SPG7;rs2292954;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;SPG7;rs2292954;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
ANTINEOPLASTIC AGENTS;CTH;rs648743;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
DOCETAXEL;ABCC6;rs2238472;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;ABCC6;rs2238472;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
DOCETAXEL;ATP7A;rs2227291;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;ATP7A;rs2227291;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
MERCAPTOPURINE;GNMT;rs10948059;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMATOLOGIC DISORDER;;;
ACENOCOUMAROL;CYP4F2;rs2108622;CC;OTHER, LADME-PK;DECREASED_;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS;;;
ACENOCOUMAROL;CYP4F2;rs2108622;CT;OTHER, LADME-PK;DECREASED_;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS;;;
DABIGATRAN;CES1;rs2244613;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;BLEEDING EVENTS;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENT;;;
ACENOCOUMAROL;CYP4F2;rs2108622;CC;DOSAGE, EFFICACY, TOXICITY;DECREASED_;SIDE_EFFECT;DOSAGE REQUIREMENT;;;
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
IRINOTECAN;SLCO1B1;rs4149015;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
ISONIAZID;NAT2;NAT2*4;*16/*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;A MILD INCREASE OF LIVER ENZYMES;;;
ISONIAZID;NAT2;NAT2*16;*16/*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;A MILD INCREASE OF LIVER ENZYMES;;;
PYRAZINAMIDE;NAT2;NAT2*4;*16/*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;A MILD INCREASE OF LIVER ENZYMES;;;
PYRAZINAMIDE;NAT2;NAT2*16;*16/*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;A MILD INCREASE OF LIVER ENZYMES;;;
RIFAMPIN;NAT2;NAT2*4;*16/*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;A MILD INCREASE OF LIVER ENZYMES;;;
RIFAMPIN;NAT2;NAT2*16;*16/*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;A MILD INCREASE OF LIVER ENZYMES;;;
SALBUTAMOL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ASTHMA EXACERBATIONS;;;
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ASTHMA EXACERBATIONS;;;
IRINOTECAN;UGT1A9;rs3832043;del/del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
ANTIPSYCHOTICS;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
ARIPIPRAZOLE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
CLOZAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
OLANZAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
QUETIAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
CISPLATIN;SLC16A5;rs4788863;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY;;;
ISONIAZID;NAT2;NAT2*1;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*4;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*5;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*5G;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*5J;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*6;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*7;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*14;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*16;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*17;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*30;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
ISONIAZID;NAT2;NAT2*34;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*1;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*4;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*5;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*5G;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*5J;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*6;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*7;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*14;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*16;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*17;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*30;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
RIFAMPIN;NAT2;NAT2*34;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS;;;
IRINOTECAN;ABCC2;rs3740066;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
ETHAMBUTOL;NAT2;NAT2*4;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*6;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*16;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*4;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*6;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*16;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*4;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*6;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*16;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*4;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*6;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*16;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ENALAPRIL;BDKRB2;rs1799722;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
IMIDAPRIL;BDKRB2;rs1799722;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
LISINOPRIL;BDKRB2;rs1799722;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
IRINOTECAN;ABCG2;rs2231137;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
CLOZAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;METABOLIC SYNDROME;;;
HMG COA REDUCTASE INHIBITORS;SREBF1;rs11868035;AA + AG;OTHER;INCREASED_LIKELIHOOD;OTHER;TOTAL CHOLESTEROL;;;
OXYCODONE;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;DOSAGE;INCREASED_PK;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS;;;
OXYCODONE;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;DOSAGE;INCREASED_PK;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS;;;
OXYCODONE;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;DOSAGE;INCREASED_PK;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS;;;
OXYCODONE;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;DOSAGE;INCREASED_PK;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS;;;
OXYCODONE;CYP2D6;CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;DOSAGE;INCREASED_PK;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS;;;
OXYCODONE;CYP2D6;CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;DOSAGE;INCREASED_PK;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS;;;
CISPLATIN;GSTP1;rs1695;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY;;;
ACE INHIBITORS;BDKRB2;rs1799722;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
PLAIN;BDKRB2;rs1799722;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
ATORVASTATIN;ABCG2;rs2231142;TT;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;LADME-PK;DECREASED_;OTHER;GASTRIC PH;;;
ETHAMBUTOL;NAT2;NAT2*5;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*6;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*7;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*5;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*6;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*5;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*6;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*7;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*5;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*6;*6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*7;*6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*6;*6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*6;*6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*7;*6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
IRBESARTAN;AGTR1;rs5186;AC + CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BLOOD PRESSURE RESPONSE;;;
ETHAMBUTOL;NAT2;NAT2*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
ISONIAZID;NAT2;NAT2*1;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*4;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*5;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*6;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*1;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*4;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*5;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
DEXMEDETOMIDINE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BISPECTRAL INDEX AND RAMSAY SEDATION SCORES;;;
DEXMEDETOMIDINE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INDICATING A LONGER PERIOD FOR FALLING ASLEEP;;;
PACLITAXEL;CYP2C8;rs1113129;G;TOXICITY;DECREASED_RISK;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
OPIOIDS;MUC16;rs11882256;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;MUC16;rs11882256;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
ISONIAZID;NAT2;NAT2*6;*6;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*6;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ROSUVASTATIN;ABCG2;rs2231142;TT;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
ISONIAZID;NAT2;NAT2*6;*6/*6;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*6;*6/*6;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*6/*6;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
SULFAMETHOXAZOLE;NAT2;NAT2*5;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
SULFAMETHOXAZOLE;NAT2;NAT2*6;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
SULFAMETHOXAZOLE;NAT2;NAT2*7;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
SULFAMETHOXAZOLE;NAT2;NAT2*14;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
SULFAMETHOXAZOLE;NAT2;NAT2*16;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TRIMETHOPRIM;NAT2;NAT2*5;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TRIMETHOPRIM;NAT2;NAT2*6;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TRIMETHOPRIM;NAT2;NAT2*7;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TRIMETHOPRIM;NAT2;NAT2*14;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
TRIMETHOPRIM;NAT2;NAT2*16;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
ROSUVASTATIN;ABCG2;rs2231142;GG;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;AUC;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*6;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
SORAFENIB;TNF;rs1800629;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
IRINOTECAN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
ALFENTANIL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RISK;nan;DISEASE;PAIN ;;
ISONIAZID;NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
ISONIAZID;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
ISONIAZID;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
ISONIAZID;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""INTERFERON ALFA-2B";ITPA;rs1127354;CC;TOXICITY;DECREASED_;SIDE_EFFECT;HEMOGLOBIN LEVELS;;;
"RECOMBINANT""";ITPA;rs1127354;CC;TOXICITY;DECREASED_;SIDE_EFFECT;HEMOGLOBIN LEVELS;;;
"""RIBAVIRIN""";ITPA;rs1127354;CC;TOXICITY;DECREASED_;SIDE_EFFECT;HEMOGLOBIN LEVELS;;;
ETHAMBUTOL;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ALFENTANIL;OPRM1;rs1799971;AG + GG;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
ETHAMBUTOL;NAT2;NAT2*4;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*4;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*4;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*4;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISK;OTHER;ASTHMA EXACERBATIONS;;;
PEGINTERFERON ALFA-2B;DNAAF9;rs6051702;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
PEGINTERFERON ALFA-2B;ITPA;rs6051702;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;DNAAF9;rs6051702;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs6051702;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
CLOPIDOGREL;MIR6076;rs1463411;GG + GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;LADME-PK;DECREASED_;OTHER;GASTRIC PH;;;
TAMOXIFEN;LRMDA;rs10509373;C;EFFICACY;DECREASED_;OTHER;RECURRENCE-FREE SURVIVAL;;;
OPIOIDS;CRYBG2;rs36024412;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;CRYBG2;rs36024412;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
ETHAMBUTOL;NAT2;rs1799930;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;rs1799930;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;rs1799930;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;rs1799930;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*6;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*7;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*6;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*6;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*7;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*6/*7;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
OPIOIDS;CLCC1;rs168107;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;CLCC1;rs168107;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
CAPECITABINE;CDA;rs1048977;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
BOCEPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
BOCEPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
OPIOIDS;POM121L2;rs41269255;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;POM121L2;rs41269255;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;NAT2*1;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"COMBINATIONS""";NAT2;NAT2*1;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"COMBINATIONS""";NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"COMBINATIONS""";NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"COMBINATIONS""";NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"COMBINATIONS""";NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;NAT2*1;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
DIPYRONE;NAT2;NAT2*6;*16 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
DIPYRONE;NAT2;NAT2*7;*16 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
DIPYRONE;NAT2;NAT2*14;*16 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
DIPYRONE;NAT2;NAT2*16;*16 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
ETHAMBUTOL;NAT2;NAT2*6;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*7;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*14;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*16;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*6;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*14;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*16;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*6;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*7;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*14;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*16;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*14;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*16;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
METHOTREXATE;ABCC2;rs3740065;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
IRINOTECAN;NR3C1;rs61754806;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;VKORC1;rs7294;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
OPIOIDS;ZNF165;rs9393888;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;ZNF165;rs9393888;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
CISPLATIN;TPMT;rs1142345;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;TPMT;rs1142345;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;SLCO1B1*5;*5;TOXICITY;DECREASED_RISK;SIDE_EFFECT;CATARACT;;;
GEMCITABINE;RRM1;rs9937;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
OLANZAPINE;DRD2;rs1799978;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME UNTIL RESPONSE;;;
RISPERIDONE;DRD2;rs1799978;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME UNTIL RESPONSE;;;
PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING EVENTS;;;
ETHAMBUTOL;NAT2;NAT2*5;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*6;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*6J;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*7;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*16;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*5;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*6;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*6J;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*7;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*16;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*5;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*6;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*6J;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*7;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*16;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*5;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*6;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*6J;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*7;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*16;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
METHOTREXATE;ABCC4;rs9516519;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXICITY;;;
ESCITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PSYCHOMOTOR AGITATION;;;
ESCITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERKINESIS;;;
ESCITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;IMPULSE CONTROL DISORDER;;;
RISPERIDONE;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISCONTINUATION;;;
PALIPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PALIPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ETHAMBUTOL;NAT2;NAT2*4;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*6;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*4;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*6;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*4;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*6;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*4;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*6;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TRAMADOL;CYP2D6;CYP2D6*10;*10/*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;MAGNITUDE OF PLATELET REACTIVITY;;;
ISONIAZID;NAT2;NAT2*6;*6 + *7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*7;*6 + *7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ETHAMBUTOL;NAT2;NAT2*4;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*6;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*7;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*4;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*6;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*4;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*6;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*7;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*4;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
PYRAZINAMIDE;NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
PYRAZINAMIDE;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
PYRAZINAMIDE;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
PYRAZINAMIDE;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
RIFAMPIN;NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
RIFAMPIN;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
RIFAMPIN;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
RIFAMPIN;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ETHAMBUTOL;NAT2;NAT2*16;*16;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*16;*16;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*16;*16;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*16;*16;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*6;*6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
ETHAMBUTOL;NAT2;NAT2*7;*6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
ISONIAZID;NAT2;NAT2*6;*6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
ISONIAZID;NAT2;NAT2*7;*6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
PYRAZINAMIDE;NAT2;NAT2*6;*6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
PYRAZINAMIDE;NAT2;NAT2*7;*6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
RIFAMPIN;NAT2;NAT2*6;*6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
RIFAMPIN;NAT2;NAT2*7;*6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
ANTIINFLAMMATORY AGENTS;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NON-STEROIDS;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ON-TREATMENT PLATELET REACTIVITY;;;
ETHAMBUTOL;NAT2;NAT2*4;*16/*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;NAT2*16;*16/*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*4;*16/*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*16;*16/*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*4;*16/*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*16;*16/*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*4;*16/*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*16;*16/*4;TOXICITY, LADME-PK;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
CAPECITABINE;CDA;rs2072671;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;CDA;rs2072671;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
ETHAMBUTOL;NAT2;NAT2*4;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ETHAMBUTOL;NAT2;NAT2*6;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ETHAMBUTOL;NAT2;NAT2*7;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ETHAMBUTOL;NAT2;NAT2*16;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*4;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*6;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*7;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*16;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
PYRAZINAMIDE;NAT2;NAT2*4;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
PYRAZINAMIDE;NAT2;NAT2*6;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
PYRAZINAMIDE;NAT2;NAT2*7;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
PYRAZINAMIDE;NAT2;NAT2*16;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
RIFAMPIN;NAT2;NAT2*4;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
RIFAMPIN;NAT2;NAT2*6;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
RIFAMPIN;NAT2;NAT2*7;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
RIFAMPIN;NAT2;NAT2*16;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*16;*16;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
OLANZAPINE;DRD2;rs1799732;del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO RESPOND;;;
RISPERIDONE;DRD2;rs1799732;del;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO RESPOND;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*5;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*6;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*7;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
OPIOIDS;CYP2A7P1;rs3745274;GG;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOIDS;CYP2B6;rs3745274;GG;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ETHAMBUTOL;NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*4;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ANTIINFLAMMATORY AGENTS;HLA-B;HLA-B*35:03;*35:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NON-STEROIDS;HLA-B;HLA-B*35:03;*35:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
nan;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD;OTHER;TOBACCO USE DISORDER;;;
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMOLYTIC ANEMIA;;;
SOFOSBUVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMOLYTIC ANEMIA;;;
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;TOXICITY;DECREASED_RISK;SIDE_EFFECT;INFECTIOUS DISEASE;;;
ANTINEOPLASTIC AGENTS;TYMS;rs2853539;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
DACTINOMYCIN;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
VINCRISTINE;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizers;;LADME-PK;DECREASED_;OTHER;GASTRIC PH;;;
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;HOT FLASHES;;;
ANTINEOPLASTIC AGENTS;AKR1C3;rs1937840;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ANTIHYPERTENSIVES;ADIPOQ;rs266729;CG + GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERTENSION;;;
MYCOPHENOLIC ACID;IMPDH1;rs2278293;T;EFFICACY;DECREASED_LIKELIHOOD;OTHER;SUBCLINICAL ACUTE REJECTION;;;
TACROLIMUS;IMPDH1;rs2278293;T;EFFICACY;DECREASED_LIKELIHOOD;OTHER;SUBCLINICAL ACUTE REJECTION;;;
GEMCITABINE;CDA;rs2072671;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*1;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*1;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*1;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*1;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*1xN;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*1xN;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*1xN;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*1xN;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*3;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*3;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*3;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*3;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*4;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*4;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*4;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*4;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*4xN;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*4xN;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*4xN;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*4xN;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*5;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*5;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*5;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*5;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*7;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*7;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*7;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*7;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
ATOMOXETINE;CYP2D6;CYP2D6*17;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRY MOUTH;;;
ATOMOXETINE;CYP2D6;CYP2D6*17;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
ATOMOXETINE;CYP2D6;CYP2D6*17;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERHIDROSIS;;;
ATOMOXETINE;CYP2D6;CYP2D6*17;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
CODEINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
NICOTINE;CYP2D6;CYP2D6*2xN;*2xN;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOBACCO USE DISORDER;;;
NICOTINE;CYP2D6;CYP2D6*4;*2xN;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOBACCO USE DISORDER;;;
NICOTINE;CYP2D6;CYP2D6*5;*2xN;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOBACCO USE DISORDER;;;
GEMCITABINE;DCK;rs4694362;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOPHOSPHAMIDE;RBX1;rs141084494;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;RBX1;rs141084494;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;RBX1;rs141084494;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ETHAMBUTOL;NAT2;rs1801280;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;rs1801280;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;rs1801280;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;rs1801280;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PLATINUM COMPOUNDS;SLC31A1;rs4978536;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
OPIOIDS;BDNF-AS;rs11030096;CC + CT;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
IRINOTECAN;NAT2;rs1799930;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;NAT2;rs1799930;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;SLC31A1;rs10817464;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM COMPOUNDS;SLC31A1;rs10817464;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HEMATOLOGIC DISORDER;;;
PLATINUM COMPOUNDS;SLC31A1;rs10817464;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
PLATINUM COMPOUNDS;SLC31A1;rs10817464;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
COCAINE;SYT1;rs2251214;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;COCAINE DEPENDENCE;;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
VALGANCICLOVIR;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOXETINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE PLASMA CONCENTRATION;;;
FLUOXETINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE PLASMA CONCENTRATION;;;
TETRABENAZINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;EFFICACY;nan;OTHER;LONGER TITRATION TO ACHIEVE OPTIMAL BENEFIT;;;
MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF MYCOPHENOLIC ACID;;;
OLANZAPINE;CYP2C9;CYP2C9 poor metabolizers;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
"""FOLIC ACID""";MTRR;rs1801394;AA + AG;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;PAIN ;;
"""VITAMIN B-COMPLEX";MTRR;rs1801394;AA + AG;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;PAIN ;;
"PLAIN""";MTRR;rs1801394;AA + AG;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;PAIN ;;
NICOTINE;HTR3B;rs3758987;TT;TOXICITY;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
CAPECITABINE;TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
CAPECITABINE;TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
ENALAPRIL;PCGF3;rs1044147;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*7;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*11;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
PAROXETINE;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
PAROXETINE;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
PAROXETINE;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
PAROXETINE;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;PAROXETINE PLASMA CONCENTRATION;;;
TRAMADOL;COMT;rs4680;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SEDATION;;;
ANTICHOLINERGIC AGENTS;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;SERUM ANTICHOLINERGIC ACTIVITY;;;
VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
ANTINEOPLASTIC AGENTS;ABCG2;rs2231164;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
CITALOPRAM;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
CLOMIPRAMINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
DULOXETINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
ESCITALOPRAM;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
FLUOXETINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
FLUVOXAMINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
MIRTAZAPINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
PAROXETINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
SERTRALINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;NUMBER OF FAILED MEDICATION TRAILS;;;
MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF MYCOPHENOLIC ACID-7-O-GLUCURONIDE;;;
MYCOPHENOLATE MOFETIL;ABCC2;rs2273697;AG;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF THE ACYL GLUCURONIDE OF MYCOPHENOLIC ACID;;;
CAPECITABINE;DPYD;rs2297595;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OPIOIDS;OPRM1;rs1799971;GG;TOXICITY;DECREASED_;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;OPRM1;rs1799971;GG;TOXICITY;DECREASED_;SIDE_EFFECT;VOMITING;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ATENOLOL;PAH;rs2245360;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INSULIN RESISTANCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*3/*4 + *3/*5 + *4/*4 + *4/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*4 + *3/*5 + *4/*4 + *4/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3/*4 + *3/*5 + *4/*4 + *4/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3/*4 + *3/*5 + *4/*4 + *4/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
TAMOXIFEN;CYP2D6;CYP2D6*7;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
ASPIRIN;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
OPIOIDS;DRD2;rs1125394;CC + CT;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_;SIDE_EFFECT;ADVERSE EVENTS;;;
SORAFENIB;VEGFA;rs3025040;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*2;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OPIOIDS;DRD2;rs1079596;CT + TT;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
TRAMADOL;COMT;rs4680;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*2;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer and intermediate metabolizer genotypes;;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDE;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
AZATHIOPRINE;TPMT;TPMT intermediate metabolizers;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
MERCAPTOPURINE;TPMT;TPMT intermediate metabolizers;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
PURINE ANALOGUES;TPMT;TPMT intermediate metabolizers;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FLUOROURACIL;TYMS;rs2847153;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SURVIVAL;;;
MORPHINE;ABCC3;rs4148412;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOVENTILATION;;;
SORAFENIB;UGT1A9;rs7574296;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*1 + *1/*28;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*1 + *1/*28;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE;INCREASED_LIKELIHOOD;OTHER;DRUG DOSAGE ALTERED;;;
TRAMADOL;COMT;rs4680;GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE_PAIN;;;
"""FOLIC ACID""";MTHFR;rs1801133;AG + GG;;SIDE_EFFECT;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE;;;
"""VITAMIN B-COMPLEX";MTHFR;rs1801133;AG + GG;;SIDE_EFFECT;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE;;;
"PLAIN""";MTHFR;rs1801133;AG + GG;;SIDE_EFFECT;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE;;;
AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;ANTIDEPRESSANT SERUM LEVELS;;;
CLOMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;ANTIDEPRESSANT SERUM LEVELS;;;
DOXEPIN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;ANTIDEPRESSANT SERUM LEVELS;;;
IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;ANTIDEPRESSANT SERUM LEVELS;;;
TRIMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;ANTIDEPRESSANT SERUM LEVELS;;;
SORAFENIB;SLC15A2;rs2257212;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;CCND1;rs9344;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME-TO-TUMOR RECURRENCE;;;
AZATHIOPRINE;TPMT;TPMT intermediate metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
CAPECITABINE;UMPS;rs2279199;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
CAPECITABINE;UMPS;rs2279199;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
METFORMIN;nan;rs578427;TT;LADME-PK;INCREASED_PK;METABOLISM;RENAL CLEARANCE AND SECRETION CLEARANCE OF METFORMIN;;;
CAPECITABINE;TYMS;rs2853741;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
CLOPIDOGREL;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
CAPECITABINE;SLC22A7;rs4149178;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
CISPLATIN;ABCC3;rs1051640;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
GALANTAMINE;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*1xN;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*41;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*7;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;CYP2C19 normal metabolizers;;OTHER;DECREASED_RISK;OTHER;MAJOR ADVERSE CARDIAC EVENTS;;;
METHOTREXATE;SLC19A1;rs1051266;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ABT-751;UGT1A4;rs6755571;AC;LADME-PK;DECREASED_PK;METABOLISM;PLASMA PREDOSE CONCENTRATION (CTROUGH);;;
CAPECITABINE;UMPS;rs4678145;CC + CG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ASTHENIA;;;
ABT-751;UGT1A8;rs6431558;CC + CT;LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION METABOLIC RATIOS;;;
IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;MEAN AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC) OF DESIPRAMINE;;;
ANTINEOPLASTIC AGENTS;DPYD;rs1760217;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
AZATHIOPRINE;TPMT;rs1142345;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ANTINEOPLASTIC AGENTS;SERPINA3;rs17091162;AC + CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*17;LADME-PK;DECREASED_PK;METABOLISM;MEAN PEAK PLASMA CONCENTRATION OF H4;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*17;LADME-PK;DECREASED_PK;METABOLISM;MEAN PEAK PLASMA CONCENTRATION OF H4;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*17;LADME-PK;DECREASED_PK;METABOLISM;MEAN PEAK PLASMA CONCENTRATION OF H4;;;
VALPROIC ACID;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
ASPIRIN;PTGS1;rs10306114;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;PTGS1;rs10306114;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
METFORMIN;SLC47A2;rs12943590;AA;LADME-PK;INCREASED_PK;METABOLISM;RENAL CLEARANCE AND SECRETION CLEARANCE OF METFORMIN;;;
TAMOXIFEN;NCOA1;rs1804645;CT;OTHER;INCREASED_SEVERITY;SIDE_EFFECT;CHANGE IN LUMBAR BONE MINERAL DENSITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;EFFICACY;INCREASED_RISK;OTHER;CARDIOVASCULAR DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;EFFICACY;INCREASED_RISK;OTHER;MYOCARDIAL INFARCTION OR STROKE;;;
CITALOPRAM;nan;rs352428;A;;SIDE_EFFECT;EFFICACY;POOR RESPONSE AT 8 WEEK OF TREATMENT;;;
ESCITALOPRAM;nan;rs352428;A;;SIDE_EFFECT;EFFICACY;POOR RESPONSE AT 8 WEEK OF TREATMENT;;;
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;EFFICACY;INCREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
CITALOPRAM;nan;rs352428;A;;SIDE_EFFECT;EFFICACY;POOR RESPONSE AT 6 WEEK OF TREATMENT;;;
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;EFFICACY;INCREASED_RISK;OTHER;CARDIOVASCULAR DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;EFFICACY;INCREASED_RISK;OTHER;MYOCARDIAL INFARCTION OR STROKE;;;
MIDAZOLAM;POR;rs1057868;CT;LADME-PK;DECREASED_PK;METABOLISM;MIDAZOLAM METABOLIC RATIOS BY 45%;;;
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;EFFICACY;INCREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
LENVATINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRY MOUTH;;;
LENVATINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MUCOSITIS;;;
NICOTINE;CHRNA3;rs578776;G;LADME-PK;INCREASED_PK;METABOLISM;PLASMA LEVEL;;;
GALANTAMINE;CYP2D6;CYP2D6*1;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*3;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*4;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*6;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
GALANTAMINE;CYP2D6;CYP2D6*41;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED PLASMA LEVELS;;;
TRAZODONE;CYP2D6;CYP2D6 normal metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
CAPECITABINE;DPYD;rs17376848;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;STOMATITIS;;;
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
ASPIRIN;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
LENVATINIB;CYP3A4;rs2242480;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
LENVATINIB;CYP3A5;rs776746;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
CAPECITABINE;ENOSF1;rs699517;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
CAPECITABINE;ENOSF1;rs699517;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
CAPECITABINE;TYMS;rs699517;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
CAPECITABINE;TYMS;rs699517;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
HEROIN;OPRK1;rs6473797;C;TOXICITY;DECREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
HEROIN;CSNK1E;rs1534891;T;TOXICITY;DECREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
CAPECITABINE;DPYD;rs12119882;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ETHANOL;CHRNA5;rs16969968;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ALCOHOL ABUSE ;;
HEROIN;GAL;rs694066;A;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *3/*3 + *2/*3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *3/*3 + *2/*3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *3/*3 + *2/*3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
HEROIN;OPRD1;rs2236861;A;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
CAPECITABINE;SLC22A7;rs2270860;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
HEROIN;OPRD1;rs3766951;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
METHADONE;CRHBP;rs1500;G;OTHER;DECREASED_;OTHER;RECURRENCE;;;
METHAMPHETAMINE;FAAH;rs324420;A;OTHER;INCREASED_LIKELIHOOD;OTHER;DEPENDENCE;;;
ETHANOL;CHRNA3;rs1051730;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ALCOHOL ABUSE ;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*1xN;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*2xN;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*7;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
HEROIN;OPRD1;rs2236857;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
NALOXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PEAK CORTISOL RESPONSE;;;
TAMOXIFEN;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
CAPECITABINE;ENOSF1;rs699517;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ASTHENIA;;;
CAPECITABINE;TYMS;rs699517;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ASTHENIA;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*1/*1 + *1/*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEIOMYOMA;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*1/*1 + *1/*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LIVER DISORDER;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*1/*1 + *1/*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVARIAN CYSTS;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*1/*1 + *1/*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEIOMYOMA;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*1/*1 + *1/*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LIVER DISORDER;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*1/*1 + *1/*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVARIAN CYSTS;;;
HEROIN;HTR3B;rs3758987;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
METOPROLOL;CYP2D6;CYP2D6 poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
OSIMERTINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ESCITALOPRAM;HTR2C;rs6318;C;EFFICACY;DECREASED_;nan;DISEASE;PAIN ;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_PK;METABOLISM;PLASMA OXYMORPHONE/OXYCODONE RATIO;;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN PAIN AUC;;;
MERCAPTOPURINE;GNMT;rs10948059;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
NICOTINE;CHRNA5;rs16969968;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_PK;PK;PLASMA OXYMORPHONE/OXYCODONE RATIO;;;
NICOTINE;CHRNA3;rs1051730;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
PAROXETINE;CYP2D6;CYP2D6 normal metabolizers;;OTHER;INCREASED_LIKELIHOOD;OTHER;METABOLIC RATIO DEM/DOR;;;
IRINOTECAN;NAT2;rs1799931;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;NAT2;rs1799931;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEXUAL DYSFUNCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
HEROIN;OPRM1;rs3778151;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
ESCITALOPRAM;CYP2D6;CYP2D6 intermediate metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION;;;
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;MEDIAN AUC;;;
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_PK;METABOLISM;PLASMA HALF-LIFE AND STEADY-STATE PLASMA CONCENTRATIONS OF PAROXETINE;;;
CAPECITABINE;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HAND-FOOT SYNDROME ;;
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEXUAL DYSFUNCTION;;;
FLUOXETINE;CYP2D6;CYP2D6*1;*1/*1;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE/(S)-NORFLUOXETINE RATIO;;;
FLUOXETINE;CYP2D6;CYP2D6*1xN;*1/*1;LADME-PK;INCREASED_PK;METABOLISM;FLUOXETINE/(S)-NORFLUOXETINE RATIO;;;
CAPECITABINE;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
ALKYLATING AGENTS;ESR1;rs2207396;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OLIGOSPERMIA ;;
CISPLATIN;ESR1;rs2207396;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OLIGOSPERMIA ;;
HEROIN;OPRM1;rs510769;T;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
CITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION IF TOLERANT TO CITALOPRAM TREATMENT;;;
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;*1/*1;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;*1/*1;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PARKINSONIAN DISORDER;;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
OSIMERTINIB;STAT3;rs4796793;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAIL DISORDER;;;
ESCITALOPRAM;CYP2D6;rs1065852;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE AND REMISSION RATE;;;
3;CYP2C19;CYP2C19 poor metabolizer genotype;;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERTENSION;;;
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;CYP2C19 poor metabolizer genotype;;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERTENSION;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;SLCO1B1;rs4149014;GG + GT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DOCETAXEL;nan;poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
EPIRUBICIN;nan;poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CAFFEINE;CYP1A2;rs6968865;T;DOSAGE;INCREASED_METABOLISM;OTHER;COFFEE CONSUMPTION;;;
SULFAMETHOXAZOLE;GCLC;rs761142;AA;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG HYPERSENSITIVITY ;;
AZATHIOPRINE;TPMT;TPMT intermediate metabolizer genotype;;EFFICACY, TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;6-TG LEVELS;;;
MERCAPTOPURINE;TPMT;TPMT intermediate metabolizer genotype;;EFFICACY, TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;6-TG LEVELS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CAFFEINE;CYP1A1;rs2472297;T;DOSAGE;INCREASED_METABOLISM;OTHER;COFFEE CONSUMPTION;;;
SULFAMETHOXAZOLE;GCLC;rs761142;A;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG HYPERSENSITIVITY ;;
APIXABAN;CES1;rs2244613;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
DABIGATRAN;CES1;rs2244613;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
EDOXABAN;CES1;rs2244613;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
RIVAROXABAN;CES1;rs2244613;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
TRAMADOL;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs2273697;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
SORAFENIB;KDR;rs1870377;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TACROLIMUS;CYP3A4;rs35599367;AG;OTHER;INCREASED_PK;PK;CREATININE CLEARANCE;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;PON1;rs662;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ON-CLOPIDOGREL PLATELET REACTIVITY (PR) AT 1 MONTH AND AT 6 MONTHS AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI);;;
ANTIPSYCHOTICS;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
ISONIAZID;ASTN2;rs117491755;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ALECTINIB;PPARA;rs4253728;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
VALPROIC ACID;SCN1A;rs2298771;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
CISPLATIN;GSTT1;GSTT1 non-null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY;;;
CISPLATIN;GSTT1;GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY;;;
CISPLATIN;GSTM1;GSTM1 non-null;;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY;;;
CISPLATIN;GSTM1;GSTM1 null;;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*1;*1/*4 + *4/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ARIPIPRAZOLE;CYP2D6;CYP2D6*4;*1/*4 + *4/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
OLANZAPINE;CYP2D6;CYP2D6*1;*1/*4 + *4/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
OLANZAPINE;CYP2D6;CYP2D6*4;*1/*4 + *4/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*1/*4 + *4/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*1/*4 + *4/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
CODEINE;ABCB1;rs2032582;AA;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS;;;
ETHANOL;CRHBP;rs10055255;TT;TOXICITY;INCREASED_SEVERITY;OTHER;ALCOHOL ABUSE;;;
SUNITINIB;NR1I2;rs2276707;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEXUAL DYSFUNCTION;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
OXALIPLATIN;HLA-DRB1;HLA-DRB1*12:01;*12:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
TEGAFUR;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
TEGAFUR;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GIMERACIL;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*1;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*4;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*7;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*9;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
OTERACIL;CYP2A6;CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
CEFACLOR;HLA-DRB1;HLA-DRB1*14:54;*14:54;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_SEVERITY;OTHER;ALCOHOL ABUSE;;;
SULFASALAZINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SULFASALAZINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
SULFASALAZINE;HLA-B;HLA-B*56:03;*56:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SULFASALAZINE;HLA-B;HLA-B*56:03;*56:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
METOPROLOL;CYP2D6;CYP2D6*1;*1/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HEART RATE;;;
METOPROLOL;CYP2D6;CYP2D6*2;*1/*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HEART RATE;;;
METHAMPHETAMINE;DAOA;rs778293;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PSYCHOTIC DISORDER ;;
CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANAPHYLAXIS;;;
CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*20;*20;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*20;*20;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*37;*37;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*37;*37;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ANGINA PECTORIS;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*37;*37;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*37;*37;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ANGINA PECTORIS;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
SORAFENIB;KDR;rs2071559;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
ATORVASTATIN;SLCO1B1;SLCO1B1*14;*14;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
SIMVASTATIN;SLCO1B1;SLCO1B1*14;*14;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
TACROLIMUS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RISK;nan;DISEASE;HYPOKALEMIA ;;
RISPERIDONE;ADRB2;rs1042713;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEXUAL ADVERSE EVENTS;;;
BECLOMETHASONE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
BECLOMETHASONE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
BUDESONIDE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
BUDESONIDE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
FLUTICASONE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
FLUTICASONE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
MOMETASONE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
MOMETASONE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
NICOTINE;CYP2A6;CYP2A6*1;*1/*1x2;TOXICITY;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
NICOTINE;CYP2A6;CYP2A6*1x2;*1/*1x2;TOXICITY;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
CYTARABINE;GLI1;rs2228224;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CYTARABINE;ARHGAP9;rs2229300;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CYTARABINE;ARHGAP9;rs2229300;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CYTARABINE;GLI1;rs2229300;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CYTARABINE;GLI1;rs2229300;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CODEINE;ABCB1;rs1128503;A;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS;;;
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
LEUCOVORIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
SORAFENIB;KDR;rs1870377;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CODEINE;ABCB1;rs2032582;AA;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;CNS DEPRESSION;;;
CODEINE;ABCB1;rs1045642;A;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
RESPIRATORY SYSTEM;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
RESPIRATORY SYSTEM;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
RESPIRATORY SYSTEM;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
nan;CELSR2;rs602633;T;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL;;;
nan;PSRC1;rs602633;T;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL;;;
COCAINE;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
COCAINE;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
COCAINE;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ETHANOL;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
ETHANOL;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
ETHANOL;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOIDS;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
OPIOIDS;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
OPIOIDS;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
INDINAVIR;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
INDINAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
PHENPROCOUMON;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PHENPROCOUMON;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
METHOTREXATE;SLCO1B1;rs4149081;G;OTHER, LADME-PK;INCREASED_PK;METABOLISM;CLEARANCE;;;
BETA BLOCKING AGENTS;GRK5;rs2230345;AA;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
VALPROIC ACID;SCN1A;rs10167228;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE;;;
TACROLIMUS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RISK;nan;DISEASE;TRANSPLANT REJECTION ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
CLOPIDOGREL;CYP2C19;CYP2C19*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
MIRTAZAPINE;CYP2D6;CYP2D6*1;*4/*4 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*4;*4/*4 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE;;;
MIRTAZAPINE;CYP2D6;CYP2D6*6;*4/*4 + *4/*6;LADME-PK;INCREASED_PK;METABOLISM;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE;;;
TROGLITAZONE;nan;rs10811661;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BETA CELL FUNCTION;;;
PLATINUM COMPOUNDS;ERCC2;rs1799793;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
NEVIRAPINE;CYP2B6;rs3745274;T;LADME-PK;INCREASED_LIKELIHOOD;OTHER;PLASMA LEVEL;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*3;LADME-PK;DECREASED_PK;METABOLISM;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM;;;
CITALOPRAM;CYP2C19;CYP2C19*3;*3;LADME-PK;DECREASED_PK;METABOLISM;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM;;;
METHAMPHETAMINE;PICK1;rs713729;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
IMATINIB;ABCG2;rs2231142;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;EXANTHEMA;;;
CAFFEINE;DRD2;rs1110976;GG;OTHER;DECREASED_;SIDE_EFFECT;ANXIETY;;;
OPIOIDS;nan;rs4530637;AG + GG;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
NEVIRAPINE;ABCB1;rs1045642;A;TOXICITY;DECREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
COCAINE;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
COCAINE;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
COCAINE;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ETHANOL;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
ETHANOL;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
ETHANOL;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOIDS;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
OPIOIDS;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
OPIOIDS;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
nan;nan;rs1111875;C;LADME-PK;DECREASED_PK;METABOLISM;INSULIN SECRETION AT BASELINE;;;
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
FLUOXETINE;CYP2D6;CYP2D6*1;*4 + *6;LADME-PK;INCREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE;;;
FLUOXETINE;CYP2D6;CYP2D6*4;*4 + *6;LADME-PK;INCREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE;;;
FLUOXETINE;CYP2D6;CYP2D6*6;*4 + *6;LADME-PK;INCREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE;;;
OPIOIDS;TACR3;rs1384401;AG + GG;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
CISPLATIN;COMT;rs4646316;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
FOLFIRI;ABCC2;rs2273697;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE;;;
CITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE;;;
CITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE;;;
PLATINUM COMPOUNDS;SLC22A2;rs316003;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PLATINUM COMPOUNDS;SLC22A2;rs316003;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;ABCC2;rs717620;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*4/*4;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
METHAMPHETAMINE;PICK1;rs713729;T;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;RECURRENCE;;;
OPIOIDS;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
FOLFIRI;ABCC2;rs1885301;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO;;;
CITALOPRAM;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO;;;
ESCITALOPRAM;CYP2C19;CYP2C19*1;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO;;;
ESCITALOPRAM;CYP2C19;CYP2C19*2;*1/*2;LADME-PK;INCREASED_PK;METABOLISM;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO;;;
OPIOIDS;DRD3;rs6280;CC + CT;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
HYDROCHLOROTHIAZIDE;nan;rs17137967;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;FASTING GLUCOSE;;;
nan;CYP2A6;CYP2A6*1;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;OTHER;DECREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
nan;CYP2A6;CYP2A6*4;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;OTHER;DECREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
nan;CYP2A6;CYP2A6*7;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;OTHER;DECREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
nan;CYP2A6;CYP2A6*9;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;OTHER;DECREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
OPIOIDS;DRD3;rs324029;AA + AG;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;BREAST TENDERNESS, VAGINAL DRYNESS, VOMITING, ;;
OPIOIDS;EXOC4;rs718656;TT;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ETHAMBUTOL;NAT2;rs4646244;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
ISONIAZID;NAT2;rs4646244;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
PYRAZINAMIDE;NAT2;rs4646244;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
RIFAMPIN;NAT2;rs4646244;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
AMISULPRIDE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
AMISULPRIDE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
CLOZAPINE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
CLOZAPINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
HALOPERIDOL;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
HALOPERIDOL;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
OLANZAPINE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
OLANZAPINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
QUETIAPINE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
QUETIAPINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ZIPRASIDONE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ZIPRASIDONE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
NICOTINE;CHRNB2;rs2072660;T;OTHER;INCREASED_SEVERITY;nan;DISEASE;TOBACCO USE DISORDER ;;
DIRECT ACTING ANTIVIRALS;IFNL4;rs11322783;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PLATINUM COMPOUNDS;APLF;rs3213239;CCGG/CCGG + CCGG/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;APLF;rs3213239;CCGG/CCGG + CCGG/del;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;GG;;SIDE_EFFECT;EFFICACY;LACK OF TREATMENT RESPONSE;;;
RIBAVIRIN;IFNL3;rs8099917;GG;;SIDE_EFFECT;EFFICACY;LACK OF TREATMENT RESPONSE;;;
ATAZANAVIR;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ATAZANAVIR;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PLATINUM COMPOUNDS;ERCC2;rs50872;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM COMPOUNDS;ABCG2;rs1448784;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ETHAMBUTOL;NAT2;rs1799930;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
ISONIAZID;NAT2;rs1799930;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
PYRAZINAMIDE;NAT2;rs1799930;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
RIFAMPIN;NAT2;rs1799930;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;HEPATITIS ;;
NICOTINE;CHRNB2;rs2072661;A;OTHER;INCREASED_SEVERITY;nan;DISEASE;TOBACCO USE DISORDER ;;
CODEINE;CYP2D6;CYP2D6*1;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*3;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*4;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
HYDROCODONE;CYP2D6;CYP2D6*1;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
HYDROCODONE;CYP2D6;CYP2D6*3;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
HYDROCODONE;CYP2D6;CYP2D6*4;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
OXYCODONE;CYP2D6;CYP2D6*1;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
OXYCODONE;CYP2D6;CYP2D6*3;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
OXYCODONE;CYP2D6;CYP2D6*4;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*1 + *1/*28;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*1 + *1/*28;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
BOCEPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
BOCEPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
HYDROXYCHLOROQUINE;CYP2C8;rs10882526;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs660652;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOBACCO USE DISORDER ;;
METHAMPHETAMINE;nan;rs1421292;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PSYCHOTIC DISORDER ;;
ACE INHIBITORS;ABO;rs495828;GT + TT;TOXICITY;nan;nan;DISEASE;COUGH ;;
PLAIN;ABO;rs495828;GT + TT;TOXICITY;nan;nan;DISEASE;COUGH ;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
CLOMIPRAMINE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
CLOMIPRAMINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
DOXEPIN;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
DOXEPIN;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
IMIPRAMINE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
IMIPRAMINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
MAPROTILINE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
MAPROTILINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
OPIPRAMOL;CYP2D6;CYP2D6*1;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
OPIPRAMOL;CYP2D6;CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
GLICLAZIDE;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EFFICACY AS MEASURED BY DECREASE IN HBA1C;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1 + *17;EFFICACY;DECREASED_;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1 + *17;EFFICACY;DECREASED_;OTHER;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1 + *17;EFFICACY;DECREASED_;OTHER;PLATELET REACTIVITY;;;
PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE;;;
OPIOIDS;ZNF804A;rs7597593;CC;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1;*4/*4;LADME-PK;DECREASED_PK;METABOLISM;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_PK;METABOLISM;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE;;;
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA3;rs1051730;AA;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
HYDROXYCHLOROQUINE;CYP3A5;rs776746;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
PLATINUM COMPOUNDS;IL16;rs7170924;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
INDOMETHACIN;CYP2C9;CYP2C9*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
INDOMETHACIN;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
nan;CHRNA3;rs1051730;AA + AG;OTHER;INCREASED_LIKELIHOOD;OTHER;NON-SMALL CELL LUNG CARCINOMA;;;
NEVIRAPINE;HLA-B;HLA-B*15:10;*15:10;TOXICITY;DECREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ASPIRIN;TBXA2R;rs1131882;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
OPIOIDS;CNR1;rs2023239;TT;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
nan;NQO1;rs1800566;AA;OTHER;nan;OTHER;SIGNIFICANTLY SHORTER SURVIVAL;;;
BUSULFAN;CYP2C9;CYP2C9*1;*2 + *3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO;;;
BUSULFAN;CYP2C9;CYP2C9*2;*2 + *3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO;;;
BUSULFAN;CYP2C9;CYP2C9*3;*2 + *3;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO;;;
PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METFORMIN;SLC29A4;rs3889348;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
nan;NQO1;rs1800566;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKEMIA ;;
HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTT1;GSTT1 null;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
OPIOIDS;CNR1;rs6928499;CC;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*2;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
NEVIRAPINE;CYP2B6;rs58425034;CC + CG;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_;nan;DISEASE;EVENT-FREE SURVIVAL, OVERALL SURVIVAL ;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
DOCETAXEL;CHST3;rs4148945;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;CHST3;rs4148945;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
"""FOLIC ACID""";MTHFR;rs1801133;AG + GG;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;PAIN ;;
"""VITAMIN B-COMPLEX";MTHFR;rs1801133;AG + GG;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;PAIN ;;
"PLAIN""";MTHFR;rs1801133;AG + GG;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;PAIN ;;
CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
DOCETAXEL;SLC10A2;rs2301159;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;SLC10A2;rs2301159;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
AXITINIB;HIF1A;rs11549465;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SORAFENIB;HIF1A;rs11549465;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DISEASE PROGRESSION;;;
IRINOTECAN;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DISEASE PROGRESSION;;;
LEUCOVORIN;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DISEASE PROGRESSION;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*6/*6;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
METHOTREXATE;SLC19A1;rs1051266;CC + CT;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;RHEUMATOID ARTHRITIS ;;
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
NICOTINE;DBH;rs77905;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
METHOTREXATE;ADORA2A;rs2298383;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*2;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*5/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2;OTHER;INCREASED_LIKELIHOOD;OTHER;PLATELET AGGREGATION WITH ADP;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2;OTHER;INCREASED_LIKELIHOOD;OTHER;PLATELET AGGREGATION WITH ADP;;;
RISPERIDONE;CYP2D6;rs3892097;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
RISPERIDONE;CYP2D6;rs3892097;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREMOR;;;
RISPERIDONE;CYP2D6;rs3892097;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCLE RIGIDITY;;;
nan;CYP2B6;rs3211371;TT;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
nan;CYP2B6;rs3211371;CT;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*3 + *4 + *5 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*3 + *4 + *5 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*3 + *4 + *5 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;PSYCHOMOTOR AGITATION;;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;PSYCHOMOTOR AGITATION;;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
IRINOTECAN;UGT1A1;rs4124874;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
nan;CYP24A1;rs2762939;C;OTHER;DECREASED_RISK;nan;DISEASE;CORONARY ARTERY DISEASE ;;
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs16969968;A;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*2 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE OUTCOME;;;
WARFARIN;CYP2C9;CYP2C9*2;*1/*2 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE OUTCOME;;;
WARFARIN;CYP2C9;CYP2C9*3;*1/*2 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE OUTCOME;;;
MORPHINE;ABCC3;rs739923;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOVENTILATION;;;
CITALOPRAM;PAPLN;rs11628713;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
WARFARIN;CYP2C9;CYP2C9*1;*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER ANTI-COAGULATION;;;
WARFARIN;CYP2C9;CYP2C9*2;*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER ANTI-COAGULATION;;;
SULFONAMIDES;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EFFICACY AS MEASURED BY DECREASE IN HBA1C AFTER 6-MONTH TREATMENT;;;
UREA DERIVATIVES;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EFFICACY AS MEASURED BY DECREASE IN HBA1C AFTER 6-MONTH TREATMENT;;;
FLUOXETINE;CYP2D6;CYP2D6*1;*1/*1xN;LADME-PK;DECREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE;;;
FLUOXETINE;CYP2D6;CYP2D6*1xN;*1/*1xN;LADME-PK;DECREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE;;;
IMATINIB;SLC22A1;rs1867351;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIORBITAL EDEMA;;;
FLUOROURACIL;ERCC2;rs13181;GG + GT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
LEUCOVORIN;ERCC2;rs13181;GG + GT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
VERAPAMIL;KCNIP1;rs11739136;CT + TT;;SIDE_EFFECT;EFFICACY;EARLIER ACHIEVEMENT OF BLOOD PRESSURE CONTROL;;;
VERAPAMIL;KCNMB1;rs11739136;CT + TT;;SIDE_EFFECT;EFFICACY;EARLIER ACHIEVEMENT OF BLOOD PRESSURE CONTROL;;;
OPIOIDS;DRD3;rs9288993;AG + GG;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
PEGINTERFERON ALFA-2A;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
OSIMERTINIB;CYP2C9;rs1057910;AC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OPIOIDS;DRD3;rs2654754;AG + GG;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOIDS;ZNF568;rs10405238;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;ZNF568;rs10405238;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
ANTIEPILEPTICS;HLA-B;HLA-B*53:01;*53:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
PENICILLIN G;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
APIXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
DABIGATRAN;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
EDOXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
RIVAROXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
METFORMIN;AMHR2;rs784892;G;LADME-PK;DECREASED_PK;METABOLISM;METFORMIN SECRETORY CLEARANCE;;;
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED AREA UNDER THE CURVE (AUC6-12) OF MYCOPHENOLIC ACID (MPA);;;
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer;;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*9;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*9;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*9;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*9;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*13;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*13;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*13;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*13;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
OPIOIDS;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *4;OTHER;INCREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *4;OTHER;INCREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
CLOPIDOGREL;CYP2C19;CYP2C19*4;*2 + *4;OTHER;INCREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
CLOPIDOGREL;CYP2C19;CYP2C19*17;*2 + *4;OTHER;INCREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*8;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*8;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR);;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR);;;
ATEZOLIZUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THYROTOXICOSIS;;;
ATEZOLIZUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTHYROIDISM;;;
DURVALUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THYROTOXICOSIS;;;
DURVALUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTHYROIDISM;;;
IPILIMUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THYROTOXICOSIS;;;
IPILIMUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTHYROIDISM;;;
NIVOLUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THYROTOXICOSIS;;;
NIVOLUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTHYROIDISM;;;
PEMBROLIZUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THYROTOXICOSIS;;;
PEMBROLIZUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTHYROIDISM;;;
CARBOPLATIN;RRM1;rs9937;GG;TOXICITY;RISK;nan;DISEASE;HEMATOLOGIC DISORDER ;;
GEMCITABINE;RRM1;rs9937;GG;TOXICITY;RISK;nan;DISEASE;HEMATOLOGIC DISORDER ;;
ETHANOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_SEVERITY;OTHER;ALCOHOL ABUSE;;;
METFORMIN;SLC22A1;rs628031;A;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
OPIOIDS;GABRB3;rs4906902;AA;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*4;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA NORTRIPTYLINE;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA NORTRIPTYLINE;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*10;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA NORTRIPTYLINE;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*10;*10;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA NORTRIPTYLINE;;;
BECLOMETHASONE DIPROPIONATE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
BECLOMETHASONE DIPROPIONATE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EMERGENCIES;;;
BECLOMETHASONE DIPROPIONATE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
BECLOMETHASONE DIPROPIONATE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EMERGENCIES;;;
FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EMERGENCIES;;;
FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STATUS ASTHMATICUS;;;
FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EMERGENCIES;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1;*1/*3 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*2;*1/*3 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT;;;
AMITRIPTYLINE;CYP2C19;CYP2C19*3;*1/*3 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT;;;
MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;AA;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED AREA UNDER THE CURVE (AUC6-12) OF MYCOPHENOLIC ACID (MPA);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL3;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL4;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ISONIAZID;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
RIFAMPIN;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ETHANOL;DRD2;rs1799732;GG;TOXICITY;INCREASED_SEVERITY;OTHER;ALCOHOL ABUSE;;;
SALBUTAMOL;THRB;rs892940;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (BDR);;;
OPIOIDS;TACR1;rs735668;AA;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1xN;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*2;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*7;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*9;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*35;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
ASPIRIN;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;THROMBOTIC DISEASE;;;
APIXABAN;APOB;rs13306198;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
DABIGATRAN;APOB;rs13306198;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
EDOXABAN;APOB;rs13306198;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
RIVAROXABAN;APOB;rs13306198;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1xN;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1xN;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*3;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*3;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*4;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*4;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*5;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*1xN;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
TAMOXIFEN;CYP2D6;CYP2D6*1xN;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
TAMOXIFEN;CYP2D6;CYP2D6*3;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
TAMOXIFEN;CYP2D6;CYP2D6*4;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
TAMOXIFEN;CYP2D6;CYP2D6*5;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
TAMOXIFEN;CYP2D6;CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*1;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*1;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
OPIOIDS;OPRM1;rs510769;CC;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
FIRST-GENERATION CEPHALOSPORINS;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
FOURTH-GENERATION CEPHALOSPORINS;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
OTHER CEPHALOSPORINS;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
THIRD-GENERATION CEPHALOSPORINS;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
AMOXICILLIN;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
"""METFORMIN""";SLC22A1;rs72552763;GAT/del;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
"""SULFONAMIDES";SLC22A1;rs72552763;GAT/del;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
"UREA DERIVATIVES""";SLC22A1;rs72552763;GAT/del;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ETHAMBUTOL;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
PYRAZINAMIDE;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEPATOTOXICITY;;;
ISONIAZID;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*6;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*7;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
FIRST-GENERATION CEPHALOSPORINS;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
FOURTH-GENERATION CEPHALOSPORINS;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
OTHER CEPHALOSPORINS;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
THIRD-GENERATION CEPHALOSPORINS;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
FIRST-GENERATION CEPHALOSPORINS;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
FOURTH-GENERATION CEPHALOSPORINS;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
OTHER CEPHALOSPORINS;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
THIRD-GENERATION CEPHALOSPORINS;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISCONTINUATION;;;
NICOTINE;CYP2A13;rs72552266;CT;TOXICITY;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*1;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*1;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1;*1/*3 + *1/*6 + *3/*3 + *3/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;CYSTITIS;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*3;*1/*3 + *1/*6 + *3/*3 + *3/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;CYSTITIS;;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;CYSTITIS;;;
nan;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_LIKELIHOOD;OTHER;GILBERT SYNDROME;;;
nan;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_LIKELIHOOD;OTHER;CRIGLER-NAJJAR SYNDROME;;;
DOXORUBICIN;GSTT1;GSTT1 non-null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;GSTT1;GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BULLOUS PEMPHIGOID;;;
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;GRAFT VS HOST DISEASE;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*6 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*6;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*6 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
FOLFIRI;UGT1A1;UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*6;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28 + *1/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *1/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
SUNITINIB;KDR;rs1870377;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*28 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*6;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
MIRABEGRON;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MIRABEGRON;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
MIRABEGRON;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INSOMNIA;;;
MIRABEGRON;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
MIRABEGRON;SLCO1B1;SLCO1B1 deficiency;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MIRABEGRON;SLCO1B1;SLCO1B1 deficiency;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
MIRABEGRON;SLCO1B1;SLCO1B1 deficiency;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INSOMNIA;;;
MIRABEGRON;SLCO1B1;SLCO1B1 deficiency;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer;;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
METHOTREXATE;MTR;rs3768142;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES;;;
PURINE ANALOGUES;TPMT;TPMT*1;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES;;;
PURINE ANALOGUES;TPMT;TPMT*3A;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES;;;
PURINE ANALOGUES;TPMT;TPMT*3C;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES;;;
CISPLATIN;GSTT1;GSTT1 non-null;non-null;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEARING LOSS;;;
CISPLATIN;GSTT1;GSTT1 null;non-null;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEARING LOSS;;;
SULFAMETHOXAZOLE;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;NAT2;NAT2*5;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;NAT2;NAT2*6;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;NAT2;NAT2*7;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;NAT2;NAT2*16;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
TRIMETHOPRIM;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
TRIMETHOPRIM;NAT2;NAT2*5;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
TRIMETHOPRIM;NAT2;NAT2*6;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
TRIMETHOPRIM;NAT2;NAT2*7;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
TRIMETHOPRIM;NAT2;NAT2*16;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
MERCAPTOPURINE;TPMT;TPMT*1;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ASPIRIN;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
ASPIRIN;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
ASPIRIN;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ASPIRIN;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
ASPIRIN;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
ASPIRIN;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
TACROLIMUS;CYP3A4;rs4646437;AG + GG;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
DIHYDROPYRIDINE DERIVATIVES;RYR3;rs877087;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEART FAILURE;;;
DIHYDROPYRIDINE DERIVATIVES;RYR3;rs877087;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
DIHYDROPYRIDINE DERIVATIVES;RYR3;rs877087;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ANGINA PECTORIS;;;
nan;CYP4A11;rs1126742;AG + GG;LADME-PK;DECREASED_PK;METABOLISM;HDL-C CONCENTRATION;;;
CODEINE;CYP2D6;CYP2D6*1;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*1x2;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*2;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*2x2;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*2xN;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*4;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*9;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*10;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*41;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CODEINE;CYP2D6;CYP2D6*41x2;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
TICAGRELOR;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*17 + *3/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
TICAGRELOR;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*17 + *3/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
TICAGRELOR;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*17 + *3/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
TICAGRELOR;CYP2C19;CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
PEMETREXED;SLC19A1;rs914232;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*6 + *28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*6 + *28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*6 + *28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
FLUOROURACIL;UGT1A1;UGT1A1*1;*1/*28 + *28/*28 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;UGT1A1;UGT1A1*6;*1/*28 + *28/*28 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;UGT1A1;UGT1A1*28;*1/*28 + *28/*28 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*28 + *28/*28 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*1/*28 + *28/*28 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*1/*28 + *28/*28 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
CITALOPRAM;CYP2C19;CYP2C19*1;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT);;;
CITALOPRAM;CYP2C19;CYP2C19*2;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT);;;
CITALOPRAM;CYP2C19;CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED_PK;METABOLISM;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT);;;
PEMETREXED;SLC19A1;rs1051298;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RISPERIDONE;CYP2C19;CYP2C19*1;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
RISPERIDONE;CYP2C19;CYP2C19*1;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCLE SPASM;;;
RISPERIDONE;CYP2C19;CYP2C19*1;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
RISPERIDONE;CYP2C19;CYP2C19*1;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
RISPERIDONE;CYP2C19;CYP2C19*2;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
RISPERIDONE;CYP2C19;CYP2C19*2;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCLE SPASM;;;
RISPERIDONE;CYP2C19;CYP2C19*2;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
RISPERIDONE;CYP2C19;CYP2C19*2;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
RISPERIDONE;CYP2C19;CYP2C19*4;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
RISPERIDONE;CYP2C19;CYP2C19*4;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCLE SPASM;;;
RISPERIDONE;CYP2C19;CYP2C19*4;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
RISPERIDONE;CYP2C19;CYP2C19*4;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
CETUXIMAB;FCGR2A;rs1801274;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
AMOXICILLIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
AMPICILLIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
BACAMPICILLIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
METHAMPHETAMINE;DRD3;rs6280;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;COGNITIVE DISORDER;;;
NICOTINE;CYP2A6;CYP2A6 low activity;;OTHER;DECREASED_RISK;nan;DISEASE;LUNG NEOPLASMS ;;
VINCRISTINE;ACTN1;rs2268979;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CAPECITABINE;UPB1;rs2070474;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MUCOSITIS;;;
FLUOROURACIL;UPB1;rs2070474;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MUCOSITIS;;;
PEMETREXED;MTHFR;rs1801133;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CAPECITABINE;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CAPECITABINE;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
CAPECITABINE;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STOMATITIS;;;
CAPECITABINE;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
FLUOROURACIL;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STOMATITIS;;;
FLUOROURACIL;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FOLFIRI;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STOMATITIS;;;
FOLFIRI;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FOLFIRINOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRINOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
FOLFIRINOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STOMATITIS;;;
FOLFIRINOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FOLFOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
FOLFOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STOMATITIS;;;
FOLFOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
VINCRISTINE;PAPPA;rs12235805;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CAPECITABINE;UPB1;rs2070474;GG;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
FLUOROURACIL;UPB1;rs2070474;GG;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
CAPECITABINE;DPYD;rs1801265;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
FLUOROURACIL;DPYD;rs1801265;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
PEMETREXED;SLC19A1;rs3788189;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
NICOTINE;ANKK1;rs1800497;AA + AG;TOXICITY;DECREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
NICOTINE;DRD2;rs1800497;AA + AG;TOXICITY;DECREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
CAPECITABINE;DPYD;DPYD c.1129-5923C>G;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CAPECITABINE;DPYD;c.1236G>A (HapB3);c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CAPECITABINE;DPYD;DPYD c.1679T>G (*13);c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CAPECITABINE;DPYD;DPYD c.2846A>T;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FLUOROURACIL;DPYD;DPYD c.1129-5923C>G;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FLUOROURACIL;DPYD;c.1236G>A (HapB3);c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FLUOROURACIL;DPYD;DPYD c.1679T>G (*13);c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FLUOROURACIL;DPYD;DPYD c.2846A>T;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FOLFOX;DPYD;DPYD c.1129-5923C>G;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FOLFOX;DPYD;c.1236G>A (HapB3);c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FOLFOX;DPYD;DPYD c.1679T>G (*13);c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FOLFOX;DPYD;DPYD c.2846A>T;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ANTIDEPRESSANTS;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CLOMIPRAMINE;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CLOMIPRAMINE;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CLOMIPRAMINE;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CLOMIPRAMINE;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
DESIPRAMINE;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
DESIPRAMINE;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
DESIPRAMINE;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
DESIPRAMINE;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOXETINE;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOXETINE;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOXETINE;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOXETINE;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMIPRAMINE;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMIPRAMINE;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMIPRAMINE;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMIPRAMINE;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
NORTRIPTYLINE;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PAROXETINE;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PAROXETINE;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PAROXETINE;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PAROXETINE;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
VENLAFAXINE;CYP2D6;CYP2D6*3;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
VENLAFAXINE;CYP2D6;CYP2D6*4;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
VENLAFAXINE;CYP2D6;CYP2D6*5;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
VENLAFAXINE;CYP2D6;CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
SIROLIMUS;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOTAL CHOLESTEROL;;;
FOLFIRI;UGT1A1;UGT1A1*1;*28/*28 + *1/*28 + *1/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*6;*28/*28 + *1/*28 + *1/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*28/*28 + *1/*28 + *1/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *1/*28 + *1/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*28/*28 + *1/*28 + *1/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *1/*28 + *1/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*1;*1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*6;*1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*6;*1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;UGT1A1;UGT1A1*28;*1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
VINCRISTINE;NRG3;rs12253008;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*28/*28 + *6/*6 + *6/*28;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*6;*28/*28 + *6/*6 + *6/*28;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*28;*28/*28 + *6/*6 + *6/*28;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*3B;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3B;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
MERCAPTOPURINE;TPMT;TPMT intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
METHOTREXATE;TPMT;TPMT intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
VINCRISTINE;LRRTM3;rs10997459;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
AZATHIOPRINE;TPMT;TPMT*1;*1/*3A + *1/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
AZATHIOPRINE;TPMT;TPMT*3A;*1/*3A + *1/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
AZATHIOPRINE;TPMT;TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
VINCRISTINE;ARHGAP5;rs8006511;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
MERCAPTOPURINE;TPMT;TPMT normal metabolizer;;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
METHOTREXATE;TPMT;TPMT normal metabolizer;;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
NICOTINE;CYP2A6;rs28399433;CC;TOXICITY;DECREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
VINCRISTINE;METTL8;rs79802223;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HEART FAILURE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HEART FAILURE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DEATH;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HEART FAILURE;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
nan;UGT1A1;rs4148325;CT;LADME-PK;DECREASED_LIKELIHOOD;OTHER;NEONATAL HYPERBILIRUBINEMIA;;;
nan;UGT1A1;rs11888492;G;LADME-PK;DECREASED_LIKELIHOOD;OTHER;NEONATAL HYPERBILIRUBINEMIA;;;
NALOXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;CORTISOL RESPONSE;;;
CISPLATIN;CERS6;rs13022792;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY;;;
CISPLATIN;TLR4;rs10759932;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY;;;
VINCRISTINE;NFIB;rs10961381;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
ANTIARRHYTHMICS;nan;rs10033464;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE;;;
CLASS I AND III;nan;rs10033464;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE;;;
VINCRISTINE;MCM3AP;rs1815857;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
VINCRISTINE;SPDYA;rs12474420;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
VINCRISTINE;PDE4D;rs12658429;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
VINCRISTINE;FBN2;rs12656510;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
VINCRISTINE;VTI1A;rs17129858;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
VINCRISTINE;ZFAND3;rs200858088;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
ANTIINFLAMMATORY AGENTS;HLA-DRB1;HLA-DRB1*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANAPHYLAXIS;;;
NON-STEROIDS;HLA-DRB1;HLA-DRB1*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANAPHYLAXIS;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL VASCULAR DISEASES;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL VASCULAR DISEASES;;;
MYCOPHENOLATE MOFETIL;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;VIRUS DISEASES;;;
MYCOPHENOLATE MOFETIL;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;VIRUS DISEASES;;;
PREDNISONE;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;VIRUS DISEASES;;;
PREDNISONE;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;VIRUS DISEASES;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1 + *1/*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;VIRUS DISEASES;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*1 + *1/*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;VIRUS DISEASES;;;
SIROLIMUS;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LOW-DENSITY LIPOPROTEIN CHOLESTEROL;;;
ACETAMINOPHEN;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;CONSTIPATION;;;
CODEINE;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;CONSTIPATION;;;
RASBURICASE;G6PD;G6PD deficiency;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMOLYTIC ANEMIA;;;
NEVIRAPINE;CYP2B6;CYP2B6*1;*1/*6 + *6/*6;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NEVIRAPINE;CYP2B6;CYP2B6*6;*1/*6 + *6/*6;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
SIROLIMUS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TRIGLYCERIDES;;;
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ATRIAL FIBRILLATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ATRIAL FIBRILLATION;;;
CLOPIDOGREL;CYP2C19;CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ATRIAL FIBRILLATION;;;
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ISONIAZID;NAT2;NAT2*5;*5/*7 + *5/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*6;*5/*7 + *5/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*7;*5/*7 + *5/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DECREASED GLOMERULAR FILTRATION RATE;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*1/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DECREASED GLOMERULAR FILTRATION RATE;;;
ADALIMUMAB;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
AMIODARONE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
BEVACIZUMAB;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
BICALUTAMIDE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
CARBOPLATIN;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
CYCLOPHOSPHAMIDE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
DOCETAXEL;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
ERLOTINIB;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
EVEROLIMUS;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
FLUOROURACIL;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
GEFITINIB;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
GEMCITABINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
IRINOTECAN;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
LEUCOVORIN;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
METHOTREXATE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
OXALIPLATIN;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
PACLITAXEL;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
PEMBROLIZUMAB;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
SITAGLIPTIN;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
TEGAFUR;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
GIMERACIL;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
OTERACIL;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
TRASTUZUMAB;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
TAMSULOSIN;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES;;;
ANASTROZOLE;CCDC148;rs79048288;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
EXEMESTANE;CCDC148;rs79048288;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
LETROZOLE;CCDC148;rs79048288;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ERYTHEMA MULTIFORME;;;
PEMETREXED;DHFR;rs1650697;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
TACROLIMUS;CYP3A5;CYP3A5*6;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
TACROLIMUS;CYP3A5;CYP3A5*7;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
TACROLIMUS;CYP2C8;CYP2C8*1;*1/*1;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
TACROLIMUS;CYP2C8;CYP2C8*3;*1/*1;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
FLUOROURACIL;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
FOLFIRI;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FOLFIRI;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
FOLFOX;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFOX;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FOLFOX;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
LACOSAMIDE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
LACOSAMIDE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
LACOSAMIDE;CYP2C19;CYP2C19*1;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
LACOSAMIDE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
LACOSAMIDE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
LACOSAMIDE;CYP2C19;CYP2C19*2;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
LACOSAMIDE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
LACOSAMIDE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
LACOSAMIDE;CYP2C19;CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
FOLFIRI;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFIRI;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FOLFIRI;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
FOLFOX;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FOLFOX;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FOLFOX;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ASPIRIN;PTGS2;rs12042763;GG;EFFICACY;DECREASED_RISK;nan;DISEASE;PROSTATIC NEOPLASMS ;;
METHOTREXATE;SLCO1B1;SLCO1B1*1;*37/*37 + *37/*15;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
METHOTREXATE;SLCO1B1;SLCO1B1*15;*37/*37 + *37/*15;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
METHOTREXATE;SLCO1B1;SLCO1B1*37;*37/*37 + *37/*15;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
nan;CYP2A6;rs56267346;G;OTHER;DECREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
nan;DBH;rs6479643;C;OTHER;DECREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
ETHAMBUTOL;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*4;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ETHAMBUTOL;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*4;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*4;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*4;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*6;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*7;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*1;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*4;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*5;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*6;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*7;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*14;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;NAT2*16;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
FLURBIPROFEN;UGT1A1;UGT1A1*1;*1/*36;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLURBIPROFEN;UGT1A1;UGT1A1*36;*1/*36;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*1;*1/*36;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;UGT1A1*36;*1/*36;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ISONIAZID;NAT2;NAT2*1;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*5;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*6;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*7;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*1;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*5;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*6;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*7;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TACROLIMUS;CYP3A5;CYP3A5*1;*3/*3;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
IRINOTECAN;UGT1A1;rs4148323;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
nan;CASP9;rs1052576;T;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOCYTOSIS;;;
CAPECITABINE;DPYD;rs1801265;AA + AG;TOXICITY;DECREASED_;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs1801265;AA + AG;TOXICITY;DECREASED_;SIDE_EFFECT;DRUG TOXICITY;;;
IRINOTECAN;UGT1A1;rs4148323;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOSPORINE;SLC19A1;rs1051266;CC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;SLC19A1;rs1051266;CC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CYCLOSPORINE;ATIC;rs17514110;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;ATIC;rs17514110;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CYCLOSPORINE;NFATC2;rs3787186;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;NFATC2;rs3787186;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CYCLOSPORINE;ABCC2;rs3740065;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;ABCC2;rs3740065;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CETUXIMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY;;;
CYCLOSPORINE;ABCC1;rs8058040;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;ABCC1;rs8058040;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LAMOTRIGINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ATAZANAVIR;TPH2;rs7305115;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
EFAVIRENZ;TPH2;rs7305115;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
CARBAMAZEPINE;HLA-A;HLA-A*01:02;*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
LAMOTRIGINE;HLA-A;HLA-A*01:02;*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-A;HLA-A*01:02;*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
LAMOTRIGINE;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
LAMOTRIGINE;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ATAZANAVIR;TPH2;rs1386493;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
EFAVIRENZ;TPH2;rs1386493;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LAMOTRIGINE;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CAPECITABINE;ENOSF1;rs2612091;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LAMOTRIGINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
LAMOTRIGINE;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
PHENYTOIN;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
CARBAMAZEPINE;HLA-A;HLA-A*31:03;*31:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LAMOTRIGINE;HLA-A;HLA-A*31:03;*31:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;HLA-A;HLA-A*31:03;*31:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBOPLATIN;OPRM1;rs544093;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PACLITAXEL;OPRM1;rs544093;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
MYCOPHENOLATE MOFETIL;IMPDH1;rs2228075;T;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GI INTOLERANCE;;;
CAPECITABINE;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ISONIAZID;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ERLOTINIB;USP36;rs3744797;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
GEFITINIB;USP36;rs3744797;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
OSIMERTINIB;HLA-B;HLA-B*51:02;*51:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
OSIMERTINIB;HLA-B;HLA-B*51:02;*51:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
DEXMEDETOMIDINE;CACNB2;rs10764319;CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA;;;
DEXMEDETOMIDINE;CACNB2;rs10764319;CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
DEXMEDETOMIDINE;CACNA2D2;rs2236957;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA;;;
DEXMEDETOMIDINE;CACNA2D2;rs2236957;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DEXMEDETOMIDINE;UGT2B10;rs1841042;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA;;;
DEXMEDETOMIDINE;UGT2B10;rs1841042;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
DEXMEDETOMIDINE;ADRA2B;rs3813662;AA + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA;;;
DEXMEDETOMIDINE;ADRA2B;rs3813662;AA + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
METHYLPHENIDATE;CES1;rs2307227;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
PURINE ANALOGUES;NUDT15;NUDT15*1;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
PURINE ANALOGUES;NUDT15;NUDT15*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
CLOPIDOGREL;THSD7A;rs7807369;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;nan;rs1149515;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;nan;rs1149515;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ONDANSETRON;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;POSTOPERATIVE NAUSEA AND VOMITING;;;
nan;ERAP2;rs17524572;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
PEMBROLIZUMAB;HLA-DRB1;HLA-DRB1*13:01;*13:01;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
PEMBROLIZUMAB;HLA-DPB1;HLA-DPB1*02:02;*02:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS;;;
CAPECITABINE;DPYD;rs1801158;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs1801158;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
MORPHINE;SLC22A1;rs72552763;del/del;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOVENTILATION;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 non-null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
nan;CASP9;rs4661636;C;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOCYTOSIS;;;
nan;CASP8;rs6736233;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
CLOZAPINE;LEPR;rs6657868;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PNEUMONIA;;;
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEIZURES ;;
CISPLATIN;GGT1;rs2017869;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CISPLATIN;GGT1;rs2017869;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
PACLITAXEL;GGT1;rs2017869;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
PACLITAXEL;GGT1;rs2017869;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
nan;UGT1A1;rs4148323;A;OTHER;INCREASED_LIKELIHOOD;OTHER;GILBERT SYNDROME;;;
nan;UGT1A1;rs4148323;A;OTHER;INCREASED_LIKELIHOOD;OTHER;CRIGLER-NAJJAR SYNDROME;;;
CLOZAPINE;LEPR;rs1137101;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PNEUMONIA;;;
CLOZAPINE;LEPROT;rs1137101;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PNEUMONIA;;;
DOLUTEGRAVIR;NR1I2;rs2472677;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
DOLUTEGRAVIR;NR1I2;rs2472677;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
CISPLATIN;TPMT;rs1800460;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
CLOZAPINE;LEPR;rs1805096;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PNEUMONIA;;;
CLOZAPINE;LEPR;rs9436746;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PNEUMONIA;;;
RISPERIDONE;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
nan;UGT1A1;rs35350960;A;OTHER;INCREASED_LIKELIHOOD;OTHER;GILBERT SYNDROME;;;
nan;UGT1A1;rs35350960;A;OTHER;INCREASED_LIKELIHOOD;OTHER;CRIGLER-NAJJAR SYNDROME;;;
CISPLATIN;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
WARFARIN;ASPH;rs4379440;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
CARBOPLATIN;SLCO1B3;rs7311358;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
PACLITAXEL;SLCO1B3;rs7311358;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ASPIRIN;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
TICAGRELOR;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY;;;
PEGINTERFERON ALFA-2A;ITPA;rs1127354;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS;;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS;;;
RIBAVIRIN;ITPA;rs1127354;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS;;;
HMG COA REDUCTASE INHIBITORS;CETP;rs3764261;A;EFFICACY, LADME-PK;INCREASED_LIKELIHOOD;OTHER;HDL CHOLESTEROL;;;
METHOTREXATE;ITPA;rs1127354;A;TOXICITY;nan;SIDE_EFFECT;GASTROINTESTINAL TOXICITIES;;;
GEFITINIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
PEGINTERFERON ALFA-2A;CTLA4;rs231775;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS;;;
PEGINTERFERON ALFA-2B;CTLA4;rs231775;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS;;;
RIBAVIRIN;CTLA4;rs231775;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS;;;
CAFFEINE;nan;rs4410790;T;OTHER;nan;OTHER;HABITUAL CONSUMPTION;;;
LIRAGLUTIDE;GLP1R;rs6923761;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;WEIGHT LOSS;;;
METHAMPHETAMINE;ESR1;rs2234693;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PSYCHOTIC DISORDER ;;
nan;ABCG8;rs11887534;CG;OTHER;INCREASED_RISK;nan;DISEASE;CORONARY ARTERY DISEASE ;;
PLATINUM;ERCC5;rs17655;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
PLATINUM;ERCC5;rs17655;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
RISPERIDONE;HTR2C;rs3813929;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
PACLITAXEL;FGD4;rs10771973;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SENSORY PERIPHERAL NEUROPATHY;;;
CAFFEINE;CYP1A1;rs2470893;T;OTHER;nan;OTHER;HABITUAL CONSUMPTION;;;
CITALOPRAM;SLC6A4;rs25531;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SIDE EFFECTS;;;
PEGINTERFERON ALFA-2A;SOCS3;rs4969170;AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS;;;
PEGINTERFERON ALFA-2B;SOCS3;rs4969170;AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS;;;
RIBAVIRIN;SOCS3;rs4969170;AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS;;;
MIDAZOLAM;POR;rs1057868;TT;OTHER, LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO OF MIDAZOLAM;;;
ENALAPRIL;PNPT1;rs13009649;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
METHOTREXATE;ITPA;rs1127354;A;;SIDE_EFFECT;EFFICACY;RESPONSE TO METHOTREXATE;;;
NICOTINE;HTR3B;rs11606194;CT + TT;TOXICITY;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
ASPIRIN;SLC6A12;rs499368;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ASTHMA ;;
GEFITINIB;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
WARFARIN;CYP4F2;rs2189784;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
ASPIRIN;SLC6A12;rs557881;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ASTHMA ;;
PLATINUM COMPOUNDS;WIF1;rs10878232;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTIEPILEPTICS;ABCB1;rs1045642;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;NON-RESPONSE;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
PLATINUM COMPOUNDS;WNT5B;rs12819505;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;AXIN2;rs4541111;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
MERCAPTOPURINE;PACSIN2;rs2413739;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GI TOXICITY;;;
METHOTREXATE;PACSIN2;rs2413739;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GI TOXICITY;;;
MERCAPTOPURINE;SLCO1B1;rs11045879;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GI TOXICITY;;;
MERCAPTOPURINE;ITPA;rs1127354;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
METHOTREXATE;ITPA;rs1127354;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
PLATINUM COMPOUNDS;CXXC4;rs4413407;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ENALAPRIL;PNPT1;rs13015243;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
AZATHIOPRINE;nan;rs11969064;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
MERCAPTOPURINE;nan;rs11969064;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
THIOGUANINE;nan;rs11969064;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS;;;
RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS;;;
PLATINUM COMPOUNDS;ERCC2;rs13181;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PNEUMONITIS ;;
PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PNEUMONITIS ;;
DOXORUBICIN;NCF4;rs1883112;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
AMPHETAMINE;DRD2;rs12364283;AA;EFFICACY;DECREASED_;OTHER;STOP REACTION TIME;;;
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DRUG-RESISTANCE;;;
ANTIEPILEPTICS;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DRUG-RESISTANCE;;;
PAROXETINE;HTR2A;rs6313;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATIONS DUE TO ADVERSE EVENTS AND GREATER SEVERITY OF SIDE EFFECTS;;;
CLOPIDOGREL;CD80;rs34394661;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
MYCOPHENOLATE MOFETIL;UGT1A9;rs6714486;A;LADME-PK;PK;PK;CHANGES IN MYCOPHENOLIC ACID EXPOSURE-RELATED PARAMETERS ON DAY 7 AFTER TRANSPLANTATION (TREATMENT WITH 2G PER DAY);;;
CARBAMAZEPINE;nan;rs1633021;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
PLATINUM COMPOUNDS;AXIN2;rs11868547;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
MYCOPHENOLATE MOFETIL;UGT1A9;rs17868320;T;LADME-PK;PK;PK;CHANGES IN MYCOPHENOLIC ACID EXPOSURE-RELATED PARAMETERS ON DAY 7 AFTER TRANSPLANTATION (TREATMENT WITH 2G PER DAY);;;
MORPHINE;ABCB1;rs1045642;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MORPHINE;ABCB1;rs1045642;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
CYCLOSPORINE;UGT1A8;rs1042597;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
TACROLIMUS;IL10;rs1800871;AA;LADME-PK;INCREASED_LIKELIHOODPK;PK;ACHIEVING TARGET CONCENTRATIONS;;;
METHOTREXATE;ARID5B;rs4948496;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
nan;CYP2B6;rs3760657;AA;OTHER;DECREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
FOLLITROPIN BETA;FSHR;rs6166;T;EFFICACY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION;;;
THYROTROPIN ALFA;FSHR;rs6166;T;EFFICACY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION;;;
UROFOLLITROPIN;FSHR;rs6166;T;EFFICACY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION;;;
ASPIRIN;CYP2C19;rs4244285;AA + AG;EFFICACY, OTHER;INCREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, OTHER;INCREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
nan;UGT2B10;rs11726322;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOEMBOLISM;;;
ASPIRIN;CYP2C19;rs12248560;CT + TT;EFFICACY, OTHER;DECREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY, OTHER;DECREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOEMBOLISM;;;
CLOPIDOGREL;ABCB1;rs1045642;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CAPECITABINE;TYMP;rs11479;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;TYMP;rs11479;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
WARFARIN;CYP4F2;rs2108622;CT + TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA MK-4 CONCENTRATION;;;
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CAPECITABINE;DPYD;rs75017182;CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs75017182;CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BONE MINERAL DENSITY;;;
FENOFIBRATE;PPARA;rs135543;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN FASTING LDL-C;;;
FENOFIBRATE;PPARA;rs9626730;CC + CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN FASTING IL-2;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;DECREASED_;OTHER;WARFARIN SENSITIVITY INDEX (INR/CPSS);;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;OTHER;MAJOR ADVERSE CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
FENOFIBRATE;PPARA;rs135550;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN FASTING LDL-C;;;
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;URINARY DPD/CR LEVELS;;;
EXEMESTANE;CYP19A1;rs7176005;TT;TOXICITY;nan;SIDE_EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS;;;
TACROLIMUS;PPARA;rs4253728;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ACUTE CELLULAR REJECTION;;;
VINCRISTINE;SLC5A7;rs1013940;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ETHANOL;ADH1B;rs1229984;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERURICEMIA;;;
VINCRISTINE;NKAIN3;rs10504361;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
SIMVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES;;;
ATENOLOL;PROX1;rs340874;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GLUCOSE ELEVATION;;;
TACROLIMUS;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEPSIS;;;
TACROLIMUS;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEIZURES;;;
TACROLIMUS;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
ABEMACICLIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
PALBOCICLIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
RIBOCICLIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
SIMVASTATIN;ABCG2;rs2231142;GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
VINCRISTINE;ABCC1;rs3784867;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;SIGNIFICANTLY HIGHER ON-TREATMENT PLATELET REACTIVITY WITH A MAINTENANCE DOSE OF 75 MG DAILY;;;
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
OPIOIDS;IL6;rs1800795;CG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
OPIOIDS;IL6;rs1800795;CG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;IL6;rs1800795;CG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
SUNITINIB;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ABEMACICLIB;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ABEMACICLIB;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
PALBOCICLIB;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
PALBOCICLIB;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
RIBOCICLIB;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
RIBOCICLIB;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
METOPROLOL;CYP2D6;rs1065852;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HEART RATE;;;
CONJUGATED ESTROGENS;VDR;rs1544410;TT;EFFICACY;INCREASED_SEVERITY;OTHER;SPINE BONE MINERAL DENSITY;;;
MEDROXYPROGESTERONE;VDR;rs1544410;TT;EFFICACY;INCREASED_SEVERITY;OTHER;SPINE BONE MINERAL DENSITY;;;
VERAPAMIL;CACNB2;rs2357928;GG;EFFICACY, TOXICITY;INCREASED_RISK;EVENT;ADVERSE OUTCOME;;;
METFORMIN;SLC47A1;rs2252281;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE TO METFORMIN;;;
TACROLIMUS;CYP3A5;rs4646450;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
METFORMIN;SLC47A1;rs2252281;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE TO METFORMIN;;;
TRAZODONE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PROLONGED QTC INTERVAL;;;
INTERFERONS;BCL2;rs1800477;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;FREQUENCY (ABOUT DOUBLE) IN NON-RESPONDER PATIENTS COMPARED WITH RESPONDER PATIENTS (HCV GENOTYPE 4);;;
RIBAVIRIN;BCL2;rs1800477;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;FREQUENCY (ABOUT DOUBLE) IN NON-RESPONDER PATIENTS COMPARED WITH RESPONDER PATIENTS (HCV GENOTYPE 4);;;
CETUXIMAB;KRAS;rs112445441;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;KRAS;rs112445441;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
IRINOTECAN;KRAS;rs112445441;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OXALIPLATIN;KRAS;rs112445441;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;MSH6;rs3136228;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
LEUCOVORIN;MSH6;rs3136228;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
OXALIPLATIN;MSH6;rs3136228;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
FLUOROURACIL;XRCC3;rs1799794;CC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
LEUCOVORIN;XRCC3;rs1799794;CC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
OXALIPLATIN;XRCC3;rs1799794;CC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
nan;NR1I2;rs7643645;GG;OTHER;INCREASED_RISK;OTHER;DEATH;;;
PLATINUM COMPOUNDS;CCND1;rs9344;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
PLATINUM COMPOUNDS;CCND1;rs9344;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
VERAPAMIL;CACNB2;rs11014166;AT + TT;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE OUTCOME;;;
FLUOROURACIL;ABCC1;rs2074087;C;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
LEUCOVORIN;ABCC1;rs2074087;C;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
OXALIPLATIN;ABCC1;rs2074087;C;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
FLUOROURACIL;nan;rs2960436;AA;EFFICACY;nan;OTHER;BETTER SURVIVAL OUTCOME;;;
FLUOROURACIL;ABCC2;rs1885301;AA;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
LEUCOVORIN;ABCC2;rs1885301;AA;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
OXALIPLATIN;ABCC2;rs1885301;AA;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
FLUOROURACIL;IGFBP3;rs2854744;TT;EFFICACY;nan;OTHER;BETTER SURVIVAL OUTCOME;;;
FLUOROURACIL;ABCC2;rs717620;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
LEUCOVORIN;ABCC2;rs717620;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
OXALIPLATIN;ABCC2;rs717620;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
FLUOROURACIL;ABCC2;rs3740066;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
LEUCOVORIN;ABCC2;rs3740066;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
OXALIPLATIN;ABCC2;rs3740066;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
COCAINE;DRD2;rs1125394;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COCAINE DEPENDENCE ;;
COCAINE;DRD2;rs1076560;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COCAINE DEPENDENCE ;;
COCAINE;DRD2;rs2283265;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COCAINE DEPENDENCE ;;
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149015;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG REACTIONS;;;
TACROLIMUS;CYP3A5;rs4646453;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;TT;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG REACTION;;;
OPIOIDS;COMT;rs4633;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;C;TOXICITY, LADME-PK;DECREASED_RISK;SIDE_EFFECT;ADVERSE DRUG REACTIONS;;;
ACETAMINOPHEN;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CONSTIPATION;;;
TRAMADOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CONSTIPATION;;;
OPIOIDS;COMT;rs4633;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
CAPECITABINE;ABCB1;rs1128503;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;ABCB1;rs1128503;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;OPIOID-RELATED DISORDERS ;;
CAPECITABINE;ABCB1;rs2032582;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ERECTILE DYSFUNCTION;;;
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INSOMNIA;;;
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEDATION;;;
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
FLUOROURACIL;ABCB1;rs1045642;GG;TOXICITY;DECREASED_RISK;nan;DISEASE;DIARRHEA ;;
CAPECITABINE;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
WARFARIN;CYP2C9;rs7900194;A;DOSAGE, LADME-PK;nan;OTHER;WARFARIN VARIABILITY;;;
SUNITINIB;NR1I2;rs3814055;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
AMPHETAMINE;OPRM1;rs510769;TT;OTHER;DECREASED_;OTHER;STIMULATION AND EUPHORIA SCORES AFTER AMPHETAMINE;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MUSCULAR DISEASES ;;
SUNITINIB;ABCG2;rs2231137;CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;NHLH1;rs11265375;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
BORTEZOMIB;CBS;rs915854;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
BORTEZOMIB;CBS;rs915854;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
BORTEZOMIB;CBS;rs915854;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROPATHIC PAIN;;;
nan;UGT2B15;rs3100;AA;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
AMPHETAMINE;OPRM1;rs2281617;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;EUPHORIC AND ENERGETIC AFTER AMPHETAMINE (10 MG);;;
WARFARIN;HNF4A;rs6130615;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CISPLATIN;SEMA6A;rs3806915;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ASPIRIN;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
WARFARIN;HNF4A;rs1884613;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ASPIRIN;ITGB3;rs5918;CC + CT;EFFICACY, OTHER;DECREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
CLOPIDOGREL;ITGB3;rs5918;CC + CT;EFFICACY, OTHER;DECREASED_RISK;nan;DISEASE;THROMBOTIC DISEASE ;;
WARFARIN;HNF4A;rs3212191;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ONDANSETRON;SLC6A4;rs1042173;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TREATMENT RESPONSE AMONG PATIENTS CARRYING THE SLC6A4 PROMOTER LENGTH POLYMORPHISM LONG/LONG GENOTYPE;;;
WARFARIN;nan;rs61162043;G;OTHER;INCREASED_LIKELIHOOD;OTHER;HAVING WARFARIN DOSE GREATER THAN 7.5 MG/DAY;;;
RISPERIDONE;HTR2A;rs6313;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
HEROIN;OPRM1;rs2075572;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEROIN DEPENDENCE ;;
RISPERIDONE;nan;rs1805054;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIHYPERTENSIVES;NEDD4L;rs4149601;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION;;;
ANTIHYPERTENSIVES;ADRB1;rs1801252;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION;;;
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
RISPERIDONE;HTR2C;rs3813929;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
HEROIN;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEROIN DEPENDENCE ;;
BLEOMYCIN;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
BLEOMYCIN;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
CYCLOPHOSPHAMIDE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
CYCLOPHOSPHAMIDE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
DOXORUBICIN;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
DOXORUBICIN;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
PREDNISONE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
PREDNISONE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
RITUXIMAB;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
RITUXIMAB;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
VINCRISTINE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
VINCRISTINE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
VINDESINE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
VINDESINE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
ANTIHYPERTENSIVES;CYP3A5;rs776746;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RESISTANT HYPERTENSION;;;
ANTIHYPERTENSIVES;ZSCAN25;rs776746;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RESISTANT HYPERTENSION;;;
CISPLATIN;XPC;rs2228001;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
METHADONE;OPRM1;rs1799971;G;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;RECURRENCE ;;
SUFENTANIL;CYP3A4;rs2242480;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOVENTILATION;;;
nan;ADRA2A;rs3750625;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES, GESTATIONAL ;;
nan;ADRA2A;rs11195418;G;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;DIABETES, GESTATIONAL ;;
MURAGLITAZAR;REN;rs2368564;TT;TOXICITY;DECREASED_RISK;nan;DISEASE;EDEMA ;;
CHLOROQUINE;SLCO2B1;rs12422149;GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PARASITEMIA;;;
PRIMAQUINE;SLCO2B1;rs12422149;GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PARASITEMIA;;;
ASPIRIN;IL4;rs2243250;TT;OTHER;DECREASED_;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
ANTIPSYCHOTICS;CNR1;rs806374;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TARDIVE DYSKINESIA ;;
WARFARIN;CYP2C9;rs1057910;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
METHOTREXATE;SLC16A7;rs3763980;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE TO METHOTREXATE;;;
METFORMIN;AMHR2;rs784892;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;POST-HBA1C LEVELS;;;
ACETAMINOPHEN;PLA2G4A;rs12746200;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
ASPIRIN;PLA2G4A;rs12746200;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
DICLOFENAC;PLA2G4A;rs12746200;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
PROPIONIC ACID DERIVATIVES;PLA2G4A;rs12746200;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
PYRAZOLONES;PLA2G4A;rs12746200;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
ANTIPSYCHOTICS;CNR1;rs806374;CC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TARDIVE DYSKINESIA ;;
WARFARIN;VKORC1;rs9923231;TT;;SIDE_EFFECT;EFFICACY;SHORTER TIME TO FIRST THERAPEUTIC INR AND TIME TO FIRST INR>4;;;
FLUOROURACIL;DPYD;rs75017182;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
ETHANOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ALCOHOL ABUSE ;;
NEVIRAPINE;CYCSP5;rs3099844;A;TOXICITY, OTHER;INCREASED_RISK;nan;DISEASE;STEVENS-JOHNSON SYNDROME ;;
ACETAMINOPHEN;PLCG1;rs2228246;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
ASPIRIN;PLCG1;rs2228246;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
DICLOFENAC;PLCG1;rs2228246;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
PROPIONIC ACID DERIVATIVES;PLCG1;rs2228246;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
PYRAZOLONES;PLCG1;rs2228246;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
ACETAMINOPHEN;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
ACETAMINOPHEN;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
ASPIRIN;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
ASPIRIN;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
DICLOFENAC;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
DICLOFENAC;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
PROPIONIC ACID DERIVATIVES;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
PROPIONIC ACID DERIVATIVES;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
PYRAZOLONES;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
PYRAZOLONES;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
ANTIHYPERTENSIVES;NOS3;rs1799983;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
ANTIHYPERTENSIVES;NOS3;rs2070744;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
METHOTREXATE;ABCB1;rs1045642;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
nan;ADRA2A;rs1800038;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES, GESTATIONAL ;;
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
CISPLATIN;SLC22A1;rs683369;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
NICOTINE;nan;rs4887074;G;TOXICITY;DECREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
FLUOROURACIL;ABCC5;rs10937158;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;ABCC5;rs10937158;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
LEUCOVORIN;ABCC5;rs10937158;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
FLUOROURACIL;ABCC5;rs3749438;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
IRINOTECAN;ABCC5;rs3749438;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
LEUCOVORIN;ABCC5;rs3749438;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
FLUOROURACIL;ABCG1;rs225440;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;ABCG1;rs225440;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
LEUCOVORIN;ABCG1;rs225440;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CLOPIDOGREL;PON1;rs854552;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
FLUOROURACIL;nan;rs2292997;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;nan;rs2292997;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
LEUCOVORIN;nan;rs2292997;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CISPLATIN;PPARD;rs2038067;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TACROLIMUS;CYP3A5;rs6977165;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
WARFARIN;VKORC1;rs9923231;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROPERTION OF THE FIRST 6 MONTHS' TREATMENT TIME SPENT WITHIN THE TARGET INR RANGE (PTIR);;;
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;MYELOSUPPRESSION ;;
nan;OPRM1;rs1799971;AA;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;HAND-FOOT SYNDROME ;;
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
FLUOROURACIL;DPYD;rs17376848;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
OPIOIDS;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
ACETAMINOPHEN;MIR107;rs2296616;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
TRAMADOL;MIR107;rs2296616;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
LITHIUM;GSK3B;rs334558;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE;;;
CYCLOPHOSPHAMIDE;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
CYCLOPHOSPHAMIDE;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
DOXORUBICIN;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
EPIRUBICIN;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
EPIRUBICIN;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
METHOTREXATE;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ACETAMINOPHEN;MIR23B;rs1011784;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
TRAMADOL;MIR23B;rs1011784;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
ACETAMINOPHEN;MIR23B;rs1011784;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;NEUROPATHIC PAIN;;;
TRAMADOL;MIR23B;rs1011784;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;NEUROPATHIC PAIN;;;
OPIOIDS;CYP1A2;rs2069514;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
OPIOIDS;DRD3;rs2654754;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
OPIOIDS;DRD3;rs324029;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
METHAMPHETAMINE;FAAH;rs324420;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;METHAMPHETAMINE DEPENDENCE;;;
OPIOIDS;CYP3A4;rs2740574;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
RISPERIDONE;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
ASPIRIN;UGT1A6;rs1105879;AC + CC;EFFICACY;INCREASED_RISK;nan;DISEASE;COLONIC NEOPLASMS ;;
ACETAMINOPHEN;OPRM1;rs677830;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CONSTIPATION;;;
TRAMADOL;OPRM1;rs677830;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CONSTIPATION;;;
OPIOIDS;CYP3A5;rs15524;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
REGORAFENIB;KDR;rs4864950;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
EFAVIRENZ;NR1I2;rs2472677;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEATH;;;
ETHAMBUTOL;NR1I2;rs2472677;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEATH;;;
ISONIAZID;NR1I2;rs2472677;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEATH;;;
RIFAMPIN;NR1I2;rs2472677;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEATH;;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
EFAVIRENZ;NR1I2;rs2472677;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ETHAMBUTOL;NR1I2;rs2472677;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ISONIAZID;NR1I2;rs2472677;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
RIFAMPIN;NR1I2;rs2472677;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CYCLOPHOSPHAMIDE;ABCB1;rs2032582;AA + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;ABCB1;rs2032582;AA + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
TAXANES;NR1I3;rs11584174;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ATAZANAVIR;UGT1A1;rs8330;G;OTHER;INCREASED_RISK;SIDE_EFFECT;NEPHROLITHIASIS;;;
RITONAVIR;UGT1A1;rs8330;G;OTHER;INCREASED_RISK;SIDE_EFFECT;NEPHROLITHIASIS;;;
CYCLOPHOSPHAMIDE;ABCB1;rs2032582;AC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;ABCB1;rs2032582;AC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EFAVIRENZ;CYP2B6;rs28399499;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER ;;
NEVIRAPINE;ABCB1;rs10276036;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG HYPERSENSITIVITY ;;
TAXANES;UGT2B7;rs7438284;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ATAZANAVIR;UGT1A1;rs10929303;T;OTHER;INCREASED_RISK;SIDE_EFFECT;NEPHROLITHIASIS;;;
RITONAVIR;UGT1A1;rs10929303;T;OTHER;INCREASED_RISK;SIDE_EFFECT;NEPHROLITHIASIS;;;
TAXANES;UGT2B7;rs7439366;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ATAZANAVIR;UGT1A1;rs1042640;G;OTHER;INCREASED_RISK;SIDE_EFFECT;NEPHROLITHIASIS;;;
RITONAVIR;UGT1A1;rs1042640;G;OTHER;INCREASED_RISK;SIDE_EFFECT;NEPHROLITHIASIS;;;
TAXANES;UGT2B7;rs7662029;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
TAXANES;UGT2B7;rs7668258;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER ;;
ANTIPSYCHOTICS;GRM3;rs1468412;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MEMORY IMPAIRMENT;;;
ASPIRIN;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NON-RESPONSIVENESS;;;
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NON-RESPONSIVENESS;;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
RISPERIDONE;BDNF;rs6265;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
CORTICOSTEROIDS;FCER2;rs28364072;G;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ASTHMA-RELATED ER VISIT OR HOSPITALIZATION;;;
FLUOROURACIL;CXCL8;rs4073;AA;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
RADIOTHERAPY;CXCL8;rs4073;AA;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
FLUOROURACIL;KDR;rs1870377;AA;TOXICITY;RISK;SIDE_EFFECT;MUCOSITIS;;;
RADIOTHERAPY;KDR;rs1870377;AA;TOXICITY;RISK;SIDE_EFFECT;MUCOSITIS;;;
PEGINTERFERON ALFA-2B;IL6;rs1800795;CC;TOXICITY;DECREASED_RISK;nan;DISEASE;DEPRESSION ;;
RIBAVIRIN;IL6;rs1800795;CC;TOXICITY;DECREASED_RISK;nan;DISEASE;DEPRESSION ;;
ATORVASTATIN;CYP7A1;rs3808607;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN PERCENTAGE REDUCTION OF TRIGLYCERIDES LEVEL;;;
CANGRELOR;P2RY12;rs6787801;G;OTHER;nan;OTHER;5% LOWER ADP-INDUCED PEAK PLATELET AGGREGATION IN-VITRO;;;
nan;APOC1;rs445925;A;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL;;;
nan;APOE;rs445925;A;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL;;;
SUNITINIB;FGFR2;rs2981582;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SULFAMETHOXAZOLE;NAT2;rs1799931;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
TRIMETHOPRIM;NAT2;rs1799931;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE REACTIONS;;;
SUNITINIB;FLT4;rs307826;CC + CT;EFFICACY;DECREASED_;nan;DISEASE;OVERALL SURVIVAL ;;
HEROIN;OPRM1;rs1799971;AG + GG;TOXICITY;DECREASED_RISK;nan;DISEASE;HEROIN DEPENDENCE ;;
SUNITINIB;NR1I3;rs2307424;AA + AG;EFFICACY;DECREASED_;nan;DISEASE;OVERALL SURVIVAL ;;
nan;FADS1;rs174541;T;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL;;;
nan;FEN1;rs174541;T;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL;;;
nan;MIR611;rs174541;T;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL;;;
nan;TMEM258;rs174541;T;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL;;;
nan;nan;rs258494;C;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL;;;
nan;LDLR;rs6511720;T;OTHER;PK;PK;BASELINE LDL CHOLESTEROL;;;
nan;PNMT;rs2934965;T;OTHER;DECREASED_RISK;OTHER;SICKLE CELL PAIN CRISIS;;;
FLUOROURACIL;GSTP1;rs1695;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
LEUCOVORIN;GSTP1;rs1695;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
LEVAMISOLE;GSTP1;rs1695;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RADIOTHERAPY;GSTP1;rs1695;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DEXAMETHASONE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
LENALIDOMIDE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
AZATHIOPRINE;DDRGK1;rs1127354;AC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;NON-RESPONSE;;;
AZATHIOPRINE;ITPA;rs1127354;AC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;NON-RESPONSE;;;
nan;PNMT;rs2941523;GG;OTHER;DECREASED_RISK;OTHER;SICKLE CELL PAIN CRISIS;;;
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;INCREASED_RISK;OTHER;CHRONIC LUNG ALLOGRAFT DYSFUNCTION;;;
nan;PNMT;rs876493;AA + AG;OTHER;DECREASED_RISK;OTHER;SICKLE CELL PAIN CRISIS;;;
ATENOLOL;ACY3;rs2514036;C;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
ATENOLOL;ACY3;rs2514036;C;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE;;;
BISOPROLOL;ACY3;rs2514036;C;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
BISOPROLOL;ACY3;rs2514036;C;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE;;;
LOSARTAN;KIRREL2;rs3814995;T;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
LOSARTAN;NPHS1;rs3814995;T;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
ASPIRIN;ADORA1;rs16851030;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA;;;
ANTINEOPLASTIC AGENTS;FPGS;rs1544105;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
SUNITINIB;NR1I3;rs4073054;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SUNITINIB;FLT4;rs307821;AA + AC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ALPRAZOLAM;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;EFFICACY;INCREASED_RISK;OTHER;TRANSPLANT REJECTION;;;
MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;OTHER;OVERALL SURVIVAL;;;
SUNITINIB;ABCB1;rs1128503;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OLANZAPINE;CYP1A1;rs2472297;T;LADME-PK;PK;PK;25% HIGHER MEAN 4'-DESMETHYL OLA/OLANZAPINE (OLA) RATIO;;;
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;INCREASED_RISK;OTHER;TRANSPLANT REJECTION;;;
BEVACIZUMAB;MGAT4A;rs885036;G;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;PROGRESSION-FREE SURVIVAL ;;
CAPECITABINE;MGAT4A;rs885036;G;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;PROGRESSION-FREE SURVIVAL ;;
CETUXIMAB;MGAT4A;rs885036;G;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;PROGRESSION-FREE SURVIVAL ;;
OXALIPLATIN;MGAT4A;rs885036;G;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;PROGRESSION-FREE SURVIVAL ;;
OPIOIDS;ADGRV1;rs2366929;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
BEVACIZUMAB;MGAT4A;rs885036;G;EFFICACY;DECREASED_;nan;DISEASE;PROGRESSION-FREE SURVIVAL ;;
CAPECITABINE;MGAT4A;rs885036;G;EFFICACY;DECREASED_;nan;DISEASE;PROGRESSION-FREE SURVIVAL ;;
OXALIPLATIN;MGAT4A;rs885036;G;EFFICACY;DECREASED_;nan;DISEASE;PROGRESSION-FREE SURVIVAL ;;
CLOPIDOGREL;FMO3;rs1736557;AA;EFFICACY;DECREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;OTHER;OVERALL SURVIVAL;;;
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
ASPIRIN;PEAR1;rs2644592;G;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;PEAR1;rs2644592;G;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;PEAR1;rs11264580;C;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;PEAR1;rs11264580;C;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
BUPROPION;APOE;rs429358;CC + CT;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;RECURRENCE ;;
NICOTINE;APOE;rs429358;CC + CT;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;RECURRENCE ;;
ASPIRIN;PEAR1;rs57731889;TT;;SIDE_EFFECT;EFFICACY;LOW ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;PEAR1;rs57731889;TT;;SIDE_EFFECT;EFFICACY;LOW ON-TREATMENT PLATELET REACTIVITY;;;
ALENDRONATE;SIRT1;rs932658;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS OF THE JAW;;;
IBANDRONATE;SIRT1;rs932658;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS OF THE JAW;;;
RISEDRONATE;SIRT1;rs932658;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS OF THE JAW;;;
ZOLEDRONATE;SIRT1;rs932658;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS OF THE JAW;;;
VALPROIC ACID;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
ANTINEOPLASTIC AGENTS;GSTM5;rs3754446;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ATORVASTATIN;APOE;rs449647;AT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;LIPID-LOWERING EFFECT;;;
BEZAFIBRATE;APOE;rs449647;AT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;LIPID-LOWERING EFFECT;;;
HALOPERIDOL;SLC6A5;rs2298826;AA;TOXICITY;nan;SIDE_EFFECT;MOTOR SIDE EFFECTS;;;
OLANZAPINE;AHR;rs4410790;T;LADME-PK;PK;PK;29% LOWER MEAN 4'-DESMETHYL OLA/OLANZAPINE (OLA) RATIO;;;
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
ASPIRIN;PEAR1;rs3737224;T;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;PEAR1;rs3737224;T;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EPISTAXIS;;;
ASPIRIN;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
ASPIRIN;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMATOMA;;;
ASPIRIN;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMATURIA;;;
CLOPIDOGREL;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EPISTAXIS;;;
CLOPIDOGREL;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
CLOPIDOGREL;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMATOMA;;;
CLOPIDOGREL;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMATURIA;;;
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ALCOHOL ABUSE ;;
VENLAFAXINE;CYP2D6;rs5030655;del;LADME-PK;PK;PK;IMPAIRED METABOLIC ACTIVITY;;;
ASPIRIN;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EPISTAXIS;;;
ASPIRIN;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
ASPIRIN;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMATOMA;;;
ASPIRIN;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMATURIA;;;
TICAGRELOR;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EPISTAXIS;;;
TICAGRELOR;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
TICAGRELOR;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMATOMA;;;
TICAGRELOR;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMATURIA;;;
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
CISPLATIN;CASP3;rs2720376;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DOXORUBICIN;CASP3;rs2720376;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ACE INHIBITORS;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs59502379;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
NEVIRAPINE;CCHCR1;rs1265112;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEVIRAPINE-INDUCED RASH;;;
CISPLATIN;CYP3A4;rs4646437;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DOXORUBICIN;CYP3A4;rs4646437;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
nan;GLI1;rs2228226;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RECURRENCE FREE SURVIVAL;;;
NICOTINE;ANKK1;rs1800497;AA + AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TOBACCO USE DISORDER ;;
NICOTINE;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TOBACCO USE DISORDER ;;
VALPROIC ACID;UGT1A6;rs2070959;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREMOR;;;
ESCITALOPRAM;CYP1A2;rs4646425;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;FATIGUE ;;
CLOZAPINE;ACKR1;rs2814778;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
ESCITALOPRAM;nan;rs2069521;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;FATIGUE ;;
ASPIRIN;PEAR1;rs41273215;T;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CLOPIDOGREL;PEAR1;rs41273215;T;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ESCITALOPRAM;CYP1A2;rs4646427;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;FATIGUE ;;
ESCITALOPRAM;nan;rs2069521;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA/VOMITING;;;
ESCITALOPRAM;CYP1A2;rs4646425;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA/VOMITING;;;
ESCITALOPRAM;CYP1A2;rs4646427;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA/VOMITING;;;
ALLOPURINOL;CYCSP5;rs3099844;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
ALLOPURINOL;CYCSP5;rs3099844;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CLOPIDOGREL;CYP1A2;rs762551;AA + AC;EFFICACY, LADME-PK;DECREASED_;SIDE_EFFECT;ON-TREATMENT PLATELET REACTIVITY;;;
ETHANOL;OPRK1;rs6473797;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ALCOHOL ABUSE;;;
CYCLOPHOSPHAMIDE;NQO1;rs1800566;A;;SIDE_EFFECT;EFFICACY;WORSE OUTCOME (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL);;;
DOXORUBICIN;NQO1;rs1800566;A;;SIDE_EFFECT;EFFICACY;WORSE OUTCOME (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL);;;
HEROIN;GRM3;rs274618;T;OTHER;INCREASED_RISK;nan;DISEASE;HEROIN DEPENDENCE ;;
THIAZOLIDINEDIONES;AQP2;rs296766;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;EDEMA ;;
ETHANOL;CHRNA3;rs578776;G;TOXICITY, OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;ALCOHOL ABUSE ;;
CISPLATIN;ABCC5;rs939338;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DOXORUBICIN;ABCC5;rs939338;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;FASLG;rs763110;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DOXORUBICIN;FASLG;rs763110;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;MSH2;rs4638843;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DOXORUBICIN;MSH2;rs4638843;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC1A1;rs3087879;C;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PHARMACOLOGICAL RESISTANCE;;;
COCAINE;CHRNA5;rs684513;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;COCAINE DEPENDENCE ;;
ACE INHIBITORS;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
ALLOPURINOL;nan;rs2734583;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
ALLOPURINOL;nan;rs2734583;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
ALLOPURINOL;PSORS1C1;rs9263726;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;;;
ALLOPURINOL;PSORS1C1;rs9263726;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
FEXOFENADINE;SLCO2B1;rs2306168;T;LADME-PK;DECREASED_PK;METABOLISM;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE;;;
ANTINEOPLASTIC AGENTS;SLC28A3;rs17343066;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION (P<0.001);;;
CLOZAPINE;TRAT1;rs116982346;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PANCYTOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
EFAVIRENZ;CYP2A6;rs8192726;AC + CC;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION (P=0.028);;;
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
DOXORUBICIN;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
FLUOROURACIL;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
DOXORUBICIN;CYP3A4;rs2740574;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
FLUOROURACIL;CYP3A4;rs2740574;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
nan;ADH1B;rs1789891;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;ALCOHOL ABUSE ;;
ANTINEOPLASTIC AGENTS;DCTD;rs12067645;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
EFAVIRENZ;UGT2B7;rs7439366;CC + CT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
MERCAPTOPURINE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
MERCAPTOPURINE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PANCYTOPENIA;;;
MERCAPTOPURINE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
FLUOROURACIL;ERCC2;rs13181;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
LEUCOVORIN;ERCC2;rs13181;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
OXALIPLATIN;ERCC2;rs13181;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CLOZAPINE;TRAC;rs377360;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
NEVIRAPINE;CCHCR1;rs746647;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
nan;FGFBP1;rs2245964;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;BONE MINERAL DENSITY;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
nan;FGFBP1;rs16892645;TT;OTHER;INCREASED_LIKELIHOOD;OTHER;BONE MINERAL DENSITY;;;
ATORVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN LDL;;;
nan;nan;rs2824292;G;OTHER;INCREASED_RISK;nan;DISEASE;VENTRICULAR FIBRILLATION ;;
NEVIRAPINE;nan;rs6545803;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEVIRAPINE-INDUCED RASH;;;
NICOTINE;FMO1;rs10912675;C;OTHER;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
NEVIRAPINE;POLR3G;rs2562519;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
NICOTINE;FMO1;rs7877;T;OTHER;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
PACLITAXEL;CYP17A1;rs743572;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ACENOCOUMAROL;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ACENOCOUMAROL;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
CISPLATIN;ERCC1;rs3212986;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;ERCC1;rs3212986;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
ANASTROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;METABOLIC BONE DISORDER, OSTEOPOROSIS ;;
LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;METABOLIC BONE DISORDER, OSTEOPOROSIS ;;
CARBOPLATIN;SOX10;rs139887;CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
DOCETAXEL;SOX10;rs139887;CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
PACLITAXEL;SOX10;rs139887;CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
ANASTROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
ANASTROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
ANASTROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
ANASTROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;METABOLIC BONE DISORDER, OSTEOPOROSIS ;;
LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;METABOLIC BONE DISORDER, OSTEOPOROSIS ;;
ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
CAPECITABINE;CES2;rs11075646;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
WARFARIN;VKORC1;rs9923231;T;;SIDE_EFFECT;EFFICACY;TIME TO THERAPEUTIC INR;;;
ANASTROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
ANASTROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
ANASTROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;SOD2;rs4880;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
"""ANALGESICS AND ANESTHETICS""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
"""ANTIBIOTICS""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
"""ANTIEPILEPTICS""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
"""ANTIFUNGALS FOR SYSTEMIC USE""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
"""ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
"NON-STEROIDS""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
"""ANTIMYCOBACTERIALS""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
"""ANTITHYROID PREPARATIONS""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
METFORMIN;PPARG;rs1801282;G;OTHER;INCREASED_LIKELIHOOD;OTHER;SHORT AND LONG-TERM WEIGHT LOSS;;;
MITOTANE;CYP2B6;rs3745274;GT + TT;LADME-PK;PK;PK;BEING A PREDICTOR OF MITOTANE PLASMA CONCENTRATIONS OF AT LEAST 14 Ï¿½G/ML AFTER 3 MONTHS OF TREATMENT;;;
BORTEZOMIB;CTLA4;rs4553808;GG;TOXICITY;nan;SIDE_EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY;;;
MELPHALAN;CTLA4;rs4553808;GG;TOXICITY;nan;SIDE_EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY;;;
PREDNISONE;CTLA4;rs4553808;GG;TOXICITY;nan;SIDE_EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY;;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PK;METABOLISM;PBMC-ASSOCIATED DRUG CONCENTRATIONS;;;
nan;CRHR1;rs1876828;TT;LADME-PK;DECREASED_PK;METABOLISM;BASELINE CORTISOL LEVELS;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;INTRACELLULAR PBMC EXPOSURE;;;
VALPROIC ACID;SOD2;rs4880;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ALOPECIA;;;
nan;ABCB1;rs1045642;AA;OTHER;INCREASED_LIKELIHOOD;OTHER;HELICOBACTER PYLORI INFECTION;;;
VALPROIC ACID;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ALOPECIA;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_SEVERITY;OTHER;ADP-STIMULATED PLATELET AGGREGATION;;;
CAPECITABINE;CDA;rs10916825;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
ANTINEOPLASTIC AGENTS;ABCB1;rs4148737;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
CLOPIDOGREL;CYP4F2;rs3093135;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP4F2;rs3093135;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
TICAGRELOR;CYP4F2;rs3093135;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
TICAGRELOR;CYP4F2;rs3093135;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME-PK;INCREASED_PK;METABOLISM;MINIMUM PLASMA CONCENTRATIONS;;;
DEFERASIROX;UGT1A3;rs3806596;CC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;IRON OVERLOAD;;;
CAPECITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
EPIRUBICIN;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DEFERASIROX;UGT1A1;rs887829;TT;EFFICACY;DECREASED_RISK;nan;DISEASE;IRON OVERLOAD ;;
METFORMIN;SLC47A2;rs12943590;AA + AG;LADME-PK;INCREASED_PK;METABOLISM;RENAL AND SECRETORY CLEARANCE OF METFORMIN;;;
METFORMIN;SLC47A2;rs12943590;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE TO METFORMIN;;;
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;DECREASED_PK;METABOLISM;ORAL CLEARANCE OF ATORVASTATIN;;;
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
DEFERASIROX;CYP1A2;rs762551;AA;EFFICACY;DECREASED_RISK;SIDE_EFFECT;IRON OVERLOAD;;;
ANTINEOPLASTIC AGENTS;CYP3A5;rs776746;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
CAPECITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DOCETAXEL;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
EPIRUBICIN;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
GEMCITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DEFERASIROX;CYP1A1;rs2606345;CC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;IRON OVERLOAD;;;
HEROIN;GRM3;rs274622;C;OTHER;INCREASED_RISK;nan;DISEASE;HEROIN DEPENDENCE ;;
EFAVIRENZ;ABCB1;rs3842;CC + CT;LADME-PK;INCREASED_PK;METABOLISM;ACCUMULATION OF DRUG IN PBMCS;;;
ETHANOL;CHRNA4;rs1044394;G;TOXICITY;DECREASED_RISK;OTHER;ALCOHOL ABUSE;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;VENOUS THROMBOSIS ;;
OPIOIDS;ENPP2;rs2249015;AA;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;VENOUS THROMBOSIS ;;
CAPECITABINE;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
EPIRUBICIN;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ASPIRIN;ADORA1;rs2228079;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA;;;
LOVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
METHOTREXATE;MTHFR;rs1801131;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;SKIN DISORDER;;;
METHOTREXATE;FASTKD3;rs1801394;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;MTRR;rs1801394;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PROPRANOLOL;CYP2D6;rs1065852;AA;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER PLASMA CONCENTRATION OF PROPRANOLOL;;;
CAPECITABINE;DPYD;rs6668296;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs6668296;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
CLOZAPINE;HLA-DQB1;rs113332494;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;AGRANULOCYTOSIS;;;
CAPECITABINE;ERCC2;rs1799793;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;ERCC2;rs1799793;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;ERCC2;rs1799793;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
EPIRUBICIN;ERCC2;rs1799793;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;ERCC2;rs1799793;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;APOE;rs7412;CT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;HYPERURICEMIA;;;
CAPECITABINE;DPYD;rs115349832;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs115349832;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
METFORMIN;PPARG;rs1801282;G;OTHER;INCREASED_LIKELIHOOD;OTHER;WEIGHT REGAIN AFTER INTENTIONAL WEIGHT LOSS;;;
nan;APOE;rs429358;CC + CT;OTHER;INCREASED_LIKELIHOOD;OTHER;HYPERTRIGLYCERIDEMIA;;;
CLOZAPINE;HLA-DQB1;rs113332494;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
SIMVASTATIN;APOE;rs429358;C;EFFICACY;INCREASED_RISK;OTHER;MORTALITY AFTER MYOCARDIAL INFARCTION;;;
SIMVASTATIN;APOE;rs429358;C;EFFICACY;INCREASED_RISK;OTHER;HOWEVER THIS CAN BE ELIMINATED;;;
CLOZAPINE;HTR2C;rs518147;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
HALOPERIDOL;HTR2C;rs518147;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;HTR2C;rs518147;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
RISPERIDONE;HTR2C;rs518147;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
AMISULPRIDE;HTR2C;rs3813929;C;OTHER;INCREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
CLOZAPINE;HTR2C;rs3813929;C;OTHER;INCREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
HALOPERIDOL;HTR2C;rs3813929;C;OTHER;INCREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
ILOPERIDONE;HTR2C;rs3813929;C;OTHER;INCREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;HTR2C;rs3813929;C;OTHER;INCREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
QUETIAPINE;HTR2C;rs3813929;C;OTHER;INCREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
RISPERIDONE;HTR2C;rs3813929;C;OTHER;INCREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
ZIPRASIDONE;HTR2C;rs3813929;C;OTHER;INCREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
HEROIN;SOD2;rs5746136;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEROIN DEPENDENCE ;;
OPIOIDS;ENPP2;rs7832704;A;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
CARBOPLATIN;BCL2;rs2849380;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
DOCETAXEL;BCL2;rs2849380;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
PACLITAXEL;BCL2;rs2849380;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
CARBOPLATIN;OPRM1;rs544093;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
DOCETAXEL;OPRM1;rs544093;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
PACLITAXEL;OPRM1;rs544093;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
CARBOPLATIN;nan;rs879207;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
DOCETAXEL;nan;rs879207;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
PACLITAXEL;nan;rs879207;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
TOLCAPONE;nan;rs4680;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REACTION TIME;;;
DOLASETRON;NOS1AP;rs10494366;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;QTC PROLONGATION;;;
GRANISETRON;NOS1AP;rs10494366;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;QTC PROLONGATION;;;
SUNITINIB;ABCB1;rs2032582;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CAPECITABINE;DPYD;rs56276561;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs56276561;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
CLOZAPINE;ELAVL2;rs73482673;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PK;METABOLISM;MID-DOSE PLASMA CONCENTRATIONS;;;
FLUOROURACIL;DPYD;rs2297595;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
DOCETAXEL;SLCO1B3;rs4149118;G;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA EXPOSURE;;;
TOLCAPONE;COMT;rs4680;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REACTION TIME;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA EXPOSURE;;;
HEROIN;SOD2;rs2758339;AC + CC;TOXICITY;DECREASED_RISK;nan;DISEASE;HEROIN DEPENDENCE ;;
DOCETAXEL;SLCO1B3;rs11045585;G;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
DOCETAXEL;SLCO1B3;rs7311358;A;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
IRINOTECAN;TOP1;rs6072262;GG;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
WARFARIN;APOB;rs679899;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ERLOTINIB;EGFR;rs712829;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
ERLOTINIB;ABCG2;rs2622604;CC;OTHER, LADME-PK;DECREASED_PK;METABOLISM;MEAN AUC;;;
WARFARIN;APOB;rs1367117;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CAPECITABINE;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
MORPHINE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN PAIN;;;
MORPHINE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN PAIN;;;
PHENYTOIN;ABCB1;rs1045642;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DRUG RESISTANCE;;;
ATORVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;nan;SIDE_EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY;;;
FLUVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;nan;SIDE_EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;nan;SIDE_EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY;;;
PRAVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;nan;SIDE_EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY;;;
ROSUVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;nan;SIDE_EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY;;;
SIMVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;nan;SIDE_EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY;;;
ASPIRIN;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
LEFLUNOMIDE;CYB5A;rs1790834;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STROKE ;;
NEVIRAPINE;CYP2B6;rs28399499;CT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
NEVIRAPINE;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
CETUXIMAB;KRAS;rs61764370;C;;SIDE_EFFECT;EFFICACY;NONRESPONSE TO ANTI-EGFR-BASED TREATMENT;;;
PANITUMUMAB;KRAS;rs61764370;C;;SIDE_EFFECT;EFFICACY;NONRESPONSE TO ANTI-EGFR-BASED TREATMENT;;;
EDOXABAN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
CYCLOSPORINE;ABCB1;rs1045642;GG;EFFICACY, LADME-PK;DECREASED_PK;METABOLISM;INTRACELLULAR AND BLOOD CONCENTRATION;;;
BLEOMYCIN;BLMH;rs1050565;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
CISPLATIN;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE HEARING IMPAIRMENT;;;
CITALOPRAM;FKBP5;rs4713916;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
OPIOIDS;TH;rs10770141;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
DISULFIRAM;DBH;rs1611115;CC;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;COCAINE DEPENDENCE;;;
OPIOIDS;COMT;rs4680;AA;TOXICITY;DECREASED_RISK;OTHER;DEATH;;;
nan;VEGFA;rs2010963;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SOFOSBUVIR;IFNL3;rs12979860;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
SOFOSBUVIR;IFNL4;rs12979860;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
VELPATASVIR;IFNL3;rs12979860;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
VELPATASVIR;IFNL4;rs12979860;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
VOXILAPREVIR;IFNL3;rs12979860;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
VOXILAPREVIR;IFNL4;rs12979860;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
OPIOIDS;TH;rs10770140;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
PHENYTOIN;ABCB1;rs1128503;A;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA DRUG LEVELS;;;
PHENYTOIN;ABCB1;rs1045642;A;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA DRUG LEVELS;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CARDIOMYOPATHIES ;;
DEXMEDETOMIDINE;PRKCB;rs9922316;T;OTHER;INCREASED_LIKELIHOOD;OTHER;DEXMEDETOMIDINE ED50 VALUES FOR DRUG-INDUCED DORSAL HAND VEIN (DHV) CONSTRICTION;;;
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY INDEX (PRI) VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) AT 1 MONTH OF TREATMENT;;;
CYCLOSPORINE;ABCB1;rs2229109;CC;EFFICACY, LADME-PK;INCREASED_PK;METABOLISM;INTRACELLULAR AND BLOOD CONCENTRATION;;;
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RATE OF HIGH ON-TREATMENT PLATELET REACTIVITY (HTPR) AT 1 MONTH OF TREATMENT;;;
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CORONARY DISEASE;;;
EFAVIRENZ;CYP2B6;rs28399499;C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
PRASUGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING COMPLICATIONS;;;
NICOTINE;DRD1;rs686;A;EFFICACY, TOXICITY, OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RATE OF HYPER-RESPONSE AT 1 MONTH OF TREATMENT;;;
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
MITOTANE;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_PK;METABOLISM;MITOTANE PLASMA CONCENTRATIONS;;;
NICOTINE;DRD1;rs4532;T;EFFICACY, TOXICITY, OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
REPAGLINIDE;SLC30A8;rs16889462;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EFFICACY;;;
ATAZANAVIR;UGT1A7;rs17863778;AA;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A7;rs17863778;AA;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
BEVACIZUMAB;EDN1;rs5370;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;EFFICACY;DECREASED_RISK;nan;DISEASE;TRANSPLANT REJECTION ;;
ATAZANAVIR;UGT1A3;rs3806596;CC;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A3;rs3806596;CC;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
GEFITINIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
GEFITINIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
ATAZANAVIR;UGT1A7;rs7586110;GG;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A7;rs7586110;GG;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
OXALIPLATIN;ERCC2;rs13181;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;ERCC2;rs13181;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OXALIPLATIN;KLC3;rs13181;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;KLC3;rs13181;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
APREPITANT;HTR3C;rs6766410;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;NAUSEA;;;
APREPITANT;HTR3C;rs6766410;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;VOMITING;;;
OLANZAPINE;HTR3C;rs6766410;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;NAUSEA;;;
OLANZAPINE;HTR3C;rs6766410;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;VOMITING;;;
ATAZANAVIR;UGT1A7;rs17868323;GG;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;UGT1A7;rs17868323;GG;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
BEVACIZUMAB;VEGFA;rs3025039;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
APREPITANT;MTHFR;rs1801131;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
APREPITANT;MTHFR;rs1801131;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
OLANZAPINE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
OLANZAPINE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
APREPITANT;HTR3B;rs7943062;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
APREPITANT;HTR3B;rs7943062;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
OLANZAPINE;HTR3B;rs7943062;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
OLANZAPINE;HTR3B;rs7943062;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
TAFENOQUINE;nan;rs62103056;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
METHOTREXATE;GGH;rs719235;CC;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;BONE MARROW TOXICITY;;;
TIMOLOL;ADRB1;rs1801252;AA;OTHER;INCREASED_LIKELIHOOD;OTHER;SYSTOLIC (SAP) AND DIASTOLIC (DAP) ARTERIAL PRESSURE RESPONSES TO TIMOLOL;;;
CISPLATIN;LRP2;rs2228171;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
DISULFIRAM;DBH;rs1611115;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FENTANYL;ADRB2;rs1042718;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
PROPOFOL;ADRB2;rs1042718;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
REMIFENTANIL;ADRB2;rs1042718;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
SEVOFLURANE;ADRB2;rs1042718;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;SEVERITY-;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
nan;SLC30A8;rs13266634;C;OTHER;INCREASED_RISK;nan;DISEASE;DIABETES MELLITUS, TYPE 2 ;;
THIAZIDES;SLCO2A1;rs34550074;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPONATREMIA;;;
PLAIN;SLCO2A1;rs34550074;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPONATREMIA;;;
ROSUVASTATIN;FMO3;rs1736557;A;EFFICACY;SEVERITY-;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
WARFARIN;GGCX;rs699664;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR);;;
CISPLATIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
WARFARIN;GGCX;rs11676382;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
METHYLPHENIDATE;COMT;rs4680;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ANTIEPILEPTICS;SCN2A;rs2304016;A;;SIDE_EFFECT;EFFICACY;DRUG RESISTANCE;;;
WARFARIN;GGCX;rs11676382;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR);;;
WARFARIN;NQO1;rs1800566;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ANTITHYROID PREPARATIONS;KLRC4;rs2734565;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;AGRANULOCYTOSIS;;;
METHIMAZOLE;KLRC4;rs2734565;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;AGRANULOCYTOSIS;;;
PROPYLTHIOURACIL;KLRC4;rs2734565;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;AGRANULOCYTOSIS;;;
OXALIPLATIN;ERCC1;rs11615;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;ERCC1;rs11615;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ACE INHIBITORS;nan;rs4267385;CC + CT;OTHER;nan;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH;;;
PLAIN;nan;rs4267385;CC + CT;OTHER;nan;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH;;;
ACE INHIBITORS;nan;rs4459610;AA + AT;OTHER;nan;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH;;;
PLAIN;nan;rs4459610;AA + AT;OTHER;nan;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH;;;
METHOTREXATE;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ALOPECIA ;;
ACE INHIBITORS;BDKRB2;rs8016905;AG;TOXICITY;nan;nan;DISEASE;COUGH ;;
PLAIN;BDKRB2;rs8016905;AG;TOXICITY;nan;nan;DISEASE;COUGH ;;
nan;F5;rs6025;C;OTHER;INCREASED_LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS;;;
CARBOPLATIN;TRIM5;rs7950311;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;TRIM5;rs7950311;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;MTHFR;rs1801131;G;OTHER;INCREASED_LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS;;;
ANTINEOPLASTIC AGENTS;nan;rs6674079;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;MTHFR;rs1801133;G;OTHER;INCREASED_LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS;;;
CARBOPLATIN;nan;rs2549714;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;nan;rs2549714;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;SERPINE1;rs2227631;A;OTHER;INCREASED_LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS;;;
ANTINEOPLASTIC AGENTS;nan;rs4910232;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR);;;
ASPIRIN;PPARG;rs3856806;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN HYPERSENSITIVITY;;;
CYCLOSPORINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
ANTINEOPLASTIC AGENTS;ZNF100;rs3795247;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN INR DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT;;;
ASPIRIN;PTGIR;rs1126510;AG + GG;OTHER;DECREASED_RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA;;;
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NUMBER OF EXAMINATIONS ABOVE THE THERAPEUTIC RANGE DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT;;;
ASPIRIN;TBXA2R;rs1131882;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA;;;
ASPIRIN;PTGER3;rs7551789;A;OTHER;INCREASED_RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA;;;
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR>=2;;;
ASPIRIN;PTGER2;rs1353411;GG;OTHER;INCREASED_RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA;;;
ASPIRIN;PTGER2;rs2075797;G;OTHER;DECREASED_RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA;;;
DOCETAXEL;CYP3A4;rs2740574;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
PACLITAXEL;CYP3A4;rs2740574;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
DOXORUBICIN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
DOXORUBICIN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_;OTHER;STABLE WARFARIN DOSE;;;
CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;VASP INDEX;;;
ASPIRIN;PPARG;rs3856806;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DECLINE IN FEV 1 AFTER ASPIRIN PROVOCATION;;;
CLOPIDOGREL;CYP2C19;rs4986893;AG + GG;;SIDE_EFFECT;EFFICACY;HIGH POST-CLOPIDOGREL PLATELET REACTIVITY;;;
ASPIRIN;NECAB1;rs74569896;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;NECAB1;rs74569896;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;;SIDE_EFFECT;EFFICACY;HIGH POST-CLOPIDOGREL PLATELET REACTIVITY;;;
WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ATHEROTHROMBOTIC EVENTS DURING THE 6-YEAR FOLLOW UP IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT;;;
WARFARIN;CYP2C9;rs1799853;T;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLOOD COAGULATION DISORDERS;;;
ASPIRIN;EFR3A;rs4736529;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;EFR3A;rs4736529;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
DOCETAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
PACLITAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
GEMCITABINE;SLC28A1;rs2242046;GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMATOLOGIC TOXICITY;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT ;
WARFARIN;CYP2C9;rs1057910;C;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLOOD COAGULATION DISORDERS;;;
GEMCITABINE;CDA;rs1048977;CC + CT;OTHER, LADME-PK;INCREASED_PK;METABOLISM;ELIMINATION CLEARANCE OF DFDU AND FORMATION CLEARANCE OF DFDCTP;;;
PACLITAXEL;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CORONARY ARTERY DISEASE ;;
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CORONARY ARTERY DISEASE ;;
CYTARABINE;ABCB1;rs1128503;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;;SIDE_EFFECT;EFFICACY;POORER REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDLC);;;
ETHAMBUTOL;NAT2;rs1799930;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;rs1799930;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;rs1799930;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;rs1799930;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;;SIDE_EFFECT;EFFICACY;POORER REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDLC);;;
PRAVASTATIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PERCENT REDUCTION IN LDL-CHOLESTEROL;;;
GEMCITABINE;CMPK1;rs1044457;CC;OTHER, LADME-PK;DECREASED_PK;METABOLISM;FORMATION CLEARANCE OF DFDCTP;;;
ASPIRIN;WDR24;rs11640115;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;WDR24;rs11640115;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
GEMCITABINE;CDA;rs4655226;CC;OTHER, LADME-PK;INCREASED_PK;METABOLISM;ELIMINATION CLEARANCE OF DFDU;;;
CARBOPLATIN;MAD1L1;rs1801368;CT + TT;OTHER;DECREASED_;OTHER;BIOCHEMICAL RESPONSE;;;
CARBOPLATIN;MAD1L1;rs1801368;CT + TT;OTHER;DECREASED_;OTHER;OPTIMAL CYTOREDUCTION;;;
CARBOPLATIN;MAD1L1;rs1801368;CT + TT;OTHER;DECREASED_;OTHER;AND SENSITIVITY TO THE INDUCTION CHEMOTHERAPY TREATMENT;;;
PACLITAXEL;MAD1L1;rs1801368;CT + TT;OTHER;DECREASED_;OTHER;BIOCHEMICAL RESPONSE;;;
PACLITAXEL;MAD1L1;rs1801368;CT + TT;OTHER;DECREASED_;OTHER;OPTIMAL CYTOREDUCTION;;;
PACLITAXEL;MAD1L1;rs1801368;CT + TT;OTHER;DECREASED_;OTHER;AND SENSITIVITY TO THE INDUCTION CHEMOTHERAPY TREATMENT;;;
VARENICLINE;ICAM5;rs901886;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SLEEP DISORDERS;;;
METHOTREXATE;ABCC1;rs2238476;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
MITOXANTRONE;ABCB1;rs1128503;AA;OTHER;INCREASED_LIKELIHOOD;OTHER;SENSITIVITY IN VITRO;;;
MERCAPTOPURINE;FOLH1;rs61886492;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;FOLH1;rs61886492;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CYTARABINE;ABCB1;rs2032582;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
ETHAMBUTOL;NAT2;rs1041983;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;rs1041983;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;NAT2;rs1041983;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;NAT2;rs1041983;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME/EPIDERMAL NECROLYSIS;;;
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC;;;
nan;PPARA;rs135561;AA + AG;OTHER;DECREASED_RISK;OTHER;ALL-CAUSE MORTALITY;;;
CLOZAPINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
CLOZAPINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;nan;rs1495741;AA;TOXICITY;DECREASED_;SIDE_EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ABNORMAL LIVER-FUNCTION TESTS (ALFTS);;;
ISONIAZID;nan;rs1495741;AA;TOXICITY;DECREASED_;SIDE_EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ABNORMAL LIVER-FUNCTION TESTS (ALFTS);;;
METHOTREXATE;ATIC;rs4673993;C;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DISEASE ACTIVITY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;nan;rs1495741;AA;TOXICITY;DECREASED_;SIDE_EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ANTITUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY (ATDIH);;;
ISONIAZID;nan;rs1495741;AA;TOXICITY;DECREASED_;SIDE_EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ANTITUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY (ATDIH);;;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;APOC3;rs5128;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERLIPIDEMIAS;;;
COMBINATIONS;APOC3;rs5128;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERLIPIDEMIAS;;;
FLUTICASONE PROPIONATE;CYP3A4;rs35599367;AA + AG;;SIDE_EFFECT;EFFICACY;IMPROVED ASTHMA CONTROL (AS MEASURED BY DECREASE IN AVERAGE ASTHMA CONTROL SCORE);;;
ALLOPURINOL;CCHCR1;rs9263745;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
LETROZOLE;nan;rs74418677;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
LETROZOLE;nan;rs74418677;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
LETROZOLE;nan;rs74418677;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
ACE INHIBITORS;AGTR1;rs5186;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE;;;
PLAIN;AGTR1;rs5186;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE;;;
CYTARABINE;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CYTARABINE;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DAUNORUBICIN;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
DAUNORUBICIN;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ETOPOSIDE;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ETOPOSIDE;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
MITOXANTRONE;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
MITOXANTRONE;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PK;METABOLISM;TROUGH BLOOD CONCENTRATION NORMALIZED FOR THE DAILY DOSE (C) PER KILOGRAM BODY WEIGHT (D) (C/D;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PK;METABOLISM;NG/ML/MG/KG/DAY) RATIO DURING THE FIRST MONTH AFTER TRANSPLANTATION;;;
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DELAYED GRAFT FUNCTION;;;
ALLOPURINOL;CYCSP5;rs3099844;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
METHOTREXATE;FOXP3;rs3761548;GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
nan;CHAT;rs1880676;G;OTHER;INCREASED_RISK;nan;DISEASE;SCHIZOPHRENIA ;;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;SIK3;rs139961185;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERLIPIDEMIAS;;;
COMBINATIONS;SIK3;rs139961185;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERLIPIDEMIAS;;;
OXALIPLATIN;XRCC1;rs25487;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY;DECREASED_;SIDE_EFFECT;RENAL FUNCTION (LOWER CREATININE CLEARANCE) AT 3 MONTHS OF FOLLOW-UP;;;
METFORMIN;SLC22A1;rs622342;AA;LADME-PK;DECREASED_PK;METABOLISM;CL RENAL REFERENCE AND LOWER AND CL SEC REFERENCE;;;
ALLOPURINOL;PSORS1C2;rs9263733;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
CYCLOSPORINE;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DELAYED GRAFT FUNCTION;;;
METHOTREXATE;ABCG2;rs13120400;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
ALLOPURINOL;PSORS1C1;rs9263726;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ALLOPURINOL;PSORS1C2;rs9263726;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;nan;rs1495741;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
EXEMESTANE;nan;rs912571;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
EXEMESTANE;nan;rs912571;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
EXEMESTANE;nan;rs912571;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
LETROZOLE;nan;rs912571;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
LETROZOLE;nan;rs912571;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
LETROZOLE;nan;rs912571;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;APOA5;rs964184;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERLIPIDEMIAS;;;
COMBINATIONS;APOA5;rs964184;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERLIPIDEMIAS;;;
VALPROIC ACID;POLG;rs2307441;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CISPLATIN;ADH1C;rs698;CT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;COMPLETE RESPONSE;;;
CYCLOPHOSPHAMIDE;ADH1C;rs698;CT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;COMPLETE RESPONSE;;;
EXEMESTANE;CCDC148;rs79048288;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
EXEMESTANE;CCDC148;rs79048288;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
EXEMESTANE;CCDC148;rs79048288;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
LETROZOLE;CCDC148;rs79048288;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
LETROZOLE;CCDC148;rs79048288;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
LETROZOLE;CCDC148;rs79048288;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
OXALIPLATIN;GSTP1;rs1695;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ATORVASTATIN;CYP3A4;rs35599367;AA + AG;DOSAGE, LADME-PK;DECREASED_;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL;;;
LOVASTATIN;CYP3A4;rs35599367;AA + AG;DOSAGE, LADME-PK;DECREASED_;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL;;;
SIMVASTATIN;CYP3A4;rs35599367;AA + AG;DOSAGE, LADME-PK;DECREASED_;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL;;;
VALPROIC ACID;POLG;rs3087374;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
EDOXABAN;SLCO1B1;rs2306283;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
EDOXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
HYDROCHLOROTHIAZIDE;ADD1;rs4961;TT;OTHER;INCREASED_LIKELIHOOD;OTHER;HYDROCHLOROTHIAZIDE INDUCED CALCIUM RETENTION;;;
EDOXABAN;SLCO1B1;rs999278;AA + AC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
LEVODOPA;DRD3;rs6280;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
LEVODOPA;DRD2;rs1799732;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
BUSULFAN;CTH;rs1021737;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEPATIC VENO-OCCLUSIVE DISEASE ;;
CYCLOPHOSPHAMIDE;CTH;rs1021737;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEPATIC VENO-OCCLUSIVE DISEASE ;;
FUROSEMIDE;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS;;;
SPIRONOLACTONE;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS;;;
EDOXABAN;SLCO1B1;rs4149057;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
SIMVASTATIN;ABCB1;rs2032582;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN TOTAL CHOLESTEROL;;;
SIMVASTATIN;ABCB1;rs2032582;AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN TOTAL CHOLESTEROL;;;
FUROSEMIDE;ACE;rs4341;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS;;;
SPIRONOLACTONE;ACE;rs4341;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS;;;
SIMVASTATIN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN TOTAL CHOLESTEROL;;;
ATORVASTATIN;NOS3;rs2070744;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTI-INFLAMMATORY EFFECTS;;;
ATORVASTATIN;NOS3;rs2070744;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;WHOLE BLOOD NITRITE;;;
PAROXETINE;CYP1A2;rs2472304;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
FUROSEMIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS;;;
SPIRONOLACTONE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DIURETIC UNRESPONSIVENESS;;;
PAROXETINE;CYP1A2;rs4646425;T;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;REMISSION;;;
ATORVASTATIN;ABCB1;rs2032582;AA;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
CISPLATIN;ERCC1;rs11615;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
DOXORUBICIN;ERCC1;rs11615;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
METHAMPHETAMINE;ARRB2;rs4790694;C;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
METHOTREXATE;ABCG2;rs2231142;GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PAROXETINE;CYP1A2;rs2470890;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PEGINTERFERON ALFA-2A;SCARB1;rs10846744;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;SCARB1;rs10846744;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PLATINUM COMPOUNDS;nan;rs1829346;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DERMATITIS;;;
RADIOTHERAPY;nan;rs1829346;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DERMATITIS;;;
CISPLATIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
CISPLATIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
DOXORUBICIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
ATORVASTATIN;ABCB1;rs1128503;AA;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
CLOZAPINE;CYP2C19;rs4244285;AA;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
ATORVASTATIN;ABCB1;rs1045642;AA;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
PRASUGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
IRINOTECAN;SLCO1B1;rs2306283;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
PLATINUM COMPOUNDS;nan;rs2027701;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
RADIOTHERAPY;nan;rs2027701;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
SIMVASTATIN;ABCB1;rs1128503;AA;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC SIMVASTATIN ACID;;;
PRASUGREL;CYP2C19;rs4244285;A;;SIDE_EFFECT;EFFICACY;HIGHER PLATELET REACTIVITY INDEX (PRI) VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) AT 1 MONTH OF TREATMENT;;;
ANTIPSYCHOTICS;SLC18A2;rs363341;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM COMPOUNDS;nan;rs1059698;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
RADIOTHERAPY;nan;rs1059698;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
ANTIPSYCHOTICS;GRIK3;rs1334802;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM COMPOUNDS;nan;rs73594404;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PLATINUM COMPOUNDS;nan;rs73594404;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
RADIOTHERAPY;nan;rs73594404;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
RADIOTHERAPY;nan;rs73594404;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
PAROXETINE;CYP1A2;rs4646427;TT;;SIDE_EFFECT;EFFICACY;SLOWER RESPONSE TIME;;;
METHOTREXATE;SHMT1;rs1979277;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ABDOMINAL PAIN;;;
PAROXETINE;CYP1A2;rs762551;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;FATIGUE ;;
ANTIPSYCHOTICS;HTR2A;rs9567733;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM COMPOUNDS;nan;rs36080650;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DERMATITIS;;;
RADIOTHERAPY;nan;rs36080650;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DERMATITIS;;;
METHOTREXATE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
ANTIPSYCHOTICS;DRD2;rs1124491;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM COMPOUNDS;MEG3;rs10132552;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
RADIOTHERAPY;MEG3;rs10132552;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;LADME-PK;INCREASED_PK;METABOLISM;SERUM R -WARFARIN CONCENTRATION;;;
MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;TOXICITY;nan;SIDE_EFFECT;DIMINISHED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DURING THE FIRST YEAR AFTER ENGRAFTMENT;;;
METHOTREXATE;ABCC2;rs17222723;AT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHAMPHETAMINE;SLC6A9;rs2486001;T;TOXICITY, OTHER;INCREASED_RISK;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;PROTEINURIA ;;
ANTIPSYCHOTICS;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
CLOZAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
OLANZAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
nan;KCNH2;rs1805123;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;ATRIAL FIBRILLATION ;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
METHAMPHETAMINE;ARRB2;rs2036657;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
ASPIRIN;P2RY1;rs1065776;CT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-RESISTANT PHENOTYPE;;;
ROSUVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
nan;CRHR1;rs110402;AA;OTHER;INCREASED_RISK;DISEASE;MAJOR DEPRESSIVE DISORDER;;;
NICOTINE;ARRB2;rs4790694;A;OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_;SIDE_EFFECT;MEDIAN WEEKLY WARFARIN DOSE REQUIREMENTS;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGICAL TOXICITY;;;
ATORVASTATIN;ABCB1;rs1045642;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYALGIA;;;
CAPECITABINE;MTHFR;rs1801133;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
CARVEDILOL;ADRB2;rs1042714;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN RESTING BLOOD PRESSURE;;;
CLOPIDOGREL;PON1;rs662;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ANTIDEPRESSANTS;NTRK2;rs1439050;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SUICIDE ;;
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
BEVACIZUMAB;nan;rs1478947;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ASPIRIN;TBXA2R;rs4523;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN RESISTANCE;;;
METHAMPHETAMINE;ARRB2;rs1045280;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
ASPIRIN;GP1BA;rs6065;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN RESISTANCE;;;
OLANZAPINE;PMCH;rs7973796;G;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OBESITY;;;
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
WARFARIN;VKORC1;rs9934438;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ASPIRIN;TGFB1;rs1800469;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT CHRONIC URTICARIA;;;
WARFARIN;F7;rs6046;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SEN SITIVITY TO WARFARIN DURING INDUCTION;;;
WARFARIN;F7;rs6046;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
CARBOPLATIN;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY;;;
CISPLATIN;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY;;;
DOCETAXEL;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY;;;
GEMCITABINE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY;;;
PACLITAXEL;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY;;;
VINORELBINE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE TO CHEMOTHERAPY;;;
ASPIRIN;KRTAP10-4;rs201441480;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ASPIRIN;TSPEAR;rs201441480;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;KRTAP10-4;rs201441480;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;TSPEAR;rs201441480;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT MODIFICATION;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT MODIFICATION;;;
METHOTREXATE;MTHFD1;rs2236225;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PACLITAXEL;ABCB1;rs1128503;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
METHOTREXATE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
METHOTREXATE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ATORVASTATIN;NOS3;rs2070744;CC;OTHER;DECREASED_;OTHER;ERYTHROCYTE PLASMA MEMBRANE FLUIDITY;;;
WARFARIN;CYP2C9;rs7900194;A;LADME-PK;DECREASED_PK;METABOLISM;S-WARFARIN CLEARANCE;;;
ASPIRIN;ECHS1;rs140410716;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;ECHS1;rs140410716;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CYCLOPHOSPHAMIDE;PIGB;rs12050587;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOPHOSPHAMIDE;PIGB;rs12050587;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;PIGB;rs12050587;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
EPIRUBICIN;PIGB;rs12050587;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;PIGB;rs12050587;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;PIGB;rs12050587;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
ATORVASTATIN;SLCO1B1;rs4149035;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
FLUVASTATIN;SLCO1B1;rs4149035;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
LOVASTATIN;SLCO1B1;rs4149035;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PITAVASTATIN;SLCO1B1;rs4149035;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
SIMVASTATIN;SLCO1B1;rs4149035;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ASPIRIN;AGAP3;rs75750968;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;AGAP3;rs75750968;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ATORVASTATIN;SLCO1B1;rs11045818;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
FLUVASTATIN;SLCO1B1;rs11045818;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
LOVASTATIN;SLCO1B1;rs11045818;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PITAVASTATIN;SLCO1B1;rs11045818;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
SIMVASTATIN;SLCO1B1;rs11045818;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
GEMCITABINE;SLC28A2;rs11854484;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMATOLOGIC TOXICITY;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
ACETAMINOPHEN;TLR4;rs1927911;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ASTHMA;;;
TIMOLOL;nan;rs16947;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;BRADYCARDIA ;;
CYCLOPHOSPHAMIDE;nan;rs11636687;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOPHOSPHAMIDE;nan;rs11636687;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;nan;rs11636687;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
EPIRUBICIN;nan;rs11636687;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;nan;rs11636687;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;nan;rs11636687;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
GEMCITABINE;SLC28A2;rs1060896;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMATOLOGIC TOXICITY;;;
ATORVASTATIN;ABCG2;rs2622629;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
FLUVASTATIN;ABCG2;rs2622629;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
LOVASTATIN;ABCG2;rs2622629;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PITAVASTATIN;ABCG2;rs2622629;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
SIMVASTATIN;ABCG2;rs2622629;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
ASPIRIN;ZDHHC3;rs3749187;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;ZDHHC3;rs3749187;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
VENLAFAXINE;CYP2D6;rs3892097;CT + TT;LADME-PK;INCREASED_PK;METABOLISM;VENLAFAXINE CONCENTRATION PER UNIT DOSE;;;
nan;ADORA2A;rs5996696;AC + CC;OTHER;DECREASED_RISK;nan;DISEASE;PARKINSON DISEASE ;;
nan;ADORA2A;rs71651683;CT;OTHER;DECREASED_RISK;nan;DISEASE;PARKINSON DISEASE ;;
nan;IFITM3;rs12252;GG;OTHER;INCREASED_SEVERITY;OTHER;COVID-19;;;
METHOTREXATE;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CAFFEINE;CYP1A2;rs762551;CC;OTHER;DECREASED_RISK;nan;DISEASE;PARKINSON DISEASE ;;
CAFFEINE;CYP1A2;rs2470890;CC;OTHER;DECREASED_RISK;nan;DISEASE;PARKINSON DISEASE ;;
CLOZAPINE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
WARFARIN;VKORC1;rs9934438;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN AUC (AREA UNDER CURVE) PROTHROMBIN TIME;;;
PEGINTERFERON ALFA-2A;ITPA;rs1127354;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs1127354;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ATORVASTATIN;SLCO1B1;rs374113543;A;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
SIMVASTATIN;SLCO1B1;rs374113543;A;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
ATORVASTATIN;SLCO1B1;rs373327528;A;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
SIMVASTATIN;SLCO1B1;rs373327528;A;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
PEGINTERFERON ALFA-2A;DNAAF9;rs6051702;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PEGINTERFERON ALFA-2B;DNAAF9;rs6051702;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
RIBAVIRIN;DNAAF9;rs6051702;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
DEXAMETHASONE;SERPINE1;rs6092;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OSTEONECROSIS ;;
GEMCITABINE;CDA;rs2072671;AA + AC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
NICOTINE;CHRNB2;rs2072661;GG;EFFICACY, TOXICITY, OTHER;INCREASED_LIKELIHOOD;OTHER;ABSTINENCE;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CLOZAPINE;CYP1A2;rs2069514;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED INSULIN LEVELS;;;
CISPLATIN;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
DOXORUBICIN;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
CISPLATIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
METHOTREXATE;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
EVEROLIMUS;MTOR;rs2024627;C;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CISPLATIN;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
DOXORUBICIN;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
METHOTREXATE;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
NICOTINE;CHRM2;rs324650;T;TOXICITY, OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
CETUXIMAB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
PANITUMUMAB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
CLOZAPINE;CYP1A2;rs35694136;del;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED INSULIN LEVELS;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CETUXIMAB;AREG;rs9996584;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PANITUMUMAB;AREG;rs9996584;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
BEVACIZUMAB;VEGFA;rs1570360;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;VEGFA;rs1570360;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;PON1;rs662;CT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;SMALL-DENSE LDL LEVELS;;;
PROTON PUMP INHIBITORS;TRPM6;rs3750425;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPOMAGNESEMIA PRIMARY;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CLOZAPINE;HTR2C;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
CLOZAPINE;MIR1264;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
CLOZAPINE;MIR1912;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
OLANZAPINE;HTR2C;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
OLANZAPINE;MIR1264;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
OLANZAPINE;MIR1912;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
QUETIAPINE;HTR2C;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
QUETIAPINE;MIR1264;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
QUETIAPINE;MIR1912;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;HTR2C;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;MIR1264;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;MIR1912;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
METHOTREXATE;GGH;rs3758149;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
HALOTHANE;RYR1;rs193922803;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs193922803;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
CETUXIMAB;AREG;rs11942466;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
PANITUMUMAB;AREG;rs11942466;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
SIMVASTATIN;ABCB1;rs1045642;AA;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC SIMVASTATIN ACID;;;
PROTON PUMP INHIBITORS;TRPM6;rs2274924;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPOMAGNESEMIA PRIMARY;;;
DOXORUBICIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
DOXORUBICIN;ERCC1;rs3212986;AA + AC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;INFECTIOUS DISEASE;;;
DOXORUBICIN;ERCC1;rs3212986;AA + AC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CLOZAPINE;HTR2C;rs518147;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
OLANZAPINE;HTR2C;rs518147;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
QUETIAPINE;HTR2C;rs518147;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;HTR2C;rs518147;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
SIMVASTATIN;ABCB1;rs2032582;AA;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC SIMVASTATIN ACID;;;
DESFLURANE;RYR1;rs118192172;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs118192172;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs118192172;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs118192172;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs118192172;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs118192172;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
NEVIRAPINE;CYP2B6;rs2054675;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ASUNAPREVIR;IFNL3;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
ASUNAPREVIR;IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
DACLATASVIR;IFNL3;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
DACLATASVIR;IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
DIRECT ACTING ANTIVIRALS;IFNL3;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
DIRECT ACTING ANTIVIRALS;IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
LEDIPASVIR;IFNL3;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
LEDIPASVIR;IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
SOFOSBUVIR;IFNL3;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
SOFOSBUVIR;IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
OMBITASVIR;IFNL3;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
OMBITASVIR;IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
PARITAPREVIR;IFNL3;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
PARITAPREVIR;IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
RITONAVIR;IFNL3;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
RITONAVIR;IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA;;;
DESFLURANE;RYR1;rs118192176;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs118192176;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs118192176;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs118192176;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs118192176;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs118192176;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
DESFLURANE;RYR1;rs118192177;T;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs118192177;T;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs118192177;T;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs118192177;T;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs118192177;T;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs118192177;T;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
DESFLURANE;RYR1;rs121918593;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs121918593;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs121918593;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs121918593;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs121918593;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs121918593;A;OTHER;INCREASED_RISK;SEVERITY;SIDE_EFFECT;MALIGNANT HYPERTHERMIA ;;
NEVIRAPINE;CYP2B6;rs3786547;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;DPYD;rs1801160;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
DESFLURANE;RYR1;rs121918592;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs121918592;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs121918592;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs121918592;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs121918592;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs121918592;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
CAPECITABINE;DPYD;rs1801159;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
METHYLPHENIDATE;DRD3;rs6280;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTOLERABILITY;;;
CISPLATIN;ACYP2;rs1872328;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
CLOPIDOGREL;PON1;rs662;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS (COMPOSITE OF CARDIAC DEATH;;;
CLOPIDOGREL;PON1;rs662;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MI;;;
CLOPIDOGREL;PON1;rs662;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS) IN KOREAN PATIENTS AFTER PCI;;;
DOXORUBICIN;XPC;rs2228001;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;INFECTIOUS DISEASE;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
HEROIN;OPRM1;rs9479757;GG;TOXICITY;INCREASED_SEVERITY;OTHER;HEROIN DEPENDENCE;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BLUNTING OF ALCOHOL CRAVING;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;;SIDE_EFFECT;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;;SIDE_EFFECT;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL3;rs8099917;TT;;SIDE_EFFECT;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs1125338;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
BETA-LACTAM ANTIBACTERIALS;nan;rs71542416;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
PENICILLINS;nan;rs71542416;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
IRINOTECAN;ABCG1;rs425215;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
XELOX;ABCA2;rs2271862;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;ABCC5;rs562;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
OPIOIDS;TACR1;rs6715729;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERDOSE;;;
OPIOIDS;DRD2;rs4436578;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERDOSE;;;
OPIOIDS;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERDOSE;;;
IRINOTECAN;SLCO1B1;rs2306283;AG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
TRAMADOL;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
nan;ABCB1;rs2032582;CC + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CARBOPLATIN;SLCO1B3;rs7311358;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PACLITAXEL;SLCO1B3;rs7311358;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
METHOTREXATE;FPGS;rs10106;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ALOPECIA;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ALOPECIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
nan;HIF1A;rs11549467;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs12596638;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs12596638;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
COUMARIN;CYP2A6;rs28399433;C;OTHER, LADME-PK;DECREASED_;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM;;;
NICOTINE;CYP2A6;rs28399433;C;OTHER, LADME-PK;DECREASED_;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM;;;
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
ANTIBIOTICS;LGALS3;rs11125;AT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;THROMBOCYTOPENIA ;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;nan;rs12600192;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
nan;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HAND-FOOT SYNDROME ;;
METHOTREXATE;DHFR;rs1650723;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MUCOSITIS;;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;nan;rs12600192;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;nan;rs12600192;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
METHOTREXATE;ABCG2;rs2231135;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
NICOTINE;HINT1;rs3852209;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;METASTATIC NEOPLASM;;;
nan;VDR;rs1544410;CC;OTHER;DECREASED_LIKELIHOOD;OTHER;PRE-ECLAMPSIA;;;
ETHAMBUTOL;ALAS1;rs352139;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;ALAS1;rs352139;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;ALAS1;rs352139;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;ALAS1;rs352139;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RISPERIDONE;SLC6A4;rs3813034;AA;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ISONIAZID;GSTP1;rs1695;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;GSTP1;rs1695;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CYCLOPHOSPHAMIDE;ALDH1A1;rs3764435;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
DOXORUBICIN;ALDH1A1;rs3764435;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CYCLOPHOSPHAMIDE;ALDH1A1;rs168351;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
DOXORUBICIN;ALDH1A1;rs168351;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CARBOPLATIN;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PACLITAXEL;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs117648444;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs117648444;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs117648444;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs117648444;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs117648444;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs117648444;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ETHANOL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;INTOXICATION;;;
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;INTOXICATION;;;
ISONIAZID;NAT2;rs1799929;TT;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;rs1799929;TT;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
OPIOIDS;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERALGESIA;;;
ISONIAZID;NAT2;rs1799930;AA;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;rs1799930;AA;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
METHOTREXATE;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;DHFR;rs1053129;CC;TOXICITY;INCREASED_RISK;DISEASE;METASTATIC NEOPLASM;;;
METHOTREXATE;MTHFR;rs1801133;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
TAMOXIFEN;HS6ST3;rs118042719;A;EFFICACY;DECREASED_RISK;EFFICACY;RECURRENCE FREE SURVIVAL;;;
PHENYTOIN;ABCB1;rs2229107;A;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA DRUG LEVELS;;;
"""3";OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
"4-METHYLENEDIOXYMETHAMPHETAMINE""";OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
"""COCAINE""";OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
"""ETHANOL""";OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
"""OPIOIDS""";OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
TRASTUZUMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
MYCOPHENOLIC ACID;ABCC2;rs717620;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE;;;
MYCOPHENOLIC ACID;ABCC2;rs717620;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;KIDNEY TUBULAR NECROSIS;;;
MYCOPHENOLIC ACID;ABCC2;rs717620;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACUTE;;;
TACROLIMUS;ABCC2;rs717620;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PRIMARY GRAFT FAILURE;;;
TACROLIMUS;ABCC2;rs717620;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;KIDNEY TUBULAR NECROSIS;;;
TACROLIMUS;ABCC2;rs717620;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACUTE;;;
METHADONE;CYP2B6;rs1038376;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
METHOTREXATE;SLC19A1;rs1051266;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SUCCINYLCHOLINE;BCHE;rs1799807;C;LADME-PK;INCREASED_RISK;SIDE_EFFECT;BUTYRYLCHOLINESTERASE DEFICIENCY;;;
SUCCINYLCHOLINE;BCHE;rs1803274;T;LADME-PK;INCREASED_RISK;SIDE_EFFECT;BUTYRYLCHOLINESTERASE DEFICIENCY;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;THROMBOCYTOPENIA ;;
CLOPIDOGREL;CYP2C18;rs1042192;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOZAPINE;HNMT;rs2737385;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;SEDATION;;;
FLUOROURACIL;DPYD;rs1801160;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
METHADONE;CYP2B6;rs2279343;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
CLOPIDOGREL;NOC3L;rs12572897;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
TAMOXIFEN;LPP;rs6790761;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;RECURRENCE FREE SURVIVAL;;;
ETHAMBUTOL;NAT2;rs1799929;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
ISONIAZID;NAT2;rs1799929;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
PYRAZINAMIDE;NAT2;rs1799929;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
RIFAMPIN;NAT2;rs1799929;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
SUNITINIB;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
NICOTINE;CHRNA5;rs16969968;A;TOXICITY, OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
CLOPIDOGREL;CYP2C8;rs1058932;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
SUNITINIB;ABCB1;rs2032582;AA + AC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
NICOTINE;CHRNA3;rs578776;A;TOXICITY, OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
TAMOXIFEN;LPP;rs77693286;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;RECURRENCE FREE SURVIVAL;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;rs17863783;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_RISK;nan;DISEASE;TRANSPLANT REJECTION ;;
RIFAMPIN;RIPOR2;rs10946739;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
nan;EGFR;rs763317;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
nan;GAL;rs948854;C;OTHER;INCREASED_SEVERITY;nan;DISEASE;ANXIETY DISORDERS ;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
CARBAMAZEPINE;ZNRD1-AS1;rs3869066;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;ZNRD1-AS1;rs3869066;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ATAZANAVIR;ABCB1;rs2032582;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
HMG COA REDUCTASE INHIBITORS;EYS;rs1337512;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;RHABDOMYOLYSIS ;;
RIFAMPIN;AGBL4;rs393994;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ATAZANAVIR;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
HMG COA REDUCTASE INHIBITORS;EYS;rs9342288;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;RHABDOMYOLYSIS ;;
OTHER COMBINATIONS;EYS;rs9342288;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;RHABDOMYOLYSIS ;;
ASPIRIN;SLC30A9;rs1047626;A;TOXICITY, OTHER;DECREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
ESCITALOPRAM;BDNF;rs962369;C;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SUICIDAL IDEATION;;;
NORTRIPTYLINE;BDNF;rs962369;C;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SUICIDAL IDEATION;;;
ACE INHIBITORS;KCNMA1;rs2253201;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
PLAIN;KCNMA1;rs2253201;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
HMG COA REDUCTASE INHIBITORS;EYS;rs3857532;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;RHABDOMYOLYSIS ;;
OTHER COMBINATIONS;EYS;rs3857532;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;RHABDOMYOLYSIS ;;
ASPIRIN;TSC1;rs7862221;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
RIFAMPIN;AGBL4;rs320003;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ASPIRIN;THRA;rs11819745;G;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
RIFAMPIN;CUX2;rs7958375;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
ASPIRIN;CHIA;rs3818822;A;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
ATAZANAVIR;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
ASPIRIN;nan;rs1074373;C;TOXICITY, OTHER;DECREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;PLASMA FREE PHENYTOIN CONCENTRATION;;;
PHENYTOIN;CYP2C9;rs1057910;C;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;PLASMA FREE PHENYTOIN CONCENTRATION;;;
HEROIN;GRM3;rs1990040;A;OTHER;INCREASED_RISK;nan;DISEASE;HEROIN DEPENDENCE ;;
ASPIRIN;ZBTB22;rs3130100;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
CYCLOSPORINE;TCF7L2;rs7903146;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS ;;
SIROLIMUS;TCF7L2;rs7903146;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS ;;
TACROLIMUS;TCF7L2;rs7903146;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS ;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;RHABDOMYOLYSIS ;;
PHENYTOIN;CYP2C9;rs1057910;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
ASPIRIN;HLA-DPB1;rs3097671;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
ASPIRIN;HLA-DPB2;rs3129294;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
ASPIRIN;HLA-DPB1;rs1042151;G;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
ASPIRIN;HLA-DPB1;rs1042136;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
RIFAMPIN;RIPOR2;rs10946737;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PREDNISOLONE;GATA3;rs3824662;AA;LADME-PD;INCREASED_RISK;SIDE_EFFECT;SEPSIS;;;
RIFAMPIN;AGBL4;rs319952;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NICOTINE;OPRM1;rs10485057;AA;TOXICITY;INCREASED_RISK;OTHER;TOBACCO USE DISORDER;;;
ETHANOL;DPP6;rs2533200;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CISPLATIN;EPHX1;rs1051740;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY GRADES 1-4;;;
CYCLOPHOSPHAMIDE;EPHX1;rs1051740;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY GRADES 1-4;;;
CARBAMAZEPINE;nan;rs192543598;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ETHANOL;nan;rs7900002;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;nan;rs2582405;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CISPLATIN;NAT2;rs1801280;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ANEMIA ;;
CYCLOPHOSPHAMIDE;NAT2;rs1801280;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ANEMIA ;;
ETHANOL;nan;rs56722963;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CISPLATIN;MUTYH;rs3219484;CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA GRADE 3-4;;;
CYCLOPHOSPHAMIDE;MUTYH;rs3219484;CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA GRADE 3-4;;;
CARBAMAZEPINE;ALK;rs187926838;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ETHANOL;MED19;rs576859;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;TMX2;rs576859;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
METHOTREXATE;ATIC;rs7563206;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ENZYMES;A2M;rs669;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGIC TRANSFORMATION;;;
METHOTREXATE;ATIC;rs3821353;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CHOP;NCF4;rs1883112;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CHOP;NCF4;rs1883112;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RITUXIMAB;NCF4;rs1883112;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RITUXIMAB;NCF4;rs1883112;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ENZYMES;F12;rs1801020;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
SUNITINIB;ABCB1;rs1128503;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;ABCB1;rs1128503;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
METHOTREXATE;ATIC;rs2372536;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ETHANOL;nan;rs6589386;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
ETHANOL;ADH1C;rs13125415;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
METHOTREXATE;ATIC;rs12995526;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CISPLATIN;RAD52;rs11226;AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA GRADE 3-4;;;
CYCLOPHOSPHAMIDE;RAD52;rs11226;AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA GRADE 3-4;;;
ETHANOL;SLC39A8;rs13135092;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CISPLATIN;LIG3;rs1052536;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA GRADE 3-4;;;
CYCLOPHOSPHAMIDE;LIG3;rs1052536;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA GRADE 3-4;;;
ABIRATERONE;TSPYL1;rs3828743;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PREDNISOLONE;TSPYL1;rs3828743;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEPRESSION;;;
CISPLATIN;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
FLUOROURACIL;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
RADIOTHERAPY;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
INDINAVIR;UGT1A1;rs4148323;AG;TOXICITY;INCREASED_RISK;EVENT;DISEASE;HYPERBILIRUBINEMIA ;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
METHOTREXATE;FPGS;rs10760502;AA;EFFICACY, TOXICITY, OTHER;DECREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
METHOTREXATE;FPGS;rs10106;TT;EFFICACY, TOXICITY, OTHER;DECREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
CAPECITABINE;DPYD;rs55886062;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs55886062;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TEGAFUR;DPYD;rs55886062;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;FPGS;rs10106;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ETHANOL;nan;rs9679319;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;nan;rs1402398;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;THSD7B;rs13382553;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
PEGINTERFERON ALFA-2A;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
METHOTREXATE;ABCB1;rs868755;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ETHANOL;nan;rs2673136;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;nan;rs13129401;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
METHOTREXATE;ABCB1;rs10280623;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ETHANOL;CADM2;rs62250713;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;ADH1B;rs75967634;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CARBOPLATIN;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEVER;;;
CARBOPLATIN;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
CYCLOPHOSPHAMIDE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEVER;;;
CYCLOPHOSPHAMIDE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
ETOPOSIDE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEVER;;;
ETOPOSIDE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
LOMUSTINE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEVER;;;
LOMUSTINE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEVER;;;
METHOTREXATE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
VINCRISTINE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEVER;;;
VINCRISTINE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
HEROIN;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_SEVERITY;OTHER;HEROIN DEPENDENCE;;;
PEGINTERFERON ALFA-2A;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
nan;CYP2A6;rs56113850;T;OTHER;DECREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
ETHANOL;PDE4B;rs6421482;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;nan;rs61767420;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;GCKR;rs1260326;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;nan;rs494904;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
nan;CHRNA5;rs503464;AA + AT;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
METHOTREXATE;SPATA9;rs72783407;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
METHOTREXATE;BIRC5;rs9904341;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS;;;
PROTEIN KINASE INHIBITORS;STAT6;rs324011;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ADVERSE EVENTS;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TEGAFUR;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
OPIOIDS;ANKK1;rs1800497;AA + AG;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
OPIOIDS;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
TAMOXIFEN;C1QTNF6;rs114557570;C;EFFICACY;DECREASED_RISK;SIDE_EFFECT;RECURRENCE FREE SURVIVAL;;;
nan;CHRNA5;rs637137;AA + AT;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
DOCETAXEL;VEGFA;rs833061;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;VEGFA;rs13207351;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DOCETAXEL;VEGFA;rs35864111;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ASPARAGINASE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
CYCLOPHOSPHAMIDE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
CYTARABINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
DAUNORUBICIN;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
DEXAMETHASONE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
DOXORUBICIN;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
LEUCOVORIN;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
MERCAPTOPURINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
METHOTREXATE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
PEGASPARGASE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
PREDNISONE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
THIOGUANINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
VINCRISTINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
ASPARAGINASE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
CYCLOPHOSPHAMIDE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
CYTARABINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
DAUNORUBICIN;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
DEXAMETHASONE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
DOXORUBICIN;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
LEUCOVORIN;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
MERCAPTOPURINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
METHOTREXATE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
PEGASPARGASE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
PREDNISONE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
THIOGUANINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
VINCRISTINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MINIMAL RESIDUAL DISEASE;;;
DOCETAXEL;VEGFA;rs699947;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
EXEMESTANE;nan;rs62293499;C;EFFICACY;DECREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ASPIRIN;CYP4F2;rs2108622;CT;OTHER;INCREASED_LIKELIHOOD;OTHER;PLATELET AGGREGATION WITH EPINEPHRINE;;;
CLOPIDOGREL;CYP4F2;rs2108622;CT;OTHER;INCREASED_LIKELIHOOD;OTHER;PLATELET AGGREGATION WITH EPINEPHRINE;;;
FLUOROURACIL;DPYD;rs4294451;AT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
CITALOPRAM;COL26A1;rs17135437;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEARING AND VISION-RELATED SIDE-EFFECTS;;;
CITALOPRAM;nan;rs16965962;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GENERAL SIDE-EFFECT BURDEN;;;
ALLOPURINOL;PSORS1C1;rs9263726;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ALLOPURINOL;PSORS1C2;rs9263726;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ASPIRIN;ACE;rs4292;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN INTOLERANCE;;;
CLOPIDOGREL;P2RY12;rs6809699;AA;;SIDE_EFFECT;EFFICACY;STRONGER AGGREAGTION;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;rs4982753;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIABETES MELLITUS;;;
FLUOROURACIL;DPYD;rs4294451;AT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
nan;ACE2;rs2074192;T;OTHER;INCREASED_SEVERITY;OTHER;COVID-19;;;
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CLOPIDOGREL RESISTANCE;;;
ASPIRIN;F2R;rs168753;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
ASPIRIN;P2RY1;rs1065776;CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NET DECREASE IN AA-INDUCED PLATELET AGGREGATION AFTER ASPIRIN TREATMENT;;;
MERCAPTOPURINE;ITPA;rs1127354;AC;LADME-PK;INCREASED_PK;METABOLISM;6-MMPN LEVELS;;;
nan;FGFR2;rs1219648;G;TOXICITY, OTHER;INCREASED_RISK;nan;DISEASE;BREAST NEOPLASMS ;;
ANASTROZOLE;nan;rs6735923;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ACENOCOUMAROL;CYP2C9;rs1799853;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;GASTROINTESTINAL HEMORRHAGE ;;
ASPIRIN;CYP2C19;rs4244285;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;rs7319981;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
nan;AGT;rs699;AG;OTHER;INCREASED_LIKELIHOOD;OTHER;COVID-19;;;
ANASTROZOLE;nan;rs1877193;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
CAPECITABINE;DPYD;rs2786783;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
nan;COMT;rs4818;CC + CG;OTHER;INCREASED_SEVERITY;OTHER;PAIN;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7662029;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7439366;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CEFACLOR;LIMD1;rs62242178;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
CEFACLOR;LIMD1;rs62242177;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
REPAGLINIDE;SLCO1B1;rs4149056;CC;OTHER, LADME-PK;INCREASED_PK;METABOLISM;MEAN PLASMA AUC;;;
DIHYDROPYRIDINE DERIVATIVES;ADRA1A;rs1048101;AG + GG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;KIDNEY DISORDER;;;
THALIDOMIDE;XRCC5;rs1051685;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
THALIDOMIDE;ERCC1;rs735482;AC + CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOZAPINE;GCG;rs13429709;C;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;GCG;rs13429709;C;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
CLOZAPINE;GLP1R;rs2268639;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;GLP1R;rs2268639;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
NICOTINE;OPRM1;rs1799971;AA + AG;DOSAGE;INCREASED_RISK;OTHER;SMOKING;;;
NICOTINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_RISK;OTHER;SMOKING;;;
TOLCAPONE;COMT;rs4680;AA;EFFICACY;DECREASED_EFFICACY;nan;DISEASE;ALCOHOLISM;;
NICOTINE;UGT2B10;rs112561475;AG + GG;LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION OF NICOTINE;;;
NICOTINE;UGT2B10;rs61750900;T;LADME-PK;DECREASED_PK;METABOLISM;NICOTINE GLUCURONIDATION;;;
CLOZAPINE;GCG;rs13429709;CC;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;GCG;rs13429709;CC;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;KIDNEY DISORDER;;;
METHAMPHETAMINE;HTR1A;rs878567;A;TOXICITY, OTHER;nan;nan;DISEASE;PSYCHOTIC DISORDER ;;
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
CISPLATIN;GALNT14;rs9679162;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
CISPLATIN;GALNT14;rs9679162;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;GALNT14;rs9679162;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
FLUOROURACIL;GALNT14;rs9679162;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
CAPTOPRIL;ACE;rs4291;AA;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;KIDNEY FAILURE ;;
ANTIEPILEPTICS;nan;rs4471527;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ANTIEPILEPTICS;nan;rs4471527;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ANTIPSYCHOTICS;LEPR;rs1137101;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;OBESITY ;;
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
ANTIEPILEPTICS;nan;rs77542827;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ANTIEPILEPTICS;nan;rs77542827;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
STAVUDINE;SAMHD1;rs8124728;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE (HEART-RATE LOWERING);;;
IRINOTECAN;TGFB1;rs1800469;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
CYTARABINE;DCK;rs4643786;CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DAUNORUBICIN;DCK;rs4643786;CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
MITOXANTRONE;DCK;rs4643786;CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTIEPILEPTICS;NIPAL2;rs199755581;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ANTIEPILEPTICS;NIPAL2;rs199755581;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
OXALIPLATIN;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
PACLITAXEL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
AMLODIPINE;ACE;rs4291;AA + AT;OTHER;DECREASED_;SIDE_EFFECT;FASTING GLUCOSE;;;
CHLORTHALIDONE;ACE;rs4291;AA + AT;OTHER;DECREASED_;SIDE_EFFECT;FASTING GLUCOSE;;;
LISINOPRIL;ACE;rs4291;AA + AT;OTHER;DECREASED_;SIDE_EFFECT;FASTING GLUCOSE;;;
SORAFENIB;KDR;rs1870377;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
IRINOTECAN;TGFBR2;rs3087465;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
SORAFENIB;KDR;rs1870377;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
SUNITINIB;FLT4;rs307826;CT;;SIDE_EFFECT;EFFICACY;REDUCED PROGRESSION-FREE SURVIVAL;;;
SUNITINIB;CYP3A5;rs776746;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DOSE REDUCTIONS DUE TO TOXICITY;;;
RITODRINE;PDE4B;rs17128809;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
CYCLOPHOSPHAMIDE;ABCC1;rs246221;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DOCETAXEL;ABCC1;rs246221;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
EPIRUBICIN;ABCC1;rs246221;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
SUNITINIB;FLT4;rs307821;AC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
BETA BLOCKING AGENTS;ADRB2;rs1042713;AG + GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HEART TRANSPLANTATION;;;
BETA BLOCKING AGENTS;ADRB2;rs1042713;AG + GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
SALBUTAMOL;nan;rs9552679;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SALBUTAMOL;COL22A1;rs6988229;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SALBUTAMOL;nan;rs17495520;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
ASPIRIN;CDH15;rs72819363;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;;
ASPIRIN;CDH15;rs72819363;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISEASE PROGRESSION;;;
CLOPIDOGREL;CDH15;rs72819363;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;;
CLOPIDOGREL;CDH15;rs72819363;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISEASE PROGRESSION;;;
ANTIEPILEPTICS;DDX12P;rs77491650;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ANTIEPILEPTICS;DDX12P;rs77491650;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
SALBUTAMOL;nan;rs1663332;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SALBUTAMOL;nan;rs1663330;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SALBUTAMOL;nan;rs17701271;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SALBUTAMOL;nan;rs518350;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SALBUTAMOL;nan;rs10511905;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SORAFENIB;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
SALBUTAMOL;CLOCK;rs1522113;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SALBUTAMOL;nan;rs1423515;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SALBUTAMOL;nan;rs1419555;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SALBUTAMOL;nan;rs6002674;C;EFFICACY;DECREASED_SENSITIVITY;TOLERANCE;BRONCHODILATOR RESPONSE (FEV1);;;
nan;ACE2;rs2106809;A;OTHER;INCREASED_LIKELIHOOD;OTHER;COVID-19;;;
DOXORUBICIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
ASPIRIN;CDH13;rs11859453;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CORONARY RESTENOSIS;;;
ASPIRIN;CDH13;rs11859453;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISEASE PROGRESSION;;;
CLOPIDOGREL;CDH13;rs11859453;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CORONARY RESTENOSIS;;;
CLOPIDOGREL;CDH13;rs11859453;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISEASE PROGRESSION;;;
ALLOPURINOL;CYCSP5;rs3099844;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
ALLOPURINOL;nan;rs1634776;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
PACLITAXEL;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
SALBUTAMOL;nan;rs11252394;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BRONCHODILATOR RESPONSE (FEV1);;;
SORAFENIB;SLCO1B1;rs4149056;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
COCAINE;GABRA2;rs11503014;G;TOXICITY;INCREASED_SEVERITY;OTHER;COCAINE DEPENDENCE;;;
COCAINE;OPRM1;rs2236256;C;TOXICITY;DECREASED_SEVERITY;OTHER;COCAINE DEPENDENCE;;;
SORAFENIB;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
SORAFENIB;SLCO1B1;rs2306283;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
METHOTREXATE;ABCB1;rs1128503;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
nan;AGT;rs699;A;OTHER;DECREASED_SEVERITY;OTHER;COVID-19;;;
CANGRELOR;P2RY12;rs9859552;TT;OTHER;nan;OTHER;20% AND 17% LESS INHIBITION OF PLATELET AGGREGATION WITH CRANGRELOR (0.05 AND 0.25 MICROM) IN-VITRO;;;
SORAFENIB;NOS3;rs2070744;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RADIOTHERAPY;TANC1;rs10497203;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
SORAFENIB;NOS3;rs1799983;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SORAFENIB;NOS3;rs1799983;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GLUCOCORTICOIDS;GLCCI1;rs37973;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;POOR RESPONSE;;;
FLUOROURACIL;ABCG2;rs7699188;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TUMOR RESPONSE RATE;;;
IRINOTECAN;ABCG2;rs7699188;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TUMOR RESPONSE RATE;;;
LEUCOVORIN;ABCG2;rs7699188;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TUMOR RESPONSE RATE;;;
SORAFENIB;NOS3;rs2070744;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;DECREASED_;SIDE_EFFECT;INTERVAL OF THERAPY TO LEUKOPENIA ONSET;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTLA4;rs3087243;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;PSORIASIS;;;
WARFARIN;VKORC1;rs8050894;G;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FBXL19;rs10782001;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PSORIASIS;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL23R;rs11209026;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PSORIASIS;;;
AZATHIOPRINE;NUDT15;rs116855232;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;LEUKOPENIA ;;
METHOTREXATE;MTHFR;rs1801133;A;LADME-PK;INCREASED_RISKPK;PK;PROLONGED HIGH CONCENTRATIONS;;;
WARFARIN;VKORC1;rs8050894;G;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ALCOHOL ABUSE ;;
MORPHINE;ABCB1;rs2032582;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MORPHINE;ABCB1;rs2032582;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
COLISTIMETHATE;SLC15A2;rs2257212;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
HEROIN;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEROIN DEPENDENCE ;;
ASPARAGINASE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FOLIC ACID DEFICIENCY ANEMIA;;;
DAUNORUBICIN;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FOLIC ACID DEFICIENCY ANEMIA;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FOLIC ACID DEFICIENCY ANEMIA;;;
PREDNISOLONE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FOLIC ACID DEFICIENCY ANEMIA;;;
VINCRISTINE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;FOLIC ACID DEFICIENCY ANEMIA;;;
ASPARAGINASE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
DAUNORUBICIN;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
PREDNISOLONE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
VINCRISTINE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
WARFARIN;GGCX;rs699664;CT + TT;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
CETUXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL;;;
WARFARIN;CYP2C9;rs28371685;CT;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
CETUXIMAB;CCND1;rs9344;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL;;;
WARFARIN;F7;rs510335;GT + TT;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
TACROLIMUS;IL10;rs1800871;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION;;;
ESCITALOPRAM;HTR1B;rs11568817;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE COGNITIVE EFFECTS;;;
CETUXIMAB;CCND1;rs9344;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
FLUVOXAMINE;MDGA2;rs1160351;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEXSUAL DYS;FUNCTION ;;
MILNACIPRAN;MDGA2;rs1160351;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEXSUAL DYS;FUNCTION ;;
PAROXETINE;MDGA2;rs1160351;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEXSUAL DYS;FUNCTION ;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOC1;rs429358;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-HDL CHOLESTEROL;;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOE;rs429358;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-HDL CHOLESTEROL;;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";TOMM40;rs429358;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-HDL CHOLESTEROL;;;
"COMBINATIONS""";APOC1;rs429358;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-HDL CHOLESTEROL;;;
"COMBINATIONS""";APOE;rs429358;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-HDL CHOLESTEROL;;;
"COMBINATIONS""";TOMM40;rs429358;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-HDL CHOLESTEROL;;;
"""RITONAVIR""";APOC1;rs429358;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-HDL CHOLESTEROL;;;
"""RITONAVIR""";APOE;rs429358;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-HDL CHOLESTEROL;;;
"""RITONAVIR""";TOMM40;rs429358;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-HDL CHOLESTEROL;;;
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE COGNITIVE EFFECTS;;;
TACROLIMUS;IL10;rs1800872;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION;;;
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;DECREASED_SENSITIVITY;DOSE_INCREASE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_FAILURE;
LEVODOPA;HOMER1;rs4704559;AG + GG;TOXICITY;DECREASED_RISK;nan;DISEASE;DYSKINESIAS ;;
CYCLOPHOSPHAMIDE;SOD2;rs4880;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DOCETAXEL;SOD2;rs4880;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
EPIRUBICIN;SOD2;rs4880;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
LEVODOPA;HOMER1;rs4704559;AG + GG;TOXICITY;DECREASED_RISK;nan;DISEASE;HALLUCINATIONS ;;
ESTRADIOL;NFE2L2;rs6721961;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;VENOUS THROMBOEMBOLISM ;;
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
WARFARIN;F2;rs5896;CT + TT;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CISPLATIN;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ONE YEAR PROGRESSION FREE SURVIVAL;;;
PACLITAXEL;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ONE YEAR PROGRESSION FREE SURVIVAL;;;
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FLU-LIKE SYMPTOMS;;;
CLOPIDOGREL;CES1;rs71647871;CT;LADME-PD;INCREASED_LIKELIHOOD;EFFICACY;PLATELET REACTIVITY;;;
nan;IL6;rs1800797;AG + GG;OTHER;INCREASED_SEVERITY;OTHER;PAIN;;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
nan;CDKN2B-AS1;rs10965219;G;OTHER;INCREASED_LIKELIHOOD;OTHER;PLATELET REACTIVITY;;;
MORPHINE;COMT;rs4680;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NUMERICAL RATING SCALE (NRS) SCORE FOR PAIN DURING PAINFUL PROCEDURE;;;
ETHANOL;RABGAP1L;rs61826952;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
MORPHINE;COMT;rs4680;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL MEAN NUMERICAL RATING SCALE (NRS) SCORE FOR PAIN;;;
nan;CDKN2B-AS1;rs10965219;G;OTHER;INCREASED_RISK;nan;DISEASE;CORONARY ARTERY DISEASE ;;
TRAMADOL;CYP2D6;rs1058172;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERDOSE;;;
CLOZAPINE;CYP2D6;rs16947;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
TRAMADOL;CYP2B6;rs4803419;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVERDOSE;;;
nan;ACE2;rs4240157;CC;OTHER;INCREASED_RISK;OTHER;DEATH;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TROUGH CONCENTRATIONS;;;
nan;ACE2;rs4240157;C;OTHER;INCREASED_LIKELIHOOD;OTHER;COVID-19;;;
CLOZAPINE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;;
CLOZAPINE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CLOZAPINE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PK;METABOLISM;CONCENTRATION-TO-ADJUSTED DOSE RATIO;;;
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PANCREATITIS;;;
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
CLOZAPINE;CYP2D6;rs16947;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;;
CLOZAPINE;CYP2D6;rs16947;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
HMG COA REDUCTASE INHIBITORS;COQ5;rs10849757;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
ZOLEDRONATE;FDPS;rs2297480;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS;;;
HMG COA REDUCTASE INHIBITORS;COQ3;rs11548336;TT;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
IMATINIB;CYP2B6;rs3745274;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
CYCLOPHOSPHAMIDE;ABCB1;rs2032582;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
DOXORUBICIN;ABCB1;rs2032582;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
DOXORUBICIN;CYP2B6;rs3211371;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
ATORVASTATIN;CLMN;rs8014194;A;;SIDE_EFFECT;EFFICACY;CHANGE IN TOTAL CHOLESTEROL;;;
PRAVASTATIN;CLMN;rs8014194;A;;SIDE_EFFECT;EFFICACY;CHANGE IN TOTAL CHOLESTEROL;;;
SIMVASTATIN;CLMN;rs8014194;A;;SIDE_EFFECT;EFFICACY;CHANGE IN TOTAL CHOLESTEROL;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs12721655;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
DOXORUBICIN;CYP2B6;rs12721655;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
NINTEDANIB;DSP;rs2076295;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
CYCLOPHOSPHAMIDE;CYP2B6;rs8192709;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO PROGRESSION;;;
DOXORUBICIN;CYP2B6;rs8192709;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO PROGRESSION;;;
FLUOROURACIL;MTHFR;rs1801133;GG;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
LEUCOVORIN;MTHFR;rs1801133;GG;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
WARFARIN;F2;rs5896;CT + TT;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
BUSULFAN;CYP2C19;rs12248560;CC;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO;;;
CAPECITABINE;MTHFR;rs1801131;TT;TOXICITY;DECREASED_;nan;DISEASE;DRUG TOXICITY ;;
WARFARIN;F7;rs510317;GG;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TAP1;rs1135216;CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;PSORIASIS;;;
OLANZAPINE;ANKK1;rs1800497;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEADACHE ;;
QUETIAPINE;ANKK1;rs1800497;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEADACHE ;;
RISPERIDONE;ANKK1;rs1800497;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HEADACHE ;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLC12A8;rs651630;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;PSORIASIS;;;
RADIOTHERAPY;TANC1;rs264588;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
RADIOTHERAPY;TANC1;rs264631;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
BUSULFAN;CYP2C9;rs1799853;CT + TT;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO;;;
CYCLOPHOSPHAMIDE;SLC22A16;rs714368;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
DOXORUBICIN;SLC22A16;rs714368;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
RADIOTHERAPY;TANC1;rs7582141;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
FLUOROURACIL;ABCG2;rs7699188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY;;;
IRINOTECAN;ABCG2;rs7699188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY;;;
LEUCOVORIN;ABCG2;rs7699188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY;;;
RADIOTHERAPY;TANC1;rs6432512;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
RADIOTHERAPY;TANC1;rs264663;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
FLUOROURACIL;ABCB1;rs2032582;CC;;SIDE_EFFECT;EFFICACY;OVERALL SURVIVAL;;;
IRINOTECAN;ABCB1;rs2032582;CC;;SIDE_EFFECT;EFFICACY;OVERALL SURVIVAL;;;
LEUCOVORIN;ABCB1;rs2032582;CC;;SIDE_EFFECT;EFFICACY;OVERALL SURVIVAL;;;
RADIOTHERAPY;TANC1;rs264651;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
DOXORUBICIN;CYP2B6;rs3745274;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs8192709;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
DOXORUBICIN;CYP2B6;rs8192709;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
PLATINUM COMPOUNDS;XPC;rs2228000;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
PLATINUM COMPOUNDS;XPC;rs2228000;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMATOLOGIC DISORDER;;;
PLATINUM COMPOUNDS;XPC;rs2228000;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
SECUKINUMAB;ERAP2;rs2248374;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
CYCLOPHOSPHAMIDE;SLC22A16;rs12210538;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
DOXORUBICIN;SLC22A16;rs12210538;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
CYCLOPHOSPHAMIDE;SLC22A16;rs723685;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
DOXORUBICIN;SLC22A16;rs723685;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
CYCLOPHOSPHAMIDE;SLC22A16;rs6907567;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
DOXORUBICIN;SLC22A16;rs6907567;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DOSE DELAY;;;
ASPIRIN;LTC4S;rs730012;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;URTICARIA;;;
ATORVASTATIN;COQ2;rs4693075;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MUSCULAR DISEASES ;;
ROSUVASTATIN;COQ2;rs4693075;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MUSCULAR DISEASES ;;
ATEZOLIZUMAB;SEMA5A;rs35719165;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
AVELUMAB;SEMA5A;rs35719165;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DURVALUMAB;SEMA5A;rs35719165;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
IPILIMUMAB;SEMA5A;rs35719165;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NIVOLUMAB;SEMA5A;rs35719165;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PEMBROLIZUMAB;SEMA5A;rs35719165;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
METHOTREXATE;MTHFD1;rs2236225;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
WARFARIN;VKORC1;rs2884737;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
EFAVIRENZ;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;RISE IN CD4-CELL COUNT;;;
NELFINAVIR;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;RISE IN CD4-CELL COUNT;;;
EFAVIRENZ;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;FAVORABLE VIROLOGIC RESPONSES;;;
ATEZOLIZUMAB;EDIL3;rs1862167;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
AVELUMAB;EDIL3;rs1862167;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DURVALUMAB;EDIL3;rs1862167;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
IPILIMUMAB;EDIL3;rs1862167;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NIVOLUMAB;EDIL3;rs1862167;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PEMBROLIZUMAB;EDIL3;rs1862167;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATION;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
DOXORUBICIN;ABCC2;rs17222723;A;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
AMITRIPTYLINE;ABCB1;rs2032583;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs2032583;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs2032583;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs2032583;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
AZATHIOPRINE;XDH;rs2295475;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
nan;ATP8B3;rs10421558;G;TOXICITY;DECREASED_LIKELIHOOD;OTHER;ASPIRIN-INDUCED ASTHMA;;;
nan;ABCB1;rs1045642;AA;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
ISONIAZID;NAT2;rs1799929;T;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;rs1799929;T;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;rs1799929;T;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;rs1799930;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;rs1799930;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;rs1799930;A;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO PROGRESSION;;;
DOXORUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO PROGRESSION;;;
EPIRUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO PROGRESSION;;;
RITONAVIR;APOC3;rs2854117;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERTRIGLYCERIDEMIA ;;
nan;AGTR1;rs5186;CC;OTHER;INCREASED_RISK;nan;DISEASE;ISCHEMIA ;;
IMATINIB;ARID5B;rs10821936;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
ISONIAZID;NAT2;rs1041983;T;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;rs1041983;T;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;rs1041983;T;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;rs1801280;C;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;rs1801280;C;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;rs1801280;C;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
FEXOFENADINE;ABCB1;rs1045642;AA;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CMIN VALUES;;;
EFAVIRENZ;CYP2B6;rs4803419;T;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CMIN VALUES;;;
IMATINIB;ATIC;rs2372536;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
ATORVASTATIN;CYP3A4;rs2740574;CC + CT;OTHER;DECREASED_RISK;OTHER;DOSE DECREASE OR DRUG SWITCHING;;;
SIMVASTATIN;CYP3A4;rs2740574;CC + CT;OTHER;DECREASED_RISK;OTHER;DOSE DECREASE OR DRUG SWITCHING;;;
FEXOFENADINE;ABCB1;rs2032582;AA;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
RITODRINE;KCNMB2;rs7625907;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CMIN VALUES;;;
DOXORUBICIN;ABCC1;rs45511401;T;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;ABCC2;rs8187710;A;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
CAPECITABINE;SMAD7;rs4939827;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FOLFOX;SMAD7;rs4939827;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TEGAFUR;SMAD7;rs4939827;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOXORUBICIN;NCF4;rs1883112;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
nan;ATP8B3;rs10403288;A;TOXICITY;DECREASED_LIKELIHOOD;OTHER;ASPIRIN-INDUCED ASTHMA;;;
SIMVASTATIN;ABCB1;rs1128503;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYALGIA;;;
nan;ACE2;rs2074192;T;OTHER;INCREASED_SEVERITY;OTHER;COVID-19;;;
DOXORUBICIN;CYBA;rs4673;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
SIMVASTATIN;ABCB1;rs1045642;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYALGIA;;;
DOXORUBICIN;RAC2;rs13058338;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
SIMVASTATIN;ABCB1;rs2032582;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYALGIA;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION-TO-ADJUSTED DOSE RATIO;;;
ATORVASTATIN;PON1;rs705379;AA + AG;;SIDE_EFFECT;EFFICACY;CHANGE IN HDL-CHOLESTEROL;;;
SIMVASTATIN;PON1;rs705379;AA + AG;;SIDE_EFFECT;EFFICACY;CHANGE IN HDL-CHOLESTEROL;;;
ATORVASTATIN;PON1;rs662;CC + CT;;SIDE_EFFECT;EFFICACY;CHANGE IN HDL-CHOLESTEROL;;;
SIMVASTATIN;PON1;rs662;CC + CT;;SIDE_EFFECT;EFFICACY;CHANGE IN HDL-CHOLESTEROL;;;
ATORVASTATIN;PON1;rs705379;GG;OTHER;DECREASED_;OTHER;OXIDATIVE STRESS;;;
CLOZAPINE;TACR1;rs58933792;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRY MOUTH;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_PK;METABOLISM;CONCENTRATION/DOSE RATIO;;;
FLUCONAZOLE;CYP3A5;rs776746;CC;DOSAGE;DECREASED_PK;PK;TIME TO REACH STABLE DOSE OF TACROLIMUS;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_PK;PK;TIME TO REACH STABLE DOSE OF TACROLIMUS;;;
FLUCONAZOLE;CYP3A5;rs776746;CC;DOSAGE;DECREASED_PK;PK;DOSE OF TACROLIMUS;;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_PK;PK;DOSE OF TACROLIMUS;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_PK;PK;TIME TO REACH STABLE DOSE;;;
TAMOXIFEN;SLCO1A2;rs10841795;AG + GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DIZZINESS;;;
CLOZAPINE;ERBB4;rs3942465;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRY MOUTH;;;
DIAZEPAM;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ADVERSE EVENTS;;;
"""ACE INHIBITORS";ADRB2;rs1042713;GG;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION;;;
"PLAIN""";ADRB2;rs1042713;GG;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION;;;
"""ANGIOTENSIN II ANTAGONISTS""";ADRB2;rs1042713;GG;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION;;;
"""BETA BLOCKING AGENTS""";ADRB2;rs1042713;GG;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION;;;
"""DIGOXIN""";ADRB2;rs1042713;GG;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION;;;
"""DIURETICS""";ADRB2;rs1042713;GG;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION;;;
"""SPIRONOLACTONE""";ADRB2;rs1042713;GG;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION;;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;ITPA;rs1127354;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
L-ASPARAGINE;ASNS;rs1049674;AT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CUSHING SYNDROME;;;
PREDNISONE;ASNS;rs1049674;AT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CUSHING SYNDROME;;;
VINCRISTINE;ASNS;rs1049674;AT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CUSHING SYNDROME;;;
"""ACE INHIBITORS";NOS3;rs1799983;TT;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION;;;
"PLAIN""";NOS3;rs1799983;TT;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION;;;
"""ANGIOTENSIN II ANTAGONISTS""";NOS3;rs1799983;TT;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION;;;
"""BETA BLOCKING AGENTS""";NOS3;rs1799983;TT;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION;;;
"""DIGOXIN""";NOS3;rs1799983;TT;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION;;;
"""DIURETICS""";NOS3;rs1799983;TT;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION;;;
"""SPIRONOLACTONE""";NOS3;rs1799983;TT;OTHER;INCREASED_RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION;;;
EFAVIRENZ;nan;rs2853826;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE;;;
LOPINAVIR;nan;rs2853826;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE;;;
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;nan;rs2853826;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE;;;
RITONAVIR;nan;rs2853826;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE;;;
DIAZEPAM;CYP2C19;rs12248560;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ADVERSE EVENTS;;;
"""ACE INHIBITORS";ADRB1;rs1801253;GG;OTHER;DECREASED_RISK;OTHER;EMERGENCIES;;;
"PLAIN""";ADRB1;rs1801253;GG;OTHER;DECREASED_RISK;OTHER;EMERGENCIES;;;
"""ANGIOTENSIN II ANTAGONISTS""";ADRB1;rs1801253;GG;OTHER;DECREASED_RISK;OTHER;EMERGENCIES;;;
"""BETA BLOCKING AGENTS""";ADRB1;rs1801253;GG;OTHER;DECREASED_RISK;OTHER;EMERGENCIES;;;
"""DIGOXIN""";ADRB1;rs1801253;GG;OTHER;DECREASED_RISK;OTHER;EMERGENCIES;;;
"""DIURETICS""";ADRB1;rs1801253;GG;OTHER;DECREASED_RISK;OTHER;EMERGENCIES;;;
"""SPIRONOLACTONE""";ADRB1;rs1801253;GG;OTHER;DECREASED_RISK;OTHER;EMERGENCIES;;;
L-ASPARAGINE;ABCB1;rs9282564;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
PREDNISONE;ABCB1;rs9282564;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
VINCRISTINE;ABCB1;rs9282564;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
OLANZAPINE;UGT1A4;rs2011425;GG + GT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;AUTONOMIC NERVOUS SYSTEM DISORDER;;;
OLANZAPINE;CYP3A4;rs2740574;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRY MOUTH ;;
CABAZITAXEL;ABCB1;rs17327624;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SIMVASTATIN;ABCB1;rs1128503;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN TOTAL CHOLESTEROL;;;
OLANZAPINE;UGT1A4;rs2011425;GG + GT;LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATED METABOLITES OF OLANZAPINE;;;
CYCLOSPORINE;ABCB1;rs1045642;AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;GINGIVAL HYPERPLASIA ;;
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ACUTE REJECTION;;;
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DRUG RESISTANCE;;;
CABAZITAXEL;ABCB1;rs2235040;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ASTHENIA;;;
TACROLIMUS;NOD2;rs2066844;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;HOSPITAL STAY;;;
TACROLIMUS;CYP3A5;rs776746;TT;EFFICACY;INCREASED_RISK;OTHER;ACUTE REJECTION;;;
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;INCREASED_RISK;OTHER;ACUTE REJECTION;;;
CYCLOSPORINE;CYP3A4;rs2740574;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
TACROLIMUS;CYP3A4;rs2740574;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
WARFARIN;VKORC1;rs2359612;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE;;;
AZATHIOPRINE;FTO;rs16952570;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;FTO;rs16952570;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;FTO;rs16952570;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;FTO;rs16952570;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
OSELTAMIVIR;CES1;rs121912777;CT + TT;LADME-PK;PK;PK;SIGNIFICANTLY LARGER MEAN AUC OF OSELTAMIVIR;;;
OSELTAMIVIR;CES1;rs121912777;CT + TT;LADME-PK;PK;PK;LOWER CMAX OF OSELTAMIVIR CARBOXYLATE;;;
OSELTAMIVIR;CES1;rs121912777;CT + TT;LADME-PK;PK;PK;AND A SMALLER OSELTAMIVIR CARBOXYLATE-TO-OSELTAMIVIR AUC RATIO;;;
AZATHIOPRINE;FTO;rs16952570;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;FTO;rs16952570;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;FTO;rs16952570;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;FTO;rs16952570;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PK;METABOLISM;PBMC CONCENTRATIONS;;;
CABAZITAXEL;CYP2C8;rs11572093;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ASTHENIA;;;
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE;;;
CITALOPRAM;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTOLERANCE;;;
WARFARIN;VKORC1;rs9934438;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE;;;
NORTRIPTYLINE;GNB3;rs5443;TT;TOXICITY;nan;nan;DISEASE;WEIGHT GAIN ;;
WARFARIN;VKORC1;rs8050894;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE;;;
NORTRIPTYLINE;GNB3;rs5443;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SLEEP INITIATION AND MAINTENANCE DISORDERS;;;
WARFARIN;VKORC1;rs2884737;AC + CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE;;;
NORTRIPTYLINE;GNB3;rs5443;TT;;SIDE_EFFECT;EFFICACY;IMPROVEMENTS IN NEUROVEGETATIVE SYMPTOMS;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATION;;;
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATION;;;
nan;SLC19A1;rs1051266;C;OTHER;INCREASED_LIKELIHOOD;OTHER;DOWN SYNDROME;;;
DIGOXIN;ABCB1;rs1045642;AA;LADME-PK;DECREASED_PK;METABOLISM;DUODENAL ABSORPTION OF DIGOXIN AFTER DIRECT DELIVERY TO THE SURFACE OF THE DUODENUM BY ENDOSCOPE;;;
OLANZAPINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
CAPECITABINE;DPYD;rs3918290;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs3918290;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
TEGAFUR;DPYD;rs3918290;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
TEGAFUR;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
OLANZAPINE;ABCB1;rs1045642;A;;SIDE_EFFECT;EFFICACY;POSITIVE RELATIONSHIP BETWEEN OLANZAPINE PLASMA LEVELS AND POSITIVE SYMPTOM REDUCTION COMPARED TO SUBJECTS WITH THE GG GENOTYPE;;;
OLANZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
NICOTINE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
OLANZAPINE;DRD2;rs6275;A;OTHER, LADME-PK;INCREASED_LIKELIHOOD;OTHER;PROLACTIN;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR1;rs9024;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CARDIOMYOPATHIES ;;
OLANZAPINE;DRD2;rs6279;G;OTHER, LADME-PK;INCREASED_LIKELIHOOD;OTHER;PROLACTIN;;;
CEPHALEXIN;nan;rs34545984;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
OLANZAPINE;DRD2;rs1124493;T;OTHER, LADME-PK;INCREASED_LIKELIHOOD;OTHER;PROLACTIN;;;
OLANZAPINE;DRD2;rs2734841;A;OTHER, LADME-PK;INCREASED_LIKELIHOOD;OTHER;PROLACTIN;;;
ASPIRIN;nan;rs115346678;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
METHOTREXATE;MTHFD1;rs2236225;A;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EVENT FREE SURVIVAL;;;
SIMVASTATIN;PPARA;rs4253728;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL;;;
METHOTREXATE;MTHFR;rs1801133;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
CODEINE;WBP2NL;rs9620007;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY ;
CODEINE;OPRM1;rs62436463;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
HYDROCODONE;OPRM1;rs62436463;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
OXYCODONE;OPRM1;rs62436463;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
TRAMADOL;OPRM1;rs62436463;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
METFORMIN;SLC22A2;rs316009;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
METFORMIN;SLC22A2;rs316019;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SIMVASTATIN;PPARA;rs4823613;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL;;;
nan;ANKK1;rs1800497;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
NICOTINE;COMT;rs4680;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SUICIDAL IDEATION;;;
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DELIBERATE SELF-HARM;;;
NICOTINE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
AMIODARONE;KCNE1;rs1805128;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TORSADES DE POINTES ;;
ANTIBIOTICS;KCNE1;rs1805128;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TORSADES DE POINTES ;;
ANTIPSYCHOTICS;KCNE1;rs1805128;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TORSADES DE POINTES ;;
DIURETICS;KCNE1;rs1805128;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TORSADES DE POINTES ;;
QUINIDINE;KCNE1;rs1805128;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TORSADES DE POINTES ;;
SOTALOL;KCNE1;rs1805128;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TORSADES DE POINTES ;;
NICOTINE;OPRM1;rs1799971;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
NICOTINE;OPRM1;rs1799971;AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
BUPROPION;ANKK1;rs1800497;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
OLANZAPINE;DRD2;rs2734842;G;OTHER, LADME-PK;INCREASED_LIKELIHOOD;OTHER;PROLACTIN;;;
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
PYRIMIDINE ANALOGUES;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ROSUVASTATIN;ABCG2;rs2231142;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PERCENTAGE CHANGE IN LDL-CHOLESTEROL LEVELS;;;
AMITRIPTYLINE;CYP2C19;rs4244285;AA;OTHER, LADME-PK;INCREASED_PK;METABOLISM;LOG METABOLIC RATIO OF AMITRIPTYLINE/NORTRIPTYLINE;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DEATH;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OR STROKE;;;
ROSUVASTATIN;SLCO1B1;rs4149056;TT;LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATIONS OF ROSUVASTATIN;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DEATH;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OR STROKE;;;
ROSUVASTATIN;ABCG2;rs2231142;TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS OF ROSUVASTATIN;;;
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR DEATH;;;
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OR STROKE;;;
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CORONARY RESTENOSIS;;;
CISPLATIN;CCL2;rs1024611;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
DOCETAXEL;CCL2;rs1024611;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;CCL2;rs1024611;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
nan;SERPINE1;rs7242;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;MAJOR DEPRESSIVE DISORDER ;;
nan;SERPINE1;rs2227684;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;MAJOR DEPRESSIVE DISORDER ;;
METHOTREXATE;MTHFR;rs1801131;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CLINICAL RESPONSE;;;
GEMCITABINE;CDA;rs60369023;A;TOXICITY, LADME-PK;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
METHOTREXATE;GGH;rs3758149;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
BISPHOSPHONATES;IL1B;rs16944;GG;EFFICACY;INCREASED_LIKELIHOODPK;PK;RESISTANCE;;;
CLODRONATE;VDR;rs1544410;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESISTANCE;;;
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER ANTI-COAGULATION;;;
CLODRONATE;VDR;rs731236;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESISTANCE;;;
CYTARABINE;NT5C3A;rs3750117;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;INDUCTION FAILURE;;;
IDARUBICIN;NT5C3A;rs3750117;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;INDUCTION FAILURE;;;
ATORVASTATIN;APOA5;rs662799;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN LDLC;;;
LOVASTATIN;APOA5;rs662799;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN LDLC;;;
SIMVASTATIN;APOA5;rs662799;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN LDLC;;;
CITALOPRAM;HTR2A;rs6311;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
SERTRALINE;HTR2A;rs6311;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
CISPLATIN;IL6;rs1800796;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
DOCETAXEL;IL6;rs1800796;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
FLUOROURACIL;IL6;rs1800796;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CITALOPRAM;HTR2A;rs6313;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
BUPRENORPHINE;OPRM1;rs648893;AG + GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
NALOXONE;OPRM1;rs648893;AG + GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DEPRESSION;;;
METHOTREXATE;ADORA2A;rs2267076;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
METHOTREXATE;ADORA2A;rs2236624;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
METHOTREXATE;ADORA2A;rs2298383;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;OTHER;INCREASED_PK;PK;BLOOD PRESSURE;;;
METHOTREXATE;ADORA2A;rs3761422;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
CISPLATIN;TNF;rs1799964;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
DOCETAXEL;TNF;rs1799964;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
FLUOROURACIL;TNF;rs1799964;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DRUG RESISTANCE;;;
ASPIRIN;PEAR1;rs12041331;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;PEAR1;rs12041331;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CISPLATIN;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
DOCETAXEL;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
HYDROCHLOROTHIAZIDE;NELL1;rs12279250;C;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;PLASMA TRIGLYCERIDES;;;
BUPRENORPHINE;OPRD1;rs678849;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANXIETY DISORDERS;;;
NALOXONE;OPRD1;rs678849;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANXIETY DISORDERS;;;
ARIPIPRAZOLE;DAOA;rs2391191;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;BRIEF PSYCHIATRIC RATING SCALE SCORES;;;
BUPRENORPHINE;OPRD1;rs569356;A;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CRAVING;;;
NALOXONE;OPRD1;rs569356;A;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CRAVING;;;
OLANZAPINE;HTR2C;rs6318;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED_RISK;OTHER;TACROLIMUS NEPHROTOXICITY;;;
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY, TOXICITY;INCREASED_RISK;OTHER;SUBCLINICAL ALLOGRAFT NEPHROPATHY;;;
SIMVASTATIN;CYBA;rs4673;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN DNA DAMAGE;;;
BUPROPION;CYP2B6;rs3211371;CT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
ASPIRIN;ABCB1;rs1045642;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DRUG RESISTANCE;;;
OLANZAPINE;DRD3;rs6280;CC;;SIDE_EFFECT;EFFICACY;GREATER POSITIVE SYMPTOM IMPROVEMENT AND POSITIVE SYMPTOM REMISSION;;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
OLANZAPINE;RGS4;rs951439;CT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
CABAZITAXEL;TUBB1;rs151352;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RISPERIDONE;RGS4;rs951439;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
OLANZAPINE;RGS4;rs951439;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;POSITIVE RESPONSE;;;
PERPHENAZINE;RGS4;rs951439;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;POSITIVE RESPONSE;;;
CABAZITAXEL;CYP2C8;rs1341164;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OLANZAPINE;LEP;rs4731426;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
HEROIN;GRM3;rs13242038;T;OTHER;INCREASED_RISK;nan;DISEASE;HEROIN DEPENDENCE ;;
AMITRIPTYLINE;ABCB1;rs2235015;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs2235015;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs2235015;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs2235015;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
nan;ACE;rs4343;G;LADME-PK;INCREASED_LIKELIHOOD;OTHER;ACE ACTIVITY;;;
ANTIDEPRESSANTS;HTR1A;rs6295;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TREATMENT RESPONSE;;;
OPIOIDS;ABCB1;rs9282564;CC + CT;TOXICITY;DECREASED_RISK;OTHER;DEATH;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;rs1045642;AA;EFFICACY, LADME-PK;INCREASED_LIKELIHOOD;EFFICACY;COMPLETE RESPONSE;;;
TAXANES;ABCB1;rs1045642;AA;EFFICACY, LADME-PK;INCREASED_LIKELIHOOD;EFFICACY;COMPLETE RESPONSE;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PAROXETINE;HTR1A;rs6295;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;NON-RESPONSE;;;
SERTRALINE;HTR1A;rs6295;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;NON-RESPONSE;;;
OPIOIDS;KCNJ6;rs2070995;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;FREQUENCY OF RESCUE ANALGESIC ADMINISTRATION;;;
WARFARIN;VKORC1;rs8050894;G;DOSAGE, ;SIDE_EFFECT;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED  RISK OF OVER-ANTICOAGULATION;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE, ;SIDE_EFFECT;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED  RISK OF OVER-ANTICOAGULATION;;;
NEVIRAPINE;CYP2B6;rs28399499;CT;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
NEVIRAPINE;CYP3A5;rs776746;CC + CT;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs3849942;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
METHAMPHETAMINE;DTNBP1;rs3213207;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PSYCHOTIC DISORDER;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs2814707;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
METHAMPHETAMINE;PICK1;rs2076369;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;RELAPSE OF PSYCHOSIS;;;
NEVIRAPINE;CYP2B6;rs12721646;CT + TT;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;GBP6;rs928655;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL GASTROINTESTINAL_TOXICITY;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs774359;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CSRP3;rs983332;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs868856;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE BASE ON DISEASE ACTIVITY SCORE IN 44 JOINTS IMPROVEMENT AT 6 MONTHS OF TREATMENT;;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE ACTIVITY AS ASSESSED BY THE PHYSICIAN;;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;LESS PATIENT-ASSESSED DIFFICULTY WITH PHYSICAL TASKS;;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;AND FEWER SWOLLEN JOINTS;;;
GEFITINIB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
ANTIANDROGENS;AKR1C3;rs12529;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;PROSTATE CANCER-SPECIFIC MORTALITY;;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_;OTHER;MAINTENANCE DOSE OF WARFARIN;;;
CISPLATIN;ERCC1;rs11615;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEPHROTOXICITY ;;
CYCLOPHOSPHAMIDE;ERCC1;rs11615;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEPHROTOXICITY ;;
CISPLATIN;TP53;rs1042522;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
CYCLOPHOSPHAMIDE;TP53;rs1042522;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
PACLITAXEL;CYP2C8;rs11572080;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES ;;
METHOTREXATE;ABCC1;rs2238476;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6028945;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6071980;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CST5;rs6138150;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
CISPLATIN;GSTP1;rs1695;AA;EFFICACY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;GSTP1;rs1695;AA;EFFICACY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION FREE SURVIVAL;;;
ANTIPSYCHOTICS;CLCN6;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;METABOLIC SYNDROME ;;
ANTIPSYCHOTICS;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;METABOLIC SYNDROME ;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854548;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854555;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs7046653;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
BUPRENORPHINE;CYP3A4;rs2740574;CC + CT;EFFICACY;INCREASED_RISK;OTHER;SUBSTANCE WITHDRAWAL SYNDROME;;;
WARFARIN;VKORC1;rs9934438;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE OF INR (TTR);;;
DOCETAXEL;nan;rs11185648;CT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS IN JAPANESE PATIENTS ;
DOCETAXEL;RXRA;rs11185647;AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA, NEUTROPENIA ;;
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
DOCETAXEL;RXRA;rs2234753;AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
DOCETAXEL;RXRA;rs6413517;GT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
DOCETAXEL;RXRA;rs62576288;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
nan;SCN1A;rs2298771;CT;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;EPILEPSY ;;
METHOTREXATE;nan;rs9345389;G;TOXICITY;nan;SIDE_EFFECT;END-OF-INDUCTION MINIMAL RISIDUAL DISEASE (MRD) IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND IS ALSO ASSOCIATED WITH GREATER METHOTREXATE CLEARANCE.;;;
DOCETAXEL;HNF4A;rs6130615;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
ANTIPSYCHOTICS;HTR2A;rs7997012;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DRUG RESISTANCE;;;
SIMVASTATIN;nan;rs76103438;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
DIAZEPAM;CYP3A4;rs35599367;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ADVERSE EVENTS;;;
ANTIPSYCHOTICS;HTR2A;rs6314;AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DRUG RESISTANCE;;;
DOCETAXEL;HNF4A;rs2273618;CT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
DOCETAXEL;HNF4A;rs3746574;CT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE, EFFICACY;nan;OTHER;A MORE RAPID ATTAINMENT OF TARGET INR AND HIGHER FREQUENCY OF DOSE ADJUSTMENTS;;;
DOCETAXEL;NR1I2;rs3732360;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
nan;NRXN1;rs985919;C;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
"""BETA BLOCKING AGENTS";NEDD4L;rs4149601;AG + GG;EFFICACY;DECREASED_RISK;OTHER;CARDIOVASCULAR EVENTS;;;
"SELECTIVE""";NEDD4L;rs4149601;AG + GG;EFFICACY;DECREASED_RISK;OTHER;CARDIOVASCULAR EVENTS;;;
"""DIURETICS""";NEDD4L;rs4149601;AG + GG;EFFICACY;DECREASED_RISK;OTHER;CARDIOVASCULAR EVENTS;;;
MEPERIDINE;SERINC5;rs185462714;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
CISPLATIN;GSTA1;rs3957357;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;NR1I2;rs3732359;AA;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
nan;CHRNA5;rs17408276;C;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
BETA BLOCKING AGENTS;nan;rs139945292;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS;;;
NICOTINE;COMT;rs4680;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MUSCULAR DISEASES ;;
PENICILLIN G;nan;rs115200108;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
PENICILLIN V;nan;rs115200108;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
NICOTINE;COMT;rs4680;AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RELAPSE;;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
DOCETAXEL;NR1I2;rs3814058;CC + TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
nan;CHRNA5;rs16969968;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
nan;NRXN1;rs1882296;C;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
DOCETAXEL;NR1I3;rs10538494;TT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
CODEINE;SEPTIN3;rs739296;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
CODEINE;WBP2NL;rs739296;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
HYDROCODONE;SEPTIN3;rs739296;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
HYDROCODONE;WBP2NL;rs739296;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
OXYCODONE;SEPTIN3;rs739296;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
OXYCODONE;WBP2NL;rs739296;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
TRAMADOL;SEPTIN3;rs739296;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
TRAMADOL;WBP2NL;rs739296;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
MEPERIDINE;FIP1L1;rs113100019;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
DOCETAXEL;NR1I3;rs75114882;AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
nan;NRXN1;rs10865246;C;OTHER;INCREASED_SEVERITY;nan;DISEASE;TOBACCO USE DISORDER ;;
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
DOCETAXEL;NR1I3;rs2501873;CC;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
CISPLATIN;ERCC2;rs1799793;CT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
CISPLATIN;ERCC1;rs3212986;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEPHROTOXICITY ;;
CYCLOPHOSPHAMIDE;ERCC1;rs3212986;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEPHROTOXICITY ;;
CISPLATIN;XRCC1;rs25487;CC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
CYCLOPHOSPHAMIDE;XRCC1;rs25487;CC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
MEPERIDINE;nan;rs11049274;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
DOCETAXEL;RXRA;rs1536475;AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
CISPLATIN;XPC;rs2228001;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
DOCETAXEL;NR1I3;rs2502815;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
DOCETAXEL;NR1I3;rs9725457;AA;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA ;;
CISPLATIN;ERCC2;rs13181;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
CISPLATIN;KLC3;rs13181;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
ETHANOL;ACSS2;rs6088638;T;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
CAPECITABINE;DPYD;rs17376848;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs17376848;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ALCOHOL ABUSE ;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1058164;C;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
CISPLATIN;ERCC1;rs11615;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL;;;
nan;APOE;rs429358;CC;OTHER;INCREASED_SEVERITY;OTHER;COVID-19;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1985842;T;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
nan;NAT2;rs1801280;T;OTHER;INCREASED_SEVERITY;nan;DISEASE;INSULIN RESISTANCE ;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1135840;G;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
CLOPIDOGREL;CYP2C19;rs28399504;G;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371713;G;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
nan;NAT2;rs1208;A;OTHER;INCREASED_SEVERITY;nan;DISEASE;INSULIN RESISTANCE ;;
AMOXICILLIN;nan;rs72631546;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;nan;rs72631546;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
FLUCLOXACILLIN;nan;rs72631546;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
GEFITINIB;ABCG2;rs2231142;GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs112568578;G;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
CAPECITABINE;MIR23A;rs895819;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CAPECITABINE;MIR24-2;rs895819;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CAPECITABINE;MIR27A;rs895819;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;MIR23A;rs895819;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;MIR24-2;rs895819;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;MIR27A;rs895819;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;nan;nan;DISEASE;NEUTROPENIA ;;
AMOXICILLIN;PTPN22;rs2476601;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;PTPN22;rs2476601;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SLEEP APNEA SYNDROMES;;;
COCAINE;CNR1;rs6454674;GT + TT;OTHER;INCREASED_RISK;nan;DISEASE;COCAINE DEPENDENCE ;;
ATENOLOL;PPARA;rs4253778;GG;EFFICACY;DECREASED_;OTHER;CARDIAC REHOSPITALIZATION;;;
BETA BLOCKING AGENTS;PPARA;rs4253778;GG;EFFICACY;DECREASED_;OTHER;CARDIAC REHOSPITALIZATION;;;
CARVEDILOL;PPARA;rs4253778;GG;EFFICACY;DECREASED_;OTHER;CARDIAC REHOSPITALIZATION;;;
METOPROLOL;PPARA;rs4253778;GG;EFFICACY;DECREASED_;OTHER;CARDIAC REHOSPITALIZATION;;;
DOXORUBICIN;RARG;rs2229774;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
FLUVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ASPIRIN;TMEM196;rs9886152;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
PAZOPANIB;HIF1A;rs11549467;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
nan;CLOCK;rs1801260;AA + AG;OTHER;INCREASED_LIKELIHOOD;OTHER;ADHD;;;
MERCAPTOPURINE;ITPA;rs7270101;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;ITPA;rs7270101;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;ITPA;rs7270101;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;ITPA;rs7270101;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
COCAINE;CNR1;rs6454674;GT + TT;OTHER;INCREASED_RISK;nan;DISEASE;COCAINE DEPENDENCE ;;
RITUXIMAB;FCGR3A;rs396991;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE RESPONSE RATE;;;
MERCAPTOPURINE;IMPDH1;rs2278293;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;IMPDH1;rs2278293;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
COCAINE;CNR1;rs806368;C;OTHER;DECREASED_RISK;nan;DISEASE;COCAINE DEPENDENCE ;;
MERCAPTOPURINE;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT IN BONE MINERAL DENSITY;;;
RALOXIFENE;VDR;rs1544410;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT IN BONE MINERAL DENSITY;;;
ASPARAGINASE;PYGL;rs7142143;CC + CT;DOSAGE;INCREASED_RISK;SIDE_EFFECT;RELAPSE;;;
DEXAMETHASONE;PYGL;rs7142143;CC + CT;DOSAGE;INCREASED_RISK;SIDE_EFFECT;RELAPSE;;;
METHOTREXATE;PYGL;rs7142143;CC + CT;DOSAGE;INCREASED_RISK;SIDE_EFFECT;RELAPSE;;;
INTERFERONS;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
INTERFERONS;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PAZOPANIB;CXCL8;rs4073;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ERLOTINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
ERLOTINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
INTERFERONS;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (SVR) TO INTERFERON MONOTHERAPY IN HCV GENOTYPE 1 PATIENTS;;;
CAPECITABINE;DPYD;rs17376848;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
IRINOTECAN;DPYD;rs17376848;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
OXALIPLATIN;DPYD;rs17376848;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;nan;rs4888024;G;TOXICITY;nan;SIDE_EFFECT;END-OF-INDUCTION MINIMAL RISIDUAL DISEASE (MRD) IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND IS ALSO ASSOCIATED WITH GREATER METHOTREXATE CLEARANCE;;;
TACROLIMUS;ABCB1;rs1128503;AG;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
TACROLIMUS;ABCB1;rs2032582;AC + CT;LADME-PK;INCREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
METHOTREXATE;ABCC1;rs3784862;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXICITY;;;
ETHANOL;OPRM1;rs1799971;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CAPECITABINE;DPYD;rs2297595;CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
CLOPIDOGREL;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs945665113;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (SVR) IN HCV GENOTYPE 1 PATIENTS;;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (SVR) IN HCV GENOTYPE 1 PATIENTS;;;
CAPECITABINE;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
LEUCOVORIN;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
OXALIPLATIN;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SUNITINIB;SLC22A5;rs2631367;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL (OS) TIME;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;PRIMARY CLINICAL ENDPOINT OF DEATH DUE TO CARDIOVASCULAR CAUSES;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;NON-FATAL MI OR STENT THROMBOSIS;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
SUNITINIB;SLC22A5;rs2631370;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs376695472;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ANTIDEPRESSANTS;HTR2A;rs6311;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
BETA BLOCKING AGENTS;ADRB2;rs1042713;GG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
FLUOROURACIL;DPYS;rs2959023;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SUNITINIB;IL4R;rs1805015;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OMEGA-3 POLYUNSATURATED FATTY ACIDS;PTGS2;rs20417;CG + GG;OTHER;INCREASED_RISK;nan;DISEASE;COLONIC NEOPLASMS ;;
nan;PTGS2;rs20417;CG + GG;OTHER;DECREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
FLUOROURACIL;DPYS;rs2669429;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;CLCN6;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
METHOTREXATE;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
SUNITINIB;SLC22A5;rs2631372;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CAPECITABINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
LEUCOVORIN;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
OXALIPLATIN;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
SUNITINIB;IL4R;rs1801275;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
HEROIN;BDNF;rs16917234;TT;TOXICITY;DECREASED_AGE AT ONSET;SIDE_EFFECT;HEROIN DEPENDENCE;;;
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606619;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
TENOFOVIR;ABCC4;rs1751034;CC + CT;LADME-PK;INCREASED_PK;METABOLISM;INTRACELLULAR TENOFOVIR DIPHOSPHATE (TFV-DP) CONCENTRATIONS;;;
AZITHROMYCIN;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
AZITHROMYCIN;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
ERYTHROMYCIN;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
ERYTHROMYCIN;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
CORTICOSTEROIDS;DTNBP1;rs35514893;T;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
nan;CYP1B1;rs1056836;CC + CG;OTHER;INCREASED_RISK;nan;DISEASE;BREAST NEOPLASMS ;;
THIOTEPA;GSTP1;rs1138272;T;OTHER;INCREASED_PK;PK;NON-INDUCIBLE THIOTEPA CLEARANCE AND DECREASED TEPA CLEARANCE;;;
TENOFOVIR;ABCC4;rs1751034;TT;OTHER;INCREASED_PK;PK;TENOFOVIR RENAL CLEARANCE;;;
TENOFOVIR;ABCC4;rs1751034;TT;OTHER;INCREASED_PK;PK;AND LOWER AUC;;;
FLUOROURACIL;DPYD;rs2786783;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
nan;G6PD;rs72554664;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS, TYPE 2 ;;
OPIOIDS;nan;rs12442183;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;OPIOID-RELATED DISORDERS ;;
CORTICOSTEROIDS;KL;rs450789;G;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
INTERFERON BETA-1A;IRF6;rs2205986;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
INTERFERON BETA-1B;IRF6;rs2205986;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
METHOTREXATE;NR1I2;rs3814058;C;TOXICITY;DECREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
METHOTREXATE;ABCC2;rs2273697;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BONE MARROW DISORDER;;;
FLUOROURACIL;WNT5B;rs2010851;CC;EFFICACY;DECREASED_;OTHER;TIME TO TUMOR RECURRENCE (TTR);;;
CORTICOSTEROIDS;ME3;rs2125362;A;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
HEROIN;OPRD1;rs508448;GG;TOXICITY;DECREASED_AGE AT ONSET;SIDE_EFFECT;HEROIN DEPENDENCE;;;
METHOTREXATE;NR1I2;rs6785049;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CORTICOSTEROIDS;LHX2;rs7851998;A;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
FLUOROURACIL;DPYD;rs2811178;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CORTICOSTEROIDS;LHFPL3;rs61585310;G;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
ASPARAGINASE;IL10;rs1800896;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CORTICOSTEROIDS;IL10;rs1800896;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CYCLOPHOSPHAMIDE;IL10;rs1800896;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CYTARABINE;IL10;rs1800896;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
MERCAPTOPURINE;IL10;rs1800896;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;IL10;rs1800896;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
VINCRISTINE;IL10;rs1800896;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;GSK3B;rs3732361;A;LADME-PK;DECREASED_RISK;SIDE_EFFECT;BONE MARROW DISORDER;;;
METHOTREXATE;GSK3B;rs3732361;A;LADME-PK;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
HEROIN;BDNF;rs6265;TT;TOXICITY;DECREASED_AGE AT ONSET;SIDE_EFFECT;HEROIN DEPENDENCE;;;
MORPHINE;SLC22A1;rs12208357;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
CORTICOSTEROIDS;TRDN;rs4897302;T;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
NICOTINE;CHRNA5;rs55781567;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOBACCO USE DISORDER ;;
HEROIN;OPRD1;rs4654327;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEROIN DEPENDENCE;;;
OLANZAPINE;GIPR;rs10423928;AA + AT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
NICOTINE;CHRNA5;rs16969968;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOBACCO USE DISORDER ;;
NICOTINE;CHRNA5;rs503464;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOBACCO USE DISORDER ;;
ALLOPURINOL;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
FLUOROURACIL;DPYD;rs1801265;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
DAUNORUBICIN;SLC22A17;rs4982753;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;SLC22A17;rs4982753;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
ALLOPURINOL;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
NICOTINE;CHRNA5;rs55853698;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOBACCO USE DISORDER ;;
AMANTADINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
ANTICHOLINERGICS;SLC22A1;rs622342;C;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
DOPAMINE AGONISTS;SLC22A1;rs622342;C;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
LEVODOPA;SLC22A1;rs622342;C;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
SELEGILINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
MELPHALAN;POLR1G;rs967591;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVERALL SURVIVAL AND TIME-TO-TREAT FAILURE;;;
CORTICOSTEROIDS;ACOT7;rs11121611;G;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
TELAPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
MORPHINE;TLR2;rs3804100;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MORPHINE;TLR2;rs3804100;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
MORPHINE;TLR2;rs3804100;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;COGNITIVE DISORDER;;;
MORPHINE;TLR2;rs3804100;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CONSTIPATION;;;
DAUNORUBICIN;SLC22A7;rs4149178;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;SLC22A7;rs4149178;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
ROSUVASTATIN;SCAP;rs12487736;CC + CT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERLIPIDEMIAS;;;
ALLOPURINOL;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CORTICOSTEROIDS;APOBEC3B;rs5995653;A;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
ALLOPURINOL;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
MORPHINE;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MORPHINE;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
MORPHINE;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DEPRESSION;;;
GEMCITABINE;CDA;rs2072671;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
PACLITAXEL;CDA;rs2072671;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
MONTELUKAST;ABCC1;rs119774;CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;CHANGES IN FEV1;;;
TRIAMCINOLONE;HCG22;rs2523864;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OCULAR HYPERTENSION;;;
ANTIDEPRESSANTS;CREB1;rs7569963;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
ANTIDEPRESSANTS;METTL21A;rs7569963;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
MORPHINE;IL6;rs10499563;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MORPHINE;IL6;rs10499563;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
MORPHINE;IL6;rs10499563;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEPRESSION;;;
ALLOPURINOL;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
ALLOPURINOL;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs184278615;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CITALOPRAM;nan;rs4675690;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT-EMERGENT SUICIDALITY;;;
CITALOPRAM;CREB1;rs7569963;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT-EMERGENT SUICIDALITY;;;
CITALOPRAM;METTL21A;rs7569963;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT-EMERGENT SUICIDALITY;;;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs201469165;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOE;rs7412;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA;;;
"COMBINATIONS""";APOE;rs7412;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA;;;
"""RITONAVIR""";APOE;rs7412;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA;;;
ALLOPURINOL;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TRIAMCINOLONE;HCG22;rs3873352;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OCULAR HYPERTENSION;;;
ALLOPURINOL;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
MORPHINE;IL6R;rs2228145;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MORPHINE;IL6R;rs2228145;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
MORPHINE;IL6R;rs2228145;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DEPRESSION;;;
ALLOPURINOL;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
MORPHINE;BDNF;rs6265;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MORPHINE;BDNF;rs6265;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
MORPHINE;BDNF;rs6265;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DEPRESSION;;;
ALLOPURINOL;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
MORPHINE;IL2;rs2069762;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MORPHINE;IL2;rs2069762;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
MORPHINE;IL2;rs2069762;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DEPRESSION;;;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs1071748;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ASPIRIN;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
METHOTREXATE;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
ALLOPURINOL;nan;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;nan;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
MERCAPTOPURINE;SLC28A2;rs2413775;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;SLC28A2;rs2413775;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CHLORTHALIDONE;NPPA;rs5065;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
METHOTREXATE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
MERCAPTOPURINE;SLC28A2;rs2413775;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;SLC28A2;rs2413775;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOPHOSPHAMIDE;SOD2;rs4880;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;PRIMARY OVARIAN FAILURE;;;
DOXORUBICIN;SLC22A16;rs714368;CC;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;DOXORUBICINOL AUC;;;
MERCAPTOPURINE;SLC29A1;rs747199;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
MERCAPTOPURINE;SLC29A1;rs747199;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;SLC29A1;rs747199;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;AGRANULOCYTOSIS;;;
METHOTREXATE;SLC29A1;rs747199;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
ALLOPURINOL;nan;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ALLOPURINOL;nan;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CARBAMAZEPINE;nan;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
CARBAMAZEPINE;nan;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PHENYTOIN;nan;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
PHENYTOIN;nan;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;ORAL MUCOSITIS;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs8192709;CT + TT;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGIC CYSTITIS;;;
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;KIR3DL2;rs973541788;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
AMOXICILLIN;HLA-DRA;rs3129880;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLAVULANATE;HLA-DRA;rs3129880;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
FLUCLOXACILLIN;HLA-DRA;rs3129880;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;TOXICITY, LADME-PK;DECREASED_RISK;SIDE_EFFECT;VENOOCCLUSIVE DISEASE OF THE LIVER;;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371725;C;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
OPIOIDS;OPRM1;rs1799971;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SLEEP DISORDERS;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CYCLOSPORINE;MTHFR;rs1801133;A;OTHER;nan;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;MTHFR;rs1801133;A;OTHER;nan;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
CARBOPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CISPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
GEMCITABINE;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs2004511;T;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
MERCAPTOPURINE;ABCC4;rs2274407;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;ABCC4;rs2274407;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;ABCC4;rs2274407;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;ABCC4;rs2274407;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;CBR3;rs8133052;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TUMOR RESPONSE;;;
DOXORUBICIN;CBR3;rs8133052;G;TOXICITY, LADME-PK;DECREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
DOXORUBICIN;CBR3;rs1056892;A;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;DOXORUBICINOL AUC;;;
ANTIHYPERTENSIVES;ATP2B1;rs1401982;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESISTANT HYPERTENSION;;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371702;A;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PRURITUS;;;
MERCAPTOPURINE;SLC28A3;rs10868138;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;SLC28A3;rs10868138;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
HEROIN;GRM3;rs724226;A;OTHER;INCREASED_RISK;nan;DISEASE;HEROIN DEPENDENCE ;;
ACENOCOUMAROL;VKORC1;rs7294;T;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESIDUAL PLATELET REACTIVITY;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
CORTICOSTEROIDS;CRHR1;rs242941;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PERCENT CHANGE IN FEV;;;
METHOTREXATE;CLCN6;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
CORTICOSTEROIDS;FKBP5;rs4713916;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;GLUCOCORTICOID RESPONSIVENESS;;;
BUDESONIDE;CRHR1;rs242941;AA;EFFICACY;PK;PK;DELAYED CORTISOL RESPONSE TO STRESS;;;
FLUTICASONE PROPIONATE;CRHR1;rs242941;AA;EFFICACY;PK;PK;DELAYED CORTISOL RESPONSE TO STRESS;;;
OPIOIDS;ABCB1;rs1045642;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
CORTICOSTEROIDS;CRHR1;rs1876828;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PERCENT CHANGE IN FEV;;;
GEMCITABINE;nan;rs1155463;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CENTRAL NERVOUS SYSTEM DISORDER;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212090;AA + AT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212090;AA + AT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212090;AA + AT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212090;AA + AT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
BUDESONIDE;CRHR1;rs1876828;TT;EFFICACY;PK;PK;DELAYED CORTISOL RESPONSE TO STRESS;;;
FLUTICASONE PROPIONATE;CRHR1;rs1876828;TT;EFFICACY;PK;PK;DELAYED CORTISOL RESPONSE TO STRESS;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149171;CC + CT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149171;CC + CT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149171;CC + CT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149171;CC + CT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;nan;rs955434;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;nan;rs955434;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;nan;rs955434;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;nan;rs955434;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
CHLOROTHIAZIDE;nan;rs61824877;A;EFFICACY, TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERGLYCEMIA;;;
HYDROCHLOROTHIAZIDE;nan;rs61824877;A;EFFICACY, TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERGLYCEMIA;;;
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149170;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149170;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149170;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149170;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
TRAMADOL;OPRM1;rs1799971;GG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;NAUSEA ;;
CHLOROTHIAZIDE;HMGCS2;rs9943291;G;EFFICACY, TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERGLYCEMIA;;;
HYDROCHLOROTHIAZIDE;HMGCS2;rs9943291;G;EFFICACY, TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERGLYCEMIA;;;
METHOTREXATE;CLCN6;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METHADONE;DAO;rs55944529;TT;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;SUBSTANCE WITHDRAWAL SYNDROME;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148579;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148579;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148579;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148579;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
nan;KCNIP1;rs11739136;CT + TT;OTHER;DECREASED_RISK;nan;DISEASE;HYPERTENSION ;;
nan;KCNMB1;rs11739136;CT + TT;OTHER;DECREASED_RISK;nan;DISEASE;HYPERTENSION ;;
INFLIXIMAB;IL1B;rs1143634;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT FAILURE;;;
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
ATAZANAVIR;ABCB1;rs2032582;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERBILIRUBINEMIA ;;
DABIGATRAN;ABCB1;rs4148738;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212087;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212087;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212087;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212087;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
INFLIXIMAB;IL23R;rs10489629;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT FAILURE;;;
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148580;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148580;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148580;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148580;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
INFLIXIMAB;SLCO1C1;rs3794271;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT FAILURE;;;
NICOTINE;CHRNA3;rs578776;A;OTHER;DECREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT IN LEFT VENTRICULAR FUNCTION (LVEF);;;
PEGINTERFERON ALFA-2A;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA;;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IL7;rs16906115;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
IRINOTECAN;ABCC1;rs3743527;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
NICOTINE;CHRNA3;rs1051730;A;OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
IRINOTECAN;ABCB1;rs12720066;AC + CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
NICOTINE;CHRNA3;rs3743078;C;OTHER;DECREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148575;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148575;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148575;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148575;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
NICOTINE;CHRNB4;rs3813567;G;OTHER;DECREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
IRINOTECAN;ABCC1;rs17501331;AG + GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
CARVEDILOL;ADRB1;rs1801253;CC;;SIDE_EFFECT;EFFICACY;SIGNIFICANTLY GREATER IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION (LVEF);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA;;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA;;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;CRYOGLOBULINEMIA;;;
nan;UGT1A1;rs4148323;AA;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
nan;UGT1A1;rs4148323;AA;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CEREBRAL PALSY;;;
nan;UGT1A1;rs4148323;AA;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEARING LOSS;;;
PEGINTERFERON ALFA-2A;NT5C2;rs10883841;CT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CRYOGLOBULINEMIA;;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
INFLIXIMAB;ADAM17;rs10929587;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT FAILURE;;;
CLOPIDOGREL;MED12L;rs10935838;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;P2RY12;rs10935838;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
nan;ago-02;rs4961280;AA + AC;OTHER;DECREASED_;OTHER;PROGRESSION-FREE SURVIVAL;;;
STAVUDINE;TNF;rs1799964;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROPATHY;;;
CLOPIDOGREL;MED12L;rs2046934;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;P2RY12;rs2046934;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;MED12L;rs6809699;AC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;P2RY12;rs6809699;AC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs3749442;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs3749442;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs3749442;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs3749442;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
NICOTINE;CHRNA5;rs684513;G;OTHER;DECREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606618;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs1132776;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs1132776;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs1132776;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs1132776;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
NICOTINE;CHRNA5;rs637137;A;OTHER;DECREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
nan;IL1A;rs1800587;A;OTHER;INCREASED_SEVERITY;nan;DISEASE;PAIN ;;
FLUTICASONE;CRHR1;rs242941;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN CHANGE IN FEV;;;
SALMETEROL;CRHR1;rs242941;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN CHANGE IN FEV;;;
PROPRANOLOL;COMT;rs4680;G;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs939338;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs939338;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs939338;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs939338;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
PEGINTERFERON ALFA-2A;CYP27B1;rs10877012;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;METTL1;rs10877012;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PROPRANOLOL;COMT;rs4818;G;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
CORTICOSTEROIDS;APOBEC3B;rs6001366;T;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CORTICOSTEROIDS;KCNN1;rs2278992;C;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
PEGINTERFERON ALFA-2A;VDR;rs7975232;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CORTICOSTEROIDS;ANKRD30B;rs12959468;A;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;ASTHMA ;;
ROSUVASTATIN;CRP;rs1205;CT + TT;EFFICACY, OTHER, LADME-PK;DECREASED_;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN;;;
PROPRANOLOL;COMT;rs6269;G;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs129081;CC + CG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs129081;CC + CG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs129081;CC + CG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs129081;CC + CG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
RISPERIDONE;HTR2A;rs6311;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
HEROIN;GRM3;rs2189814;T;OTHER;INCREASED_RISK;nan;DISEASE;HEROIN DEPENDENCE ;;
ROSUVASTATIN;nan;rs2808630;CC + CT;EFFICACY, OTHER, LADME-PK;DECREASED_;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN;;;
METHADONE;OPRD1;rs204076;AT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ROSUVASTATIN;HNF1A;rs1169288;AC + CC;EFFICACY, OTHER, LADME-PK;DECREASED_;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN;;;
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING AND GREATER INCREASE IN LVEF (LEFT VENTRICULAR EJECTION FRACTION);;;
PROPRANOLOL;COMT;rs4633;C;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
BUCINDOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE;;;
ERYTHROMYCIN;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ASPIRIN;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYOCARDIAL INFARCTION ;;
nan;KCNIP1;rs11739136;CT + TT;OTHER;DECREASED_;OTHER;BLOOD PRESSURE;;;
nan;KCNMB1;rs11739136;CT + TT;OTHER;DECREASED_;OTHER;BLOOD PRESSURE;;;
TACROLIMUS;ABCB1;rs2032582;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION;;;
CAFFEINE;RYR1;rs118192162;AC;TOXICITY;nan;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs118192162;AC;TOXICITY;nan;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
RISPERIDONE;NR1I2;rs7643645;GG;LADME-PK;DECREASED_PK;METABOLISM;9-HYDROXY-RISPERIDONE LEVELS;;;
REPAGLINIDE;SLCO1B1;rs2306283;GG;OTHER, LADME-PK;DECREASED_PK;METABOLISM;REPAGLINIDE PLASMA CONCENTRATION (AUC) AND CMAX;;;
HALOTHANE;RYR1;rs118192161;CT;TOXICITY;nan;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
RISPERIDONE;NR1I2;rs7643645;GG;LADME-PK;DECREASED_PK;METABOLISM;ACTIVE MOIETY LEVELS;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
TACROLIMUS;ABCB1;rs1045642;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION;;;
GEFITINIB;CYP2D6;rs1065852;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DALCETRAPIB;ADCY9;rs1967309;AA;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
EGFR INHIBITORS;PIK3CA;rs6443624;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;EXANTHEMA ;;
EGFR INHIBITORS;PIK3CA;rs2677760;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;EXANTHEMA ;;
MISOPROSTOL;SLCO1B1;rs4149087;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEVER;;;
MISOPROSTOL;ABCC4;rs11568658;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FEVER;;;
ASPIRIN;PEAR1;rs12041331;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;COLLAGEN INDUCED PLATELET AGGREGATION AFTER ASPIRIN OR DUAL ANTIPLATELET THERAPY (DAPT) ADMINISTRATION;;;
CLOPIDOGREL;PEAR1;rs12041331;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;COLLAGEN INDUCED PLATELET AGGREGATION AFTER ASPIRIN OR DUAL ANTIPLATELET THERAPY (DAPT) ADMINISTRATION;;;
ETHAMBUTOL;CYP2E1;rs2031920;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;CYP2E1;rs2031920;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;CYP2E1;rs2031920;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;CYP2E1;rs2031920;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CARBOPLATIN;RAF1;rs11710163;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;RAF1;rs11710163;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;RAF1;rs11710163;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;RAF1;rs11710163;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;RAF1;rs11710163;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;DECREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
ASPIRIN;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI;;;
CLOPIDOGREL;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
OLANZAPINE;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
ASPIRIN;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI;;;
CLOPIDOGREL;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI;;;
ANTIINFLAMMATORY AGENTS;ALOX15;rs3892408;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
NON-STEROIDS;ALOX15;rs3892408;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
METHADONE;CCL11;rs1129844;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INSOMNIA;;;
EGFR INHIBITORS;PIK3CA;rs2699905;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;EXANTHEMA ;;
FLUOXETINE;nan;rs2433320;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;HAMD SCORES;;;
ANTIPSYCHOTICS;MTHFR;rs1801133;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
ASPARAGINASE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CYCLOPHOSPHAMIDE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CYTARABINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
DAUNORUBICIN;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
MERCAPTOPURINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PREDNISOLONE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
VINCRISTINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ANTIINFLAMMATORY AGENTS;PTGS1;rs5789;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
NON-STEROIDS;PTGS1;rs5789;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
CLOZAPINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
OLANZAPINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CYCLOPHOSPHAMIDE;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYTARABINE;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
DAUNORUBICIN;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
DOXORUBICIN;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
MERCAPTOPURINE;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
METHOTREXATE;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
PEGASPARGASE;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
THIOGUANINE;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
VINCRISTINE;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
LEUCOVORIN;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
LEUCOVORIN;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434568;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
CARBOPLATIN;MAP3K1;rs726501;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;MAP3K1;rs726501;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;MAP3K1;rs726501;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;MAP3K1;rs726501;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ETHAMBUTOL;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
ISONIAZID;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
PYRAZINAMIDE;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
RIFAMPIN;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP4X1;rs17102977;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP4X1;rs17102977;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
FLUOROURACIL;CYP4X1;rs17102977;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TAXANES;CYP4X1;rs17102977;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CYTARABINE;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
DAUNORUBICIN;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
DOXORUBICIN;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
MERCAPTOPURINE;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
METHOTREXATE;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
PEGASPARGASE;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
THIOGUANINE;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
VINCRISTINE;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
ETHAMBUTOL;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
ISONIAZID;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
PYRAZINAMIDE;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
RIFAMPIN;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MACULOPAPULAR EXANTHEMA ;;
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG;;;
ANTIINFLAMMATORY AGENTS;PTGS1;rs10306135;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
NON-STEROIDS;PTGS1;rs10306135;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
IMATINIB;SLC22A1;rs683369;CG + GG;EFFICACY;DECREASED_;nan;DISEASE;EVENT-FREE SURVIVAL ;;
ANTIPSYCHOTICS;GABRG3;rs2061051;A;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TARDIVE DYSKINESIA ;;
GEMCITABINE;nan;rs642990;CT + TT;TOXICITY;DECREASED_RISK;nan;DISEASE;NEUTROPENIA ;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;LONGER MEDIAN PROGRESSION-FREE SURVIVAL TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
CARBOPLATIN;MAP3K1;rs16886403;CC + CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;MAP3K1;rs16886403;CC + CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;MAP3K1;rs16886403;CC + CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;MAP3K1;rs16886403;CC + CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;RRM1;rs1042858;A;DOSAGE;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CARBOPLATIN;nan;rs17661089;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;nan;rs17661089;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;nan;rs17661089;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;nan;rs17661089;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CARBOPLATIN;ACSS2;rs17309872;AT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;ACSS2;rs17309872;AT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOCETAXEL;ACSS2;rs17309872;AT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;ACSS2;rs17309872;AT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;ACSS2;rs17309872;AT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;ABCC1;rs246240;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ONSET OF TOXICITY;;;
BUPROPION;EPB41;rs6702335;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ABSTINENCE;;;
NICOTINE;EPB41;rs6702335;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ABSTINENCE;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL14;rs62328061;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
nan;IL17F;rs763780;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS;;;
DAUNORUBICIN;NOS3;rs1799983;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;IL17A;rs2275913;AA;OTHER;INCREASED_LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS;;;
ACE INHIBITORS;KCNIP4;rs145489027;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
PLAIN;KCNIP4;rs145489027;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
PEMETREXED;ATIC;rs12995526;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OPIOIDS;PDYN;rs910080;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
ACE INHIBITORS;KCNIP4;rs1495509;C;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
PLAIN;KCNIP4;rs1495509;C;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
FOLFIRI;MTHFR;rs1801131;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FOLFOX;MTHFR;rs1801131;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
XELOX;MTHFR;rs1801131;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;ALG10;rs1705772;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXICITY;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
CYCLOPHOSPHAMIDE;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
CYTARABINE;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
DAUNORUBICIN;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
DOXORUBICIN;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
MERCAPTOPURINE;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
METHOTREXATE;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
PEGASPARGASE;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
THIOGUANINE;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
VINCRISTINE;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
RITONAVIR;APOC3;rs2854116;C;OTHER;INCREASED_RISK;nan;DISEASE;HYPERTRIGLYCERIDEMIA ;;
PEMETREXED;GGH;rs16930092;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ANASTROZOLE;UGT1A4;rs3732218;GG;LADME-PK;INCREASED_PK;METABOLISM;GLUCURONIDATION;;;
HALOPERIDOL;CYP2D6;rs3892097;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FOLFIRI;ABCB1;rs1045642;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FOLFOX;ABCB1;rs1045642;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
XELOX;ABCB1;rs1045642;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ACE INHIBITORS;KCNIP4;rs7675300;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
PLAIN;KCNIP4;rs7675300;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
CYCLOPHOSPHAMIDE;VEGFA;rs2010963;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
NICOTINE;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING;;;
NEVIRAPINE;TRAF3IP2;rs76228616;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
NEVIRAPINE;TRAF3IP2;rs76228616;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
GEMCITABINE;ALOX5AP;rs4769060;AG + GG;LADME-PK;DECREASED_PK;METABOLISM;CMAX AND A LOWER MEAN AUC;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
SUFENTANIL;OPRM1;rs1799971;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
IPILIMUMAB;IL7;rs16906115;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
NIVOLUMAB;IL7;rs16906115;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
PEMBROLIZUMAB;IL7;rs16906115;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
GEMTUZUMAB OZOGAMICIN;CD33;rs1803254;CC + CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
FOLFIRI;BRAF;rs113488022;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FOLFOX;BRAF;rs113488022;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
XELOX;BRAF;rs113488022;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;CLCN6;rs1801133;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;MTHFR;rs1801133;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
OPIOIDS;TH;rs2070762;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OPIOID-RELATED DISORDERS ;;
GEMTUZUMAB OZOGAMICIN;CD33;rs35112940;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ISONIAZID;CYP2E1;rs6413432;AT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;DUX1;rs6413432;AT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;CYP2E1;rs6413432;AT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;DUX1;rs6413432;AT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CISPLATIN;SLC22A2;rs316019;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
ANTINEOPLASTIC AGENTS;SPARC;rs1059829;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO TUMOR RECURRENCE;;;
FLUOROURACIL;SPARC;rs1059829;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO TUMOR RECURRENCE;;;
LEUCOVORIN;SPARC;rs1059829;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO TUMOR RECURRENCE;;;
OPIOIDS;DBH;rs1611131;G;TOXICITY;DECREASED_RISK;nan;DISEASE;OPIOID-RELATED DISORDERS ;;
ANTIPSYCHOTICS;HSPG2;rs2445142;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TARDIVE DYSKINESIA ;;
FOLFIRI;DPYD;rs1801265;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FOLFOX;DPYD;rs1801265;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
XELOX;DPYD;rs1801265;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTIPSYCHOTICS;HSPG2;rs878949;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TARDIVE DYSKINESIA ;;
QUETIAPINE;RIMS1;rs502046;CC + CT;EFFICACY, TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
ETHANOL;TAS2R16;rs846664;C;OTHER;INCREASED_RISK;nan;DISEASE;ALCOHOL ABUSE ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
METHOTREXATE;C1orf167;rs1801131;GG + GT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;CLCN6;rs1801131;GG + GT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;MTHFR;rs1801131;GG + GT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOSIS;;;
SORAFENIB;KDR;rs2239702;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;SCN1A;rs3812718;CC;OTHER;DECREASED_;OTHER;TIME TO TUMOR RECURRENCE (TTR);;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISCONTINUATION;;;
"""ACETAMINOPHEN""";OPRM1;rs510769;CT + TT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
"""ANTIEPILEPTICS""";OPRM1;rs510769;CT + TT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
"""ANTIINFLAMMATORY AGENTS";OPRM1;rs510769;CT + TT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
"NON-STEROIDS""";OPRM1;rs510769;CT + TT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
"""OPIOIDS""";OPRM1;rs510769;CT + TT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME IN THERAPEUTIC RANGE;;;
OPIOIDS;DRD2;rs1076560;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OPIOID-RELATED DISORDERS ;;
EFAVIRENZ;NR1I2;rs2472677;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;VIROLOGICAL RESPONSE;;;
CETUXIMAB;KRAS;rs112445441;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
CYCLOPHOSPHAMIDE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
DACTINOMYCIN;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
DOXORUBICIN;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
VINCRISTINE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
SORAFENIB;VEGFA;rs2010963;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CISPLATIN;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
CYCLOPHOSPHAMIDE;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
DACTINOMYCIN;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
DOXORUBICIN;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
VINCRISTINE;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
SORAFENIB;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
SORAFENIB;VEGFA;rs1570360;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ATORVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ATORVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES;;;
ATORVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;RHABDOMYOLYSIS;;;
ATORVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
COCAINE;OPRM1;rs62638690;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;COCAINE DEPENDENCE, HEROIN DEPENDENCE ;;
HEROIN;OPRM1;rs62638690;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;COCAINE DEPENDENCE, HEROIN DEPENDENCE ;;
SORAFENIB;KDR;rs2239702;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
EFAVIRENZ;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CENTRAL NERVOUS SYSTEM DISORDER;;;
CETUXIMAB;KRAS;rs112445441;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PANITUMUMAB;KRAS;rs112445441;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;CYP2C9;rs1799853;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOSIS;;;
nan;MTR;rs1805087;GG;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;RHEUMATOID ARTHRITIS ;;
METHOTREXATE;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METHOTREXATE-INDUCED NODULOSIS;;;
"""ACETAMINOPHEN""";OPRD1;rs2236861;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
"""ANTIEPILEPTICS""";OPRD1;rs2236861;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
"""ANTIINFLAMMATORY AGENTS";OPRD1;rs2236861;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
"NON-STEROIDS""";OPRD1;rs2236861;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
"""OPIOIDS""";OPRD1;rs2236861;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_PK;METABOLISM;AUC0-12;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOSIS;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
FLUOROURACIL;SCN1A;rs3812718;TT;OTHER;DECREASED_;OTHER;TIME TO TUMOR RECURRENCE (TTR);;;
ATAZANAVIR;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
SIMVASTATIN;SLCO1B1;rs4363657;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES;;;
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;CENTRAL NERVOUS SYSTEM DISORDER;;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
TACROLIMUS;CYP3A5;rs776746;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEPHROTOXICITY ;;
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;MUSCULAR DISEASES ;;
EFAVIRENZ;CYP2B6;rs4803419;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CENTRAL NERVOUS SYSTEM DISORDER;;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
FLUOROURACIL;DPYD;rs1801160;CT;LADME-PK;DECREASED_PK;METABOLISM;DPD ACTIVITY;;;
ALLOPURINOL;PSORS1C1;rs3131003;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
FLUOROURACIL;MTHFR;rs1801133;GG;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;EVENT-FREE SURVIVAL, OVERALL SURVIVAL ;;
OPIOIDS;PDYN;rs1997794;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;OPIOID-RELATED DISORDERS ;;
ONDANSETRON;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
DEXMEDETOMIDINE;CYP2A6;rs8192733;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA;;;
DEXMEDETOMIDINE;CYP2A6;rs8192733;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
"""ACETAMINOPHEN""";OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
"""ANTIEPILEPTICS""";OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
"""ANTIINFLAMMATORY AGENTS";OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
"NON-STEROIDS""";OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
"""OPIOIDS""";OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
OPIOIDS;PDYN;rs1022563;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;OPIOID-RELATED DISORDERS ;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;;SIDE_EFFECT;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;;SIDE_EFFECT;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;;SIDE_EFFECT;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;;SIDE_EFFECT;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RISPERIDONE;LEP;rs7799039;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OBESITY;;;
PERINDOPRIL;AGTR1;rs5182;TT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;CARDIAC EVENTS;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;;SIDE_EFFECT;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) AND CHANGES IN VIRAL LOAD AFTER 4 WEEKS OF TREATMENT;;;
RIBAVIRIN;IFNL3;rs8099917;TT;;SIDE_EFFECT;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) AND CHANGES IN VIRAL LOAD AFTER 4 WEEKS OF TREATMENT;;;
GEMCITABINE;CDA;rs2072671;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE NEUTROPENIA;;;
CYTARABINE;CDA;rs602950;GG;EFFICACY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;CYTOTOXICITY;;;
HALOPERIDOL;CYP2D6;rs3892097;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
CYTARABINE;CDA;rs532545;TT;EFFICACY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;CYTOTOXICITY;;;
ALLOPURINOL;CYCSP5;rs3099844;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
BISPHOSPHONATES;RBMS3;rs17024608;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;OSTEONECROSIS ;;
nan;NEDD4L;rs4149601;AG;OTHER;INCREASED_RISK;nan;DISEASE;CARDIOVASCULAR DISEASE ;;
FLUOROURACIL;DPYD;rs55886062;AC;LADME-PK;DECREASED_PK;METABOLISM;DPD ACTIVITY;;;
ANTIPSYCHOTICS;INSIG2;rs17587100;C;OTHER;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
ONDANSETRON;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
nan;CTLA4;rs3087243;A;OTHER;DECREASED_RISK;nan;DISEASE;RHEUMATOID ARTHRITIS ;;
EPIRUBICIN;GCKR;rs780094;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;GCKR;rs780094;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;GCKR;rs780094;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;DPYD;rs115232898;CT;LADME-PK;DECREASED_PK;METABOLISM;DPD ACTIVITY;;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TENOFOVIR;ABCC4;rs1059751;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;KIDNEY DISORDER ;;
EPIRUBICIN;IGF2BP2;rs6769511;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISEASE PROGRESSION;;;
FLUOROURACIL;IGF2BP2;rs6769511;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISEASE PROGRESSION;;;
OXALIPLATIN;IGF2BP2;rs6769511;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;DISEASE PROGRESSION;;;
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
CYTARABINE;CDA;rs2072671;CC;EFFICACY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;CYTOTOXICITY;;;
WARFARIN;VKORC1;rs9934438;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ALLOPURINOL;NOTCH4;rs367398;AA + AG;TOXICITY;DECREASED_RISK;nan;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS ;;
EPIRUBICIN;KCNQ1;rs163182;CC + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISEASE PROGRESSION;;;
FLUOROURACIL;KCNQ1;rs163182;CC + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISEASE PROGRESSION;;;
OXALIPLATIN;KCNQ1;rs163182;CC + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISEASE PROGRESSION;;;
nan;NQO1;rs1800566;AA;OTHER;DECREASED_LIKELIHOOD;OTHER;SURVIVAL;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;;SIDE_EFFECT;EFFICACY;RAPID VIRAL RESPONSE (RVR) TO PEG-IFN/RIBAVIRIN THERAPY AT 4 WEEKS IN HCV GENOTYPE 3 PATIENTS;;;
RIBAVIRIN;IFNL3;rs8099917;TT;;SIDE_EFFECT;EFFICACY;RAPID VIRAL RESPONSE (RVR) TO PEG-IFN/RIBAVIRIN THERAPY AT 4 WEEKS IN HCV GENOTYPE 3 PATIENTS;;;
EPIRUBICIN;IGF2BP2;rs4402960;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISEASE PROGRESSION;;;
FLUOROURACIL;IGF2BP2;rs4402960;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISEASE PROGRESSION;;;
OXALIPLATIN;IGF2BP2;rs4402960;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISEASE PROGRESSION;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;;SIDE_EFFECT;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;;SIDE_EFFECT;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;;SIDE_EFFECT;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;;SIDE_EFFECT;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR);;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
EFAVIRENZ;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;IMMUNOLOGICAL FAILURE;;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOPHOSPHAMIDE;NQO1;rs1800566;AA;TOXICITY;DECREASED_LIKELIHOOD;OTHER;SURVIVAL;;;
EPIRUBICIN;NQO1;rs1800566;AA;TOXICITY;DECREASED_LIKELIHOOD;OTHER;SURVIVAL;;;
FLUOROURACIL;NQO1;rs1800566;AA;TOXICITY;DECREASED_LIKELIHOOD;OTHER;SURVIVAL;;;
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
EFAVIRENZ;CYP2B6;rs3745274;GT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;SLEEP DISORDERS ;;
SUNITINIB;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
VERAPAMIL;CACNA1C;rs1051375;AA;EFFICACY;DECREASED_RISK;OTHER;PRIMARY OUTCOME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEDIAN SURVIVAL TIME (MST);;;
CISPLATIN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;THROMBOCYTOPENIA ;;
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;THROMBOCYTOPENIA ;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL (OS) TIME;;;
SUNITINIB;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA LEVEL;;;
CISPLATIN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL (OS) TIME;;;
EFAVIRENZ;CYP2A6;rs28399433;AC + CC;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
nan;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DEATH ;;
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
VERAPAMIL;CACNA1C;rs1051375;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;PRIMARY OUTCOME;;;
EPIRUBICIN;GCKR;rs780093;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;GCKR;rs780093;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;GCKR;rs780093;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG IN USERS WITH A STARTING DOSE OF MORE THAN 20 MG;;;
CARBOPLATIN;nan;rs12118636;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;nan;rs12118636;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;nan;rs12118636;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CISPLATIN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
AZATHIOPRINE;NUDT15;rs116855232;TT;TOXICITY;nan;SIDE_EFFECT;ALOPECIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;TT;TOXICITY;nan;SIDE_EFFECT;ALOPECIA;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
ANTINEOPLASTIC AGENTS;ABCB1;rs1045642;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEDIAN SURVIAL TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL (OS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
CARBOPLATIN;NRAS;rs1065634;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;NRAS;rs1065634;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;NRAS;rs1065634;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
CARBOPLATIN;GPX5;rs451774;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;GPX5;rs451774;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEMCITABINE;GPX5;rs451774;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
VINCRISTINE;ACTG1;rs1135989;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
ACENOCOUMAROL;VKORC1;rs9923231;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
METHADONE;CYP2B6;rs3745274;GG;TOXICITY;INCREASED_SEVERITY;OTHER;NEONATAL ABSTINENCE SYNDROME;;;
CARBOPLATIN;ATP7B;rs1801249;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TAXANES;ATP7B;rs1801249;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
VINCRISTINE;CAPG;rs3770102;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
VALPROIC ACID;COL1A1;rs1800012;AA + AC;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
VINCRISTINE;ABCB1;rs4728709;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
DOXORUBICIN;AKR1C3;rs1937840;GG;OTHER;DECREASED_;OTHER;ABSOLUTE LEUCOCYTE AND NEUTROPHIL COUNTS ON DAY 15;;;
METHADONE;CYP2B6;rs2279343;AA;TOXICITY;INCREASED_SEVERITY;OTHER;NEONATAL ABSTINENCE SYNDROME;;;
KETOPROFEN;CYP2C9;rs1799853;CC;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DYSPEPSIA;;;
ACENOCOUMAROL;VKORC1;rs9923231;T;EFFICACY;INCREASED_SEVERITY;OTHER;TIME TO THERAPEUTIC INR;;;
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_SEVERITY;OTHER;TIME TO THERAPEUTIC INR;;;
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
REMIFENTANIL;OPRM1;rs1799971;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
MERCAPTOPURINE;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
CARBOPLATIN;GSR;rs3594;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TAXANES;GSR;rs3594;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ACENOCOUMAROL;APOE;rs429358;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;APOE;rs429358;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
ETHANOL;SLC6A4;rs4251417;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CARBOPLATIN;VEGFA;rs6900017;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TAXANES;VEGFA;rs6900017;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ACENOCOUMAROL;CYP2C9;rs1057910;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;rs1057910;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
METHYLPHENIDATE;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
NALOXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;CORTISOL RESPONSE;;;
ETHANOL;SLC6A4;rs25531;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
INTERFERONS;VDR;rs2228570;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;CRYOGLOBULINEMIA;;;
RIBAVIRIN;VDR;rs2228570;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;CRYOGLOBULINEMIA;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
EGFR INHIBITORS;PIK3CA;rs2677760;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIARRHEA ;;
CETUXIMAB;EGFR;rs2227983;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
EGFR INHIBITORS;PIK3CA;rs2459693;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIARRHEA ;;
IRINOTECAN;CES1;rs7187684;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
METHOTREXATE;ATIC;rs2372536;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ETHANOL;SLC6A4;rs2066713;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CORTICOSTEROIDS;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;EXACERBATIONS;;;
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;EXACERBATIONS;;;
ANTIPSYCHOTICS;IL1B;rs4849127;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
BETA BLOCKING AGENTS;CYP2D6;rs1065852;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA;;;
FLUOROURACIL;DPYD;rs1801265;GG;LADME-PK;INCREASED_PK;METABOLISM;DPD ACTIVITY;;;
EGFR INHIBITORS;PIK3CA;rs6443624;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTIPSYCHOTICS;IL1B;rs16944;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
DAUNORUBICIN;SLC28A3;rs885004;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;CARDIOTOXICITY ;;
DOXORUBICIN;SLC28A3;rs885004;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;CARDIOTOXICITY ;;
CYCLOSPORINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GINGIVAL OVERGROWTH;;;
EGFR INHIBITORS;PIK3CA;rs2677760;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CORTICOSTEROIDS;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;UNCONTROLLED ASTHMA;;;
IRINOTECAN;CES1;rs2244614;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
EXEMESTANE;CYP19A1;rs6493497;AA;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
LETROZOLE;CYP19A1;rs6493497;AA;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
ANTIPSYCHOTICS;IL1B;rs1143634;AA;TOXICITY;DECREASED_;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;TOXICITY;DECREASED_;SIDE_EFFECT;WEIGHT GAIN;;;
METHYLPHENIDATE;ADGRL3;rs2345039;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
DAUNORUBICIN;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;CARDIOTOXICITY ;;
DOXORUBICIN;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;CARDIOTOXICITY ;;
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
WARFARIN;CYP2C9;rs1799853;T;;SIDE_EFFECT;EFFICACY;TIME TO THERAPEUTIC INR;;;
CARBOPLATIN;ATP7B;rs1061472;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TAXANES;ATP7B;rs1061472;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
IRINOTECAN;UGT1A1;rs4148323;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SUGCT;rs4379368;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOSIS;;;
nan;FMO3;rs2266780;AG + GG;OTHER;DECREASED_SEVERITY;nan;DISEASE;TOBACCO USE DISORDER ;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;KNG1;rs710446;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOSIS;;;
FLUOROURACIL;DPYD;rs1801265;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
IRINOTECAN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ASPIRIN;LPA;rs3798220;CT;EFFICACY;DECREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
BOCEPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
BOCEPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
WARFARIN;CYP2C19;rs3814637;T;TOXICITY;RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
FLUOROURACIL;DPYD;rs72728438;CT;LADME-PK;DECREASED_PK;METABOLISM;DPD ACTIVITY;;;
FLUOROURACIL;ABCC11;rs7194667;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
EGFR INHIBITORS;PIK3CA;rs2699905;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;DPYD;rs115632870;CT;LADME-PK;DECREASED_PK;METABOLISM;DPD ACTIVITY;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs56392308;del;TOXICITY;DECREASED_RISK;SIDE_EFFECT;VENOUS THROMBOSIS;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
ETHANOL;SLC6A3;rs6350;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ALCOHOL ABUSE ;;
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs8176719;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOSIS;;;
METHOTREXATE;SLCO1B1;rs4149056;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROCR;rs9574;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOSIS;;;
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F11;rs2289252;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOSIS;;;
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INFECTIOUS DISEASE;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
DEXMEDETOMIDINE;NR1I2;rs3814057;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA;;;
DEXMEDETOMIDINE;NR1I2;rs3814057;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOTENSIVE DISORDER;;;
nan;MAOA;rs1137070;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOBACCO USE DISORDER;;;
nan;MAOB;rs1799836;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOBACCO USE DISORDER;;;
CAPECITABINE;nan;rs9936750;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INFECTIOUS DISEASE;;;
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
DOXORUBICIN;ABCB1;rs1045642;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;CBR3;rs1056892;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
CAPECITABINE;DPYD;rs3918290;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FOLFIRI;UGT1A1;rs4124874;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION;;;
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CETUXIMAB;EGF;rs4444903;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;COMPLETE PATHOLOGIC RESPONSE;;;
AFATINIB;UHRF1;rs2261988;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
AFATINIB;UHRF1;rs2261988;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
ERLOTINIB;UHRF1;rs2261988;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
ERLOTINIB;UHRF1;rs2261988;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GEFITINIB;UHRF1;rs2261988;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GEFITINIB;UHRF1;rs2261988;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
nan;HAVCR2;rs10515746;AA + AC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
nan;HAVCR2;rs1036199;AC + CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
AFATINIB;DVL2;rs2074216;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
AFATINIB;DVL2;rs2074216;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
ERLOTINIB;DVL2;rs2074216;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
ERLOTINIB;DVL2;rs2074216;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GEFITINIB;DVL2;rs2074216;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GEFITINIB;DVL2;rs2074216;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GLATIRAMER ACETATE;nan;rs12459996;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CORONARY ARTERY DISEASE ;;
WARFARIN;VKORC1;rs9923231;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
FLUOROURACIL;OR10AE3P;rs10876844;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIARRHEA ;;
FLUOROURACIL;PSMB3P;rs10876844;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIARRHEA ;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
HEROIN;BDNF;rs6265;TT;OTHER;INCREASED_RISK;OTHER;ADDICTION;;;
METHAMPHETAMINE;BDNF;rs6265;T;OTHER;INCREASED_RISK;OTHER;ADDICTION;;;
DOXORUBICIN;ABCB1;rs2235047;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
PACLITAXEL;ABCB1;rs2235047;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
TRASTUZUMAB;ABCB1;rs2235047;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;CBR3;rs1056892;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
PACLITAXEL;CBR3;rs1056892;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
TRASTUZUMAB;CBR3;rs1056892;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
FENTANYL;OPRM1;rs540825;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
ASPIRIN;CYP4F2;rs3093135;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
TICAGRELOR;CYP4F2;rs3093135;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION;;;
CLOPIDOGREL;ABCB1;rs2032582;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
AFATINIB;NUP62;rs9523;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
AFATINIB;NUP62;rs9523;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
ERLOTINIB;NUP62;rs9523;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
ERLOTINIB;NUP62;rs9523;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GEFITINIB;NUP62;rs9523;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GEFITINIB;NUP62;rs9523;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
nan;nan;rs2207418;GG;OTHER;INCREASED_RISK;nan;DISEASE;DEATH ;;
ALFENTANIL;OPRM1;rs1799971;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY;;;
WARFARIN;CYP2C9;rs9332197;C;;SIDE_EFFECT;EFFICACY;TIME TO ACHIEVE STABLE DOSE;;;
WARFARIN;CYP2C9;rs1057910;C;TOXICITY;RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP2C18;rs2901783;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
WARFARIN;F5;rs6018;G;TOXICITY;RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;PROS1;rs8178607;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
nan;CHRM3;rs2165870;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING ;;
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
CISPLATIN;CDA;rs2072671;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
GEMCITABINE;CDA;rs2072671;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
CAPECITABINE;DPYD;rs1801265;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
DOXORUBICIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MICRONUCLEATED BINUCLEATED CELLS;;;
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
METHOTREXATE;MTHFR;rs1801133;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS;;;
nan;SCN5A;rs7626962;GT + TT;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;CARDIAC RHYTHM DISEASE ;;
CARBOPLATIN;VEGFA;rs879825;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TAXANES;VEGFA;rs879825;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
EXEMESTANE;ESR1;rs4870061;CT + TT;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
LETROZOLE;ESR1;rs4870061;CT + TT;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
METHOTREXATE;MTRR;rs1801394;AG + GG;LADME-PK;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CARBOPLATIN;SCN10A;rs9825762;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TAXANES;SCN10A;rs9825762;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
CARBOPLATIN;VEGFA;rs9369421;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TAXANES;VEGFA;rs9369421;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
LETROZOLE;ESR1;rs4870061;TT;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
WARFARIN;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
METHOTREXATE;ABCC2;rs2273697;AA + AG;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
EXEMESTANE;ESR1;rs9322335;TT;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
LETROZOLE;ESR1;rs9322335;TT;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
LETROZOLE;ESR1;rs9322335;TT;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
CISPLATIN;NQO1;rs1800566;AA;OTHER;DECREASED_;OTHER;OVERALL SURVIVAL;;;
ETOPOSIDE;NQO1;rs1800566;AA;OTHER;DECREASED_;OTHER;OVERALL SURVIVAL;;;
CISPLATIN;SLC22A2;rs316019;AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEPHROTOXICITY;;;
LETROZOLE;ESR2;rs10140457;CC;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
EXEMESTANE;ESR1;rs2813543;AA;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
EXEMESTANE;CYP19A1;rs6493497;AA;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
BISPHOSPHONATES;nan;rs2736308;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS OF THE JAW;;;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
BISPHOSPHONATES;nan;rs2736308;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS OF THE JAW;;;
ANTIINFLAMMATORY AGENTS;PTGS1;rs10306135;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;PTGS1;rs10306135;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
BEVACIZUMAB;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CISPLATIN;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
DOCETAXEL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
EPIRUBICIN;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
OXALIPLATIN;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
TRASTUZUMAB;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CARBOPLATIN;TNF;rs1800629;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;TNF;rs1800629;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
SORAFENIB;KDR;rs2305948;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SORAFENIB;KDR;rs2305948;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
nan;COMT;rs4680;AG + GG;OTHER;DECREASED_;OTHER;LENGTH OF HOSPITAL STAY;;;
CARBOPLATIN;PRRC2A;rs11229;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;PRRC2A;rs11229;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CARBOPLATIN;PRRC2A;rs10885;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;PRRC2A;rs10885;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
METHADONE;COMT;rs4680;AG + GG;OTHER;DECREASED_LIKELIHOOD;OTHER;TREATMENT;;;
MORPHINE;COMT;rs4680;AG + GG;OTHER;DECREASED_LIKELIHOOD;OTHER;TREATMENT;;;
SORAFENIB;FLT1;rs664393;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SORAFENIB;FLT1;rs664393;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CARBOPLATIN;MSH5;rs3115672;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;MSH5;rs3115672;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CYCLOPHOSPHAMIDE;ALDH1A1;rs13959;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;ALDH1A1;rs13959;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
FEC100;ALDH1A1;rs13959;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;ALDH1A1;rs13959;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
HMG COA REDUCTASE INHIBITORS;ATP2B1;rs17381194;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYALGIA ;;
CARBOPLATIN;DOCK8;rs10491684;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;DOCK8;rs10491684;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
HMG COA REDUCTASE INHIBITORS;nan;rs4693570;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYALGIA ;;
nan;EPO;rs1617640;A;OTHER;INCREASED_LIKELIHOOD;OTHER;ENDOGENOUS LEVELS OF EPO;;;
HMG COA REDUCTASE INHIBITORS;DMPK;rs672348;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYALGIA ;;
ASPIRIN;EYA1;rs12678747;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PEPTIC ULCER DISEASE;;;
CARBOPLATIN;CYP2C8;rs1058932;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;CYP2C8;rs1058932;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CARBOPLATIN;CYP2C8;rs11572078;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;CYP2C8;rs11572078;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
AZITHROMYCIN;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
CHLORPROMAZINE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
CILOSTAZOL;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
CIPROFLOXACIN;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
CITALOPRAM;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
CLARITHROMYCIN;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
DOFETILIDE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
DONEPEZIL;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
DRONEDARONE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
ERYTHROMYCIN;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
ESCITALOPRAM;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
FLECAINIDE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
FLUCONAZOLE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
HALOPERIDOL;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
HYDROXYCHLOROQUINE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
LEVOFLOXACIN;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
METHADONE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
MOXIFLOXACIN;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
ONDANSETRON;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
OXALIPLATIN;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
PAPAVERINE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
PENTAMIDINE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
PROCAINAMIDE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
PROPOFOL;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
QUINIDINE;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
SOTALOL;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
CARBOPLATIN;C6orf15;rs2233980;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;C6orf15;rs2233980;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CARBOPLATIN;CDSN;rs3130985;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;CDSN;rs3130985;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ETOPOSIDE;DYNC2H1;rs716274;AG + GG;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
PLATINUM COMPOUNDS;DYNC2H1;rs716274;AG + GG;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
METHADONE;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_LIKELIHOOD;OTHER;TREATMENT;;;
MORPHINE;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_LIKELIHOOD;OTHER;TREATMENT;;;
CYCLOPHOSPHAMIDE;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
CYCLOPHOSPHAMIDE;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOPHOSPHAMIDE;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
DOXORUBICIN;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
FEC100;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
FEC100;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FEC100;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
FLUOROURACIL;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ETOPOSIDE;YAP1;rs10895256;GT + TT;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
PLATINUM COMPOUNDS;YAP1;rs10895256;GT + TT;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
HMG COA REDUCTASE INHIBITORS;COQ2;rs6535454;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN INTOLERANCE;;;
HMG COA REDUCTASE INHIBITORS;COQ2;rs6535454;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEFINED PRIMARILY THROUGH MUSCLE SYMPTOMATOLOGY;;;
HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN INTOLERANCE;;;
HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEFINED PRIMARILY THROUGH MUSCLE SYMPTOMATOLOGY;;;
CARBOPLATIN;HLA-C;rs1049709;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;HLA-C;rs1049709;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
CARBOPLATIN;HCP5;rs3130907;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;HCP5;rs3130907;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
LENALIDOMIDE;CTNNB1;rs4135385;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CARBOPLATIN;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CARBOPLATIN;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PACLITAXEL;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CARBOPLATIN;SERPINC1;rs5877;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;SERPINC1;rs5877;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
IBRUTINIB;KCNQ1;rs2237895;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIAC RHYTHM DISEASE;;;
IBRUTINIB;KCNQ1;rs2237895;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
TAMOXIFEN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MUCOSITIS;;;
nan;SCN5A;rs7626962;GG;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;SUDDEN INFANT DEATH ;;
LENALIDOMIDE;CTNNB1;rs4533622;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CARBOPLATIN;nan;rs886423;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;nan;rs886423;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CARBOPLATIN;nan;rs886424;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;nan;rs886424;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
BETA BLOCKING AGENTS;ADRB1;rs1801252;AG + GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CARBOPLATIN;ATAT1;rs9262132;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;ATAT1;rs9262132;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
SORAFENIB;VEGFA;rs2010963;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SORAFENIB;VEGFA;rs2010963;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
nan;ABO;rs495828;GG;LADME-PK;INCREASED_LIKELIHOOD;OTHER;ACE ACTIVITY;;;
CARBOPLATIN;PPP1R18;rs9262143;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;PPP1R18;rs9262143;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
nan;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_;OTHER;LENGTH OF HOSPITAL STAY;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE;;;
SORAFENIB;nan;rs4604006;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
IBRUTINIB;KCNQ1;rs163182;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIAC RHYTHM DISEASE;;;
IBRUTINIB;KCNQ1;rs163182;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
CARBOPLATIN;MUCL3;rs3094086;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;MUCL3;rs3094086;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
OLANZAPINE;GIPR;rs10423928;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PLASMA INSULIN LEVELS;;;
SORAFENIB;nan;rs4604006;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SORAFENIB;VEGFA;rs25648;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;nan;rs28714259;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
CYCLOSPORINE;CTLA4;rs231775;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GINGIVAL OVERGROWTH;;;
SORAFENIB;VEGFA;rs833061;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SORAFENIB;VEGFA;rs699947;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SORAFENIB;VEGFA;rs699947;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SORAFENIB;VEGFA;rs25648;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FENTANYL;OPRM1;rs9397685;AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
FENTANYL;OPRM1;rs9397685;AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;VOMITING;;;
SORAFENIB;VEGFA;rs833061;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
nan;ABCC4;rs2274407;AA + AC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PHYSICAL AND LIFE WELL-BEING QUALITY OF LIFE (QOL) SCALES;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL (OS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL (OS) TIME;;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PAZOPANIB;HFE;rs2858996;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PACLITAXEL;ABCB1;rs1128503;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
nan;nan;rs2207418;GG;OTHER;INCREASED_RISK;nan;DISEASE;HEART FAILURE ;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME-PK;DECREASED_PK;METABOLISM;TROUGH CONCENTRATIONS;;;
GLATIRAMER ACETATE;nan;rs75041078;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CORONARY ARTERY DISEASE ;;
GLATIRAMER ACETATE;nan;rs1056854;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CORONARY ARTERY DISEASE ;;
METHAMPHETAMINE;GAD2;rs2236418;AG + GG;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;METHAMPHETAMINE DEPENDENCE, PSYCHOTIC DISORDER, SUBSTANCE-RELATED DISORDERS, ;;
GLICLAZIDE;ABCC8;rs757110;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
GLICLAZIDE;KCNJ11;rs757110;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
GLYBURIDE;ABCC8;rs757110;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
GLYBURIDE;KCNJ11;rs757110;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
PEGINTERFERON ALFA-2A;IFNL3;rs4803217;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
PEGINTERFERON ALFA-2B;IFNL3;rs4803217;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
RIBAVIRIN;IFNL3;rs4803217;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
TACROLIMUS;ABCB1;rs2229109;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RENAL TRANSPLANT FAILURE;;;
PEGINTERFERON ALFA-2A;IFNL3;rs4803217;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs4803217;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs4803217;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
FENTANYL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPOVENTILATION;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME-PK;DECREASED_PK;METABOLISM;TROUGH LEVELS;;;
AFATINIB;ARF1;rs11541557;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
AFATINIB;ARF1;rs11541557;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
ERLOTINIB;ARF1;rs11541557;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
ERLOTINIB;ARF1;rs11541557;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
GEFITINIB;ARF1;rs11541557;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
GEFITINIB;ARF1;rs11541557;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;rs2031920;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
OSELTAMIVIR;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEPRESSION;;;
OSELTAMIVIR;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTRITIS;;;
OSELTAMIVIR;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
METHOTREXATE;ABCC3;rs9895420;AA + AT;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;PLASMA LEVELS;;;
METHOTREXATE;ABCC3;rs9895420;AA + AT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
COCAINE;OPRD1;rs678849;T;TOXICITY;DECREASED_RISK;OTHER;COCAINE DEPENDENCE;;;
CERIVASTATIN;RYR2;rs2819742;AA;TOXICITY;DECREASED_RISK;nan;DISEASE;RHABDOMYOLYSIS ;;
CYCLOPHOSPHAMIDE;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
CYTARABINE;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DAUNORUBICIN;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DEXAMETHASONE;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DOXORUBICIN;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
METHOTREXATE;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PEGASPARGASE;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PREDNISONE;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
THIOGUANINE;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
VINCRISTINE;nan;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
ANTIEPILEPTICS;ABCC2;rs2273697;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROBABILITY OF ANTIEPILEPTIC DRUG RESPONSE;;;
METHOTREXATE;ABCC3;rs9895420;AA + AT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RELAPSE IN THE CENTRAL NERVOUS SYSTEM;;;
nan;CYP1A2;rs35694136;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE ;;
ANTITHYMOCYTE GLOBULIN;FCGR3A;rs396991;AC + CC;OTHER;INCREASED_LIKELIHOOD;OTHER;SENSITIVE TO ANTILYMPHOCYTE SERUM;;;
CYCLOPHOSPHAMIDE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
CYTARABINE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DAUNORUBICIN;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DEXAMETHASONE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DOXORUBICIN;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
METHOTREXATE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PEGASPARGASE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PREDNISONE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
THIOGUANINE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
VINCRISTINE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
CYCLOPHOSPHAMIDE;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
CYTARABINE;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DAUNORUBICIN;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DEXAMETHASONE;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DOXORUBICIN;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
METHOTREXATE;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PEGASPARGASE;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PREDNISONE;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
THIOGUANINE;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
VINCRISTINE;nan;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PEGASPARGASE;ARHGAP28;rs9958628;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
CYCLOPHOSPHAMIDE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
CYTARABINE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DAUNORUBICIN;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DEXAMETHASONE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DOXORUBICIN;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
METHOTREXATE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PEGASPARGASE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PREDNISONE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
THIOGUANINE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
VINCRISTINE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
CYCLOPHOSPHAMIDE;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
CYTARABINE;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DAUNORUBICIN;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DEXAMETHASONE;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DOXORUBICIN;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
METHOTREXATE;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PEGASPARGASE;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PREDNISONE;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
THIOGUANINE;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
VINCRISTINE;nan;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
CARBOPLATIN;ABCG2;rs3114020;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ETOPOSIDE;ABCG2;rs3114020;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
IFOSFAMIDE;ABCG2;rs3114020;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
THEOPHYLLINE;CYP1A2;rs35694136;T/del + TT;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE ;;
THEOPHYLLINE;CYP1A2;rs35694136;T;EFFICACY, LADME-PK;DECREASED_PK;METABOLISM;PLASMA DRUG LEVELS;;;
nan;CYP1A2;rs762551;C;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE ;;
ETHAMBUTOL;ATP7B;rs1061472;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;ATP7B;rs1061472;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;ATP7B;rs1061472;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;ATP7B;rs1061472;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
VERAPAMIL;NR1H3;rs2279238;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
VERAPAMIL;NR1H3;rs2279238;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
VERAPAMIL;NR1H3;rs12221497;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
VERAPAMIL;NR1H3;rs12221497;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
ATENOLOL;NR1H3;rs11039149;G;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ATENOLOL;NR1H3;rs11039149;G;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
VERAPAMIL;NR1H3;rs11039149;G;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
VERAPAMIL;NR1H3;rs11039149;G;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
SEVOFLURANE;KCNK2;rs6686529;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SEDATION;;;
CHOP;SLC35F4;rs74832512;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RITUXIMAB;SLC35F4;rs74832512;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PROTEASE INHIBITORS;APOC3;rs2854116;CC + CT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA;;;
VARENICLINE;CHRNB1;rs2302764;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NAUSEA ;;
VARENICLINE;ZBTB4;rs2302764;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NAUSEA ;;
PROTEASE INHIBITORS;APOC3;rs2854117;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA;;;
VARENICLINE;CHRNB2;rs2072661;A;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NAUSEA ;;
CYCLOPHOSPHAMIDE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
CYTARABINE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DAUNORUBICIN;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DEXAMETHASONE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
DOXORUBICIN;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
METHOTREXATE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PEGASPARGASE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PREDNISONE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
THIOGUANINE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
VINCRISTINE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
VARENICLINE;CHRNB2;rs4292956;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NAUSEA ;;
VARENICLINE;CHRNB2;rs2072660;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NAUSEA ;;
CARBOPLATIN;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ETOPOSIDE;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
IFOSFAMIDE;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
AZATHIOPRINE;DDRGK1;rs1127354;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;ITPA;rs1127354;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MORPHINE;FAAH;rs324420;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY;;;
CHOP;OXNAD1;rs11721010;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RITUXIMAB;OXNAD1;rs11721010;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
MORPHINE;FAAH;rs11576941;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
PROTEASE INHIBITORS;APOC3;rs5128;CG + GG;TOXICITY;DECREASED_;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA;;;
SUNITINIB;ABCB1;rs2032582;AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DOCETAXEL;SLCO1B3;rs11045585;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
APIXABAN;ABCB1;rs4148738;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
DOCETAXEL;ABCC2;rs12762549;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
ASPIRIN;ITGB3;rs5918;CT;OTHER;INCREASED_LIKELIHOOD;OTHER;SENSITIVITY TO ASPIRIN;;;
CHOP;CIDEA;rs75614943;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RITUXIMAB;CIDEA;rs75614943;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CYTARABINE;CDA;rs3215400;C/del + del/del;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
METHAMPHETAMINE;BDNF;rs6265;CC;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
CHOP;NOS1;rs77241831;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RITUXIMAB;NOS1;rs77241831;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
METHAMPHETAMINE;BDNF;rs6265;CC;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT;PSYCHOTIC DISORDER;;;
CYTARABINE;CDA;rs2072671;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
ANTIPSYCHOTICS;nan;rs9346455;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
SUFENTANIL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE_PAIN;;;
CYTARABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
HEROIN;OPRD1;rs2236857;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
CYTARABINE;CDA;rs532545;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
HEROIN;OPRD1;rs2236855;A;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
SUNITINIB;ABCB1;rs1128503;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RIVAROXABAN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;THROMBOEMBOLISM;;;
HEROIN;OPRD1;rs3766951;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
NICOTINE;NRXN1;rs2193225;C;OTHER;nan;OTHER;SMOKING QUANTITY;;;
HEROIN;OPRD1;rs2298897;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
NICOTINE;NRXN1;rs2193225;C;OTHER;nan;OTHER;SMOKING QUANTITY;;;
NICOTINE;NRXN1;rs2193225;C;OTHER;nan;OTHER;HEAVINESS OF SMOKING INDEX AND FAGERSTROM TEST FOR NICOTINE DEPENDENCE;;;
NICOTINE;NRXN1;rs6721498;A;OTHER;nan;OTHER;SMOKING QUANTITY;;;
NICOTINE;NRXN1;rs6721498;A;OTHER;nan;OTHER;HEAVINESS OF SMOKING INDEX AND FAGERSTROM TEST FOR NICOTINE DEPENDENCE;;;
SUNITINIB;ABCB1;rs1045642;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CHOP;nan;rs1607795;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RITUXIMAB;nan;rs1607795;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SUFENTANIL;COMT;rs4680;AA;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE_PAIN;;;
ETHANOL;FUT2;rs492602;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;FTO;rs9937709;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
PLATINUM;RICTOR;rs6878291;GG;TOXICITY;DECREASED_;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
ANTIDEPRESSANTS;NR3C1;rs852977;G;EFFICACY;INCREASED_PK;PK;ANTIDEPRESSANT RESPONSE;;;
CERIVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;RHABDOMYOLYSIS ;;
PAROXETINE;HTR3B;rs1176744;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NAUSEA ;;
ETHANOL;nan;rs1783835;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
CHOP;TNIP3;rs116665727;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RITUXIMAB;TNIP3;rs116665727;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;APEX1;rs1760944;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
FLUOROURACIL;APEX1;rs1760944;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
RADIOTHERAPY;APEX1;rs1760944;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
CHOP;IL10;rs1800871;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CHOP;IL10;rs1800871;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RITUXIMAB;IL10;rs1800871;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RITUXIMAB;IL10;rs1800871;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;ABCB1;rs2032582;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;MUTYH;rs3219489;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;MUTYH;rs3219489;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
RADIOTHERAPY;MUTYH;rs3219489;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
ETHANOL;SLC4A8;rs12296477;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ASPIRIN;ITGB3;rs5918;CC + CT;OTHER;nan;OTHER;SHORTER BLEEDING TIME;;;
ESCITALOPRAM;HTR2A;rs9316233;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTIDEPRESSANT RESPONSE;;;
ETHANOL;ARID4A;rs61974485;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;nan;rs8008020;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
NICOTINE;OPRM1;rs1799971;AG;TOXICITY;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
ETHANOL;TNRC6A;rs72768626;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
GLIMEPIRIDE;NOS1AP;rs10494366;T;TOXICITY;INCREASED_RISK;OTHER;HYPOGLYCEMIA;;;
GLIPIZIDE;NOS1AP;rs10494366;T;TOXICITY;INCREASED_RISK;OTHER;HYPOGLYCEMIA;;;
GLYBURIDE;NOS1AP;rs10494366;T;TOXICITY;INCREASED_RISK;OTHER;HYPOGLYCEMIA;;;
KETOROLAC;nan;rs2562456;CC;;SIDE_EFFECT;EFFICACY;SLOWER ANALGESIC ONSET IN EUROPEAN AMERICANS UNDERGOING ORAL SURGERY;;;
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
AZATHIOPRINE;ABCC1;rs2074087;CC + CG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LYMPHOPENIA;;;
FLUVASTATIN;SREBF1;rs60282872;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;APOLIPOPROTEIN A1 AND C3;;;
BEVACIZUMAB;SLC19A1;rs1051298;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PEMETREXED;SLC19A1;rs1051298;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CISPLATIN;TP53;rs1042522;CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RADIOTHERAPY;TP53;rs1042522;CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;SLC30A8;rs13266634;C;OTHER, LADME-PK;INCREASED_LIKELIHOOD;OTHER;BASELINE PROINSULIN LEVELS AFTER ADJUSTING FOR INSULIN LEVELS;;;
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
ANTIINFLAMMATORY AGENTS;AGT;rs943580;GG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;AGT;rs943580;GG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
ANTIINFLAMMATORY AGENTS;MMP1;rs2071230;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
ANTIINFLAMMATORY AGENTS;MMP10;rs2071230;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;MMP1;rs2071230;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;MMP10;rs2071230;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
LEVONORGESTREL;ADAMTS10;rs7255721;CG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ANTIINFLAMMATORY AGENTS;MMP1;rs7945189;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
ANTIINFLAMMATORY AGENTS;MMP10;rs7945189;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;MMP1;rs7945189;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;MMP10;rs7945189;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
CITALOPRAM;HTR2A;rs6313;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEART PALPITATIONS;;;
ANTIINFLAMMATORY AGENTS;PTGS1;rs12353214;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;PTGS1;rs12353214;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
ANTIINFLAMMATORY AGENTS;KL;rs211247;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;KL;rs211247;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
ANTIINFLAMMATORY AGENTS;CRP;rs1205;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;CRP;rs1205;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NICOTINE;CHRNA4;rs1044396;AG;OTHER;INCREASED_LIKELIHOOD;OTHER;SMOKING INITIATION;;;
ANTIINFLAMMATORY AGENTS;CDKN2B-AS1;rs10757274;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;CDKN2B-AS1;rs10757274;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NICOTINE;CHRNA4;rs1044396;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
ANTIINFLAMMATORY AGENTS;AGT;rs699;GG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
NON-STEROIDS;AGT;rs699;GG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
NICOTINE;CHRNA4;rs1044397;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOBACCO USE DISORDER ;;
COXIBS;PTGS2;rs20417;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
COXIBS;PTGS2;rs4648276;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ACUTE CORONARY SYNDROME ;;
SEVOFLURANE;FASTKD3;rs3733784;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;VOL% END-TIDAL SEVOFLURANE CONCENTRATION;;;
SEVOFLURANE;MTRR;rs3733784;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;VOL% END-TIDAL SEVOFLURANE CONCENTRATION;;;
HEROIN;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
HEROIN;OPRM1;rs511435;T;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
HEROIN;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
AZATHIOPRINE;ADK;rs10824095;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
HEROIN;OPRM1;rs510769;T;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
CISPLATIN;ACYP2;rs1872328;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
AZATHIOPRINE;SLC29A1;rs747199;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-TREATMENT PLATELET AGGREGATION;;;
AZATHIOPRINE;IMPDH2;rs11706052;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LYMPHOPENIA;;;
HEROIN;OPRM1;rs3778151;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
AZATHIOPRINE;IMPDH1;rs2278294;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LYMPHOPENIA;;;
CLOZAPINE;SLC1A1;rs2228622;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS;;;
OLANZAPINE;SLC1A1;rs2228622;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS;;;
RISPERIDONE;SLC1A1;rs2228622;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS;;;
HEROIN;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
CLOZAPINE;SLC1A1;rs3780413;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS;;;
OLANZAPINE;SLC1A1;rs3780413;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS;;;
RISPERIDONE;SLC1A1;rs3780413;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS;;;
CLOZAPINE;SLC1A1;rs3780412;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS;;;
OLANZAPINE;SLC1A1;rs3780412;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS;;;
RISPERIDONE;SLC1A1;rs3780412;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS;;;
HEROIN;nan;rs9478495;A;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
ASPIRIN;ITGA2;rs1062535;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESIDUAL PLATELET REACTIVITY;;;
CLOPIDOGREL;ITGA2;rs1062535;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESIDUAL PLATELET REACTIVITY;;;
nan;ITGB1;rs1187075;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
HEROIN;OPRM1;rs562859;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
FLUOROURACIL;DPYD;rs3918290;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
LETROZOLE;nan;rs1324052;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN;;;
LETROZOLE;nan;rs1324052;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ARTHRITIS;;;
LETROZOLE;nan;rs1324052;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PLATINUM;STMN1;rs182455;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
VINORELBINE;STMN1;rs182455;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
TEGAFUR;DPYD;rs1801159;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;ITGB1;rs2230395;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
HEROIN;OPRM1;rs3778150;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
BEVACIZUMAB;GGH;rs3780126;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PEMETREXED;GGH;rs3780126;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;TPH2;rs1843809;TT;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT;AGGRESSION;;;
nan;TPH2;rs1843809;TT;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT;DEPRESSION;;;
ASPIRIN;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESIDUAL PLATELET REACTIVITY;;;
CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESIDUAL PLATELET REACTIVITY;;;
HEROIN;nan;rs9384169;C;TOXICITY;INCREASED_RISK;OTHER;HEROIN DEPENDENCE;;;
ANTIPSYCHOTICS;CYP1A2;rs762551;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;QT INTERVAL;;;
PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ANTIDEPRESSANTS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;CARDIAC ARREST;;;
ANTIDEPRESSANTS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;RESPIRATORY INSUFFICIENCY;;;
ANTIPSYCHOTICS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;CARDIAC ARREST;;;
ANTIPSYCHOTICS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;RESPIRATORY INSUFFICIENCY;;;
BENZODIAZEPINE DERIVATIVES;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;CARDIAC ARREST;;;
BENZODIAZEPINE DERIVATIVES;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;RESPIRATORY INSUFFICIENCY;;;
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;CARDIAC ARREST;;;
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;RESPIRATORY INSUFFICIENCY;;;
SYMPATHOMIMETICS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;CARDIAC ARREST;;;
SYMPATHOMIMETICS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER;RESPIRATORY INSUFFICIENCY;;;
BEVACIZUMAB;GGH;rs11545077;CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PEMETREXED;GGH;rs11545077;CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DIGOXIN;NOS1AP;rs10494366;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SHORTENED QT INTERVAL;;;
SUNITINIB;ABCB1;rs2032582;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
SUNITINIB;ABCB1;rs2032582;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
SUNITINIB;ABCB1;rs2032582;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
ASPIRIN;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION AFTER STIMULI WITH ADENOSINE DIPHOSPHATE;;;
ASPIRIN;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COLLAGEN;;;
ASPIRIN;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;AND EPINEPHRINE;;;
CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION AFTER STIMULI WITH ADENOSINE DIPHOSPHATE;;;
CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COLLAGEN;;;
CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;AND EPINEPHRINE;;;
FENTANYL;OPRM1;rs1799971;GG;DOSAGE;nan;SIDE_EFFECT;HIGHER FENTANYL DOSE REQUIREMENT TO ACHIEVE ADEQUATE PAIN RELIEF IN CHINESE WOMEN UNDERGOING GYNECOLOGIC SURGERY;;;
CANNABINOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
COCAINE;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
ETHANOL;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
NICOTINE;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
CAPECITABINE;MIR27A;rs895819;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;MIR27A;rs895819;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SUNITINIB;FLT1;rs7993418;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;NFE2L2;rs6721961;GG + GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY;;;
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FENTANYL;OPRM1;rs1799971;AG + GG;DOSAGE, ;SIDE_EFFECT;EFFICACY;HIGHER RESPONSIVENESS TO OPIOIDS AND REQUIRED LESS ANALGESIC DRUGS IN LABORING WOMEN;;;
FLUVOXAMINE;HTR2A;rs6311;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL SIDE EFFECTS;;;
FENTANYL;OPRM1;rs1799971;AG + GG;;SIDE_EFFECT;EFFICACY;LESS PAIN CONTROL IN JAPANESE PATIENTS UNDERGOING PAINFUL OROFACIAL COSMETIC SURGERY;;;
OLANZAPINE;FMO3;rs2266780;GG;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED SERUM OLANZAPINE N-OXIDE CONCENTRATIONS;;;
METOPROLOL;CYP2D6;rs3892097;T;EFFICACY, LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS OF METOPROLOL AND GREATER REDUCTIONS IN HEART RATE;;;
METOPROLOL;CYP2D6;rs3892097;T;EFFICACY, LADME-PK;INCREASED_PK;METABOLISM;DIASTOLIC BLOOD PRESSURE;;;
METOPROLOL;CYP2D6;rs3892097;T;EFFICACY, LADME-PK;INCREASED_PK;METABOLISM;AND MEAN ARTERIAL PRESSURE IN PMS THAN IN NON-PMS.;;;
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESIDUAL PLATELET REACTIVITY;;;
PLATINUM COMPOUNDS;CCN4;rs10956697;AA + AC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;CCN4;rs10956697;AA + AC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
ASPIRIN;ITGB3;rs5918;CC + CT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;THE LACK OF ASPIRIN EFFECT;;;
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OLANZAPINE;FMO1;rs12720462;AA + AC;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED SERUM OLANZAPINE CONCENTRATIONS;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ARIPIPRAZOLE;DRD2;rs2514218;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PSYCHOMOTOR AGITATION;;;
PLATINUM COMPOUNDS;GSTP1;rs1695;AA;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGICAL TOXICITY;;;
TAXANES;GSTP1;rs1695;AA;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;HEMATOLOGICAL TOXICITY;;;
PLATINUM;ABCB1;rs2032582;CC;TOXICITY, LADME-PK;DECREASED_RISK;SIDE_EFFECT;GRADE 3 OR 4 GASTROINTESTINAL_TOXICITY;;;
TAXANES;ABCB1;rs2032582;CC;TOXICITY, LADME-PK;DECREASED_RISK;SIDE_EFFECT;GRADE 3 OR 4 GASTROINTESTINAL_TOXICITY;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OLANZAPINE;FMO1;rs7877;CT + TT;LADME-PK;INCREASED_PK;METABOLISM;DOSE-ADJUSTED SERUM OLANZAPINE CONCENTRATIONS;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESIDUAL PLATELET REACTIVITY;;;
BUMETANIDE;SLC12A3;rs1529927;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;24-H EXCRETION OF CHLORIDE AND POTASSIUM;;;
FUROSEMIDE;SLC12A3;rs1529927;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;24-H EXCRETION OF CHLORIDE AND POTASSIUM;;;
TORASEMIDE;SLC12A3;rs1529927;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;24-H EXCRETION OF CHLORIDE AND POTASSIUM;;;
AMPHETAMINE;KAT2B;rs9829896;C;TOXICITY;DECREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
CANNABINOIDS;KAT2B;rs9829896;C;TOXICITY;DECREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
COCAINE;KAT2B;rs9829896;C;TOXICITY;DECREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
OPIOIDS;KAT2B;rs9829896;C;TOXICITY;DECREASED_RISK;OTHER;SUBSTANCE-RELATED DISORDERS;;;
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
IMATINIB;ABCG2;rs2231142;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ASPIRIN;NAT2;rs4271002;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INTOLERANCE;;;
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
METHADONE;ARRB2;rs3786047;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT;;;
BUMETANIDE;SCNN1G;rs5723;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME;;;
FUROSEMIDE;SCNN1G;rs5723;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME;;;
TORASEMIDE;SCNN1G;rs5723;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME;;;
PLATINUM COMPOUNDS;CCN4;rs2929973;GG + GT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
ENALAPRIL;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
ANTIPSYCHOTICS;HTR2A;rs6311;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TARDIVE DYSKINESIA ;;
METHADONE;ARRB2;rs1045280;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT;;;
METHADONE;MYOCD;rs1714984;AA + AG;;SIDE_EFFECT;EFFICACY;INCREASED  RISK OF BEING NONRESPONDERS;;;
METHADONE;ARRB2;rs2036657;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT;;;
BUMETANIDE;SCNN1G;rs5729;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME;;;
FUROSEMIDE;SCNN1G;rs5729;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME;;;
TORASEMIDE;SCNN1G;rs5729;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME;;;
ANTIPSYCHOTICS;CYP1A2;rs762551;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TARDIVE DYSKINESIA ;;
ANTIPSYCHOTICS;CYP2D6;rs1065852;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TARDIVE DYSKINESIA ;;
OLANZAPINE;HTR2C;rs518147;C;TOXICITY;DECREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
PRAVASTATIN;CETP;rs708272;AG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;CORONARY ARTERY DISEASE;;;
ATORVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BENEFIT;;;
ASPIRIN;ITGB3;rs5918;TT;;SIDE_EFFECT;EFFICACY;ASPIRIN-DEPRESSED THROMBIN GENERATION AND PROLONGED BLEEDING TIME AFTER ASPIRIN;;;
ASPIRIN;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;INHIBITION OF FXIII ACTIVATION BY ASPIRIN;;;
VERAPAMIL;ADRB1;rs1801253;CC + CG;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
AZATHIOPRINE;ITPA;rs1127354;C;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
CHOP;NCF4;rs1883112;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RITUXIMAB;NCF4;rs1883112;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;BONE_DENSITY;;;
CHOP;ABCG2;rs2231137;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
RITUXIMAB;ABCG2;rs2231137;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PRAVASTATIN;CETP;rs708272;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN LUMINAL DIAMETER;;;
AMIODARONE;NOS1AP;rs10800397;T;TOXICITY;nan;SIDE_EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION;;;
DIURETICS;NOS1AP;rs10800397;T;TOXICITY;nan;SIDE_EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION;;;
SOTALOL;NOS1AP;rs10800397;T;TOXICITY;nan;SIDE_EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION;;;
ANTIPSYCHOTICS;nan;rs6977820;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TARDIVE DYSKINESIA ;;
AMIODARONE;NOS1AP;rs10800397;T;TOXICITY;nan;SIDE_EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION;;;
WARFARIN;VKORC1;rs17880887;T;DOSAGE;nan;SIDE_EFFECT;LOWER LEVELS OF TRANSTHYRETIN PRECUROR;;;
AMIODARONE;NOS1AP;rs10919035;T;TOXICITY;nan;SIDE_EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION;;;
ASPIRIN;HNMT;rs1050891;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ACETYLSALICYLIC ACID-INTOLERANT CHRONIC URTICARIA;;;
AMIODARONE;NOS1AP;rs10919035;T;TOXICITY;nan;SIDE_EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION;;;
ASPIRIN;LTC4S;rs730012;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SENSITIVITY TO ASPIRIN;;;
ANTIPSYCHOTICS;SMYD3;rs2485914;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TARDIVE DYSKINESIA ;;
ETHAMBUTOL;NAT2;rs1799929;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICTY;;;
ISONIAZID;NAT2;rs1799929;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICTY;;;
PYRAZINAMIDE;NAT2;rs1799929;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICTY;;;
RIFAMPIN;NAT2;rs1799929;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOTOXICTY;;;
ETHAMBUTOL;NAT2;rs1799929;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEPATOTOXICTY;;;
ISONIAZID;NAT2;rs1799929;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEPATOTOXICTY;;;
PYRAZINAMIDE;NAT2;rs1799929;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEPATOTOXICTY;;;
RIFAMPIN;NAT2;rs1799929;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEPATOTOXICTY;;;
CYTARABINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;COMPLETE REMISSION;;;
IDARUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;COMPLETE REMISSION;;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS REQUIREMENTS ON DAY 14 ;
LEVONORGESTREL;TP53;rs1042522;CG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ASPIRIN;GP6;rs1613662;AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE TO ASPIRIN;;;
CISPLATIN;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
DOXORUBICIN;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
IFOSFAMIDE;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
METHOTREXATE;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
CYTARABINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;3-YEAR EVENT FREE SURVIVAL;;;
IDARUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;3-YEAR EVENT FREE SURVIVAL;;;
CISPLATIN;ERCC2;rs13181;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
CISPLATIN;KLC3;rs13181;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
DOXORUBICIN;ERCC2;rs13181;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
DOXORUBICIN;KLC3;rs13181;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
IFOSFAMIDE;ERCC2;rs13181;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
IFOSFAMIDE;KLC3;rs13181;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
METHOTREXATE;ERCC2;rs13181;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
METHOTREXATE;KLC3;rs13181;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;nan;SIDE_EFFECT;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR);;;
PHENPROCOUMON;CYP4F2;rs2108622;CT + TT;DOSAGE;nan;SIDE_EFFECT;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR);;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;nan;SIDE_EFFECT;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR);;;
ASPIRIN;ITGB3;rs5918;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLOOD LOSS;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
SUNITINIB;KDR;rs2305948;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;GSTP1;rs1695;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
EPIRUBICIN;GSTP1;rs1695;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PLATINUM;GSTP1;rs1695;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR);;;
nan;ITGB3;rs5918;CC + CT;OTHER;nan;OTHER;SHORTER BLEEDING TIME;;;
BETA BLOCKING AGENTS;GRK5;rs2230345;AA;OTHER;INCREASED_RISK;OTHER;DEATH;;;
FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
HYDROMORPHONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
OXYCODONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ADP-INDUCED PLATELET AGGREGATION;;;
BEVACIZUMAB;CXCR4;rs2228014;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
BETA BLOCKING AGENTS;ADRB1;rs1801253;CC;OTHER;DECREASED_RISK;OTHER;DEATH;;;
DOCETAXEL;PPCDC;rs147451859;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
FEC100;PPCDC;rs147451859;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
GEMCITABINE;PPCDC;rs147451859;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
TRASTUZUMAB;PPCDC;rs147451859;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
ZOLEDRONATE;PPCDC;rs147451859;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
SUNITINIB;FLT4;rs6877011;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DISEASE PROGRESSION;;;
HALOPERIDOL;ABCB5;rs17143212;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
DOCETAXEL;nan;rs17587029;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
FEC100;nan;rs17587029;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
GEMCITABINE;nan;rs17587029;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
TRASTUZUMAB;nan;rs17587029;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
ZOLEDRONATE;nan;rs17587029;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;AMENORRHEA;;;
SUNITINIB;ABCG2;rs2231142;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
OPIOIDS;CNIH3;rs10799590;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
AZATHIOPRINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
SUNITINIB;VEGFA;rs3025039;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
ANTIPSYCHOTICS;CYP1A2;rs762551;CC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TARDIVE DYSKINESIA ;;
METHOTREXATE;MTHFR;rs1801133;A;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
CISPLATIN;SLC22A2;rs316019;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
SUNITINIB;CYP3A4;rs4646437;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
ATORVASTATIN;ABCB1;rs2032582;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
"""ACE INHIBITORS";F5;rs6025;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"PLAIN""";F5;rs6025;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"""ANGIOTENSIN II ANTAGONISTS""";F5;rs6025;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
CISPLATIN;NFE2L2;rs6721961;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
CARVEDILOL;ADRB2;rs1042714;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;IMPROVED LEFT VENTRICULAR EJECTION FRACTION;;;
TACROLIMUS;FOXP3;rs3761548;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
TACROLIMUS;CYP3A4;rs2740574;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DIABETES MELLITUS;;;
METHOTREXATE;RAVER2;rs72675408;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
PHENYTOIN;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ATAXIA;;;
PHENYTOIN;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DIPLOPIA;;;
PHENYTOIN;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DIZZINESS;;;
PHENYTOIN;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DYSARTHRIA;;;
PHENYTOIN;CYP2C9;rs1799853;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;ATAXIA;;;
PHENYTOIN;CYP2C9;rs1799853;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DIPLOPIA;;;
PHENYTOIN;CYP2C9;rs1799853;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DIZZINESS;;;
PHENYTOIN;CYP2C9;rs1799853;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DYSARTHRIA;;;
CAPECITABINE;PPARD;rs2016520;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;PPARD;rs2016520;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
EFAVIRENZ;CYP2B6;rs8192719;CT + TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
nan;SULT1A1;rs1801030;CC + CT;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HOT FLASHES ;;
nan;SULT1A2;rs1801030;CC + CT;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HOT FLASHES ;;
OPIOIDS;MCOLN1;rs116181528;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;OVERDOSE;;;
CERIVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
nan;AKT1;rs2494732;CC;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;PSYCHOTIC DISORDER ;;
CAPECITABINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
WARFARIN;VKORC1;rs8050894;G;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS REQUIREMENTS ON DAY 14 ;
BEVACIZUMAB;KCNAB1;rs6770663;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS REQUIREMENTS ON DAY 14 ;
CYCLOPHOSPHAMIDE;GSTP1;rs1695;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;TOXICITY;;;
EPIRUBICIN;GSTP1;rs1695;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;TOXICITY;;;
ASPIRIN;CEP68;rs7572857;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DECLINE OF FORCED EXPIRATORY VOLUME IN 1S (FEV(1)) BY ASPIRIN PROVOCATION;;;
OPIOIDS;MCOLN1;rs114077267;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;OVERDOSE;;;
ACENOCOUMAROL;VKORC1;rs9923231;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
PLATINUM COMPOUNDS;MDM2;rs2279744;GT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
SUNITINIB;FLT3;rs1933437;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
ASPIRIN;ITGB3;rs5918;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET INHIBITION BY ASPIRIN;;;
nan;SLC2A9;rs62293298;AG;OTHER;DECREASED_LIKELIHOOD;OTHER;HYPERURICEMIA;;;
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
ASPIRIN;TLR3;rs3775291;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-EXACERBATED RESPIRATORY DISEASE;;;
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATION;;;
OPIOIDS;MCOLN1;rs115208233;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;OVERDOSE;;;
TACROLIMUS;CYP3A4;rs2740574;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;ACUTE CELLULAR REJECTION;;;
NICOTINE;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CRAVING;;;
NICOTINE;DRD2;rs1800497;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;CRAVING;;;
WARFARIN;VKORC1;rs2884737;CC;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS REQUIREMENTS ON DAY 14 ;
PEGINTERFERON ALFA-2A;IL6;rs1800795;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IL6;rs1800795;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IL6;rs1800795;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
nan;ABCG2;rs2231142;GT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;HYPERURICEMIA;;;
ACENOCOUMAROL;CYP2C9;rs72558189;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
WARFARIN;CYP2C9;rs72558189;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
TELBIVUDINE;TK2;rs3826160;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;;
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS REQUIREMENTS ON DAY 14 ;
nan;SLC22A12;rs3825017;CT;OTHER;INCREASED_LIKELIHOOD;OTHER;HYPERURICEMIA;;;
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
SUNITINIB;CYP1A1;rs1048943;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
SUNITINIB;CYP1A1;rs1048943;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
OLANZAPINE;DRD2;rs2440390;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
PRAVASTATIN;ADAMTS1;rs428785;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;FATAL CORONARY DISEASE OR NONFATAL MYOCARDIAL INFARCTION;;;
OLANZAPINE;HTR2C;rs6318;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;NEURAL TUBE DEFECTS ;;
OLANZAPINE;HTR2C;rs2497538;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;HTR2C;rs1414334;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
PIOGLITAZONE;LPL;rs328;CG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE RATE AFTER 10 WEEKS OF PIOGLITAZONE TREATMENT;;;
PACLITAXEL;EPHA5;rs7349683;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
nan;SCN1A;rs3812718;T;OTHER;INCREASED_RISK;nan;DISEASE;SEIZURES, FEBRILE ;;
nan;UGT1A1;rs4148323;AA + AG;OTHER;INCREASED_SEVERITY;OTHER;NEONATAL HYPERBILIRUBINEMIA;;;
nan;UGT1A1;rs4148323;AA + AG;OTHER;INCREASED_SEVERITY;OTHER;HYPERBILIRUBINEMIA;;;
nan;CHRNA5;rs16969968;A;OTHER;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
PACLITAXEL;ABCB1;rs3213619;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
VERAPAMIL;NOS1AP;rs10494366;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;QTC PROLONGATION;;;
MERCAPTOPURINE;PACSIN2;rs2413739;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
nan;nan;rs1051730;A;OTHER;INCREASED_SEVERITY;OTHER;TOBACCO USE DISORDER;;;
nan;CYP2R1;rs12794714;A;OTHER;INCREASED_LIKELIHOOD;OTHER;VITAMIN D DEFICIENCY;;;
OLANZAPINE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SOCIAL AND CLINICAL NEEDS;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ETHAMBUTOL;NAT2;rs1799930;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;rs1799930;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;rs1799930;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;rs1799930;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
nan;CYP2R1;rs10741657;A;OTHER;DECREASED_LIKELIHOOD;OTHER;VITAMIN D DEFICIENCY;;;
ETHAMBUTOL;NAT2;rs1799929;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;rs1799929;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;rs1799929;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;rs1799929;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
PAROXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE AT 4 WEEKS AFTER THE INITIATION OF TREATMENT;;;
TAMOXIFEN;E2F7;rs310786;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LUMBAR BONE LOSS;;;
ALENDRONATE;DKK1;rs2241529;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;BONE_DENSITY;;;
CLOPIDOGREL;CES1;rs8192950;G;EFFICACY;DECREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
CLOPIDOGREL;CES1;rs8192950;G;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
ANTIPSYCHOTICS;DRD2;rs1799732;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SIDE EFFECTS;;;
SUNITINIB;KDR;rs2305948;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
WARFARIN;CYP2C9;rs4918758;C;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS REQUIREMENT IN MECHANICAL HEART VALVE REPLACEMENT PATIENTS ;
SUNITINIB;VEGFA;rs3025039;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
OLANZAPINE;ANKK1;rs1800497;GG;OTHER;DECREASED_PK;PK;AREA UNDER THE CURVE FROM BASELINE TO THE LAST MEASURED CONCENTRATION;;;
EXEMESTANE;ESR1;rs9322336;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL TOXICITY;;;
WARFARIN;CYP2C9;rs9332096;T;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS REQUIREMENT IN MECHANICAL HEART VALVE REPLACEMENT PATIENTS ;
OLANZAPINE;ANKK1;rs1800497;GG;OTHER;DECREASED_;OTHER;PEAK PLASMA CONCENTRATION OF INCREASED  PROLACTIN;;;
SUNITINIB;VEGFA;rs2010963;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
SUNITINIB;FLT4;rs6877011;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;FLT4;rs6877011;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OLANZAPINE;GSTP1;rs1695;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;SYNCOPE ;;
SUNITINIB;NR1I2;rs2276707;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;DECREASED_SENSITIVITY;DOSE_INCREASE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS;
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CARDIOMYOPATHIES ;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
SUNITINIB;FLT3;rs1933437;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
NORTRIPTYLINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ORTHOSTATIC HYPOTENSION ;;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
MORPHINE;OPRM1;rs1799971;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
OXYCODONE;OPRM1;rs1799971;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
MORPHINE;COMT;rs4680;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
OXYCODONE;COMT;rs4680;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
CARBAMAZEPINE;HNF4A;rs2071197;GG;EFFICACY;INCREASED_PK;PK;CONCENTRATION-TO-DOSE RATIOS;;;
WARFARIN;VKORC1;rs8050894;G;DOSAGE;INCREASED_SENSITIVITY;DOSE_REDUCE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_SUCCESS ;
PRAVASTATIN;MTHFR;rs1801133;GG;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;CORONARY ARTERY DISEASE, MYOCARDIAL INFARCTION ;;
SUNITINIB;ABCB1;rs1128503;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;VEGFA;rs833061;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;VEGFA;rs833061;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CYCLOSPORINE;IMPDH2;rs11706052;AG + GG;EFFICACY;INCREASED_RISK;nan;DISEASE;TRANSPLANT REJECTION ;;
MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG + GG;EFFICACY;INCREASED_RISK;nan;DISEASE;TRANSPLANT REJECTION ;;
CYCLOSPORINE;TNF;rs1800629;AA + AG;EFFICACY;INCREASED_RISK;nan;DISEASE;TRANSPLANT REJECTION ;;
MYCOPHENOLATE MOFETIL;TNF;rs1800629;AA + AG;EFFICACY;INCREASED_RISK;nan;DISEASE;TRANSPLANT REJECTION ;;
METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
CYCLOSPORINE;IL10;rs1800872;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
MYCOPHENOLATE MOFETIL;IL10;rs1800872;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
SUNITINIB;ABCB1;rs2032582;AA + AT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSIENT ISCHEMIC ATTACK;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
SUNITINIB;VEGFA;rs2010963;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED_SEVERITY;OTHER;SMOKING;;;
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED_SEVERITY;OTHER;SMOKING;;;
nan;CHRNA5;rs16969968;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;SCHIZOPHRENIA ;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
CLOPIDOGREL;N6AMT1;rs2254638;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
NICOTINE;GALR1;rs2717162;CT + TT;OTHER;INCREASED_SEVERITY;OTHER;CRAVING;;;
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
CAPECITABINE;DPYD;rs3918290;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs3918290;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
ERYTHROMYCIN;SLCO1B1;rs4149056;C;LADME-PK;DECREASED_PK;METABOLISM;ERYTHROMYCIN METABOLISM;;;
PAZOPANIB;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
SIMVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
GENTAMICIN;MT-RNR1;rs267606617;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
CYCLOSPORINE;LEP;rs2167270;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS ;;
TACROLIMUS;LEP;rs2167270;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS ;;
ERLOTINIB;ABCB1;rs1045642;AA;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
MERCAPTOPURINE;NUDT15;rs73189762;GT;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
ETHANOL;HTR3B;rs1176744;C;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;ALCOHOL ABUSE ;;
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;DECREASED_;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;ADORA2A;rs5760410;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
METHOTREXATE;SPECC1L;rs5760410;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
CALCIUM CHANNEL BLOCKERS;KCNH2;rs1137617;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
NITRENDIPINE;KCNH2;rs1137617;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
CLOPIDOGREL;KDR;rs7667298;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ANGINA PECTORIS;;;
METHOTREXATE;MTHFR;rs1801131;G;EFFICACY;INCREASED_RISK;nan;DISEASE;GRAFT VS HOST DISEASE ;;
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RISK;nan;DISEASE;GRAFT VS HOST DISEASE ;;
NICOTINE;GALR1;rs2717162;CT + TT;OTHER;INCREASED_SEVERITY;OTHER;CRAVING;;;
ANTINEOPLASTIC AGENTS;CLCN6;rs1801133;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
ANTINEOPLASTIC AGENTS;MTHFR;rs1801133;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
IRINOTECAN;UGT1A1;rs4148323;AG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
nan;MTHFR;rs1801131;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
BUSULFAN;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
CYCLOPHOSPHAMIDE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
ERLOTINIB;ABCB1;rs1128503;AA;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;RELAPSE;;;
CLOPIDOGREL;KDR;rs2305948;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGINA PECTORIS;;;
CLOPIDOGREL;KDR;rs2305948;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
METHOTREXATE;ABCB1;rs1128503;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ORAL MUCOSITIS;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ERLOTINIB;ABCB1;rs2032582;AA;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PACLITAXEL;ARHGEF10;rs9657362;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
nan;FKBP5;rs3800373;AA + AC;OTHER;INCREASED_RISK;nan;DISEASE;ADHD ;;
PACLITAXEL;ARHGEF10;rs9657362;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
nan;PSMB4;rs2296840;T;OTHER;INCREASED_RISK;nan;DISEASE;MAJOR DEPRESSIVE DISORDER ;;
METFORMIN;SLC22A1;rs34059508;A;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;BIOAVAILABILITY;;;
METFORMIN;SLC22A1;rs12208357;C;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;BIOAVAILABILITY (AUC;;;
METFORMIN;SLC22A1;rs12208357;C;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;CL & AUC/CL RATIO);;;
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING EVENTS;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
nan;CHRNA5;rs680244;C;OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
METHOTREXATE;PTPN22;rs2476601;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
METHOTREXATE;TNFAIP3;rs6920220;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
RISPERIDONE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
CARBAMAZEPINE;CYP1A1;rs2606345;A;EFFICACY, LADME-PK;INCREASED_RISK;nan;DISEASE;SEIZURES ;;
PHENOBARBITAL;CYP1A1;rs2606345;A;EFFICACY, LADME-PK;INCREASED_RISK;nan;DISEASE;SEIZURES ;;
PHENYTOIN;CYP1A1;rs2606345;A;EFFICACY, LADME-PK;INCREASED_RISK;nan;DISEASE;SEIZURES ;;
VALPROIC ACID;CYP1A1;rs2606345;A;EFFICACY, LADME-PK;INCREASED_RISK;nan;DISEASE;SEIZURES ;;
nan;SLCO1B3;rs2417940;C;OTHER;INCREASED_SEVERITY;OTHER;NEONATAL HYPERBILIRUBINEMIA;;;
nan;SLCO1B3;rs2417940;C;OTHER;INCREASED_SEVERITY;OTHER;HYPERBILIRUBINEMIA;;;
SERTRALINE;nan;rs13432159;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GENERAL SIDE-EFFECTS;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RELAPSE FREE TIME;;;
nan;KIF6;rs20455;AG + GG;OTHER;INCREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;A;TOXICITY;DECREASED_;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED_;SIDE_EFFECT;ANEMIA;;;
ROSUVASTATIN;GATM;rs9806699;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
TAMOXIFEN;CYP2D6;rs3892097;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
PEGINTERFERON ALFA-2B;ITPA;rs7270101;C;TOXICITY;DECREASED_;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs7270101;C;TOXICITY;DECREASED_;SIDE_EFFECT;ANEMIA;;;
IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
FLUOROURACIL;GSTP1;rs1695;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES, NEUTROPENIA ;;
IRINOTECAN;GSTP1;rs1695;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES, NEUTROPENIA ;;
OXALIPLATIN;GSTP1;rs1695;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUROTOXICITY SYNDROMES, NEUTROPENIA ;;
PRAVASTATIN;IL1B;rs16944;GG;OTHER;INCREASED_LIKELIHOOD;OTHER;CORONARY FLOW RESERVE;;;
HMG COA REDUCTASE INHIBITORS;nan;rs116561224;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
nan;KCNH2;rs3815459;T;OTHER;INCREASED_LIKELIHOOD;OTHER;QT INTERVAL;;;
FENOFIBRATE;nan;rs114577328;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
SERTRALINE;nan;rs114577328;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TERBINAFINE;nan;rs114577328;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TICLOPIDINE;nan;rs114577328;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ANTIDEPRESSANTS;HTR2A;rs17288723;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
nan;KCNH2;rs3807375;CT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;QT INTERVAL;;;
CITALOPRAM;GRIK4;rs1954787;C;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NON-RESPONSE;;;
nan;KCNH2;rs1805123;GT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;QT INTERVAL;;;
CYCLOSPORINE;NR1I2;rs2276707;C;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;BIOAVAILABILITY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799930;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PLATINUM COMPOUNDS;GSTP1;rs1695;G;TOXICITY, LADME-PK;DECREASED_RISK;nan;DISEASE;NEUTROPENIA ;;
CLOZAPINE;nan;rs149104283;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
nan;KCNH2;rs1805123;G;OTHER;DECREASED_;OTHER;QT INTERVAL;;;
ASPARAGINASE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CYCLOPHOSPHAMIDE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
DAUNORUBICIN;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PREDNISOLONE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
VINCRISTINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
nan;KCNH2;rs3807375;T;OTHER;INCREASED_LIKELIHOOD;OTHER;QT INTERVAL;;;
OXALIPLATIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUROTOXICITY SYNDROMES ;;
nan;KCNQ1;rs757092;G;OTHER;INCREASED_LIKELIHOOD;OTHER;QT INTERVAL;;;
nan;KCNH2;rs3815459;T;OTHER;INCREASED_LIKELIHOOD;OTHER;QT INTERVAL;;;
PRAVASTATIN;IL1B;rs16944;GG;OTHER;INCREASED_LIKELIHOOD;OTHER;ADENOSINE-STIMULATED MYOCARDIAL FLOW;;;
nan;VEGFA;rs2010963;CG + GG;OTHER;INCREASED_RISK;OTHER;PREMATURE BIRTH;;;
nan;KCNH2;rs1805123;GG;OTHER;DECREASED_;OTHER;QT INTERVAL;;;
nan;KCNQ1;rs757092;G;OTHER;INCREASED_LIKELIHOOD;OTHER;QT INTERVAL;;;
OXALIPLATIN;GSTP1;rs1695;AA;TOXICITY, LADME-PK;INCREASED_SEVERITY;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
METHOTREXATE;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;INFECTIOUS DISEASE;;;
CYCLOSPORINE;NR1I2;rs2276707;T;DOSAGE, LADME-PK;INCREASED_PK;METABOLISM;BIOAVAILABILITY;;;
RIFAMPIN;NR1I2;rs3814055;TT;OTHER;INCREASED_PK;PK;ERYTHROMYCIN BREATH TEST;;;
PLATINUM COMPOUNDS;CCN4;rs2977549;CC + CT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
CITALOPRAM;HTR2A;rs7997012;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
TACROLIMUS;CYP3A4;rs2740574;CC + TT;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
CITALOPRAM;HTR2A;rs7997012;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
CYCLOSPORINE;NR1I2;rs3814055;C;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;BIOAVAILABILTY;;;
ASPIRIN;MYOM2;rs17064642;CC + CT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;MYOM2;rs17064642;CC + CT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
ANTIDEPRESSANTS;HTR2A;rs7997012;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;HTR2A;rs7997012;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
SUFENTANIL;COMT;rs4680;AA + AG;DOSAGE;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
ANTIDEPRESSANTS;GRIK4;rs1954787;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
ANTIDEPRESSANTS;GRIK4;rs12800734;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
nan;KIF6;rs20455;AG + GG;OTHER;INCREASED_RISK;nan;DISEASE;CORONARY DISEASE ;;
PRAVASTATIN;SLCO1B1;rs2306283;G;LADME-PK;DECREASED_PK;METABOLISM;PLASMA AUC;;;
PRAVASTATIN;SLCO1B1;rs4149015;AG;OTHER, LADME-PK;INCREASED_PK;METABOLISM;AUC0-12;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
PLATINUM COMPOUNDS;CCN4;rs2977551;CC + CT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;CCN4;rs2977551;CC + CT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
FLUOROURACIL;TP53;rs1042522;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PEGINTERFERON ALFA-2A;ITPA;rs6051702;AC + CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs6051702;AC + CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
NICOTINE;CHRNA3;rs578776;GG;TOXICITY;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
NICOTINE;CHRNA5;rs578776;GG;TOXICITY;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
NICOTINE;CHRNA4;rs1044396;AA;TOXICITY;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
NICOTINE;CHRNA4;rs2229959;CC;TOXICITY;INCREASED_LIKELIHOOD;OTHER;SMOKING CESSATION;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;COMT;rs13306278;T;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;REMISSION;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;TXNRD2;rs13306278;T;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;REMISSION;;;
PRAVASTATIN;TLR4;rs4986790;AG + GG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
PHENPROCOUMON;VKORC1;rs9923231;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606617;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
PEGINTERFERON ALFA-2A;VDR;rs1544410;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;VDR;rs1544410;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PHENPROCOUMON;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
FLUOROURACIL;IGFBP3;rs2854746;CC;EFFICACY;nan;OTHER;BETTER SURVIVAL OUTCOME;;;
PHENPROCOUMON;VKORC1;rs9923231;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO ACHIEVE STABLE DOSE;;;
PLATINUM COMPOUNDS;GSTP1;rs1695;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DYING;;;
PLATINUM COMPOUNDS;ERCC2;rs13181;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DYING;;;
PLATINUM COMPOUNDS;KLC3;rs13181;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DYING;;;
PHENPROCOUMON;EPHX1;rs1051740;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DYING;;;
CLOPIDOGREL;ABCB1;rs2032582;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
PLATINUM COMPOUNDS;GSTP1;rs1695;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DISEASE PROGRESSION;;;
CARBOPLATIN;NR1I2;rs1523130;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PACLITAXEL;NR1I2;rs1523130;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CETUXIMAB;EGF;rs4444903;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
CARBOPLATIN;NR1I2;rs1523127;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PACLITAXEL;NR1I2;rs1523127;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
IRINOTECAN;UGT1A1;rs10929302;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
CARBOPLATIN;SLCO1B3;rs4149117;GT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PACLITAXEL;SLCO1B3;rs4149117;GT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA;;;
NICOTINE;CHRNA4;rs1044396;G;OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
CISPLATIN;LRP2;rs2075252;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
CETUXIMAB;EGF;rs4444903;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CAPECITABINE;CDA;rs3215400;C/del + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CLOPIDOGREL;POR;rs2286823;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
SUNITINIB;POR;rs1057868;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SUNITINIB;SLCO1B3;rs4149117;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;SLC19A1;rs1051266;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
PHENPROCOUMON;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE;;;
CAPECITABINE;CDA;rs532545;T;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;HAND-FOOT SYNDROME ;;
CLOPIDOGREL;CES1P1;rs3785161;AC + CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-TREATMENT PLATELET ACTIVITY;;;
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
LEUCOVORIN;FASTKD3;rs1801394;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;STOMATITIS ;;
LEUCOVORIN;MTRR;rs1801394;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;STOMATITIS ;;
TEGAFUR;FASTKD3;rs1801394;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;STOMATITIS ;;
TEGAFUR;MTRR;rs1801394;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;STOMATITIS ;;
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
LEUCOVORIN;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
LEUCOVORIN;UMPS;rs1801019;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANY GRADE 3 ADVERSE EVENT;;;
TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANY GRADE 3 ADVERSE EVENT;;;
ASPIRIN;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
CLOPIDOGREL;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
PAZOPANIB;CXCL8;rs1126647;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
NICOTINE;CHRNA4;rs2236196;G;OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs111564371;CT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs111564371;CT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE;;;
METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
NICOTINE;CHRNA3;rs1051730;AA + AG;TOXICITY;DECREASED_;SIDE_EFFECT;LUNG FUNCTION;;;
CYCLOPHOSPHAMIDE;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
LEDIPASVIR;IFNL3;rs12979860;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
LEDIPASVIR;IFNL4;rs12979860;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
SOFOSBUVIR;IFNL3;rs12979860;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
SOFOSBUVIR;IFNL4;rs12979860;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
CARBAMAZEPINE;HSPA1A;rs1043620;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERSENSITIVITY;;;
ASPIRIN;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
CLOPIDOGREL;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
LEDIPASVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
LEDIPASVIR;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CARBAMAZEPINE;HSPA1A;rs506770;G;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERSENSITIVITY;;;
ASPIRIN;F13A1;rs5985;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;FIBRIN CLOT FORMATION TIME;;;
CLOPIDOGREL;F13A1;rs5985;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;FIBRIN CLOT FORMATION TIME;;;
CYCLOPHOSPHAMIDE;TP53;rs1042522;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;TP53;rs1042522;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
CARBAMAZEPINE;HSPA1L;rs2227956;G;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;HYPERSENSITIVITY;;;
CLOPIDOGREL;P2RY12;rs6787801;AG + GG;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CYP2C19*1/*1 CARRIERS;;;
CLOZAPINE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE;;;
CLOZAPINE;ABCC1;rs212090;AT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
CARBAMAZEPINE;MLN;rs2894342;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY SYNDROME;;;
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME-PK;INCREASED_PK;METABOLISM;EXPOSURE;;;
CLOZAPINE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
CLOZAPINE;ABCC1;rs212090;AT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
CAFFEINE;ADORA2A;rs5751876;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANXIETY;;;
CAFFEINE;ADORA2A;rs2298383;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANXIETY;;;
CAFFEINE;nan;rs4822492;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANXIETY;;;
nan;MT-RNR1;rs267606617;G;OTHER;INCREASED_LIKELIHOOD;OTHER;HEARING LOSS;;;
nan;MT-RNR1;rs267606617;G;OTHER;INCREASED_LIKELIHOOD;OTHER;SENSORINEURAL;;;
CARBAMAZEPINE;nan;rs3130690;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
CAFFEINE;ADORA2A;rs5751876;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;BEING SENSITIVE TO CAFFEINE;;;
CAFFEINE;ADORA2A;rs5751876;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INSOMNIA;;;
ETHANOL;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
ETHANOL;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEROIN DEPENDENCE;;;
ETHANOL;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;METHAMPHETAMINE DEPENDENCE;;;
HEROIN;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
HEROIN;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEROIN DEPENDENCE;;;
HEROIN;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;METHAMPHETAMINE DEPENDENCE;;;
METHAMPHETAMINE;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
METHAMPHETAMINE;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEROIN DEPENDENCE;;;
METHAMPHETAMINE;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;METHAMPHETAMINE DEPENDENCE;;;
CARBAMAZEPINE;MICA;rs2848716;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
"""ANTIINFLAMMATORY AGENTS";nan;rs2965667;TT;OTHER;DECREASED_RISK;nan;DISEASE;COLORECTAL NEOPLASMS ;;
"NON-STEROIDS""";nan;rs2965667;TT;OTHER;DECREASED_RISK;nan;DISEASE;COLORECTAL NEOPLASMS ;;
"""ASPIRIN""";nan;rs2965667;TT;OTHER;DECREASED_RISK;nan;DISEASE;COLORECTAL NEOPLASMS ;;
CAFFEINE;ADORA2A;rs5751876;TT;DOSAGE;DECREASED_;OTHER;HABITUAL CONSUMPTION;;;
CARBAMAZEPINE;BAG6;rs750332;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
CARBAMAZEPINE;PRRC2A;rs750332;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;STEVENS-JOHNSON SYNDROME ;;
"""ANTIINFLAMMATORY AGENTS";nan;rs16973225;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;COLORECTAL NEOPLASMS ;;
"NON-STEROIDS""";nan;rs16973225;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;COLORECTAL NEOPLASMS ;;
"""ASPIRIN""";nan;rs16973225;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;COLORECTAL NEOPLASMS ;;
nan;CHRNA5;rs588765;T;;SIDE_EFFECT;EFFICACY;DECREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IN THE PLACEBO GROUP;;;
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;DECREASED_SENSITIVITY;DOSE_INCREASE;DRUG;WARFARIN;LIKELIHOOD_THERAPEUTIC_FAILURE ;
RIBAVIRIN;ITPA;rs7270101;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMOLYTIC ANEMIA;;;
SIMVASTATIN;LEPR;rs1137101;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PERCENTAGE CHANGE IN HDL-C LEVELS;;;
ALENDRONATE;SOST;rs1234612;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;BONE_DENSITY;;;
CYTARABINE;ABCB1;rs1128503;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DAUNORUBICIN;ABCB1;rs1128503;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
CYTARABINE;CDA;rs532545;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;COLITIS;;;
DAUNORUBICIN;CDA;rs532545;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;COLITIS;;;
CYTARABINE;ABCB1;rs1045642;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
DAUNORUBICIN;ABCB1;rs1045642;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;;SIDE_EFFECT;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
ALENDRONATE;SOST;rs865429;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;BONE_DENSITY;;;
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMOLYTIC ANEMIA;;;
CYTARABINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;MED12L;rs6801273;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY;;;
CLOPIDOGREL;P2RY12;rs6801273;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY;;;
CYTARABINE;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;MED12L;rs6798347;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY;;;
ERLOTINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL (PFS) TIME;;;
CYTARABINE;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SEVOFLURANE;ABCB1;rs1128503;GG;OTHER;DECREASED_LIKELIHOOD;OTHER;ADVERSE EVENTS;;;
TACROLIMUS;KCNJ11;rs5219;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIABETES MELLITUS;;;
TACROLIMUS;KCNJ11;rs5219;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TYPE 2;;;
ACE INHIBITORS;ETV6;rs2724635;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
PLAIN;ETV6;rs2724635;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
SUNITINIB;ABCB1;rs1128503;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ASPIRIN;TAPBP;rs2071888;CC + CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;FEV1 DECREASE AFTER ASPIRIN CHALLENGE;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;ABCC2;rs3740065;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;COMPOSITE OUTCOME OF NON-FATAL MI;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALL CAUSE DEATH AND STENT THROMBOSIS;;;
HYDROCHLOROTHIAZIDE;KCNJ1;rs12795437;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS ;;
PHENPROCOUMON;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
VALPROIC ACID;LEPR;rs1137101;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
PHENYTOIN;CFHR4;rs78239784;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MACULOPAPULAR EXANTHEMA ;;
HYDROCHLOROTHIAZIDE;KCNJ1;rs11600347;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS ;;
CABAZITAXEL;ABCB1;rs2032582;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
VALPROIC ACID;ANKK1;rs1800497;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
HYDROCHLOROTHIAZIDE;KCNJ1;rs658903;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS ;;
CABAZITAXEL;ABCB1;rs1045642;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
CLOPIDOGREL;P2RY12;rs6787801;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY;;;
CABAZITAXEL;CYP3A5;rs776746;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ACE INHIBITORS;PRKCQ;rs500766;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
PLAIN;PRKCQ;rs500766;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
HYDROCHLOROTHIAZIDE;KCNJ1;rs675388;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DIABETES MELLITUS ;;
DOXORUBICIN;GSTP1;rs1695;GG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;CHEMORESISTANCE;;;
CABAZITAXEL;ABCB1;rs1128503;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
PROPOFOL;DRD2;rs2283265;AA + AC;OTHER;DECREASED_;OTHER;HEART RATE;;;
NICOTINE;CHRNA4;rs2236196;A;OTHER;INCREASED_LIKELIHOOD;OTHER;NICOTINE DEPENDENCE;;;
ACETAMINOPHEN;UGT1A;rs1042640;CG + GG;TOXICITY;DECREASED_RISK;nan;DISEASE;LIVER FAILURE, ACUTE ;;
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;DECREASED_;SIDE_EFFECT;BLEEDING EVENTS;;;
ACETAMINOPHEN;UGT1A;rs8330;CG + GG;TOXICITY;DECREASED_RISK;nan;DISEASE;LIVER FAILURE, ACUTE ;;
GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RESPONSE RATE (RR);;;
HYDROCHLOROTHIAZIDE;KCNJ1;rs59172778;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SERUM POTASSIUM;;;
ETHANOL;CACNA1C;rs1034936;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALCOHOL ABUSE;;;
DOXORUBICIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PREDNISOLONE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PREDNISOLONE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
VINCRISTINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
VINCRISTINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;MYOCARDIAL INFARCTION ;;
WARFARIN;EPHA7;rs114504854;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ACETAMINOPHEN;UGT1A;rs10929303;CT + TT;TOXICITY;DECREASED_RISK;nan;DISEASE;LIVER FAILURE, ACUTE ;;
ACE INHIBITORS;XPNPEP2;rs2050011;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
PLAIN;XPNPEP2;rs2050011;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
ETHAMBUTOL;TNF;rs1800629;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;TNF;rs1800629;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;TNF;rs1800629;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;TNF;rs1800629;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
NICOTINE;ADGRL3;rs2271339;AG;TOXICITY;INCREASED_RISK;OTHER;TOBACCO USE DISORDER;;;
NICOTINE;ADGRL3;rs1456862;AT;TOXICITY;INCREASED_RISK;OTHER;TOBACCO USE DISORDER;;;
GEFITINIB;EGFR;rs2293347;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE (RR);;;
GEFITINIB;EGFR;rs2293347;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
ETHANOL;MAP2K4;rs2159140;CT;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
SUNITINIB;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
SUNITINIB;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
SORAFENIB;UGT1A9;rs17868320;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL (OS) TIME;;;
GEFITINIB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE (RR);;;
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPOVENTILATION;;;
ACE INHIBITORS;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) (MORE THAN ONE YEAR) WHEN RECEIVING A LOADING DOSE OF 300 MG;;;
DOCETAXEL;ABCC10;rs2125739;CT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
nan;ARNT;rs2228099;CG + GG;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;COLORECTAL NEOPLASMS ;;
ETHAMBUTOL;CYP2E1;rs3813867;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;CYP2E1;rs3813867;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;CYP2E1;rs3813867;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;CYP2E1;rs3813867;GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;TOXIC LIVER DISEASE ;;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EARLY MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE);;;
nan;DEPTOR;rs4871827;AA + AG;OTHER;INCREASED_LIKELIHOOD;OTHER;HDL CHOLESTEROL;;;
CISPLATIN;SYNE3;rs8020368;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;SYNE3;rs8020368;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;DEPTOR;rs4871827;AG;OTHER;DECREASED_LIKELIHOOD;OTHER;BRAIN ISCHEMIA;;;
nan;DEPTOR;rs4871827;AG;OTHER;DECREASED_LIKELIHOOD;OTHER;MYOCARDIAL INFARCTION;;;
nan;DEPTOR;rs4871827;AG;OTHER;DECREASED_LIKELIHOOD;OTHER;PERIPHERAL VASCULAR DISEASES;;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"COMBINATIONS""";CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
nan;DEPTOR;rs4871827;AG;OTHER;DECREASED_LIKELIHOOD;OTHER;DIABETIC RETINOPATHY;;;
nan;DEPTOR;rs4871827;AG;OTHER;DECREASED_LIKELIHOOD;OTHER;CHRONIC KIDNEY FAILURE;;;
LOSARTAN;STK39;rs6749447;GG + GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN AMBULATORY BLOOD PRESSURE;;;
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EARLY MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE);;;
nan;AHR;rs2066853;AA + AG;OTHER;INCREASED_RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS;;;
RISPERIDONE;HTR6;rs9659997;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
CISPLATIN;DCBLD1;rs17574269;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;DCBLD1;rs17574269;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;nan;rs7186128;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;nan;rs7186128;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RISPERIDONE;TYMS;rs3786362;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
nan;TNF;rs1800630;C;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOCYTOSIS;;;
CISPLATIN;nan;rs2166219;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;nan;rs2166219;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RISPERIDONE;HTR2A;rs6311;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
CISPLATIN;nan;rs4655567;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;nan;rs4655567;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANTINEOPLASTIC AGENTS;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ANTINEOPLASTIC AGENTS;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CORTICOSTEROIDS;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
CORTICOSTEROIDS;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CISPLATIN;nan;rs2018683;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;nan;rs2018683;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
RISPERIDONE;BDNF;rs6265;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
ANTINEOPLASTIC AGENTS;ADORA2A;rs2236624;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CORTICOSTEROIDS;ADORA2A;rs2236624;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
LEUCOVORIN;ABCC2;rs717620;CT + TT;LADME-PK;INCREASED_PK;METABOLISM;DISTRIBUTION VOLUME;;;
METHOTREXATE;ABCC2;rs717620;CT + TT;LADME-PK;INCREASED_PK;METABOLISM;DISTRIBUTION VOLUME;;;
CISPLATIN;nan;rs2018683;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANT RELAPSE;;;
IRINOTECAN;nan;rs2018683;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANT RELAPSE;;;
nan;OPRM1;rs1799971;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;HEROIN DEPENDENCE ;;
CISPLATIN;SYNE3;rs8020368;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANT RELAPSE;;;
IRINOTECAN;SYNE3;rs8020368;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANT RELAPSE;;;
CISPLATIN;nan;rs4655567;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANT RELAPSE;;;
IRINOTECAN;nan;rs4655567;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANT RELAPSE;;;
METHOTREXATE;ABCC4;rs7317112;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
RISPERIDONE;UGT1A1;rs1976391;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
RISPERIDONE;HTR2C;rs6318;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
CYCLOSPORINE;nan;rs2275913;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TRANSPLANT REJECTION;;;
LENALIDOMIDE;ABCB1;rs2032582;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
HEROIN;DBH;rs1611114;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MEMORY IMPAIRMENT;;;
DILTIAZEM;PLCD3;rs12946454;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
CAPECITABINE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CAPECITABINE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;MTHFR;rs1801131;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
FLUOROURACIL;MTHFR;rs1801131;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;MTHFR;rs1801131;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
OXALIPLATIN;MTHFR;rs1801131;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;AC;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs1127354;AC;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
DOCETAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
"""BETA BLOCKING AGENTS""";nan;rs11191548;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN DIASTOLIC BLOOD PRESSURE;;;
"""THIAZIDES";nan;rs11191548;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN DIASTOLIC BLOOD PRESSURE;;;
"PLAIN""";nan;rs11191548;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN DIASTOLIC BLOOD PRESSURE;;;
NICOTINE;COMT;rs4680;GG;OTHER;INCREASED_SEVERITY;SIDE_EFFECT;WITHDRAWAL;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PK;METABOLISM;MINIMUM PLASMA CONCENTRATIONS;;;
MORPHINE;ABCB1;rs9282564;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPOVENTILATION;;;
ANTINEOPLASTIC AGENTS;ABCC1;rs246240;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CORTICOSTEROIDS;ABCC1;rs246240;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
LENALIDOMIDE;NCF4;rs1883112;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
NICOTINE;COMT;rs4680;GG;OTHER;INCREASED_LIKELIHOOD;OTHER;BLOOD PRESSURE;;;
LENALIDOMIDE;GSTP1;rs1695;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
CISPLATIN;ABCC4;rs16950650;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;ABCC4;rs16950650;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ASPIRIN;ITGA2;rs1126643;CT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;COLLAGEN-INDUCED PLATELET AGGREGATION;;;
CLOPIDOGREL;ITGA2;rs1126643;CT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;COLLAGEN-INDUCED PLATELET AGGREGATION;;;
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
EFAVIRENZ;ABCB1;rs1045642;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
LAMIVUDINE;ABCB1;rs1045642;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
TENOFOVIR;ABCB1;rs1045642;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
GEMCITABINE;SLC29A3;rs780668;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIARRHEA ;;
ATORVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
PEGINTERFERON ALFA-2B;ITPA;rs7270101;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs7270101;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
CAFFEINE;CYP1A2;rs762551;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ALBUMINURIA;;;
CAFFEINE;CYP1A2;rs762551;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
GEMCITABINE;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
CAPECITABINE;CDA;rs1048977;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;LADME-PK;DECREASED_PK;METABOLISM;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;RHABDOMYOLYSIS;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ALLOPURINOL;CFLAR;rs1594;A;TOXICITY;nan;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
OXYCODONE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
CAPECITABINE;CES2;rs11075646;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;TIME TO PROGRESSION;;;
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE OF DISEASE;;;
CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS;;;
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;DECREASED_;OTHER;PROGRESSION-FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS;;;
ASPIRIN;AGT;rs5050;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;PEPTIC ULCER HEMORRHAGE ;;
SUNITINIB;NR1I2;rs6785049;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
BUPROPION;SACM1L;rs2251954;C;TOXICITY;DECREASED_;SIDE_EFFECT;SEXUAL SIDE-EFFECTS;;;
ROSUVASTATIN;GATM;rs9806699;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;LADME-PK;DECREASED_PK;METABOLISM;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE;;;
BUPROPION;SACM1L;rs2742421;G;TOXICITY;DECREASED_;SIDE_EFFECT;SEXUAL SIDE-EFFECTS;;;
ETHAMBUTOL;CYP3A4;rs28371759;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;CYP3A4;rs28371759;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
PYRAZINAMIDE;CYP3A4;rs28371759;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
RIFAMPIN;CYP3A4;rs28371759;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ROSUVASTATIN;SLCO1B1;rs4149081;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;LDL-C REDUCTION;;;
BUPROPION;SACM1L;rs2742423;G;TOXICITY;DECREASED_;SIDE_EFFECT;SEXUAL SIDE-EFFECTS;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;nan;SIDE_EFFECT;EARLY (< 3 MONTHS) TERMINATION OF EFAVIRENZ THERAPY;;;
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;LADME-PK;DECREASED_PK;METABOLISM;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE;;;
BUPROPION;SACM1L;rs1969624;T;TOXICITY;DECREASED_;SIDE_EFFECT;SEXUAL SIDE-EFFECTS;;;
EFAVIRENZ;NR1I3;rs2307424;GG;TOXICITY;nan;SIDE_EFFECT;EARLY (< 3 MONTHS) TERMINATION OF EFAVIRENZ THERAPY;;;
BUPROPION;SACM1L;rs2245705;C;TOXICITY;DECREASED_;SIDE_EFFECT;SEXUAL SIDE-EFFECTS;;;
BUPROPION;SACM1L;rs2742435;G;TOXICITY;DECREASED_;SIDE_EFFECT;SEXUAL SIDE-EFFECTS;;;
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS;;;
BUPROPION;SACM1L;rs2742390;A;TOXICITY;DECREASED_;SIDE_EFFECT;SEXUAL SIDE-EFFECTS;;;
SIMVASTATIN;SLCO1B1;rs4149081;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;LDL-C REDUCTION;;;
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_LIKELIHOOD;OTHER;EARLY RELAPSE;;;
SIMVASTATIN;SLCO1B1;rs4149081;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;LDL-C REDUCTION;;;
PEMETREXED;DHFR;rs442767;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;FATIGUE ;;
FLUOROURACIL;MTHFR;rs1801131;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
BUPROPION;SACM1L;rs2742417;T;TOXICITY;DECREASED_;SIDE_EFFECT;SEXUAL SIDE-EFFECTS;;;
TEMSIROLIMUS;NR1I2;rs3814055;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
SUNITINIB;FLT3;rs1933437;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
SUNITINIB;FLT3;rs1933437;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CAPECITABINE;CES1;rs71647871;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;CES1;rs71647871;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
GEMCITABINE;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
ROSUVASTATIN;SLCO1B1;rs4149081;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;LDL-C REDUCTION;;;
NALTREXONE;OPRD1;rs4654327;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;NALTREXONE-INDUCED BLUNTING OF ALCOHOL STIMULATION AND ALCOHOL CRAVING;;;
IRINOTECAN;UGT1A;rs11563250;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ATORVASTATIN;RYR2;rs2819742;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;MUSCULAR DISEASES, MYALGIA ;;
SIMVASTATIN;RYR2;rs2819742;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;MUSCULAR DISEASES, MYALGIA ;;
CAPECITABINE;SPARC;rs2347128;GG;EFFICACY;INCREASED_SEVERITY;OTHER;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;SPARC;rs2347128;GG;EFFICACY;INCREASED_SEVERITY;OTHER;PROGRESSION-FREE SURVIVAL;;;
GEMCITABINE;SPARC;rs2347128;GG;EFFICACY;INCREASED_SEVERITY;OTHER;PROGRESSION-FREE SURVIVAL;;;
nan;MET;rs40239;AG + GG;OTHER;INCREASED_LIKELIHOOD;OTHER;OVERALL SURVIVAL;;;
AZATHIOPRINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
AZATHIOPRINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
AZATHIOPRINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
CAPECITABINE;SPARC;rs17718347;TT;EFFICACY;INCREASED_SEVERITY;OTHER;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;SPARC;rs17718347;TT;EFFICACY;INCREASED_SEVERITY;OTHER;PROGRESSION-FREE SURVIVAL;;;
GEMCITABINE;SPARC;rs17718347;TT;EFFICACY;INCREASED_SEVERITY;OTHER;PROGRESSION-FREE SURVIVAL;;;
nan;MET;rs40239;AG + GG;OTHER;INCREASED_LIKELIHOOD;OTHER;OVERALL SURVIVAL;;;
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";ABCB1;rs1045642;AA;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"COMBINATIONS""";ABCB1;rs1045642;AA;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;rs1045642;AA;TOXICITY, LADME-PK;INCREASED_RISK;nan;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
EFAVIRENZ;CYP2B6;rs3745274;T;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA EFAVIRENZ EXPOSURE (AUC) DURING THE FIRST 24 WEEKS OF ANTIRETROVIRAL THERAPY;;;
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER ;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
DESFLURANE;RYR1;rs112563513;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs112563513;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs112563513;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs112563513;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs112563513;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs112563513;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
EFAVIRENZ;CYP3A4;rs2740574;C;OTHER, LADME-PK;INCREASED_PK;METABOLISM;PLASMA EFAVIRENZ EXPOSURE;;;
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISCONTINUATION;;;
EFAVIRENZ;CYP3A5;rs776746;C;LADME-PK;DECREASED_PK;METABOLISM;PLASMA EFAVIRENZ EXPOSURE;;;
CLOPIDOGREL;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
ACE INHIBITORS;MME;rs989692;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
PLAIN;MME;rs989692;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA;;;
HMG COA REDUCTASE INHIBITORS;LILRB5;rs12975366;TT;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ESCITALOPRAM;HTR2A;rs6311;TT;TOXICITY;INCREASED_LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER;;;
FLUOXETINE;HTR2A;rs6311;TT;TOXICITY;INCREASED_LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER;;;
PAROXETINE;HTR2A;rs6311;TT;TOXICITY;INCREASED_LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER;;;
SERTRALINE;HTR2A;rs6311;TT;TOXICITY;INCREASED_LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER;;;
VENLAFAXINE;HTR2A;rs6311;TT;TOXICITY;INCREASED_LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER;;;
CABAZITAXEL;CYP3A5;rs776746;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;rs4986893;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
CITALOPRAM;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
ESCITALOPRAM;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
FLUOXETINE;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
PAROXETINE;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
SERTRALINE;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
CABAZITAXEL;TUBB1;rs463312;AC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CLOPIDOGREL;CYP2C19;rs28399504;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ISCHAEMIC EVENTS;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CLOPIDOGREL;CYP2C19;rs4986893;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
NEVIRAPINE;CYP2B6;rs28399499;C;LADME-PK;INCREASED_LIKELIHOOD;OTHER;PLASMA LEVEL;;;
nan;SLC2A9;rs16890979;T;LADME-PK;DECREASED_PK;METABOLISM;SERUM URIC ACID;;;
CYCLOPHOSPHAMIDE;IKZF3;rs9908694;CC;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;EVENT-FREE SURVIVAL ;;
METHOTREXATE;ABCB1;rs1045642;AG;TOXICITY;DECREASED_RISK;nan;DISEASE;DRUG TOXICITY ;;
DESFLURANE;RYR1;rs118192122;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs118192122;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs118192122;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs118192122;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs118192122;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs118192122;A;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
DESFLURANE;RYR1;rs193922816;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs193922816;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs193922816;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs193922816;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs193922816;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs193922816;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
METHAMPHETAMINE;DRD4;rs1800955;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG PSYCHOSIS;;;
BEVACIZUMAB;GC;rs4588;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CETUXIMAB;GC;rs4588;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DESFLURANE;RYR1;rs28933397;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs28933397;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs28933397;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs28933397;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs28933397;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs28933397;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ASPIRIN;TAPBP;rs1059288;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;FEV1 DECREASE AFTER ASPIRIN CHALLENGE;;;
"""ACE INHIBITORS";F5;rs140530655;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"PLAIN""";F5;rs140530655;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"""ANGIOTENSIN II ANTAGONISTS""";F5;rs140530655;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
GEFITINIB;IKBKB;rs2272733;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
"""METFORMIN""";SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
"""SULFONAMIDES";SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
"UREA DERIVATIVES""";SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
DESFLURANE;RYR1;rs193922772;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ENFLURANE;RYR1;rs193922772;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
HALOTHANE;RYR1;rs193922772;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
ISOFLURANE;RYR1;rs193922772;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SEVOFLURANE;RYR1;rs193922772;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
SUCCINYLCHOLINE;RYR1;rs193922772;T;OTHER;INCREASED_RISK;nan;DISEASE;MALIGNANT HYPERTHERMIA ;;
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
FENOTEROL;SLC22A1;rs12208357;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FENOTEROL;SLC22A1;rs34130495;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ACE INHIBITORS;AGT;rs699;GG;EFFICACY;DECREASED_RISK;nan;DISEASE;STROKE ;;
PLAIN;AGT;rs699;GG;EFFICACY;DECREASED_RISK;nan;DISEASE;STROKE ;;
nan;P2RY12;rs2046934;G;OTHER;INCREASED_RISK;nan;DISEASE;PERIPHERAL VASCULAR DISEASES ;;
GEFITINIB;RELA;rs11227247;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
FENOTEROL;SLC22A1;rs55918055;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
IRINOTECAN;KCNQ5;rs9351963;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
FENOTEROL;SLC22A1;rs34059508;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
nan;P2RY12;rs2046934;G;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;PLATELET AGGREGATION;;;
GEFITINIB;IKBKE;rs2151222;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
ISONIAZID;NAT2;rs1801280;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;NAT2;rs1801280;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ISONIAZID;NAT2;rs1799931;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;NAT2;rs1799931;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TAMOXIFEN;CYP2D6;rs28371725;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
TAMOXIFEN;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
PAROXETINE;HTR2A;rs6314;AG;;SIDE_EFFECT;EFFICACY;IMPROVED RESPONSE;;;
GABAPENTIN;SLC7A5;rs4240803;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
PREGABALIN;SLC7A5;rs4240803;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
BEVACIZUMAB;CXCR2;rs2230054;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;CXCR2;rs2230054;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
PAROXETINE;HTR2A;rs6314;AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
TAMOXIFEN;CYP2C19;rs12248560;T;EFFICACY;DECREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
GEMCITABINE;SLCO1B1;rs4149086;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PAROXETINE;HTR2A;rs6313;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG REACTION;;;
HYDROCHLOROTHIAZIDE;CDCA3;rs5443;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
HYDROCHLOROTHIAZIDE;GNB3;rs5443;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
HYDROCHLOROTHIAZIDE;USP5;rs5443;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;OTHER;DECREASED_RISK;nan;DISEASE;DEATH ;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
nan;CHRNA3;rs1051730;A;OTHER;INCREASED_RISK;nan;DISEASE;LUNG NEOPLASMS ;;
CITALOPRAM;GRIK2;rs2518224;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TREATMENT-EMERGENT SUICIDAL IDEATION;;;
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
IRINOTECAN;UGT1A9;rs7586110;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ANEMIA ;;
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
WARFARIN;CYP4F2;rs2108622;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
nan;HYKK;rs8034191;C;OTHER;INCREASED_RISK;nan;DISEASE;LUNG NEOPLASMS ;;
ISONIAZID;NAT2;rs1041983;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;NAT2;rs1041983;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TACROLIMUS;TCF7L2;rs290487;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
ACE INHIBITORS;AGT;rs699;GG;EFFICACY;DECREASED_RISK;nan;DISEASE;STROKE ;;
PLAIN;AGT;rs699;GG;EFFICACY;DECREASED_RISK;nan;DISEASE;STROKE ;;
GEMCITABINE;POLR2A;rs2228130;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
VALPROIC ACID;CYP2C9;rs1057910;AC;OTHER, LADME-PK;INCREASED_PK;METABOLISM;MEAN PLASMA DRUG CONCENTRATIONS;;;
CITALOPRAM;GRIA3;rs4825476;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TREATMENT-EMERGENT SUICIDAL IDEATION;;;
IMATINIB;SLC22A5;rs274558;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMATINIB;SLC22A5;rs274558;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;EYE DISEASES;;;
ISONIAZID;NAT2;rs1208;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;NAT2;rs1208;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ANTIPSYCHOTICS;COMT;rs4818;CC + CG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
nan;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL VASCULAR DISEASES ;;
nan;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;LUNG NEOPLASMS ;;
DACARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
ISONIAZID;NAT2;rs1799930;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;NAT2;rs1799930;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
nan;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD;OTHER;NUMBER OF CIGARETTES SMOKED PER DAY;;;
ISONIAZID;NAT2;rs1799929;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PHENYTOIN;NAT2;rs1799929;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMATINIB;ABCB1;rs2235040;CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMATINIB;ABCB1;rs2235040;CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;EYE DISEASES;;;
DEXAMETHASONE;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DOXORUBICIN;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
VINCRISTINE;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DACARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) ;;
PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) ;;
IMATINIB;EGFR;rs10258429;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMATINIB;EGFR;rs10258429;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EYE DISEASES;;;
ANTIPSYCHOTICS;COMT;rs165599;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
IMATINIB;SLC22A1;rs683369;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMATINIB;SLC22A1;rs683369;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EYE DISEASES;;;
RISPERIDONE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OBESITY;;;
DACLATASVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
DACLATASVIR;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
"""ANALGESICS""";HTR2A;rs6305;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ANTIINFLAMMATORY AGENTS";HTR2A;rs6305;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"NON-STEROIDS""";HTR2A;rs6305;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ERGOT ALKALOIDS""";HTR2A;rs6305;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""OPIOIDS""";HTR2A;rs6305;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""SUMATRIPTAN""";HTR2A;rs6305;A;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
ASPIRIN;TBXA2R;rs4523;AA;EFFICACY;INCREASED_RISK;OTHER;HIGH ON-ASPIRIN RESIDUAL PLATELET REACTIVITY;;;
"""ANALGESICS""";DBH;rs1611115;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ANTIINFLAMMATORY AGENTS";DBH;rs1611115;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"NON-STEROIDS""";DBH;rs1611115;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ERGOT ALKALOIDS""";DBH;rs1611115;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""OPIOIDS""";DBH;rs1611115;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""SUMATRIPTAN""";DBH;rs1611115;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
RISPERIDONE;DRD2;rs1799978;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INSULIN RESISTANCE;;;
PACLITAXEL;ABCB1;rs2032582;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
PACLITAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
"""ANALGESICS""";OPRM1;rs1799971;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ANTIINFLAMMATORY AGENTS";OPRM1;rs1799971;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"NON-STEROIDS""";OPRM1;rs1799971;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ERGOT ALKALOIDS""";OPRM1;rs1799971;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""OPIOIDS""";OPRM1;rs1799971;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""SUMATRIPTAN""";OPRM1;rs1799971;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
"""ANALGESICS""";BDNF;rs6265;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ANTIINFLAMMATORY AGENTS";BDNF;rs6265;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"NON-STEROIDS""";BDNF;rs6265;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ERGOT ALKALOIDS""";BDNF;rs6265;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""OPIOIDS""";BDNF;rs6265;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""SUMATRIPTAN""";BDNF;rs6265;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
ANTIPSYCHOTICS;COMT;rs4680;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;TARDIVE DYSKINESIA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
"""ANALGESICS""";COMT;rs4680;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ANTIINFLAMMATORY AGENTS";COMT;rs4680;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"NON-STEROIDS""";COMT;rs4680;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ERGOT ALKALOIDS""";COMT;rs4680;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""OPIOIDS""";COMT;rs4680;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""SUMATRIPTAN""";COMT;rs4680;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
RISPERIDONE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
TACROLIMUS;CAPN10;rs5030952;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
IDARUBICIN;RAC2;rs13058338;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
"""ANALGESICS""";DRD2;rs6275;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""NON-STEROIDS ANTIINFLAMMATORY AGENTS""";DRD2;rs6275;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""ERGOT ALKALOIDS""";DRD2;rs6275;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""OPIOIDS""";DRD2;rs6275;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
"""SUMATRIPTAN""";DRD2;rs6275;AA;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME ;;
IDARUBICIN;NCF4;rs1883112;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOTOXICITY;;;
OPIOIDS;OPRM1;rs9479757;AG;OTHER;DECREASED_RISK;nan;DISEASE;OPIOID-RELATED DISORDERS ;;
TACROLIMUS;CYP3A5;rs776746;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;AA + AC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PROTEASE INHIBITORS;ITPA;rs1127354;AA + AC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs1127354;AA + AC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
OPIOIDS;GAL;rs948854;CC;OTHER;INCREASED_RISK;nan;DISEASE;OPIOID-RELATED DISORDERS ;;
OPIOIDS;ABCB1;rs1045642;GG;OTHER;DECREASED_RISK;nan;DISEASE;OPIOID-RELATED DISORDERS ;;
OPIOIDS;OPRD1;rs2236861;A;OTHER;DECREASED_RISK;nan;DISEASE;OPIOID-RELATED DISORDERS ;;
IDARUBICIN;CYBA;rs4673;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
HYDROCHLOROTHIAZIDE;NOS3;rs1799983;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN DIASTOLIC BLOOD PRESSURE;;;
IDARUBICIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PRAVASTATIN;CETP;rs708272;A;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
PEGINTERFERON ALFA-2B;SLC28A2;rs11854484;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PROTEASE INHIBITORS;SLC28A2;rs11854484;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;SLC28A2;rs11854484;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DACLATASVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
DACLATASVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SOFOSBUVIR;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
DIURETICS;PDE4D;rs702553;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;BASELINE MEAN ARTERIAL BLOOD PRESSURE;;;
CITALOPRAM;ABCB1;rs2235040;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
FLUVOXAMINE;ABCB1;rs2235040;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
PAROXETINE;ABCB1;rs2235040;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
SERTRALINE;ABCB1;rs2235040;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
VENLAFAXINE;ABCB1;rs2235040;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
ESCITALOPRAM;KCNE1;rs1805127;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET INHIBITION;;;
ESCITALOPRAM;KCNE1;rs4817668;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;OTHER;HIGH PLATELET REACTIVITY;;;
NICOTINE_SUBSTITUTES;CHRNA5;rs588765;T;;SIDE_EFFECT;EFFICACY;INCREASED  CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IF PRESCRIBED NRT (NICOTIENE REPLACEMENT THERAPY);;;
nan;CHRNA3;rs1051730;A;;SIDE_EFFECT;EFFICACY;DECREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IN THE PLACEBO GROUP;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCYTOPENIA;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCYTOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
NICOTINE_SUBSTITUTES;CHRNA3;rs1051730;A;;SIDE_EFFECT;EFFICACY;INCREASED  CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IF PRESCRIBED NRT (NICOTIENE REPLACEMENT THERAPY);;;
CITALOPRAM;ABCB1;rs2032583;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
FLUVOXAMINE;ABCB1;rs2032583;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
PAROXETINE;ABCB1;rs2032583;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
SERTRALINE;ABCB1;rs2032583;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
VENLAFAXINE;ABCB1;rs2032583;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS;;;
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
CISPLATIN;ABCB1;rs4148737;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CYCLOPHOSPHAMIDE;ABCB1;rs4148737;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
DOXORUBICIN;ABCB1;rs4148737;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
METHOTREXATE;ABCB1;rs4148737;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
VINCRISTINE;ABCB1;rs4148737;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CISPLATIN;ABCC3;rs4148416;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CYCLOPHOSPHAMIDE;ABCC3;rs4148416;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
DOXORUBICIN;ABCC3;rs4148416;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
METHOTREXATE;ABCC3;rs4148416;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
VINCRISTINE;ABCC3;rs4148416;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
nan;FOXO3;rs4946936;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
NEVIRAPINE;ABCB1;rs1045642;A;TOXICITY;DECREASED_RISK;nan;DISEASE;TOXIC LIVER DISEASE ;;
nan;FOXO3;rs17069665;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;ARNT;rs3215133;T/del + del/del;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;COLORECTAL NEOPLASMS ;;
METHADONE;ARRB2;rs2036657;GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
CYCLOPHOSPHAMIDE;ABCB1;rs2032582;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;ABCB1;rs2032582;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;ABCB1;rs2032582;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
ETHANOL;GHSR;rs2232165;AG;OTHER;nan;OTHER;HEAVY CONSUMPTION;;;
CYCLOPHOSPHAMIDE;ABCB1;rs1045642;G;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;ABCB1;rs1045642;G;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;ABCB1;rs1045642;G;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
CISPLATIN;ABCB1;rs10276036;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVERALL SURVIVAL;;;
CYCLOPHOSPHAMIDE;ABCB1;rs10276036;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVERALL SURVIVAL;;;
DOXORUBICIN;ABCB1;rs10276036;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVERALL SURVIVAL;;;
METHOTREXATE;ABCB1;rs10276036;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVERALL SURVIVAL;;;
VINCRISTINE;ABCB1;rs10276036;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVERALL SURVIVAL;;;
ANTIPSYCHOTICS;NEFM;rs1379357;G;;SIDE_EFFECT;EFFICACY;RESPONSE TIME;;;
CISPLATIN;ABCB1;rs1128503;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CYCLOPHOSPHAMIDE;ABCB1;rs1128503;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
DOXORUBICIN;ABCB1;rs1128503;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
METHOTREXATE;ABCB1;rs1128503;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
VINCRISTINE;ABCB1;rs1128503;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
ANTIPSYCHOTICS;NEFM;rs1457266;G;;SIDE_EFFECT;EFFICACY;RESPONSE TIME;;;
nan;ARNT;rs12410394;AA + AG;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;COLORECTAL NEOPLASMS ;;
CELECOXIB;IL23R;rs7518660;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ADENOMA ;;
CELECOXIB;ALOX12;rs11078659;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ADENOMA ;;
nan;CYP1A2;rs2470890;CT + TT;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;COLORECTAL NEOPLASMS ;;
nan;nan;rs11072508;CT + TT;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;COLORECTAL NEOPLASMS ;;
CELECOXIB;PTGES;rs2302821;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR TOXICITY AND SYMPTOMS;;;
nan;CSK;rs4886410;CG + GG;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;COLORECTAL NEOPLASMS ;;
CELECOXIB;PTGER4;rs4133101;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITIES;;;
CARBOPLATIN;ALDH3A1;rs2228100;CC + CG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;CYSTITIS ;;
CYCLOPHOSPHAMIDE;ALDH3A1;rs2228100;CC + CG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;CYSTITIS ;;
THIOTEPA;ALDH3A1;rs2228100;CC + CG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;CYSTITIS ;;
TAMOXIFEN;ABCC2;rs3740065;AA;EFFICACY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;RECURRENCE OF BREAST CANCER;;;
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INSOMNIA;;;
DEXAMETHASONE;ABCB1;rs1045642;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
DOXORUBICIN;ABCB1;rs1045642;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
VINCRISTINE;ABCB1;rs1045642;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
FARGLITAZAR;SCNN1B;rs34241435;A;TOXICITY;nan;SIDE_EFFECT;OEDEMA;;;
INSULINS AND ANALOGUES;SCNN1B;rs34241435;A;TOXICITY;nan;SIDE_EFFECT;OEDEMA;;;
HYDROCHLOROTHIAZIDE;SCNN1G;rs5723;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN OFFICE DIASTOLIC BLOOD PRESSURE;;;
FARGLITAZAR;SCNN1B;rs889299;A;TOXICITY;nan;SIDE_EFFECT;OEDEMA;;;
GLYBURIDE;SCNN1B;rs889299;A;TOXICITY;nan;SIDE_EFFECT;OEDEMA;;;
HYDROCHLOROTHIAZIDE;SCNN1G;rs5729;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN OFFICE DIASTOLIC BLOOD PRESSURE;;;
GEFITINIB;IKBKE;rs12142086;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
NICOTINE;CHRNA5;rs680244;C;OTHER;DECREASED_LIKELIHOOD;OTHER;ABSTINENCE;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ORAL ULCER;;;
METHADONE;ARRB2;rs1045280;CC;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DOSE-ADJUSTED TACROLIMUS BLOOD CONCENTRATION;;;
LORAZEPAM;UGT2B15;rs1902023;AA;LADME-PK;INCREASED_PK;METABOLISM;AREA UNDER THE VISUAL ANALOG SCALE-TIME CURVE DURING THE INDUCED STATE;;;
CYCLOPHOSPHAMIDE;ABCB1;rs3213619;G;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;ABCB1;rs3213619;G;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;ABCB1;rs3213619;G;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
CYCLOPHOSPHAMIDE;TUBB2A;rs9501929;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;TUBB2A;rs9501929;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;TUBB2A;rs9501929;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
NALOXONE;COMT;rs4680;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ERYTHEMA;;;
OXYCODONE;COMT;rs4680;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ERYTHEMA;;;
TACROLIMUS;CYP3A4;rs2740574;CT;LADME-PK;DECREASED_PK;METABOLISM;DOSE-ADJUSTED TACROLIMUS BLOOD CONCENTRATIONS;;;
NICOTINE;CHRNA5;rs16969968;A;OTHER;DECREASED_LIKELIHOOD;OTHER;ABSTINENCE;;;
METHADONE;ARRB2;rs3786047;AA;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED_LIVER_ENZYMES;;;
BISOPROLOL;CYP3A5;rs776746;TT;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE;;;
BISOPROLOL;CYP3A5;rs776746;TT;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
NALOXONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ERYTHEMA;;;
OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ERYTHEMA;;;
PAZOPANIB;VEGFA;rs2010963;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
HYDROCHLOROTHIAZIDE;WNK1;rs1159744;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE;;;
TAMOXIFEN;CYP2C19;rs12248560;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
nan;SLC22A3;rs2504938;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
NALOXONE;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
OXYCODONE;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
FLUOROURACIL;UMPS;rs1801019;CC + CG;TOXICITY, LADME-PK;nan;nan;DISEASE;DIARRHEA ;;
LEUCOVORIN;UMPS;rs1801019;CC + CG;TOXICITY, LADME-PK;nan;nan;DISEASE;DIARRHEA ;;
FLUOROURACIL;UMPS;rs1801019;CC;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
LEUCOVORIN;UMPS;rs1801019;CC;TOXICITY, LADME-PK;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
BUPRENORPHINE;COMT;rs4680;AG + GG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
METHADONE;COMT;rs4680;AG + GG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
CAPECITABINE;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
nan;SLC22A3;rs512077;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
BUPRENORPHINE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
METHADONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;PAIN;;;
CAPECITABINE;DPYD;rs2297595;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs2297595;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
GLUCARPIDASE;ABCC4;rs7317112;AG + GG;TOXICITY;INCREASED_RISK;OTHER;NEPHROTOXICITY;;;
HYDROCHLOROTHIAZIDE;ADRB2;rs2400707;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
NICOTINE;CHRNA5;rs16969968;GG;OTHER;INCREASED_LIKELIHOOD;OTHER;FUNCTIONAL MRI REACTIVITY TO SMOKING IMAGES;;;
HYDROCHLOROTHIAZIDE;WNK1;rs1159744;CC;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;URINARY POTASSIUM EXCRETION;;;
HEROIN;DRD2;rs1076560;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;HEROIN DEPENDENCE ;;
SUFENTANIL;ABCB1;rs1128503;GG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE_PAIN;;;
HYDROCHLOROTHIAZIDE;WNK1;rs2107614;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE;;;
HYDROCHLOROTHIAZIDE;RAD52;rs2277869;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE;;;
HYDROCHLOROTHIAZIDE;WNK1;rs2277869;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE;;;
ASPARAGINASE;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
CYCLOPHOSPHAMIDE;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
CYTARABINE;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
DOXORUBICIN;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
MERCAPTOPURINE;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
PREDNISONE;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
VINCRISTINE;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
METFORMIN;SLC47A2;rs34399035;T;LADME-PK;DECREASED_PK;METABOLISM;METFORMIN UPTAKE IN HEK-293 CELLS AND REDUCTION IN PROTEIN EXPRESSION LEVELS;;;
OXALIPLATIN;ABCB1;rs1128503;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ANLOTINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
ANLOTINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
APATINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
APATINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
AXITINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
AXITINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
BEVACIZUMAB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
BEVACIZUMAB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
SORAFENIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
SORAFENIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
SUNITINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
SUNITINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CYTARABINE;CBR3;rs8133052;GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
IDARUBICIN;CBR3;rs8133052;GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
WARFARIN;nan;rs16871327;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;EPHA7;rs78132896;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
FENOFIBRATE;FABP1;rs2241883;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERTRIGLYCERIDEMIA ;;
ANTIPSYCHOTICS;SNAP25;rs1051312;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
GEFITINIB;TAB2;rs577001;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
PEGINTERFERON ALFA-2B;IFIT1;rs304478;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SVR (SUSTAINED VIROLOGICAL RESPONSE);;;
RIBAVIRIN;IFIT1;rs304478;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SVR (SUSTAINED VIROLOGICAL RESPONSE);;;
PEGINTERFERON ALFA-2B;OASL;rs12819210;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;OASL;rs12819210;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
OXALIPLATIN;ABCB1;rs1045642;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RECURRENCE-FREE SURVIVAL;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PAZOPANIB;VEGFA;rs833061;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
COCAINE;SLC6A3;rs6347;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE (RR);;;
ATORVASTATIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
CYCLOPHOSPHAMIDE;ABCC2;rs8187710;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;ABCC2;rs8187710;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;ABCC2;rs8187710;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL (PFS) TIME;;;
COCAINE;DRD2;rs1076560;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
ANTIINFLAMMATORY AGENTS;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
NON-STEROIDS;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
CYCLOPHOSPHAMIDE;ABCC2;rs17222723;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;ABCC2;rs17222723;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;ABCC2;rs17222723;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
CYCLOPHOSPHAMIDE;CYP1B1;rs1056836;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;CYP1B1;rs1056836;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;CYP1B1;rs1056836;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
ANLOTINIB;KDR;rs1870377;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
APATINIB;KDR;rs1870377;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
AXITINIB;KDR;rs1870377;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
BEVACIZUMAB;KDR;rs1870377;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
SORAFENIB;KDR;rs1870377;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
SUNITINIB;KDR;rs1870377;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE (RR);;;
GEFITINIB;NFKBIA;rs2233407;AA + AT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CYCLOPHOSPHAMIDE;SPIDR;rs6473187;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;SPIDR;rs6473187;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;SPIDR;rs6473187;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
GEFITINIB;NR1H2;rs2695121;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
CYCLOPHOSPHAMIDE;SLCO1B1;rs3829306;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;SLCO1B1;rs3829306;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;SLCO1B1;rs3829306;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
SUNITINIB;VEGFA;rs2010963;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;EPHA6;rs301927;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;EPHA6;rs301927;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;EPHA6;rs301927;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
WARFARIN;nan;rs115112393;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ANTIPSYCHOTICS;HTR2C;rs6318;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIPSYCHOTICS;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIPSYCHOTICS;HTR2C;rs518147;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ATORVASTATIN;ABCB1;rs2032582;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
COCAINE;DRD2;rs2283265;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
ANLOTINIB;KDR;rs2305948;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
APATINIB;KDR;rs2305948;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
AXITINIB;KDR;rs2305948;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
BEVACIZUMAB;KDR;rs2305948;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
SORAFENIB;KDR;rs2305948;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
SUNITINIB;KDR;rs2305948;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
ANTIPSYCHOTICS;DRD2;rs6275;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIPSYCHOTICS;DRD2;rs7131056;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIPSYCHOTICS;INSIG2;rs17047764;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIPSYCHOTICS;GNB3;rs5443;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIPSYCHOTICS;MC4R;rs489693;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
TIANEPTINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK;OTHER;SUICIDAL IDEATION;;;
ATORVASTATIN;ABCB1;rs1128503;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
ANTIPSYCHOTICS;BDNF;rs6265;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIPSYCHOTICS;BDNF-AS;rs6265;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ANTIPSYCHOTICS;ADRA2A;rs1800544;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
ANLOTINIB;KDR;rs2071559;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
APATINIB;KDR;rs2071559;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
AXITINIB;KDR;rs2071559;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
BEVACIZUMAB;KDR;rs2071559;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
SORAFENIB;KDR;rs2071559;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
SUNITINIB;KDR;rs2071559;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PROGRESSION-FREE SURVIVAL;;;
THEOPHYLLINE;CYP1A2;rs2069514;GG;LADME-PK;INCREASED_PK;METABOLISM;RATIO OF 1;;;
THEOPHYLLINE;CYP1A2;rs2069514;GG;LADME-PK;INCREASED_PK;METABOLISM;3 DMU/THEOPHYLLINE;;;
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
GEFITINIB;NFKBIA;rs2233409;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
GEFITINIB;NFKBIA;rs8904;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CLOPIDOGREL RESISTANCE;;;
GEFITINIB;NFKBIB;rs2053071;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
LEVODOPA;DRD3;rs6280;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HALLUCINATIONS;;;
GEFITINIB;NFKBIA;rs2233406;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
CLOPIDOGREL;ITGB3;rs5918;C;;SIDE_EFFECT;EFFICACY;LESS DECREASE IN THE PLATELET REACTIVITY AFTER 600 MG OF CLOPIDOGREL;;;
CLOPIDOGREL;ITGB3;rs5918;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ANTIPLATELET EFFECT TO A 300 MG CLOPIDOGREL LOADING-DOSE UP TO 24 H FOLLOWING INTERVENTION;;;
CYTARABINE;CYP2E1;rs2070673;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
FLUDARABINE;CYP2E1;rs2070673;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
GEMTUZUMAB OZOGAMICIN;CYP2E1;rs2070673;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
IDARUBICIN;CYP2E1;rs2070673;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
CYTARABINE;CYP2E1;rs2515641;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
FLUDARABINE;CYP2E1;rs2515641;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
GEMTUZUMAB OZOGAMICIN;CYP2E1;rs2515641;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
IDARUBICIN;CYP2E1;rs2515641;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
CYTARABINE;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
FLUDARABINE;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
GEMTUZUMAB OZOGAMICIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
IDARUBICIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PERINDOPRIL;AGTR1;rs275651;TT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;CARDIAC EVENTS;;;
CYTARABINE;SULT2B1;rs2302948;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;FEVER ;;
FLUDARABINE;SULT2B1;rs2302948;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;FEVER ;;
GEMTUZUMAB OZOGAMICIN;SULT2B1;rs2302948;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;FEVER ;;
IDARUBICIN;SULT2B1;rs2302948;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;FEVER ;;
ESCITALOPRAM;KCNH2;rs3807372;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS);;;
HEROIN;OPRM1;rs1799971;AA + AG;OTHER;DECREASED_LIKELIHOOD;OTHER;ADDICTION;;;
GEFITINIB;IKBKB;rs9694958;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
CYTARABINE;SLC22A12;rs11231825;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FEVER ;;
FLUDARABINE;SLC22A12;rs11231825;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FEVER ;;
GEMTUZUMAB OZOGAMICIN;SLC22A12;rs11231825;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FEVER ;;
IDARUBICIN;SLC22A12;rs11231825;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FEVER ;;
GEFITINIB;IKBKE;rs3748022;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXANTHEMA;;;
ASPIRIN;FSIP1;rs7179742;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA;;;
ASPIRIN;PTGS1;rs10306114;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE TO ASPIRIN;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;XPO1;rs4430924;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ASPIRIN;CEP68;rs7572857;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA;;;
CYCLOSPORINE;ABCB1;rs2032582;A;EFFICACY;INCREASED_RISK;nan;DISEASE;TRANSPLANT REJECTION ;;
MYCOPHENOLATE MOFETIL;ABCB1;rs2032582;A;EFFICACY;INCREASED_RISK;nan;DISEASE;TRANSPLANT REJECTION ;;
PAROXETINE;HTR2A;rs6311;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NAUSEA;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;nan;rs10945919;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
AMISULPRIDE;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
CLOZAPINE;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
HALOPERIDOL;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
OLANZAPINE;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
QUETIAPINE;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
RISPERIDONE;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ZIPRASIDONE;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ZUCLOPENTHIXOL;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
DAUNORUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEFT VENTRICULAR DYSFUNCTION;;;
DOXORUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEFT VENTRICULAR DYSFUNCTION;;;
EPIRUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEFT VENTRICULAR DYSFUNCTION;;;
ETHAMBUTOL;NAT2;rs1799930;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;rs1799930;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;rs1799930;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;rs1799930;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ETHAMBUTOL;NAT2;rs1799931;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;rs1799931;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;rs1799931;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;rs1799931;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
CETUXIMAB;KRAS;rs61764370;AC + CC;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;PROGRESSION-FREE SURVIVAL ;;
PANITUMUMAB;KRAS;rs61764370;AC + CC;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;PROGRESSION-FREE SURVIVAL ;;
ETHAMBUTOL;NAT2;rs1041983;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;NAT2;rs1041983;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;NAT2;rs1041983;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NAT2;rs1041983;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
CYCLOPHOSPHAMIDE;FGFR4;rs351855;GG;EFFICACY;INCREASED_LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL;;;
FLUOROURACIL;FGFR4;rs351855;GG;EFFICACY;INCREASED_LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL;;;
METHOTREXATE;FGFR4;rs351855;GG;EFFICACY;INCREASED_LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL;;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE;;;
CLOPIDOGREL;CES1;rs71647871;CT;LADME-PK;INCREASED_PK;METABOLISM;LEVELS OF CLOPIDOGREL ACTIVE METABOLITE;;;
CLOPIDOGREL;CES1;rs71647871;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ON-TREATMENT ADP-INDUCED PLATELET AGGREGATION;;;
CLOPIDOGREL;CES1;rs71647871;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ON-TREATMENT ADP-INDUCED PLATELET AGGREGATION;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_PK;PK;CMAX OF THE ACTIVE METABOLITE;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_PK;PK;CMAX OF THE ACTIVE METABOLITE;;;
CARBOPLATIN;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PEMETREXED;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
VEMURAFENIB;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
VEMURAFENIB;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARCINOMA;;;
VEMURAFENIB;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SQUAMOUS CELL;;;
VEMURAFENIB;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
VEMURAFENIB;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY INDEX (PRI) AT 4 H AFTER THE DOSING;;;
CITALOPRAM;HTR2A;rs7997012;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
ESCITALOPRAM;HTR2A;rs7997012;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOXETINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
PAROXETINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SERTRALINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY INDEX (PRI) AT 4 H AFTER THE DOSING;;;
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
FLUOROURACIL;KLC1;rs861539;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
FLUOROURACIL;XRCC3;rs861539;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
IRINOTECAN;KLC1;rs861539;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
IRINOTECAN;XRCC3;rs861539;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
LEUCOVORIN;KLC1;rs861539;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
LEUCOVORIN;XRCC3;rs861539;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME-PK;PK;PK;RISK OF BEING UNDERDOSED;;;
OPIOIDS;SLC18A2;rs363332;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
OPIOIDS;SLC18A2;rs363334;G;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
OPIOIDS;SLC18A2;rs363338;C;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS;;;
CYCLOPHOSPHAMIDE;MISP;rs8110536;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
EPIRUBICIN;MISP;rs8110536;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
PACLITAXEL;MISP;rs8110536;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;;SIDE_EFFECT;EFFICACY;HIGHER P2Y12 REACTION UNITS (PRU) AND LOWER PERCENT INHIBITION;;;
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE TO CLOPIDOGREL;;;
SUNITINIB;VEGFA;rs699947;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PAZOPANIB;VEGFA;rs699947;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CYTARABINE;NQO2;rs1143684;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
IDARUBICIN;NQO2;rs1143684;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
PACLITAXEL;EPHA6;rs301927;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
TACROLIMUS;CYP3A5;rs776746;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HYPERLIPIDEMIAS ;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NON-RESPONSE TO CLOPIDOGREL;;;
WARFARIN;VEGFA;rs35410204;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
PACLITAXEL;EPHA8;rs209709;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
GLUCOCORTICOIDS;CDH2;rs1944294;AT + TT;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
METHOTREXATE;CDH2;rs1944294;AT + TT;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
RADIOTHERAPY;CDH2;rs1944294;AT + TT;TOXICITY;DECREASED_;SIDE_EFFECT;BONE_DENSITY;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG;TOXICITY;DECREASED_RISK;nan;DISEASE;LYMPHOPENIA ;;
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;;SIDE_EFFECT;EFFICACY;HIGHER P2Y12 REACTION UNITS (PRU) AND LOWER PERCENT INHIBITION;;;
CYTARABINE;NQO1;rs1800566;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
IDARUBICIN;NQO1;rs1800566;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
WARFARIN;VEGFA;rs866236;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
PACLITAXEL;ABCG1;rs492338;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
OXALIPLATIN;ABCB1;rs1128503;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PACLITAXEL;EPHA6;rs301927;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
nan;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
nan;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;LUNG NEOPLASMS ;;
nan;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD;OTHER;LYMPH NODE METASTASIS;;;
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET RESPONSIVENESS TO CLOPIDOGREL;;;
AMITRIPTYLINE;CYP2D6;rs3892097;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
CLOMIPRAMINE;CYP2D6;rs3892097;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
DOXEPIN;CYP2D6;rs3892097;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
IMIPRAMINE;CYP2D6;rs3892097;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
MAPROTILINE;CYP2D6;rs3892097;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
NORTRIPTYLINE;CYP2D6;rs3892097;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
OPIPRAMOL;CYP2D6;rs3892097;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
CALCIUM;VDR;rs731236;G;EFFICACY;INCREASED_RISK;nan;DISEASE;FRACTURES, BONE ;;
nan;SULT1A1;rs1042028;T;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;UROLOGIC NEOPLASMS ;;
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET RESPONSIVENESS TO CLOPIDOGREL;;;
nan;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
AMITRIPTYLINE;ABCB1;rs2235040;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs2235040;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs2235040;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs2235040;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
AMITRIPTYLINE;ABCB1;rs12720067;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs12720067;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs12720067;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs12720067;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
ASPIRIN;IRS1;rs13431554;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;IRS1;rs13431554;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
DOCETAXEL;VAC14;rs875858;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CLOPIDOGREL;CYP3A4;rs2242480;CT + TT;;SIDE_EFFECT;EFFICACY;REDUCED GP IIB/IIIA ACTIVATION AND LOWER PLATELET ACTIVATION;;;
AMITRIPTYLINE;ABCB1;rs10280101;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs10280101;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs10280101;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs10280101;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
DIRECT FACTOR XA INHIBITORS;FGG;rs1800792;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
DIRECT THROMBIN INHIBITORS;FGG;rs1800792;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
AMITRIPTYLINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs7787082;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
OPIOIDS;COMT;rs6269;AG + GG;OTHER;INCREASED_LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION;;;
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;THE TIME TO ACHIEVE A FIRST INR WITHIN THE THERAPEUTIC RANGE;;;
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;THE TIME TO ACHIEVE A FIRST INR WITHIN THE THERAPEUTIC RANGE;;;
OSIMERTINIB;EGFR;rs121434569;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
OSIMERTINIB;EGFR;rs121434569;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
AMITRIPTYLINE;ABCB1;rs4148739;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs4148739;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs4148739;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs4148739;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
FLUINDIONE;VKORC1;rs9934438;AA;;SIDE_EFFECT;EFFICACY;SHORTER TIME TO HAVE OVER-ANTICOAGULATION (INR >4) RISK;;;
OPIOIDS;COMT;rs4680;AG + GG;OTHER;INCREASED_LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION;;;
ETHANOL;ADH1B;rs1229984;TT;LADME-PK;INCREASED_PK;METABOLISM;VMAX;;;
AMITRIPTYLINE;ABCB1;rs11983225;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs11983225;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs11983225;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs11983225;C;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
FLUINDIONE;VKORC1;rs9934438;AA;;SIDE_EFFECT;EFFICACY;SHORTER TIME TO HAVE OVER-ANTICOAGULATION (INR >4) RISK;;;
OPIOIDS;COMT;rs4818;CG + GG;OTHER;INCREASED_LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION;;;
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;AVERAGE DAILY DOSE DURING THE FIRST PERIOD OF STABILITY;;;
OPIOIDS;COMT;rs4633;CC + CT;OTHER;INCREASED_LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION;;;
AMITRIPTYLINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs10248420;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
ETHAMBUTOL;NAT2;rs1799931;A;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;NAT2;rs1799931;A;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;NAT2;rs1799931;A;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;NAT2;rs1799931;A;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
DIRECT FACTOR XA INHIBITORS;F2;rs5896;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
DIRECT THROMBIN INHIBITORS;F2;rs5896;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
BORTEZOMIB;PKNOX1;rs2839629;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA;;;
SUNITINIB;VEGFA;rs699947;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED  RISK OF DEVELOPING GRADE 3 HYPERTENSION;;;
AMITRIPTYLINE;ABCB1;rs2235067;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs2235067;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs2235067;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs2235067;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
ATENOLOL;FTO;rs9940629;G;OTHER;nan;nan;DISEASE;HYPERCHOLESTEROLEMIA ;;
SUNITINIB;VEGFA;rs833061;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED  RISK OF DEVELOPING GRADE 3 HYPERTENSION;;;
ALFENTANIL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE_PAIN;;;
FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE_PAIN;;;
SUNITINIB;VEGFA;rs2010963;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED  RISK OF DEVELOPING GRADE 3 HYPERTENSION;;;
AMITRIPTYLINE;ABCB1;rs4148740;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
CITALOPRAM;ABCB1;rs4148740;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PAROXETINE;ABCB1;rs4148740;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
VENLAFAXINE;ABCB1;rs4148740;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
ATENOLOL;ABCB1;rs10267099;G;OTHER;INCREASED_RISK;nan;DISEASE;HYPERCHOLESTEROLEMIA ;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;OTHER;DECREASED_;OTHER;PLATELET FUNCTION;;;
ATENOLOL;ABCB1;rs3213619;G;OTHER;INCREASED_RISK;nan;DISEASE;HYPERCHOLESTEROLEMIA ;;
CORTICOSTEROIDS;DCAF4;rs7160796;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;CHANGE IN FORCED EXPIRATORY VOLUME IN 1 S (FEV1);;;
SUNITINIB;NOS3;rs2070744;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GRADE 3 HYPERTENSION;;;
ATENOLOL;PRKCB;rs11649514;GT + TT;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERGLYCEMIA;;;
ATENOLOL;FTO;rs12595985;AA;OTHER;INCREASED_RISK;nan;DISEASE;HYPERCHOLESTEROLEMIA ;;
CYCLOPHOSPHAMIDE;ALDH1A1;rs8187996;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CYCLOPHOSPHAMIDE;ALDH1A1;rs8187996;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT MODIFICATION;;;
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;OTHER;DECREASED_;OTHER;PLATELET FUNCTION;;;
ATENOLOL;GALNT2;rs2144297;T;OTHER;nan;nan;DISEASE;HYPERCHOLESTEROLEMIA ;;
ATENOLOL;GALNT2;rs2144300;C;OTHER;nan;nan;DISEASE;HYPERCHOLESTEROLEMIA ;;
ETHANOL;ANKK1;rs1800497;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ALCOHOL ABUSE ;;
ETHANOL;DRD2;rs1800497;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;ALCOHOL ABUSE ;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE, LADME-PK;DECREASED_PK;METABOLISM;IN VIVO METABOLISM OF (S)-WARFARIN BUT NOT (R)-WARFARIN;;;
ATENOLOL;PLA2G4A;rs10157410;C;OTHER;INCREASED_RISK;nan;DISEASE;HYPERCHOLESTEROLEMIA ;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION VALUES;;;
ATENOLOL;PTGS2;rs4648287;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HYPERCHOLESTEROLEMIA ;;
ISONIAZID;NOS2;rs11080344;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;NOS2;rs11080344;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ENALAPRIL;SLCO1B1;rs2306283;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;COUGH;;;
ISONIAZID;BACH1;rs2070401;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;BACH1;rs2070401;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET AGGREGATION VALUES;;;
ISONIAZID;MAFK;rs4720833;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;MAFK;rs4720833;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
ISONIAZID;XPO1;rs11125883;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;XPO1;rs11125883;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
CLOPIDOGREL;CYP2C19;rs12248560;CC;;SIDE_EFFECT;EFFICACY;GREATER PLATELET INHIBITION 2 H AFTER A 600-MG DOSE;;;
ISONIAZID;NAT2;rs1041983;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
ISONIAZID;NAT2;rs1495741;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CLOPIDOGREL;CYP2C9;rs1057910;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET INHIBITION 7H AFTER A CLOPIDOGREL 600-MG LOADING DOSE;;;
CAPECITABINE;DPYD;rs1801158;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs1801158;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PLATELET AGGREGATION INHIBITION;;;
PEGINTERFERON ALFA-2A;ITPA;rs7270101;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PEGINTERFERON ALFA-2B;ITPA;rs7270101;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs7270101;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
ANASTROZOLE;ESR1;rs9340799;A;OTHER;INCREASED_RISK;nan;DISEASE;MUSCULOSKELETAL PAIN ;;
LETROZOLE;ESR1;rs9340799;A;OTHER;INCREASED_RISK;nan;DISEASE;MUSCULOSKELETAL PAIN ;;
CLOPIDOGREL;CYP3A5;rs776746;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PLATELET AGGREGATION INHIBITION;;;
ANASTROZOLE;ESR1;rs2234693;C;OTHER;INCREASED_RISK;nan;DISEASE;MUSCULOSKELETAL PAIN ;;
LETROZOLE;ESR1;rs2234693;C;OTHER;INCREASED_RISK;nan;DISEASE;MUSCULOSKELETAL PAIN ;;
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PLATELET AGGREGATION INHIBITION;;;
nan;CYP3A4;rs2740574;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;;
OPIOIDS;OPRM1;rs1799971;AA + AG;OTHER;DECREASED_LIKELIHOOD;OTHER;ADDICTION;;;
CAPECITABINE;DPYD;rs75017182;C;DOSAGE, TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs75017182;C;DOSAGE, TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
REPAGLINIDE;NEUROD1;rs1801262;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DIFFERENCE IN POSTPRANDIAL PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT);;;
REPAGLINIDE;PAX4;rs114202595;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DIFFERENCE IN POSTPRANDIAL PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT);;;
nan;CYP3A4;rs2740574;CT;OTHER;INCREASED_RISK;nan;DISEASE;ENDOMETRIAL NEOPLASMS ;;
VINCRISTINE;COCH;rs1045644;CG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CETUXIMAB;EGFR;rs712830;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
IRINOTECAN;EGFR;rs712830;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
LEUCOVORIN;EGFR;rs712830;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
TEGAFUR;EGFR;rs712830;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
TAMOXIFEN;CYP3A4;rs2740574;CT;OTHER;INCREASED_RISK;nan;DISEASE;ENDOMETRIAL NEOPLASMS ;;
VINCRISTINE;nan;rs7963521;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
REPAGLINIDE;NEUROD1;rs1801262;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;DIFFERENCE IN FASTING PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT);;;
nan;VDR;rs3782905;G;OTHER;INCREASED_RISK;nan;DISEASE;ASTHMA ;;
OPIOIDS;OPRL1;rs6090043;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OPIOID-RELATED DISORDERS ;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH-ON CLOPIDOGREL PLATELET REACTIVITY;;;
CLOPIDOGREL;P2RY12;rs6785930;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;NEUROLOGICAL EVENTS;;;
OPIOIDS;COMT;rs165599;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
DOCETAXEL;ABCB1;rs2032582;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
PACLITAXEL;ABCB1;rs2032582;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ANTIPLATELET EFFECT;;;
CALCITRIOL;VDR;rs2228570;A;EFFICACY;INCREASED_RISK;nan;DISEASE;FRACTURES, BONE ;;
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ANEMIA;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH POST-TREATMENT PLATELET REACTIVITY;;;
PERINDOPRIL;BDKRB1;rs12050217;AA;EFFICACY;DECREASED_RISK;SIDE_EFFECT;CARDIAC EVENTS;;;
CISPLATIN;AQP1;rs1049305;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ATENOLOL;GRK4;rs1801058;TT;EFFICACY, TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES;;;
VERAPAMIL;GRK4;rs1801058;TT;EFFICACY, TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES;;;
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;BIOPSY-PROVEN ACUTE REJECTION;;;
PLATINUM COMPOUNDS;HLA-DOB;rs2071554;CT + TT;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
PLATINUM COMPOUNDS;nan;rs2900420;AA + AG;EFFICACY;DECREASED_RISK;nan;DISEASE;DEATH ;;
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
CYCLOPHOSPHAMIDE;DROSHA;rs639174;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CYTARABINE;DROSHA;rs639174;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
DAUNORUBICIN;DROSHA;rs639174;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
MERCAPTOPURINE;DROSHA;rs639174;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;DROSHA;rs639174;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
PREDNISONE;DROSHA;rs639174;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
VINCRISTINE;DROSHA;rs639174;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
OPIOIDS;DRD2;rs6275;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
ISONIAZID;CYP2E1;rs6413432;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
PYRAZINAMIDE;CYP2E1;rs6413432;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
RIFAMPIN;CYP2E1;rs6413432;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
CISPLATIN;nan;rs3746444;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ACENOCOUMAROL;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
WARFARIN;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ASPIRIN;PTGS2;rs20417;G;OTHER;DECREASED_RISK;nan;DISEASE;CORONARY DISEASE ;;
CISPLATIN;AQP1;rs28362731;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ETHAMBUTOL;CYP2E1;rs2031920;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;CYP2E1;rs2031920;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;CYP2E1;rs2031920;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;CYP2E1;rs2031920;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ASPIRIN;PTGS2;rs20417;G;OTHER;INCREASED_RISK;nan;DISEASE;CORONARY DISEASE ;;
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;CLOPIDOGREL INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
FOLFIRI;ABCC1;rs17501011;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OPIOIDS;OPRL1;rs6090041;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OPIOID-RELATED DISORDERS ;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ANTIPLATELET EFFECT;;;
ANTIDEPRESSANTS;CUX1;rs365836;G;EFFICACY;LIKELIHOOD-;SIDE_EFFECT;NON-RESPONSE;;;
nan;SULT1A1;rs1042028;CT + TT;OTHER;INCREASED_RISK;nan;DISEASE;BREAST NEOPLASMS ;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;CLOPIDOGREL INHIBITION OF ADP-INDUCED PLATELET AGGREGATION;;;
nan;SULT1A1;rs1042028;CT + TT;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;BREAST NEOPLASMS ;;
CLOZAPINE;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
ACENOCOUMAROL;VKORC1;rs9923231;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;VKORC1;rs9923231;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ANTIDEPRESSANTS;CUX1;rs201522;A;EFFICACY;LIKELIHOOD-;SIDE_EFFECT;NON-RESPONSE;;;
BORTEZOMIB;PKNOX1;rs2839629;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
BORTEZOMIB;PKNOX1;rs2839629;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
BORTEZOMIB;PKNOX1;rs2839629;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROPATHIC PAIN;;;
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
CISPLATIN;COMT;rs4646316;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
CAPECITABINE;ENOSF1;rs2741171;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HAND-FOOT SYNDROME ;;
CAPECITABINE;ENOSF1;rs2612091;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;HAND-FOOT SYNDROME ;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CISPLATIN;ABCC3;rs1051640;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
CAPECITABINE;DPYD;rs12022243;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
FOLFIRI;CES1;rs9921399;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
DEXTROAMPHETAMINE;DRD1;rs4532;CC;TOXICITY;INCREASED_SEVERITY;OTHER;SOCIAL WITHDRAWAL;;;
METHYLPHENIDATE;DRD1;rs4532;CC;TOXICITY;INCREASED_SEVERITY;OTHER;SOCIAL WITHDRAWAL;;;
CISPLATIN;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
METHAMPHETAMINE;GRIN1;rs1126442;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;PSYCHOTIC DISORDER ;;
FOLFIRI;UGT1A10;rs1113193;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FOLFIRI;UGT1A8;rs1113193;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;TPMT;rs1800460;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;OTOTOXICITY ;;
CAPECITABINE;ENOSF1;rs2741171;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CAPECITABINE;ENOSF1;rs2612091;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CAPECITABINE;DPYD;rs12022243;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24;;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24;;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24;;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24;;;
IODINE (131I) COMPOUNDS;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SIALOADENITIS;;;
RADIOTHERAPY;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SIALOADENITIS;;;
NICOTINE;CHRNA5;rs588765;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING CESSATION;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE;;;
RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE;;;
CAPECITABINE;DPYD;rs76387818;A;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;HAND-FOOT SYNDROME ;;
CAPECITABINE;DPYD;rs12132152;A;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;HAND-FOOT SYNDROME ;;
CAPECITABINE;DPYD;rs76387818;A;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
ATENOLOL;DPYS;rs2669429;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPERGLYCEMIA;;;
LENALIDOMIDE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ADVERSE EVENTS;;;
CAPECITABINE;DPYD;rs12132152;A;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
nan;IFNL3;rs12979860;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;SPONTANEOUS HCV CLEARANCE;;;
nan;IFNL4;rs12979860;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;SPONTANEOUS HCV CLEARANCE;;;
RISPERIDONE;LEP;rs7799039;G;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
WARFARIN;VKORC1;rs9923231;T;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLOOD COAGULATION DISORDERS;;;
IODINE (131I) COMPOUNDS;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
RADIOTHERAPY;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CARBOPLATIN;EIF4E2;rs1656402;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
CARBOPLATIN;TIGD1;rs1656402;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
PACLITAXEL;EIF4E2;rs1656402;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
PACLITAXEL;TIGD1;rs1656402;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
IODINE (131I) COMPOUNDS;ATM;rs11212570;AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
RADIOTHERAPY;ATM;rs11212570;AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;FATIGUE;;;
NICOTINE;nan;rs2056527;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SMOKING CESSATION;;;
NICOTINE;nan;rs2056527;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SMOKING CESSATION;;;
CAPECITABINE;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
FLUOROURACIL;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
PIRFENIDONE;TOLLIP;rs5743890;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CAPECITABINE;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
WARFARIN;VKORC1;rs9923231;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;TIME TO THERAPEUTIC INR;;;
IMATINIB;ABCB1;rs1045642;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM COMPOUNDS;XBP1;rs2269577;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NAUSEA ;;
IMATINIB;SLC22A1;rs683369;CC;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
CARBOPLATIN;DSCAM;rs9981861;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
PACLITAXEL;DSCAM;rs9981861;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
CARBOPLATIN;ETS2;rs1209950;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
PACLITAXEL;ETS2;rs1209950;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL;;;
IODINE (131I) COMPOUNDS;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
IODINE (131I) COMPOUNDS;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
RADIOTHERAPY;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
RADIOTHERAPY;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
IODINE (131I) COMPOUNDS;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
IODINE (131I) COMPOUNDS;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
RADIOTHERAPY;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
RADIOTHERAPY;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEADACHE;;;
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
IODINE (131I) COMPOUNDS;ATG10;rs1864183;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
RADIOTHERAPY;ATG10;rs1864183;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
MERCAPTOPURINE;NUDT15;rs186364861;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AMISULPRIDE;MC4R;rs17782313;CC;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
CLOZAPINE;MC4R;rs17782313;CC;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
OLANZAPINE;MC4R;rs17782313;CC;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
PALIPERIDONE;MC4R;rs17782313;CC;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
QUETIAPINE;MC4R;rs17782313;CC;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
RISPERIDONE;MC4R;rs17782313;CC;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
AMISULPRIDE;MC4R;rs489693;A;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
ARIPIPRAZOLE;MC4R;rs489693;A;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
CLOZAPINE;MC4R;rs489693;A;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
HALOPERIDOL;MC4R;rs489693;A;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
QUETIAPINE;MC4R;rs489693;A;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
RISPERIDONE;MC4R;rs489693;A;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
ZIPRASIDONE;MC4R;rs489693;A;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AMISULPRIDE;MC4R;rs489693;AA;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HYPERTRIGLYCERIDEMIA, WEIGHT GAIN ;;
ARIPIPRAZOLE;MC4R;rs489693;AA;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HYPERTRIGLYCERIDEMIA, WEIGHT GAIN ;;
CLOZAPINE;MC4R;rs489693;AA;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HYPERTRIGLYCERIDEMIA, WEIGHT GAIN ;;
HALOPERIDOL;MC4R;rs489693;AA;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HYPERTRIGLYCERIDEMIA, WEIGHT GAIN ;;
QUETIAPINE;MC4R;rs489693;AA;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HYPERTRIGLYCERIDEMIA, WEIGHT GAIN ;;
RISPERIDONE;MC4R;rs489693;AA;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HYPERTRIGLYCERIDEMIA, WEIGHT GAIN ;;
ZIPRASIDONE;MC4R;rs489693;AA;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HYPERTRIGLYCERIDEMIA, WEIGHT GAIN ;;
ATENOLOL;PLEKHH2;rs11124945;G;TOXICITY;DECREASED_RISK;nan;DISEASE;DIABETES MELLITUS ;;
VERAPAMIL;PLEKHH2;rs11124945;G;TOXICITY;DECREASED_RISK;nan;DISEASE;DIABETES MELLITUS ;;
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED_SEVERITY;nan;DISEASE;PLATELET AGGREGATION ;;
REGADENOSON;AMPD1;rs17602729;AA + AG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE;;;
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SOMNOLENCE;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
CAPECITABINE;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
nan;nan;rs2952768;CC;EFFICACY;DECREASED_SEVERITY;OTHER;SUBSTANCE-RELATED DISORDERS;;;
CISPLATIN;ERCC2;rs1799793;CT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
NICOTINE;DBH;rs1541333;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;END OF TREATMENT ABSTINENCE;;;
REGADENOSON;AMPD1;rs17602729;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
RISPERIDONE;CNR1;rs806378;T;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
RISPERIDONE;CNR1;rs1049353;C;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
MERCAPTOPURINE;ABCC4;rs3765534;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
ASPARAGINASE;NFATC2;rs6021191;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
ASPARAGINASE;HLA-DRB1;rs17885382;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERSENSITIVITY;;;
CYCLOPHOSPHAMIDE;GSTP1;rs1695;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EPIRUBICIN;GSTP1;rs1695;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;CYSTIC FIBROSIS PULMONARY EXACERBATION ;;
VANCOMYCIN;nan;rs2789047;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;;
LISINOPRIL;MMP3;rs35068180;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CARBOPLATIN;SERPINA5;rs6113;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;SERPINA5;rs6113;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;;SIDE_EFFECT;EFFICACY;SUBOPTIMAL REPERFUSION (POST-PCI TIMI FLOW <3);;;
CARBOPLATIN;SERPINA5;rs6118;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;SERPINA5;rs6118;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CARBOPLATIN;XYLT2;rs6504649;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;XYLT2;rs6504649;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
CARBOPLATIN;SERPINA5;rs6119;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;SERPINA5;rs6119;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
ETHANOL;CAT;rs1001179;T;OTHER;INCREASED_RISK;nan;DISEASE;ALCOHOL ABUSE ;;
CARBOPLATIN;ETS2;rs73450548;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;ETS2;rs73450548;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
BEVACIZUMAB;VEGFA;rs2010963;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTI-VEGF INJECTIONS;;;
PEGAPTANIB;VEGFA;rs2010963;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTI-VEGF INJECTIONS;;;
RANIBIZUMAB;VEGFA;rs2010963;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ANTI-VEGF INJECTIONS;;;
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_SEVERITY;OTHER;PLATELET REACTIVITY;;;
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;nan;DISEASE;RECURRENCE ;;
DOXORUBICIN;GSTA1;rs3957357;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
AMISULPRIDE;MC4R;rs489693;AA;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
CLOZAPINE;MC4R;rs489693;AA;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
OLANZAPINE;MC4R;rs489693;AA;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
PALIPERIDONE;MC4R;rs489693;AA;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
QUETIAPINE;MC4R;rs489693;AA;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
RISPERIDONE;MC4R;rs489693;AA;OTHER;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
ETHANOL;CAT;rs1001179;T;OTHER;INCREASED_SEVERITY;nan;DISEASE;ALCOHOL ABUSE ;;
nan;ERCC1;rs3212986;AC;OTHER;DECREASED_;OTHER;DISEASE-FREE SURVIVAL AND OVERALL SURVIVAL;;;
DEXMEDETOMIDINE;GABRA2;rs279847;GG;TOXICITY;DECREASED_;SIDE_EFFECT;HEART RATE;;;
TAMOXIFEN;ESR1;rs9340799;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VENOUS THROMBOEMBOLISM;;;
"""ACE INHIBITORS";F5;rs149389480;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"PLAIN""";F5;rs149389480;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"""ANGIOTENSIN II ANTAGONISTS""";F5;rs149389480;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
MORPHINE;FAAH;rs3766246;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
CLOZAPINE;TBC1D1;rs9852;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;TBC1D1;rs9852;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;WEIGHT GAIN ;;
FLUOROURACIL;DPYD;rs67376798;AT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
MORPHINE;FAAH;rs4141964;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
nan;ABCB11;rs2287622;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEPATOCELLULAR INJURY;;;
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPOVENTILATION;;;
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SIDE EFFECTS;;;
nan;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ALCOHOL ABUSE, SUBSTANCE-RELATED DISORDERS ;;
OPIOIDS;GNB3;rs5443;CT + TT;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;INCREASED  PULSE RATE;;;
ARIPIPRAZOLE;FAAH;rs324420;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
CLOZAPINE;FAAH;rs324420;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
HALOPERIDOL;FAAH;rs324420;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
OLANZAPINE;FAAH;rs324420;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
QUETIAPINE;FAAH;rs324420;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
RISPERIDONE;FAAH;rs324420;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
MORPHINE;FAAH;rs2295632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
CAFFEINE;CYP1A2;rs762551;AC + CC;OTHER;DECREASED_RISK;nan;DISEASE;BREAST NEOPLASMS ;;
MORPHINE;FAAH;rs324420;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
PEGINTERFERON ALFA-2B;VDR;rs2228570;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;VDR;rs2228570;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
nan;ABCB11;rs2287622;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG-INDUCED_LIVER_INJURY ;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
SIMEPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DOCETAXEL;NR1I3;rs3003593;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ANTITHYROID PREPARATIONS;EHMT2;rs652888;G;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;AGRANULOCYTOSIS ;;
IODINE (131I) COMPOUNDS;TNF;rs1800629;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
RADIOTHERAPY;TNF;rs1800629;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CONSTIPATION ;;
HMG COA REDUCTASE INHIBITORS;HLA-G;rs1063320;G;OTHER;DECREASED_LIKELIHOOD;nan;DISEASE;ASTHMA ;;
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRY MOUTH ;;
DEXMEDETOMIDINE;CYP2A6;rs28399433;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SEDATION;;;
DEFERIPRONE;UGT1A6;rs6759892;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
DEFERIPRONE;UGT1A6;rs6759892;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
ANTITHYROID PREPARATIONS;nan;rs111618861;del;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;AGRANULOCYTOSIS ;;
ANTITHYROID PREPARATIONS;HLA-B;rs1071816;C;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;AGRANULOCYTOSIS ;;
IODINE (131I) COMPOUNDS;ATM;rs11212570;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
RADIOTHERAPY;ATM;rs11212570;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
EFAVIRENZ;IL10;rs1800896;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
ETHANOL;ANKK1;rs1800497;A;OTHER;INCREASED_RISK;nan;DISEASE;ALCOHOL ABUSE ;;
ETHANOL;DRD2;rs1800497;A;OTHER;INCREASED_RISK;nan;DISEASE;ALCOHOL ABUSE ;;
IODINE (131I) COMPOUNDS;NFKB1;rs230493;AT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
RADIOTHERAPY;NFKB1;rs230493;AT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK;OTHER;OPIOID-RELATED DISORDERS;;;
ETHANOL;DRD2;rs1800497;A;OTHER;INCREASED_RISK;nan;DISEASE;ALCOHOL ABUSE ;;
IODINE (131I) COMPOUNDS;TGFB1;rs2241716;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
RADIOTHERAPY;TGFB1;rs2241716;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
IODINE (131I) COMPOUNDS;TGFB1;rs1800469;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
RADIOTHERAPY;TGFB1;rs1800469;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PAIN;;;
ANTITHYROID PREPARATIONS;FOXF2;rs199564443;del;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;AGRANULOCYTOSIS ;;
CAPECITABINE;CES1P1;rs7187684;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ASPARAGINASE;nan;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
CYCLOPHOSPHAMIDE;nan;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
CYTARABINE;nan;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
DAUNORUBICIN;nan;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
HYDROCORTISONE;nan;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;nan;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
PREDNISONE;nan;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
VINCRISTINE;nan;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
CAPECITABINE;CES1P1;rs11861118;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM;XRCC1;rs25487;TT;EFFICACY;nan;OTHER;WORSE OVERALL SURVIVAL OUTCOME;;;
PLATINUM;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RESPONSE;;;
CAPECITABINE;CES1;rs2244613;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PLATINUM;ERCC1;rs3212986;AA + AC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOZAPINE;CYP1A2;rs2069514;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
ETHANOL;CYP1A2;rs2069514;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
MERCAPTOPURINE;PACSIN2;rs2413739;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
METHOTREXATE;PACSIN2;rs2413739;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RECURRENCE;;;
ASPARAGINASE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
CYCLOPHOSPHAMIDE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
CYTARABINE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
DAUNORUBICIN;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
HYDROCORTISONE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
METHOTREXATE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
PREDNISONE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
VINCRISTINE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
CAPECITABINE;CES1;rs2244614;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CITALOPRAM;CYP2C19;rs4244285;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
IODINE (131I) COMPOUNDS;ATM;rs620815;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
RADIOTHERAPY;ATM;rs620815;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS;;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS;;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS;;;
RIBAVIRIN;IFNL3;rs12979860;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS;;;
RIBAVIRIN;IFNL4;rs12979860;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS;;;
TENOFOVIR;ABCC2;rs17222723;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;RENAL PROXIMAL TUBULOPATHY;;;
TENOFOVIR;ABCC2;rs2273697;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;RENAL PROXIMAL TUBULOPATHY;;;
FLUOROURACIL;DPYD;rs1801160;CT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CYTARABINE;nan;rs12036333;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
IDARUBICIN;nan;rs12036333;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
ASPARAGINASE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
CYCLOPHOSPHAMIDE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
CYTARABINE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
DAUNORUBICIN;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
HYDROCORTISONE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
METHOTREXATE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
PREDNISONE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
VINCRISTINE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
NEVIRAPINE;CYP2B6;rs28399499;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
NEVIRAPINE;CYP2B6;rs28399499;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PEGINTERFERON ALFA-2B;CYP2R1;rs10741657;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;CYP2R1;rs10741657;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
ASPARAGINASE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
CYCLOPHOSPHAMIDE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
CYTARABINE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
DAUNORUBICIN;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
HYDROCORTISONE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
METHOTREXATE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
PREDNISONE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
VINCRISTINE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
NEVIRAPINE;CYP2B6;rs3745274;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
NEVIRAPINE;CYP2B6;rs3745274;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
TENOFOVIR DISOPROXIL FUMARATE;CYP24A1;rs2248359;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEPHROTOXICITY;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TENOFOVIR DISOPROXIL FUMARATE;CYP27B1;rs4646536;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;NEPHROTOXICITY;;;
NICOTINE;DDC;rs2060761;C;OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;RIPOR2;rs10946737;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
NICOTINE;DDC;rs12718541;A;OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1;;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1;;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1;;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1;;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1;;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1;;;
IMIPRAMINE;CYP2C19;rs12248560;CT + TT;LADME-PK;DECREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS;;;
IMIPRAMINE;CYP2C19;rs11188072;CT + TT;LADME-PK;DECREASED_PK;METABOLISM;DOSE-CORRECTED PLASMA CONCENTRATIONS;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
nan;CXCL5;rs352046;GG;OTHER;INCREASED_RISK;nan;DISEASE;DEATH ;;
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
CAPECITABINE;CDA;rs602950;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
CAPECITABINE;CDA;rs532545;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
TENOFOVIR DISOPROXIL FUMARATE;ABCC2;rs717620;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEPHROTOXICITY;;;
CAPECITABINE;CDA;rs6690069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
TENOFOVIR;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;KIDNEY TUBULAR DYSFUNCTION;;;
METHYLPHENIDATE;DRD1;rs4532;CC;TOXICITY;INCREASED_SEVERITY;OTHER;SOCIAL WITHDRAWAL;;;
CAPECITABINE;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;SUBCLINICAL INTRA-STENT THROMBUS;;;
CAPECITABINE;CES1;rs3217164;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;CDA;rs10916825;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
CAPECITABINE;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
TENOFOVIR DISOPROXIL FUMARATE;SLC28A2;rs11854484;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEPHROTOXICITY;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DIZZINESS;;;
CAPECITABINE;NSUN3;rs144470777;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;PHC1;rs187805828;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SERUM OSTEOCALCIN;;;
ASPIRIN;ITGB3;rs5918;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;INADEQUATE INHIBITION OF PLATELET ACTIVITY;;;
CAPECITABINE;FAT1;rs116134453;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CISPLATIN;XPC;rs2228001;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
CAPECITABINE;TENM4;rs141531882;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
TICAGRELOR;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DYSPNEA;;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;nan;SIDE_EFFECT;A 22% INCREASE IN THERAPEUTIC WARFARIN DOSE REQUIREMENT AFTER ADJUSTMENT FOR CLINICAL AND GENETIC COVARIATES IN HISPANIC-AMERICANS;;;
AMOXICILLIN;HLA-DQB1;rs9274407;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG INDUCED LIVER INJURY;;;
CLAVULANATE;HLA-DQB1;rs9274407;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG INDUCED LIVER INJURY;;;
CAPECITABINE;CD96;rs77475703;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CYCLOPHOSPHAMIDE;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AMENORRHEA;;;
DOCETAXEL;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AMENORRHEA;;;
DOXORUBICIN;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AMENORRHEA;;;
EPIRUBICIN;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AMENORRHEA;;;
FLUOROURACIL;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AMENORRHEA;;;
GOSERELIN;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AMENORRHEA;;;
WARFARIN;NQO1;rs1800566;A;DOSAGE;nan;SIDE_EFFECT;A 34% INCREASE IN THERAPEUTIC WARFARIN DOSE REQUIREMENT WHILE HOLDING CLINICAL AND GENETIC PREDICTORS CONSTANT IN HISPANIC-AMERICANS;;;
CAPECITABINE;ZMIZ1;rs117484357;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;VPS13D;rs138385713;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CETUXIMAB;RASSF1;rs2236947;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PAROXETINE;CYP1A2;rs4646425;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SLOWER RESPONSE TIME;;;
CAPECITABINE;CCDC77;rs141213385;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
ANTIPSYCHOTICS;RGS2;rs4606;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS;;;
ANTIPSYCHOTICS;RGS2;rs4606;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PARKINSONIAN DISORDER;;;
PRAVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC);;;
DEXMEDETOMIDINE;WBP2NL;rs5758550;AA;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;SEDATION;;;
CAPECITABINE;ADGRG7;rs117308378;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CARBOPLATIN;AKT1;rs1130214;AA + AC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DISEASE PROGRESSION;;;
CISPLATIN;AKT1;rs1130214;AA + AC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DISEASE PROGRESSION;;;
CYCLOSPORINE;NFATC1;rs2280055;CC;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
MYCOPHENOLIC ACID;NFATC1;rs2280055;CC;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
PREDNISONE;NFATC1;rs2280055;CC;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
ASPIRIN;PEAR1;rs41273215;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ASPIRIN;PEAR1;rs41273215;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;PEAR1;rs41273215;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;PEAR1;rs41273215;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;PEAR1;rs41273215;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;PEAR1;rs41273215;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CARBOPLATIN;nan;rs2498804;AA + AC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DISEASE PROGRESSION;;;
CISPLATIN;nan;rs2498804;AA + AC;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DISEASE PROGRESSION;;;
CLOZAPINE;DRD2;rs4436578;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BODY WEIGHT GAIN;;;
OLANZAPINE;DRD2;rs4436578;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BODY WEIGHT GAIN;;;
RISPERIDONE;DRD2;rs4436578;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BODY WEIGHT GAIN;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
TELAPREVIR;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
VINCRISTINE;ABCC2;rs12826;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA EXPOSURE;;;
NICOTINE;GRIN3A;rs10121600;C;OTHER;INCREASED_RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
ASPIRIN;CYP1A2;rs762551;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ASPIRIN;CYP1A2;rs762551;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;CYP1A2;rs762551;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP1A2;rs762551;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP1A2;rs762551;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP1A2;rs762551;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY;;;
ASPIRIN;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ASPIRIN;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CITALOPRAM;HTR1B;rs6296;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;AGITATION;;;
PRAVASTATIN;ABCA1;rs2230806;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;HDL-CHOLESTEROL;;;
ASPIRIN;PON1;rs662;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ASPIRIN;PON1;rs662;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;PON1;rs662;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;PON1;rs662;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;PON1;rs662;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;PON1;rs662;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DEATH;;;
DEXMEDETOMIDINE;ABCG2;rs2231142;GG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;SEDATION;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SIMEPREVIR;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
"""ANTIINFLAMMATORY AGENTS";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL BLEEDING;;;
"NON-STEROIDS""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL BLEEDING;;;
"""CELECOXIB""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL BLEEDING;;;
"""DICLOFENAC""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL BLEEDING;;;
"""IBUPROFEN""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL BLEEDING;;;
"""NAPROXEN""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL BLEEDING;;;
"""PIROXICAM""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL BLEEDING;;;
CAPECITABINE;DPYD;rs75267292;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
NICOTINE;GRIN3A;rs11788456;G;OTHER;RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;FATIGUE ;;
"""ANTIINFLAMMATORY AGENTS";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ACUTE GASTROINTESTINAL BLEEDING;;;
"NON-STEROIDS""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ACUTE GASTROINTESTINAL BLEEDING;;;
"""CELECOXIB""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ACUTE GASTROINTESTINAL BLEEDING;;;
"""DICLOFENAC""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ACUTE GASTROINTESTINAL BLEEDING;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;SLEEP DISORDERS ;;
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED_RISK;nan;DISEASE;CORONARY DISEASE ;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
"""ACE INHIBITORS";F5;rs368967198;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"PLAIN""";F5;rs368967198;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"""ANGIOTENSIN II ANTAGONISTS""";F5;rs368967198;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
CAPECITABINE;SSU72;rs146898897;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
ASPIRIN;F2R;rs168753;T;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
ASPIRIN;F2R;rs168753;T;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
ASPIRIN;F2R;rs168753;T;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED_RISK;SIDE_EFFECT;MYOCARDIAL INFARCTION;;;
CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED_RISK;SIDE_EFFECT;STROKE;;;
CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;OTHER;DECREASED_;OTHER;HEART RATE;;;
CARBOPLATIN;PIK3CA;rs2699887;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CISPLATIN;PIK3CA;rs2699887;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;OTHER;DECREASED_;OTHER;HEART RATE;;;
CARBOPLATIN;PTEN;rs2299939;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CISPLATIN;PTEN;rs2299939;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CAPECITABINE;MAN1A1;rs185346775;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CARBOPLATIN;AKT1;rs3803304;C;EFFICACY;RISK;DISEASE_PROGRESSION;NON-SMALL CELL LUNG CANCER;;;
CISPLATIN;AKT1;rs3803304;C;EFFICACY;RISK;DISEASE_PROGRESSION;NON-SMALL CELL LUNG CANCER;;;
COCAINE;BCHE;rs1803274;TT;OTHER;nan;nan;DISEASE;COCAINE DEPENDENCE ;;
PRAVASTATIN;SLCO1B1;rs4149056;CC;LADME-PK;INCREASED_PK;METABOLISM;MEAN PEAK CONCENTRATION IN PLASMA AND AREA UNDER THE PLASMA CONCENTRATION;;;
PEGINTERFERON ALFA-2A;EGFR;rs11506105;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;EGFR;rs11506105;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;EGFR;rs11506105;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;EGFR;rs11506105;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;EGFR;rs11506105;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;EGFR;rs11506105;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
CISPLATIN;ABCB1;rs1045642;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL RATE;;;
FLUOROURACIL;ABCB1;rs1045642;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;SURVIVAL RATE;;;
ASPIRIN;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET REACTIVITY;;;
HMG COA REDUCTASE INHIBITORS;STAT4;rs7574865;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CISPLATIN;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;LYMPH NODE METASTASES;;;
FLUOROURACIL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RISK;SIDE_EFFECT;LYMPH NODE METASTASES;;;
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
HEROIN;ALDH2;rs671;AA + AG;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HEROIN DEPENDENCE ;;
FENTANYL;CALCA;rs145837941;GG;DOSAGE;DECREASED_SEVERITY;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
"""METFORMIN""";KCNJ11;rs5219;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
"""SULFONAMIDES";KCNJ11;rs5219;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
"UREA DERIVATIVES""";KCNJ11;rs5219;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TREATMENT FAILURE;;;
ANTIHYPERTENSIVES;ADRB1;rs1801253;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
BETA BLOCKING AGENTS;ADRB1;rs1801253;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
DIURETICS;ADRB1;rs1801253;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
NICOTINE;GRIN3A;rs17189632;T;OTHER;RISK;nan;DISEASE;TOBACCO USE DISORDER ;;
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
HMG COA REDUCTASE INHIBITORS;SLCO1A2;rs4149000;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;POOR-RESPONSE TO CLOPIDOGREL;;;
TRAMADOL;SLC22A1;rs35167514;del;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL;;;
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SEVOFLURANE;FASTKD3;rs2307116;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;VOL% END-TIDAL SEVOFLURANE CONCENTRATION;;;
SEVOFLURANE;MTRR;rs2307116;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;VOL% END-TIDAL SEVOFLURANE CONCENTRATION;;;
ASPIRIN;P2RY12;rs2046934;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
TRAMADOL;SLC22A1;rs34130495;A;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL;;;
TRAMADOL;SLC22A1;rs12208357;T;LADME-PK;PK;PK;HIGHER PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL;;;
METHADONE;KCNJ6;rs2070995;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;WITHDRAWAL EFFECTS;;;
IMATINIB;SLCO1A2;rs3764043;CC;LADME-PK;DECREASED_PK;METABOLISM;IMATINIB CLEARANCE;;;
IMATINIB;SLCO1A2;rs4148978;CC;LADME-PK;INCREASED_PK;METABOLISM;IMATINIB CLEARANCE;;;
VINCRISTINE;ABCC2;rs3740066;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
IMATINIB;SLCO1A2;rs4148977;CC;LADME-PK;INCREASED_PK;METABOLISM;IMATINIB CLEARANCE;;;
FLUOROURACIL;DPYD;rs55886062;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
FLUCLOXACILLIN;NR1I2;rs3814055;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
CYCLOSPORINE;NFATC1;rs3894049;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
MYCOPHENOLIC ACID;NFATC1;rs3894049;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
PREDNISONE;NFATC1;rs3894049;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
SEVOFLURANE;FASTKD3;rs1801394;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;VOL% END-TIDAL SEVOFLURANE CONCENTRATION;;;
SEVOFLURANE;MTRR;rs1801394;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;VOL% END-TIDAL SEVOFLURANE CONCENTRATION;;;
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
EFAVIRENZ;CYP2B6;rs28399499;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
"""ACE INHIBITORS";F5;rs143509841;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"PLAIN""";F5;rs143509841;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"""ANGIOTENSIN II ANTAGONISTS""";F5;rs143509841;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs8099917;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;G;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
"""ACE INHIBITORS";F5;rs200157005;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"PLAIN""";F5;rs200157005;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
"""ANGIOTENSIN II ANTAGONISTS""";F5;rs200157005;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANGIOEDEMA;;;
PAROXETINE;CYP1A2;rs4646427;TT;;SIDE_EFFECT;EFFICACY;SLOWER RESPONSE TIME;;;
CARBAMAZEPINE;SCN1A;rs3812718;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;CORTICAL SILENT PERIOD DURATION;;;
METHOTREXATE;MIR1206;rs2114358;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
PAROXETINE;CYP1A2;rs4646425;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SLOWER RESPONSE TIME;;;
ATORVASTATIN;SLCO1B1;rs2306283;G;LADME-PK;DECREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
FOLIC ACID;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG EVENT;;;
METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG EVENT;;;
CYTARABINE;BRD10;rs10758713;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
IDARUBICIN;BRD10;rs10758713;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUSCULAR DISEASES;;;
SORAFENIB;KDR;rs4864950;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;T;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;T;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;T;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;T;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;T;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;T;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
SORAFENIB;PIK3R5;rs444904;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
IRINOTECAN;UGT1A10;rs17868323;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA WITHIN 24 HOURS AND THROMBOCYTOPENIA;;;
IRINOTECAN;UGT1A6;rs17868323;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA WITHIN 24 HOURS AND THROMBOCYTOPENIA;;;
IRINOTECAN;UGT1A7;rs17868323;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA WITHIN 24 HOURS AND THROMBOCYTOPENIA;;;
IRINOTECAN;UGT1A8;rs17868323;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA WITHIN 24 HOURS AND THROMBOCYTOPENIA;;;
IRINOTECAN;UGT1A9;rs17868323;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA WITHIN 24 HOURS AND THROMBOCYTOPENIA;;;
CYTARABINE;nan;rs2897047;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IDARUBICIN;nan;rs2897047;AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;ABCC2;rs2273697;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CYTARABINE;nan;rs6550826;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
IDARUBICIN;nan;rs6550826;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
METHOTREXATE;ABCB1;rs1128503;AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
AZATHIOPRINE;ABCC4;rs3765534;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;LEUKOPENIA ;;
MERCAPTOPURINE;ABCC4;rs3765534;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;LEUKOPENIA ;;
METHOTREXATE;ABCC2;rs4148396;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME TO DISCONTINUATION OR DOSE REDUCTION;;;
METHOTREXATE;ABCC2;rs4148396;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ALOPECIA ;;
CYTARABINE;nan;rs9883101;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
IDARUBICIN;nan;rs9883101;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
FOLIC ACID;TLR4;rs4986790;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG EVENTS;;;
METHOTREXATE;TLR4;rs4986790;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE DRUG EVENTS;;;
ROSUVASTATIN;ABCG2;rs2231142;T;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
ROSUVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS;;;
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
LEUCOVORIN;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
PRAVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
HYDROCHLOROTHIAZIDE;nan;rs10792367;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;BLOOD PRESSURE (BP) REDUCTION;;;
IRINOTECAN;UGT1A10;rs17868323;G;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT;NECESSITY TO REDUCE IRINOTECAN DOSAGE;;;
IRINOTECAN;UGT1A6;rs17868323;G;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT;NECESSITY TO REDUCE IRINOTECAN DOSAGE;;;
IRINOTECAN;UGT1A7;rs17868323;G;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT;NECESSITY TO REDUCE IRINOTECAN DOSAGE;;;
IRINOTECAN;UGT1A8;rs17868323;G;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT;NECESSITY TO REDUCE IRINOTECAN DOSAGE;;;
IRINOTECAN;UGT1A9;rs17868323;G;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT;NECESSITY TO REDUCE IRINOTECAN DOSAGE;;;
nan;HMGCR;rs12654264;AT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;SERUM TOTAL CHOLESTEROL;;;
DOXORUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
HMG COA REDUCTASE INHIBITORS;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;;
NICOTINE;CHRNA3;rs3743075;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;TOBACCO USE DISORDER;;;
NICOTINE;CHRNB4;rs7178270;G;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;TOBACCO USE DISORDER;;;
VINCRISTINE;NDRG1;rs2272653;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
NICOTINE;CHRNB4;rs1948;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;TOBACCO USE DISORDER;;;
PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
HMG COA REDUCTASE INHIBITORS;nan;rs1719247;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MUSCULAR DISEASES ;;
SIMVASTATIN;nan;rs1719247;T;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MUSCULAR DISEASES ;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;;
HMG COA REDUCTASE INHIBITORS;nan;rs1346268;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MUSCULAR DISEASES ;;
SIMVASTATIN;nan;rs1346268;C;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MUSCULAR DISEASES ;;
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_PK;METABOLISM;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX;;;
CYCLOPHOSPHAMIDE;ABCC2;rs3740066;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
DOXORUBICIN;ABCC2;rs3740066;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
FLUOROURACIL;ABCC2;rs3740066;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
IMATINIB;UGT2A1;rs11249454;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;ECT2L;rs11155012;A;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
HMG COA REDUCTASE INHIBITORS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION;;;
CYCLOPHOSPHAMIDE;ATM;rs1801516;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
DOXORUBICIN;ATM;rs1801516;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
FLUOROURACIL;ATM;rs1801516;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
GEMCITABINE;SLC28A1;rs3825876;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC;LADME-PK;INCREASED_PK;METABOLISM;AUC;;;
GEMCITABINE;CDA;rs2072671;AC + CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
RISPERIDONE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PROLONGED QTC INTERVAL;;;
PITAVASTATIN;SLCO1B1;rs2306283;AG + GG;LADME-PK;INCREASED_PK;METABOLISM;PITAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX;;;
SORAFENIB;EGFR;rs2330951;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
ROSUVASTATIN;SLCO1B1;rs4149056;CC;LADME-PK;INCREASED_PK;METABOLISM;AUC (P=0.002) AND CMAX (P=0.003);;;
HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;MUSCULAR DISEASES ;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;OTHER;MAJOR ADVERSE CARDIOVASCULAR EVENTS;;;
EVEROLIMUS;ABCB1;rs2032582;A;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;LYMPHOPENIA;;;
CYCLOPHOSPHAMIDE;CYP1B1;rs1056836;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
DOXORUBICIN;CYP1B1;rs1056836;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
FLUOROURACIL;CYP1B1;rs1056836;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
AZATHIOPRINE;nan;rs2647087;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCREATITIS;;;
MERCAPTOPURINE;nan;rs2647087;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCREATITIS;;;
EVEROLIMUS;RPTOR;rs9906827;T;TOXICITY, OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS;;;
RADIOTHERAPY;XPC;rs2228001;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
EVEROLIMUS;ABCB1;rs1045642;A;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
CYCLOPHOSPHAMIDE;ATM;rs1801516;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
DOXORUBICIN;ATM;rs1801516;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
FLUOROURACIL;ATM;rs1801516;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
AZATHIOPRINE;NUDT15;rs116855232;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL ISCHEMIA;;;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
SUNITINIB;VEGFA;rs833061;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
AZACITIDINE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH POST-TREATMENT PLATELET REACTIVITY;;;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs2768759;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL INFARCTION;;;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs2768759;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;MYOCARDIAL ISCHEMIA;;;
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs2768759;AA;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STROKE;;;
CYCLOPHOSPHAMIDE;ERCC1;rs3212986;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;ERCC1;rs3212986;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;ERCC1;rs3212986;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IMATINIB;SLC22A1;rs628031;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ACETAMINOPHEN;nan;rs6500265;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ACETAMINOPHEN;nan;rs6500265;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
IBUPROFEN;nan;rs6500265;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
IBUPROFEN;nan;rs6500265;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LOXOPROFEN;nan;rs6500265;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
LOXOPROFEN;nan;rs6500265;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
SALICYLAMIDE;nan;rs6500265;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SALICYLAMIDE;nan;rs6500265;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
IMATINIB;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA1;rs1994862;CC;OTHER;DECREASED_RISK;SIDE_EFFECT;AROUSAL DYSFUNCTION;;;
EVEROLIMUS;RPTOR;rs9906827;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
IMATINIB;CHST1;rs9787901;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
IMATINIB;CYP2F1;rs305968;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ACETAMINOPHEN;nan;rs9933632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
ACETAMINOPHEN;nan;rs9933632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
IBUPROFEN;nan;rs9933632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
IBUPROFEN;nan;rs9933632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
LOXOPROFEN;nan;rs9933632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
LOXOPROFEN;nan;rs9933632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
SALICYLAMIDE;nan;rs9933632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS;;;
SALICYLAMIDE;nan;rs9933632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME;;;
CYCLOPHOSPHAMIDE;CBR1;rs20572;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
DOXORUBICIN;CBR1;rs20572;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
FLUOROURACIL;CBR1;rs20572;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
CYCLOPHOSPHAMIDE;TP53;rs1042522;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
DOXORUBICIN;TP53;rs1042522;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
FLUOROURACIL;TP53;rs1042522;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
SORAFENIB;PRKCE;rs11125039;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
CYCLOPHOSPHAMIDE;SLC22A16;rs714368;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
DOXORUBICIN;SLC22A16;rs714368;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
FLUOROURACIL;SLC22A16;rs714368;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
ANTIINFLAMMATORY AGENTS;IL10;rs1800896;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NON-STEROIDS;IL10;rs1800896;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
CYCLOPHOSPHAMIDE;XRCC1;rs25487;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
DOXORUBICIN;XRCC1;rs25487;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
FLUOROURACIL;XRCC1;rs25487;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
ANTIINFLAMMATORY AGENTS;CTLA4;rs231775;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
NON-STEROIDS;CTLA4;rs231775;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
nan;ADH7;rs971074;CT + TT;OTHER;INCREASED_SEVERITY;OTHER;PAIN;;;
SORAFENIB;ADAMTS18;rs1346563;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERTENSION;;;
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CYCLOPHOSPHAMIDE;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
DOXORUBICIN;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
FLUOROURACIL;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
CISPLATIN;SLC31A1;rs10981694;GG + GT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;OTOTOXICITY ;;
CYCLOPHOSPHAMIDE;CYP2C19;rs12248560;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
DOXORUBICIN;CYP2C19;rs12248560;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;CYP2C19;rs12248560;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOPHOSPHAMIDE;ABCC2;rs3740066;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;ABCC2;rs3740066;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;ABCC2;rs3740066;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DEXMEDETOMIDINE;ABCC9;rs11046209;AA;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT;SEDATION;;;
CYCLOPHOSPHAMIDE;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
VINCRISTINE;CEP72;rs12522955;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CAPECITABINE;nan;rs72765700;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CYCLOPHOSPHAMIDE;ABCG2;rs2231142;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;ABCG2;rs2231142;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;ABCG2;rs2231142;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
ANTINEOPLASTIC AGENTS;ABCC4;rs2274407;AC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;THROMBOCYTOPENIA ;;
MERCAPTOPURINE;ABCC4;rs2274407;AC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;THROMBOCYTOPENIA ;;
METHOTREXATE;ABCC4;rs2274407;AC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;THROMBOCYTOPENIA ;;
AZATHIOPRINE;FTO;rs79206939;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;FTO;rs79206939;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOPHOSPHAMIDE;ALDH3A1;rs2228100;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
CYCLOPHOSPHAMIDE;ALDH3A1;rs2228100;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
DOXORUBICIN;ALDH3A1;rs2228100;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;ALDH3A1;rs2228100;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;ALDH3A1;rs2228100;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;ALDH3A1;rs2228100;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
ANTINEOPLASTIC AGENTS;ABCC4;rs2274407;AC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
MERCAPTOPURINE;ABCC4;rs2274407;AC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
METHOTREXATE;ABCC4;rs2274407;AC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
PRAVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN TOTAL CHOLESTEROL;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH POST-TREATMENT PLATELET REACTIVITY;;;
CYCLOPHOSPHAMIDE;ABCC2;rs2273697;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;ABCC2;rs2273697;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;ABCC2;rs2273697;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
CYCLOPHOSPHAMIDE;SLC22A16;rs6907567;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;SLC22A16;rs6907567;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;SLC22A16;rs6907567;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
EVEROLIMUS;FGFR4;rs351855;A;TOXICITY, OTHER;DECREASED_LIKELIHOOD;OTHER;DISCONTINUATION;;;
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
AZATHIOPRINE;nan;rs2834826;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;nan;rs2834826;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
FLUOROURACIL;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
IMATINIB;SLC19A1;rs12659;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AZATHIOPRINE;FTO;rs16952570;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;FTO;rs16952570;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
AZACITIDINE;XRCC1;rs25487;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IMATINIB;NQO1;rs10517;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
EVEROLIMUS;PIK3R1;rs10515074;G;TOXICITY, OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT;HYPERGLYCEMIA;;;
DESLORATADINE;HRH1;rs901865;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;SEDATION;;;
IMATINIB;ABCC2;rs2273697;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CYTARABINE;NOS3;rs1799983;TT;TOXICITY;DECREASED_;SIDE_EFFECT;IQ;;;
DOXORUBICIN;NOS3;rs1799983;TT;TOXICITY;DECREASED_;SIDE_EFFECT;IQ;;;
LEUCOVORIN;NOS3;rs1799983;TT;TOXICITY;DECREASED_;SIDE_EFFECT;IQ;;;
METHOTREXATE;NOS3;rs1799983;TT;TOXICITY;DECREASED_;SIDE_EFFECT;IQ;;;
PREDNISONE;NOS3;rs1799983;TT;TOXICITY;DECREASED_;SIDE_EFFECT;IQ;;;
VINCRISTINE;NOS3;rs1799983;TT;TOXICITY;DECREASED_;SIDE_EFFECT;IQ;;;
IMATINIB;ABCB4;rs1202283;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
EVEROLIMUS;PIK3R1;rs10515074;G;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CAPECITABINE;MIR2054;rs10024471;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;DHFR;rs1105525;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
ANTIPSYCHOTICS;PRKAB2;rs3766522;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
CLOZAPINE;PRKAB2;rs3766522;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
OLANZAPINE;PRKAB2;rs3766522;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
METHADONE;NECTIN4;rs11265549;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PRURITUS;;;
CAPECITABINE;SPRY2;rs117876855;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CAPECITABINE;SPRY2;rs139544515;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;EFFICACY;DECREASED_RISK;nan;DISEASE;COLONIC NEOPLASMS ;;
RIVAROXABAN;CYP3A4;rs2246709;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
METHOTREXATE;GGH;rs11545078;A;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;THROMBOCYTOPENIA ;;
CAPECITABINE;NCOA7;rs185217050;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;CCDC70;rs139368788;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
nan;HMGCR;rs12654264;AT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;SERUM LDL;;;
CYCLOPHOSPHAMIDE;ERCC1;rs11615;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
CYCLOPHOSPHAMIDE;ERCC1;rs11615;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
DOXORUBICIN;ERCC1;rs11615;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
DOXORUBICIN;ERCC1;rs11615;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
FLUOROURACIL;ERCC1;rs11615;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;ERCC1;rs11615;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
CAPECITABINE;TMEM131L;rs117412990;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
PRAVASTATIN;HMGCR;rs17244841;AT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN TOTAL CHOLESTEROL;;;
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;TT;EFFICACY;DECREASED_RISK;nan;DISEASE;COLONIC NEOPLASMS ;;
CAPECITABINE;SIRPA;rs191934521;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
ANTIPSYCHOTICS;PRKAA2;rs10789038;AA;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
CLOZAPINE;PRKAA2;rs10789038;AA;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
OLANZAPINE;PRKAA2;rs10789038;AA;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
RIVAROXABAN;CYP3A4;rs3735451;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
CAPECITABINE;LMNTD1;rs146644707;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
METHOTREXATE;MTHFR;rs1801133;GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ANTINEOPLASTIC AGENTS;RBFOX1;rs6500843;G;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;EFFICACY;DECREASED_RISK;nan;DISEASE;COLONIC NEOPLASMS ;;
PLATINUM;XRCC5;rs1051685;G;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;ANEMIA, LEUKOPENIA, NEUTROPENIA, THROMBOCYTOPENIA;;
CLOZAPINE;LEP;rs7799039;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
OLANZAPINE;LEP;rs7799039;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;LEP;rs7799039;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
IRINOTECAN;ABCC1;rs17287570;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION;;;
SORAFENIB;EPAS1;rs1868089;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY;;;
PLATINUM;XRCC5;rs6941;A;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA, LEUKOPENIA, NEUTROPENIA, THROMBOCYTOPENIA;;
CYCLOPHOSPHAMIDE;CYP2A6;rs143731390;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEATH;;;
IRINOTECAN;ABCG2;rs2622604;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION;;;
FOLIC ACID;MTHFD1;rs2236225;AA;OTHER;DECREASED_LIKELIHOOD;OTHER;DIABETES;;;
FOLIC ACID;MTHFD1;rs2236225;AA;OTHER;DECREASED_LIKELIHOOD;OTHER;GESTATIONAL;;;
METHOTREXATE;DHFR;rs442767;GG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
IRINOTECAN;UGT1A10;rs11692021;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION;;;
IRINOTECAN;UGT1A6;rs11692021;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION;;;
IRINOTECAN;UGT1A7;rs11692021;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION;;;
IRINOTECAN;UGT1A8;rs11692021;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION;;;
IRINOTECAN;UGT1A9;rs11692021;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION;;;
PLATINUM;AQP2;rs10875989;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA, LEUKOPENIA, NEUTROPENIA, THROMBOCYTOPENIA;;
APIXABAN;ABCG2;rs3114018;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
RIVAROXABAN;ABCG2;rs3114018;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
IRINOTECAN;SLCO1B3;rs7977213;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION;;;
METHOTREXATE;DHFR;rs408626;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
PLATINUM;AQP2;rs3759125;AA + AC;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;ANEMIA, LEUKOPENIA, NEUTROPENIA, THROMBOCYTOPENIA;;
IRINOTECAN;SLCO1B3;rs10841661;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION;;;
METHOTREXATE;DHFR;rs1650697;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
APIXABAN;ABCG2;rs2622604;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
RIVAROXABAN;ABCG2;rs2622604;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
PLATINUM;AQP2;rs461872;A;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DIARRHEA, NAUSEA, VOMITING, ;;
PLATINUM;AQP2;rs7305534;CC + CT;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA, NAUSEA, VOMITING, ;;
MEPHENYTOIN;CYP2C19;rs41291556;C;LADME-PK;PK;PK;DRAMATIC (APPROXIMATELY 90% AND 70%) REDUCTION IN THE METABOLISM OF S-MEPHENYTOIN AND TOLBUTAMIDE;;;
TOLBUTAMIDE;CYP2C19;rs41291556;C;LADME-PK;PK;PK;DRAMATIC (APPROXIMATELY 90% AND 70%) REDUCTION IN THE METABOLISM OF S-MEPHENYTOIN AND TOLBUTAMIDE;;;
PLATINUM;CD74;rs2748249;A;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
ASPIRIN;TBXAS1;rs6962291;AA;OTHER;DECREASED_RISK;SIDE_EFFECT;INTOLERANCE;;;
PLATINUM;CD74;rs1560661;C;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
CYTARABINE;CDA;rs2072671;AA;TOXICITY, LADME-PK;DECREASED_RISK;SIDE_EFFECT;GRADE III/IV LIVER TOXICITY;;;
WARFARIN;nan;rs12777823;A;DOSAGE;nan;SIDE_EFFECT;REDUCED WARFARIN DOSE IN AFRICAN AMERICANS;;;
WARFARIN;nan;rs12777823;A;DOSAGE;nan;SIDE_EFFECT;INDEPENDENT OF CYP2C9*2 AND CYP2C9*3.;;;
WARFARIN;nan;rs12777823;A;DOSAGE;nan;SIDE_EFFECT;REDUCED WARFARIN DOSE IN AFRICAN AMERICANS;;;
WARFARIN;nan;rs12777823;A;DOSAGE;nan;SIDE_EFFECT;INDEPENDENT OF CYP2C9*2 AND CYP2C9*3.;;;
nan;ALDH1A2;rs12915901;A;OTHER;INCREASED_LIKELIHOOD;OTHER;OSTEOARTHRITIS;;;
RALOXIFENE;nan;rs10030044;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY;;;
TAMOXIFEN;nan;rs10030044;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY;;;
CAPECITABINE;DPYD;rs2297595;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
CAPECITABINE;DPYD;rs2297595;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
CAPECITABINE;DPYD;rs2297595;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
FLUOROURACIL;DPYD;rs2297595;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
FLUOROURACIL;DPYD;rs2297595;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
FLUOROURACIL;DPYD;rs2297595;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
nan;SLC2A1;rs841844;CG + GG;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
CAPECITABINE;DPYD;rs2297595;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
FLUOROURACIL;DPYD;rs2297595;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DIARRHEA;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT;INSUFFICIENT ANTIPLATELET RESPONSE TO CLOPIDOGREL;;;
DASATINIB;ABL1;rs121913459;CT;OTHER, LADME-PK;DECREASED_PK;METABOLISM;AUC 0-4 HOURS;;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;HEPATITIS C VIRUS INFECTION ;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;HEPATITIS C VIRUS INFECTION ;;
HYDROCHLOROTHIAZIDE;AGT;rs5051;T;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
HYDROCHLOROTHIAZIDE;AGTR1;rs5186;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
TAMOXIFEN;ESR2;rs4986938;CC;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;TRIGLYCERIDES IN POSTMENOPAUSAL WOMAN;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
ONDANSETRON;ABCB1;rs1045642;AA;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING ;;
TAMOXIFEN;ESR1;rs9340799;GG;OTHER;DECREASED_;SIDE_EFFECT;IN TOTAL CHOLESTEROL IN POSTMENOPAUSAL WOMAN AND INCREASE IN TRIGLYCERIDES AND DECREASE IN HIGH DENSITY LIPOPROTEIN IN PREMENOPAUSAL WOMEN;;;
TALINOLOL;ABCC2;rs2273697;A;OTHER;INCREASED_PK;PK;RESIDUAL CLEARANCE OF INTRAVENOUS TALINOLOL AND LOWER BIOAVAILABLILTY OF ORALLY ADMINISTERED TALINOLOL;;;
CLOZAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
OLANZAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
DOXORUBICIN;CBR3;rs8133052;G;TOXICITY, LADME-PK;INCREASED_PK;METABOLISM;DOXORUBICINOL AUC;;;
ONDANSETRON;ABCB1;rs2032582;AA;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING ;;
CLOZAPINE;HTR2C;rs518147;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
OLANZAPINE;HTR2C;rs518147;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
RISPERIDONE;HTR2C;rs518147;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME;;;
BEVACIZUMAB;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CYANOCOBALAMIN;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FOLIC ACID;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PEMETREXED;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ARTESUNATE;G6PD;rs1050828;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
ARTESUNATE;IKBKG;rs1050828;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
PRIMAQUINE;G6PD;rs1050828;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
PRIMAQUINE;IKBKG;rs1050828;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
PYRIMETHAMINE;G6PD;rs1050828;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
PYRIMETHAMINE;IKBKG;rs1050828;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
SULFADOXINE;G6PD;rs1050828;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
SULFADOXINE;IKBKG;rs1050828;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
RALOXIFENE;ZNF423;rs8060157;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY;;;
TAMOXIFEN;ZNF423;rs8060157;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY;;;
TACROLIMUS;ABCB1;rs1045642;AA + AG;;SIDE_EFFECT;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE;;;
CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;TOXICITY, LADME-PK;INCREASED_RISK;SIDE_EFFECT;NEUROLOGICAL ADR;;;
ARTESUNATE;G6PD;rs1050828;TT;OTHER;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
ARTESUNATE;IKBKG;rs1050828;TT;OTHER;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
PRIMAQUINE;G6PD;rs1050828;TT;OTHER;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
PRIMAQUINE;IKBKG;rs1050828;TT;OTHER;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
PYRIMETHAMINE;G6PD;rs1050828;TT;OTHER;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
PYRIMETHAMINE;IKBKG;rs1050828;TT;OTHER;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
SULFADOXINE;G6PD;rs1050828;TT;OTHER;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
SULFADOXINE;IKBKG;rs1050828;TT;OTHER;INCREASED_RISK;SIDE_EFFECT;MODERATE ANEMIA;;;
SORAFENIB;VEGFB;rs12366035;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY;;;
CYTARABINE;CDA;rs532545;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;5 YEAR SURVIVAL;;;
CYTARABINE;CDA;rs532545;TT;EFFICACY;INCREASED_RISK;nan;DISEASE;DEATH ;;
VINCRISTINE;CEP72;rs71585289;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CYCLOSPORINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RISK;nan;DISEASE;INFECTIOUS DISEASE ;;
TACROLIMUS;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RISK;nan;DISEASE;INFECTIOUS DISEASE ;;
CLOPIDOGREL;P2RY12;rs2046934;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ACUTE CORONARY SYNDROME;;;
VINCRISTINE;MIR6076;rs35650931;CC + CG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
SORAFENIB;WWOX;rs9927200;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
DOXEPIN;CYP2C19;rs4244285;AA;LADME-PK;DECREASED_PK;METABOLISM;MEDIAN ORAL CLEARANCE OF DOXEPIN;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;CARDIOTOXICITY ;;
VINCRISTINE;MIR4481;rs7896283;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
CLOMIPRAMINE;CYP2C19;rs4244285;AG;LADME-PK;INCREASED_PK;METABOLISM;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;;;
CAPECITABINE;DPYD;rs2297595;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
FLUOROURACIL;DPYD;rs2297595;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
METHOTREXATE;SLC19A1;rs1051266;CT;EFFICACY;INCREASED_RISK;OTHER;TOXIC LIVER DISEASE;;;
CORTICOSTEROIDS;ACP1;rs11553746;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS;;;
SORAFENIB;MAP2K6;rs11651488;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
METHOTREXATE;MTHFR;rs1801131;GT;EFFICACY;DECREASED_RISK;OTHER;TOXIC LIVER DISEASE;;;
SORAFENIB;CDH13;rs17682789;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RECURRENCE;;;
CLOMIPRAMINE;CYP2C19;rs4244285;AA;LADME-PK;INCREASED_PK;METABOLISM;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;;;
PAROXETINE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
CLOMIPRAMINE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
LIOTHYRONINE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
LITHIUM;FKBP5;rs1360780;T;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
NEFAZODONE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
PAROXETINE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
VENLAFAXINE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
ILOPERIDONE;CYP2D6;rs1065852;GG;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;QTC INTERVAL;;;
GEMCITABINE;SLC28A1;rs12148896;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;MYELOSUPPRESSION;;;
CLOMIPRAMINE;HTR1B;rs130058;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
LIOTHYRONINE;HTR1B;rs130058;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
LITHIUM;HTR1B;rs130058;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
NEFAZODONE;HTR1B;rs130058;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
VENLAFAXINE;HTR1B;rs130058;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
PAROXETINE;HTR1B;rs130058;A;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
GEMCITABINE;CDA;rs471760;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CANNABIDIOL;ABCC5;rs3749442;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEDATION;;;
CISPLATIN;ACYP2;rs1872328;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
CLOMIPRAMINE;ABCB1;rs2032582;A;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
LIOTHYRONINE;ABCB1;rs2032582;A;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
LITHIUM;ABCB1;rs2032582;A;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
NEFAZODONE;ABCB1;rs2032582;A;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
PAROXETINE;ABCB1;rs2032582;A;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
VENLAFAXINE;ABCB1;rs2032582;A;OTHER;INCREASED_RISK;SIDE_EFFECT;SUICIDAL IDEATION;;;
MELPHALAN;SLC7A5;rs4240803;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
ANTIPSYCHOTICS;MC4R;rs17782313;CC + CT;OTHER;INCREASED_RISK;nan;DISEASE;WEIGHT GAIN ;;
PLATINUM;SLC2A1;rs3738514;T;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
DOXORUBICIN;RARG;rs2229774;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
VINCRISTINE;GARS1;rs1049402;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
SORAFENIB;EGFR;rs917881;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIARRHEA;;;
VINCRISTINE;FGD4;rs12823621;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
CARBOPLATIN;SLC31A1;rs7851395;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
CISPLATIN;SLC31A1;rs7851395;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
VINCRISTINE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
FLUOROURACIL;ERCC2;rs13181;GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;KLC3;rs13181;GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OXALIPLATIN;ERCC2;rs13181;GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
OXALIPLATIN;KLC3;rs13181;GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PLATINUM;SLC2A1;rs4658;CC;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
TELAPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
FLUOROURACIL;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;ADD1;rs4961;GT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;AMBULATORY BLOOD PRESSURE;;;
BLEOMYCIN;ERCC2;rs238406;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CISPLATIN;ERCC2;rs238406;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
ETOPOSIDE;ERCC2;rs238406;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
CLOPIDOGREL;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
nan;RAD52;rs2277869;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;AMBULATORY BLOOD PRESSURE;;;
nan;WNK1;rs2277869;CC;OTHER;INCREASED_LIKELIHOOD;OTHER;AMBULATORY BLOOD PRESSURE;;;
FENTANYL;nan;rs13422094;C;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
MORPHINE;nan;rs13422094;C;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OPIOIDS;nan;rs13422094;C;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OXYCODONE;nan;rs13422094;C;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
SUNITINIB;IL13;rs1800925;TT;OTHER;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
FENTANYL;nan;rs12211463;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
MORPHINE;nan;rs12211463;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OPIOIDS;nan;rs12211463;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OXYCODONE;nan;rs12211463;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
FENTANYL;nan;rs7757130;A;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
MORPHINE;nan;rs7757130;A;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OPIOIDS;nan;rs7757130;A;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OXYCODONE;nan;rs7757130;A;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
FENTANYL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
FENTANYL;nan;rs2473967;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
MORPHINE;nan;rs2473967;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OPIOIDS;nan;rs2473967;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OXYCODONE;nan;rs2473967;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
THIAZIDES;ADD1;rs4961;GG;EFFICACY;DECREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
PLAIN;ADD1;rs4961;GG;EFFICACY;DECREASED_RISK;nan;DISEASE;MYOCARDIAL INFARCTION ;;
BLEOMYCIN;ERCC2;rs1799793;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
CISPLATIN;ERCC2;rs1799793;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
ETOPOSIDE;ERCC2;rs1799793;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
SUNITINIB;IL13;rs1800925;TT;OTHER;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
FENTANYL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE;;;
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY;;;
FENTANYL;RHBDF2;rs12948783;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS;;;
MORPHINE;RHBDF2;rs12948783;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS;;;
OPIOIDS;RHBDF2;rs12948783;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS;;;
OXYCODONE;RHBDF2;rs12948783;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS;;;
ACE INHIBITORS;SH2B1;rs192613545;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PLAIN;SH2B1;rs192613545;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
RADIOTHERAPY;OSMR;rs1239344;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ESOPHAGITIS;;;
BLEOMYCIN;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PAIN;;;
CISPLATIN;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PAIN;;;
ETOPOSIDE;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PAIN;;;
RADIOTHERAPY;CDK1;rs10711;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PNEUMONITIS;;;
BLEOMYCIN;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
CISPLATIN;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
ETOPOSIDE;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
CELECOXIB;CYP2C9;rs1799853;CT;LADME-PK;PK;PK;HIGHER PLASMA CONCENTRATIONS OF CELECOXIB;;;
HYDROCHLOROTHIAZIDE;REN;rs11240688;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN SBP;;;
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;C;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
ACE INHIBITORS;RBFOX3;rs62063838;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PLAIN;RBFOX3;rs62063838;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN BLOOD PRESSURE;;;
RADIOTHERAPY;PRKCE;rs940052;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ESOPHAGITIS;;;
ACE INHIBITORS;MBOAT1;rs10946364;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PLAIN;MBOAT1;rs10946364;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
RADIOTHERAPY;PRKCE;rs11125035;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ESOPHAGITIS;;;
ROFECOXIB;PTGS1;rs3842787;T;;SIDE_EFFECT;EFFICACY;REDUCTION IN COX-1 INHIBITION AND DEPRESSION OF THE URINARY THROMBOXANE METABOLITE;;;
BLEOMYCIN;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
CISPLATIN;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
ETOPOSIDE;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;FEBRILE NEUTROPENIA;;;
RADIOTHERAPY;RIGI;rs11795343;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PNEUMONITIS;;;
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
DRUGS FOR TREATMENT OF TUBERCULOSIS;nan;rs1495741;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ACE INHIBITORS;RBFOX3;rs56044629;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PLAIN;RBFOX3;rs56044629;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
HYDROCHLOROTHIAZIDE;WNK1;rs880054;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;REDUCTION IN SBP;;;
RADIOTHERAPY;nan;rs7259857;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;ESOPHAGITIS;;;
CELECOXIB;PTGS1;rs3842787;T;;SIDE_EFFECT;EFFICACY;REDUCTION IN COX-1 INHIBITION;;;
HYDROCHLOROTHIAZIDE;ADD1;rs4961;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ABSOLUTE MEAN BLOOD PRESSURE;;;
ACE INHIBITORS;GABRG2;rs77370934;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PLAIN;GABRG2;rs77370934;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
VINCRISTINE;BAHD1;rs3803357;AA + AC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
ACE INHIBITORS;RBFOX3;rs56209714;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PLAIN;RBFOX3;rs56209714;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
CAPECITABINE;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
METHYLPREDNISOLONE;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
PREDNISOLONE;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
BLEOMYCIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INFECTIOUS DISEASE;;;
CISPLATIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INFECTIOUS DISEASE;;;
ETOPOSIDE;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INFECTIOUS DISEASE;;;
ANASTROZOLE;ZNF613;rs8113308;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
LETROZOLE;ZNF613;rs8113308;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
TAMOXIFEN;ZNF613;rs8113308;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
PIRFENIDONE;CYP1A2;rs762551;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
BLEOMYCIN;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
CISPLATIN;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
ETOPOSIDE;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
CISPLATIN;OTOS;rs2291767;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;OTOTOXICITY;;;
ACE INHIBITORS;RBFOX3;rs2061538;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
PLAIN;RBFOX3;rs2061538;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIMINISHED ABILITY TO CONCENTRATE;;;
CITALOPRAM;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
CITALOPRAM;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEPHROTOXICITY;;;
MERCAPTOPURINE;MTHFR;rs1801131;GG;TOXICITY;DECREASED_RISK;nan;DISEASE;MYELOSUPPRESSION ;;
METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;DECREASED_RISK;nan;DISEASE;MYELOSUPPRESSION ;;
SUNITINIB;CXCL8;rs1126647;TT;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERTENSION;;;
BEVACIZUMAB;PDGFRB;rs2302273;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;PDGFRB;rs2302273;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
IRINOTECAN;PDGFRB;rs2302273;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
LEUCOVORIN;PDGFRB;rs2302273;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
ETHANOL;PNPLA3;rs738409;GG;TOXICITY;INCREASED_RISK;OTHER;ALCOHOL ABUSE;;;
BEVACIZUMAB;RGS5;rs2661280;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;RGS5;rs2661280;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
IRINOTECAN;RGS5;rs2661280;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
LEUCOVORIN;RGS5;rs2661280;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SORAFENIB;EPAS1;rs9973653;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
nan;WT1;rs16754;CC + CT;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;EVENT-FREE SURVIVAL ;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;TRANSPLANT REJECTION;;;
MERCAPTOPURINE;ITPA;rs1127354;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
CANNABINOIDS;FAAH;rs324420;AA;TOXICITY;DECREASED_RISK;nan;DISEASE;SUBSTANCE-RELATED DISORDERS ;;
SORAFENIB;nan;rs315498;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
CYCLOPHOSPHAMIDE;GSTA1;rs3957357;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEATH;;;
VINCRISTINE;MRPL47;rs10513762;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
VINCRISTINE;SYNE2;rs2781377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
SORAFENIB;EPAS1;rs4035887;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ANTIPSYCHOTICS;COMT;rs4680;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE;;;
ANTIPSYCHOTICS;COMT;rs4680;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_LIKELIHOOD;EVENT;ON-TREATMENT PLATELET REACTIVITY;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
METHOTREXATE;DHFR;rs408626;CC;EFFICACY;DECREASED_;OTHER;EVENT-FREE SURVIVAL;;;
METHOTREXATE;DHFR;rs408626;CC;EFFICACY;DECREASED_;OTHER;OVERALL SURVIVAL;;;
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ELEVATED TRANSAMINASES;;;
CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DEATH;;;
EFAVIRENZ;ABCB1;rs1045642;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXICITY-RELATED TREATMENT FAILURE;;;
DOXORUBICIN;GALNT14;rs9679162;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
ASPIRIN;CYP2D6;rs28360521;CC;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE;;;
DESFLURANE;ATP8B3;rs45574836;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
DESFLURANE;ATP8B3;rs45574836;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
PROPOFOL;ATP8B3;rs45574836;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING;;;
PROPOFOL;ATP8B3;rs45574836;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
LOSARTAN;CAMK1D;rs10752271;AG + GG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE;;;
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOXIC LIVER DISEASE ;;
METHOTREXATE;DHFR;rs408626;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
LOSARTAN;CAMK1D;rs10737062;AG + GG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE;;;
CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
METHOTREXATE;MTHFR;rs1801131;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
METHOTREXATE;DHFR;rs442767;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
CELECOXIB;CYP2C9;rs1057910;C;EFFICACY;DECREASED_RISK;nan;DISEASE;ADENOMA ;;
MERCAPTOPURINE;SLC19A1;rs1051266;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTIONS;;;
BLEOMYCIN;CYP3A4;rs2740574;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
CISPLATIN;CYP3A4;rs2740574;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
ETOPOSIDE;CYP3A4;rs2740574;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ALOPECIA;;;
MERCAPTOPURINE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION;;;
EFAVIRENZ;ABCB1;rs1045642;A;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EMERGING VIRAL DRUG RESISTANCE;;;
BEVACIZUMAB;CSPG4;rs1127648;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
FLUOROURACIL;CSPG4;rs1127648;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
IRINOTECAN;CSPG4;rs1127648;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
LEUCOVORIN;CSPG4;rs1127648;AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SORAFENIB;nan;rs10958704;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY;;;
METHOTREXATE;SHMT1;rs1979277;AG;TOXICITY;DECREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
METHOTREXATE;FASTKD3;rs1801394;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SPEED OF PLATELET RECOVERY;;;
METHOTREXATE;MTRR;rs1801394;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SPEED OF PLATELET RECOVERY;;;
SORAFENIB;EPAS1;rs7557402;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY;;;
METHOTREXATE;MTHFR;rs1801131;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;RED BLOOD CELL TRANSFUSIONS;;;
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE;;;
APIXABAN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
RIVAROXABAN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
EFAVIRENZ;ABCB1;rs2032582;A;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EMERGING VIRAL DRUG RESISTANCE;;;
CYCLOPHOSPHAMIDE;VEGFA;rs1570360;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
DOCETAXEL;VEGFA;rs1570360;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CARBOPLATIN;OR4D6;rs1453542;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
GEMCITABINE;OR4D6;rs1453542;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;NEUTROPENIA;;;
SORAFENIB;MAP2K6;rs12948059;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY;;;
CARBOPLATIN;DDX53;rs5925720;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
GEMCITABINE;DDX53;rs5925720;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA;;;
METHOTREXATE;MTHFD1;rs2236225;AA;OTHER;INCREASED_PK;PK;RED BLOOD CELL FOLATE;;;
METHOTREXATE;FASTKD3;rs1801394;AA;OTHER;INCREASED_PK;PK;RED BLOOD CELL FOLATE;;;
METHOTREXATE;MTRR;rs1801394;AA;OTHER;INCREASED_PK;PK;RED BLOOD CELL FOLATE;;;
IRINOTECAN;SEMA3C;rs11979430;T;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
ANTIPSYCHOTICS;DRD2;rs1800497;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
ANTIPSYCHOTICS;COMT;rs4680;AA + AG;TOXICITY;DECREASED_RISK;nan;DISEASE;TARDIVE DYSKINESIA ;;
IRINOTECAN;SEMA3C;rs7779029;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
ANTIEPILEPTICS;ABCB1;rs2032582;C;;SIDE_EFFECT;EFFICACY;PROTECTION FROM DRUG RESISTANCE;;;
ANTIPSYCHOTICS;DRD2;rs1800497;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TARDIVE DYSKINESIA ;;
ANTIEPILEPTICS;ABCB1;rs2032582;C;;SIDE_EFFECT;EFFICACY;PROTECTION FROM DRUG RESISTANCE;;;
ANTIPSYCHOTICS;DRD2;rs1800497;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TARDIVE DYSKINESIA ;;
IRINOTECAN;nan;rs1661167;G;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
ANTIEPILEPTICS;ABCB1;rs2032582;C;;SIDE_EFFECT;EFFICACY;PROTECTION FROM DRUG RESISTANCE;;;
AMISULPRIDE;HTR2C;rs498207;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
CLOZAPINE;HTR2C;rs498207;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
OLANZAPINE;HTR2C;rs498207;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
QUETIAPINE;HTR2C;rs498207;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
RISPERIDONE;HTR2C;rs498207;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
CISPLATIN;CYP2E1;rs6413432;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
CYCLOPHOSPHAMIDE;CYP2E1;rs6413432;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
BUDESONIDE;FCER2;rs28364072;G;OTHER;nan;OTHER;SEVERE EXACERBATIONS WITH ASTHMA;;;
CYCLOPHOSPHAMIDE;NOS3;rs1799983;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
AMISULPRIDE;HTR2C;rs3813928;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
CLOZAPINE;HTR2C;rs3813928;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
OLANZAPINE;HTR2C;rs3813928;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
QUETIAPINE;HTR2C;rs3813928;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
RISPERIDONE;HTR2C;rs3813928;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
MYCOPHENOLATE MOFETIL;IL12A;rs568408;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT;;;
IRINOTECAN;PLCB1;rs2745761;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
CYCLOPHOSPHAMIDE;NOS3;rs2070744;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
AMISULPRIDE;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
CLOZAPINE;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
OLANZAPINE;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
QUETIAPINE;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
RISPERIDONE;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN;;;
CYCLOPHOSPHAMIDE;NOS3;rs1799983;GG + GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
DOXORUBICIN;NOS3;rs1799983;GG + GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
FLUOROURACIL;NOS3;rs1799983;GG + GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
METHOTREXATE;NOS3;rs1799983;GG + GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;DISEASE FREE SURVIVAL;;;
IRINOTECAN;PDZRN3;rs11128347;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;NEUTROPENIA ;;
METHADONE;UGT2B7;rs4554144;TT;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
DAPSONE;HLA-DRB1;rs201929247;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
OLANZAPINE;PPARG;rs1801282;CG;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;WEIGHT GAIN ;;
METHADONE;UGT2B7;rs11940316;CC;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
CORTICOSTEROIDS;BCL2L11;rs2241843;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
METHADONE;UGT2B7;rs7438135;AA;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
METHADONE;UGT2B7;rs7662029;GG;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
CISPLATIN;GSTA1;rs3957357;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ANEMIA ;;
CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;ANEMIA ;;
OXALIPLATIN;PIN1;rs2233678;CC + CG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
OXALIPLATIN;PIN1;rs2233678;CC + CG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
METHADONE;UGT2B7;rs7668258;CC;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
ETHAMBUTOL;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
ISONIAZID;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
PYRAZINAMIDE;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
RIFAMPIN;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
METHOTREXATE;ABCG2;rs2231142;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
METHOTREXATE;AMPD1;rs17602729;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CNS ADVERSE EVENTS;;;
ANTIEPILEPTICS;ABCB1;rs1045642;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DRUG RESISTANCE;;;
METHADONE;UGT2B7;rs7439366;CC;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
ANTIEPILEPTICS;ABCB1;rs1128503;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DRUG RESISTANCE;;;
ANTIEPILEPTICS;ABCB1;rs3789243;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DRUG RESISTANCE;;;
METHADONE;UGT2B7;rs4292394;GG;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
ETHAMBUTOL;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
ISONIAZID;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
PYRAZINAMIDE;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
RIFAMPIN;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA;;;
CISPLATIN;CYP2E1;rs2070676;CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE EMESIS;;;
CYCLOPHOSPHAMIDE;CYP2E1;rs2070676;CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;SEVERE EMESIS;;;
ANTIEPILEPTICS;ABCB1;rs3789243;G;EFFICACY;INCREASED_RISK;SIDE_EFFECT;DRUG RESISTANCE;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
THIAZIDES;GNB3;rs5443;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
PLAIN;GNB3;rs5443;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
AMLODIPINE;RYR3;rs877087;TT;EFFICACY;INCREASED_RISK;nan;DISEASE;HEART FAILURE ;;
FLUOROURACIL;GSTP1;rs1695;GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HAEMATOLOGICAL TOXICITY;;;
METHADONE;UGT2B7;rs6600879;GG;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
METHADONE;UGT2B7;rs6600880;AA;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
PLATINUM COMPOUNDS;EIF3A;rs10510050;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PLATINUM COMPOUNDS;EIF3A;rs10510050;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PLATINUM COMPOUNDS;EIF3A;rs10510050;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
THIAZIDES;AGTR1;rs5186;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
PLAIN;AGTR1;rs5186;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
THIAZIDES;ACE;rs4341;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
PLAIN;ACE;rs4341;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
ATORVASTATIN;SLCO1B1;rs4149056;TT;LADME-PK;PK;PK;A NEARLY TRIPLED INCREASED  PERCENTAGE OF ATORVASTATIN AUC(0 - 48) VALUES AFTER A SINGLE ORAL DOSE OF RIFAMPICIN;;;
RIFAMPIN;SLCO1B1;rs4149056;TT;LADME-PK;PK;PK;A NEARLY TRIPLED INCREASED  PERCENTAGE OF ATORVASTATIN AUC(0 - 48) VALUES AFTER A SINGLE ORAL DOSE OF RIFAMPICIN;;;
CAPECITABINE;MIR27A;rs895819;C;TOXICITY;RISK;SIDE_EFFECT;DRUG TOXICITY;;;
FLUOROURACIL;MIR27A;rs895819;C;TOXICITY;RISK;SIDE_EFFECT;DRUG TOXICITY;;;
ATORVASTATIN;FDPS;rs2297480;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BONE_DENSITY;;;
nan;ABCC2;rs3740066;C;LADME-PK;nan;OTHER;ALLELIC IMBALENCE;;;
CISPLATIN;GSTM4;rs560018;CC;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;IC-50;;;
ATORVASTATIN;FDPS;rs11264359;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BONE_DENSITY;;;
IRINOTECAN;C8orf34;rs1517114;C;TOXICITY;INCREASED_SEVERITY;nan;DISEASE;DIARRHEA ;;
DICLOXACILLIN;ABCB1;rs1045642;GG;OTHER, LADME-PK;INCREASED_PK;METABOLISM;CLEARANCE OF DICLOXACILLIN;;;
PROBENECID;ABCB1;rs1045642;GG;OTHER, LADME-PK;INCREASED_PK;METABOLISM;CLEARANCE OF DICLOXACILLIN;;;
ANTIPSYCHOTICS;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OBESITY;;;
CLOZAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OBESITY;;;
OLANZAPINE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OBESITY;;;
RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OBESITY;;;
ETHANOL;OPRM1;rs1799971;G;OTHER;RISK;nan;DISEASE;ALCOHOL ABUSE ;;
CYCLOSPORINE;ABCB1;rs2032582;CC;OTHER, LADME-PK;INCREASED_PK;METABOLISM;CLEARANCE OF DICLOXACILLIN;;;
DICLOXACILLIN;ABCB1;rs2032582;CC;OTHER, LADME-PK;INCREASED_PK;METABOLISM;CLEARANCE OF DICLOXACILLIN;;;
ETHAMBUTOL;CYP2E1;rs2031920;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
ISONIAZID;CYP2E1;rs2031920;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PYRAZINAMIDE;CYP2E1;rs2031920;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
RIFAMPIN;CYP2E1;rs2031920;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PLATINUM COMPOUNDS;MDM2;rs1690924;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
METHOTREXATE;SLC19A1;rs1051266;TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA DRUG LEVELS;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET INHIBITION AFTER A CLOPIDOGREL 600-MG LOADING DOSE;;;
SEVOFLURANE;GRIN2B;rs1806201;AA + AG;OTHER;INCREASED_LIKELIHOOD;OTHER;MEAN ARTERIAL PRESSURE;;;
CLOPIDOGREL;CYP2C19;rs28399504;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PLATELET INHIBITION AFTER A CLOPIDOGREL 600-MG LOADING DOSE;;;
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRB2;rs1042714;GG;EFFICACY;INCREASED_SEVERITY;OTHER;STATUS ASTHMATICUS;;;
METHOTREXATE;CCND1;rs9344;AA;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;DRUG TOXICITY ;;
RISPERIDONE;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;DECREASED_SEVERITY;nan;DISEASE;LEUKOPENIA ;;
PACLITAXEL;SOD2;rs4880;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
MERCAPTOPURINE;SLC19A1;rs1051266;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
METHYLPHENIDATE;ABCB1;rs2032582;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ADVERSE EVENTS;;;
DOCETAXEL;ERCC2;rs13181;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NEUTROPENIA;;;
CYCLOSPORINE;CRTC2;rs8450;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERLIPIDEMIAS;;;
TACROLIMUS;CRTC2;rs8450;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERLIPIDEMIAS;;;
DOCETAXEL;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;RATES OF TARGET LESION REVASCULARIZATION AND MAJOR ADVERSE CARDIOVASCULAR EVENTS;;;
METFORMIN;SP1;rs2683511;C;LADME-PK;DECREASED_PK;METABOLISM;METFORMIN SECRETORY CLEARANCE;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
NICOTINE;CHRNA3;rs16969968;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOBACCO USE DISORDER ;;
NICOTINE;CHRNA5;rs16969968;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;TOBACCO USE DISORDER ;;
METFORMIN;nan;rs10747673;G;EFFICACY;DECREASED_LIKELIHOOD;EVENT;POST-HBA1C LEVELS;;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;TO BE CLASSIFIED AS CLOPIDOGREL POOR RESPONDERS;;;
METFORMIN;nan;rs10747673;G;LADME-PK;DECREASED_PK;METABOLISM;METFORMIN SECRETORY CLEARANCE;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE;;;
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
CLOPIDOGREL;ATP10A;rs12913988;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE);;;
PLATINUM COMPOUNDS;EIF3A;rs4752220;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PLATINUM COMPOUNDS;EIF3A;rs4752220;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
PLATINUM COMPOUNDS;EIF3A;rs4752220;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PLATINUM COMPOUNDS;EIF3A;rs4752220;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CHOP;NCF4;rs1883112;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXICITY;;;
RITUXIMAB;NCF4;rs1883112;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TOXICITY;;;
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;CLOPIDOGREL POOR RESPONSE;;;
PLATINUM COMPOUNDS;EIF3A;rs1409314;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PLATINUM COMPOUNDS;EIF3A;rs1409314;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
PLATINUM COMPOUNDS;EIF3A;rs1409314;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PLATINUM COMPOUNDS;EIF3A;rs1409314;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PLATINUM COMPOUNDS;EIF3A;rs4752219;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PLATINUM COMPOUNDS;EIF3A;rs4752219;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
PLATINUM COMPOUNDS;EIF3A;rs4752219;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PLATINUM COMPOUNDS;EIF3A;rs4752219;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY;;;
MERCAPTOPURINE;GSTP1;rs1695;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
METHOTREXATE;GSTP1;rs1695;GG;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;DRUG TOXICITY ;;
CLOZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
ACENOCOUMAROL;ABCB1;rs1045642;GG + GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
RISPERIDONE;ABCB1;rs2032582;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
METHOTREXATE;SLC19A1;rs1051266;TT;LADME-PK;INCREASED_PK;METABOLISM;PLASMA DRUG LEVELS;;;
SEVOFLURANE;KCNK3;rs1275988;CT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER;MEAN ARTERIAL PRESSURE;;;
LEUCOVORIN;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
MERCAPTOPURINE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;TOXIC LIVER DISEASE ;;
LEUCOVORIN;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;MYELOSUPPRESSION ;;
MERCAPTOPURINE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;MYELOSUPPRESSION ;;
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;nan;DISEASE;MYELOSUPPRESSION ;;
DOCETAXEL;CYP3A4;rs2740574;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;INFUSION RELATED REACTION;;;
METFORMIN;SP1;rs784888;G;EFFICACY;DECREASED_SEVERITY;nan;DISEASE;HYPERGLYCEMIA ;;
PLATINUM COMPOUNDS;MTR;rs1805087;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
SEVOFLURANE;GABRA2;rs279858;CC + CT;OTHER;DECREASED_;OTHER;MEAN ARTERIAL PRESSURE;;;
LEUCOVORIN;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STAYING IN REMISSION;;;
MERCAPTOPURINE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STAYING IN REMISSION;;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;STAYING IN REMISSION;;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PLATINUM COMPOUNDS;EIF3A;rs7091672;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
PLATINUM COMPOUNDS;EIF3A;rs7091672;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;LEUKOPENIA;;;
PLATINUM COMPOUNDS;EIF3A;rs7091672;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;THROMBOCYTOPENIA;;;
PLATINUM COMPOUNDS;EIF3A;rs7091672;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PACLITAXEL;CYP2C8;rs1113129;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
METFORMIN;PPARA;rs149711321;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;POST-HBA1C LEVELS;;;
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
PLATINUM COMPOUNDS;SLC19A1;rs1051266;TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PACLITAXEL;CYP2C8;rs1934951;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ANEMIA;;;
LENALIDOMIDE;VEGFA;rs699947;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
METFORMIN;SP1;rs2683511;C;EFFICACY;DECREASED_LIKELIHOOD;EVENT;POST-HBA1C LEVELS;;;
SEVOFLURANE;FASTKD3;rs1801394;AG + GG;OTHER;DECREASED_;OTHER;MEAN ARTERIAL PRESSURE;;;
SEVOFLURANE;MTRR;rs1801394;AG + GG;OTHER;DECREASED_;OTHER;MEAN ARTERIAL PRESSURE;;;
CLOPIDOGREL;CYP2C19;rs28399504;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
BUPROPION;DRD1;rs2168631;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS;;;
NICOTINE;DRD1;rs2168631;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS;;;
SIMVASTATIN;HMGCR;rs17238540;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION OF LDL CHOLESTEROL;;;
nan;NR3C1;rs9324918;C;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;SICKLE CELL PAIN CRISIS ;;
CLOPIDOGREL;CYP2C19;rs4986893;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DEATH ;;
SEVOFLURANE;FASTKD3;rs2307116;AA + AG;OTHER;DECREASED_;OTHER;MEAN ARTERIAL PRESSURE;;;
SEVOFLURANE;MTRR;rs2307116;AA + AG;OTHER;DECREASED_;OTHER;MEAN ARTERIAL PRESSURE;;;
PACLITAXEL;ERCC1;rs3212986;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
MORPHINE;ABCC3;rs1978153;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOVENTILATION;;;
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;BLEEDING;;;
BUPROPION;DRD1;rs11749035;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS;;;
NICOTINE;DRD1;rs11749035;T;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS;;;
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;ADP-INDUCED PLATELET AGGREGATION;;;
PAZOPANIB;CXCL8;rs1126647;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;CXCL8;rs1126647;T;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
nan;NR3C1;rs2963155;G;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;SICKLE CELL PAIN CRISIS ;;
MORPHINE;ABCC3;rs733392;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOVENTILATION;;;
METHADONE;UGT2B7;rs6600893;CC;EFFICACY, LADME-PK;INCREASED_SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS;;;
FENTANYL;MYD88;rs6853;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT;COGNITIVE DISORDER;;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
PREDNISONE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;REMISSION;;;
BUPROPION;DRD1;rs11746641;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS;;;
NICOTINE;DRD1;rs11746641;G;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS;;;
nan;NR3C1;rs33389;T;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;SICKLE CELL PAIN CRISIS ;;
SPIRONOLACTONE;ACE;rs4343;AA + AG;;SIDE_EFFECT;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION;;;
SPIRONOLACTONE;ACE;rs4343;AA + AG;;SIDE_EFFECT;EFFICACY;END-SYSTOLIC AND END-DIASTOLIC VOLUME;;;
SIMVASTATIN;HMGCR;rs17244841;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION OF LDL CHOLESTEROL;;;
DOCETAXEL;ERCC1;rs3212986;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;MUCOSITIS;;;
SEVOFLURANE;CYP2E1;rs3813867;CC + CG;OTHER;DECREASED_;OTHER;MEAN ARTERIAL PRESSURE;;;
CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL;;;
DOXORUBICIN;GSTA1;rs3957357;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL;;;
PREDNISONE;GSTA1;rs3957357;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL;;;
RITUXIMAB;GSTA1;rs3957357;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL;;;
VINCRISTINE;GSTA1;rs3957357;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EVENT-FREE SURVIVAL;;;
SEVOFLURANE;CYP2E1;rs2031920;CT + TT;OTHER;DECREASED_;OTHER;MEAN ARTERIAL PRESSURE;;;
SEVOFLURANE;DUX1;rs2031920;CT + TT;OTHER;DECREASED_;OTHER;MEAN ARTERIAL PRESSURE;;;
ANTIHYPERTENSIVES;NOS3;rs2070744;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANT HYPERTENSION;;;
DIURETICS;NOS3;rs2070744;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANT HYPERTENSION;;;
CYCLOPHOSPHAMIDE;CYBA;rs4673;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
DOXORUBICIN;CYBA;rs4673;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
PREDNISONE;CYBA;rs4673;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
RITUXIMAB;CYBA;rs4673;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
VINCRISTINE;CYBA;rs4673;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EVENT-FREE SURVIVAL;;;
IBUPROFEN;PTGS2;rs20417;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PAIN RELIEF;;;
DIFLOMOTECAN;ABCG2;rs2231142;T;LADME-PK;INCREASED_PK;METABOLISM;PLASMA CONCENTRATIONS OF DIFLOMOTECAN;;;
CYCLOSPORINE;ABCB1;rs2032582;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANCE;;;
CYCLOSPORINE;CRTC2;rs8450;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIABETES MELLITUS;;;
TACROLIMUS;CRTC2;rs8450;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIABETES MELLITUS;;;
ROFECOXIB;PTGS2;rs20417;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PAIN RELIEF;;;
FENTANYL;nan;rs2884129;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
MORPHINE;nan;rs2884129;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OPIOIDS;nan;rs2884129;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OXYCODONE;nan;rs2884129;G;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
HMG COA REDUCTASE INHIBITORS;nan;rs13210472;C;TOXICITY;INCREASED_RISK;OTHER;NEOPLASMS;;;
FENTANYL;nan;rs7104613;T;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
MORPHINE;nan;rs7104613;T;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OPIOIDS;nan;rs7104613;T;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OXYCODONE;nan;rs7104613;T;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
PAZOPANIB;CXCL8;rs4073;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SUNITINIB;CXCL8;rs4073;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
BLEOMYCIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
CISPLATIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
ETOPOSIDE;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;NAUSEA;;;
FENTANYL;nan;rs10413396;T;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
MORPHINE;nan;rs10413396;T;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OPIOIDS;nan;rs10413396;T;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
OXYCODONE;nan;rs10413396;T;;SIDE_EFFECT;EFFICACY;OPIOIDS RESPONSE;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_LIKELIHOOD;EVENT;PHARMACODYNAMIC RESPONSE;;;
METHOTREXATE;CCND1;rs9344;AA;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT FREE SURVIVAL;;;
BLEOMYCIN;ERCC1;rs3212986;AC + CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;VOMITING;;;
CISPLATIN;ERCC1;rs3212986;AC + CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;VOMITING;;;
ETOPOSIDE;ERCC1;rs3212986;AC + CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT;VOMITING;;;
ASPIRIN;PTGS1;rs10306114;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;DRUG TOXICITY;;;
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;rs2032582;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT;RESISTANCE;;;
CYCLOSPORINE;CRTC2;rs8450;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
TACROLIMUS;CRTC2;rs8450;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;WEIGHT GAIN;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;LADME-PK;DECREASED_PK;METABOLISM;PLASMA EXPOSURE TO THE ACTIVE METABOLITE OF CLOPIDOGREL;;;
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_;SIDE_EFFECT;ACENOCOUMAROL DOSE;;;
FLUOROURACIL;DPYD;rs1801160;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;STENT THROMBOSIS;;;
MORPHINE;ABCC3;rs886493;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOVENTILATION;;;
BLEOMYCIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
CISPLATIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
ETOPOSIDE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;VOMITING;;;
MORPHINE;ABCC3;rs7216383;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;HYPOVENTILATION;;;
METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
ETHANOL;nan;rs10516440;A;TOXICITY;DECREASED_RISK;OTHER;ALCOHOL ABUSE;;;
TRAMADOL;ABCB1;rs1045642;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;A DECREASE IN VISUAL ANALOG SCALE >30MM WITHIN 6 HOURS;;;
CITALOPRAM;CYP2C19;rs12248560;TT;LADME-PK;DECREASED_PK;METABOLISM;METABOLIC RATIO CIT/DCIT VALUES;;;
TRAMADOL;ABCB1;rs2032582;A;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;A DECREASE IN VISUAL ANALOG SCALE >30MM WITHIN 6 HOURS;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2B;ITPA;rs1127354;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT;ANEMIA;;;
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
METHOTREXATE;ABCC2;rs17222723;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES;;;
RISPERIDONE;UGT1A1;rs887829;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
FLUOXETINE;CRHR1;rs242941;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RESPONSE;;;
RISPERIDONE;UGT1A1;rs10929302;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HYPERPROLACTINEMIA;;;
SARILUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
CISPLATIN;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CISPLATIN;GSTP1;rs1138272;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;EVENT-FREE SURVIVAL;;;
CISPLATIN;GSTP1;rs1138272;CT + TT;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
SARILUMAB;IL6R;rs4845625;TT;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
VITAMIN K ANTAGONISTS;CYP4F2;rs2108622;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT;STROKE;;;
RISPERIDONE;HTR2C;rs6318;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT;WEIGHT GAIN;;;
WARFARIN;CRP;rs1205;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
HYDROCHLOROTHIAZIDE;TCF7L2;rs4132670;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DIABETES;;;
HYDROCHLOROTHIAZIDE;TCF7L2;rs7917983;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
ATORVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;REACHING TARGET CHOLESTEROL LEVELS;;;
CERIVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;REACHING TARGET CHOLESTEROL LEVELS;;;
FLUVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;REACHING TARGET CHOLESTEROL LEVELS;;;
PRAVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;REACHING TARGET CHOLESTEROL LEVELS;;;
ROSUVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;REACHING TARGET CHOLESTEROL LEVELS;;;
SIMVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;REACHING TARGET CHOLESTEROL LEVELS;;;
HYDROCHLOROTHIAZIDE;TCF7L2;rs4506565;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;RECURRENCE;;;
CITALOPRAM;CYP2C19;rs4244285;AA;LADME-PK;INCREASED_PK;METABOLISM;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE;;;
LENALIDOMIDE;ABCB1;rs2032582;CC;EFFICACY;DECREASED_LIKELIHOOD;EVENT;OVERALL SURVIVAL;;;
FLUOROURACIL;XRCC1;rs25487;CC;OTHER;nan;OTHER;LATER ONSET OF SENSORY NEUROPATHY;;;
LEUCOVORIN;XRCC1;rs25487;CC;OTHER;nan;OTHER;LATER ONSET OF SENSORY NEUROPATHY;;;
OXALIPLATIN;XRCC1;rs25487;CC;OTHER;nan;OTHER;LATER ONSET OF SENSORY NEUROPATHY;;;
DOCETAXEL;CHST3;rs4148950;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
THALIDOMIDE;CHST3;rs4148950;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXICITY;;;
IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA;;;
BUPRENORPHINE;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
FENTANYL;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
TRAMADOL;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
SARILUMAB;IL6R;rs4537545;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DYSLIPIDAEMIA;;;
CALCIUM;VDR;rs1544410;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN SPINAL BONE MINERAL DENSITY CHANGES;;;
ETIDRONIC ACID;VDR;rs1544410;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;MEAN SPINAL BONE MINERAL DENSITY CHANGES;;;
SARILUMAB;IL6R;rs2228145;AA;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DYSLIPIDAEMIA;;;
BUPRENORPHINE;OPRD1;rs2234918;CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
FENTANYL;OPRD1;rs2234918;CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
TRAMADOL;OPRD1;rs2234918;CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
VALPROIC ACID;SOD2;rs4880;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
SARILUMAB;IL6R;rs4329505;TT;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
BUPRENORPHINE;ARRB2;rs1045280;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FENTANYL;ARRB2;rs1045280;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
TRAMADOL;ARRB2;rs1045280;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
PEGINTERFERON ALFA-2A;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
RIBAVIRIN;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
BISPHOSPHONATES;CYP2C8;rs1934951;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS OF THE JAW;;;
BUPRENORPHINE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
FENTANYL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
TRAMADOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
BUPRENORPHINE;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
FENTANYL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
TRAMADOL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
BUPRENORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FENTANYL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
TRAMADOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
BUPRENORPHINE;COMT;rs4680;AA + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
BUPRENORPHINE;COMT;rs4680;AA + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
FENTANYL;COMT;rs4680;AA + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
FENTANYL;COMT;rs4680;AA + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
TRAMADOL;COMT;rs4680;AA + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
TRAMADOL;COMT;rs4680;AA + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER;;;
nan;IFNL3;rs12979860;CC;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;JAUNDICE ;;
nan;IFNL4;rs12979860;CC;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;JAUNDICE ;;
BUPRENORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
FENTANYL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
TRAMADOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
FLUOROURACIL;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
LEUCOVORIN;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
OXALIPLATIN;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DRUG TOXICITY ;;
BUPRENORPHINE;OPRM1;rs1799971;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
FENTANYL;OPRM1;rs1799971;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
TRAMADOL;OPRM1;rs1799971;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
LENALIDOMIDE;CRBN;rs1705814;CC;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION;;;
LENALIDOMIDE;CRBN;rs1705814;CC;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION;;;
BUPRENORPHINE;COMT;rs4680;AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
FENTANYL;COMT;rs4680;AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
TRAMADOL;COMT;rs4680;AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
FLUOROURACIL;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
LEUCOVORIN;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
OXALIPLATIN;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
FLUOROURACIL;XRCC1;rs25487;CC;TOXICITY;DECREASED_RISK;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
LEUCOVORIN;XRCC1;rs25487;CC;TOXICITY;DECREASED_RISK;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
OXALIPLATIN;XRCC1;rs25487;CC;TOXICITY;DECREASED_RISK;nan;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES ;;
RIFAMPIN;NR1I2;rs2472677;T;OTHER, LADME-PK;DECREASED_PK;METABOLISM;CYP3A4 ACITVITY;;;
CARBAMAZEPINE;SCN2A;rs2304016;A;;SIDE_EFFECT;EFFICACY;DRUG RESISTANCE;;;
LAMOTRIGINE;SCN2A;rs2304016;A;;SIDE_EFFECT;EFFICACY;DRUG RESISTANCE;;;
OXCARBAZEPINE;SCN2A;rs2304016;A;;SIDE_EFFECT;EFFICACY;DRUG RESISTANCE;;;
PHENYTOIN;SCN2A;rs2304016;A;;SIDE_EFFECT;EFFICACY;DRUG RESISTANCE;;;
TOPIRAMATE;SCN2A;rs2304016;A;;SIDE_EFFECT;EFFICACY;DRUG RESISTANCE;;;
CAPECITABINE;PTGS2;rs5275;AA;EFFICACY;INCREASED_SEVERITY;OTHER;PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL;;;
OXALIPLATIN;PTGS2;rs5275;AA;EFFICACY;INCREASED_SEVERITY;OTHER;PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL;;;
HMG COA REDUCTASE INHIBITORS;CETP;rs708272;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS;;;
DIURETICS;ADD1;rs4961;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;nan;DISEASE;MYOCARDIAL INFARCTION ;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;nan;SIDE_EFFECT;LOWER WARFARIN DOSE REQUIREMENT;;;
ETHANOL;DRD2;rs1076560;A;OTHER;INCREASED_RISK;nan;DISEASE;ALCOHOL ABUSE ;;
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PLATELET ACTIVATION RESPONSE TO ADP;;;
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN MEAN BLOOD PRESSURE;;;
FLUOROURACIL;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
LEUCOVORIN;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
OXALIPLATIN;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;NEUTROPENIA ;;
BROMPERIDOL;DRD2;rs1799732;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT IN ANXIETY-DEPRESSION SYMPTOMS;;;
NEMONAPRIDE;DRD2;rs1799732;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;IMPROVEMENT IN ANXIETY-DEPRESSION SYMPTOMS;;;
THIAZIDES;SLC12A3;rs13306673;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN MEAN BLOOD PRESSURE;;;
PLAIN;SLC12A3;rs13306673;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN MEAN BLOOD PRESSURE;;;
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL_TOXICITY;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
RIBAVIRIN;IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOOD;EVENT;RAPID VIROLOGICAL RESPONSE (RVR);;;
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;LEUKOPENIA ;;
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ALOPECIA;;;
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HYPERSENSITIVITY;;;
ATORVASTATIN;CYP3A5;rs776746;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES;;;
ROSUVASTATIN;CYP3A5;rs776746;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES;;;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RECURRENCE;;;
THIAZIDES;ADRB3;rs4994;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN MEAN BLOOD PRESSURE;;;
PLAIN;ADRB3;rs4994;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN MEAN BLOOD PRESSURE;;;
TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION FREE SURVIVAL;;;
IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DIARRHEA;;;
ASPARAGINASE;CPA2;rs199695765;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;PANCREATITIS;;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_LIKELIHOOD;EVENT;COMPLETE EARLY VIROLOGICAL RESPONSE;;;
DAPSONE;HLA-DRB1;rs701829;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
TACROLIMUS;POR;rs1057868;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
WARFARIN;THBD;rs1042580;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT;HEMORRHAGE;;;
PEGINTERFERON ALFA-2A;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
METHYLPHENIDATE;CES1;rs3815583;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;APPETITE SUPPRESSION;;;
ACE INHIBITORS;BDKRB2;rs8012552;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
PLAIN;BDKRB2;rs8012552;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
CORTICOSTEROIDS;BCL2L11;rs724710;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT;OSTEONECROSIS;;;
ACE INHIBITORS;MME;rs2016848;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
PLAIN;MME;rs2016848;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;COUGH ;;
IRINOTECAN;PIN1;rs2233678;CC + CG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;PROGRESSION-FREE SURVIVAL;;;
PEGINTERFERON ALFA-2A;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
RIBAVIRIN;nan;rs4273729;GG;EFFICACY;INCREASED_LIKELIHOOD;EVENT;SUSTAINED VIROLOGICAL RESPONSE (SVR);;;
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN MEAN ARTERIAL PRESSURE;;;
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION;;;
ASPIRIN;ACE;rs4291;AT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;ASPIRIN INTOLERANCE;;;
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572103;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT;;;
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_LIKELIHOOD;EVENT;REDUCTION IN MEAN BLOOD PRESSURE;;;
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT;;;
ACE INHIBITORS;PTGER3;rs11209716;C;TOXICITY;DECREASED_RISK;nan;DISEASE;COUGH ;;
PLAIN;PTGER3;rs11209716;C;TOXICITY;DECREASED_RISK;nan;DISEASE;COUGH ;;
MYCOPHENOLATE MOFETIL;HUS1;rs1056663;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT;;;
DAPSONE;HLA-DRB1;rs17211071;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY;;;
TACROLIMUS;PPARA;rs4253728;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DISEASE;DIABETES MELLITUS ;;
MYCOPHENOLATE MOFETIL;HUS1;rs2037483;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT;;;
nan;ADD1;rs4961;GT + TT;OTHER;INCREASED_LIKELIHOOD;nan;DISEASE;HYPERTENSION ;;
FLUOROURACIL;ABCB1;rs2032582;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
FLUOROURACIL;SLCO1B1;rs2306283;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
nan;ARG1;rs2781666;TT;OTHER;INCREASED_SEVERITY;OTHER;ASTHMA;;;
TACROLIMUS;CYP3A4;rs2740574;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
EPIRUBICIN;ABCC1;rs246221;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEFT VENTRICULAR DYSFUNCTION;;;
LEVODOPA;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DYSKINESIA;;;
LEVODOPA;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED;;;
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
DAUNORUBICIN;ABCC2;rs8187710;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;ABCC2;rs8187710;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
FOLFOX;DPYD;DPYD c.1129-5923C>G;c.1129-5923C>G, c.1236G>A (HapB3);EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RECURRENCE FREE SURVIVAL;;;
FOLFOX;DPYD;c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RECURRENCE FREE SURVIVAL;;;
DAUNORUBICIN;HFE;rs1799945;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;HFE;rs1799945;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DAUNORUBICIN;GPR35;rs12468485;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;GPR35;rs12468485;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DAUNORUBICIN;UGT1A6;rs17863783;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;UGT1A6;rs17863783;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DAUNORUBICIN;GSTA2;rs2180314;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;GSTA2;rs2180314;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DAUNORUBICIN;ETFB;rs79338777;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;ETFB;rs79338777;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DAUNORUBICIN;HNMT;rs17583889;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;HNMT;rs17583889;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DAUNORUBICIN;ABCC5;rs7627754;AA + AT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
DOXORUBICIN;ABCC5;rs7627754;AA + AT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY;;;
CEFAZOLIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CEFDINIR;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CEFTRIAXONE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CEFUROXIME;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
CEPHALEXIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED_LIVER_INJURY;;;
TACROLIMUS;CYP2B6;rs3745274;GT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
CORTICOSTEROIDS;WNT7B;rs73175102;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS;;;
CORTICOSTEROIDS;POGK;rs115587273;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS;;;
CORTICOSTEROIDS;FAM240C;rs78233573;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS;;;
CORTICOSTEROIDS;ZNF37A;rs376867011;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS;;;
CODEINE;CYP2D6;CYP2D6 intermediate metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EMERGENCIES;;;
CODEINE;CYP2D6;CYP2D6 intermediate metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
HYDROCODONE;CYP2D6;CYP2D6 intermediate metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EMERGENCIES;;;
HYDROCODONE;CYP2D6;CYP2D6 intermediate metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
TRAMADOL;CYP2D6;CYP2D6 intermediate metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;EMERGENCIES;;;
TRAMADOL;CYP2D6;CYP2D6 intermediate metabolizer;;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PAIN;;;
VALPROIC ACID;ACOT1;rs758109;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
TACROLIMUS;SLCO1B1;rs2306283;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
AZATHIOPRINE;MOCOS;rs73430958;GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
VALPROIC ACID;GABPA;rs59288687;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
VALPROIC ACID;NQO1;rs10517;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
VALPROIC ACID;PPARA;rs881740;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
METHOTREXATE;SLCO1B3;rs7311358;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
METHOTREXATE;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ANEMIA;;;
APIXABAN;APOE;rs7412;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INTRACRANIAL HEMORRHAGES;;;
APIXABAN;APOE;rs429358;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;INTRACRANIAL HEMORRHAGES;;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs8099917;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS;;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12980275;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS;;;
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12979860;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS;;;
TACROLIMUS;ABCB1;rs9282564;TT;EFFICACY;DECREASED_RISK;SIDE_EFFECT;DEATH;;;
TACROLIMUS;ABCC2;rs2273697;GG;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;OVERALL SURVIVAL;;;
TACROLIMUS;SLCO1B1;rs4149056;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION;;;
TACROLIMUS;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
AZATHIOPRINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;RRM1;rs1735053;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;rs9465102;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
CISPLATIN;TRPA1;rs920829;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY;;;
FOLFOX;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
XELOX;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
FLUOXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TREATMENT MODIFICATION;;;
CYCLOSPORINE;SLC29A1;rs693955;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;OVERALL SURVIVAL;;;
CYCLOSPORINE;SLC29A1;rs693955;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT;RECURRENCE FREE SURVIVAL;;;
AFATINIB;AKT1;rs2494750;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
ERLOTINIB;AKT1;rs2494750;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
GEFITINIB;AKT1;rs2494750;CC;EFFICACY;INCREASED_LIKELIHOOD;EFFICACY;PROGRESSION-FREE SURVIVAL;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TRIMETHOPRIM;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TRIMETHOPRIM;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
SULFAMETHOXAZOLE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
TRIMETHOPRIM;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS;;;
FOLFOX;GSTP1;rs1695;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
FOLFOX;GSTP1;rs1695;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
XELOX;GSTP1;rs1695;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
XELOX;GSTP1;rs1695;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
FOLFOX;TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
FOLFOX;TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
XELOX;TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES;;;
XELOX;TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION;;;
FOLFOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
FOLFOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
FOLFOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
XELOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME;;;
XELOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;EXANTHEMA;;;
XELOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
FOLFOX;GSTP1;rs1695;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
XELOX;GSTP1;rs1695;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;MUCOSITIS;;;
AZATHIOPRINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PANCREATITIS;;;
AZATHIOPRINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;PANCREATITIS;;;
HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY;;;
HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*1xN;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*2;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*5;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*10;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AMITRIPTYLINE;CYP2D6;CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT;DRUG TOXICITY;;;
AZATHIOPRINE;TPMT;TPMT*1;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3A;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3B;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
AZATHIOPRINE;TPMT;TPMT*3C;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*1;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3A;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3B;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
MERCAPTOPURINE;TPMT;TPMT*3C;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA;;;
RISPERIDONE;CYP2D6;CYP2D6*1;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*1xN;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*2;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*2xN;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*3;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*4;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*4xN;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*5;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*9;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*10;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*17;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*29;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*35;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
RISPERIDONE;CYP2D6;CYP2D6*41;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS;;;
CODEINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;URINARY RETENTION;;;
CODEINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CONSTIPATION;;;
CODEINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
CODEINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;URINARY RETENTION;;;
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CONSTIPATION;;;
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;URINARY RETENTION;;;
OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;CONSTIPATION;;;
OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;NAUSEA;;;
OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT;VOMITING;;;
